

WO9804528

Publication Title:

SUBSTITUTED PYRIDINES AND BIPHENYLS AS
ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND
ANTI-HYPERGLYCEMIC AGENTS

Abstract:

Abstract of WO9804528

Substituted pyridines of formula (IA) are produced by reaction of suitably substituted pyridylaldehydes with Grignard or Wittig reagents, and the resulting products are appropriately reduced. The pyridines of formula (IA) are suitable as active compounds in pharmaceutical products, particularly in pharmaceutical products for the inhibition of cholesterol ester transfer proteins. 3-Heteroalkyl-aryl-substituted pyridines of formula (IB) are produced from pyridines which are correspondingly protected at the hydroxy group and correspondingly substituted. The compounds of formula (IB) according to the invention are suitable as active compounds in pharmaceutical products, particularly pharmaceutical products for the treatment of hyperlipoproteinemia. Substituted pyridines and benzenes of formula (IC) are produced by procedures disclosed herein, and are useful as active ingredients in pharmaceutical products, particularly pharmaceutical products for inhibition of the glucagon receptor, leading to treatment of glucagon-mediated conditions such as diabetes. Data supplied from the esp@cenet database - Worldwide

Courtesy of <http://v3.espacenet.com>



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 213/20, 403/06, 213/32, A61K 31/44	A2	(11) International Publication Number: WO 98/04528 (43) International Publication Date: 5 February 1998 (05.02.98)
(21) International Application Number: PCT/US97/13248 (22) International Filing Date: 29 July 1997 (29.07.97) (30) Priority Data: 08/690,111 31 July 1996 (31.07.96) US (71) Applicants: BAYER CORPORATION [US/US]; 100 Bayer Road, Pittsburgh, PA 15205 (US). BAYER AKTIENGESELLSCHAFT [DE/DE]; D-51368 Leverkusen (DE). (72) Inventors: SCHMIDT, Gunter; Pahlkestrasse 63, D-42115 Wuppertal (DE). ANGERBAUER, Rolf; Moospfad 20, D-42113 Wuppertal (DE). BRANDES, Arndt; Pahlkestrasse 5, D-42115 Wuppertal (DE). MULLER-GLIEMANN, Matthias; Holz 24, D-42719 Solingen (DE). BISCHOFF, Hilmar; Am Rohm 78, D-42113 Wuppertal (DE). SCHMIDT, Delf; Am Eckbusch 55b, D-42113 Wuppertal (DE). WOHLFEIL, Stefan; Dorothea-Erxleben-Strasse 31, D-40721 Hilden (DE). SCHOEN, William, R.; 60 Field Brook Road, Madison, CT 06443 (US). LADOUCEUR, Gaetan, H.; 31 Stone Ridge Lane, Branford, CT 06405 (US). COOK, James, H., II; 36 Mallard Cove, East Hampton, CT 06424 (US). LEASE, Timothy, G.; 74 Christopher Lane, Guilford, CT 06437 (US). WOLANIN, Donald, J.; 320 Longmeadow Road, Orange, CT 06477		(US). KRAMSS, Richard, H.; 978 Little Meadow Road, Guilford, CT 06437 (US). HERTZOG, Donald, L.; 421 Warpas Road, Madison, CT 06443 (US). OSTERHOUT, Martin, H.; Apartment 11, 409 Whitney Avenue, New Haven, CT 06511 (US). (74) Agents: GRAY, William, F. et al.; Bayer Corporation, 400 Morgan Lane, West Haven, CT 06516 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS		
(57) Abstract <p>Substituted pyridines of formula (IA) are produced by reaction of suitably substituted pyridylaldehydes with Grignard or Witting reagents, and the resulting products are appropriately reduced. The pyridines of formula (IA) are suitable as active compounds in pharmaceutical products, particularly in pharmaceutical products for the inhibition of cholesterol ester transfer proteins. 3-Heteroalkyl-aryl-substituted pyridines of formula (IB) are produced from pyridines which are correspondingly protected at the hydroxy group and correspondingly substituted. The compounds of formula (IB) according to the invention are suitable as active compounds in pharmaceutical products, particularly pharmaceutical products for the treatment of hyperlipoproteinemia. Substituted pyridines and benzenes of formula (IC) are produced by procedures disclosed herein, and are useful as active ingredients in pharmaceutical products, particularly pharmaceutical products for inhibition of the glucagon receptor, leading to treatment of glucagon-mediated conditions such as diabetes.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

0

SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS**Field**

5 This application relates to substituted biaryl compounds which inhibit cholesterol ester transfer proteins (CETPs), stimulate reverse cholesterol transport, and inhibit the action of glucagon.

Background

10 The present invention concerns certain substituted pyridines, processes for the production thereof, and the use thereof in pharmaceutical products. It also concerns certain substituted biphenyls, processes for their production, pharmaceutical compositions containing them, and methods for their use.

15 7-(polysubstituted pyridyl) hept-6-enoates for the treatment of arteriosclerosis, lipoproteinemia, and hyperlipoproteinemia are known from US 5 169 857. In addition, the production of 7-(4-aryl-3-pyridyl)-3,5-dihydroxy-hept-6-enoate is described in EP 325 130.

20 Glucagon is a peptide hormone whose main function is to increase hepatic glucose production. Insulin, on the other hand, functions to decrease glucose production. Together, these two hormones are necessary for maintaining a correct level of glucose in the blood.

25 Diabetes is a complex disease characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Diabetes is also associated with elevated glucagon levels. The heterogeneous nature of the disease requires different strategies to address the different abnormalities in metabolism found in affected individuals.

30 In the diabetic state (all forms of Type I and Type II), hyperglycemia often is associated with elevated glucagon levels. Accordingly, a means of treating all forms of diabetes is to block the glucagon receptor with a suitable antagonist, thereby inhibiting glucose production by the liver and reducing glucose levels in the patient.

Glucagon receptor antagonists, materials which block the action of endogenous glucagon, are known to have many and varied applications. Among these applications are the following:

- 0 1. Treatment of hyperglycemia associated with diabetes of any cause and associated with any other diseases or conditions. A glucagon receptor antagonist can be used either alone or in combination with any other therapies to treat hyperglycemia.
2. Treatment of impaired glucose tolerance (IGT).
- 5 3. Treatment of insulin resistance syndromes including those due to obesity, polycystic ovarian syndrome, "Syndrome X", drugs and hormones, endocrinopathies and genetic syndromes.
4. To decrease free fatty acid levels and treat conditions associated with elevated free fatty acids levels such as insulin resistance, obesity, all or part of
- 10 Syndrome X, Type I and II diabetes, hyperlipidemias and elevated hepatic glucose output associated with insulin resistance, Type I and Type II diabetes, obesity, and Syndrome X.
5. To treat conditions associated with genetic defects in insulin action due to alterations in insulin receptor structure and function or alterations in post
- 15 receptor signal transduction. To treat diabetes associated with anti-insulin antibodies, drug induced diabetes, diabetes associated with endocrinopathies and diabetes associated with genetic syndromes.
6. To treat gestational diabetes mellitus.
7. To treat autoimmune and non autoimmune causes of Type I diabetes
- 20 including those due to known genetic defects of the beta cell, pancreatic diseases, drug or toxin induced beta cell dysfunction, endocrinopathies, infectious causes, malnutrition associated and idiopathic Type I diabetes.
8. To prevent and treat diabetic ketoacidosis and decrease hepatic ketone body production
- 25 9. To treat hyperglycemia of exercise in diabetes.
10. To reduce fasting and postprandial glucose.
11. Treatment of insulin resistance in liver, muscle, and fat.
12. Treatment of conditions of hyperlipidemia.
13. To treat glucagonomas and all other conditions associated with elevated
- 30 glucagon levels.
14. To treat conditions of increased futile cycling of glucose in the liver.
15. To increase insulin secretion.
16. To decrease glucose toxicity.

- 0 17. To decrease the renal prostaglandin response to protein and amino acids.
18. To decrease elevated GFR and albumin clearance due to diabetes or proteins or amino acids.
19. To decrease renal albumin clearance and excretion.
- 5 20. To treat acute pancreatitis.
21. To treat cardiovascular disease including causes of increased cardiac contractility.
22. To treat cardiac hypertrophy and its consequences.
23. As a diagnostic agent and as a diagnostic agent to identify patients
- 10 having a defect in the glucagon receptor.
24. Treatment of gastrointestinal disorders, treatment of decreased gut motility.
25. As a therapy to increase gastric acid secretions.
26. To reverse intestinal hypomobility due to glucagon administration.
- 15 27. To reverse catabolism and nitrogen loss in states of negative nitrogen balance and protein wasting including all causes of Type I and Type II diabetes, fasting, AIDS, cancer, anorexia, aging and other conditions.
28. To treat any of the above conditions or diseases in post-operative or operative period.
- 20 29. To decrease satiety and increase energy intake.

 Glucagon receptor antagonists of the prior art, such as those described in WO9518153-A and references cited therein, are predominantly peptide analogues of glucagon. They are susceptible to the actions of endogenous proteases, may precipitate antibody production and immune reactions and can be difficult and

25 expensive to manufacture. Such peptides are usually unsuitable for oral delivery.

 One non-peptide glucagon receptor antagonist has been reported (Collins, et al; *BioMed. Chem Lett.* 1992, 2, 915-918). This quinoxaline derivative, CP-99,711, was shown to inhibit glucagon binding and glucagon action in rat liver membrane at micromolar concentrations.

30

 It would be desirable to have inhibitors of CETP which possess valuable pharmacological properties that are superior to those of the state of the art. Certain of the substituted pyridine compounds of the invention are highly effective

0 inhibitors of cholesterol ester transfer proteins (CETP) and stimulate reverse
cholesterol transport. They cause a reduction in LDL cholesterol levels in the blood,
while at the same time increasing HDL cholesterol levels. They can therefore be
used for the treatment of hyperlipoproteinemia or arteriosclerosis.


5 It would also be desirable to have readily prepared non-peptidic glucagon
receptor antagonists which are metabolically more stable than peptidic antagonists
of the prior art, and which afford good activity and bioavailability. Certain of the
substituted pyridine compounds as well as the substituted biphenyls of the
invention are highly effective inhibitors of the glucagon receptor. Accordingly,
these compounds may be used to treat glucagon-mediated conditions such as those
10 listed above.

Summary

15 The present invention concerns substituted biaryl compounds which fall
within the three general formulae (IA), (IB), and (IC) shown below. The definitions
of these general formulae are given broadly in the following text. In the
subsequent detailed description sections, each of these broad general formulae is
discussed in more detail in terms of its preferred and most preferred molecular
constituents, procedures for making, examples of particular materials made, testing
20 procedures, and results obtained.

It should be noted that in the text below, and in the subsequent detailed
description sections, the definitions of the various constituent and substituent
groups apply only to the particular subset of the compounds of the invention then
under consideration. The same symbols may have different definitions in
25 connection with the other subsets of compounds.

The present invention concerns substituted pyridines of the general formula
(IA),



(IA)

30 in which

A stands for aryl with 6 to 10 carbon atoms, which is optionally substituted up
to 3 times in an identical manner or differently by halogen, hydroxy,
trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl,

0 acyl, or alkoxy with up to 7 carbon atoms each, or by a group of the formula
-NR¹R²,

wherein

5 R¹ and R² are identical or different and denote hydrogen, phenyl, or
straight-chain or branched alkyl with up to 6 carbon atoms,

D stands for straight-chain or branched alkyl with up to 8 carbon atoms, which
is substituted by hydroxy,

10 E and L are either identical or different and stand for straight-chain or branched
alkyl with up to 8 carbon atoms, which is optionally substituted by cycloalkyl
with 3 to 8 carbon atoms,

or

15 stand for cycloalkyl with 3 to 8 carbon atoms,

or

E has the above-mentioned meaning

20 and

L in this case stands for aryl with 6 to 10 carbon atoms, which is optionally
substituted up to 3 times in an identical manner or differently by halogen,
25 hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or
branched alkyl, acyl, or alkoxy with up to 7 carbon atoms each, or by a
group of the formula -NR³R⁴,

wherein

30 R³ and R⁴ are identical or different and have the meaning given above for
R¹ and R²,

or

35 E stands for straight-chain or branched alkyl with up to 8 carbon atoms,
or

stands for aryl with 6 to 10 carbon atoms, which is optionally substituted up to 3 times in an identical manner or differently by halogen, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl, acyl, or alkoxy with up to 7 carbon atoms each, or by a group of the formula -NR⁵R⁶,


wherein

R⁵ and R⁶ are identical or different and have the meaning given above for R¹ and R²,

and

L in this case stands for straight-chain or branched alkoxy with up to 8 carbon atoms or for cycloalkoxy with 3 to 8 carbon atoms,

T stands for a radical of the formula



wherein

R⁷ and R⁸ are identical or different and

denote cycloalkyl with 3 to 8 carbon atoms, or aryl with 6 to 10 carbon atoms,

or denote a 5- to 7-member aromatic, optionally benzo-condensed, heterocyclic compound with up to 3 heterocyclic atoms from the series S, N and/or O, which are optionally substituted up to 3 times in an identical manner or differently by trifluoromethyl, trifluoromethoxy, halogen, hydroxy, carboxyl, by straight-chain or branched alkyl, acyl, alkoxy, or alkoxycarbonyl with up to 6 carbon atoms each, or by phenyl, phenoxy, or thiophenyl, which can in turn be substituted by halogen, trifluoromethyl, or trifluoromethoxy,

and/or the rings are substituted by a group of the formula -NR¹¹R¹²,

wherein

0 R^{11} and R^{12} are identical or different and have the meaning given
above for R^1 and R^2 ,

5 X denotes a straight or branched alkyl chain or alkenyl chain with 2 to
10 carbon atoms each, which are optionally substituted up to 2 times
by hydroxy,

R^9 denotes hydrogen,

and

10 R^{10} denotes hydrogen, halogen, azido, trifluoromethyl, hydroxy,
mercapto, trifluoromethoxy, straight-chain or branched alkoxy with
up to 5 carbon atoms, or a radical of the formula $-NR^{13}R^{14}$,

15 wherein

R^{13} and R^{14} are identical or different and have the meaning given
above for R^1 and R^2 ,


20 or

R^9 and R^{10} form a carbonyl group together with the carbon atom,

and the salts thereof.

25

The present invention also concerns substituted pyridines of general formula
(IB)



30

in which

A stands for aryl with 6 to 10 carbon atoms, which is optionally substituted up
to 3 times in an identical manner or differently by halogen, hydroxy,

0 trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl, acyl, or alkoxy with up to 7 carbon atoms each, or by a group of the formula $-NR^2R^3$ and/or $-WR^4$,

wherein

5

R^2 and R^3 are the same or different and

denote hydrogen, phenyl, or straight-chain or branched alkyl with up to 6 carbon atoms,

10

W denotes an oxygen or sulfur atom,

R^4 denotes aryl with 6 to 10 carbon atoms, which is optionally substituted up to 3 times in an identical manner or differently by halogen, trifluoromethyl, trifluoromethoxy, hydroxy, or by straight-chain or branched alkyl or alkoxy with up to 6 carbon atoms each,

15

D and E are identical or different and

stand for a straight-chain or branched alkyl chain with up to 8 carbon atoms,

20

or

E stands for a bond,

25

V stands for an oxygen or sulfur atom or for a group of the formula $-NR^5$,

wherein

R^5 denotes hydrogen or straight-chain or branched alkyl with up to 6 carbon atoms or phenyl,

30

R^1 stands for cycloalkyl with 3 to 6 carbon atoms, or stands for aryl with 6 to 10 carbon atoms or for a 5- to 7-member, optionally benzocondensed, saturated or unsaturated, mono-, bi-, or tricyclic heterocyclic compound with up to 4 carbon atoms from the series S, N, and/or O,

35

0 in which the heterocycles, also via the N function in the case of
nitrogen-containing rings, are optionally substituted up to 3 times in an
identical manner or differently by halogen, trifluoromethyl, hydroxy, cyano,
carboxyl, trifluoromethoxy, straight-chain or branched acyl, alkyl, alkylthio,
5 alkylalkoxy, alkoxy, or alkoxycarbonyl with up to 6 carbon atoms each, by
aryl with 6 to 10 carbon atoms, or by an optionally benzo-condensed,
aromatic 5- to 7-member heterocyclic compound with up to 3 heterocyclic
atoms from the series S, N, and/or O,
and/or are substituted by a group of the formula -OR⁶, -SR⁷, -SO₂R⁸, or
-NR⁹R¹⁰,

10

wherein

R⁶, R⁷, and R⁸ are identical or different and
denote aryl with 6 to 10 carbon atoms, which in turn is substituted up
15 to 2 times in an identical manner or differently by phenyl or halogen
or by straight-chain or branched alkyl with up to 4 carbon atoms,

R⁹ and R¹⁰ are identical or different and have the above-indicated meaning
of R² and R³,

20

L and T are identical or different and

stand for trifluoromethyl or straight-chain or branched alkyl with up to 8
carbon atoms, which are optionally substituted by cycloalkyl with 3 to 7
carbon atoms, or by aryl with 6 to 10 carbon atoms, which in turn can be
25 substituted up to 2 times in an identical manner or differently by halogen,
trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl,
acyl, or alkoxy with up to 7 carbon atoms each,

or

30


L and/or T stand for cycloalkyl with 3 to 7 carbon atoms or

stand for aryl with 6 to 10 carbon atoms or for a 5- to 7-member, saturated,
partially unsaturated, or unsaturated heterocyclic compound with up to 3
heterocyclic atoms from the series S, N and/or O, with binding in the case of
35 a nitrogen atom also being possible via this atom, with the heterocycles
optionally being substituted up to 3 times in an identical manner or
differently by halogen, nitro, trifluoromethyl, trifluoromethoxy, or by

0 straight-chain or branched alkyl, acyl, or alkoxy with up to 7 carbon atoms each,

and the salts thereof.

5 This invention also relates to compounds having glucagon receptor antagonistic activity and the general formula (IC) shown below.



10 In general formula IC, the groups X, R^{1a}, R^{1b}, R², R³, and Ar have the following meanings:

X represents N or CR⁸.

15 R⁸ represents hydrogen, halogen, trifluoromethyl, phenyl, substituted phenyl, (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₁-C₆)-alkoxy, (C₃-C₇)-cycloalkyl, phenyl-(C₁-C₃)-alkoxy, (C₁-C₆)-alkanoyloxy, (C₁-C₆)-alkoxycarbonyl, carboxy, formyl, or -NR⁴R⁵. The substituents on the substituted phenyl or substituted alkyl R⁸ groups are from 1 to 3 of, for example, hydroxy, fluoro, (C₁-C₆)-alkoxy, (C₃-C₇)-cycloalkyl, phenyl, phenyl-(C₁-C₃)-alkoxy, (C₁-C₆)-alkanoyloxy, (C₁-C₆)-alkoxycarbonyl, carboxy, formyl, or -NR⁴R⁵.

20 The groups R⁴ and R⁵ are independently hydrogen, (C₁-C₆)-alkyl, (C₃-C₆)-alkenyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-cycloalkyl-(C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl, naphthyl-(C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl. The substituents on the substituted phenyl or substituted naphthyl R⁴ and R⁵ groups are 1 to 3 of, for example, halogen, cyano, trifluoromethyl, (C₁-C₄)-alkyl, or (C₁-C₄)-alkoxy groups.

25 R⁴ and R⁵ may be joined together to form -(CH₂)_rA(CH₂)_s- wherein the subscripts r and s are independently 1 to 3 and A is CHR⁶, NR⁶, O, or S(O)_n in which n is 0, 1, or 2; and R⁶ is hydrogen, (C₁-C₆)-alkyl, piperidin-1-yl, phenyl, or phenyl-(C₁-C₆)-alkyl.

30 R^{1a} and R^{1b} are independently trifluoromethyl, (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl,

0 substituted (C₂-C₁₀)-alkynyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-cycloalkenyl, or (C₁-C₆)-
 alkanoyl. The substituents on the substituted alkyl, substituted alkenyl, and
 substituted alkynyl R^{1a} and R^{1b} groups are independently from 1 to 3 of, for
 example, -OR⁴, -C(O)R⁴, -CO₂R⁴, -C(O)NR⁴R⁵, -NR⁴R⁵, or phenyl which is
 5 optionally substituted with from 1 to 3 of, for example, halogen, (C₁-C₄)-alkyl, or
 (C₁-C₄)-alkoxy groups.

R² is (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl,
 substituted (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, substituted (C₂-C₁₀)-alkynyl, (C₃-
 C₆)-cycloalkyl-(C₁-C₆)-alkyl, or substituted (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl. The
 substituents on the substituted alkyl, substituted alkenyl, substituted alkynyl, and
 10 substituted cycloalkyl R² groups are independently from 1 to 3 of halogen, phenyl,
 substituted phenyl, 1,3-dioxolan-2-yl, -C(O)NR⁴R⁵, or -S(O)_mR⁷ wherein m is 0, 1,
 or 2. The substituents on the substituted phenyl R² substituent group are from 1 to
 3 of, for example, halogen, (C₁-C₄)-alkyl, or (C₁-C₄)-alkoxy.

R⁷ is (C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl,
 15 substituted phenyl-(C₁-C₆)-alkyl, pyridyl, substituted pyridyl, pyridyl-(C₁-C₆)-
 alkyl, substituted pyridyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl, naphthyl-
 (C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl. The substituents on the
 substituted phenyl, substituted pyridyl or substituted naphthyl R⁷ groups are from
 1 to 5 of, for example, halogen, trifluoromethyl, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy,
 20 nitro, cyano, or hydroxy.

R² and R^{1b} may be joined to form an alkylene bridge containing from 3 to 5
 carbon atoms, between the ring carbon atoms to which R² and R^{1b} are attached.

R³ is hydroxy, trifluoroacetyl, (C₁-C₆)-alkanoyl, substituted (C₁-C₆)-alkyl,
 or substituted (C₃-C₆)-alkenyl. The substituents on the substituted alkyl and
 25 substituted alkenyl R³ groups are from 1 to 3 hydroxy or trifluoromethyl groups.

Ar is an optionally substituted aromatic or heteroaromatic ring. Examples of
 possible Ar groups are: phenyls, naphthyls, pyridyls, furanyls, thiophenyls,
 pyrrolyls, imidazolyls, pyrazolyls, triazolyls, tetrazolyls, oxazolyls, isoxazolyls,
 thiazolyls and isothiazolyls. The optional substituents on the group Ar are
 30 independently 1 to 3 of, for example, halogen, (C₁-C₆)-alkyl, substituted (C₁-C₆)-
 alkyl, (C₂-C₆)-alkenyl, substituted (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, substituted
 (C₂-C₆)-alkynyl, (C₃-C₇)-cycloalkyl, cyano, nitro, trifluoromethyl, -OR⁴, -C(O)R⁴, -
 OC(O)R⁴, -CO₂R⁴, -NR⁴R⁵, -C(O)NR⁴R⁵, or -S(O)_mR⁷. The substituents on the
 substituted alkyl, substituted alkenyl, and substituted alkynyl substituent groups on
 35 Ar are from 1 to 3 of, for example, halogen, hydroxy, -NR⁴R⁵, phenyl, or

- 0 substituted phenyl in which the phenyl group may bear, for example, one or more halogen, (C₁-C₄) alkyl, or (C₁-C₄) alkoxy groups.

Pharmaceutically acceptable salts of these materials are within the scope of the invention.

- 5 The invention also relates to a pharmaceutical product containing the substituted pyridines according to general formula (IA) and, if appropriate, a pharmacologically tolerable formulation adjuvant. It further relates to such pharmaceutical product for the inhibition of cholesterol ester transfer proteins, and to the use of the claimed substituted pyridines for the production of pharmaceutical
10 products, and to use of the claimed substituted pyridines for the production of cholesterol ester transfer protein inhibitors.

- The invention further relates to a pharmaceutical product containing the substituted pyridines 3-heteroalkyl-aryl-substituted pyridines according to general formula (IB) and, if appropriate, a pharmacologically tolerable formulation
15 adjuvant. It further relates to such pharmaceutical product for the treatment of hyperlipoproteinemia, and to the use of the claimed substituted pyridines for the production of pharmaceutical products, and to use of the claimed substituted pyridines for the production of pharmaceutical products for the treatment of hyperlipoproteinemia.

- 20 The invention also relates to a pharmaceutical composition for use in treating a glucagon-mediated condition, which comprises: a compound having glucagon receptor antagonistic activity and a structure within general structural formula IC, plus a pharmaceutically acceptable carrier.

- The invention further relates to a method for treating a glucagon-mediated
25 condition which comprises administering to a subject an effective amount of a compound having glucagon receptor antagonistic activity and a structure within general structural formula IC.

0 **Detailed description with reference to compounds of general formula (IA)**

The substituted pyridines according to the invention can also occur in the form of the salts thereof. In general, salts with organic or inorganic bases or acids are mentioned here.

5

Within the context of the present invention, physiologically safe salts are preferred. Physiologically safe salts of the compounds according to the invention can be salts of substances according to the invention with mineral acids, carboxylic acids, or sulfonic acids. Salts with, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalene disulfonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid, or benzoic acid are particularly preferred.

15 Physiologically safe salts can also be metallic or ammonium salts of the compounds according to the invention that possess a free carboxyl group. For example, sodium salts, potassium salts, magnesium salts, or calcium salts, as well as ammonium salts, that are derived from ammonia, or organic amines such as ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine, ethylenediamine, or 2-phenyl-ethylamine
20 are particularly preferred.

The compounds according to the invention can exist in stereoisomeric forms, which either behave like an image and mirror image (enantiomers) or do not
25 behave like an image and mirror image (diastereomers). The invention concerns both enantiomers or diastereomers or the mixtures thereof. These mixtures of enantiomers and diastereomers can be separated in the known manner into stereoisomerically homogeneous components.

30 Within the context of the invention, the heterocyclic compound, which is optionally benzo-condensed, stands in general for a saturated or unsaturated, 5-to 7-member, preferably 5- to 6-member, heterocyclic compound that can contain up to 3 heteroatoms from the series S, N, and/or O. Indolyl, isoquinolyl, quinolyl, benzothiazolyl, benzo[b]thiophene, benzo[b]furanyl, benzoxazolyl, pyridyl, thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, morpholinyl, or piperidyl are
35 cited as examples. Quinolyl, pyridyl, indolyl, benzothiazolyl, or benzoxazolyl are preferred.

0

Compounds of the general formula (IA) are preferred,

in which

5 A stands for naphthyl or phenyl, which are optionally substituted up to 3 times in an identical manner or differently by fluorine, chlorine, bromine, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl, acyl, or alkoxy with up to 6 carbon atoms each, or by a group of the formula -NR¹R²,

10

wherein

R¹ and R² are identical or different and denote hydrogen, phenyl, or straight-chain or branched alkyl with up to 4 carbon atoms,

15

D stands for straight-chain or branched alkyl with up to 6 carbon atoms, which is substituted by hydroxy,

20 E and L are either identical or different and stand for straight-chain or branched alkyl with up to 6 carbon atoms, which is optionally substituted by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, or stand for cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl,

or

25

E has the above-mentioned meaning

and

30 L in this case stands for naphthyl or phenyl, which are optionally substituted up to 3 times in an identical manner or differently by fluorine, chlorine, bromine, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl or alkoxy with up to 6 carbon atoms each, or by a group of the formula -NR³R⁴,

35

0 wherein

R^3 and R^4 are identical or different and have the meaning given above for R^1 and R^2 ,

5 or

E stands for straight-chain or branched alkyl with up to 5 carbon atoms, or stands for naphthyl or phenyl, which are optionally substituted up to 3 times in an identical manner or differently by fluorine, chlorine, bromine, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl, acyl, or alkoxy with up to 6 carbon atoms each, or by a group of the formula $-NR^5R^6$,

15 wherein


R^5 and R^6 are identical or different and have the meaning given above for R^1 and R^2 ,

and

20

L in this case stands for straight-chain or branched alkoxy with up to 6 carbon atoms, or for cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, or cycloheptyloxy,

25 T stands for a radical of the formula



wherein

R^7 and R^8 are identical or different and

30 denote cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or adamantyl, or

denote naphthyl, phenyl, pyridyl, quinolyl, indolyl, benzothiazolyl, or benzoxazolyl, which are optionally substituted up to 3 times in an identical manner or differently by trifluoromethyl, trifluoromethoxy, fluorine, chlorine, bromine, hydroxy, carboxyl, by straight-chain or

35

0 branched alkyl, alkoxy, or alkoxycarbonyl with up to 5 carbon atoms each, or by phenyl, phenoxy, or thiophenyl, which can in turn be substituted by fluorine, chlorine, bromine, trifluoromethyl, or trifluoromethoxy,

5 and/or the rings are optionally substituted by a group of the formula $-NR^{11}R^{12}$,

 wherein

10 R^{11} and R^{12} are identical or different and have the meaning given above for R^1 and R^2 ,

 X denotes a straight or branched alkyl chain or alkenyl chain with 2 to 8 carbon atoms each, which are optionally substituted up to 2 times by hydroxy,

R^9 denotes hydrogen,

 and

20 R^{10} denotes hydrogen, fluorine, chlorine, bromine, azido, trifluoromethyl, hydroxy, mercapto, trifluoromethoxy, straight-chain or branched alkoxy with up to 4 carbon atoms, or a radical of the formula $-NR^{13}R^{14}$,

25 wherein

R^{13} and R^{14} are identical or different and have the meaning given above for R^1 and R^2 ,

30 or

R^9 and R^{10} form a carbonyl group together with the carbon atom,

35 and the salts thereof.

0 Compounds of the general formula (IA) are particularly preferred,

in which

5 A stands for phenyl, which is optionally substituted up to 2 times in an identical manner or differently by fluorine, chlorine, bromine, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl or alkoxy with up to 5 carbon atoms each,

10 D stands for straight-chain or branched alkyl with up to 5 carbon atoms, which is substituted by hydroxy,

15 E and L are either identical or different and stand for straight-chain or branched alkyl with up to 5 carbon atoms, which is optionally substituted by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, or stand for cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl,

or

20 E has the above-mentioned meaning
and

25 L in this case stands for phenyl, which is optionally substituted up to 2 times in an identical manner or differently by fluorine, chlorine, bromine, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl or alkoxy with up to 5 carbon atoms each,


or

30 E stands for straight-chain or branched alkyl with up to 4 carbon atoms, or stands for phenyl, which is optionally substituted up to 2 times in an identical manner or differently by fluorine, chlorine, bromine, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl or alkoxy with up to 5 carbon atoms each,

35 and

0 L in this case stands for straight-chain or branched alkoxy with up to 5 carbon atoms, or for cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, or cycloheptyloxy,

T stands for a radical of the formula



wherein

R^7 and R^8 are identical or different and

10 denote cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or adamantyl, or

15 denote phenyl, pyridyl, quinolyl, indolyl, naphthyl, benzothiazolyl, or benzoxazolyl, which are optionally substituted up to 2 times in an identical manner or differently by trifluoromethyl, trifluoromethoxy, fluorine, chlorine, bromine, hydroxy, carboxyl, by straight-chain or branched alkyl, alkoxy, or alkoxycarbonyl with up to 4 carbon atoms each, or by phenyl, phenoxy, or thiophenyl, which can in turn be substituted by fluorine, chlorine, bromine, trifluoromethyl, or trifluoromethoxy,

20 X denotes a straight or branched alkyl chain with 2 to 6 carbon atoms each, which are optionally substituted up to 2 times by hydroxy,

R^9 denotes hydrogen,

25 and

R^{10} denotes hydrogen, fluorine, chlorine, bromine, azido, amino, trifluoromethyl, hydroxy, mercapto, trifluoromethoxy, straight-chain or branched alkoxy with up to 3 carbon atoms,

30

or

R^9 and R^{10} form a carbonyl group together with the carbon atom,

35 and the salts thereof.

0

Compounds according to the invention of the general formula (IA) are most preferred, in which



5

A stands for phenyl, which is optionally substituted by fluorine, chlorine, or methyl.

10

Furthermore, a process for the production of compounds according to the invention of the general formula (IA) has been discovered, characterized by the fact that

compounds of the general formula (II) or (III)



15 in which

A, E, L, and T have the above-mentioned meanings,

and

20

R¹⁵ stands for straight-chain or branched alkoxy carbonyl with up to 4 carbon atoms,


25


are either first reacted, using the Grignard or Wittig reaction, in an inert solvent, with further derivatization optionally being carried out according to the customary methods, and then are reduced in inert solvents,

or, in the case of compounds of the general formula (III), direct reductions are carried out, optionally via several steps.

30

The compounds according to the invention can be explained, for example, by means of the following reaction diagram:





0

Suitable solvents are ethers, such as diethyl ether, dioxane, tetrahydrofuran, or glycol dimethyl ether, or hydrocarbons, such as benzene, toluene, xylene, hexane, or cyclohexane, or petroleum fractions, or halocarbons, such as dichloromethane, trichloromethane, tetrachloromethane, dichloroethylene, or trichloroethylene, or chlorobenzene, or ethyl acetate, or triethylamine, pyridine, dimethyl sulfoxide, dimethyl formamide, hexamethylphosphoric triamide, acetonitrile, acetone, or nitromethane. It is likewise possible to use mixtures of said solvents. Dichloromethane is preferred.

0

Suitable organometallic reagents are systems such as Mg/bromobenzene trifluoride and p-trifluoromethylphenyllithium. The Mg/bromobenzene trifluoride system is preferred.

5

The reductions and derivatizations are carried out according to the above-mentioned methods.

In general, the reductions are carried out in ethers, such as dioxane, tetrahydrofuran, or diethyl ether, or in hydrocarbons, such as benzene, hexane, or toluene. Toluene and tetrahydrofuran are preferred.

10

Suitable reductants are complex metal hydrides, such as lithium aluminum hydride, sodium cyanoborohydride, sodium aluminum hydride, diisobutylaluminum hydride, dimethoxymethylaluminate sodium salt, or sodium-bis-(2-methoxyethoxy)-dihydroaluminate (Red-Al). Diisobutyl-aluminum hydride and dimethoxymethylaluminate sodium salt are preferred.

15

The reductant is generally added in a quantity ranging from 4 moles to 10 moles, preferably from 4 moles to 5 moles, relative to 1 mole of the compound to be reduced.

20

The reduction generally takes place within a temperature range of -78°C to +50°C, preferably from -78°C to 0°C, and most preferably at -78°C, depending on the choice of both the reductant and the solvent.

25

The reduction generally takes place at normal pressure, but it is also possible to work at increased or reduced pressure.

However, the reductions can also be carried out with reductants that are suitable for the reduction of ketones to hydroxy compounds. Particularly suitable in this regard is reduction using metal hydrides or complex metal hydrides in inert solvents, if appropriate in the presence of a trialkyl borane. Preferably, the reduction is carried out using complex metal hydrides, such as lithium borohydride, sodium borohydride, potassium borohydride, zinc borohydride, lithium trialkyl borohydride, or lithium aluminum hydride. More particularly preferably, the reduction is carried out using sodium borohydride in the presence of triethylborane.

30

35

0

The reaction can also take place via hydrogenation. The hydrogenation takes place according to the customary methods using hydrogen in the presence of noble metal catalysts, such as Pd/C, Pt/C, or Raney nickel in one of the above-mentioned solvents, preferably in alcohols such as methanol, ethanol, or propanol, within a temperature range of -20°C to +100°C, preferably from 0°C to +50°C, at normal pressure or elevated pressure.

As derivatizations, the following types of reactions are cited by way of examples: oxidations, reductions, hydrogenations, halogenation, Wittig reactions/Grignard reactions, and amidation/sulfoamidation.

The customary strong basic compounds can be used as auxiliary agents. Among these are, preferably, organolithium compounds, such as n-butyllithium, sec-butyllithium, tert-butyllithium, or phenyllithium, or amides, such as lithium diisopropylamide, sodium amide, or potassium amide, or lithium hexamethylsilylamide, or alkali hydrides, such as sodium hydride or potassium hydride. Particularly preferably, n-butyllithium, or sodium hydride are used.

Furthermore, the customary inorganic bases are suitable bases. Among these are, preferably, alkali hydroxides or alkaline earth hydroxides, such as sodium hydroxide, potassium hydroxide, or barium hydroxide, or alkali carbonates, such as sodium carbonate, potassium carbonate, or sodium hydrogen carbonate. Particularly preferably, sodium hydroxide or potassium hydroxide are used.

25

Alcohols, such as methanol, ethanol, propanol, butanol, or tert-butanol, are also suitable solvents for the individual reaction steps. Tert-butanol is preferred.

It may possibly be necessary to carry out several reaction steps under a protective gas atmosphere.

30

The halogenation generally takes place in one of the above-mentioned chlorinated hydrocarbons, whereby methylene chloride is preferred.

35

Diethylamino sulfur trifluoride (DAST) or SOCl₂, for example, are suitable halogenation agents.

0 The halogenation generally takes place within a temperature range of -78°C to +50°C, preferably from -78°C to 0°C, and most preferably at -78°C, depending on the choice of both the halogenation agent and the solvent.

5 The halogenation generally takes place at normal pressure, but it is also possible to work at increased or reduced pressure.

 The customary reagents are suitable as Wittig reagents. 3-Trifluoromethylbenzyl triphenylphosphonium bromide is preferred.


10 One of the above-mentioned bases are generally suitable as bases, preferably Li-bis-(triethylbutyl)amide.

15 The base is introduced in a quantity ranging from 0.1 mole to 5 moles, preferably from 0.5 mole to 2 moles, relative to 1 mole of the starting compound.

 The reaction using Wittig reagents is generally carried out within a temperature range of 0°C to 150°C, preferably at 25°C to 40°C.

20 In general, the Wittig reactions are carried out at normal pressure. However, it is also possible to carry out the process at reduced pressure or high pressure (e.g., within a range from 0.5 to 5 bar).

25 Compounds of the general formula (II) in the case wherein L is other than alkoxy/cyclooxy (L') are known or can be produced by processing compounds of the general formula (IV)



in which

A, E, and L' have the above-mentioned meanings,

30 R¹⁶ and R¹⁷ are identical or different and

stand for straight-chain or branched alkyl with up to 4 carbon atoms,

0 in inert solvents with oxidants,

and

selectively reducing the alkoxycarbonyl function (CO_2R^{17}) to the hydroxy function
5 in a second step.

Suitable solvents for the oxidation are ethers, such as diethyl ether, dioxane, tetrahydrofuran, or glycol dimethyl ether, or hydrocarbons, such as benzene, toluene, xylol, hexane, or cyclohexane, or petroleum fractions, or halocarbons, such
10 as dichloromethane, trichloromethane, tetrachloromethane, dichloroethylene, or trichloroethylene, or chlorobenzene, or ethyl acetate, or triethylamine, pyridine, dimethyl sulfoxide, dimethyl formamide, hexamethylphosphoric triamide, acetonitrile, acetone, or nitromethane. It is likewise possible to use a mixture of said solvents. Dichloromethane is preferred.

15

Suitable oxidants are, for example, 2,3-dichloro-5,6-dicyanobenzoquinone, pyridinium chlorochromate (PCC), osmium tetroxide, and manganese dioxide. For the above-mentioned step, 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) is preferred.

20

The oxidant is introduced in a quantity ranging from 1 mole to 10 moles, preferably from 2 moles to 5 moles, relative to 1 mole of the compound of the general formula (IV).

25

The oxidation generally takes place within a temperature range of -50°C to $+100^\circ\text{C}$, preferably from 0°C to room temperature.


The oxidation generally takes place at normal pressure. However, it is also possible to carry out the oxidation at increased or reduced pressure.

30

1,4-Dihydropyridine-3,5-dicarboxylic acid esters of the general formula (IV) are known and can be produced according to known methods.

The reaction is generally carried out at normal pressure. However, it is also
35 possible to carry out the process at reduced pressure or high pressure (e.g., within a range of 0.5 to 5 bar).

0 Compounds of the general formula (II) in the case wherein L is alkoxy/cyclooxy (L') are known and can be produced by first oxidizing compounds of the general formula (V)



5 in which

A and E have the above-mentioned meanings


and

10

R¹⁸ and R¹⁹ have the meaning given above for R¹⁶ and R¹⁷ and are identical to or different from these,

with ceric(IV) ammonium nitrate into compounds of the general formula (VI)

15



in which

A, E, R¹⁸, and R¹⁹ have the above-mentioned meanings,

20

then, by reaction with alkylation agents of the general formula (VII)




25 in which

R²⁰ stands for cycloalkyl with 3 to 8 carbon atoms, or stands for straight-chain or branched alkyl with up to 8 carbon atoms,

0 and

Y stands for halogen, preferably for bromine or iodine,

in inert solvents and in the presence of a base, converting them into compounds of
5 the general formula (VIII)



in which

10

A, E, R¹⁸, R¹⁹, and R²⁰ have the above-mentioned meanings,

and finally, as described above, carrying out a selective reduction with
diisobutylaluminum hydride of the alkoxycarbonyl group -CO₂R¹⁸ to the
15 hydroxymethylene function, followed by an oxidation to the corresponding
aldehyde, likewise as described above, preferably with PCC.


The individual reaction steps each take place in one of the above-mentioned
solvents and/or bases; preferably, the oxidation is carried out with ceric(IV)
20 ammonium nitrate in acetonitrile, the alkylation is carried out with dimethyl
formamide and sodium hydride, and the reduction is carried out in toluene within a
temperature range of -30°C to 100°C, at normal pressure, and, if applicable, under a
protective gas atmosphere.

25 Compounds of the general formulas (V) and (VII) are known in and of
themselves or can be produced according to the customary methods.

Compounds of the general formulas (VI) and (VIII) are known in part or are
novel and can therefore be produced according to the above-mentioned process.

30

Compounds of the general formula (III) are novel and are produced by
converting compounds of the general formula (IX)



0


in which

A, E, L, and T have the above-mentioned meanings

5 and

R²¹ denotes a straight-chain or branched alkoxy carbonyl with up to 3 carbon atoms,

10 first by reduction of the alkoxy carbonyl function, into compounds of the general formula (Ia)



in which

15 A, E, L, and T have the above-mentioned meanings,

and in a second step, oxidizing the hydroxymethyl function into the aldehyde according to the above-mentioned conditions, preferably with pyridinium chlorochromate (PCC).

20

The individual reaction steps are generally carried out within a temperature range of -10°C to +160°C, preferably 0°C to +100°C, and at normal pressure.

25 Compounds of the general formula (IX) are produced analogously to the methods described above for the production of compounds of the general formula (II).

Compounds of the general formula (Ia) are also novel and can be produced as described above.

30

0 Compounds of the general formulas (IA) and (Ia) according to the invention have an unforeseeable pharmacological spectrum of action.

 Compounds of the general formulas (IA) and (Ia) according to the invention possess valuable pharmacological properties that are superior to those of the state
5 of the art; in particular, they are highly effective inhibitors of cholesterol ester transfer proteins (CETP) and stimulate reverse cholesterol transport. The active compounds according to the invention cause a reduction in LDL cholesterol levels in the blood, while at the same time increasing HDL cholesterol levels. They can therefore be used for the treatment of hyperlipoproteinemia or arteriosclerosis.

10 The invention additionally concerns the combination of compounds according to the invention with a glucosidase and/or amylase inhibitor for the treatment of familial hyperlipidemia, obesity (adiposis), and diabetes mellitus. Within the context of the invention, glucosidase and/or amylase inhibitors are, for
15 example, acarbose, adiposine, voglibose, miglitol, emiglitate, MDL-25637, camiglibose (MDL-73945), tendamistat, AI-3688, testatin, pradimicin-Q, and salbostatin.

 The combination of acarbose, miglitol, emiglitate, or voglibose and one of
20 the above-mentioned compounds of the general formula (IA) according to the invention is preferred.

 The pharmacological action of the substances according to the invention was determined in the following test:

25

CETP Inhibition Test

1. Obtaining CETP

30 CETP is obtained in partially purified form from human plasma by differential centrifugation and column chromatography and is used for testing. In so doing, human plasma is adjusted with NaBr to a density of 1.21 g per ml and is centrifuged for 18 h at 50,000 rpm at 4°C. The bottom fraction ($d > 1.21$ g/ml) is applied to a Sephadex[®] Phenyl-Sepharose 4B (Pharmacia) column, washed with
35 0.15 m NaCl/0.001 m TrisHCl, pH 7.4, and then eluted with dist. water. The CETP-active fractions were pooled, dialyzed against 50 mM Na acetate, pH 4.5, and applied to a CM-Sepharose[®] (Pharmacia) column. They were then eluted with a

0 linear gradient (0-1 M NaCl). The pooled CETP fractions were dialyzed against 10 mM TrisHCl, pH 7.4, and were then further purified by chromatography over a Mono Q[®] column (Pharmacia).

2. Obtaining Radioactively Tagged HDL

5

50 ml of fresh human EDTA plasma was adjusted with NaBr to a density of 1.12 and centrifuged at 4°C for 18 h at 50,000 rpm in the Ty 65 rotor. The upper phase was used to obtain cold LDL. The lower phase was dialyzed against 3x4 l of PDB buffer (10 mM Tris/HCl, pH 7.4, 0.15 mM NaCl, 1 mM EDTA, 0.02% NaN₃).

10 20 µl 3H cholesterol (Du Pont NET-725; 1 -µC/µl dissolved in ethanol) was subsequently added per 10 ml of dialysis residue volume and incubated for 72 h at 37°C under N₂.

15 The sediment was then adjusted with NaBr to a density of 1.21 and centrifuged in the Ty 65 rotor for 18 h at 50,000 rpm at 20°C. The upper phase was obtained and the lipoprotein fractions were purified by gradient centrifugation. In so doing, the isolated, tagged lipoprotein fraction was adjusted with NaBr to a density of 1.26. Every 4 ml of this solution was covered in centrifuge tubes (SW 40 rotor) with 4 ml of a solution with a density of 1.21 and 4.5 ml of a solution with a density of 1.063 (density solutions from PDB buffer and NaBr) and then centrifuged for 24 h at 38,000 rpm and 20°C in the SW 40 rotor. The intermediate layer between the densities 1.063 and 1.21 that contained the tagged HDL was dialyzed against 3x100 volumes of PDB buffer at 4°C.

25 The dialysis residue contained radioactively tagged ³H-CE-HDL, which was adjusted to approx. 5x10⁶ cpm per ml and used for the test.

3. Conducting the Test

30 In order to test the CETP activity, the transfer of ³H cholesterol ester from human HD lipoproteins to biotinylated LD lipoproteins was measured.

The reaction was ended by adding Streptavidin-SPA[®] beads (Amersham), and the transferred radioactivity was determined directly in the liquid scintillation counter.

35 In the test batch, 10 µl HDL-³H cholesterol ester (≈ 50,000 cpm) was incubated for 18 h at 37°C with 10 µl biotin-LDL (Amersham) in 50 mM HEPES / 0.15 m NaCl / 0.1% bovine serum albumin / 0.05% NaN₃, pH 7.4, with 10 µl CETP (1 mg/ml) and 3 µl solution of the substance to be tested (dissolved in 10% DMSO /

0 1% BSA). Then 200 μ l of the SPA-Streptavidin bead solution (Amersham TRKQ 7005) was added, and the mixture was further incubated for 1 h under agitation and subsequently measured in the scintillation counter. Corresponding incubations with 10 μ l buffer, 10 μ l CETP at 4°C, and 10 μ l CETP at 37°C served as controls.

5 The transferred activity in the control batches with CETP at 37°C was assessed as 100% transfer. The substance concentration in which this transfer was reduced by half was indicated as an IC₅₀ value.

CETP inhibitory activity of the following compounds:

Example No.	IC ₅₀ (μ M)
7	0.6
24	1.0

10 Syrian golden hamsters from the company's own breeding were anesthetized after fasting for 24 h (0.80 mg/kg atropine, 0.80 mg/kg Ketavet® s.c., 30' later 50 mg/kg Nembutal i.p.). The jugular vein was then exposed and cannulated. The test substance was dissolved in a suitable solvent (as a rule, Adalat
15 placebo solution: 60 g glycerin, 100 ml H₂O, ad 100 ml PEG-400) and administered to the animals via a PE catheter inserted into the jugular vein. The control animals received the same volume of solvent without any test substance. The vein was then ligated and the wound closed up. At different intervals — up to 24 hours after administration of the test substance — blood was drawn from the animals by
20 puncture of the retroorbital venous plexus (approx. 250 μ l). Coagulation was completed by incubating at 4°C overnight, then the blood was centrifuged for 10 minutes at 6000 g. The cholesterol and triglyceride content in the serum obtained in this manner was determined using modified commercially available enzyme tests (cholesterol enzymatic 14366 Merck, triglyceride 14364 Merck). The serum was
25 diluted in a suitable manner with physiological saline solution.

100 μ l serum dilution was mixed with 100 μ l test substance in 96-hole perforated plates and incubated 10 minutes at room temperature. The optical density was then determined with an automatic plate reader at a wavelength of 492
30 nM (SLT-Spectra). The triglyceride/cholesterol concentration contained in the samples was determined using a parallel-measured standard curve.

0 The determination of the HDL cholesterol content was carried out after precipitation of the lipoproteins containing Apo B by means of a reagent mixture (Sigma 352-4 HDL cholesterol reagent) according to the manufacturer's instructions.

5 In attempting to determine oral efficacy, the test substance, which was dissolved in DMSO and suspended in 0.5% methylcellulose, was administered orally to Syrian golden hamsters from the company's own breeding via a pharyngeal tube. The control animals received identical volumes of solvent without any test substance. Feed was then withheld from the animals and blood was drawn at
10 different intervals — up to 24 hours after administration of the substance — via puncture of the retroorbital venous plexus. It was further processed as described above.

15 The new active compounds can be converted in a known manner into the customary formulations, such as tablets, coated tablets, pills, granules, aerosols, syrups, emulsions, suspensions, and solutions, using inert, non-toxic, pharmaceutically suitable excipients or solvents. In this connection, the therapeutically active compound should be present in each case in a concentration of about 0.5% to 90% by weight, i.e., in amounts that are sufficient to achieve the
20 dosage range indicated.

25 The formulations are prepared, for example, by extending the active compounds using solvents and/or excipients, if appropriate using emulsifiers and/or dispersants, where, for example, in the case of the use of water as a diluent, organic solvents can be used, if appropriate, as auxiliary solvents.

 The administration takes place in a customary manner, preferably orally or parenterally, in particular, perlingually or intravenously.

30 In the case of parenteral use, solutions of the active compound can be employed using suitable liquid excipients.

35 In general, it has proved advantageous in intravenous administration to administer amounts of about 0.001 to 1 mg/kg, preferably about 0.01 to 0.5 mg/kg of body weight, to attain effective results, and in oral administration, the dosage is about 0.01 to 20 mg/kg, preferably 0.1 to 10 mg/kg of body weight.


0 In spite of this, it may be necessary to deviate from the amounts mentioned,
depending on the body weight or the type of administration route, individual
behavior toward the medication, the type of formulation thereof, and the time or
interval at which administration takes place. Thus, in some cases it may be
sufficient to manage with less than the minimum amount previously mentioned,
5 whereas in other cases the upper limit mentioned must be exceeded. If larger
amounts are administered, it may be advisable to divide these into several
individual doses over the day.

10

Starting Compounds

Example I

15 Diethyl 4-(4-fluorophenyl)-6-isopropyl-(1H)-pyrid-2-one-3,5-dicarboxylate



20 149 g (0.395 mmol) of diethyl 3,4-dihydro-4-(4-fluorophenyl)-6-isopropyl-
(1H)-pyrid-2-one-3,5-dicarboxylate is dissolved in 800 ml of acetonitrile, mixed with
475 g (0.867 mol) of ceric(IV) ammonium nitrate dissolved in 500 ml of H₂O, and
subsequently stirred for 3 h. The aqueous phase is extracted two times with ethyl
acetate. The combined ethyl acetate phases are washed with salt water, dried, and
concentrated. The residue is mixed with isopropanol immediately thereafter,
25 whereby crystallization is started by cooling with ice. The product is drawn off by
suction and dried in a high vacuum.


Yield: 58.8 g (39.6% of theory)

R_f = 0.5 (toluene / ethyl acetate 1:1)

30

0 **Example II**

Diethyl 4-(4-fluorophenyl)-6-isopropyl-2-methoxy-3,5-dicarboxylate



5

1.72 mg (42.9 mmol; 1.61 eq.) of sodium hydride (60% dispersion in mineral oil) is added to 10 g (26.6 mmol) of the compound from Example I dissolved in 40 g of DMF, and the mixture is suspended in 30 ml at -20°C. Afterwards, the suspension is heated to +30°C, 3.3 ml (53.2 mmol; 2 eq.) of methyl iodide is added, and it is heated for 2.5 hours to 80°C - 100°C. The reaction solution is mixed with 500 ml ethyl acetate and 300 ml H₂O, and the aqueous layer is separated off and extracted one time with ethyl acetate. The combined ethyl acetate phases are washed with water and saline solution, dried, and concentrated. The crude product is dissolved in 20 ml of toluene and chromatographed over 200 ml of silica gel 60 using toluene as the eluant.

15


Yield: 10 g (96.4% of theory)

R_f = 0.28 (toluene)

Example III

20

Ethyl 4-(4-fluorophenyl)-6-isopropyl-2-methoxy-3-hydroxymethyl-pyridine-5-carboxylate



0

500 mg (1.284 mmol) of the compound from Example II in 40 g of toluene p.a. is mixed under argon at -78°C with 3.21 ml (3.852 mmol) of diisobutylaluminum hydride (DIBAL-H, 1.2 molar in toluene). The mixture is stirred 30 min at -78°C , and the batch is allowed to stand overnight at -30°C in the refrigerator. It is further cooled to -70°C , 20% potassium sodium tartrate solution is added, and the mixture is extracted with ethyl acetate. The organic layer is dried with Na_2SO_4 and concentrated.


Yield: 287 mg (64.5% of theory)

$R_f = 0.41$ (toluene / ethyl acetate 9:1)

10

Example IV

Ethyl 4-(4-fluorophenyl)-6-isopropyl-2-methoxy-3-formyl-pyridine-5-carboxylate



15

21.3 g (0.0988 mol, 3.8 eq.) of pyridinium chlorochromate (PCC) is added to a solution of 9.07 g (0.026 mol) of the compound from Example III in 400 ml CH_2Cl_2 in the presence of neutral Al_2O_3 (10.07 g = 0.0988 mol), and the mixture is stirred for 1 h at room temperature. It is drawn off by suction over silica gel and subsequently washed with CH_2Cl_2 , then the filtrate is concentrated in a vacuum and chromatographed on silica gel 60 (500 ml) using toluene / ethyl acetate (8:2).

Yield: 8.88 g (98.4% of theory)


$R_f = 0.62$ (toluene / ethyl acetate 9:1)

25

30

0 **Example V**

Ethyl 4-(4-fluorophenyl)-6-isopropyl-2-methoxy-3-[2-(benzoxazol-2-yl)-1-hydroxy-ethyl]-pyridine-5-carboxylate



5


400 mg (3 mmol) of 2-methylbenzoxazole dissolved in 5 g THF p.a. is cooled under argon to -78°C. 1.83 ml (3 mmol) of n-butyllithium (1.6 molar in hexane) is added to this, and the mixture is stirred for 120 min at -78°C. 1.036 g (3 mmol) of the compound from Example IV is then added by drops at -78°C; the mixture is stirred for 10 min at -78°C and overnight until it reaches room temperature. After adding 50 ml of water, it is extracted by shaking with 100 ml of ethyl acetate. The aqueous phase is separated off, washed two times with saline solution, dried over Na₂SO₄, and concentrated. The residue is chromatographed on 60 ml of silica gel using toluene and toluene / ethyl acetate (8:2). The concentrated fractions are dried in a high vacuum.

Yield: 450 mg (31.4% of theory)

R_f = 0.22 (toluene / ethyl acetate 9:1)

20 **Example VI**

Ethyl 4-(4-fluorophenyl)-6-isopropyl-2-methoxy-3-[2-(benzoxazol-2-yl)-ethenyl]-pyridine-5-carboxylate




- 0 100 mg (0.209 mmol) of the compound from Example V is boiled in 10 g
toluene p.a. under argon in the presence of 25 mg (0.131 mmol) of p-
toluenesulfonic acid hydrate for 6 h under reflux, and afterwards the mixture is
stirred at room temperature overnight. The reaction solution is then applied to a
column filled with 40 ml of silica gel and consecutively eluted with toluene and
5 toluene / ethyl acetate (9.5:0.5). The desired fractions are concentrated and dried in
a high vacuum.

Yield: 91 mg (94.6% of theory)

R_f = 0.59 (toluene / ethyl acetate 9:1)

10 Example VII

Diethyl 1,4-dihydro-2,6-diisopropyl-4-(4-fluorophenyl)pyridine-3,5-dicarboxylate



15

- 528 g (2 mol) of (E/Z)-4-carboxymethyl-5-(4-fluorophenyl)-2-methyl-pent-4-
en-3-one and 350 g (2 mol) of 90% ethyl 3-amino-4-methyl-pent-2-enoate are stirred
in 1800 ml ethanediol overnight at a bath temperature of 200°C. The mixture is
cooled slowly and poured into a large glass beaker at approx. 80°C. After further
cooling to 0°C, the solution is drawn off by suction from the precipitated sediment,
20 then the sediment is washed well with ice cold ethanol and dried in a desiccator.
The ethanol solution is concentrated, and the residue together with the ethanediol
mother liquor is extracted four times with 1.5 l ether each time. The combined
ether phases are washed three times each with 500 ml of 10% hydrochloric acid and
25 once each with 500 ml of saturated sodium hydrogen carbonate solution and water,
dried over magnesium sulfate, filtered, and allowed to stand overnight at room
temperature. The solution is drawn off by suction from the precipitated sediment,
subsequently washed with ice cold ethanol, and dried in a desiccator. The ethanol
solution and the ether mother liquor are concentrated together in a vacuum to a

0 volume of approx. 2 l, allowed to stand overnight again, and drawn off by suction from the precipitated sediment.


Total yield: 556.9 g (69.1% of theory)

$^1\text{H-NMR}$ (CDCl_3): $\delta = 1.1 - 1.3$ (m, 18H); 4.05 - 4.25 (m, 6H); 5.0 (s, 1H); 6.13 (s, 1H); 6.88 (m, 2OH); 7.2 (m, 2H) ppm.

5

Example VIII

Diethyl 2,6-diisopropyl-4-(4-fluorophenyl)-pyridine-3,5-dicarboxylate



10

171.7 g (0.757 mol) of 2,3-dichloro-5,6-dicyano-p-benzoquinone is added to a solution of 304.8 g (0.757 mol) of the compound from Example VII in 2 l of dichloromethane, and the mixture is stirred overnight at room temperature. The mixture is drawn off by suction over diatomaceous earth and subsequently washed well with dichloromethane. After concentration of the dichloromethane phase to a volume of approx. 800 ml, it is chromatographed on a column (2 kg of silica gel 70-230 mesh) with dichloromethane.

15

Yield: 222 g (73.4% of theory)

20


$^1\text{H-NMR}$ (CDCl_3): $\delta = 0.98$ (t, 6H); 1.41 (d, 12H); 3.1 (m, 2H); 4.11 (q, 4H); 7.04 (m, 2H); 7.25 (m, 2H) ppm.

25

30

0 **Example IX**

Ethyl 2,6-diisopropyl-4-(4-fluorophenyl)-3-hydroxymethylpyridine-5-carboxylate



5

257 ml (0.9 mol) of a 3.5 molar solution of sodium-bis-(2-methoxyethoxy)dihydroaluminate is steadily added by drops under nitrogen to a solution of 120 g (0.3 mol) of the compound from Example VIII in 800 ml of dried tetrahydrofuran at room temperature, and the mixture is subsequently stirred for 5 h. After cooling to 0°C, 500 ml of water is carefully added by drops, the phases are separated, and the aqueous phase is extracted three times with 250 ml ethyl acetate each time. The combined organic phases are washed with saturated sodium chloride solution, dried over magnesium sulfate, and evaporated in a vacuum. The residue is mixed with petroleum ether, drawn off by suction, and dried in a desiccator.


15

Yield: 69.1 g (64.2% of theory)

¹H-NMR (CDCl₃): δ = 0.95 (t, 3H); 1.31 (m, 12H); 3.05 (m, 1H); 3.48 (m, 1H); 3.95 (q, 2H); 4.93 (d, 2H); 7.05 - 7.31 (m, 4H) ppm.

20 **Example X**

Ethyl 2,6-diisopropyl-4-(4-fluorophenyl)-3-formyl-pyridine-5-carboxylate




0 14.18 g (0.139 mol) of neutral Al_2O_3 and 29.96 g (0.13 mol) of pyridinium chlorochromate (PCC) are added to a solution of 25.0 g (0.0695 mol) of the compound from Example IX in 500 ml CH_2Cl_2 and the mixture is stirred for 1 h at room temperature. It is drawn off by suction over silica gel and subsequently washed with CH_2Cl_2 , and the filtrate is concentrated in a vacuum, whereby the
5 product precipitates out.

Yield: 20 g (80.48% of theory)

$^1\text{H-NMR}$ (DMSO-d_6): δ = 0.92 (t, 3H); 1.39 (dd, 6H); 3.02 - 3.13 (m, 1H); 3.75 - 3.86 (m, 1H); 3.95 - 4.05 (q, 2H); 7.32 (m, 4H); 9.8 (s, 1H) ppm.

10 Example XI

Ethyl 2,6-diisopropyl-4-(4-fluorophenyl)-3-[(4-fluorophenyl)hydroxymethyl]-pyridine-5-carboxylate



15


10.0 g (27.98 mmol) of aldehyde from Example X is cooled to -70°C in 100 g THF p.a. under argon, 33.6 ml (33.58 mmol, 1.2 eq.) of p-fluorophenyl magnesium bromide solution is added by drops at -70°C , and the mixture is then stirred for
20 another 2 h at -70°C . The reaction solution is mixed with 200 ml of conc. NH_4Cl solution, the cooling bath is removed, and the solution is adjusted with 1 molar HCl , $\text{pH} = 6$. After extraction with 400 ml of CH_2Cl_2 and drying over Na_2SO_4 , the organic phase is concentrated in a vacuum and the rigid foam is crystallized using n-heptane.

25 Yield: 8.97 g (70.7% of theory)
 R_f = 0.18 (toluene)

30

0 Example XII

Ethyl 2,6-diisopropyl-4-(4-fluorophenyl)-3-[(4-fluorophenyl)-chloromethyl]-pyridine-5-carboxylate



5

907 mg (2 mmol) of the compound from Example XI is dissolved in 20 g of CH_2Cl_2 p.a. and cooled under argon at -40°C , and 0.44 ml (6 mmol) SOCl_2 are added. The solution is stirred for 1.5 h from -40°C to -5°C and afterwards agitated in 50 ml of ethyl acetate / 40 ml of NaHCO_3 solution. The organic phase is separated off, dried over Na_2SO_4 , concentrated in a vacuum, and chromatographed on diatomaceous earth using toluene.

10

Yield: 899 mg (95% of theory)


$R_f = 0.79$ (toluene)

15

Example XIII

3-Ethyl 5-methyl 3,4-dihydro-4-(4-fluorophenyl)-6-p-fluorophenyl-(1H)-pyrid-2-one-3,5-dicarboxylate

20



0

30.69 g (115.3 mmol) of ethyl 1-carboethoxy-2-(4-fluorophenyl)-propenate, 22.5 g (115.3 mmol) of methyl 3-amino-3-(4-fluorophenyl)-acrylate, 115 mg of sodium methylate, and 0.6 ml of ethanol are stirred for 48 h at a bath temperature of 140°C. The reaction mixture is absorbed in ethyl acetate, washed three times with water, dried over Na₂SO₄, and concentrated in a vacuum.

5


Yield: 43.2 g (90.2% of theory)

R_f = 0.26 (toluene / ethyl acetate 9:1)

Example XIV

10

3-Ethyl 5-methyl 4-(4-fluorophenyl)-6-p-fluorophenyl-(1H)-pyrid-2-one-3,5-dicarboxylate



15

Analogously to Example I, 1.00 g (0.2407 mol) of the compound from Example XIII is stirred with 277 g (0.506 mol) of ceric(IV) ammonium nitrate in 600 ml of acetonitrile and 600 ml of water for 3 h at room temperature. After extraction with ethyl acetate, the residue is crystallized from isopropanol.

Yield: 28.59 g (28.7% of theory)


20

R_f = 0.16 (toluene / ethyl acetate 8:2)

25

0 **Example XV**

3-Ethyl 5-methyl 4-(4-fluorophenyl)-6-(4-fluorophenyl)-2-cyclopentoxo-3,5-dicarboxylate



5


Following the instructions in Example II, 5.0 g (0.0121 mol) of the mixture from Example XIV in 20 ml of DMF is reacted in the presence of 0.783 g (0.0196 mol) of 60% NaH with 3.61 g (0.0242 mol) of cyclopentyl bromide. After chromatography on silica gel using toluene, 5.14 g (88.3% of theory) is obtained.

10

$R_f = 0.34$ (toluene)

Example XVI

15 Methyl 4-(4-fluorophenyl)-6-(4-fluorophenyl)-2-cyclopentoxo-3-hydroxymethylpyridine-5-carboxylate



20 Analogously to Example III, 3.719 g (7.72 mmol) of the compound from Example XV in 150 g of toluene is stirred with 11.58 ml (11.58 mmol) of DIBAL-H


- 0 (1.0 molar) for 2.5 h at -78°C. The compound is chromatographed on silica gel first with toluene and then with toluene / ethyl acetate (9:1).

Yield: 1.648 g (48.5% of theory)

R_f = 0.45 (toluene / ethyl acetate 9:1)

5 Example XVII

Methyl 4-(4-fluorophenyl)-6-(4-fluorophenyl)-2-cyclopentoxymethyl-3-formyl-pyridine-5-carboxylate



10

Following the instructions in Example IV, 1.636 g (3.72 mmol) of the compound from Example XVI in 150 ml of CH₂Cl₂ is stirred with 0.759 g (7.44 mmol) of Al₂O₃ (neutral) and 1.604 g (7.44 mmol) of PCC for 1.5 h. The crude product is purified by chromatography on silica gel using toluene.

15


Yield: 1.484 g (91.2% of theory)

R_f = 0.59 (toluene / ethyl acetate 9:1)

Example XVIII

20

Methyl 4-(4-fluorophenyl)-6-(4-fluorophenyl)-2-cyclopentoxymethyl-3-[(naphthyl-2)-hydroxy-methyl]-pyridine-5-carboxylate



0


53.4 mg (2.2 mmol) of magnesium shavings is heated to reflux in 10 ml of THF p.a. under argon. 313 mg (1.51 mmol) of 2-bromonaphthalene dissolved in 15 ml of THF is added to this and the solution is boiled 75 min to reflux in the presence of iodine crystals (= Grignard reagent). 220 mg (0.503 mmol) of the compound from Example XVII is dissolved in 5 ml of THF p.a. and cooled under argon to -70°C, and the Grignard reagent is sprayed in. The batch is subsequently stirred for one hour without cooling. The reaction solution is distributed in ethyl acetate / ammonium chloride solution, and the organic phase is separated off, washed with NaCl solution, dried, and concentrated. Chromatography is then carried out on silica gel using toluene.

Yield: 261 mg (91.9% of theory)

R_f = 0.57 (toluene / ethyl acetate 9:1)

15 Example XIX

Methyl 4-(4-fluorophenyl)-6-(4-fluorophenyl)-2-cyclopentoxymethyl-3-[(naphthyl-2)-fluoromethyl]pyridine-5-carboxylate



20

0

0.08 mmol (0.602 mmol) of diethylamino sulfur trifluoride (DAST) is added to a solution of 227 mg (0.401 mmol) of the compound from Example XVIII in 10 g of CH_2Cl_2 at -40°C under argon, the cooling bath is removed, and the solution is stirred for 20 min. The reaction solution is subsequently distributed in ethyl acetate / NaHCO_3 solution, and the organic layer is dried with Na_2SO_4 and concentrated in a vacuum. The crude product is chromatographed on silica gel using toluene.

5

Yield: 224 mg (98.6% of theory)


$R_f = 0.67$ (toluene)

10

Production Examples

Example 1

15 2,6-Diisopropyl-3-p-fluorobenzyl-4-p-fluorophenyl-5-hydroxymethyl-pyridine



5.7 g (150 mmol) of LiAlH_4 are suspended in 200 ml of THF, heated to 80°C , and mixed by drops with a solution of 23.7 g of the compound from Example XII in 150 ml of THF. After being stirred for 5 h, the mixture is cooled, carefully neutralized with 20% Na-K-tartrate solution, and extracted three times with ethyl acetate, and the organic phase is dried, concentrated, and chromatographed over silica gel 60 (toluene).

25


Yield: 13.6 g (69% of theory)

$R_f = 0.59$ (toluene / ethyl acetate = 9/1)

30

0 The compounds listed in Table 1(A) are produced in analogy to the instructions in Example I:

Table 1(A):



5


Ex. No.	G	R _f	Solvent
2		0.60	toluene / ethyl acetate 9:1
3		0.74	toluene / ethyl acetate 9:1
4		0.75	toluene / ethyl acetate 9:1

10

15

0 Example 5

4-(4-fluorophenyl)-6-(4-fluorophenyl)-2-cyclopentoxy-3-[(naphthyl-2)-fluoromethyl]-5-hydroxymethyl-pyridine




Analogously to the instructions of Example 1, 182 mg (0.321 mmol) of the compound from Example XIX in 10 ml of THF p.a. is boiled with 18.3 mg (0.481 mmol) of LiAlH_4 for 1 h under reflux. The compound is purified by chromatography on silica gel first with toluene and then with toluene / ethyl acetate (9:1).

Yield: 86 mg (49.7% of theory)
R_f = 0.47

0 The compounds listed in Table 2(B) are produced in analogy to the instructions of Example 5:

Table 2(B):



5


Ex. No.	E	R ²²	Z ¹ /Z ²	L	R _f (solvent)
6	cyclo-C ₆ H ₁₁	H	p-F / H	CH(CH ₃) ₂	0.59 toluene / ethyl acetate 9:1
7	CH(CH ₃) ₂	NH ₂	p-F / H	CH(CH ₃) ₂	0.60 toluene / ethyl acetate 1:1
8	CH(CH ₃) ₂	SH	p-F / H	CH(CH ₃) ₂	0.31 toluene / ethyl acetate 9:1
9	CH(CH ₃) ₂	Cl	p-CF ₃ / H	CH(CH ₃) ₂	0.54 toluene / ethyl acetate 9:1
10	CH(CH ₃) ₂	H	3,4-F ₂	CH(CH ₃) ₂	0.26 toluene
11	4-F-C ₆ H ₄	F	p-CF ₃ / H	-OCH ₃	0.48 toluene / ethyl acetate 9:1

0 Table 2(B), contd.

Ex. No.	E	R ²²	Z ¹ /Z ²	L	R _f (solvent)
12	CH(CH ₃) ₂	F	p-F / H	CH(CH ₃) ₂	0.21 toluene
13	4-F-C ₆ H ₄	F	p-CF ₃ / H	(cyclo-C ₇ H ₁₃)O	0.28 petroleum ether / ethyl acetate 5:1

Example 14

- 5 2-Isopropyl-6-methoxy-4-(4-fluorophenyl)-5-[2-(benzoxazol-2-yl)ethyl]-3-hydroxymethylpyridine



- 10 69 mg (0.15 mmol) of the compound from Example VI is dissolved in 5 g of toluene and mixed with 0.6 ml DIBAL-H (1.0 molar in toluene). The mixture is then stirred without a cooling bath for 4 h to +15°C. 30 ml of ethyl acetate and 15 ml of a 20% potassium sodium tartrate solution is added, and the solution is stirred for 10 min. The aqueous layer is separated off, and the organic phase is dried, concentrated, and chromatographed. After chromatography on 20 ml of silica gel using toluene / ethyl acetate (9:1), 19 mg (30.2% of theory) is obtained.
- 15 R_f = 0.28 (toluene / ethyl acetate 9:1)

0 **Detailed description with reference to compounds of general formula (IB)**

The compounds according to the invention can also occur in the form of the salts thereof. In general, salts with organic or inorganic bases or acids are mentioned here.

5

Within the context of the present invention, physiologically safe salts are preferred. Physiologically safe salts from the compounds according to the invention can be salts of substances according to the invention with mineral acids, carboxylic acids, or sulfonic acids. Salts with, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalene disulfonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid, or benzoic acid are particularly preferred.

15 Physiologically safe salts can also be metallic or ammonium salts of the compounds according to the invention that possess a free carboxyl group. For example, sodium salts, potassium salts, magnesium salts, or calcium salts, as well as ammonium salts, that are derived from ammonia, or organic amines such as ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine, ethylenediamine, or 2-phenylethylamine
20 are particularly preferred.

The compounds according to the invention can exist in stereoisomeric forms, which either behave like an image and mirror image (enantiomers) or do not
25 behave like an image and mirror image (diastereomers). The invention concerns both enantiomers or diastereomers or the mixtures thereof. These mixtures of enantiomers and diastereomers can be separated in the known manner into stereoisomerically homogeneous components.

30 Within the context of the invention, the heterocyclic compound, which is optionally benzo-condensed, stands in general for a saturated or unsaturated, 5- to 7-member, and preferably 5- to 6-member, heterocyclic compound that can contain up to 3 heteroatoms from the series S, N, and/or O. Tetrazolyl, isoquinolyl, quinolyl, benzo[b]thiophene, benzo[b]furanyl, pyridyl, pyrimidinyl, pyrazinyl, thienyl, furyl, pyriny, benzothiazolyl, phenoxathinyl, benzoxazolyl, tetrahydropyrimidyl, pyrazolopyrimidyl, pyrrolyl, thiazolyl, oxazolyl, and
35 imidazolyl are cited as examples. Quinolyl, furyl, pyridyl, tetrahydropyrimidyl,

0 indolyl, benzothiazolyl, benzoxazolyl, pyrinyl, and pyrazolopyrimidyl are preferred.

This also includes 5- to 7-member saturated heterocyclic compounds bound via N, which can also contain up to 2 oxygen, sulfur, and/or nitrogen atoms as
5 heteroatoms, such as piperidyl, morpholinyl, or piperazine or pyrrolidinyl. Piperidyl and pyrrolidinyl are particularly preferred.

Compounds of general formula (IB) are preferred, in which

10

A stands for naphthyl or phenyl, which are optionally substituted up to 3 times in an identical manner or differently by fluorine, chlorine, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl, acyl, or alkoxy with up to 6 carbon atoms each, or by a group of the formula
15 -NR²R³ and/or by a group of the formula -W-R⁴,

wherein

R² and R³ are identical or different and
20 denote hydrogen, phenyl, or straight-chain or branched alkyl with up to 4 carbon atoms,

W denotes an oxygen or sulfur atom,

25 R⁴ denotes phenyl or benzyl, which are optionally substituted up to 3 times in an identical manner or differently by fluorine, chlorine, trifluoromethyl, trifluoromethoxy, hydroxy, or by straight-chain or branched alkyl or alkoxy with up to 5 carbon atoms each,

30 D and E are identical or different and stand for a straight-chain or branched alkyl chain with up to 6 carbon atoms,

or

35 E stands for a bond,

V stands for an oxygen or sulfur atom or for a group of the formula -NR⁵,

0

wherein

R⁵ denotes hydrogen or straight-chain or branched alkyl with up to 4 carbon atoms or phenyl,

5

R¹ stands for cyclopropyl, cyclopentyl, or cyclohexyl, or tetrahydropyrimidyl stands for phenyl, naphthyl, pyridyl, tetrazolyl, pyrimidinyl, pyrazinyl, pyrrolidinyl, tetrahydropyrimidinyl, indolyl, morpholinyl, imidazolyl, benzothiazolyl, phenoxathiin-2-yl, benzoxazolyl, furyl, quinolyl, pyrazolopyrimidyl, or purine-yl,

10

with the rings, also via the N function in the case of nitrogen-containing rings, being optionally substituted up to 3 times in an identical manner or differently by fluorine, chlorine, bromine, trifluoromethyl, hydroxy, cyano, carboxyl, trifluoromethoxy, straight-chain or branched acyl, alkyl, alkylthio, alkylalkoxy, alkoxy, or alkoxycarbonyl with up to 4 carbon atoms each, triazolyl, tetrazolyl, benzoxathiazolyl, or phenyl, and/or by a group of the formula -OR⁶, -SR⁷, or -SO₂R⁸,

15

wherein

20

R⁶, R⁷, and R⁸ are identical or different and denote phenyl, which in turn is substituted up to 2 times in an identical manner or differently by phenyl, fluorine, chlorine, or by straight-chain or branched alkyl with up to 4 carbon atoms,

25

L and T are identical or different and

stand for trifluoromethyl, pyrrolidinyl, or for straight-chain or branched alkyl with up to 7 carbon atoms, which is optionally substituted by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, naphthyl, or phenyl, which in turn can be substituted up to 2 times in an identical manner or differently by fluorine, chlorine, bromine, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl, acyl, or alkoxy with up to 6 carbon atoms each,

30

35 or

0 L and/or T stand for cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or
cycloheptyl, or
for naphthyl, phenyl, pyridyl, or furyl, which optionally can be substituted
up to 3 times in an identical manner or differently by fluorine, chlorine,
bromine, nitro, trifluoromethyl, trifluoromethoxy, or by straight-chain or
5 branched alkyl, acyl, or alkoxy with up to 6 carbon atoms each,

and the salts thereof.

10 Compounds of general formula (IB) are particularly preferred,

in which

15 A stands for phenyl, which is optionally substituted up to 2 times in an identical
manner or differently by fluorine, chlorine, hydroxy, trifluoromethyl,
trifluoromethoxy, or by straight-chain or branched alkyl, acyl, or alkoxy
with up to 4 carbon atoms each or by benzyloxy, which in turn can be
substituted by fluorine or chlorine.

20 D and E are identical or different and
stand for a straight-chain or branched alkyl chain with up to 3 carbon atoms,

or

25 E stands for a bond,

V stands for an oxygen or sulfur atom or for a group of the formula -NR⁵,

wherein

30 R⁵ denotes hydrogen or straight-chain or branched alkyl with up to 3
carbon atoms,

35 R¹ stands for cyclopropyl, cyclopentyl, or cyclohexyl, or tetrahydropyridinyl
stands for phenyl, naphthyl, pyridyl, tetrazolyl, pyrimidyl, pyrazinyl,
tetrahydropyrimidyl, phenoxathiin-2-yl, indolyl, imidazolyl, pyrrolidinyl,

0 morpholinyl, benzothiazolyl, benzoxazolyl, furyl, quinolyl,
pyrazolopyrimidyl, or purine-yl,
with the rings, also via the N-function in the case of nitrogen-containing
rings, optionally being substituted up to 3 times in an identical manner or
differently by fluorine, chlorine, trifluoromethyl, hydroxy, cyano, carboxyl,
5 trifluoromethoxy, straight-chain or branched alkyl, alkylthio, alkylalkoxy,
alkoxy, or alkoxycarbonyl with up to 3 carbon atoms each, triazolyl,
tetrazolyl, benzoxathiazolyl, or phenyl,
and/or substituted by a group of the formula -OR⁶, -SR⁷, or -SO₂R⁸,

10 wherein

R⁶, R⁷, and R⁸ are identical or different and
denote phenyl, which in turn is substituted up to 2 times in an
identical manner or differently by phenyl, fluorine, chlorine, or is
15 substituted by straight-chain or branched alkyl with up to 3 carbon
atoms,

L and T are identical or different and
stand for trifluoromethyl, pyrrolidinyl, or for straight-chain or branched
20 alkyl with up to 6 carbon atoms, which are optionally substituted by
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or phenyl,
which in turn may be substituted up to 2 times in an identical manner or
differently by fluorine, chlorine, trifluoromethyl, trifluoromethoxy, or by
straight-chain or branched alkyl or alkoxy with up to 4 carbon atoms each,

25
or

L and/or T stand for cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or
cycloheptyl, or stand for naphthyl, phenyl, or furyl, which are optionally
30 substituted up to 2 times in an identical manner or differently by fluorine,
chlorine, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched
alkyl or alkoxy with up to 3 carbon atoms each,


and the salts thereof.
35

0 The compounds according to the invention of general formula (IB) are particularly preferred, in which

5 A stands for phenyl, which is optionally substituted up to 2 times in an identical manner or differently by fluorine, chlorine, trifluoromethyl, methoxy, methyl, or by fluorine- or chlorine-substituted benzyloxy.

10 Moreover, a process for the production of compounds according to the invention of general formula (IB) has been discovered, characterized in that

[A] in the case of $V = O$
compounds of general formula (II)




15 in which

A, D, L, and T have the indicated meaning,

20 and

R^{11} stands for straight-chain or branched alkoxy carbonyl with up to 4 carbon atoms or for the group of the formula $-CH_2-O-Si(CH_3)_2C(CH_3)_3$,

25 are reacted with compounds of general formula (III)



in which

30 R^1 and E have the indicated meaning

and

0 Z stands for halogen, preferably chlorine or bromine,


in inert solvents, optionally in the presence of bases and/or auxiliary agents, and reductive separation is then carried out, depending on the meaning of the group R¹¹,

5

or

[B] compounds of general formula (II) are first converted by reactions with compounds of general formula (IV)


10



in which

15 R¹² stands for straight-chain alkyl with up to 4 carbon atoms,

into compounds of general formula (V)




20

in which

A, D, L, T, R¹¹, and R¹² have the indicated meaning,

and these are then reacted with compounds of general formula (VI)

25



in which


30 R¹, E, and V have the indicated meaning,

and reductive separation is carried out,


0

and optionally, the groups listed under substituents A, L, T, and R¹ are introduced or varied according to customary methods.


5 The processes according to the invention can be explained, for example, by means of the following reaction diagrams:



[B]



[C]



0

Suitable solvents for this process are inert organic solvents which do not change under the reaction conditions. These include ethers such as diethyl ether or tetrahydrofuran, halocarbons such as dichloromethane, trichloromethane, tetrachloromethane, 1,2-dichloroethane, trichloroethane, tetrachloroethane, 1,2-dichloroethane, or trichloroethylene, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane, or petroleum fractions, nitromethane, dimethylformamide, acetone, acetonitrile, or hexamethylphosphoric triamide. It is

0 also possible to use mixtures of the solvents. Dichloromethane, tetrahydrofuran, toluene, or dimethylformamide are particularly preferred.

In general, as auxiliary agents for the process according to the invention, inorganic or organic bases may be used. These preferably include alkali hydroxides
5 such as sodium hydroxide or potassium hydroxide, alkaline earth hydroxides such as barium hydroxide, alkali carbonates such as sodium carbonate or potassium carbonate, alkaline earth carbonates such as calcium carbonate, or alkali or alkaline earth alcoholates such as sodium or potassium ethanolate, sodium or potassium methanolate, or potassium tert-butylate, or organic amines (trialkyl(C₁-C₆)amines)
10 such as triethylamine, or heterocyclic compounds such as 1,4-diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), pyridine, diaminopyridine, methylpiperidine, or morpholine. It is also possible to use alkali metals such as sodium and hydrides thereof such as sodium hydride as bases. Sodium and potassium carbonate and triethylamine are preferred.

15 As bases, the usual strongly basic compounds can be used for the individual steps. These preferably include lithium organic compounds such as n-butyl lithium, sec-butyl lithium, tert-butyl lithium, or phenyl lithium, or amides such as lithium diisopropylamide, sodium amide or potassium amide, or lithiumhexamethylsilyl
20 amide, or alkali hydrides such as sodium hydride or potassium hydride. N-butyl lithium or sodium hydride should preferably be used.

The bases are used in a mixture of 1 mole to 5 moles, and preferably 1 mole to 3 moles, relative to 1 mole of the compound of general formula (II).
25

In general, the reaction is carried out in a temperature range of 0°C to 150°C, and preferably from +20°C to +110°C.

The reaction can be carried out at normal, increased, or reduced pressure
30 (for example, 0.5 to 5 bar). In general, the reaction is carried out at normal pressure.

As derivatizations, the following types of reactions are cited as examples: oxidations, reductive separation, reductions, hydrogenations, halogenation,
35 Wittig/Grignard reactions, and amidation/sulfoamidation.

0 Suitable solvents are ethers such as diethyl ether, dioxane, tetrahydrofuran,
or glycol dimethyl ether, or hydrocarbons such as benzene, toluene, xylene,
hexane, or cyclohexane, or petroleum fractions, or halocarbons such as
dichloromethane, trichloromethane, tetrachloromethane, dichloroethylene, or
trichloroethylene, or chlorobenzene, or ethyl acetate, or triethylamine, pyridine,
5 dimethyl sulfoxide, dimethyl formamide, hexamethylphosphoric triamide,
acetonitrile, acetone, or nitromethane. It is also possible to use mixtures of said
solvents. Dichloromethane is preferred.

 Suitable organometallic reagents are Grignard systems such as
10 Mg/bromobenzotrifluoride and p-trifluoromethylphenyl lithium. The
Mg/bromobenzotrifluoride system is preferred.

 The reductions and derivatizations are carried out according to the
above-mentioned methods.

15 In general, the reductions are carried out in ethers such as dioxane,
tetrahydrofuran, or diethyl ether, or in hydrocarbons such as benzene, hexane, or
toluene. Toluene and tetrahydrofuran are preferred.

20 Suitable reductants are complex metal hydrides such as lithium aluminum
hydride, sodium cyanoborohydride, sodium aluminum hydride, diisobutyl
aluminum hydride, dimethoxymethyl aluminate sodium salt, or
sodium-bis(2-methoxyethoxy) dihydroaluminate (Red-Al). Diisobutyl aluminum
hydride and dimethoxymethylaluminate sodium salt are preferred.

25 The reductant is generally added in the amount of 4 moles to 10 moles, and
preferably from 4 moles to 5 moles, relative to 1 mole of the compound to be
reduced.

30 The reduction generally takes place within a temperature range of -78°C to
+50°C, preferably from -78°C to 0°C, and particularly preferably at -78°C,
depending on the choice of both the reductant and the solvent.

 The reduction generally takes place at normal pressure, but it is also possible
35 to work at increased or reduced pressure.

0 However, the reductions can also be carried out with reductants that are
suitable for the reduction of ketones to hydroxy compounds. Particularly suitable
in this regard is reduction using metal hydrides or complex metal hydrides in inert
solvents, if appropriate, in the presence of a trialkyl borane. Preferably, the
reduction is carried out using complex metal hydrides such as lithium borohydride,
5 sodium borohydride, potassium borohydride, zinc borohydride, lithium
trialkylborohydride, or lithium aluminum hydride. More preferably, the reaction is
carried out using sodium borohydride in the presence of triethyl borane.

10 The hydrogenation takes place according to the customary methods using
hydrogen in the presence of noble metal catalysts such as Pd/C, Pt/C, or Raney
nickel in one of the above-mentioned solvents, preferably in alcohols such as
methanol, ethanol, or propanol, within a temperature range of -20°C to +100°C,
preferably from 0°C to 50°C, at normal pressure or elevated pressure.

15 As derivatizations, the following types of reactions are cited by way of
examples: oxidations, reductions, hydrogenations, halogenation, Wittig/Grignard
reactions, and amidation/sulfoamidation.

20 The customary strongly basic compounds can be used as bases for the
individual steps. These preferably include organolithium compounds such as
n-butyl lithium, sec-butyl lithium, tert-butyl lithium, or phenyl lithium, or amides
such as lithium diisopropylamide, sodium amide, or potassium amide, or lithium
hexamethylsilyl amide, or alkali hydrides such as sodium hydride or potassium
hydride. n-butyl lithium or sodium hydride are particularly preferred.

25 Furthermore, the customary inorganic bases are suitable bases. These
preferably include alkali hydroxides or alkaline earth hydroxides such as sodium
hydroxide, potassium hydroxide, or barium hydroxide, or alkali carbonates such as
sodium carbonate, potassium carbonate, or sodium hydrogencarbonate. Sodium
30 hydroxide or potassium hydroxide are particularly preferred.

 Alcohols such as methanol, ethanol, propanol, or tert-butanol are also
suitable solvents for the individual reaction steps. Tert butanol is preferred.

35 It may possibly be necessary to carry out several reaction steps under a
protective gas atmosphere.

0 The halogenations generally take place in one of the above-mentioned chlorinated hydrocarbons, with methylene chloride being preferred.

Diethylamino sulfur trifluoride (DAST) or SOCl_2 , for example, are suitable halogenation agents.

5

The halogenation generally takes place within a temperature range of -78°C to $+50^\circ\text{C}$, preferably from -78°C to 0°C , and particularly preferably at -78°C , depending on the choice of both the halogenation agent and the solvent.

10 The halogenation generally takes place at normal pressure, but it is also possible to work at increased or reduced pressure.

The customary reagents are suitable as Wittig reagents. 3-Trifluoromethylbenzyltriphenylphosphonium bromide is preferred.

15


In general, one of the above-mentioned bases is suitable as a base, preferably Li-bis-(triethylbutyl)amide.

20 The base is used in an amount of 0.1 moles to 5 moles, preferably 0.5 moles to 2 moles, in relation to 1 mole of the parent compound.

The reaction with Wittig reagents is generally carried out in a temperature range of 0°C to 150°C , preferably at 25°C to 40°C .

25 The Wittig reactions are generally carried out at normal pressure. However, it is also possible to carry out the process at reduced or high pressure (e.g., within a range of 0.5 to 5 bar).

30 The compounds of general formula (II) are known in part or new and can then be produced from the corresponding dihydropyridines of general formula (VII)



0 in which

A, L, and T have the above-indicated meaning,

and

5

R¹³ and R¹⁴ are identical or different and denote straight-chain or branched alkyl with up to 4 carbon atoms,

10 through oxidation into the corresponding pyridines and finally depending on the substituents a reduction according to conventional methods can be carried out.

Suitable solvents for the oxidation are ethers such as diethyl ether, dioxane, tetrahydrofuran, or glycol dimethyl ether; or hydrocarbons such as benzene, 15 toluene, xylene, hexane, or cyclohexane, or petroleum fractions, or halocarbons such as dichloromethane, trichloromethane, tetrachloromethane, dichloroethylene, or trichloroethylene, or chlorobenzene, or ethyl acetate, or triethylamine, pyridine, dimethylsulfoxide, dimethylformamide, hexamethylphosphoric triamide, acetonitrile, acetone, or nitromethane. It is also possible to use a mixture of said 20 solvents. Dichloromethane is preferred.

Suitable oxidants are, for example, 2,3-dichloro-5,6-dicyanobenzoquinone, pyridinium chlorochromate (PCC), osmium tetroxide, and manganese dioxide. For 25 the above-mentioned step, 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) is preferred.

The oxidant is introduced in an amount of 1 mole to 10 moles, preferably 2 moles to 5 moles, relative to 1 mole of the compound of general formula (VII).

30 The oxidation generally takes place within a temperature range of -50°C to +100°C, preferably from 0°C to room temperature.

The oxidation generally takes place at normal pressure. However, it is also possible to carry out the oxidation at increased or reduced pressure.

35

The dihydropyridines of general formula (VII) are known per se or can be produced by customary methods.

0

The compounds of general formulas (III), (IV), and (VI) are known per se or can be produced by customary methods.

5

The compounds of general formula (V) are new or can be manufactured as described above.

10

The 3-heteroalkyl-aryl-substituted pyridines according to the invention possess valuable pharmacological properties that are superior to those of the state of the art; in particular, they are highly effective inhibitors of cholesterol ester transfer proteins (CETP) and stimulate reverse cholesterol transport. The active compounds according to the invention cause a reduction in LDL cholesterol levels in the blood, while at the same time increasing HDL cholesterol levels. They can therefore be used for the treatment of hyperlipoproteinemia or arteriosclerosis.

15

The invention additionally concerns the combination of compounds according to the invention with a glucosidase and/or amylase inhibitor for the treatment of familial hyperlipidemia, obesity (adiposis), and diabetes mellitus. Within the context of the invention, glucosidase and/or amylase inhibitors are, for example, acarbose, adiposine, voglibose, miglitol, emiglitate, MDL-25637, camiglibose (MDL-73945), tendamistate, AI-3688, testratin, pradimicin-Q, and salbostatin.

20

The combination of acarbose, miglitol, emiglitate, or voglibose and one of the above-mentioned compounds of general formula (IB) according to the invention is preferred.

CETP Inhibition Test

1. Obtaining CETP

30

35

CETP was obtained in partially purified form from human plasma by differential centrifugation and column chromatography and was used for testing. In so doing, human plasma was adjusted with NaBr to a density of 1.21 g/ml and was centrifuged for 18 h at 50,000 rpm at 4°C. The bottom fraction ($d > 1.21$ g/ml) was applied to a Sephadex[®] Phenyl-Sepharose 4B (Pharmacia) column, washed with 0.15 M NaCl/0.001 M Tris HCl, pH 7.4, and then eluted with dist. water. The CETP-active fractions were pooled, dialyzed against 50 mM Na acetate, pH 4.5, and applied to a CM-Sepharose[®]

0 (Pharmacia) column. They were then eluted with a linear gradient (0-1 M NaCl). The pooled CETP fractions were dialyzed against 10 mM Tris HCl, pH 7.4, and were then further purified by chromatography over a Mono Q[®] column (Pharmacia).

5 2. Obtaining radioactively-labeled HDL

10 50 ml of fresh human EDTA plasma was adjusted with NaBr to a density of 1.12 and centrifuged at 4°C for 18 h at 50,000 rpm in the Ty 65 rotor. The upper phase was used to obtain cold LDL. The lower phase was dialyzed against 3 x 4 l PDB buffer (10 mM Tris/HCl, pH 7.4, 0.15 mM NaCl, 1 mM EDTA, 0.02% NaN₃). 20 µl of 3H cholesterol (Du Pont NET-725; 1 -µC/µl dissolved in ethanol) was subsequently added per 10 ml of dialysis residue volume and incubated for 72 h at 37°C under N₂.

15 The sediment was then adjusted with NaBr to a density of 1.21 and centrifuged in the Ty 65 rotor for 18 h at 50,000 rpm at 20°C. The upper phase was obtained, and the lipoprotein fractions were purified by gradient centrifugation. In so doing, the isolated, tagged lipoprotein fraction was adjusted with NaBr to a density of 1.26. Every 4 ml of this solution was covered in centrifuge tubes (SW 40 rotor) with 4 ml of a solution with a density of 1.21 and 4.5 ml of a solution with a density of 1.063 (density solutions from PDB buffer and NaBr) and then centrifuged for 24 h at 38,000 rpm and 20°C in the SW 40 rotor. The intermediate layer between the density of 1.063 and 1.21 that contained the labeled HDL was dialyzed against 3 x 100 volumes of PDB buffer at 4°C.

25 The dialysis residue contained radioactively-labeled ³H-CE-HDL, which was adjusted to approx. 5 x 10⁶ cpm per ml and used for the test.

3. Conducting the test

30 In order to test the CETP activity, the transfer of ³H cholesterol ester from human HD lipoproteins to biotinylated LD lipoproteins was measured.

The reaction was ended by adding Streptavidin-SPA[®] beads (Amersham), and the transferred radioactivity was determined directly in the liquid scintillation counter.

35 In the test batch, 10 µl of HDL-³H cholesterol ester (~50,000 cpm) was incubated for 18 h at 37°C with 10 µl of biotin-LDL (Amersham) in 50 mM HEPES / 0.15 m NaCl / 0.1% bovine serum albumin / 0.05% NaN₃, pH 7.4, with 10 µl of CETP (1 mg/ml) and 3 µl solution of the substance to be tested

0 (dissolved in 10% DMSO / 1% BSA). Then, 200 μ l of the SPA-Streptavidin bead solution (Amersham TRKQ 7005) was added, and the mixture was further incubated for 1 h under agitation and subsequently measured in the scintillation counter. Corresponding incubations with 10 μ l buffer, 10 μ l CETP at 4°C, and 10 μ l CETP at 37°C served as controls.

5 The transferred activity in the control batches with CETP at 37°C was assessed as 100% transfer. The substance concentration in which this transfer was reduced by half was indicated as the IC₅₀ value.

10 Syrian golden hamsters from the company's own breeding were anesthetized after fasting for 24 h (0.88 mg/kg atropine, 0.80 mg/kg Ketavet® s.c., 30' later 50 mg/kg Nembutal i.p.). The jugular vein was then exposed and cannulated. The test substance was dissolved in a suitable solvent (as a rule, Adalat placebo solution: 60 g glycerin, 100 ml H₂O, ad 100 ml PEG-400) and administered to the animals via a PE catheter inserted into the jugular vein. The control animals
15 received the same volume of solvent without any test substance. The vein was then ligated and the wound closed up. At different intervals--up to 24 h after administration of the test substance blood was drawn from the animals by puncture of the retroorbital venous plexus (approx. 250 μ l). Coagulation was completed by incubating at 4°C overnight, and the blood was then centrifuged for
20 10 minutes at 6,000 g. The cholesterol and triglyceride content in the serum obtained in this manner was determined using modified commercially-available enzyme tests (cholesterol enzymatic 14366 Merck, triglyceride 14364 Merck). The serum was diluted in a suitable manner with physiological saline solution. 100 μ l serum dilution was mixed with 100 μ l of test substance in 96-well plates and
25 incubated for 10 minutes at room temperature. The optical density was then determined with an automatic plate reader at a wavelength of 492 nm (SLT-Spectra). The triglyceride/cholesterol concentration contained in the samples was determined using a parallel-measured standard curve.

30 The determination of the HDL cholesterol content was carried out after precipitation of the lipoproteins containing Apo B by means of a reagent mixture (Sigma 352-4 HDL cholesterol reagent) according to the manufacturer's instructions.

35 In attempting to determine oral efficacy, the test substance, which was dissolved in DMSO and suspended in 0.5% methylcellulose, was administered orally to Syrian golden hamsters from the company's own breeding via a pharyngeal

0 tube. The control animals received identical volumes of solvent without any test substance. Feed was then withheld from the animals, and blood was drawn at different intervals--up to 24 h after administration of the substance--via puncture of the retroorbital venous plexus. Further processing was carried out as described above.

5

The new active compounds can be converted in a known manner into the customary formulations, such as tablets, coated tablets, pills, granules, aerosols, syrups, emulsions, suspensions, and solutions, using inert, nontoxic, pharmaceutically-suitable excipients or solvents. In this connection, the
10 therapeutically-active compound should be present in each case in a concentration of about 0.5% to 90% by weight, i.e., in amounts that are sufficient to achieve the dosage range indicated.

The formulations are prepared, for example, by extending the active
15 compounds using solvents and/or excipients, if appropriate using emulsifiers and/or dispersants, with it being possible, for example, in the case of the use of water as a diluent, to use organic solvents, if appropriate, as auxiliary solvents.

Administration takes place in a customary manner, preferably orally or
20 parenterally, in particular, perlingually or intravenously.

In the case of parenteral use, solutions of the active compound can be employed using suitable liquid excipients.

25 In general, it has proved to be advantageous in intravenous administration to administer amounts of about 0.001 to 1 mg/kg, preferably about 0.01 to 0.5 mg/kg of body weight, to obtain effective results, and in oral administration, the dosage is about 0.01 to 20 mg/kg, preferably 0.1 to 10 mg/kg of body weight.

30 In spite of this, it may be necessary to deviate from the amounts mentioned, depending on the body weight or the type of administration route, individual response to the medication, the type of formulation thereof, and the time or interval at which administration takes place. Thus in some cases, it may be sufficient to manage with less than the minimum amount previously mentioned,
35 whereas in other cases, the upper limit mentioned must be exceeded. If larger amounts are administered, it may be advisable to divide these into several individual doses over the day.

0


I. Mobile solvents for thin-layer chromatography

	A ₁	=	PE 98 : EE 2	
	A ₂	=	PE 95 : EE 5	
5	A ₃	=	PE 9 : EE 1	
	A ₄	=	PE 85 : EE 15	
	A ₅	=	PE 8 : EE 2	
	A ₆	=	PE 75 : EE 25	
	A ₇	=	PE 7 : EE 3	
10	A ₈	=	PE 65 : EE 35	
	A ₉	=	PE 6 : EE 4	
	A ₁₀	=	PE 55 : EE 45	
	A ₁₁	=	PE 1 : EE 1	
	A ₁₂	=	Toluene/ethyl acetate	1/1
15	A ₁₃	=	Toluene/ethyl acetate	8/2
	A ₁₄	=	Acetonitrile/water	9/1

PE = petroleum ether; EE = ethyl acetate

20 Example I

1,4-Dihydro-2-cyclopentyl-6-ethyl-4-(4-fluorophenyl)pyridine-3,5-dicarboxylic acid-3-methylester-5-ethylester



25

6.2 g (50 mmol) of 4-fluorobenzaldehyde, 8.5 g (50 mmol) of 3-amino-cyclopentylprop-2-ene-carboxylic methylester, and 7.2 g (50 mmol) of 4-methylacetoacetic ethylester are heated for 18 hours to 130°C while stirring.
 30 After cooling to room temperature, chromatography is carried out over silica gel

- 0 (200 g of silica gel, 230-400 mesh; d 3.5 cm, mobile solvent ethyl acetate/petroleum ether 1 : 9).


Yield: 2.8 g (14% of theory)

R_f (ethyl acetate / petroleum ether 2 : 8) = 0.31

5

Example II

2-Cyclopentyl-6-ethyl-4-(4-fluorophenyl)pyridine-3,5-dicarboxylic acid-3-methylester- 5-ethylester



10

- 2.8 g (6.98 mmol) of 1,4-dihydro-2-cyclopentyl-6-ethyl-4-(4-fluorophenyl)pyridine-3,5-dicarboxylic acid-3-methylester-5-ethylester is dissolved in 100 ml of absol. methylene chloride, and after addition of 1.6 g (6.98 mmol) of 2,3-dichloro-5,6-dicyano- p-benzoquinone (DDQ), the mixture is stirred for 1 hour at room temperature. After this, it is drawn off by suction over diatomaceous earth and concentrated in a vacuum. The residue is chromatographed over silica gel (100 g of silica gel, 230-400 mesh, d 3.5 cm, mobile solvent ethyl acetate / petroleum ether 5:95).

20

Yield: 2.1 g (75.4% of theory)

R_f (ethyl acetate / petroleum ether 1:9) = 0.56

$^1\text{H-NMR}$ (CDCl_3): δ = 0.95 (t, 3H); 1.32 (t, 3H); 1.6 - 2.1 (m, 8H); 2.83 (q, 2H); 3.14 (m, 1H); 3.53 (s, 3H); 4.02 (q, 2H); 7.0-7.3 (m, 4H) ppm.

25



Example III and Example IV

2-Cyclopentyl-6-ethyl-4-(4-fluorophenyl)-3-hydroxymethylpyridine-5-carboxylic acid ethylester (Example III) and

- 2-Cyclopentyl-6-ethyl-4-(4-fluorophenyl)-5-hydroxymethylpyridine-3-carboxylic acid methylester (Example IV)

30

0



Under argon, 2.1 g (5.26 mmol) of 2-cyclopentyl-6-ethyl-4-(4-fluorophenyl)pyridine-3,5-dicarboxylic acid-3-methylester5-ethylester is dissolved in 50 ml of absol. toluene. 26.6 ml of diisobutyl aluminum hydride (1 M solution in toluene) is added dropwise to this solution at -60°C. After this, the mixture is stirred for 15 minutes at -60°C, and the reaction solution is then cooled at -30°C for 18 h. After heating to 0°C, 50 ml of water is added, and the resulting sediment is drawn off by suction and washed 4 times with 50 ml of ethyl acetate. The aqueous phase is washed with 100 ml of ethyl acetate, and the combined organic phases are shaken out with 150 ml of saturated sodium chloride solution, dried with sodium sulfate, and concentrated in a vacuum. The residue is chromatographed over silica gel (100 g of silica gel, 230-400 mesh, d 3.5 cm, mobile solvent ethyl acetate / petroleum ether 15:85).

Yield (Example III): 0.263 g (13.5% of theory)

R_f (ethyl acetate / petroleum ether 2:8) = 0.42

$^1\text{H-NMR}$ (CDCl_3): δ = 0.95 (t, 3H); 1.28 (t, 3H); 1.6-2.1 (m, 8H); 2.76 (q, 4H); 3.55 (m, 1H); 3.97 (q, 4H); 4.48 (d, 2H); 7.0-7.3 (m, 4H) ppm.


Yield (Example IV): 0.907 g (48.3% of theory)

R_f (ethyl acetate / petroleum ether 2:8) = 0.32

$^1\text{H-NMR}$ (CDCl_3): δ = 1.32 (t, 3H); 1.6-2.1 (m, 8H); 2.97 (t, 3H); 3.06 (m, 1H); 3.45 (s, 3H); 4.45 (d, 2H) ppm.

The compounds shown in Table I(B) are produced analogously to the instructions for Examples I-IV:

Table I(B)



Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ²⁰	T	L	R _f (solvent)
V	H	H	F	H	H	C ₂ H ₅	CH(CH ₃) ₂	CH(CH ₃) ₂	0.51 (A5)
VI	H	H	F	H	H	C ₂ H ₅	CH(CH ₃) ₂	CH ₃	0.28 (A5)
VII	H	H	F	H	H	CH ₃	CH ₃	CH ₃	0.33 (A7)
VIII	H	H	F	H	H	C ₂ H ₅	CH(CH ₃) ₂	cyclo-C ₃ H ₅	0.41 (A5)
IX	H	H	F	H	H	C ₂ H ₅	cyclo-C ₃ H ₅	cyclo-C ₃ H ₅	0.44 (A5)
X	H	H	H	H	H	C ₂ H ₅	CH(CH ₃) ₂	CH(CH ₃) ₂	0.41 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ²⁰	T	L	R _f (solvent)
XI	H	H	F	H	H	C ₂ H ₅	CH(CH ₃) ₂	cyclo-C ₄ H ₇	0.45 (A5)
XII	H	H	F	H	H	C ₂ H ₅	CH(CH ₃) ₂	cyclo-C ₅ H ₉	0.46 (A5)
XIII	H	H	F	H	H	CH ₃	cyclo-C ₅ H ₉	CH(CH ₃) ₂	0.41 (A5)
XIV	H	CH ₃	F	H	H	C ₂ H ₅	CH(CH ₃) ₂	CH(CH ₃) ₂	0.26 (A3)
XV	CH ₃	H	F	H	H	C ₂ H ₅	CH(CH ₃) ₂	CH(CH ₃) ₂	0.48 (A5)
XVI	H	H	F	H	H	C ₂ H ₅	CH(CH ₃) ₂	sec-C ₄ H ₉	0.58 (A5)
XVII	H	H	F	H	H	CH ₃	sec-C ₄ H ₉	CH(CH ₃) ₂	0.53 (A5)
XVIII	H	H	F	H	H	C ₂ H ₅	CH(CH ₃) ₂	CH(OCH ₃) ₂	0.45 (A5)
XIX	H	H	F	H	H	C ₂ H ₅	CH ₂ CH ₃	CH(CH ₃) ₂	0.49 (A5)
XX	H	H	F	H	H	C ₂ H ₅	CH(CH ₃) ₂	CH ₂ CH ₃	0.44 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ²⁰	T	L	R _f (solvent)
XXI	H	H	OH	H	H	C ₂ H ₅	CH(CH ₃) ₂	CH(CH ₃) ₂	0.21 (A7)
XXII	H	H	CH ₃	H	H	C ₂ H ₅	CH(CH ₃) ₂	CH(CH ₃) ₂	0.25 (A3)
XXIII	H	H	F	H	H	CH ₃	CH ₃	cyclo-C ₃ H ₅	0.43 (A7)
XXIV	H	H	F	H	H	CH ₃	cyclo-C ₃ H ₅	CH ₃	0.36 (A7)
XXV	H	H	F	H	H	C ₂ H ₅	thiophen-2-yl	CH(CH ₃) ₂	0.5 (A5)
XXVI	H	H	F	H	H	C ₂ H ₅	C ₆ H ₅	CH(CH ₃) ₂	0.42 (A5)
XXVII	H	H	F	H	H	C ₂ H ₅	CH(CH ₃) ₂	4-F-C ₆ H ₄	0.49 (A5)
XXVIII	H	H	F	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.34 (A5)
XXIX	H	H	F	H	H	C ₂ H ₅	furan-2-yl	CH(CH ₃) ₂	0.36 (A5)
XXX	H	H	F	H	H	C ₂ H ₅	CH(CH ₃) ₂	C ₆ H ₅ CH ₂ CHCH ₃	0.42 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ²⁰	T	L	R _f (solvent)
XXXI	H	H	F	H	H	C ₂ H ₅	CH(CH ₃) ₂	CH(C ₂ H ₅) ₂	0.47 (A5)
XXXII	H	H	F	H	H	C ₂ H ₅	CH(CH ₃) ₂	C ₆ H ₅ CHCH ₃	0.45 (A5)
XXXIII	H	H	H	H	H	C ₂ H ₅	CH(CH ₃) ₂	cyclo-C ₃ H ₅	0.37 (A5)
XXXIV	H	H	F	H	H	C ₂ H ₅	CH(CH ₃) ₂	n-C ₃ H ₇	0.24 (A3)
XXXV	H	H	F	H	H	C ₂ H ₅	CH(CH ₃) ₂	n-C ₄ H ₉	0.27 (A3)
XXXVI	H	H	F	H	H	C ₂ H ₅	CH(CH ₃) ₂	C ₆ H ₅ (CH ₂) ₂	0.4 (A5)
XXXVII	H	H	F	H	H	CH ₃	4-CH ₃ O-C ₆ H ₄	CH(CH ₃) ₂	0.52 (A7)
XXXVIII	H	H	F	H	H	C ₂ H ₅	2-F-C ₆ H ₄	CH(CH ₃) ₂	0.34 (A5)
XXXIX	H	H	F	H	H	C ₂ H ₅	pyrrolidin-1-yl	CH(CH ₃) ₂	0.35 (A5)
XL	H	H	F	H	H	C ₂ H ₅	piperidin-1-yl	CH(CH ₃) ₂	0.47 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ²⁰	T	L	R _f (solvent)
XLI	H	H	F	H	H	C ₂ H ₅	cyclo-C ₆ H ₁₁	CH(CH ₃) ₂	0.53 (A5)
XLII	H	H	F	H	H	C ₂ H ₅	pyridin-4-yl	CH(CH ₃) ₂	0.38 (A11)
XLIII	H	H	F	H	H	C ₂ H ₅	pyridin-3-yl	CH(CH ₃) ₂	0.44 (A11)
XLIV	H	H	F	H	H	C ₂ H ₅	3-CH ₃ O-C ₆ H ₄	CH(CH ₃) ₂	0.30 (A5)
XLV	H	H	F	H	H	C ₂ H ₅	4-NO ₂ -C ₆ H ₄	CH(CH ₃) ₂	0.38 (A5)
XLVI	H	H	F	H	H	C ₂ H ₅	CH(CH ₃) ₂	C ₆ F ₅	0.22 (A3)
XLVII	H	H	F	H	H	C ₂ H ₅	2-CH ₃ -C ₆ H ₄	CH(CH ₃) ₂	0.44 (A5)
XLVIII	H	H	F	H	H	C ₂ H ₅	4-Cl-C ₆ H ₄	CH(CH ₃) ₂	0.21 (A3)
XLIX	H	H	H	H	H	C ₂ H ₅	CH(CH ₃) ₂	4-F-C ₆ H ₄	0.37 (A3)
L	H	H	H	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.2 (A3)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ²⁰	T	L	R _f (solvent)
LI	C ₆ H ₅ CH ₂ O	H	H	H	H	C ₂ H ₅	CH(CH ₃) ₂	4-F-C ₆ H ₄	0.27 (A4)
LII	C ₆ H ₅ CH ₂ O	H	H	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.18 (A4)
LIII	2-F-C ₆ H ₄ CH ₂ O	H	H	H	H	C ₂ H ₅	CH(CH ₃) ₂	CH(CH ₃) ₂	0.23 (A3)
LIV	4-F-C ₆ H ₄ CH ₂ O	H	H	H	H	C ₂ H ₅	CH(CH ₃) ₂	CH(CH ₃) ₂	0.21 (A4)
LV	4-Cl-C ₆ H ₄ CH ₂ O	H	H	H	H	C ₂ H ₅	CH(CH ₃) ₂	CH(CH ₃) ₂	0.12 (A4)
LVI	H	2-F-C ₆ H ₄ CH ₂ O	H	H	H	C ₂ H ₅	CH(CH ₃) ₂	CH(CH ₃) ₂	0.17 (A3)
LVII	H	H	H	H	H	CH ₃	4-F-C ₆ H ₄	CH ₃	0.21 (A7)
LVIII	H	H	F	H	H	C ₂ H ₅	3-Cl-C ₆ H ₄	CH(CH ₃) ₂	0.4 (A5)
LIX	H	H	F	H	H	CH ₃	CH(CH ₃) ₂	4-F-C ₆ H ₄ CH ₂	0.19 (A3)
LX	H	H	F	H	H	CH ₃	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	0.28 (A4)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ²⁰	T	L	R _f (solvent)
LXI	H	H	F	H	H	CH ₃	CH(CH ₃) ₂	4-F-C ₆ H ₄ CH ₂	0.23 (A4)
LXII	H	H	OCH ₃	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.18 (A5)
LXIII	H	H	Cl	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.16 (A3)
LXIV	H	Cl	H	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.28 (A3)
LXV	H	H	F	H	H	CH ₃	4-F-C ₆ H ₄	CH(C ₂ H ₅) ₂	0.32 (A4)
LXVI	H	Cl	Cl	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.29 (A4)
LXVII	H	CF ₃	H	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.44 (A5)
LXVIII	H	CH ₃	H	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.34 (A5)
LXIX	H	H	CH ₃	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.31 (A5)
LXX	H	Cl	H	Cl	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.22 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ²⁰	T	L	R _f (solvent)
LXXI	F	H	H	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.22 (A5)
LXXII	H	OCH ₃	H	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.25 (A5)
LXXIII	OCH ₃	H	H	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.2 (A5)
LXXIV	Cl	Cl	H	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.14 (A4)
LXXV	H	CF ₃	Cl	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.21 (A4)
LXXVI	H	CF ₃	F	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.24 (A4)
LXXVII	H	Cl	CF ₃	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.23 (A3)
LXXVIII	H	H	F	H	H	CH ₃	4-F-C ₆ H ₄	cyclo-C ₅ H ₉	0.39 (A5)
LXXIX	H	H	F	H	H	CH ₃	4-F-C ₆ H ₄	cyclo-C ₃ H ₅	0.28 (A5)
LXXX	H	F	H	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.28 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ²⁰	T	L	R _f (solvent)
LXXXI	H	H	CF ₃	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.39 (A5)
LXXXII	H	H	F	H	H	CH ₃	4-F-C ₆ H ₄	4-F-C ₆ H ₄	0.3 (A5)
LXXXIII	H	H	F	H	H	CH ₃	<i>cyclo</i> -C ₃ H ₅	<i>cyclo</i> -C ₃ H ₅	0.3 (A5)
LXXXIV	Cl	Cl	H	H	H	CH ₃	4-F-C ₆ H ₄	4-F-C ₆ H ₄	0.36 (A7)
LXXXV	H	CF ₃	F	H	H	CH ₃	CH(CH ₃) ₂	CH(CH ₃) ₂	0.41 (A5)
LXXXVI	H	CF ₃	F	H	H	CH ₃	4-F-C ₆ H ₄	4-F-C ₆ H ₄	0.25 (A5)
LXXXVII	CH ₃	H	H	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.32 (A5)
LXXXVIII	Cl	H	H	H	H	CH ₃	CH(CH ₃) ₂	CH(CH ₃) ₂	0.21 (A5)
LXXXIX	Cl	H	H	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.13 (A5)
XC	Cl	H	H	H	H	CH ₃	4-F-C ₆ H ₄	4-F-C ₆ H ₄	0.35 (A7)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ²⁰	T	L	R _f (solvent)
XCI	Cl	H	Cl	H	H	CH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.23 (A5)
XCII	Cl	H	Cl	H	H	CH ₃	4-F-C ₆ H ₄	4-F-C ₆ H ₄	0.31 (A5)
XCIII	H	H	F	H	H	CH ₃	3-CF ₃ -C ₆ H ₄	CH(CH ₃) ₂	0.31 (A5)
XCIV	H	H	F	H	H	CH ₃	3-CH ₃ -C ₆ H ₄	CH(CH ₃) ₂	0.31 (A5)
XCV	H	H	F	H	H	CH ₃	4-CH ₃ -C ₆ H ₄	CH(CH ₃) ₂	0.27 (A5)
XCVI	H	H	F	H	H	CH ₃	2-Cl-C ₆ H ₄	CH(CH ₃) ₂	0.27 (A5)
XCVII	H	H	F	H	H	CH ₃	4-CH ₃ O-C ₆ H ₄	CH(CH ₃) ₂	0.22 (A5)
XCVIII	H	H	F	H	H	CH ₃	2-CH ₃ O-C ₆ H ₄	CH(CH ₃) ₂	0.43 (A7)
XCIX	H	H	F	H	H	CH ₃	3-CH ₃ O-C ₆ H ₄	CH(CH ₃) ₂	0.25 (A5)
C	H	H	F	H	H	C ₂ H ₅	cyclo-C ₆ H ₁₁	4-F-C ₆ H ₄	0.45 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ²⁰	T	L	R _f (solvent)
CI	H	H	F	H	H	CH ₃	4-F-C ₆ H ₄	cyclo-C ₆ H ₁₁	0.33 (A5)
CII	H	H	F	H	H	C ₂ H ₅	4-Cl-C ₆ H ₄	cyclo-C ₅ H ₉	0.22 (A4)
CIII	H	H	F	H	H	CH ₃	3-CF ₃ -C ₆ H ₄	cyclo-C ₅ H ₉	0.29 (A5)
CIV	H	H	F	H	H	CH ₃	4-F-C ₆ H ₄	cyclo-C ₄ H ₇	0.2 (A5)
CV	H	H	F	H	H	C ₂ H ₅	cyclo-C ₇ H ₁₃	4-F-C ₆ H ₄	0.4 (A5)
CVI	H	H	F	H	H	CH ₃	4-F-C ₆ H ₄	cyclo-C ₇ H ₁₃	0.3 (A5)
CVII	H	H	F	H	H	C ₂ H ₅	furan-2-yl	4-F-C ₆ H ₄	0.32 (A6)
CVIII	H	H	F	H	H	CH ₃	4-F-C ₆ H ₄	furan-2-yl	0.21 (A6)
CIX	H	H	F	H	H	CH ₃	4-F-C ₆ H ₄	(cyclo-C ₅ H ₉)CH ₂	0.11 (A4)
CX	H	H	F	H	H	C ₂ H ₅	(cyclo-C ₆ H ₁₁)CH ₂	4-F-C ₆ H ₄	0.31 (A5)


Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ²⁰	T	L	R _f (solvent)
CXI	H	H	F	H	H	CH ₃	4-F-C ₆ H ₄	(cyclo-C ₆ H ₁₁)CH ₂	0.21 (A5)
CXII	H	H	F	H	H	C ₂ H ₅	CF ₃	4-F-C ₆ H ₄	0.26 (A5)
CXIII	H	H	F	H	H	CH ₃	cyclo-C ₅ H ₉	4-CF ₃ -C ₆ H ₄	0.30 (A4)
CXIV	H	H	F	H	H	C ₂ H ₅	4-CF ₃ -C ₆ H ₄	cyclo-C ₅ H ₉	0.19 (A4)
CXV	H	H	F	H	H	C ₂ H ₅	1-naphthyl	cyclo-C ₅ H ₉	0.21 (A4)
CXVI	H	H	F	H	H	CH ₃	cyclo-C ₅ H ₉	3,5-(CF ₃) ₂ -C ₆ H ₃	0.25 (A3)
CXVII	H	H	F	H	H	C ₂ H ₅	2-naphthyl	cyclo-C ₅ H ₉	0.23 (A3)
CXVIII	H	H	F	H	H	CH ₃	3-CH ₃ -C ₆ H ₄	cyclo-C ₅ H ₉	0.32 (A5)
CXIX	H	H	F	H	H	CH ₃	2-CF ₃ -C ₆ H ₄	cyclo-C ₅ H ₉	0.2 (A5)
CXX	H	H	F	H	H	CH ₃	cyclo-C ₅ H ₉	2-CF ₃ -C ₆ H ₄	0.17 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ²⁰	T	L	R _f (solvent)
CXXI	H	H	F	H	H	C ₂ H ₅	4-F-C ₆ H ₄ CH ₂	cyclo-C ₅ H ₉	0.4 (A5)
CXXII	H	H	F	H	H	CH ₃	cyclo-C ₅ H ₉	4-F-C ₆ H ₄ CH ₂	0.32 (A5)
CXXIII	H	H	F	H	H	C ₂ H ₅	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	0.28 (A5)
CXXIV	H	H	F	H	H	CH ₃	cyclo-C ₅ H ₉	2,4-F ₂ -C ₆ H ₃	0.32 (A5)
CXXV	H	H	F	H	H	C ₂ H ₅	3,4-F ₂ -C ₆ H ₄ CH ₂	cyclo-C ₅ H ₉	0.23 (A4)
CXXVI	H	H	F	H	H	CH ₃	cyclo-C ₅ H ₉	cyclo-C ₅ H ₉	0.34 (A4)
CXXVII	H	H	F	H	H	C ₂ H ₅	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄ CH ₂	0.4 (A7)
CXXVIII	H	H	F	H	H	C ₂ H ₅	3-CF ₃ -C ₆ H ₄ (CH ₂) ₂	cyclo-C ₅ H ₉	0.36 (A5)
CXXIX	H	H	F	H	H	CH ₃	cyclo-C ₅ H ₉	3-CF ₃ -C ₆ H ₄ (CH ₂) ₂	0.34 (A5)
CXXX	H	H	F	H	H	C ₂ H ₅	3-CF ₃ -C ₆ H ₄ CH ₂	3-CF ₃ -C ₆ H ₄ (CH ₂) ₂	0.35 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ²⁰	T	L	R _f (solvent)
CXXXI	H	H	F	H	H	C ₂ H ₅	C ₂ H ₅	cyclo-C ₅ H ₉	0.41 (A5)
CXXXII	H	H	F	H	H	CH ₃	cyclo-C ₅ H ₉	C ₂ H ₅	0.32 (A5)
CXXXIII	H	H	F	H	H	C ₂ H ₅	C ₂ H ₅	C ₂ H ₅	0.22 (A7)
CXXXIV	H	H	F	H	H	C ₂ H ₅	3-CF ₃ -C ₆ H ₄ CH ₂	cyclo-C ₅ H ₉	
CXXXV	H	H	F	H	H	CH ₃	cyclo-C ₅ H ₉	4-F-C ₆ H ₄ CH ₂	
CXXXVI	H	H	F	H	H	C ₂ H ₅	(cyclo-C ₅ H ₉)(CH ₂) ₂	(cyclo-C ₅ H ₉)(CH ₂) ₂	
CXXXVII	H	H	F	H	H	C ₂ H ₅	(cyclo-C ₅ H ₉)(CH ₂) ₂	4-F-C ₆ H ₄	
CXXXVIII	H	H	F	H	H	CH ₃	4-F-C ₆ H ₄	(cyclo-C ₅ H ₉)(CH ₂) ₂	

0 Example CXXXIX

2-Cyclopentyl-6-ethyl-4-(4-fluorophenyl)-3-(3-trifluoromethylbenzyloxy-methyl)-pyridine-5-carboxylic acid ethylester



5

186 mg (0.5 mmol) of 2-cyclopentyl-6-ethyl-4-(4-fluorophenyl)-3-hydroxy-methylpyridine-5-carboxylic acid ethylester dissolved in 5 ml of absol. dimethyl formamide is added dropwise at 0°C while stirring to a suspension of 18 mg (0.5 mmol) of sodium hydride (80%) in 5 ml of dimethyl formamide and subsequently stirred for 30 minutes. After this, 143 mg (0.6 mmol) of trifluoromethylbenzylbromide dissolved in 3 ml of dimethyl formamide is added, and the mixture is stirred for 18 h at room temperature. After addition of 25 ml of water, the mixture is extracted twice with 50 ml of ethyl acetate each time, and the combined ethyl acetate phases are shaken out with 10 ml of saturated sodium chloride solution, dried with sodium sulfate, and concentrated in a vacuum. The residue is chromatographed over silica gel (100 g of silica gel, 230-400 mesh, diameter 3.5 cm, mobile solvent ethyl acetate / petroleum ether 1:9).


Yield: 0.246 g (93.1% of theory)
R_f value (ethyl acetate / petroleum ether 1:9) = 0.35
¹H-NMR (CDCl₃): δ = 0.95 (t, 3H); 1.32 (t, 3H); 1.6-2.1 (m, 8H); 2.78 (q, 4H); 3.44 (m, 1H); 3.95 (q, 4H); 4.28 (s, 2H); 4.42 (s, 2H); 7.0-7.6 (m, 8H) ppm.

25

30

0 Example CXL

2,6-Diisopropyl-4-(4-fluorophenyl)pyridine-3,5-dicarboxylic acid diethylester



5

3.8 g (16.4 mmol) of 2,3-dichloro-5,6-dicyano-p-benzoquinone is added to a solution of 6.6 g (16.4 mmol) of 1,4-dihydro-2,6-diisopropyl-4-(4-fluorophenyl)pyridine-3,5-dicarboxylic acid diethylester in 200 ml of analysis grade methylene chloride, and the mixture is then stirred for 1 h at room temperature. After this, it is drawn off by suction over diatomaceous earth, and the methylene chloride phase is extracted 3 times with 100 ml of water each time and dried on magnesium sulfate. After concentrating in a vacuum, the residue is chromatographed on a column (100 g of silica gel, 70-230 mesh, diameter 3.5 cm, with ethyl acetate / petroleum ether 1:9).


15

Yield: 5.8 g (87.9% of theory)

$^1\text{H-NMR}$ (CDCl_3): δ = 0.98 (t, 6H); 1.41 (d, 12H); 3.1 (m, 2H); 4.11 (q, 4H); 7.04 (m, 2H); 7.25 (m, 2H) ppm.

20 Example CXLI

2,6-Diisopropyl-4-(4-fluorophenyl)-5-hydroxymethyl-pyridine-3,5-carboxylic acid ethylester



0

Under nitrogen, 21 ml (80.5 mmol) of a 3.5 molar solution of sodium bis(2-methoxyethoxy)dihydroaluminate in toluene is added to a solution of 9.2 g (23 mmol) of the compound from Example CXL in 100 ml of dried tetrahydrofuran at -10°C to -5°C, and the mixture is stirred for 5 h at room temperature. After cooling to 0°C, 100 ml of water is carefully added dropwise, and extraction is carried out 3 times with 100 ml of ethyl acetate each time. The combined organic phases are washed with saturated sodium chloride solution, dried over magnesium sulfate, and evaporated in a vacuum. The residue is chromatographed on a column (200 g of silica gel, 70-230 mesh, diameter 4.5 cm, with ethyl acetate / petroleum ether 3:7).

10


Yield: 7.2 g (87.2% of theory)

¹H-NMR (CDCl₃): δ = 0.95 (t, 3H); 1.31 (m, 12H); 3.05 (m, 1H); 3.48 (m, 1H); 3.95 (q, 2H); 4.93 (d, 2H); 7.05-7.31 (m, 4H) ppm.

Example CXLII

15

5-(*tert*-Butyldimethylsilyloxymethyl)-2,6-diisopropyl-4-(4-fluorophenyl)-pyridine-3-carboxylic acid ethylester



20


2.1 g (13.8 mmol) of *tert*-Butyldimethylsilyl chloride, 1.8 g (27.5 mmol) of imidazole, and 0.05 g of 4-dimethyl-aminopyridine are added to a solution of 4.5 g (12.5 mmol) of the compound from Example CXLI in 50 ml of dimethyl formamide at room temperature. The mixture is stirred overnight at room temperature, 200 ml of water is added, and the mixture is adjusted to a pH of 3 with 1 N hydrochloric acid. The mixture is extracted 3 times with 100 ml of ether each time, and the combined organic phases are washed once with saturated sodium chloride solution, dried over magnesium sulfate, and concentrated in a vacuum. The residue is chromatographed on a column (150 g of silica gel, 70-230 mesh, diameter 4 cm, with ethyl acetate / petroleum ether 1:9).

30

Yield: 4.2 g (73.7% of theory)
R_f = 0.75 (A3)

Example CXLIII

3-(*tert*-Butyldimethylsilyloxymethyl)-2,6-diisopropyl-4-(4-fluorophenyl)-5-hydroxymethylpyridine




Under argon, 76.0 ml (0.266 mmol; 3.6 eq.) of a 3.5 molar solution of sodium bis(2methoxyethoxy)dihydroaluminate (Red-Al) in toluene is slowly added to a solution of 35.0 g (0.0738 mmol) of the compound from Example CXLII in 500 ml of analysis-grade THF at room temperature, and stirring is then carried out for 3 h. The reaction solution is mixed under ice cooling with 50 ml of a 20% potassium sodium tartrate solution and extracted with 200 ml of ethyl acetate. The organic phase is washed once with a saturated NaCl solution, dried over Na₂SO₄, and concentrated in a vacuum. The residue is chromatographed over silica gel 60 with toluene / ethyl acetate (8:2).

20 Yield: 30.2 g (94.7% of theory)
R_f = 0.71 (toluene / ethyl acetate 8:2)

Example CXLIV

25 3-(*tert*-Butyldimethylsilyloxymethyl)-2,6-diisopropyl-4-(4-fluorophenyl)-5-methylsulfonyloxymethylpyridine



0

16.94 g (39.24 mmol) of 3-(tert-butyl dimethylsilyloxymethyl)-2,6-diisopropyl-4-(4-fluorophenyl)-5-hydroxymethylpyridine is dissolved in 220 g of analysis grade CH_2Cl_2 , cooled to -60°C , and mixed dropwise with 11.0 ml (78.48 mmol; 2 eq.) of triethylamine and 6.1 ml (78.48 mmol; 2 eq.) of methanesulfonyl chloride under nitrogen while stirring. Stirring is carried out for 1 h at -60°C to -20°C and for 30 minutes at 0°C . After this, the reaction solution is washed with cold NaHCO_3 solution, dried over Na_2SO_4 , concentrated, dried for 60 min. in a high vacuum, and then stored at -20°C .

10


Yield: 19.8 g (99% of theory)

$R_f = 0.77$ (toluene / ethyl acetate 8:2)

Example CXLV

15

3-(tert-Butyl dimethylsilyloxymethyl)-2,6-diisopropyl-4-(4-fluorophenyl)-5-(1-methylimidazole-2-thiomethyl)pyridine



20

1.0 g (1.96 mmol) of 3-(tert-butyl dimethylsilyloxymethyl)-2,6-diisopropyl-4-(4-fluorophenyl)-5-methylsulfonyloxymethylpyridine is placed in 15 ml of analysis-grade DMF. 0.256 g (2.25 mmol; 1.15 eq.) of 2-mercapto-1-methylimidazole and 0.41 ml (2.35 mmol; 1.2 eq.) of N,N-diisopropylamine are added, and the


- 0 mixture is stirred overnight at 60°C. After this, 80 ml of ethyl acetate is added, and the mixture is then successively washed with saturated NaHCO₃ solution, 1 N H₂SO₄, and saturated NaCl solution. The organic phase is dried over Na₂SO₄, filtered, and concentrated.

Yield: 0.93 g (89.8% of theory)

- 5 R_f = 0.35 (toluene / ethyl acetate 8:2)

Example CXLVI

- 10 3-(*tert*-Butyldimethylsilyloxymethyl)-2,6-diisopropyl-4-(4-fluorophenyl)-5-(indolyl-5-aminomethyl)pyridine



- 15 2.0 g (3.92 mmol) of 3-(*tert*-butyldimethylsilyloxymethyl)-2,6-diisopropyl-4-(4-fluorophenyl)-5-methylsulfonyloxymethylpyridine is reacted in 20 ml of analysis grade DMF under nitrogen with 0.674 g (5.1 mmol; 1.3 eq.) of 5-aminoindole and 0.82 ml (4.71 mmol) of N,N-diisopropylethylamine analogously to the instructions of Example CXLII.


Yield: 2.05 g (95.8% of theory)

- 20 R_f = 0.75 (toluene / ethyl acetate 8:2)

Production Examples

- 25 Example 1

2-Cyclopentyl-6-ethyl-4-(4-fluorophenyl)-5-hydroxymethyl-3-(3-tri-fluoromethylbenzyloxymethyl)pyridine



0

A suspension of 30 mg (0.8 mmol) of lithium aluminum hydride in 10 ml of absol. tetrahydrofuran is heated under argon. After this, 212 mg (0.4 mmol) of 2-cyclopentyl-6-ethyl-4-(4-fluorophenyl)-3-(3-(trifluoromethyl)benzyloxymethyl)-
 5 pyridine-5-carboxylic acid ethylester dissolved in 10 ml of absolute tetrahydrofuran is added. Next, the mixture is refluxed for 1 h. After cooling to room temperature, 10 ml of a 10% potassium hydroxide solution is added. The resulting sediment is drawn off by suction and boiled off several times with 10 ml of diethyl ether. The combined mother liquors are dried with sodium sulfate, concentrated in a vacuum,
 10 and chromatographed over silica gel (mobile solvent ethyl acetate / petroleum ether 2:8).


Yield: 149 mg (76.5% of theory)

R_f value (ethyl acetate / petroleum ether 2:8) = 0.08

¹H-NMR (CDCl₃): δ = 1.32 (t, 3H); 1.6-2.1 (m, 8H); 2.95 (q, 4H); 3.41 (m, 1H);
 15 4.16 (s, 2H); 4.38 (s, 2H); 7.0-7.6 (m, 8H) ppm.

Example 2

2,6-Diisopropyl-4-(4-fluorophenyl)-5-(1-methylimidazole-2-thiomethyl)-3-
 20 hydroxymethylpyridine




- 0 10 ml of 3 N hydrochloric acid is added to 0.5 g (0.947 mmol) of the compound from Example CXLII dissolved in 10 ml of methanol, and the mixture is stirred for 3 h at room temperature. The mixture is concentrated in a vacuum, covered with a layer of ethyl acetate, and adjusted to a pH of 8.0 with a saturated NaHCO₃ solution, and the organic phase is separated off. The aqueous phase is
- 5 again extracted with ethyl acetate, and the combined organic phases are washed with salt water, dried over Na₂SO₄, and concentrated.

Yield: 230 mg (58.7% of theory)

R_f = 0.76 (toluene / ethyl acetate 1:1)








0 The compounds listed in Tables 1(B) through 5(B) are produced analogously to the procedures of Examples 1 and 2:

Table 1(B):



5

Example No.	R ¹	R _f (solvents)
3		0.56 (A12)
4		0.42 (A13)
5		0.12 (A13)
6		0.62 (A13)
7		0.42 (A14)


Example No.	R ¹	R _f (solvents)
8		0.54 (A13)
9		0.59 (A13)
10		0.23 (A12)
11		0.54 (A12)
12		0.5 (A12)
13		0.68 (A13)
14		0.71 (A13)

0

5

0 **Example 15**

2,6-Diisopropyl-4-(4-fluorophenyl)-5-(indolyl-5-aminomethyl)-3-hydroxy-methylpyridine



5


Analogously to Example 2, 2.3 g (4.21 mmol) of the compound from Example CXLIII is desilylated in methanol in the presence of 3 N hydrochloric acid.

Yield: 720 mg (39.6% of theory)

10


R_f = 0.48 (A13)


The compounds listed in Table 2(B) are synthesized according to these instructions:


0 **Table 2(B):**


Example No.	R ¹	R _f (solvents)
16	<p>Chemical structure of R¹ for Example 16: (1-methyl-4-methoxyphenyl)methyl group.</p>	0.46 (A13)
17	<p>Chemical structure of R¹ for Example 17: 2-ethylfuran-3-ylmethyl group.</p>	0.33 (A13)
18	<p>Chemical structure of R¹ for Example 18: cyclopropylmethyl group.</p>	0.86 (A13)
19	<p>Chemical structure of R¹ for Example 19: 4-ethyl-3-fluorophenyl group.</p>	0.48 (A13)
20	<p>Chemical structure of R¹ for Example 20: 4-ethoxy-3-methoxyphenyl group.</p>	0.35 (A13)
21	<p>Chemical structure of R¹ for Example 21: 3-methyl-5-pyridylmethyl group.</p>	0.39 (A13)

0 Table 3(B)



Ex.	R ¹⁷	R ¹ -E	T	L	R _f (solvent)
22	F	4-F-C ₆ H ₄	CH(CH ₃) ₂	CH(CH ₃) ₂	0.43 (A5)
23	F	4-CF ₃ -C ₆ H ₄	CH(CH ₃) ₂	CH(CH ₃) ₂	0.40 (A5)
24	F	3-CF ₃ -C ₆ H ₄	CH(CH ₃) ₂	CH(CH ₃) ₂	0.47 (A5)
25	F	2-CF ₃ -C ₆ H ₄	CH(CH ₃) ₂	CH(CH ₃) ₂	0.41 (A5)
26	F	4-F-C ₆ H ₄ (CH ₂) ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.17 (A3)
27	H	2-CF ₃ -C ₆ H ₄ (CH ₂) ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.38 (A5)
28	F	2-F-C ₆ H ₄ (CH ₂) ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.16 (A3)
29	F	4-CF ₃ -C ₆ H ₄ CHCH ₃	CH(CH ₃) ₂	CH(CH ₃) ₂	0.17 (A3)
30	F	3-CF ₃ -C ₆ H ₄ (CH ₂) ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.49 (A5)
31	F	3-CF ₃ -C ₆ H ₄ CHCH ₃	CH(CH ₃) ₂	CH(CH ₃) ₂	0.47 (A5)
32	F	 NCH ₂ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.20 (A11)
33	F	(4-pyridyl)CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.16 (A9)


Ex.	R ¹⁷	R ¹ -E	T	L	R _f (solvent)
34	F	(3-pyridyl)CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.20 (A9)
35	F	(2-pyridyl)CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.38 (A9)
36	F	4-Ph-C ₆ H ₄	CH(CH ₃) ₂	CH(CH ₃) ₂	0.24 (A4)
37	F	3-Ph-C ₆ H ₄	CH(CH ₃) ₂	CH(CH ₃) ₂	0.27 (A4)
38	F	2-Ph-C ₆ H ₄	CH(CH ₃) ₂	CH(CH ₃) ₂	0.26 (A4)
39	F	4-F-C ₆ H ₄ (CH ₂) ₃	CH(CH ₃) ₂	CH(CH ₃) ₂	0.14 (A3)
40	F	 N - C ₆ H ₄	CH(CH ₃) ₂	CH(CH ₃) ₂	0.13 (A9)
41	F	(1-naphthyl)CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.14 (A3)
42	F	2-naphthyl(CH ₂) ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.15 (A3)
43	F	1-naphthyl(CH ₂) ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.15 (A3)
44	F	C ₆ H ₅	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.54 (A5)
45	F	4-F-C ₆ H ₄	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.42 (A5)
46	F	4-CF ₃ -C ₆ H ₄	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.40 (A5)
47	F	3-CF ₃ -C ₆ H ₄	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.45 (A5)
48	F	2-CF ₃ -C ₆ H ₄	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.33 (A5)
49	F	4-F-C ₆ H ₄ (CH ₂) ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.15 (A3)
50	H	2-CF ₃ -C ₆ H ₄ (CH ₂) ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.41 (A5)

Ex.	R ¹⁷	R ¹ -E	T	L	R _f (solvent)
51	F	2-F-C ₆ H ₄ (CH ₂) ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.14 (A3)
52	F	4-CF ₃ -C ₆ H ₄ CHCH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.11 (A3)
53	F	3-CF ₃ -C ₆ H ₄ (CH ₂) ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.43 (A5)
54	F	3-CF ₃ -C ₆ H ₄ CHCH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.42 (A5)
55	F	 NCH ₂ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.48 (A9)
56	F	(2-pyridyl)CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.20 (A9)
57	F	(3-pyridyl)CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.19 (A9)
58	F	4-F-C ₆ H ₄ (CH ₂) ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.33 (A5)
59	F	(4-pyridyl)CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.25 (A11)
60	F	2-Ph-C ₆ H ₄	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.38 (A5)
61	F	3-Ph-C ₆ H ₄	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.32 (A5)
62	F	4-Ph-C ₆ H ₄	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.33 (A5)
63	F	2-naphthyl(CH ₂)	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.33 (A5)
64	F	1-naphthyl(CH ₂)	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.32 (A5)
65	F	2-naphthyl(CH ₂) ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.34 (A5)
66	F	1-naphthyl(CH ₂) ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.34 (A3)
67	F	4-CF ₃ O-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.31 (A5)

Ex.	R ¹⁷	R ¹ -E	T	L	R _f (solvent)
68	F	3-CF ₃ O-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.34 (A5)
69	F	3-CF ₃ -C ₆ H ₄ (CH ₂) ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.16 (A4)
70	F	4-CF ₃ O-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	<i>cyclo</i> -C ₅ H ₉	0.35 (A5)
71	F	3-CF ₃ O-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	<i>cyclo</i> -C ₅ H ₉	0.33 (A5)
72	F	3-CF ₃ -C ₆ H ₄ (CH ₂) ₃	4-F-C ₆ H ₄	<i>cyclo</i> -C ₅ H ₉	0.28 (A4)
73	F	4-F-C ₆ H ₄ O(CH ₂) ₂	4-F-C ₆ H ₄	<i>cyclo</i> -C ₅ H ₉	0.67 (A7)
74	F	3-CF ₃ -C ₆ H ₄	4-F-C ₆ H ₄	<i>cyclo</i> -C ₅ H ₉	0.46 (A5)
75	F	4-CF ₃ -C ₆ H ₄	4-F-C ₆ H ₄	<i>cyclo</i> -C ₅ H ₉	0.42 (A5)
76	F	3-CF ₃ -C ₆ H ₄ (CH ₂) ₂	4-F-C ₆ H ₄	<i>cyclo</i> -C ₅ H ₉	0.42 (A5)
77	F	3-CF ₃ O-C ₆ H ₄ CH ₂	3-CF ₃ -C ₆ H ₄	<i>cyclo</i> -C ₅ H ₉	0.33 (A5)
78	F	3-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	4-F-C ₆ H ₄	0.20 (A7)

0

0 Table 4(B)




Ex.	R ¹ -E	T	L	R _f (solvent)
79	2-CN-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.16 (A3)
80	3-CN-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.10 (A3)
81	4-CN-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.10 (A3)
82	4-F-C ₆ H ₄ CH ₂	<i>cyclo</i> -C ₃ H ₅	CH(CH ₃) ₂	0.46 (A5)
83	4-F-C ₆ H ₄ CH ₂	C ₂ H ₅	CH(CH ₃) ₂	0.36 (A5)
84	C ₆ H ₅ CH ₂	C ₂ H ₅	CH(CH ₃) ₂	0.36 (A5)
85	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	pyrrolidin-1-yl	0.10 (A3)
86	3-CF ₃ -C ₆ H ₄ CH ₂	CH(CH ₃) ₂	<i>cyclo</i> -C ₆ H ₁₁	0.15 (A3)
87	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	<i>cyclo</i> -C ₆ H ₁₁	0.15 (A3)
88	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	2-CH ₃ -C ₆ H ₄	0.12 (A3)
89	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	4-Cl-C ₆ H ₄	0.19 (A3)
90	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄ (CH ₂) ₂	CH(CH ₃) ₂	0.11 (A3)
91	3-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CF ₃	0.24 (A5)

Ex.	R ¹ -E	T	L	R _f (solvent)
92	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CF ₃	0.25 (A5)
93	3-CF ₃ -C ₆ H ₄ CH ₂	2,4-F ₂ -C ₆ H ₃	<i>cyclo</i> -C ₅ H ₉	0.18 (A4)
94	4-CF ₃ -C ₆ H ₄ CH ₂	2,4-F ₂ -C ₆ H ₃	<i>cyclo</i> -C ₅ H ₉	0.22 (A4)

0

Table 5(B):



Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ¹ -E	T	L	R _f (solvent)
95	H	H	F	H	H	C ₆ H ₅ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.41 (A3)
96	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.20 (A3)
97	H	H	F	H	H	3-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.17 (A3)
98	H	H	F	H	H	2-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.21 (A3)
99	H	H	F	H	H	4-(benzothiazol-2-yl)-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.09 (A3)
100	H	H	F	H	H	4-CF ₃ O-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.25 (A3)


Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1-E}	T	L	R _f (solvent)
101	H	H	F	H	H	2-naphthyl-CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.20 (A3)
102	H	H	F	H	H	4-[(4-tolyl)SO ₂]-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.13 (A4)
103	H	H	F	H	H	4-Cl-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.23 (A4)
104	H	H	F	H	H	4-CH ₃ O-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.17 (A3)
105	H	H	F	H	H	3-CH ₃ O-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.27 (A3)
106	H	H	F	H	H	3,4-F ₂ -C ₆ H ₃ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.15 (A3)
107	H	H	F	H	H	2,4-F ₂ -C ₆ H ₃ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.25 (A3)
108	H	H	F	H	H	2-CH ₃ -C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.30 (A3)
109	H	H	F	H	H	3-CH ₃ -C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.68 (A5)
110	H	H	F	H	H	4-CH ₃ -C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.61 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1-E}	T	L	R _f (solvent)
111	H	H	F	H	H	4-F-C ₆ H ₄ CHCH ₃	CH(CH ₃) ₂	CH(CH ₃) ₂	0.21 (A3)
112	H	H	F	H	H	2,6-(CH ₃) ₂ -4-(<i>i</i> -C ₄ H ₉)-C ₆ H ₂ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.25 (A3)
113	H	H	F	H	H	4-(<i>i</i> -C ₃ H ₇)-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.22 (A3)
114	H	H	F	H	H	2,4,6-(<i>i</i> -C ₃ H ₇) ₃ -C ₆ H ₂ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.36 (A3)
115	H	H	F	H	H	3-(C ₆ H ₅ O)-5-CH ₃ -C ₆ H ₃ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.25 (A3)
116	H	H	F	H	H	2,4-Cl ₂ -C ₆ H ₃ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.24 (A3)
117	H	H	F	H	H	3-CF ₃ -4-Cl-C ₆ H ₃ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.19 (A3)
118	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.13 (A3)
119	H	H	F	H	H	C ₆ H ₅ CH ₂	CH(CH ₃) ₂	CH ₃	0.11 (A3)
120	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH ₃	0.29 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1-E}	T	L	R _f (solvent)
121	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH ₃	0.13 (A11)
122	H	H	F	H	H	C ₆ H ₅ CH ₂	CH ₃	cyclo-C ₃ H ₅	0.14 (A3)
123	H	H	F	H	H	C ₆ H ₅ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.53 (A5)
124	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.47 (A5)
125	H	H	F	H	H	C ₆ H ₅ CH ₂	CH(CH ₃) ₂	cyclo-C ₅ H ₉	0.57 (A5)
126	H	H	F	H	H	C ₆ H ₅ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.23 (A3)
127	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	C ₆ H ₅	CH(CH ₃) ₂	0.43 (A5)
128	H	H	F	H	H	3-F-C ₆ H ₄ CH ₂	C ₆ H ₅	CH(CH ₃) ₂	0.13 (A3)
129	H	H	F	H	H	2-F-C ₆ H ₄ CH ₂	C ₆ H ₅	CH(CH ₃) ₂	0.16 (A3)
130	H	H	F	H	H	4-(benzothiazol-2-yl)-C ₆ H ₄ CH ₂	C ₆ H ₅	CH(CH ₃) ₂	0.33 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1-E}	T	L	R _f (solvent)
131	H	H	F	H	H	2-naphthyl-CH ₂	C ₆ H ₅	CH(CH ₃) ₂	0.31 (A4)
132	H	H	F	H	H	4-CF ₃ O-C ₆ H ₄ CH ₂	C ₆ H ₅	CH(CH ₃) ₂	0.31 (A4)
133	H	H	F	H	H	4-[(4-tolyl)SO ₂]-C ₆ H ₄ CH ₂	C ₆ H ₅	CH(CH ₃) ₂	0.15 (A5)
134	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	4-F-C ₆ H ₄	0.46 (A5)
135	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.57 (A5)
136	H	H	F	H	H	4-Cl-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.21 (A3)
137	H	H	F	H	H	4-(i-C ₃ H ₇)-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.20 (A3)
138	H	H	F	H	H	3-(2-F-C ₆ H ₄ O)-C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.44 (A5)
139	H	H	F	H	H	3-(4-F-C ₆ H ₄ O)-C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.41 (A5)
140	H	H	F	H	H	3,4-F ₂ -C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.17 (A3)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ¹ E	T	L	R _f (solvent)
141	H	H	F	H	H	2,4-F ₂ -C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.18 (A3)
142	H	H	F	H	H	2-CH ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.09 (A2)
143	H	H	F	H	H	3-CH ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.22 (A3)
144	H	H	F	H	H	4-CH ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.23 (A3)
145	H	H	F	H	H	4-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.12 (A3)
146	H	H	F	H	H	4-F-C ₆ H ₄ CHCH ₃	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.28 (A3)
147	H	H	F	H	H	2,4-Cl ₂ -C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.23 (A3)
148	H	H	F	H	H	3-CF ₃ -4-Cl-C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.16 (A3)
149	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.48 (A5)
150	H	H	F	H	H	2-Cl-4-CF ₃ -C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.35 (A4)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1-E}	T	L	R _f (solvent)
151	H	H	F	H	H	3-[4-(C ₆ H ₅)-C ₆ H ₄ O]C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.19 (A5)
152	H	H	F	H	H	2-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.42 (A5)
153	H	H	F	H	H	3-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.46 (A5)
154	H	H	F	H	H	3-(C ₆ H ₅ O)-5-CH ₃ -C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.46 (A5)
155	H	H	F	H	H		4-F-C ₆ H ₄	CH(CH ₃) ₂	0.42 (A5)
156	H	H	F	H	H	3,5-(CF ₃) ₂ -C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.28 (A5)
157	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	2-F-C ₆ H ₄	CH(CH ₃) ₂	0.36 (A5)
158	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	pyrrolidin-1-yl	CH(CH ₃) ₂	0.14 (A3)
159	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	cyclo-C ₆ H ₁₁	CH(CH ₃) ₂	0.58 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1-E}	T	L	R _f (solvent)
160	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	cyclo-C ₆ H ₁₁	CH(CH ₃) ₂	0.53 (A5)
161	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	2-CH ₃ -C ₆ H ₄	CH(CH ₃) ₂	0.15 (A3)
162	H	H	F	H	H	3-CH ₃ -C ₆ H ₄ CH ₂	4-Cl-C ₆ H ₄	CH(CH ₃) ₂	0.19 (A3)
163	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-Cl-C ₆ H ₄	CH(CH ₃) ₂	0.28 (A3)
164	H	H	F	H	H	3,4-F ₂ -C ₆ H ₃ CH ₂	4-Cl-C ₆ H ₄	CH(CH ₃) ₂	0.18 (A3)
165	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-Cl-C ₆ H ₄	CH(CH ₃) ₂	0.20 (A3)
166	H	H	F	H	H	4-Cl-C ₆ H ₄ CH ₂	4-Cl-C ₆ H ₄	CH(CH ₃) ₂	0.25 (A3)
167	H	H	F	H	H	2-CH ₃ -C ₆ H ₄ CH ₂	4-Cl-C ₆ H ₄	CH(CH ₃) ₂	0.49 (A5)
168	H	H	F	H	H	4-CH ₃ -C ₆ H ₄ CH ₂	4-Cl-C ₆ H ₄	CH(CH ₃) ₂	0.51 (A5)
169	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-Cl-C ₆ H ₄	CH(CH ₃) ₂	0.29 (A4)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1-E}	T	L	R _f (solvent)
170	H	H	F	H	H	2,4-Cl ₂ -C ₆ H ₃ CH ₂	4-Cl-C ₆ H ₄	CH(CH ₃) ₂	0.19 (A3)
171	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	4-F-C ₆ H ₄	0.36 (A5)
172	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.42 (A5)
173	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.30 (A4)
174	H	H	F	H	H	3,4-F ₂ -C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.09 (A3)
175	H	H	F	H	H	2,4-F ₂ -C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.13 (A3)
176	H	H	F	H	H	2,4-Cl ₂ -C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.13 (A3)

Table 5(B): (Continued)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1-E}	T	L	R _f (solvent)
177	C ₆ H ₅ CH ₂ O	H	F	H	H	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	4-F-C ₆ H ₄	0.08 (A3)
178	C ₆ H ₅ CH ₂ O	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.11 (A3)
179	2-F-C ₆ H ₄ CH ₂ O	H	F	H	H	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.11 (A3)
180	4-F-C ₆ H ₄ CH ₂ O	H	F	H	H	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.17 (A3)
181	4-Cl-C ₆ H ₄ CH ₂ O	H	F	H	H	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.11 (A3)
182	H	2-F-C ₆ H ₄ CH ₂ O	F	H	H	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.17 (A3)

Table 5(B): (Continued)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1-E}	T	L	R _f (solvent)
183	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH ₃	0.10 (A5)
184	H	H	F	H	H	3,4-F ₂ -C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	CH ₃	0.31 (A7)
185	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH ₃	0.28 (A7)
186	H	H	F	H	H	3,4-F ₂ -C ₆ H ₃ CH ₂	3-Cl-C ₆ H ₄	CH(CH ₃) ₂	0.73 (A7)
187	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	3-Cl-C ₆ H ₄	CH(CH ₃) ₂	0.62 (A5)
188	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	4-F-C ₆ H ₄ (CH ₂) ₂	0.31 (A5)
189	H	H	F	H	H	3,4-F ₂ -C ₆ H ₃ CH ₂	CH(CH ₃) ₂	4-F-C ₆ H ₄ (CH ₂) ₂	0.37 (A5)
190	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	0.22 (A3)
191	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	4-F-C ₆ H ₄ CH ₂	0.19 (A3)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1-E}	T	L	R _f (solvent)
192	H	H	OCH ₃	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.45 (A5)
193	H	H	Cl	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.65 (A5)
194	H	H	Cl	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.09 (A3)
195	H	Cl	H	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.15 (A3)
196	H	Cl	H	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.29 (A5)
197	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(C ₂ H ₅) ₂	0.29 (A3)
198	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(C ₂ H ₅) ₂	0.56 (A5)
199	H	Cl	Cl	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.19 (A3)
200	H	CF ₃	H	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.44 (A5)
201	H	CH ₃	H	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.51 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1-E}	T	L	R _f (solvent)
202	H	CH ₃	H	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.08 (A3)
203	H	H	CH ₃	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.55 (A5)
204	H	Cl	H	Cl	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.37 (A3)
205	H	OCH ₃	H	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.37 (A5)
206	OCH ₃	H	H	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.32 (A5)
207	Cl	Cl	H	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.19 (A5)
208	H	CF ₃	Cl	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.43 (A5)
209	H	CF ₃	F	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.44 (A5)
210	H	Cl	CF ₃	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.54 (A5)
211	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	cyclo-C ₅ H ₉	0.31 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1-E}	T	L	R _f (solvent)
212	H	H	F	H	H	3,5-(CF ₃) ₂ -C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	cyclo-C ₅ H ₉	0.37 (A5)
213	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	cyclo-C ₅ H ₉	0.23 (A4)
214	H	H	F	H	H	2,4-Cl ₂ -C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	cyclo-C ₅ H ₉	0.49 (A5)
215	H	H	F	H	H	3-CF ₃ -4-Cl-C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	cyclo-C ₅ H ₉	0.47 (A5)
216	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	cyclo-C ₃ H ₅	0.34 (A5)
217	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	cyclo-C ₃ H ₅	0.14 (A4)
218	H	H	F	H	H	2,4-Cl ₂ -C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	cyclo-C ₃ H ₅	0.49 (A5)
219	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.38 (A5)
220	H	H	CF ₃	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.42 (A5)
221	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	4-F-C ₆ H ₄	0.33 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1,E}	T	L	R _f (solvent)
222	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	4-F-C ₆ H ₄	0.24 (A5)
223	Cl	Cl	H	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.42 (A5)
224	Cl	H	H	H	H	4-F-C ₆ H ₄ CH ₂	CH(CH ₃) ₂	CH(CH ₃) ₂	0.33 (A5)
225	Cl	H	H	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	4-F-C ₆ H ₄	0.18 (A5)
226	Cl	H	Cl	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	CH(CH ₃) ₂	0.50 (A5)
227	Cl	H	Cl	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	4-F-C ₆ H ₄	0.34 (A5)
228	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	3-CF ₃ -C ₆ H ₄	CH(CH ₃) ₂	0.46 (A5)
229	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	3-CF ₃ -C ₆ H ₄	CH(CH ₃) ₂	0.47 (A5)
230	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	3-CH ₃ -C ₆ H ₄	CH(CH ₃) ₂	0.25 (A4)
231	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	3-CH ₃ -C ₆ H ₄	CH(CH ₃) ₂	0.22 (A4)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1-E}	T	L	R _f (solvent)
232	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-CH ₃ -C ₆ H ₄	CH(CH ₃) ₂	0.32 (A4)
233	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-CH ₃ -C ₆ H ₄	CH(CH ₃) ₂	0.25 (A4)
234	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	2-Cl-C ₆ H ₄	CH(CH ₃) ₂	0.20 (A5)
235	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	2-Cl-C ₆ H ₄	CH(CH ₃) ₂	0.21 (A5)
236	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-CH ₃ O-C ₆ H ₄	CH(CH ₃) ₂	0.26 (A5)
237	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-CH ₃ O-C ₆ H ₄	CH(CH ₃) ₂	0.27 (A5)
238	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	2-CH ₃ O-C ₆ H ₄	CH(CH ₃) ₂	0.18 (A5)
239	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	2-CH ₃ O-C ₆ H ₄	CH(CH ₃) ₂	0.21 (A5)
240	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	3-CH ₃ O-C ₆ H ₄	CH(CH ₃) ₂	0.14 (A4)
241	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	3-CH ₃ O-C ₆ H ₄	CH(CH ₃) ₂	0.15 (A4)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1-E}	T	L	R _f (solvent)
242	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	cyclo-C ₆ H ₁₁	4-F-C ₆ H ₄	0.40 (A5)
243	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	cyclo-C ₆ H ₁₁	4-F-C ₆ H ₄	0.45 (A5)
244	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	cyclo-C ₆ H ₁₁	0.37 (A5)
245	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	cyclo-C ₆ H ₁₁	0.43 (A5)
246	H	H	F	H	H	3-CF ₃ -4-Cl-C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	cyclo-C ₆ H ₁₁	0.29 (A5)
247	H	H	F	H	H	2,4-Cl ₂ -C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	cyclo-C ₆ H ₁₁	0.35 (A5)
248	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-Cl-C ₆ H ₄	cyclo-C ₅ H ₉	0.56 (A5)
249	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	3-CF ₃ -C ₆ H ₄	cyclo-C ₅ H ₉	0.44 (A5)
250	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	3-CF ₃ -C ₆ H ₄	cyclo-C ₅ H ₉	0.41 (A5)
251	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	cyclo-C ₄ H ₇	0.36 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1-E}	T	L	R _f (solvent)
252	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	cyclo-C ₄ H ₇	0.38 (A5)
253	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	cyclo-C ₇ H ₁₃	4-F-C ₆ H ₄	0.35 (A5)
254	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	cyclo-C ₇ H ₁₃	4-F-C ₆ H ₄	0.33 (A5)
255	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	cyclo-C ₇ H ₁₃	0.39 (A5)
256	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	cyclo-C ₇ H ₁₃	0.44 (A5)
257	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	furan-2-yl	4-F-C ₆ H ₄	0.13 (A5)
258	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	furan-2-yl	0.18 (A5)
259	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	(cyclo-C ₅ H ₉)CH ₂	0.25 (A5)
260	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	(cyclo-C ₅ H ₉)CH ₂	0.23 (A5)
261	H	H	F	H	H	3,5-(CF ₃) ₂ -C ₆ H ₃ CH ₂	4-F-C ₆ H ₄	(cyclo-C ₅ H ₉)CH ₂	0.27 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1-E}	T	L	R _f (solvent)
262	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	(cyclo-C ₆ H ₁₁)CH ₂	0.24 (A5)
263	H	H	F	H	H	4-F-C ₆ H ₄ CH ₂	4-F-C ₆ H ₄	(cyclo-C ₆ H ₁₁)CH ₂	0.25 (A5)
264	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-CF ₃ -C ₆ H ₄	cyclo-C ₅ H ₉	0.40 (A5)
265	H	H	F	H	H	4-CF ₃ -C ₆ H ₄ CH ₂	4-CF ₃ -C ₆ H ₄	cyclo-C ₅ H ₉	0.30 (A4)
266	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	1-naphthyl	cyclo-C ₅ H ₉	0.24 (A5)
267	H	H	F	H	H	4-CF ₃ -C ₆ H ₄ CH ₂	1-naphthyl	cyclo-C ₅ H ₉	0.14 (A4)
268	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	2-naphthyl	cyclo-C ₅ H ₉	0.32 (A5)
269	H	H	F	H	H	4-CF ₃ -C ₆ H ₄ CH ₂	2-naphthyl	cyclo-C ₅ H ₉	0.23 (A4)
270	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	3-CH ₃ -C ₆ H ₄	cyclo-C ₅ H ₉	0.22 (A4)
271	H	H	F	H	H	4-CF ₃ -C ₆ H ₄ CH ₂	3-CH ₃ -C ₆ H ₄	cyclo-C ₅ H ₉	0.21 (A4)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1-E}	T	L	R _f (solvent)
272	H	H	F	H	H	4-CF ₃ -C ₆ H ₄ CH ₂	2-CF ₃ -C ₆ H ₄	cyclo-C ₅ H ₉	0.13 (A5)
273	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	2-CF ₃ -C ₆ H ₄	cyclo-C ₅ H ₉	0.18 (A5)
274	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄ CH ₂	cyclo-C ₅ H ₉	0.24 (A5)
275	H	H	F	H	H	4-CF ₃ -C ₆ H ₄ CH ₂	4-F-C ₆ H ₄ CH ₂	cyclo-C ₅ H ₉	0.26 (A5)
276	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	3,4-F ₂ -C ₆ H ₃	cyclo-C ₅ H ₉	0.29 (A4)
277	H	H	F	H	H	4-CF ₃ -C ₆ H ₄ CH ₂	3,4-F ₂ -C ₆ H ₃	cyclo-C ₅ H ₉	0.30 (A4)
278	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	cyclo-C ₅ H ₉	cyclo-C ₅ H ₉	0.23 (A3)
279	H	H	F	H	H	4-CF ₃ -C ₆ H ₄ CH ₂	cyclo-C ₅ H ₉	cyclo-C ₅ H ₉	0.27 (A3)
280	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	3-CF ₃ -C ₆ H ₄ (CH ₂) ₂	cyclo-C ₅ H ₉	0.35 (A5)
281	H	H	F	H	H	4-CF ₃ -C ₆ H ₄ CH ₂	3-CF ₃ -C ₆ H ₄ (CH ₂) ₂	cyclo-C ₅ H ₉	0.33 (A5)

Ex.	R ¹⁵	R ¹⁶	R ¹⁷	R ¹⁸	R ¹⁹	R ^{1-E}	T	L	R _f (solvent)
282	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	3-CF ₃ -C ₆ H ₄ (CH ₂) ₂	3-CF ₃ -C ₆ H ₄ (CH ₂) ₂	0.20 (A7)
283	H	H	F	H	H	4-CF ₃ -C ₆ H ₄ CH ₂	3-CF ₃ -C ₆ H ₄ (CH ₂) ₂	3-CF ₃ -C ₆ H ₄ (CH ₂) ₂	0.20 (A7)
284	H	H	F	H	H	3-CF ₃ -C ₆ H ₄ CH ₂	C ₂ H ₅	cyclo-C ₅ H ₉	0.36 (A6)

0 **Detailed description with reference to compounds of general formula (IC)**

In the above structural formula (IC) the following terms have the indicated meanings:

5 The term alkyl means alkyl groups which are straight chain or branched and have the designated number of carbon atoms. Examples of such alkyl groups are methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tertiary butyl, pentyl, isopentyl, hexyl, and isoheptyl.

10 The term cycloalkyl means an alkyl group which is in the form of a ring and contains the designated number of carbon atoms. Examples include the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl groups.

The term alkoxy means a group in which the alkyl portion is straight or branched and has the designated number of carbon atoms. Examples of such alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, hexoxy, and isoheptyloxy.

15 The term alkanoyl means groups of formula -C(O)-alkyl in which the alkyl group has the designated number of carbon atoms. Examples include: acetyl, propionyl and butanoyl.

20 The term alkanoyloxy means groups of formula -OC(O)-alkyl in which the alkyl group has the designated number of carbon atoms. Examples include -OC(O)CH₃, -OC(O)C₂H₅, and -OC(O)C₃H₇.

The term alkoxycarbonyl means groups of formula -C(O)O-alkyl in which the alkyl group has the designated number of carbon atoms. Examples include -C(O)OCH₃, -C(O)OC₂H₅, and -C(O)OC₃H₇.

25 The term cycloalkyl-alkyl means groups in which an alkyl group bears a cycloalkyl substituent, and the cycloalkyl and alkyl portions each contain the designated number of carbon atoms. Examples include -C₂H₄-C₅H₉.

The term phenyl-alkyl means groups in which an alkyl group bears a phenyl substituent, and the alkyl portion contains the designated number of carbon atoms. Examples include -C₂H₄-C₆H₅.

30 The term naphthyl-alkyl means groups in which an alkyl group bears a naphthyl substituent, and the alkyl portion contains the designated number of carbon atoms. Examples include -C₂H₄-C₁₀H₇.

35 The term pyridyl-alkyl means groups in which an alkyl group bears a pyridyl substituent, and the alkyl portion contains the designated number of carbon atoms. Examples include -C₂H₄-pyridyl.

0 The term alkenyl means straight chain or branched groups having the designated number of carbon atoms and containing a carbon-carbon double bond. Examples include: ethenyl, propen-1-yl, propen-2-yl and penten-1-yl.

 The term alkynyl means straight chain or branched groups having the designated number of carbon atoms and containing a carbon-carbon triple bond.
5 Examples include ethynyl, propyn-1-yl and butyn-1-yl.

 The term halogen means the halogen atoms fluorine, chlorine, bromine and iodine.

 The term "substituted" is defined implicitly by the exemplary substituents disclosed for the various substituted groups in the above discussion of general
10 formula (IC). These lists of exemplary substituents are not intended to be considered as limiting; those skilled in the art will recognize that other similar substituents can also be employed.

 Certain of the above defined terms may occur more than once in the formulae employed herein, and upon such occurrence each term shall be defined
15 independently of the other.

 Preferred and most preferred groups constituting the compounds of general formula (IC) are as follows:

 X preferably represents CR^8 .

20 When X is CR^8 , R^8 is preferably hydrogen, halogen, trifluoromethyl or (C₁-C₁₀) alkyl. R^8 is most preferably hydrogen.

R^{1a} and R^{1b} preferably are independently trifluoromethyl, (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl, (C₃-C₇)-cycloalkyl, or (C₃-C₇)-cycloalkenyl. R^{1a} and R^{1b} most preferably are
25 independently (C₁-C₆)-alkyl or (C₂-C₆)-alkenyl.

R^2 is preferably (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl or substituted (C₂-C₁₀)-alkenyl. The substituents on the substituted alkyl and substituted alkenyl R^2 groups preferably are independently from 1 to 3 of halogen, phenyl, substituted phenyl, $-C(O)NR^4R^5$, or $-S(O)_mR^7$ wherein m is 0, 1, or 2. Most
30 preferably, the substituents are halogen or $-S(O)_mR^7$ wherein m=0.

 The groups R^4 and R^5 are preferably independently hydrogen, (C₁-C₆) alkyl, (C₃-C₆)-alkenyl, (C₃-C₇)-cycloalkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl, naphthyl-(C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl. R^4 and R^5 are most
35 preferably independently hydrogen, (C₁-C₆)-alkyl, (C₃-C₇)-cycloalkyl, phenyl, substituted phenyl, phenyl (C₁-C₆)-alkyl or substituted phenyl (C₁-C₆)-alkyl.

0 When R^4 and R^5 are joined together to form $-(CH_2)_rA(CH_2)_s-$, in this linkage it is preferable that the subscripts r and s are independently 1 to 3, and A is CHR^6 , NR^6 , O , or $S(O)_n$ wherein n is 0, 1, or 2, and R^6 is hydrogen, (C1-C6) alkyl, phenyl, or phenyl (C1-C6) alkyl.


5 R^7 is preferably (C1-C6)-alkyl, phenyl, substituted phenyl, phenyl-(C1-C6)-alkyl, substituted phenyl-(C1-C6)-alkyl, pyridyl, substituted pyridyl, pyridyl-(C1-C6)-alkyl, or substituted pyridyl-(C1-C6)-alkyl. R^7 is most preferably (C1-C6)-alkyl, phenyl, substituted phenyl, phenyl (C1-C6)-alkyl or substituted phenyl (C1-C6)-alkyl. The substituents on the substituted R^7 groups are preferably 1-3 of halogen, trifluoromethyl, or (C1-C6) alkyl.

10 When R^2 and R^{1b} are joined to form an alkylene bridge, this bridge preferably contains 3 or 4 carbon atoms.

R^3 is preferably (C1-C6) alkanoyl, substituted (C1-C6)-alkyl, or substituted (C3-C6)-alkenyl, wherein the substituents are preferably from 1 to 3 hydroxyl groups. Most preferably, R^3 is substituted (C1-C6)-alkyl or substituted (C3-C6)-alkenyl where the substituents are from 1 to 2 hydroxyl groups.

20 Preferences for the aromatic and heteroaromatic groups Ar of structural formula (IC) are presented below. Compounds of general formula (IC) are further classified into four subsets represented by structural formulae 1A, 1B, 1C, and 1D, which relate respectively to 4-heteroaryl-substituted pyridines, 4-aryl-substituted pyridines, heteroaryl-substituted benzenes, and aryl-substituted benzenes.

The 4-heteroaryl pyridine compounds included within formula (IC) have the formula 1A



25 wherein

R^{1a} and R^{1b} are independently trifluoromethyl, (C1-C10)-alkyl, substituted (C1-C10)-alkyl, (C2-C10)-alkenyl, substituted (C2-C10)-alkenyl, (C2-C10)-alkynyl, substituted (C2-C10)-alkynyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkenyl, or (C1-C6)-alkanoyl. The substituents on the substituted alkyl, substituted alkenyl, and substituted alkynyl R^{1a} and R^{1b} groups are independently from 1 to 3 of, for

0 example, $-OR^4$, $-C(O)R^4$, $-CO_2R^4$, $-C(O)NR^4R^5$, $-NR^4R^5$, or phenyl which is optionally substituted with from 1 to 3 of, for example, halogen, (C1-C4)-alkyl, or (C1-C4)-alkoxy groups.

The groups R^4 and R^5 are independently hydrogen, (C1-C6)-alkyl, (C3-C6)-alkenyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(C1-C6)-alkyl, phenyl, substituted
 5 phenyl, phenyl-(C1-C6)-alkyl, substituted phenyl-(C1-C6)-alkyl, naphthyl, substituted naphthyl, naphthyl-(C1-C6)-alkyl, or substituted naphthyl-(C1-C6)-alkyl. The substituents on the substituted phenyl or substituted naphthyl R^4 and R^5 groups are 1 to 3 of, for example, halogen, cyano, trifluoromethyl, (C1-C4)-alkyl, or (C1-C4)-alkoxy groups.

10 R^4 and R^5 may be joined together to form $-(CH_2)_rA(CH_2)_s-$ wherein the subscripts r and s are independently 1 to 3 and A is CHR^6 , NR^6 , O , or $S(O)_n$ in which n is 0, 1, or 2; and R^6 is hydrogen, (C1-C6)-alkyl, piperidin-1-yl, phenyl, or phenyl-(C1-C6)-alkyl.

R^2 is (C1-C10)-alkyl, substituted (C1-C10)-alkyl, (C2-C10)-alkenyl,
 15 substituted (C2-C10)-alkenyl, (C2-C10)-alkynyl, substituted (C2-C10)-alkynyl, (C3-C6)-cycloalkyl-(C1-C6)-alkyl, or substituted (C3-C6)-cycloalkyl-(C1-C6)-alkyl. The substituents on the substituted alkyl, substituted alkenyl, substituted alkynyl, and substituted cycloalkyl R^2 groups are independently from 1 to 3 of halogen, phenyl, substituted phenyl, 1,3-dioxolan-2-yl, $-C(O)NR^4R^5$, or $-S(O)_mR^7$ wherein m is 0, 1,
 20 or 2. The substituents on the substituted phenyl R^2 substituent group are from 1 to 3 of, for example, halogen, (C1-C4)-alkyl, or (C1-C4)-alkoxy.

R^7 is (C1-C6)-alkyl, phenyl, substituted phenyl, phenyl-(C1-C6)-alkyl, substituted phenyl-(C1-C6)-alkyl, pyridyl, substituted pyridyl, pyridyl-(C1-C6)-alkyl, substituted pyridyl-(C1-C6)-alkyl, naphthyl, substituted naphthyl, naphthyl-
 25 (C1-C6)-alkyl, or substituted naphthyl-(C1-C6)-alkyl. The substituents on the substituted phenyl, substituted pyridyl or substituted naphthyl R^7 groups are from 1 to 5 of, for example, halogen, trifluoromethyl, (C1-C6)-alkyl, (C1-C6)-alkoxy, nitro, cyano, or hydroxy.

R^2 and R^{1b} may be joined to form an alkylene bridge containing from 3 to 5
 30 carbon atoms, between the ring carbon atoms to which R^2 and R^{1b} are attached.

R^3 is hydroxy, trifluoroacetyl, (C1-C6)-alkanoyl, substituted (C1-C6)-alkyl, or substituted (C3-C6)-alkenyl. The substituents on the substituted alkyl and substituted alkenyl R^3 groups from 1 to 3 hydroxy or trifluoromethyl groups.

Ar' is an optionally substituted heteroaromatic ring. Examples of possible
 35 Ar' groups are pyridyls, furanyls, thiophenyls, pyrrolyls, imidazolyls, pyrazolyls, triazolyls, tetrazolyls, oxazolyls, isoxazolyls, thiazolyls and isothiazolyls. The

- 0 optional substituents on the group Ar' are independently 1 to 3 of, for example, halogen, (C₁-C₆)-alkyl, substituted (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, substituted (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, substituted (C₂-C₆)-alkynyl, (C₃-C₇)-cycloalkyl, cyano, nitro, trifluoromethyl, -OR⁴, -C(O)R⁴, -OC(O)R⁴, -CO₂R⁴, -NR⁴R⁵, -C(O)NR⁴R⁵, or -S(O)_mR⁷. The substituents on the substituted alkyl, substituted
- 5 alkenyl, and substituted alkynyl substituent groups on Ar' are from 1 to 3 of, for example, halogen, hydroxy, -NR⁴R⁵, phenyl, or substituted phenyl in which the phenyl group may bear, for example, one or more halogen, (C₁-C₄) alkyl, or (C₁-C₄) alkoxy groups.


10 Pharmaceutically acceptable salts of these materials are within the scope of the invention.

15 In formula 1A, the preferred and most preferred groups R^{1a}, R^{1b}, R², R³, as well as the additional groups R⁴, R⁵, R⁶, and R⁷ embedded therein, and the various substituent groups thereon, are as defined in connection with general formula (IC) above.

20 In formula 1A, heteroaromatic ring Ar' is preferably selected from the group consisting of pyridyls, furanyls, thiophenyls, pyrazolyls, triazolyls, oxazolyls and thiazolyls, and the optional substituents on Ar' are preferably independently from 1 to 3 of, for example, halogen, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, (C₃-C₇)-cycloalkyl, cyano, -OR⁴, or -OC(O)R⁴ where R⁴ is hydrogen, (C₁-C₆) alkyl, phenyl (C₁-C₆) alkyl or substituted phenyl (C₁-C₆) alkyl where the phenyl substituents are from 1 to 3 of halogen or (C₁-C₄) alkyl. Heteroaromatic ring Ar' is most preferably selected from the group consisting of pyridyls, furanyls and thiophenyls, and the optional substituents thereon are most preferably

25 independently from 1 to 3 of, for example, halogen, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, -OR⁴, or -OC(O)R⁴ where R⁴ is hydrogen or (C₁-C₆) alkyl.

The 4-aryl-substituted pyridines included within formula (IC) have the formula 1B



30 wherein

0 R^{1a} and R^{1b} are independently trifluoromethyl, (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, substituted (C₂-C₁₀)-alkynyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-cycloalkenyl, or (C₁-C₆)-alkanoyl. The substituents on the substituted alkyl, substituted alkenyl, and substituted alkynyl R^{1a} and R^{1b} groups are independently from 1 to 3 of, for
 5 example, -OR⁴, -C(O)R⁴, -CO₂R⁴, -C(O)NR⁴R⁵, -NR⁴R⁵, or phenyl which is optionally substituted with from 1 to 3 halogen, (C₁-C₄)-alkyl, or (C₁-C₄)-alkoxy groups.

The groups R⁴ and R⁵ are independently hydrogen, (C₁-C₆)-alkyl, (C₃-C₆)-alkenyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-cycloalkyl-(C₁-C₆)-alkyl, phenyl, substituted
 10 phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl, naphthyl-(C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl. The substituents on the substituted phenyl or substituted naphthyl R⁴ and R⁵ groups are 1 to 3 of, for example, halogen, cyano, trifluoromethyl, (C₁-C₄)-alkyl, or (C₁-C₄)-alkoxy groups.

15 R⁴ and R⁵ may be joined together to form -(CH₂)_rA(CH₂)_s- wherein the subscripts r and s are independently 1 to 3 and A is CHR⁶, NR⁶, O, or S(O)_n in which n is 0, 1, or 2; and R⁶ is hydrogen, (C₁-C₆)-alkyl, piperidin-1-yl, phenyl, or phenyl-(C₁-C₆)-alkyl.

R² is (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, substituted (C₂-C₁₀)-alkynyl, (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl, or substituted (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl. The substituents on the substituted alkyl, substituted alkenyl, substituted alkynyl, and substituted cycloalkyl R² groups are independently from 1 to 3 of halogen, phenyl, substituted phenyl, 1,3-dioxolan-2-yl, -C(O)NR⁴R⁵, or -S(O)_mR⁷ wherein m is 0, 1,
 20 or 2. The substituents on the substituted phenyl R² substituent group are from 1 to 3 of, for example, halogen, (C₁-C₄)-alkyl, or (C₁-C₄)-alkoxy.

R⁷ is (C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, pyridyl, substituted pyridyl, pyridyl-(C₁-C₆)-alkyl, substituted pyridyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl, naphthyl-
 30 (C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl. The substituents on the substituted phenyl, substituted pyridyl or substituted naphthyl R⁷ groups are from 1 to 5 of, for example, halogen, trifluoromethyl, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, nitro, cyano, or hydroxy.

R² and R^{1b} may be joined to form an alkylene bridge containing from 3 to 5
 35 carbon atoms, between the ring carbon atoms to which R² and R^{1b} are attached.

0 R^3 is hydroxy, trifluoroacetyl, (C_1-C_6) -alkanoyl, substituted (C_1-C_6) -alkyl, or substituted (C_3-C_6) -alkenyl. The substituents on the substituted alkyl and substituted alkenyl R^3 groups are from 1 to 3 hydroxy or trifluoromethyl groups.

5 Ar'' is an optionally substituted aromatic ring. Examples of possible Ar'' groups are phenyls and naphthyls. The optional substituents on the group Ar'' are independently 1 to 3 of, for example, halogen, (C_1-C_6) -alkyl, substituted (C_1-C_6) -alkyl, (C_2-C_6) -alkenyl, substituted (C_2-C_6) -alkenyl, (C_2-C_6) -alkynyl, substituted (C_2-C_6) -alkynyl, (C_3-C_7) -cycloalkyl, cyano, nitro, trifluoromethyl, $-OR^4$, $-C(O)R^4$, $-OC(O)R^4$, $-CO_2R^4$, $-NR^4R^5$, $-C(O)NR^4R^5$, or $-S(O)_mR^7$. The substituents on the substituted alkyl, substituted alkenyl, and substituted alkynyl substituent groups on

10 Ar'' are from 1 to 3 of, for example, halogen, hydroxy, $-NR^4R^5$, phenyl, or substituted phenyl in which the phenyl group may bear, for example, one or more halogen, (C_1-C_4) alkyl, or (C_1-C_4) alkoxy groups.

Pharmaceutically acceptable salts of these materials are within the scope of the invention.

15

In formula 1B, the preferred and most preferred groups R^{1a} , R^{1b} , R^2 , R^3 , as well as the additional groups R^4 , R^5 , R^6 , and R^7 embedded therein, and the various substituent groups thereon, are as defined in connection with general formula (IC) above.


20

In formula 1B, aromatic ring Ar'' preferably is a phenyl ring wherein the optional substituents are preferably independently from 1 to 3 of, for example, halogen, (C_1-C_6) -alkyl, (C_2-C_6) -alkenyl, (C_2-C_6) -alkynyl, (C_3-C_7) -cycloalkyl, cyano, $-OR^4$ or $-OC(O)R^4$, where R^4 is hydrogen, (C_1-C_6) alkyl, phenyl (C_1-C_6) alkyl or substituted phenyl (C_1-C_6) alkyl where the phenyl substituents are from 1

25 to 3 of halogen or (C_1-C_4) alkyl. Most preferably, the optional substituents are from 1 to 3 of, for example, halogen, (C_1-C_6) -alkyl, (C_2-C_6) -alkenyl, $-OR^4$ or $-OC(O)R^4$, where R^4 is hydrogen or (C_1-C_6) alkyl.

30

0 The heteroaryl-substituted benzenes included within formula (IC) have the formula 1C



wherein

R^8 represents hydrogen, halogen, trifluoromethyl, phenyl, substituted phenyl, (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₁-C₆)-alkoxy, (C₃-C₇)-cycloalkyl, phenyl-(C₁-C₃)-alkoxy, (C₁-C₆)-alkanoyloxy, (C₁-C₆)-alkoxycarbonyl, carboxy, formyl, or -NR⁴R⁵. The substituents on the substituted phenyl or substituted alkyl R^8 groups are from 1 to 3 of, for example, hydroxy, fluoro, (C₁-C₆)-alkoxy, (C₃-C₇)-cycloalkyl, phenyl, phenyl-(C₁-C₃)-alkoxy, (C₁-C₆)-alkanoyloxy, (C₁-C₆)-alkoxycarbonyl, carboxy, formyl, or -NR⁴R⁵.

The groups R^4 and R^5 are independently hydrogen, (C₁-C₆)-alkyl, (C₃-C₆)-alkenyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-cycloalkyl-(C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl, naphthyl-(C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl. The substituents on the substituted phenyl or substituted naphthyl R^4 and R^5 groups are 1 to 3 of, for example, halogen, cyano, trifluoromethyl, (C₁-C₄)-alkyl, or (C₁-C₄)-alkoxy groups.

R^4 and R^5 may be joined together to form -(CH₂)_rA(CH₂)_s- wherein the subscripts r and s are independently 1 to 3 and A is CHR⁶, NR⁶, O, or S(O)_n in which n is 0, 1, or 2; and R^6 is hydrogen, (C₁-C₆)-alkyl, piperidin-1-yl, phenyl, or phenyl-(C₁-C₆)-alkyl.

R^{1a} and R^{1b} are independently trifluoromethyl, (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, substituted (C₂-C₁₀)-alkynyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-cycloalkenyl, or (C₁-C₆)-alkanoyl. The substituents on the substituted alkyl, substituted alkenyl, and substituted alkynyl R^{1a} and R^{1b} groups are independently from 1 to 3 of, for example, -OR⁴, -C(O)R⁴, -CO₂R⁴, -C(O)NR⁴R⁵, -NR⁴R⁵, or phenyl which is optionally substituted with from 1 to 3 of, for example, halogen, (C₁-C₄)-alkyl, or (C₁-C₄)-alkoxy groups.

R^2 is (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, substituted (C₂-C₁₀)-alkynyl, (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl, or substituted (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl. The

0 substituents on the substituted alkyl, substituted alkenyl, substituted alkynyl, and substituted cycloalkyl R^2 groups are independently from 1 to 3 of halogen, phenyl, substituted phenyl, 1,3-dioxolan-2-yl, $-C(O)NR^4R^5$, or $-S(O)_mR^7$ wherein m is 0, 1, or 2. The substituents on the substituted phenyl R^2 substituent group are from 1 to 3 of, for example, halogen, (C_1-C_4) -alkyl, or (C_1-C_4) -alkoxy.

5 R^7 is (C_1-C_6) -alkyl, phenyl, substituted phenyl, phenyl- (C_1-C_6) -alkyl, substituted phenyl- (C_1-C_6) -alkyl, pyridyl, substituted pyridyl, pyridyl- (C_1-C_6) -alkyl, substituted pyridyl- (C_1-C_6) -alkyl, naphthyl, substituted naphthyl, naphthyl- (C_1-C_6) -alkyl, or substituted naphthyl- (C_1-C_6) -alkyl. The substituents on the substituted phenyl, substituted pyridyl or substituted naphthyl R^7 groups are from
10 1 to 5 of, for example, halogen, trifluoromethyl, (C_1-C_6) -alkyl, (C_1-C_6) -alkoxy, nitro, cyano, or hydroxy.

R^2 and R^{1b} may be joined to form an alkylene bridge containing from 3 to 5 carbon atoms, between the ring carbon atoms to which R^2 and R^{1b} are attached.

R^3 is hydroxy, trifluoroacetyl, (C_1-C_6) -alkanoyl, substituted (C_1-C_6) -alkyl, or substituted (C_3-C_6) -alkenyl. The substituents on the substituted alkyl and substituted alkenyl R^3 groups are from 1 to 3 hydroxy or trifluoromethyl groups.

Ar' is an optionally substituted heteroaromatic ring. Examples of possible Ar' groups are: pyridyls, furanyls, thiophenyls, pyrrolyls, imidazolyls, pyrazolyls, triazolyls, tetrazolyls, oxazolyls, isoxazolyls, thiazolyls and isothiazolyls. The
20 optional substituents on the group Ar' are independently 1 to 3 of, for example, halogen, (C_1-C_6) -alkyl, substituted (C_1-C_6) -alkyl, (C_2-C_6) -alkenyl, substituted (C_2-C_6) -alkenyl, (C_2-C_6) -alkynyl, substituted (C_2-C_6) -alkynyl, (C_3-C_7) -cycloalkyl, cyano, nitro, trifluoromethyl, $-OR^4$, $-C(O)R^4$, $-OC(O)R^4$, $-CO_2R^4$, $-NR^4R^5$, $-C(O)NR^4R^5$, or $-S(O)_mR^7$. The substituents on the substituted alkyl, substituted
25 alkenyl, and substituted alkynyl substituent groups on Ar' are from 1 to 3 of, for example, halogen, hydroxy, $-NR^4R^5$, phenyl, or substituted phenyl in which the phenyl group may bear, for example, one or more halogen, (C_1-C_4) -alkyl, or (C_1-C_4) -alkoxy groups.


30 Pharmaceutically acceptable salts of these materials are within the scope of the invention.

In formula 1C, the preferred and most preferred groups R^{1a} , R^{1b} , R^2 , R^3 , and R^8 , as well as the additional groups R^4 , R^5 , R^6 , and R^7 embedded therein, and the various substituent groups thereon, are as defined in connection with general
35 formula (IC) above.

In formula 1C, heteroaromatic ring Ar' is preferably selected from the group consisting of pyridyls, furanyls, thiophenyls, pyrazolyls, triazolyls, oxazolyls and

- 0 thiazolyls, and the optional substituents on the group Ar' are preferably independently from 1 to 3 of, for example, halogen, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, (C₃-C₇)-cycloalkyl, cyano, -OR⁴, or -OC(O)R⁴, where R⁴ is hydrogen, (C₁-C₆) alkyl, phenyl (C₁-C₆) alkyl or substituted phenyl (C₁-C₆) alkyl where the phenyl substituents are from 1 to 3 of halogen or (C₁-C₄) alkyl.
- 5 Heteroaromatic ring Ar' is most preferably selected from the group consisting of pyridyls, furanyls and thiophenyls, and the optional substituents thereon are most preferably independently from 1 to 3 of, for example, halogen, (C₁-C₆) alkyl, (C₂-C₆) alkenyl, -OR⁴, or -OC(O)R⁴, where R⁴ is hydrogen or (C₁-C₆) alkyl.

- 10 The aryl-substituted benzenes included within formula (IC) have the formula 1D



wherein

- 15 R⁸ represents hydrogen, halogen, trifluoromethyl, phenyl, substituted phenyl, (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₁-C₆)-alkoxy, (C₃-C₇)-cycloalkyl, phenyl-(C₁-C₃)-alkoxy, (C₁-C₆)-alkanoyloxy, (C₁-C₆)-alkoxycarbonyl, carboxy, formyl, or -NR⁴R⁵. The substituents on the substituted phenyl or substituted alkyl R⁸ groups are from 1 to 3 of, for example, hydroxy, fluoro, (C₁-C₆)-alkoxy, (C₃-C₇)-cycloalkyl, phenyl, phenyl-(C₁-C₃)-alkoxy, (C₁-C₆)-alkanoyloxy, (C₁-C₆)-alkoxycarbonyl, carboxy, formyl, or -NR⁴R⁵.

- 20 The groups R⁴ and R⁵ are independently hydrogen, (C₁-C₆)-alkyl, (C₃-C₆)-alkenyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-cycloalkyl-(C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl, naphthyl-(C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl. The substituents on the substituted phenyl or substituted naphthyl R⁴ and R⁵ groups are 1 to 3 of, for example, halogen, cyano, trifluoromethyl, (C₁-C₄)-alkyl, or (C₁-C₄)-alkoxy groups.

- 25 R⁴ and R⁵ may be joined together to form -(CH₂)_rA(CH₂)_s- wherein the subscripts r and s are independently 1 to 3 and A is CHR⁶, NR⁶, O, or S(O)_n in which n is 0, 1, or 2; and R⁶ is hydrogen, (C₁-C₆)-alkyl, piperidin-1-yl, phenyl, or phenyl-(C₁-C₆)-alkyl.
- 30

0 R^{1a} and R^{1b} are independently trifluoromethyl, (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, substituted (C₂-C₁₀)-alkynyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-cycloalkenyl, or (C₁-C₆)-alkanoyl. The substituents on the substituted alkyl, substituted alkenyl, and substituted alkynyl R^{1a} and R^{1b} groups are independently from 1 to 3 of, for
 5 example, -OR⁴, -C(O)R⁴, -CO₂R⁴, -C(O)NR⁴R⁵, -NR⁴R⁵, or phenyl which is optionally substituted with from 1 to 3 of, for example, halogen, (C₁-C₄)-alkyl, or (C₁-C₄)-alkoxy groups.

R^2 is (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, substituted (C₂-C₁₀)-alkynyl, (C₃-
 10 C₆)-cycloalkyl-(C₁-C₆)-alkyl, or substituted (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl. The substituents on the substituted alkyl, substituted alkenyl, substituted alkynyl, and substituted cycloalkyl R^2 groups are independently from 1 to 3 of halogen, phenyl, substituted phenyl, 1,3-dioxolan-2-yl, -C(O)NR⁴R⁵, or -S(O)_mR⁷ wherein m is 0, 1,
 15 or 2. The substituents on the substituted phenyl R^2 substituent group are from 1 to 3 of, for example, halogen, (C₁-C₄)-alkyl, or (C₁-C₄)-alkoxy.

R^7 is (C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, pyridyl, substituted pyridyl, pyridyl-(C₁-C₆)-
 20 alkyl, substituted pyridyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl, naphthyl-(C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl. The substituents on the substituted phenyl, substituted pyridyl or substituted naphthyl R^7 groups are from
 1 to 5 of, for example, halogen, trifluoromethyl, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, nitro, cyano, or hydroxy.

R^2 and R^{1b} may be joined to form an alkylene bridge containing from 3 to 5 carbon atoms, between the ring carbon atoms between the ring carbon atoms to
 25 which R^2 and R^{1b} are attached.

R^3 is hydroxy, trifluoroacetyl, (C₁-C₆)-alkanoyl, substituted (C₁-C₆)-alkyl, or substituted (C₃-C₆)-alkenyl. The substituents on the substituted alkyl and substituted alkenyl R^3 groups are from 1 to 3 hydroxy or trifluoromethyl groups.

 Ar" is an optionally substituted aromatic ring. Examples of possible Ar"
 30 groups are phenyls and naphthyls. The optional substituents on the group Ar are independently 1 to 3 of, for example, halogen, (C₁-C₆)-alkyl, substituted (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, substituted (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, substituted (C₂-C₆)-alkynyl, (C₃-C₇)-cycloalkyl, cyano, nitro, trifluoromethyl, -OR⁴, -C(O)R⁴, -OC(O)R⁴, -CO₂R⁴, -NR⁴R⁵, -C(O)NR⁴R⁵, or -S(O)_mR⁷. The substituents on the
 35 substituted alkyl, substituted alkenyl, and substituted alkynyl substituent groups on Ar are from 1 to 3 of, for example, halogen, hydroxy, -NR⁴R⁵, phenyl, or

- 0 substituted phenyl in which the phenyl group may bear, for example, one or more halogen, (C₁-C₄)-alkyl, or (C₁-C₄)-alkoxy groups.

Pharmaceutically acceptable salts of these materials are within the scope of the invention.

- 5 In formula 1D, the preferred and most preferred groups R^{1a}, R^{1b}, R², R³, and R⁸, as well as the additional groups R⁴, R⁵, R⁶, and R⁷ embedded therein, and the various substituent groups thereon, are as defined in connection with general formula (IC) above.

- 10 In formula 1D, aromatic ring Ar" preferably is a phenyl ring wherein the optional substituents are preferably from 1 to 3 of, for example, halogen, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, (C₃-C₇)-cycloalkyl, cyano, -OR⁴ or -OC(O)R⁴, where R⁴ is hydrogen, (C₁-C₆) alkyl, phenyl (C₁-C₆) alkyl or substituted phenyl (C₁-C₆) alkyl where the phenyl substituents are from 1 to 3 of halogen or (C₁-C₄) alkyl. Most preferably, the substituents are from 1 to 3 of, for
15 example, halogen, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, -OR⁴ or -OC(O)R⁴, where R⁴ is hydrogen or (C₁-C₆) alkyl.

- Basic compounds of the invention are generally isolated in the form of their pharmaceutically acceptable acid addition salts derived using inorganic or organic
20 acids. Examples of such materials are hydrochloric, nitric, sulfuric, phosphoric, formic, acetic, trifluoroacetic, propionic, maleic, succinic, and malonic acids. Compounds of the invention which contain an acidic functionality such as a carboxyl group can be isolated in the form of pharmaceutically acceptable addition salts derived using inorganic or organic bases. The salt forming ion derived from
25 such bases can be a metal ion such as sodium, potassium, lithium, calcium, magnesium, etc., or an ion of an organic base, such as an ammonium or substituted ammonium ion derived from an amine. Examples of suitable amines for this purpose include ammonia, arylalkylamines such as dibenzylamine and *N,N*-dibenzylethylenediamine, lower alkylamines such as methylamine, *t*-butylamine,
30 procaine, lower alkylpiperidines such as *N*-ethylpiperidine, cycloalkylamines such as cyclohexylamine or dicyclohexylamine, 1-adamantylamine, benzathine, or salts derived from amino acids such as arginine or lysine.

The present invention also encompasses pharmaceutically acceptable "prodrugs" of the compounds of formula (IC) which form such derivatives. These

0 are typically acylated derivatives of alcohol-containing compounds of the invention, though other types of prodrugs are known. Preparation of such derivatives is within the skill of the art.

The inhibitors of the present invention are contemplated for use in veterinary and human applications. For such applications, the active agent(s) are
5 employed in pharmaceutical compositions which comprise the active ingredient(s) plus a pharmaceutically acceptable carrier which contains one or more diluents, fillers, binders, or other excipients, depending on the administration mode and dosage form contemplated. Examples of such agents include carriers such as sucrose, lactose, or starch; lubricating agents such as magnesium stearate;
10 adjuvants, such as wetting agents; excipients such as cocoa butter or suppository wax; emulsifying and suspending agents, and sweetening, flavoring and perfuming agents and buffering agents.

The pharmaceutical compositions of the invention may also include one or more known antidiabetic agents in addition to a compound of structural formula
15 (IC). Examples of such antidiabetic agents are: α -glucosidase inhibitors such as acarbose or voglibose, insulin sensitizers such as bromocriptine, thiazolidinediones such as troglitazone, insulin secretagogues such as glimepride, sulfonylureas such as glyburide, GLP-1 and its derivatives such as insulinotropin, amylin and its derivatives such as AC-137, calcitonin, insulin and its derivatives such as HOE-901,
20 biguanides such as metformin, aldose reductase inhibitors such as tolrestat, β_3 agonists such as BTA-243, and hypocholesterolemics such as lovastatin.

The method of treating glucagon-mediated conditions by administering a glucagon receptor antagonist of the present invention may be practiced in mammals, including humans, which exhibit such conditions. A typical application is
25 treatment of diabetes.

The compounds of this invention can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection or implant), nasal, vaginal, rectal, sublingual, or topical routes of administration and can be formulated in dosage forms appropriate for each route of administration.

30 Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than inert diluents, e.g., lubricating agents such as
35 magnesium stearate. In the case of capsules, tablets and pills, the dosage forms

0 may also comprise buffering agents. Tablets and pills can additionally be prepared
with enteric coatings such as the OROS-CT/Osmet™ and PULSINCAP™ systems
from ALZA and Scherer Drug Delivery Systems.

5 Liquid dosage forms for oral administration include pharmaceutically
acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert
diluent commonly used in the art, such as water. Besides such inert diluents,
compositions can also include adjuvants, such as wetting agents, emulsifying and
suspending agents, and sweetening, flavoring and perfuming agents.

Preparations according to this invention for parenteral administration
include sterile aqueous or non-aqueous solutions, suspensions, or emulsions.
10 Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene
glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic
esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as
preserving, wetting, emulsifying, and dispersing agents. Alternatively
intramuscular, intraarticular or subcutaneous depot injection with or without
15 encapsulation of the drug into degradable microspheres e.g., comprising poly(DL-
lactide-co-glycolide) may be used to obtain prolonged sustained drug release. For
improved convenience of the dosage form it may be possible to use an i.p.
implanted reservoir and septum such as the Percuseal system available from
Pharmacia. Improved convenience and patient compliance may also be achieved
20 by the use of either injector pens (e.g. the NovoPen or Q-pen) or needle-free jet
injectors (e.g. from Bioject, Mediject or Becton Dickinson). Prolonged zero-order or
other precisely controlled release such as pulsatile release can also be achieved as
needed using implantable pumps with delivery of the drug through a cannula into
the synovial spaces. Examples include the subcutaneously implanted osmotic
25 pumps available from ALZA, such as the ALZET osmotic pump.

Compositions for nasal or sublingual administration are also prepared with
standard excipients well known in the art.

Compositions for rectal or vaginal administration are preferably
suppositories which may contain, in addition to the active substance, excipients
30 such as cocoa butter or a suppository wax.

The compounds of this invention can be manufactured into the above listed
formulations by the addition of various therapeutically inert, inorganic or organic
carriers well known to those skilled in the art. Examples of these include, but are
not limited to, lactose, corn starch or derivatives thereof, talc, vegetable oils, waxes,
35 fats, polyols such as polyethylene glycol, water, saccharose, alcohols, glycerin and
the like. The formulations may be sterilized by, for example, filtration through a

0 bacteria-retaining filter, by incorporating sterilizing agents into the compositions,
by irradiating the compositions, or by heating the compositions. They can also be
manufactured in the form of sterile solid compositions which can be dissolved in
sterile water, or some other sterile injectable medium immediately before use.
Various preservatives, emulsifiers, dispersants, flavorants, wetting agents,
5 antioxidants, sweeteners, colorants, stabilizers, salts, buffers and the like are also
added, as required to assist in the stabilization of the formulation or to assist in
increasing bioavailability of the active ingredient(s) or to yield a formulation of
acceptable flavor or odor in the case of oral dosing.


10 The amount of the pharmaceutical composition to be employed will depend
on the recipient and the condition being treated. The requisite amount may be
determined without undue experimentation by protocols known to those skilled in
the art. Alternatively, the requisite amount may be calculated, based on a
determination of the amount of target receptor which must be inhibited to treat the
condition. An effective amount of active ingredient is generally in the range 0.0001
15 mg/kg to 100 mg/kg of body weight.

The treatment method of the invention is not limited to administration of the
above-described pharmaceutical composition. Rather, this treatment regimen may
be employed in combination with conventional treatments of diabetes (both Type I
20 and Type II) or of other conditions which are sometimes found in diabetic subjects.
Thus, for example, treatment may be administered in conjunction with (a) diet
restrictions and exercise; (b) insulin, or other drugs used to treat ketoacidosis; (c)
any drug used for the treatment of hyperlipidemia, such as lovastatin, or
cardiovascular disease, such as enalapril; (d) drugs used to treat diabetic
25 complications, such as epalrestat and (e) drugs that lower body weight, such as
dexfenfluramine.


The glucagon receptor antagonists of the invention are useful not only for
treatment of the pathophysiological conditions discussed above, but are also useful
in other applications such as a diagnostic agent. For example, these compounds
30 can be administered to humans *in vivo* in the fasting state as a diagnostic tool to
directly determine whether the glucagon receptor is functional. Serum samples
taken before and after such administration can be assayed for glucose levels;
comparison of the amounts of blood glucose in each of these samples would be a
means for directly determining the ability of the patient's glucagon receptor to

- 0 modulate hepatic glucose output. Alternatively, compounds of the present invention may be useful for finding new glucagon antagonists. For example, a binding assay employing a radiolabeled derivative (such as ^3H) of a compound of formula (IC) would be useful in identifying new compounds that competitively bind to the glucagon receptor. Such an assay is useful in identifying structurally
- 5 novel antagonists that may offer advantages in ease of chemical modification, selectivity and oral bioavailability.

- 0 The compounds of the present invention may contain asymmetric centers on the molecule, depending upon the nature of the various substituents. Each such asymmetric center will produce two optical isomers. In certain instances, asymmetry may also be present due to restricted rotation about the central bond adjoining the two aromatic rings of the specified compounds. For example, for
- 5 certain compounds of Formula (IC) wherein Ar is taken as substituted phenyl, there exist additional isomers due to restricted rotation about the central aryl-aryl bond, depending on the substitution pattern.




- 10 It is intended that all isomers, either by nature of asymmetric centers or by restricted rotation as described above, as separated, pure or partially purified isomers or racemic mixtures thereof, be included within the ambit of the instant invention. In the case of compounds of Formula (IC) wherein R³ is taken as 1-hydroxyethyl, it has been found that the isomer in which the hydroxy substituent is
- 15 above the plane of the structure, as seen in Formula Ic, is more active and thus more preferred over the compound in which the hydroxy substituent is below the plane of the structure.




Ic

0 Representative examples of the nomenclature employed herein are given below:

2,6-Dimethyl-3-hydroxymethyl-4-(3-bromophenyl)-5-isobutylpyridine



3,5-Di-*t*-butyl-2-(phenylthio)methyl-6-hydroxymethyl-3',5'-dichloro-1,1'-biphenyl




10 The compounds of general formula (IC) of the present invention are prepared as indicated in the following reaction Schemes.

15 The phenylpyridine compounds of formula (IC) (X= N) are prepared from a common intermediate 6 using the well-known Hantzsch pyridine synthesis, as shown in Scheme 1 (Stout, D. M.; Myers, A. I. *Chem. Rev.* **1982**, 223).

20

0


SCHEME 1

The ketoester 1, (commercially available or prepared according to the procedure of Deslongchamps, *Synth. Comm.*, 1976, 6, 169) is treated with an ammonium salt such as ammonium acetate, in an inert solvent such as cyclohexane capable of forming an azeotrope with water, to give the enamine 2. Compound 2 is then treated with the ketoester 3, which may or may not be identical to the ketoester 1, and an aromatic aldehyde, in a polar solvent such as ethanol, to produce the dihydropyridine 5. Certain substituents on aldehyde 4 may need to be protected during the Hantzsch pyridine synthesis. A description of suitable protecting groups may be found in: Protective Groups in Organic Synthesis, Second Edition, T. W. Greene, John Wiley and Sons, New York, 1991. Oxidation of 5 is achieved by any of several known methods. For example, treatment of 5 with 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) in a solvent such as methylene chloride (CH₂Cl₂), or with ceric ammonium nitrate (CAN) in a mixture of solvents such as aqueous acetone, affords the intermediate 6. Separation of unwanted side products and purification of intermediates is achieved by chromatography on silica gel, employing flash chromatography (Still, W.C.; Khan, M.; Mitra, A. *J. Org. Chem.*, 1978, 43, 2923)

An alternative Hantzsch pyridine synthesis of the intermediate 6, where R^{1a} and R^{1b} of formula (IC) are identical, can be accomplished following the procedure of Chucholowski (U.S. Patent 4,950,675), Scheme 2. By heating two equivalents of ketoester 1 with ammonium hydroxide and the aldehyde 4 in a polar solvent such as methanol, the dihydropyridine 5 is obtained directly. Compound 5 is oxidized to pyridine 6, according to the procedure described in Scheme 1.


0

SCHEME 2



In Scheme 3, another alternative Hantzsch pyridine synthesis of intermediate 6 is described. Ketoester 1 is condensed with aldehyde 4 by treatment with catalysts such as acetic acid and piperidine without solvent to afford intermediate 7. Treatment of 7 with ketoester 3 in the presence of a base such as sodium methoxyde, in a polar solvent such as methanol produces the diketone 8. Cyclization of 8 is achieved by treatment with an ammonium salt such as ammonium acetate in a polar solvent such as acetic acid to afford the previously described dihydropyridine 5 (Scheme 1), which is oxidized to the pyridine 6 according to the procedure as indicated in Scheme 1.

SCHEME 3




15

The synthesis of aryl pyridine derivatives of formula (IC) wherein R² is alkyl and R³ is hydroxymethyl (IIa) is described in Scheme 4.

20

0

SCHEME 4



Chemical reducing agents such as sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al) in an inert solvent, such as tetrahydrofuran (THF) or diethyl ether (Et₂O), can result in a monoreduction of the pyridinediester **6** to give the alcohol **9**. Oxidants such as pyridinium chlorochromate (PCC), in a solvent such as CH₂Cl₂, convert compound **9** to the aldehyde **10**. Wittig reaction with compound **10** and an ylide **11a**, in an inert solvent such as THF or Et₂O, affords olefin **12** obtained usually, but not always, as a mixture of *E* and *Z* isomers. The reagent **11a** is prepared from an alkyl triphenyl phosphonium salt, wherein the alkyl group may contain a heteroatom, and a suitable base such as butyllithium or sodium amide, according to known methods (Maercker, A. in *Organic Reactions*, Vol. 14, Ed.; Wiley, New York, 1965, Chapter 3). Olefin **12** is successively treated with a reducing agent such as lithium aluminum hydride (LAH), in an inert solvent such as THF or Et₂O, and hydrogen in the presence of a metal catalyst, such as palladium on carbon, in a polar solvent such as ethanol, to afford compounds of formula IIa. In some of these compounds, R² may contain substituents such as alcohol, acetate, ester, carboxylic acid, and amide. These products can be obtained directly by the procedures of Scheme 4, with or without the use of appropriate protecting groups, or by additional steps familiar to those skilled in the art. For example, a primary alcohol can be converted to a carboxylic acid by standard methods of oxidation,


0 such as those described by Eisenbraun (Eisenbraun, E. J. *Org. Syn. Coll.*, 1973, 5, 310).

5 If the Wittig reaction is performed with methoxymethyl triphenylphosphonium as ylide (11b), followed by treatment with an acid such as hydrochloric acid, the homologous aldehyde 13 is obtained. This can undergo another Wittig reaction to afford olefin 14, (Scheme 5). This known procedure (Wittig, G.; Walter, B.; Kruck, K.-H. *Chem. Ber.* 1962, 2514) allows one to synthesize extended alkyl chain (R^2) analogs of formula IIa, which may not be directly prepared by usual Wittig reaction due to limited availability of the requisite alkyl triphenylphosphonium salt.

10 Oxidation of the compounds of formula IIa by the method described in Scheme 4 affords intermediates that can be converted to homologues of compounds of formula IIa, containing the $-CH_2-CH_2-$ linkage between the pyridine nucleus and the hydroxy group (IIb).

15

SCHEME 5




20 Synthesis of aryl pyridine derivatives of formula (IC) wherein R^2 is alkyl containing a heteroatom such as sulfur and R^3 is hydroxymethyl (IIIa and IIIb), is outlined in Scheme 6. Alcohol 9 is converted to an alkyl halide 15 by treatment with a suitable reagent such as dibromotriphenylphosphorane in an inert solvent. Treatment of 15 with a thiol and a base such as N-methyl morpholine in an inert solvent produces intermediate 16. The sulfur atom of compounds 16 can be

25 oxidized ($n = 1$ or 2) by any of several known methods. For example, it can be accomplished by treatment of 16 wherein $n=0$, with an oxidant such as m-chloroperbenzoic acid in a solvent such as CH_2Cl_2 . Chemical reducing agents such

- 0 as lithium aluminum hydride (LAH) in an inert solvent such as tetrahydrofuran or diethyl ether, can reduce the ester 16 to a compound of formula IIIa. Intermediate 15 can also react with alcohols following the methods outlined in Scheme 6, to afford compounds of formula IIIc.

5


SCHEME 6



- 10 The synthesis of aryl pyridine derivatives of formula (IC) wherein R^2 is alkyl containing a heteroatom such as nitrogen and R^3 is hydroxymethyl (IVa), is outlined in Scheme 7. Treatment of 15 with a primary or secondary amine in an inert solvent results in the intermediate 17. Chemical reducing agents such as lithium aluminum hydride in an inert solvent, such as tetrahydrofuran or diethyl ether, can reduce ester 17 to a compound of formula IVa. Reduction of aldehyde 13 by the method outlined in Scheme 4 affords an intermediate that can be converted to homologues of compounds of formula IIIa and IVa, containing the $-CH_2-CH_2-$ linkage between the pyridine nucleus and the sulfur or nitrogen substituent (IIIb and IVb).


20

0

SCHEME 7

5 Synthesis of aryl pyridine derivatives of formula (IC) wherein R^2 is alkyl and R^3 is 1-hydroxyethyl (Va), is outlined in Scheme 8. Oxidants such as pyridinium chlorochromate (PCC), are used to convert compounds of formula II to the aldehyde 18. Treatment of 18 with an organometallic reagent such as methyl magnesium bromide or methyl lithium in an inert solvent such as THF or Et₂O affords racemic compounds of formula Va. Chiral 1-hydroxyethyl aryl pyridine derivatives of formula Vb are obtained by resolution of the racemates Va by classical methods. For example, resolution can be achieved by formation of diastereomeric adducts of the racemic compounds with optically active reagents such as α -methoxy- α -(trifluoromethyl)phenylacetic acid (Dale, J.A.; Dull, D.L.; Mosher, H.S. *J. Org. Chem.* **1969**, *34*, 2543). Alternatively, separation of enantiomers is achieved by HPLC on chiral solid phase. Determination of absolute stereochemistry can be achieved in a number of ways familiar to those skilled in the art, including X-ray analysis of a suitable crystalline derivative, such as a Mosher ester.

15


SCHEME 8

20

0

An alternative synthesis of aryl pyridine derivatives of formula Vb is achieved by treating aldehyde 18 with the anion of methyl toluylsulfoxide 19 to give a diastereomeric mixture of alcohols 20 as shown in Scheme 9 (Blase, F. R.; Le H. *Tet. Lett.* 1995, 36, 4559). The diastereomers are separated by flash chromatography and treated separately with Raney nickel and hydrogen in ethanol to provide pure enantiomers (>99% enantiomeric excess, e.e.) of the compounds of formula Vb. Alternatively, the chromatographic step is avoided by a two step sequence consisting of (1) oxidation of the mixture 20 with manganese dioxide in an inert solvent, followed by (2) reduction of the ketone with a chemical reductant such as LAH, to provide the enantiomerically pure alcohol 21. Treatment of 21 with Raney nickel and hydrogen in a polar solvent provides pure enantiomer (>99% e.e.) of the compounds of formula Vb.

SCHEME 9




15

A preferred alternative enantioselective synthesis of aryl pyridine derivatives of formula Vb is shown in Scheme 10. Treatment of the racemic mixture of compounds of formula Va with an oxidant such as pyridinium chlorochromate (PCC), gives the ketone 22. Reduction of 22 with a complex of LAH and N-methylephedrine (Kawasaki, M.; Susuki, Y.; Terashima, S. *Chem. Lett.* 1984, 239) in an inert solvent, provides the alcohol of formula Vb with an enantiomeric excess of 95%.

25

0


SCHEME 10



5 The synthesis of aryl pyridine derivatives of formula (IC) wherein R^2 is alkyl and R^3 is 1,2-dihydroxyalkyl (VI), is described in Scheme 11. A methyl triphenylphosphonium salt is treated with a suitable base such as butyllithium in an inert solvent and reacted with intermediate 18 to afford olefin 23. Treatment of compound 23 with a suitable oxidant such as osmium tetroxide in a polar solvent such as pyridine gives the compounds of formula VI.

10

SCHEME 11




15 The synthesis of aryl pyridine derivatives of formula (IC) wherein R^2 and R^{1b} are taken together to form an alkylene bridge and R^3 is hydroxymethyl (VIIa), is described in Scheme 12. The ketoester 1, is treated with an aromatic aldehyde and catalysts such as acetic acid and piperidine, in ethanol, to afford the α,β -unsaturated ketoester 24. Treatment of 24 with the cyclic ketone 25 and a base such as lithium bis(trimethylsilyl)amide in an inert solvent such as THF affords an intermediate which is treated with ammonium acetate and copper acetate in acetic

acid to give the pyridine 26. Chemical reducing agents reduce the ester 26 to analogs of formula VIIa. It may be appreciated that these analogs can be used as intermediates to generate new derivatives of formula (IC) wherein R² and R^{1b} are taken together and R³ is 1-hydroxyethyl (VIIb) according to the procedures described in Scheme 8.

5

SCHEME 12




The synthesis of the aryl pyridine derivative IIa wherein R^{1b} is CH₂OH is described in Scheme 13. Alcohol 27 (aryl pyridine IIa in which R^{1b} is CH₃) is treated with a trialkylsilyl chloride, such as *tert*-butyldiphenylsilyl chloride, and a base to yield silyl ether 28. Treatment of 28 with *meta*-chloroperbenzoic acid in an inert solvent, such as chloroform, provides the N-oxide 29. The N-oxide is treated with acetic anhydride to afford pyridine acetate 30. Treatment of 30 with aqueous methanol in the presence of potassium carbonate, yields alcohol 31. The silyl ether is cleaved with tetrabutylammonium fluoride in THF to provide aryl pyridine derivative 32.

20

0


SCHEME 13



5 The synthesis of aryl pyridine derivatives **Xa** wherein R^{1b} is $-\text{CH}_2\text{NR}^4\text{R}^5$ is described in Scheme 14. Oxidation of alcohol **31** as described in Scheme 4 yields aldehyde **33**. Treatment of the aldehyde with an amine in the presence of a Lewis acid, such as zinc chloride, and a reducing agent, such as sodium cyanoborohydride, provides the amine **34**. Deprotection of the alcohol as described in Scheme 13 affords aryl pyridine derivative **Xa**.

10


SCHEME 14



15 An alternative synthesis of amine **34** is shown in Scheme 15. Treatment of pyridine N-oxide **29** with phosphorus oxychloride and a base, such as triethylamine, in **CH₂Cl₂**, yields chloromethylpyridine **35**. The chloride is treated

0 with an amine providing amine 34.

SCHEME 15




5

The synthesis of aryl pyridine derivatives Xb wherein R^{1b} is -CH=CHR is described in Scheme 16. Alcohol 31 is converted to the corresponding bromide as described in Scheme 6. Treatment of 36 with sodium phosphite in benzene yields phosphonate 37. The phosphonate is treated with a base, such as sodium hydride, and subsequently with an aldehyde affording olefin 38. Deprotection of the alcohol as described affords aryl pyridine Xb.

10

SCHEME 16




15

An alternative synthesis of olefin 38 is shown in Scheme 17. Aldehyde 33 is

0 treated with an ylide as described in Scheme 4 to yield olefin 38.


SCHEME 17



5

The synthesis of aryl pyridine derivative Xc wherein R^{1b} is $-CH_2CH_2R$ is described in Scheme 18. Hydrogenation of olefin Xb as described in Scheme 4 yields the alkane Xc.


SCHEME 18



10

15 The synthesis of aryl pyridine derivative Xd wherein R^{1b} is $-CH(OH)R$ is described in Scheme 19. Treatment of aldehyde **33** with a Grignard reagent in an inert solvent, such as THF, yields alcohol **39**. Deprotection of the alcohol as described affords aryl pyridine derivative Xd.

SCHEME 19




20

The synthesis of aryl pyridine derivatives Xe wherein R^{1b} is $-COR$ is

- 0 described in Scheme 20. Oxidation of alcohol 39 as described in Scheme 4 yields ketone 40. Deprotection of the alcohol as described affords the aryl pyridine derivative Xe.


SCHEME 20

5



- 10 The synthesis of aryl pyridine derivatives Xf wherein R^{1b} is -C(OH)RR' is described in Scheme 21. Grignard addition to ketone 40 as described in Scheme 19 yields alcohol 41. Deprotection of the alcohol as described affords the aryl pyridine derivative Xf.

SCHEME 21




15

The synthesis of aryl pyridine derivatives Xg wherein R^{1b} is -C(OR⁴)RR' is described in Scheme 22. Treatment of alcohol 41 with a base, such as sodium hydride, and an alkylating agent in THF, yields ether 42. Deprotection of the

0 alcohol as described affords the aryl pyridine derivative Xg.

SCHEME 22




5

The biphenyl analogs described in formula (IC) ($X = \text{C-R}^8$, wherein R^8 is H), are prepared by the methods described by Fey, *et al.* US Patent 5,138,090. The key step of the synthesis is the coupling of an arylpalladium dimer with an aryl Grignard reagent (Scheme 23).

10


SCHEME 23




15 A specific example of this method is shown in Scheme 24. Treatment of diol 43 (prepared according to the procedure of Fey, *et al.* US Patent 5,138,090) with (2-methoxy)ethoxymethyl chloride and diisopropylethylamine in CH_2Cl_2 solvent gives MEM ether 44. Oxidation of the remaining alcohol of 44 as described in Scheme 4 provides aldehyde 45. Treatment of the aldehyde with aniline in the presence of a catalytic amount of p-toluenesulfonic acid (pTSA) and molecular
 20 sieves in toluene solvent gives imine 46. The imine is converted to the palladium dimer 47 upon treatment with palladium acetate in acetic acid solvent. Treatment of 47 with triphenylphosphine, then with 4-fluorophenylmagnesium bromide

0 (prepared from 1-bromo-4-fluorobenzene and magnesium metal), and finally with
aqueous hydrochloric acid in benzene solvent yields biphenyl 48. The aldehyde
moiety of biphenyl 48 is converted to a pentyl group by the methods described in
Scheme 4. MEM ether 50 is treated with trimethylsilyl chloride and sodium iodide
in acetonitrile solvent, and subsequently with sodium acetate in DMF solvent to
5 provide acetate 51. Saponification of the acetate using potassium hydroxide in
methanol solvent provides alcohol 52. Hydroxymethyl biphenyl 52 is transformed
to racemic hydroxyethyl biphenyl 54 as described in Scheme 8.


SCHEME 24






An alternative synthesis of biphenyls of formula (IC) is the coupling of a suitably functionalized benzene derivative 57 (where X can be trifluoromethanesulfonate, methoxy, bromide, or iodide) with an arylmetal reagent ArMY_n (where M may be B, Sn, or Mg, and Y is a ligand).

SCHEME 25




An example of such a biaryl coupling is the Suzuki reaction (Miyaura, N., Yanagi, T., Suzuki, A. *Synth. Comm.* 1981, 11, 513-519; Oh-e, T., Miyaura, N., Suzuki, A. *J. Org. Chem.* 1993, 58, 2201-2208) in which a benzene derivative 58 (in which X can be trifluoromethanesulfonate, bromide, or iodide) is coupled with an arylboronic acid (Scheme 26).

0

SCHEME 26

5

The requisite arylboronic acid 60 may be prepared by sequential reaction of an aryl halide 59 (X = Br or I) with magnesium metal, a boronic ester, and hydrochloric acid.


SCHEME 27

10


15

20

A specific example of the use of the Suzuki reaction to synthesize a biphenyl analog is depicted in Scheme 28. Phenol 61 is treated sequentially with sodium hydride and allyl bromide in dimethylformamide solvent to afford allyl ether 62. Claisen rearrangement of the ether provides phenol 63. The phenol is treated with trifluoromethanesulfonic anhydride (triflic anhydride) and pyridine in CH_2Cl_2 solvent to give triflate 64. Treatment with 4-fluorophenylboronic acid, tetrakis(triphenylphosphine) palladium (0), potassium phosphate (tribasic), and potassium bromide in 1,4-dioxane solvent affords biphenyl 65. Catalytic hydrogenation as described in Scheme 4, and reduction of the ketone with lithium aluminum hydride in THF solvent provides the desired biphenyl analog 67.


SCHEME 28

25



An alternative synthesis of biphenyls of type I uses a cycloaromatization of a ketodiester 68 with a diketone in the presence of a catalytic amount of sodium methoxide in methanol solvent to give a phenol 69. The phenol is then coupled with an arylboronic acid as described in Scheme 28 to afford biphenyl diester 70. The diester is then transformed as described in Schemes 4, 8, and 10 to give the analog with the desired R^2 and R^3 groups.


SCHEME 29



An alternative method of transforming phenol 69 to biphenyl 70 is shown in Scheme 30. Treatment of the phenol with dimethylsulfate and a base such as potassium carbonate yields the methyl ether 71. The ether is treated with an aryl Grignard reagent to afford biphenyl 70.


0

SCHEME 30



- 5 The diester 70 can be further transformed by an alternative method shown in Scheme 31, to give the analogs with the desired R^2 and R^3 groups. Chemical reducing agents such as sodium bis-(2-methoxyethoxy)-aluminum hydride (Red-Al), can result in a mono reduction of the diester 70 to give the alcohol 72. Alcohol 72 can be attached to a polymeric support such as Wang resin, by treatment with a base such as sodium hydride in DMF, to give the intermediate 73. The ester group of intermediate 73 can be transformed to an alkyl halide in a two step process; 73 is treated with a reducing agent such as LAH, then Phosphorous tribromide to afford compound 74. The alkyl halide 74 is treated with an alkyl thiol and a base such as N-methyl morpholine, then by TFA to cleave the ether linkage with the polymeric resin, to afford the alcohol 75.
- 10
- 15

SCHEME 31



0


It will be appreciated that synthesis of some compounds of formula (IC) may require use of protecting groups at various stages of the procedures. These are removed in subsequent steps. For example, the removal of O-benzyl ether protecting groups is carried out by treatment with hydrogen in the presence of a metal catalyst, such as palladium on carbon, in a polar solvent such as ethanol. The removal of silyl ether protecting groups is carried out by treatment with fluoride salts, such as tetrabutylammonium fluoride in a solvent such as THF. Conditions required to remove other protecting groups which may be present can be found in: Protective Groups in Organic Synthesis, Second Edition, T. W. Greene, John Wiley and Sons, New York, 1991.

The order of carrying out the steps of the foregoing reaction schemes is not always significant, and it is within the skill of the art to vary the order of reactions to facilitate the reaction or to avoid unwanted reaction products.

The following examples are provided for the purpose of further illustration only and are not intended to limit the disclosed invention.

20

EXAMPLE 1



2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-pentylpyridine

25 Step A: 3-Amino-4-methyl-2-pentenoic acid, ethyl ester

To 100 g (0.63 mol) of ethyl isobutyryl acetate was added ammonium acetate (68.2 g, 0.89 mol), cyclohexane (230 mL) and isopropanol (74 mL). The mixture was heated at reflux under argon atmosphere with a Dean-Stark trap. After 2 hours, a second portion of ammonium acetate (14.6 g, 0.19 mol) was added to the reaction.

30 The reaction was heated at reflux for 12 hours and then allowed to cool to room

0 temperature. A total of ~30 mL of water was collected in the Dean-Stark trap. An ice bath was used to cool the reaction to 10°C and then ammonium hydroxide (63 mL) was added dropwise. The organic layer was separated, dried with sodium sulfate, filtered, and concentrated to yield a yellow oil. The crude product (90.9 g, 0.58 mol, 92%) was taken directly to the next step without any further purification.

5

Step B: Diethyl 1,4-dihydro-2,6-diisopropyl-4-(4-fluorophenyl)-3,5-pyridinedicarboxylate

To ethyl 3-amino-4-methylpent-2-enoate (Step A) (90 g, 57 mmol) was added ethyl isobutyryl acetate (90g, 57 mmol) and 4-fluorobenzaldehyde (61.4 mL, 0.57 mmol). The mixture was heated under argon at 130°C for 26 hours (Precaution: Check the reflux condenser after a few hours as excess ammonium acetate will clog the condenser). The reaction was allowed to cool to room temperature and left to crystallize for 4 days. The solid was collected by filtration with vacuum (46.9 g, 116 mmol, 20%) and taken directly to the next step without further purification.

15

Step C: Diethyl 2,6-diisopropyl-4-(4-fluorophenyl)-3,5-pyridinedicarboxylate

To the intermediate obtained in Step B (33 g, 82 mmol) in dichloromethane (400 mL) was added 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ, 20.5 g, 90 mmol) under argon and the mixture was stirred for 2 hours. The stirring was stopped to allow the precipitate to settle. The precipitate was filtered, washed with dichloromethane (3 x 30 mL), and discarded. The filtrate was concentrated to afford a brown solid, which was subjected to flash chromatography (6/4 mixture of dichloromethane/hexanes) resulting in a pure white solid (25.8 g, 64.3 mmol, 78%).
25 ¹H NMR (300 MHz, CDCl₃): δ 7.28 (m, 2 H), 7.06 (m, 2 H), 4.03 (q, J = 7.0 Hz, 4 H), 3.11 (septet, J = 6.6 Hz, 2 H), 1.32 (d, J = 6.5 Hz, 12 H), 0.979 (t, J = 3.3 Hz, 6 H). FAB-MS: calculated for (C₂₃H₂₈NO₄F) 401, found 402 (M+H). Anal. calc for C₂₃H₂₈NO₄F: C, 68.64; H, 7.24; N, 3.48; F, 4.72. Found: C, 69.12; H, 6.98; N, 3.42; F, 4.96. mp 72-74°C. R_f=0.4 (10% ethyl acetate/hexane).

30

Step D: Ethyl 2,6-diisopropyl-4-(4-fluorophenyl)-5-hydroxymethyl-3-pyridinecarboxylate

To a solution of the intermediate obtained in Step C (23.4 g, 58.3 mmol) in anhydrous tetrahydrofuran (300 mL) stirred under argon at 0°C was added a solution of 3.4M of sodium bis(2-methoxyethoxy)aluminum hydride in toluene (Red-Al) (61 mL, 204 mmol, 65 wt% in toluene) via syringe over 20 min. The reaction mixture was allowed to stir at room temperature for 7 hr, then cooled

35

0 again to 0°C and carefully quenched by the dropwise addition of water. The solution was decanted from the solid which forms and the solvent removed *in vacuo*. The residue was purified by flash chromatography (300 g silica) via step gradient. Elution with 5% diethyl ether/hexane afforded 6.6 g (16.4 mmol, 28%) of recovered starting material and elution with 40% diethyl ether(Et₂O)/hexane
5 yielded the desired product as a yellow waxy solid (14 g, 39 mmol, 67%). ¹H NMR (300 MHz, CDCl₃): δ 7.27 (m, 2 H), 7.10 (m, 2 H), 4.46 (d, *J* = 5.2 Hz, 2 H), 3.98 (q, *J* = 7 Hz, 2 H), 3.48 (sept, *J* = 6.6 Hz, 1 H), 3.05 (sept, *J* = 6.6 Hz, 1 H), 1.32 (t, *J* = 6.6 Hz, 12 H), 0.97 (t, *J* = 7 Hz, 3 H). FAB-MS: calculated for (C₂₁H₂₆FNO₃) 359, found 360 (M+H). R_f = 0.2 (20% ethyl acetate/hexane).

10

Step E: 5-Carboethoxy-2,6-diisopropyl-4-(4-fluorophenyl)-3-pyridinecarboxaldehyde

To a solution of the intermediate obtained in Step D (13 g, 36 mmol) in dichloromethane (1 L) was added Brockman I neutral alumina (7.4 g, 72 mmol).
15 The suspension was stirred at room temperature and treated with pyridinium chlorochromate (PCC) (16 g, 72 mmol) in three portions. The suspension was stirred at room temperature for 1 hr, then poured into 1:1 diethyl ether/hex (1 L), filtered through a pad of silica, the pad washed with diethyl ether (500 mL) and the combined eluent concentrated to afford a viscous oil which slowly solidified (12.8 g,
20 35.9 mmol, 99%): R_f = 0.31 (10% ethyl acetate/hexane). ¹H NMR (300 MHz, CDCl₃): δ 9.85 (s, 1 H), 7.27 (m, 2 H), 7.13 (m, 2 H), 4.04 (q, *J* = 7 Hz, 2 H), 3.88 (sept, *J* = 6.6 Hz, 1 H), 3.12 (sept, *J* = 6.6 Hz, 1 H), 1.33 (t, *J* = 6.6 Hz, 12 H), 1.00 (t, *J* = 7 Hz, 3 H). EI-MS calcd for (C₂₁H₂₄FNO₃) 357, found 358 (M+H). Anal. Calcd for C₂₁H₂₄FNO₃: C, 70.57; H, 6.77; N, 3.92. Found: C, 70.62; H, 6.78; N, 3.84.

25

Step F: Ethyl 2,6-diisopropyl-4-(4-fluorophenyl)-5-(1-pentenyl)-3-pyridinecarboxylate

Butyltriphenylphosphonium bromide (2.7 g, 6.76 mmol) was suspended in anhydrous THF (75 mL) under argon and stirred at -78°C. A 1.6 M solution of n-butyllithium in hexanes (4.2 mL, 6.76 mmol) was added dropwise. The reaction
30 mixture was allowed to come to 0°C and was stirred at that temperature for 1.5 hr. The resulting brightly colored solution was cooled again to -78°C and treated dropwise with a solution of the intermediate obtained in Step E (2 g, 5.60 mmol) in THF (20 mL). The reaction mixture was allowed to stir at 0°C for 1 hr, then
35 quenched by the addition of water (5 mL). The THF was removed *in vacuo*, the residue partitioned between ethyl ether (200 mL) and water (50 mL). The organic layer was washed with brine (50 mL), dried over MgSO₄ and concentrated. Flash

0 chromatography through silica (5% diethyl ether/hexane) affords a viscous oil (2 g,
5 mmol, 90%) (E,Z mixture). ¹H NMR (300 MHz, CDCl₃): δ 7.14 (m, 2 H), 7.02 (m,
2 h), 6.10 (dt, *J* = 1.8, 11.4 Hz, 0.4 H), 6.04 (dt, *J* = 1.5, 16.2 Hz, 0.6 H), 5.48 (dt, *J* = 7,
11.4 Hz, 0.4 H), 5.33 (dt, *J* = 7, 16.2 Hz, 0.6 H), 4.00 (q, *J* = 7 Hz, 0.8 H), 3.98 (q, *J* = 7
5 Hz, 1.2 H), 3.39 (sept, *J* = 6.6 Hz, 0.6 H), 3.27 (sept, *J* = 6.6 Hz, 0.4 H), 3.06 (m, 1 H),
1.95 (dq, *J* = 1.5, 7 Hz, 1 H), 1.26 (m, 13 H), 1.19 (m, 2 H), 0.97 (t, *J* = 7 Hz, 3 H), 0.77
(t, *J* = 7 Hz, 1.2 H), 0.76 (t, *J* = 7 Hz, 1.8 H). EI-MS calculated for (C₂₅H₃₂FNO₂) 397,
found 397 (M⁺). R_f = 0.5 (10% ethyl acetate/hexane).

10 Step G: 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-
pentenyl)pyridine


The intermediate obtained in Step F (2 g, 5.03 mmol) was dissolved in
anhydrous THF (100 mL) under argon and treated dropwise at room temperature
with lithium aluminum hydride (1.0 M in THF, 10 mL, 10 mmol). The reaction
15 mixture was stirred at reflux for 1 hr, cooled to room temperature and quenched
by the addition of 0.38 mL H₂O, 0.38 mL 20% aqueous NaOH and 1.1 mL H₂O.
The resulting suspension was filtered through a cake of Celite and the filtrate
concentrated and purified by chromatography through silica (5% ethyl
acetate/hexane) to afford the product as a white foam (1.42 g, 4.0 mmol, 80%). R_f =
0.2 (10% ethyl acetate/hexane).

20 Step H: 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-
pentylpyridine

The intermediate obtained in Step G was dissolved in absolute ethanol (50
mL) under argon, treated with 10% palladium on carbon (140 mg, 0.1 eq), then
25 stirred under a hydrogen atmosphere for 2 hr. After purging the system with
argon, the catalyst was removed by filtration through a pad of Celite. The solvent
was removed and the product dried *in vacuo* to afford the title compound as a
white solid (1.4 g, 3.9 mmol, 98%). ¹H NMR (300 MHz, CDCl₃): δ 7.15 (m, 4 H),
4.33 (d, *J* = 4.4 Hz, 2 H), 3.41 (sept, *J* = 6.6 Hz, 1 H), 3.23 (sept, *J* = 6.6 Hz, 1 H), 2.26
30 (m, 2 H), 1.33 (d, *J* = 6.6 Hz, 6 H), 1.30 (d, *J* = 6.6 Hz, 6 H), 1.27 (m, 2 H), 1.13 (m, 5
H), 0.79 (t, *J* = 6.6 Hz, 3 H). FAB-MS: calculated for (C₂₃H₃₂FNO) 357, found 358
(M+H). Anal. calcd for C₂₃H₃₂FNO: C, 77.27; H, 9.02; N, 3.92. Found: C, 77.46;
H, 8.95; N, 3.78. R_f = 0.3 (20% ethyl acetate/hexane). mp 100-101°C.


35

0

EXAMPLE 22,6-Dimethyl-3-hydroxymethyl-4-phenyl-5-(2-methyl-1-propenyl)-pyridine

5 The title compound was prepared from ethyl acetoacetate, benzaldehyde and isopropyl triphenylphosphonium iodide according to the procedures described in Example 1, Steps A-G. ¹H NMR (300 MHz, CDCl₃): δ 7.34 (m, 3 H), 7.10 (m, 2 H), 5.70 (s, 1 H), 4.42 (s, 2 H), 2.69 (s, 3 H), 2.43 (s, 3 H), 1.60 (s, 3 H), 1.35 (s, 3 H). EI-MS calculated for (C₁₈H₂₁NO) 267, found 267 (M⁺). mp 48-50°C. R_f = 0.3 (90% ethyl acetate/hexane).

10

EXAMPLE 3

15


2,6-Dimethyl-3-hydroxymethyl-4-phenyl-5-(1-pentenyl)pyridine

The title compound was prepared from ethyl acetoacetate, benzaldehyde and butyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps A-G. The product was obtained as a mixture 3:1 trans:cis isomers; gummy oil. ¹H NMR (300 MHz, CDCl₃): δ 7.37 (m, 3 H), 7.12 (m, 2 H), 5.94 (m, 1 H), 5.40 (m, 1 H), 4.41 (bs, 2 H), 2.71 & 2.68 (2s, 3 H), 2.57 & 2.46 (2s, 3 H), 1.91 & 1.69 (2q, J = 7 Hz, 2 H), 1.52 (bs, 1 H), 1.19 (m, 2 H), 0.77 (m, 3 H). EI-MS: calculated for (C₁₉H₂₃NO) 281, found 281. R_f = 0.4 (90% ethyl acetate/hexane).

20


25

0

EXAMPLE 45 2,6-Dimethyl-3-hydroxymethyl-4-phenyl-5-pentylpyridine


The title compound was prepared from 2,6-dimethyl-3-hydroxymethyl-4-phenyl-5-(1-pentenyl)pyridine (Example 3) according to the procedure described in Example 1, Step H. ¹H NMR (300 MHz, CDCl₃): δ 7.42 (m, 3 H), 7.15 (m, 2 H), 4.33 (s, 2 H), 2.65 (s, 3 H), 2.56 (s, 3 H), 2.27 (m, 2 H), 1.29 (m, 2 H), 1.11 (m, 4 H), 0.76 (t, *J* = 7 Hz, 3 H). EI-MS: calculated for (C₁₉H₂₅NO) 283, found 283 (M⁺). Anal. calculated for C₁₉H₂₅NO: C, 80.52; H, 8.89; N, 4.94. Found: C, 80.39; H, 8.85; N, 4.85. mp 99-100°C. R_f = 0.3 (90% ethyl acetate/hexane).

15

EXAMPLE 5


20 2,6-Diethyl-3-hydroxymethyl-4-phenyl-5-(2-methyl-1-propenyl)pyridine The title compound was prepared from ethyl propionylacetate, benzaldehyde and isopropyl triphenylphosphonium iodide according to the procedures described in Example 1, Steps A-G. ¹H NMR (300 MHz, CDCl₃): δ 7.34 (m, 3 H), 7.11 (m, 2 H), 5.76 (s, 1 H), 4.44 (d, *J* = 5.5 Hz, 2 H), 3.01 (q, *J* = 7.4 Hz, 2 H), 2.75 (q, *J* = 7.4 Hz, 2 H), 1.58 (s, 3 H), 1.35 (m, 7 H), 1.21 (t, *J* = 7.4 Hz, 3 H). FAB-MS: calculated for (C₂₀H₂₅NO) 295, found 296 (M+H). Anal. Calcd for C₂₀H₂₅NO: C, 81.31; H, 8.53; N, 4.74. Found: 25 C, 81.03; H, 8.55; N, 4.65. mp 103-104°C. R_f = 0.4 (50% ethyl acetate/hexane).

0

EXAMPLE 62,6-Diethyl-3-hydroxymethyl-4-phenyl-5-(1-pentenyl)pyridine

5 The title compound was prepared from ethyl propionylacetate, benzaldehyde and butyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps A-G. The product was obtained as a mixture 6:4 trans:cis isomers. ^1H NMR (300 MHz, CDCl_3): δ 7.36 (m, 3 H), 7.14 (m, 2 H), 6.00 (m, 1 H), 5.37 (m, 1 H), 4.42 (m, 2 H), 2.90 (m, 4 H), 1.89 & 1.67 (2q, J = 7 Hz, 2 H), 1.25 (m, 9 H), 0.76 (m, 3 H). FAB-MS: calculated for ($\text{C}_{21}\text{H}_{27}\text{NO}$) 309, found 310 ($\text{M}+\text{H}$); Anal. Calcd for $\text{C}_{21}\text{H}_{27}\text{NO}$: C, 81.51; H, 8.79; N, 4.53. Found: C, 81.95; H, 8.90; N, 4.45. mp 74-76°C. R_f = 0.5 (50% ethyl acetate/hexane)


15

EXAMPLE 72,6-Diethyl-3-hydroxymethyl-4-phenyl-5-pentylpyridine

20 The title compound was prepared from 2,6-diethyl-3-hydroxymethyl-4-phenyl-5-(1-pentenyl)pyridine (Example 6) according to the procedure described in Example 1, Step H. ^1H NMR (300 MHz, CDCl_3): δ 7.42 (m, 3 H), 7.18 (m, 2 H), 4.34 (d, J = 6 Hz, 2 H), 2.96 (q, J = 7.7 Hz, 2 H), 2.84 (q, J = 7.7 Hz, 2 H), 2.28 (m, 2 H), 1.34 (m, 9 H), 1.09 (m, 4 H), 0.76 (t, J = 7 Hz, 3 H). FAB-MS: calculated for ($\text{C}_{21}\text{H}_{29}\text{NO}$) 311, found 312 ($\text{M}+\text{H}$). mp 76-77°C. R_f = 0.5 (50% ethyl acetate/hexane).

25


0

EXAMPLE 82,6-Diethyl-3-hydroxymethyl-4-phenyl-5-(1-ethenyl)pyridine

5 The title compound was prepared from ethyl propionylacetate, benzaldehyde and methyl triphenylphosphonium bromide/sodium amide according to the procedures described in Example 1, Steps A-G. ^1H NMR (300 MHz, CDCl_3): δ 7.40 (m, 3 H), 7.20 (m, 2 H), 6.36 (dd, $J = 11, 18$ Hz, 1 H), 5.22 (dd, $J = 11, 2$ Hz, 1 H), 5.00 (dd, $J = 18, 2$ Hz, 1 H), 4.41 (d, $J = 6$ Hz, 2 H), 2.96 (m, 4 H),
 10 1.35 (m, 7 H). FAB-MS: calculated for $(\text{C}_{18}\text{H}_{21}\text{NO})$ 267, found 268 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{18}\text{H}_{21}\text{NO}$: C, 80.86; H, 7.92; N, 5.24. Found: C, 80.65; H, 8.06; N, 5.09. mp 84-85°C. $R_f = 0.4$ (50% ethyl acetate/hexane).


EXAMPLE 9

15


2,5,6-Triethyl-3-hydroxymethyl-4-phenylpyridine

20 The title compound was prepared from 2,6-diethyl-3-hydroxymethyl-4-phenyl-5-(1-ethenyl)pyridine (Example 8) according to the procedure described in Example 1, Step H. ^1H NMR (300 MHz, CDCl_3): δ 7.44 (m, 3 H), 7.18 (m, 2 H), 4.33 (d, $J = 6$ Hz, 2 H), 2.97 (q, $J = 8$ Hz, 2 H), 2.86 (q, $J = 8$ Hz, 2 H), 2.36 (q, $J = 8$ Hz, 2 H), 1.34 (m, 7 H), 0.93 (t, $J = 8$ Hz, 3 H). FAB-MS: calculated for $(\text{C}_{18}\text{H}_{23}\text{NO})$ 269, found 270 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{18}\text{H}_{23}\text{NO}$: C, 80.26; H, 8.61; N, 5.20. Found:
 25 C, 79.70; H, 8.54; N, 5.08. mp 100°C. $R_f = 0.4$ (50% ethyl acetate/hexane).

0

EXAMPLE 102,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-(1-pentenyl)pyridine

5 The title compound was prepared from ethyl isobutyrylacetate, benzaldehyde and butyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps A-G. ¹H NMR (300 MHz, CDCl₃): δ 7.35 (m, 3 H), 7.14 (m, 2 H), 5.99 (m, 1 H), 5.35 (m, 1 H), 4.41 (m, 2 H), 3.36 (m, 2 H), 1.89 & 1.70 (2q, *J* = 7 Hz, 2 H), 1.24 (m, 15 H), 0.80 & 0.72 (2t, *J* = 7 Hz, 3 H). FAB-MS: 10 calculated for (C₂₃H₃₁NO) 337, found 338 (M+H). Anal. Calcd for C₂₃H₃₁NO: C, 81.85; H, 9.26; N, 4.15. Found: C, 81.88; H, 9.22; N, 3.93. mp 67-73°C. R_f = 0.1 (10% ethyl acetate/hexane).


EXAMPLE 11

15

2,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-(2-methyl-1-propenyl)-pyridine

The title compound was prepared from ethyl isobutyrylacetate, benzaldehyde and isopropyl triphenylphosphonium iodide according to the 20 procedures described in Example 1, Steps A-G. ¹H NMR (300 MHz, CDCl₃): δ 7.32 (m, 3 H), 7.11 (m, 2 H), 5.75 (s, 1 H), 4.43 (bs, 2 H), 3.46 (sept, *J* = 6.6 Hz, 1 H), 3.18 (sept, *J* = 6.6 Hz, 1 H), 1.57 (s, 3 H), 1.31 (m, 15 H). FAB-MS: calculated for (C₂₂H₂₉NO) 323, found 324 (M+H). Anal. Calcd for C₂₂H₂₉NO: C, 81.69; H, 9.04; N, 4.33. Found: C, 81.59; H, 8.94; N, 4.29. mp 93-95°C. R_f = 0.1 (10% ethyl 25 acetate/hexane).


0

EXAMPLE 122,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-(1-propenyl)pyridine

5 The title compound was prepared from ethyl isobutyrylacetate, benzaldehyde and ethyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps A-G. The product was obtained as a mixture 1:1 trans:cis isomers; gummy oil. ¹H NMR (300 MHz, CDCl₃): δ 7.4 (m, 3 H), 7.2 (m, 2 H), 6.0 (m, 1 H), 5.5 & 5.4 (2m, 1 H), 4.4 (m, 2 H), 3.4 & 3.2 (2m, 2 H),
 10 1.6 (m, 2 H), 1.4 (m, 7 H), 1.3 (m, 7 H). FAB-MS: calculated for (C₂₁H₂₇NO) 309, found 310 (M+H). Anal. Calcd for C₂₁H₂₇NO: C, 81.53; H, 9.98; N, 3.96. Found: C, 79.06; H, 9.65; N, 3.61. R_f = 0.4 (20% ethyl acetate/hexane).


EXAMPLE 13

15

2,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-(1-butenyl)pyridine


20 The title compound was prepared from ethyl isobutyrylacetate, benzaldehyde and propyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps A-G. The product was obtained as a mixture 1:1 trans:cis isomers; gummy oil. ¹H NMR (300 MHz, CDCl₃): δ 7.4 (m, 3 H), 7.2 (m, 2 H), 6.0 (m, 1 H), 5.4 (m, 1 H), 4.4 (m, 2 H), 3.3 (m, 3 H), 1.9 & 1.7 (2m, 2 H), 1.3 (m, 12 H), 0.7 (m, 3 H). FAB-MS: calculated for (C₂₂H₂₉NO) 323, found 324
 25 (M+H). R_f = 0.4 (20% ethyl acetate/hexane).

0

EXAMPLE 142,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-pentylpyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-phenyl-5-(1-pentenyl)pyridine (Example 10) according to the procedure described in Example 1, Step H. ¹H NMR (300 MHz, CDCl₃) δ 7.41 (m, 3 H), 7.18 (m, 2 H), 4.33 (s, 2 H), 3.42 (sept, *J* = 6.6 Hz, 1 H), 3.23 (sept, *J* = 6.6 Hz, 1 H), 2.26 (m, 2 H), 1.32 (m, 13 H), 1.11 (m, 5 H), 0.76 (t, *J* = 7 Hz, 3 H). FAB(HR)-MS calcd for C₂₃H₃₃NO 339.2640; found 340.2640 (M+H). mp 81-82°C. R_f = 0.1 (10% ethyl acetate/hexane).

10

EXAMPLE 15


15

2,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-(1-hexenyl)pyridine


The title compound was prepared from ethyl isobutyrylacetate, benzaldehyde and pentyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps A-G. The product was obtained as a mixture 1:1 trans:cis isomers; gummy oil. ¹H NMR (300 MHz, CDCl₃): δ 7.35 (m, 3 H), 7.14 (m, 2 H), 5.99 (m, 1 H), 5.35 (m, 1 H), 4.40 (m, 2 H), 3.36 (m, 2 H), 1.92 & 1.70 (2m, 2 H), 1.20 (m, 17 H), 0.80 (m, 3 H). FAB-MS: calculated for (C₂₄H₃₃NO) 351, found 352 (M+H). Anal. Calcd for C₂₄H₃₃NO: C, 82.00; H, 9.46; N, 3.98. Found: C, 81.58; H, 9.50; N, 4.62. R_f = 0.1 (10% ethyl acetate/hexane);

25

0

EXAMPLE 162,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-hexylpyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-phenyl-5-(1-hexenyl)pyridine (Example 15) according to the procedure described in Example 1, Step H. ¹H NMR (300 MHz, CDCl₃): δ 7.40 (m, 3 H), 7.18 (m, 2 H), 4.33 (d, *J* = 5 Hz, 2 H), 3.42 (septet, *J* = 7 Hz, 1 H), 3.23 (septet, *J* = 7 Hz, 1 H), 2.26 (m, 2 H), 1.31 (m, 13 H), 1.12 (m, 8 H), 0.80 (t, *J* = 7 Hz, 3 H). FAB-MS: calculated for (C₂₄H₃₅NO) 353, found 354 (M+H). Anal. Calcd for C₂₄H₃₅NO: C, 81.53; H, 9.98; N, 3.96. Found: C, 79.06; H, 9.65; N, 3.61. mp 71-72°C. R_f = 0.1 (10% ethyl acetate/hexane).

EXAMPLE 17


15

2,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-propylpyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-phenyl-5-(1-propenyl)pyridine (Example 12) according to the procedure described in Example 1, Step H. ¹H NMR (300 MHz, CDCl₃): δ 7.41 (m, 3 H), 7.17 (m, 2 H), 4.33 (s, 2 H), 3.42 (sept, *J* = 6.6 Hz, 1 H), 3.23 (sept, *J* = 6.6 Hz, 1 H), 2.25 (m, 2 H), 1.33 (d, *J* = 6.6 Hz, 6 H), 1.30 (d, *J* = 6.6 Hz, 6 H), 1.27 (m, 2 H), 1.20 (m, 1 H), 0.74 (t, *J* = 7 Hz, 3 H). FAB-MS: calculated for (C₂₁H₂₉NO) 311, found 312 (M+H). Anal. Calcd for C₂₁H₂₉NO: C, 80.98; H, 9.38; N, 4.50. Found: C, 80.72; H, 9.47; N, 4.38. mp 89-90°C. R_f = 0.4 (20% ethyl acetate/hexane).


25

0

EXAMPLE 182,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-butylpyridine

5 The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-phenyl-5-(1-butenyl)pyridine (Example 13) according to the procedure described in Example 1, Step H. ¹H NMR (300 MHz, CDCl₃): δ 7.41 (m, 3 H), 7.17 (m, 2 H), 4.33 (s, 2 H), 3.42 (sept, *J* = 6.6 Hz, 1 H), 3.24 (sept, *J* = 6.6 Hz, 1 H), 2.28 (m, 2 H), 1.33 (d, *J* = 6.6 Hz, 6 H), 1.31 (d, *J* = 6.6 Hz, 6 H), 1.28 (m, 2 H), 1.14 (m, 3 H), 0.71 (t, *J* = 7 Hz, 3 H). FAB-MS: calculated for (C₂₂H₃₁NO) 325, found 326 (M+H). Anal. Calcd for C₂₂H₃₁NO: C, 81.18; H, 9.60; N, 4.30. Found: C, 81.28; H, 9.87; N, 4.07. mp 83-84°C. R_f = 0.4 (20% ethyl acetate/hexane).


15

EXAMPLE 192,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-hexenyl)-pyridine

20 The title compound was prepared from ethyl isobutyrylacetate, 4-fluorobenzaldehyde and pentyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps A-G. The product was obtained as a mixture 6:4 trans:cis isomers; gummy oil. ¹H NMR (300 MHz, CDCl₃): δ 7.10 (m, 4 H), 5.98 (m, 1 H), 5.42 (dt, *J* = 7, 11.4 Hz, 0.4 H), 5.29 (dt, *J* = 7, 16.2 Hz, 0.6 H), 4.40 (d, *J* = 5.5 Hz, 2 H), 3.44 (m, 1 H), 3.36 (sept, *J* = 6.6 Hz, 0.6 H), 3.24 (sept, *J* = 6.6 Hz, 0.4 H), 1.94 (m, 1 H), 1.36 (m, 6 H), 1.23 (m, 8 H), 1.12 (m, 4 H), 0.82 (m, 3 H). FAB-

- 0 MS: calculated for (C₂₄H₃₂FNO) 369, found 370 (M+H). R_f = 0.4 (20% ethyl acetate/hexane).

EXAMPLE 20




5

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-butenyl)-pyridine

- The title compound was prepared from ethyl isobutyrylacetate, 4-fluorobenzaldehyde and propyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps A-G. The product was obtained as a mixture 1:1 trans:cis isomers; gummy oil. ¹H NMR (300 MHz, CDCl₃): δ 7.10 (m, 4 H), 5.97 (m, 1 H), 5.39 (dt, J = 7, 11.4 Hz, 0.5 H), 5.32 (dt, J = 7, 16.2 Hz, 0.5 H), 4.41 (d, J = 5.5 Hz, 2 H), 3.45 (m, 1 H), 3.36 (sept, J = 6.6 Hz, 0.5 H), 3.24 (sept, J = 6.6 Hz, 0.5 H), 1.95 (m, 1 H), 1.70 (m, 1 H), 1.35 (d, J = 6.6 Hz, 3 H), 1.34 (d, J = 6.6 Hz, 3 H), 1.25 (m, 7 H), 0.79 (t, J = 7.5 Hz, 1.5 H), 0.78 (t, J = 7.5 Hz, 1.5 H). FAB-MS: calculated for (C₂₂H₂₈FNO) 341, found 342 (M+H). R_f = 0.4 (20% ethyl acetate/hexane).

15

EXAMPLE 21




20

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-propenyl)-pyridine

The title compound was prepared from ethyl isobutyrylacetate, 4-fluorobenzaldehyde and ethyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps A-G. The product was obtained as a

- 0 mixture 1:1 trans:cis isomers. ^1H NMR (300 MHz, CDCl_3): δ 7.11 (m, 4 H), 6.04 (d, $J = 11.7$ Hz, 0.5 H), 5.96 (d, $J = 16.1$ Hz, 0.5 H), 5.53 (m, 0.5 H), 5.33 (m, 0.5 H), 4.41 (m, 3 H), 3.42 (m, 1.5 H), 3.20 (sept, $J = 6.6$ Hz, 0.5 H), 1.61 (d, $J = 6$ Hz, 2 H), 1.3 (m, 13 H). FAB-MS: calculated for $(\text{C}_{21}\text{H}_{26}\text{FNO})$ 327, found 328 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{21}\text{H}_{26}\text{FNO}$: C, 77.03; H, 8.00; N, 4.28. Found: C, 77.15; H, 8.07; N, 4.11. mp 5 46-47°C. $R_f = 0.4$ (20% ethyl acetate/hexane).

EXAMPLE 22




10

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-ethenylpyridine

- The title compound was prepared from ethyl isobutyrylacetate, 4-fluorobenzaldehyde and methyl triphenylphosphonium bromide/sodium amide according to the procedures described in Example 1, Steps A-G. ^1H NMR (300 15 MHz, CDCl_3): δ 7.12 (m, 4 H), 6.35 (dd, $J = 11.5, 18$ Hz, 1 H), 5.24 (dd, $J = 1.5, 11.4$ Hz, 1 H), 4.97 (dd, $J = 1.5, 18$ Hz, 1 H), 4.41 (d, $J = 5.5$ Hz, 2 H), 3.44 (sept, $J = 6.6$ Hz, 2 H), 1.35 (d, $J = 6.6$ Hz, 6 H), 1.28 (d, $J = 6.6$ Hz, 6 H), 1.25 (m, 1 H). FAB-MS: calculated for $(\text{C}_{20}\text{H}_{24}\text{FNO})$ 313, found 314 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{20}\text{H}_{24}\text{FNO}$: C, 76.65; H, 7.72; N, 4.47. Found: C, 76.87; H, 7.79; N, 4.33. mp 119-120°C. $R_f = 0.4$ 20 (20% ethyl acetate/hexane).

EXAMPLE 23




0

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-hexylpyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-hexenyl)pyridine (Example 19) according to the procedure described in Example 1, Step H. ¹H NMR (300 MHz, CDCl₃): δ 7.14 (m, 4 H), 4.33 (s, 2 H), 3.41 (sept, *J* = 6.6 Hz, 1 H), 3.23 (sept, *J* = 6.6 Hz, 1 H), 2.26 (m, 2 H), 1.33 (d, *J* = 6.6 Hz, 6 H), 1.30 (d, *J* = 6.6 Hz, 6 H), 1.26 (m, 1 H), 1.14 (m, 7 H), 0.82 (t, *J* = 7 Hz, 3 H). FAB-MS: calculated for (C₂₄H₃₄FNO) 371, found 372 (M+H). mp 93-95°C. R_f = 0.4 (20% ethyl acetate/hexane).

10


EXAMPLE 242,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-butylpyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-butenyl)pyridine (Example 20) according to the procedure described in Example 1, Step H. ¹H NMR (300 MHz, CDCl₃): δ 7.15 (m, 4 H), 4.33 (d, *J* = 5.2 Hz, 2 H), 3.41 (sept, *J* = 6.6 Hz, 1 H), 3.23 (sept, *J* = 6.6 Hz, 1 H), 2.27 (m, 2 H), 1.34 (d, *J* = 6.6 Hz, 6 H), 1.30 (d, *J* = 6.6 Hz, 6 H), 1.27 (m, 1 H), 1.16 (m, 3 H), 0.73 (t, *J* = 7 Hz, 3 H). FAB-MS: calculated for (C₂₂H₃₀FNO) 343, found 344 (M+H). Anal. Calcd for C₂₂H₃₀FNO: C, 76.93; H, 8.80; N, 4.08. Found: C, 76.93; H, 8.70; N, 3.96. mp 45-50°C. R_f = 0.4 (20% ethyl acetate/hexane).

25


30

0

EXAMPLE 252,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-propylpyridine

5 The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-propenyl)pyridine (Example 21) according to the procedure described in Example 1, Step H. ^1H NMR (300 MHz, CDCl_3): δ 7.15 (m, 4 H), 4.33 (s, 2 H), 3.41 (sept, $J = 6.6$ Hz, 1 H), 3.23 (sept, $J = 6.6$ Hz, 1 H), 2.25 (m, 2 H), 1.33 (d, $J = 6.6$ Hz, 6 H), 1.30 (d, $J = 6.6$ Hz, 6 H), 1.27 (m, 1 H), 1.19 (m, 1 H), 0.76 (t, $J = 7$ Hz, 3 H). FAB-MS: calculated for ($\text{C}_{21}\text{H}_{28}\text{FNO}$) 329, found 330 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{21}\text{H}_{28}\text{FNO}$: C, 76.56; H, 8.57; N, 4.25. Found: C, 76.55; H, 8.48; N, 4.11. mp 49-54 °C. $R_f = 0.4$ (20% ethyl acetate/hexane).


15

EXAMPLE 262,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-ethylpyridine

20 The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-ethenylpyridine (Example 22) according to the procedure described in Example 1, Step H. ^1H NMR (300 MHz, CDCl_3): δ 7.15 (m, 4 H), 4.33 (d, $J = 3.6$ Hz, 2 H), 3.41 (sept, $J = 6.6$ Hz, 1 H), 3.26 (sept, $J = 6.6$ Hz, 1 H), 2.34 (q, $J = 7.35$ Hz, 2 H), 1.33 (d, $J = 6.6$ Hz, 6 H), 1.31 (d, $J = 6.6$ Hz, 6 H), 1.19 (m, 1 H), 0.93 (t, $J = 7.35$ Hz, 3 H). FAB-MS: calculated for ($\text{C}_{20}\text{H}_{26}\text{FNO}$) 315, found 316 ($\text{M}+\text{H}$). Anal.

- 0 Calcd for $C_{20}H_{26}FNO$: C, 76.16; H, 8.31; N, 4.44. Found: C, 75.74; H, 8.50; N, 4.27. mp 126-129°C. R_f = 0.4 (20% ethyl acetate/hexane).


EXAMPLE 27



(Z)-2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(3-methyl-1-butenyl)pyridine

- The title compound was prepared from ethyl isobutyrylacetate, 4-fluorobenzaldehyde and isobutyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps A-G. 1H NMR (300 MHz, $CDCl_3$): δ 7.07 (m, 4 H), 5.92 (d, J = 10.7 Hz, 1 H), 5.20 (dd, J = 10.7, 11.4 Hz, 1 H), 4.42 (bs, 2 H), 3.45 (sept, J = 6.6 Hz, 1 H), 3.30 (sept, J = 6.6 Hz, 1 H), 2.06 (m, 1 H), 1.35 (d, J = 6.6 Hz, 6 H), 1.31 (m, 1 H), 1.24 (m, 5 H), 0.69 (bs, 6 H). FAB-MS: calculated for $(C_{23}H_{30}FNO)$ 355, found 356 ($M+H$). Anal. Calcd for $C_{23}H_{30}FNO$: C, 77.71; H, 8.51; N, 3.94. Found: C, 77.94; H, 8.59; N, 3.79. mp 112°C. R_f = 0.3 (20% ethyl acetate/hexane).


EXAMPLE 28



2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(4-methyl-1-pentenyl)pyridine

0 The title compound was prepared from ethyl isobutyrylacetate, 4-fluorobenzaldehyde and isoamyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps A-G. The product is obtained as a 6:4 mixture of trans:cis isomers. ¹H NMR (300 MHz, CDCl₃): δ 7.11 (m, 4 H), 6.04 (dt, J = 1.5, 11 Hz, 0.4 H), 5.96 (dt, J = 1.5, 16 Hz, 0.6 H), 5.47 (dt, J = 7, 11 Hz, 0.4 H), 5.32 (dt, J = 7, 16 Hz, 0.6 H), 4.41 (m, 2 H), 3.44 (m, 0.8 H), 3.38 (sept, J = 6.6 Hz, 0.6 H), 3.24 (sept, J = 6.6 Hz, 0.6 H), 1.84 (m, 1 H), 1.45 (m, 1 H), 1.35 (m, 6 H), 1.24 (m, 7 H), 0.79 (d, J = 6.6 Hz, 2.4 H), 0.73 (d, J = 6.6 Hz, 3.6 H). FAB-MS: calculated for (C₂₄H₃₂FNO) 369, found 370 (M+H). Anal. Calcd for C₂₄H₃₂FNO: C, 78.01; H, 8.73; N, 3.79. Found: C, 78.14; H, 8.62; N, 3.50. mp 48-50°C. R_f = 0.3 (20% ethyl acetate/hexane).

EXAMPLE 29



15


2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(3-methylbutyl)pyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(3-methyl-1-butenyl)pyridine (Example 27) according to the procedure described in Example 1, Step H. ¹H NMR (300 MHz, CDCl₃): δ 7.14 (m, 4 H) 4.33 (d, J = 5.5 Hz, 2 H), 3.41 (sept, J = 6.6 Hz, 1 H), 3.22 (sept, J = 6.6 Hz, 1 H), 2.27 (m, 2 H), 1.35 (m, 1 H), 1.33 (d, J = 7 Hz, 6 H), 1.30 (d, J = 7 Hz, 6 H), 1.17 (m, 3 H), 0.70 (d, J = 6.6 Hz, 6 H). FAB-MS: calculated for (C₂₃H₃₂FNO) 357, found 358 (M+H). Anal. Calcd for C₂₃H₃₂FNO: C, 77.27; H, 9.02; N, 3.92. Found: C, 77.34; H, 9.15; N, 3.69. mp 43-45°C. R_f = 0.2 (20% ethyl acetate/hexane).

25


30

0

EXAMPLE 302,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(4-methylpentyl)pyridine

5 The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(4-methyl-1-pentenyl)pyridine (Example 28) according to the procedure described in Example 1, Step H. ¹H NMR (300 MHz, CDCl₃): δ 7.14 (m, 4 H), 4.33 (d, *J* = 5 Hz, 2 H), 3.41 (sept, *J* = 6.6 Hz, 1 H), 3.22 (sept, *J* = 6.6 Hz, 1 H), 2.23 (m, 2 H), 1.38 (m, 1 H), 1.33 (d, *J* = 6.6 Hz, 6 H), 1.30 (d, *J* = 6.6 Hz, 6 H), 1.27 (m, 1 H), 1.17 (m, 1 H), 1.00 (m, 3 H), 0.76 (d, *J* = 6.6 Hz, 6 H). FAB-MS: calculated for (C₂₄H₃₄FNO) 371, found 372 (M+H). Anal. Calcd for C₂₄H₃₄FNO: C, 77.59; H, 9.22; N, 3.77. Found: C, 77.63; H, 9.39; N, 3.58. mp 101-103°C. R_f = 0.3 (20% ethyl acetate/hexane).

15


EXAMPLE 312,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(cyclopentylidenemethylene)pyridine

20

The title compound was prepared from ethyl isobutyrylacetate, 4-fluorobenzaldehyde and cyclopentyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps A-G. ¹H NMR (300 MHz, CDCl₃): δ 7.13 (m, 2 H), 7.07 (m, 2 H), 5.88 (s, 1 H), 4.43 (d, *J* = 5.5 Hz, 2 H), 3.44 (sept, *J* = 6.6


- 0 Hz, 1 H), 3.21 (sept, $J = 6.6$ Hz, 1 H), 2.11 (m, 2 H), 1.75 (m, 2 H), 1.47 (m, 4 H), 1.34 (d, $J = 6.6$ Hz, 6 H), 1.29 (m, 1 H), 1.21 (d, $J = 6.6$ Hz, 6 H). FAB-MS: calculated for (C₂₄H₃₀FNO) 367, found 368 (M+H). Anal. Calcd for C₂₄H₃₀FNO: C, 78.44; H, 8.23; N, 3.81. Found: C, 78.46; H, 8.18; N, 3.63. mp 97-98°C. $R_f = 0.3$ (20% ethyl acetate/hexane).

5

EXAMPLE 3210 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-heptenyl)-pyridine

- The title compound was prepared from ethyl isobutyrylacetate, 4-fluorobenzaldehyde and n-hexyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps A-G. The product was obtained as a mixture 1:1 trans:cis isomers; gummy oil. ¹H NMR (300 MHz, CDCl₃): δ 7.11 (m, 4 H), 5.99 (m, 1 H), 5.42 (dt, $J = 7, 11$ Hz, 0.5 H), 5.30 (dt, $J = 7, 16$ Hz, 0.5 H), 4.41 (d, $J = 5.5$ Hz, 2 H), 3.45 (m, 1 H), 3.37 (sept, $J = 6.6$ Hz, 0.5 H), 3.24 (sept, $J = 6.6$ Hz, 0.5 H), 1.94 (m, 1 H), 1.35 (m, 6 H), 1.29 (m, 1 H), 1.26 (d, $J = 6.6$ Hz, 3 H), 1.22 (m, 6 H), 1.15 (m, 4 H), 0.86 (m, 3 H). FAB-MS: calculated for (C₂₅H₃₄FNO) 383, found 384 (M+H). Anal. Calcd for C₂₅H₃₄FNO: C, 78.29; H, 8.93; N, 3.65. Found: C, 78.37; H, 8.88; N, 3.57. $R_f = 0.4$ (20% ethyl acetate/hexane).


20

EXAMPLE 33

0

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-octenyl)-pyridine

The title compound was prepared from ethyl isobutyrylacetate, 4-fluorobenzaldehyde and n-heptyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps A-G. The product was obtained as a mixture 1:1 trans:cis isomers; gummy oil. ¹H NMR (300 MHz, CDCl₃): δ 7.11 (m, 4 H), 5.98 (m, 1 H), 5.42 (dt, J = 7, 11 Hz, 0.5 H), 5.30 (dt, J = 7, 16 Hz, 0.5 H), 4.41 (d, J = 5.5 Hz, 2 H), 3.44 (m, 1 H), 3.37 (sept, J = 6.6 Hz, 0.5 H), 3.24 (sept, J = 6.6 Hz, 0.5 H), 1.94 (m, 1 H), 1.35 (m, 6 H), 1.30 (m, 1 H), 1.26 (d, J = 6.6 Hz, 6 H), 1.22 (m, 4 H), 1.16 (m, 5 H), 0.87 (m, 3 H). FAB-MS: calculated for (C₂₆H₃₆FNO) 397, found 398 (M+H). Anal. Calcd for C₂₆H₃₆FNO: C, 78.55; H, 9.13; N, 3.52. Found: C, 78.63; H, 9.16; N, 3.48. R_f = 0.4 (20% ethyl acetate/hexane)

EXAMPLE 34


15

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[2(E)-phenylethenyl]pyridine

The title compound was prepared from ethyl isobutyrylacetate, 4-fluorobenzaldehyde and benzyl triphenylphosphonium bromide/sodium amide according to the procedures described in Example 1, Steps A-G. ¹H NMR (300 MHz, CDCl₃): δ 7.21 (m, 9 H), 6.70 (d, J = 16.5 Hz, 1 H), 6.26 (d, J = 16.5 Hz, 1 H), 4.45 (d, J = 5.5 Hz, 2 H), 3.48 (sept, J = 6.6 Hz, 2 H), 1.37 (d, J = 6.6 Hz, 6 H), 1.31 (d, J = 6.6 Hz, 6 H), 1.29 (m, 1 H). FAB-MS: calculated for (C₂₆H₂₈FNO) 389, found 390 (M+H). Anal. Calcd for C₂₆H₂₈FNO: C, 80.17; H, 7.25; N, 3.60. Found: C, 79.89; H, 7.28; N, 3.49. mp 107-110°C. R_f = 0.3 (20% ethyl acetate/hexane).


30

0

EXAMPLE 352,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-heptylpyridine

5 The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-heptenyl)pyridine (Example 32) according to the procedure described in Example 1, Step H. ^1H NMR (300 MHz, CDCl_3): δ 7.13 (m, 4 H), 4.33 (s, 2 H), 3.41 (sept, $J = 6.6$ Hz, 1 H), 3.22 (sept, $J = 6.6$ Hz, 1 H), 2.26 (m, 2 H), 1.33 (d, $J = 6.6$ Hz, 6 H), 1.30 (d, $J = 6.6$ Hz, 6 H), 1.22 (m, 3 H), 1.11 (m, 8 H), 0.85 (t, $J = 7$ Hz, 3 H). FAB-MS: calculated for ($\text{C}_{25}\text{H}_{36}\text{FNO}$) 385, found 386 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{25}\text{H}_{36}\text{FNO}$: C, 77.88; H, 9.41; N, 3.63. Found: C, 77.86; H, 9.66; N, 3.59. mp 73-75°C. $R_f = 0.3$ (20% ethyl acetate/hexane).


15

EXAMPLE 362,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-octylpyridine

20 The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-octenyl)pyridine (Example 33) according to the procedure described in Example 1, Step H. ^1H NMR (300 MHz, CDCl_3): δ 7.14 (m, 4 H), 4.33 (d, $J = 5.5$ Hz, 2 H), 3.41 (sept, $J = 6.6$ Hz, 1 H), 3.23 (sept, $J = 6.6$ Hz, 1 H), 2.26 (m, 2 H), 1.33 (d, $J = 6.6$ Hz, 6 H), 1.30 (d, $J = 6.6$ Hz, 6 H), 1.25 (m, 3 H), 1.15 (m, 10 H), 0.87 (t, $J = 7$ Hz, 3 H). FAB-MS: calculated for ($\text{C}_{26}\text{H}_{38}\text{FNO}$) 399, found 400 ($\text{M}+\text{H}$).

- 0 Anal. Calcd for C₂₆H₃₈FNO: C, 78.15; H, 9.59; N, 3.51. Found: C, 78.27; H, 9.81; N, 3.43. Gummy oil; R_f = 0.3 (20% ethyl acetate/hexane).


EXAMPLE 37



5 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(2-phenylethyl)pyridine

- 10 The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[2(E)-phenylethenyl]pyridine (Example 34) according to the procedure described in Example 1, Step H. ¹H NMR (300 MHz, CDCl₃): δ 7.19 (m, 7 H), 6.86 (m, 2 H), 4.36 (d, J = 5.5 Hz, 2 H), 3.44 (sept, J = 6.6 Hz, 1 H), 3.35 (sept, J = 6.6 Hz, 1 H), 2.58 (m, 4 H), 1.35 (d, J = 6.6 Hz, 6 H), 1.34 (d, J = 6.6 Hz, 6 H), 1.19 (t, J = 5.5 Hz, 1 H). FAB-MS: calculated for (C₂₆H₃₀FNO) 391, found 392 (M+H). Anal. Calcd for C₂₆H₃₀FNO: C, 79.76; H, 7.72; N, 3.58. Found: C, 79.57; H, 7.61; N, 3.44. mp 158-159°C. R_f = 0.3 (20% ethyl acetate/hexane).

EXAMPLE 38




20 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(4-phenyl-1-butenyl)pyridine

The title compound was prepared from ethyl isobutyrylacetate, 4-fluorobenzaldehyde and 3-phenylpropyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps A-G. The product was obtained as a mixture 5:1 trans:cis isomers; gummy oil. ¹H NMR (300 MHz,

- 0 CDCl₃): δ 7.26 (m, 2 H), 7.19 (m, 1 H), 7.09 (m, 6 H), 6.05 (d, J = 11 Hz, 0.2 H), 5.98 (d, J = 16 Hz, 0.8 H), 5.47 (dt, J = 7, 11 Hz, 0.2 H), 5.33 (dt, J = 7, 16 Hz, 0.8 H), , 4.40 (d, J = 5 Hz, 2 H), 3.43 (m, 1 H), 3.26 (sept, J = 6.6 Hz, 1 H), 2.51 (m, 2 H), 2.29 (m, 1.6 H), 2.05 (m, 0.4 H), 1.34 (m, 6 H), 1.25 (m, 1 H), 1.22 (d, J = 6.6 Hz, 6 H). FAB-MS: calculated for (C₂₈H₃₂FNO) 417, found 418 (M+H). Anal. Calcd for C₂₈H₃₂FNO: C, 80.54; H, 7.72; N, 3.35. Found: C, 80.56; H, 7.56; N, 3.32. R_f = 0.3 (20% ethyl acetate/hexane).
- 5

EXAMPLE 39




10

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(4-phenylbutyl)pyridine

- The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(4-phenyl-1-butenyl)pyridine (Example 38) according to the procedure described in Example 1, Step H. Gummy oil; ¹H NMR (300 MHz, CDCl₃): δ 7.24 (m, 3 H), 7.08 (m, 6 H), 4.31 (d, J = 5.5 Hz, 2 H), 3.40 (sept, J = 6.6 Hz, 1 H), 3.17 (sept, J = 6.6 Hz, 1 H), 2.46 (t, J = 7.5 Hz, 2 H), 2.29 (m, 2 H), 1.47 (m, 2 H), 1.32 (d, J = 6.6 Hz, 6 H), 1.30 (m, 2 H), 1.27 (d, J = 6.6 Hz, 6 H), 1.15 (t, J = 5.5 Hz, 1 H). FAB-MS: calculated for (C₂₈H₃₄FNO) 419, found 420 (M+H). Anal. Calcd for C₂₈H₃₄FNO: C, 80.15; H, 8.17; N, 3.34. Found: C, 80.06; H, 7.94; N, 3.28. R_f = 0.3 (20% ethyl acetate/hexane).
- 15
- 20

EXAMPLE 40




0 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[2(E)-(2-methyl-
phenyl)ethenyl]pyridine

5 The title compound was prepared from ethyl isobutyrylacetate, 4-fluorobenzaldehyde and 2-methylbenzyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps A-G. ¹H NMR (300 MHz, CDCl₃): δ 7.22 (m, 3 H), 7.10 (m, 5 H), 6.62 (d, *J* = 17 Hz, 1 H), 6.45 (d, *J* = 17 Hz, 1 H), 4.45 (d, *J* = 5.5 Hz, 2 H), 3.48 (m, 2 H), 2.12 (s, 3 H), 1.37 (d, *J* = 6.6 Hz, 6 H), 1.33 (d, *J* = 6.6 Hz, 6 H), 1.31 (m, 1 H). FAB-MS: calculated for (C₂₇H₃₀FNO) 403, found 404 (M+H). Anal. Calcd for C₂₇H₃₀FNO: C, 80.36; H, 7.49; N, 3.47. Found: C, 80.23; H, 7.23; N, 3.44. mp 108-111°C. R_f = 0.3 (20% ethyl acetate/hexane).

10

EXAMPLE 41




15 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[2(E)-(3-methyl-
phenyl)ethenyl]pyridine

20 The title compound was prepared from ethyl isobutyrylacetate, 4-fluorobenzaldehyde and 3-methylbenzyl triphenylphosphonium chloride according to the procedures described in Example 1, Steps A-G. ¹H NMR (300 MHz, CDCl₃): δ 7.18 (m, 3 H), 7.11 (m, 2 H), 7.00 (m, 3 H), 6.68 (d, *J* = 17 Hz, 1 H), 6.23 (d, *J* = 17 Hz, 1 H), 4.44 (d, *J* = 5.5 Hz, 2 H), 3.47 (m, 2 H), 2.32 (s, 3 H), 1.37 (d, *J* = 6.6 Hz, 6 H), 1.31 (d, *J* = 6.6 Hz, 6 H), 1.28 (m, 1 H). FAB-MS: calculated for (C₂₇H₃₀FNO) 403, found 404 (M+H). Anal. Calcd for C₂₇H₃₀FNO: C, 80.36; H, 7.49; N, 3.47. Found: C, 80.38; H, 7.45; N, 3.45. mp 97-99°C. R_f = 0.3 (20% ethyl acetate/hexane).

25

30


0

EXAMPLE 42

5 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[2(E)-(4-methylphenyl)ethenyl]pyridine

The title compound was prepared from ethyl isobutyrylacetate, 4-fluorobenzaldehyde and 4-methylbenzyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps A-G. ¹H NMR (300 MHz, CDCl₃): δ 7.18 (m, 2 H), 7.08 (m, 6 H), 6.63 (d, J = 17 Hz, 1 H), 6.23 (d, J = 17 Hz, 1 H), 4.43 (d, J = 5 Hz, 2 H), 3.47 (sept, J = 6.6 Hz, 2 H), 2.31 (s, 3 H), 1.36 (d, J = 6.6 Hz, 6 H), 1.30 (d, J = 6.6 Hz, 6 H), 1.26 (m, 1 H). FAB-MS: calculated for (C₂₇H₃₀FNO) 403, found 404 (M+H). Anal. Calcd for C₂₇H₃₀FNO: C, 80.36; H, 7.49; N, 3.47. Found: C, 79.93; H, 7.34; N, 3.47. mp 131-133°C. R_f = 0.3 (20% ethyl acetate/hexane).

15


EXAMPLE 43

20 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[2-(2-methylphenyl)ethyl]pyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[2(E)-(2-methylphenyl)ethenyl]pyridine (Example 40) according to the procedure described in Example 1, Step H. ¹H NMR (300 MHz, CDCl₃): δ

- 0 7.16 (m, 4 H), 7.06 (m, 3 H), 6.81 (m, 1 H), 4.35 (d, $J = 4$ Hz, 2 H), 3.42 (sept, $J = 6.6$ Hz, 2 H), 2.57 (m, 4 H), 1.97 (s, 3 H), 1.36 (d, $J = 6.6$ Hz, 6 H), 1.35 (d, $J = 6.6$ Hz, 6 H), 1.19 (m, 1 H). FAB-MS: calculated for (C₂₇H₃₂FNO) 405, found 406 (M+H). Anal. Calcd for C₂₇H₃₂FNO: C, 79.96; H, 7.95; N, 3.45. Found: C, 80.08; H, 8.05; N, 3.46. mp 125-126°C. R_f = 0.3 (20% ethyl acetate/hexane).


5

EXAMPLE 44

- 10 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[2-(3-methylphenyl)ethyl]pyridine

The title compound was prepared 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[2(E)-(3-methylphenyl)ethenyl]pyridine (Example 41) according to the procedure described in Example 1, Step H. ¹H NMR (300 MHz, CDCl₃): δ

- 15 (d, $J = 7$ Hz, 4 H), 7.10 (m, 1 H), 6.97 (m, 1 H), 6.65 (m, 2 H), 4.36 (s, 2 H), 3.44 (sept, $J = 6.6$ Hz, 1 H), 3.35 (d, $J = 6.6$ Hz, 1 H), 2.57 (m, 4 H), 2.28 (s, 3 H), 1.35 (d, $J = 6.6$ Hz, 6 H), 1.34 (d, $J = 6.6$ Hz, 6 H), 1.20 (m, 1 H). FAB-MS: calculated for (C₂₇H₃₂FNO) 405, found 406 (M+H). Anal. Calcd for C₂₇H₃₂FNO: C, 79.96; H, 7.95; N, 3.45. Found: C, 79.30; H, 8.10; N, 3.36. mp 148-150°C. R_f = 0.3 (20% ethyl acetate/hexane).
- 20

EXAMPLE 45


0

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[2-(4-methylphenyl)ethyl]pyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[2(E)-(4-methylphenyl)ethenyl]pyridine (Example 42) according to the procedure described in Example 1, Step H. ¹H NMR (300 MHz, CDCl₃): δ 7.17 (m, 4 H), 7.02 (d, J = 7.7 Hz, 2 H), 6.75 (d, J = 7.7 Hz, 2 H), 4.36 (d, J = 4 Hz, 2 H), 3.43 (sept, J = 6.6 Hz, 1 H), 3.34 (sept, J = 6.6 Hz, 1 H), 2.55 (m, 4 H), 2.29 (s, 3 H), 1.34 (d, J = 6.6 Hz, 6 H), 1.33 (d, J = 6.6 Hz, 6 H), 1.20 (m, 1 H). FAB-MS: calculated for (C₂₇H₃₂FNO) 405, found 406 (M+H). Anal. Calcd for C₂₇H₃₂FNO: C, 79.96; H, 7.95; N, 3.45. Found: C, 79.40; H, 7.84; N, 3.44. mp 121-123°C. R_f = 0.3 (20% ethyl acetate/hexane).

10

EXAMPLE 46



15

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[3-(1,3-dioxolan-2-yl)propyl]pyridine


The title compound was prepared from ethyl isobutyrylacetate, 4-fluorobenzaldehyde and [2-(1,3-dioxolan-2-yl)ethyl]triphenylphosphonium bromide according to the procedures described in Example 1, Steps A-G. ¹H NMR (300 MHz, CDCl₃): δ 7.16 (m, 4 H), 4.63 (t, J = 4 Hz, 1 H), 4.33 (d, J = 5 Hz, 2 H), 3.88 (m, 2 H), 3.77 (m, 2 H), 3.41 (bm, 1 H), 3.24 (bm, 1 H), 2.34 (m, 2 H), 1.47 (m, 4 H), 1.32 (m, 12 H), 1.18 (m, 1 H). FAB-MS: calculated for (C₂₄H₃₂FNO₃) 401, found 402 (M+H). mp 90-91°C. R_f = 0.2 (20% ethyl acetate/hexane).

20

25

30

0

EXAMPLE 47

5

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(phenylthio)methyl]pyridineStep A: Methyl 2,6-diisopropyl-4-(4-fluorophenyl)-5-hydroxymethyl-3-pyridinecarboxylate

10 Prepared from methyl isobutyrylacetate, 4-fluorobenzaldehyde and ammonium acetate by the procedures described in Example 1, Steps A-D.

Step B: Methyl-2,6-diisopropyl-4-(4-fluorophenyl)-5-bromomethyl-3-pyridinecarboxylate


15 A solution of the intermediate obtained in Step A (20 g, 57.9 mmol) in acetonitrile (500 mL) was stirred at 0°C and treated with dibromotriphenylphosphorane (36.7 g, 86.9 mmol) in portions. The suspension was then allowed to warm to room temperature and stirred for 2 hr. The solvent was removed *in vacuo* and the residue partitioned between diethyl ether (400 mL) and
20 water (350 mL). The ether layer was washed with brine (150 mL), dried (MgSO₄) and concentrated. Purification by chromatography through silica (5% diethyl ether/hexane) gave a white solid (20.6 g, 50.5 mmol, 87%). ¹H NMR (300 MHz, CDCl₃): δ 7.31 (m, 2 H), 7.12 (m, 2 H), 4.29 (s, 2 H), 3.49 (s, 3H), 3.41 (sept, J = 6.6 Hz, 1 H), 3.06 (sept, J = 6.6 Hz, 1 H), 1.33 (m, 12 H). mp 109-111°C. R_f = 0.6 (50%
25 CH₂Cl₂/hexane).

Step C: 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(phenylthio)methyl]pyridine

30 A solution of the intermediate obtained in Step B (200 mg, 0.47 mmol) in anhydrous THF (5 mL), stirred under argon, was treated with benzenethiol (73 uL,

0 0.71 mmol) and *N*-methylmorpholine (0.26 mL, 2.4 mmol). The reaction mixture was stirred at reflux for 14 hr, allowed to cool to room temperature and treated with lithium aluminum hydride (1.9 mL, 1.9 mmol, 1.0M in THF). The reaction mixture was heated at reflux for 1 hr then allowed to cool to room temperature. The mixture was quenched by the successive addition of water (80 μ L), 20% NaOH (80 μ L) and water (240 μ L). The resulting suspension was filtered through a cake of
 5 celite and concentrated. Purification by flash silica gel chromatography (5% ethyl acetate/hexane) afforded a white solid (160 mg, 0.39 mmol, 83%). ^1H NMR (300 MHz, CDCl_3): δ 7.23 (m, 5 H), 7.11 (m, 4 H), 4.36 (d, $J = 5.5$ Hz, 2 H), 3.81 (s, 2 H), 3.45 (sept, $J = 6.6$ Hz, 1 H), 3.43 (sept, $J = 6.6$ Hz, 1 H), 1.35 (d, $J = 6.6$ Hz, 6 H), 1.33
 10 (d, $J = 6.6$ Hz, 6 H), 1.21 (t, $J = 5.5$ Hz, 1 H). FAB-MS calcd for ($\text{C}_{25}\text{H}_{28}\text{FNOS}$) 409, found 410 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{25}\text{H}_{28}\text{FNOS}$: C, 73.32; H, 6.89; N, 3.42; S, 7.83. Found: C, 73.24; H, 6.90; N, 3.35; S, 8.01. mp 119-121°C. $R_f = 0.3$ (20% ethyl acetate/hexane).

15


EXAMPLE 48

20 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(3-trifluoromethyl)phenyl]thio]methylpyridine

The title compound was prepared from 3-trifluoromethyl-thiophenol according to the procedures described in Example 47. ^1H NMR (300 MHz, CDCl_3): δ 7.34 (m, 2 H), 7.24 (m, 4 H), 7.10 (m, 2 H), 4.36 (d, $J = 5.5$ Hz, 2 H), 3.85 (s, 2 H), 3.45 (sept, $J = 6.6$ Hz, 1 H), 3.38 (sept, $J = 6.6$ Hz, 1 H), 1.35 (d, $J = 6.6$ Hz, 6 H), 1.34
 25 (d, $J = 6.6$ Hz, 6 H), 1.23 (t, $J = 5.5$ Hz, 1 H). FAB-MS calcd for ($\text{C}_{26}\text{H}_{27}\text{F}_4\text{NOS}$) 477, found 478 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{26}\text{H}_{27}\text{F}_4\text{NOS}$: C, 65.39; H, 5.70; N, 2.93; S, 6.71. Found: C, 65.39; H, 5.76; N, 2.88; S, 6.62. mp 110-111°C. $R_f = 0.3$ (20% ethyl acetate/hexane).

30

0

EXAMPLE 49


5

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(4-fluorophenyl)thio]methylpyridine

10

The title compound was prepared from 4-fluorothiophenol according to the procedures described in Example 47. ^1H NMR (300 MHz, CDCl_3): δ 7.24 (m, 2 H), 7.12 (m, 4 H), 6.93 (m, 2 H), 4.35 (d, $J = 5.5$ Hz, 2 H), 3.76 (s, 2 H), 3.44 (sept, $J = 6.6$ Hz, 1 H), 3.40 (sept, $J = 6.6$ Hz, 1 H), 1.34 (d, $J = 6.6$ Hz, 6 H), 1.33 (d, $J = 6.6$ Hz, 6 H), 1.22 (t, $J = 5.5$ Hz, 1 H). FAB-MS calcd for $(\text{C}_{25}\text{H}_{27}\text{F}_2\text{NOS})$ 427, found 428 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{25}\text{H}_{27}\text{F}_2\text{NOS}$: C, 70.23; H, 6.37; N, 3.28; S, 7.50. Found: C, 70.22; H, 6.41; N, 3.22; S, 7.39. mp 119-121°C. $R_f = 0.3$ (20% ethyl acetate/hexane).

15


EXAMPLE 502,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(4-methylphenyl)thio]methylpyridine

20

The title compound was prepared from *p*-thiocresol according to the procedures described in Example 47. ^1H NMR (300 MHz, CDCl_3): δ 7.27 (m, 2 H), 7.13 (m, 2 H), 7.03 (m, 4 H), 4.35 (d, $J = 5.5$ Hz, 2 H), 3.77 (s, 2 H), 3.44 (m, 2 H), 2.31 (s, 3 H), 1.34 (d, $J = 6.6$ Hz, 6 H), 1.33 (d, $J = 6.6$ Hz, 6 H), 1.22 (t, $J = 5.5$ Hz, 1 H). FAB-MS calcd for $(\text{C}_{26}\text{H}_{30}\text{FNOS})$ 423, found 424 ($\text{M}+\text{H}$). Anal. Calcd for

- 0 C₂₆H₃₀FNOS: C, 73.72; H, 7.14; N, 3.31; S, 7.57. Found: C, 74.00; H, 7.15; N, 3.36; S, 7.32. mp 90-91°C. R_f = 0.3 (20% ethyl acetate/hexane).


EXAMPLE 51



2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-naphthylthio)-methylpyridine

- 10 The title compound was prepared from 1-naphthalenethiol according to the procedures described in Example 47. ¹H NMR (300 MHz, CDCl₃): δ 8.01 (d, *J* = 8.5 Hz, 1 H), 7.82 (d, *J* = 8.5 Hz, 1 H), 7.74 (d, *J* = 8 Hz, 1 H), 7.46 (m, 3 H), 7.34 (m, 1 H), 7.20 (m, 2 H), 7.06 (m, 2 H), 4.34 (d, *J* = 5.5 Hz, 2 H), 3.82 (s, 2 H), 3.51 (sept, *J* = 6.6 Hz, 1 H), 3.45 (sept, *J* = 6.6 Hz, 1 H), 1.36 (d, *J* = 6.6 Hz, 6 H), 1.35 (d, *J* = 6.6 Hz, 6 H), 1.19 (t, *J* = 5.5 Hz, 1 H). FAB-MS calcd for (C₂₉H₃₀FNOS) 459, found 460 (M+H).
- 15 Anal. Calcd for C₂₉H₃₀FNOS: C, 75.78; H, 6.58; N, 3.05; S, 6.98. Found: C, 75.36; H, 6.52; N, 2.91; S, 6.74. mp 77-79°C. R_f = 0.4 (20% ethyl acetate/hexane).


EXAMPLE 52



2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(2-naphthylthio)methylpyridine

- 0 The title compound was prepared from 2-naphthalenethiol according to the procedures described in Example 47. ^1H NMR (300 MHz, CDCl_3): δ 7.77 (d, $J = 9$ Hz, 1 H), 7.68 (d, $J = 9$ Hz, 2 H), 7.52 (d, $J = 1.5$ Hz, 1 H), 7.45 (m, 2 H), 7.25 (m, 2 H), 7.17 (dd, $J = 1.8, 8.5$ Hz, 1 H), 7.07 (m, 2 H), 4.35 (d, $J = 5.5$ Hz, 2 H), 3.91 (s, 2 H), 3.45 (sept, $J = 6.6$ Hz, 2 H), 1.35 (d, $J = 6.6$ Hz, 6 H), 1.34 (d, $J = 6.6$ Hz, 6 H), 1.21 (t, $J = 5.5$ Hz, 1 H). FAB-MS calcd for $(\text{C}_{29}\text{H}_{30}\text{FNOS})$ 459, found 460 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{29}\text{H}_{30}\text{FNOS}$: C, 75.78; H, 6.58; N, 3.05; S, 6.98. Found: C, 75.55; H, 6.60; N, 2.95; S, 6.91. mp 127-129°C. $R_f = 0.4$ (20% ethyl acetate/hexane).


EXAMPLE 53



2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(2,3,5,6-tetrafluorophenyl)thio]methylpyridine

- 15 The title compound was prepared from pentafluorothiophenol according to the procedures described in Example 47. ^1H NMR (300 MHz, CDCl_3): δ 7.27 (m, 2 H), 7.11 (m, 2 H), 6.99 (m, 1 H), 4.35 (d, $J = 5.5$ Hz, 2 H), 3.84 (s, 2 H), 3.44 (sept, $J = 6.6$ Hz, 1 H), 3.43 (sept, $J = 6.6$ Hz, 1 H), 1.34 (d, $J = 6.6$ Hz, 6 H), 1.33 (d, $J = 6.6$ Hz, 6 H), 1.23 (t, $J = 5.5$ Hz, 1 H). FAB-MS calcd for $(\text{C}_{25}\text{H}_{24}\text{F}_5\text{NOS})$ 481, found 482 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{25}\text{H}_{24}\text{F}_5\text{NOS}$: C, 62.36; H, 5.02; N, 2.91; S, 6.66; F, 19.73. Found: C, 62.40; H, 4.96; N, 2.82; S, 6.74; F, 19.49. mp 109-110°C. $R_f = 0.4$ (20% ethyl acetate/hexane).

EXAMPLE 54




0 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(3-methoxy-phenyl)thio]methylpyridine

 The title compound was prepared from 3-methoxybenzenethiol according to the procedures described in Example 47. ¹H NMR (300 MHz, CDCl₃): d 7.24 (m, 2 H), 7.13 (m, 3 H), 6.72 (m, 2 H), 6.62 (m, 1 H), 4.35 (d, *J* = 5.5 Hz, 2 H), 3.81 (s, 2 H),
5 3.75 (s, 3 H), 3.44 (sept, *J* = 6.6 Hz, 1 H), 3.42 (sept, *J* = 6.6 Hz, 1 H), 1.34 (d, *J* = 6.6 Hz, 6 H), 1.33 (d, *J* = 6.6 Hz, 6 H), 1.23 (t, *J* = 5.5 Hz, 1 H). FAB-MS calcd for (C₂₆H₃₀FNO₂S) 339, found 440 (M+H). Anal. Calcd for C₂₆H₃₀FNO₂S: C, 71.04; H, 6.88; N, 3.19; S, 7.29. Found: C, 70.94; H, 6.77; N, 2.96; S, 7.41. mp 93-94°C. R_f = 0.4 (20% ethyl acetate/hexane).

10

EXAMPLE 55




15 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(4-hydroxy-phenyl)thio]methylpyridine

 The title compound was prepared from 4-hydroxythiophenol according to the procedures described in Example 47. ¹H NMR (300 MHz, 5:1 CDCl₃/CD₃OD):
δ 7.15 (m, 2 H), 7.06 (m, 2 H), 6.97 (d, *J* = 8.5 Hz, 2 H), 6.64 (d, *J* = 8.5 Hz, 2 H), 4.27
20 (s, 2 H), 3.66 (s, 2 H), 3.40 (m, 2 H), 1.29 (d, *J* = 6.6 Hz, 6 H), 1.28 (d, *J* = 6.6 Hz, 6 H). FAB-MS calcd for (C₂₅H₂₈FNO₂S) 425, found 426 (M+H). Anal. Calcd for C₂₅H₂₈FNO₂S: C, 70.56; H, 6.63; N, 3.29; S, 7.53. Found: C, 70.29; H, 6.34; N, 3.12; S, 7.44. mp 178-179°C. R_f = 0.3 (30% ethyl acetate/hexane).

25

30

0

EXAMPLE 56


5

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(4-methoxyphenyl)thio]methylpyridine

10

The title compound was prepared from 4-methoxybenzenethiol according to the procedures described in Example 47. ^1H NMR (300 MHz, CDCl_3): δ 7.23 (m, 2 H), 7.12 (m, 4 H), 6.77 (d, $J = 9$ Hz, 2 H), 4.35 (d, $J = 5.5$ Hz, 2 H), 3.79 (s, 3 H), 3.73 (s, 2 H), 3.44 (sept, $J = 6.6$ Hz, 2 H), 1.34 (d, $J = 6.6$ Hz, 6 H), 1.33 (d, $J = 6.6$ Hz, 6 H), 1.21 (t, $J = 5.5$ Hz, 1 H). FAB-MS calcd for $(\text{C}_{26}\text{H}_{30}\text{FNO}_2\text{S})$ 339, found 440 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{26}\text{H}_{30}\text{FNO}_2\text{S}$: C, 71.04; H, 6.88; N, 3.19; S, 7.29. Found: C, 70.96; H, 6.90; N, 3.15; S, 7.35. mp 92-93°C. $R_f = 0.4$ (20% ethyl acetate/hexane).

15

EXAMPLE 57


20

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(3-methylphenyl)thio]methylpyridine

The title compound was prepared from *m*-thiocresol according to the procedures described in Example 47. ^1H NMR (300 MHz, CDCl_3): δ 7.25 (m, 2 H), 7.11 (m, 3 H), 7.00 (m, 1 H), 6.94 (m, 2 H), 4.36 (d, $J = 5.5$ Hz, 2 H), 3.81 (s, 2 H), 3.45 (sept, $J = 6.6$ Hz, 1 H), 3.43 (sept, $J = 6.6$ Hz, 1 H), 2.28 (s, 3 H), 1.35 (d, $J = 6.6$ Hz, 6 H), 1.34 (d, $J = 6.6$ Hz, 6 H), 1.22 (t, $J = 5.5$ Hz, 1 H). FAB-MS calcd for

- 0 (C₂₆H₃₀FNOS) 423, found 424 (M+H). Anal. Calcd for C₂₆H₃₀FNOS: C, 73.72; H, 7.14; N, 3.31; S, 7.57. Found: C, 73.76; H, 7.09; N, 3.27; S, 7.42. mp 92-93°C. R_f = 0.4 (20% ethyl acetate/hexane).


5 EXAMPLE 58



2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(2-methylphenyl)thio]methylpyridine

- 10 The title compound was prepared from *o*-thiocresol according to the procedures described in Example 47. ¹H NMR (300 MHz, CDCl₃): δ 7.25 (m, 2 H), 7.11 (m, 6 H), 4.36 (d, *J* = 5.5 Hz, 2 H), 3.74 (s, 2 H), 3.45 (sept, *J* = 6.6 Hz, 2 H), 2.26 (s, 3 H), 1.35 (d, *J* = 6.6 Hz, 12 H), 1.21 (t, *J* = 5.5 Hz, 1 H). FAB-MS calcd for (C₂₆H₃₀FNOS) 423, found 424 (M+H). Anal. Calcd for C₂₆H₃₀FNOS: C, 73.72; H, 7.14; N, 3.31; S, 7.57. Found: C, 73.54; H, 7.09; N, 3.06; S, 7.37. mp 140-141°C. R_f = 0.4 (20% ethyl acetate/hexane).


EXAMPLE 59



2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(3-fluorophenyl)thio]methylpyridine

- 0 The title compound was prepared from 3-fluorothiophenol according to the procedures described in Example 47. ¹H NMR (300 MHz, CDCl₃): δ 7.27 (m, 3 H), 7.11 (m, 2 H), 6.87 (m, 2 H), 6.78 (m, 1 H), 4.36 (d, J = 5.5 Hz, 2 H), 3.82 (s, 2 H), 3.45 (sept, J = 6.6 Hz, 1 H), 3.38 (sept, J = 6.6 Hz, 1 H), 1.35 (d, J = 6.6 Hz, 6 H), 1.33 (d, J = 6.6 Hz, 6 H), 1.23 (t, J = 5.5 Hz, 1 H). FAB-MS calcd for (C₂₅H₂₇F₂NOS) 427, found 428 (M+H). Anal. Calcd for C₂₅H₂₇F₂NOS: C, 70.23; H, 6.37; N, 3.28; S, 7.50. Found: C, 70.22; H, 6.31; N, 3.20; S, 7.41. mp 99-100°C. R_f = 0.4 (20% ethyl acetate/hexane).


EXAMPLE 60



2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(2-methoxyphenyl)thio]methylpyridine

- 15 The title compound was prepared from 2-methoxythiophenol according to the procedures described in Example 47. ¹H NMR (300 MHz, CDCl₃): δ 7.22 (m, 3 H), 7.07 (m, 3 H), 6.83 (m, 2 H), 4.34 (d, J = 5.5 Hz, 2 H), 3.78 (s, 3 H), 3.75 (s, 2 H), 3.49 (sept, J = 6.6 Hz, 1 H), 3.43 (sept, J = 6.6 Hz, 1 H), 1.34 (d, J = 6.6 Hz, 12 H), 1.19 (t, J = 5.5 Hz, 1 H). FAB-MS calcd for (C₂₆H₃₀FNO₂S) 339, found 440 (M+H). Anal. Calcd for C₂₆H₃₀FNO₂S: C, 71.04; H, 6.88; N, 3.19; S, 7.29. Found: C, 70.93; H, 6.67; N, 3.12; S, 7.48. mp 129-131°C. R_f = 0.4 (20% ethyl acetate/hexane).

EXAMPLE 61




0

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(3,5-dimethyl-phenyl)thio]methylpyridine

The title compound was prepared from 3,5-dimethylthiophenol according to the procedures described in Example 47. ¹H NMR (300 MHz, CDCl₃): δ 7.24 (m, 2 H), 7.11 (m, 2 H), 6.80 (s, 1 H), 6.69 (s, 2 H), 4.35 (d, J = 5.5 Hz, 2 H), 3.79 (s, 2 H), 3.44 (sept, J = 6.6 Hz, 1 H), 3.42 (sept, J = 6.6 Hz, 1 H), 2.23 (s, 6 H), 1.34 (d, J = 6.6 Hz, 6 H), 1.33 (d, J = 6.6 Hz, 6 H), 1.21 (t, J = 5.5 Hz, 1 H). FAB-MS calcd for (C₂₇H₃₂FNOS) 437, found 438 (M+H). Anal. Calcd for C₂₇H₃₂FNOS: C, 74.11; H, 7.37; N, 3.20; S, 7.33. Found: C, 74.18; H, 7.22; N, 3.13; S, 6.86. mp 109-110°C. R_f = 0.5 (20% ethyl acetate/hexane).

10

EXAMPLE 62



15


2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(4-ethylphenyl)thio]methylpyridine

The title compound was prepared from 4-ethylthiophenol according to the procedures described in Example 47. ¹H NMR (300 MHz, CDCl₃): δ 7.24 (m, 2 H), 7.05 (m, 6 H), 4.35 (d, J = 5.5 Hz, 2 H), 3.77 (s, 2 H), 3.43 (m, 2 H), 2.60 (q, J = 7.7 Hz, 2 H), 1.34 (d, J = 6.6 Hz, 6 H), 1.32 (d, J = 6.6 Hz, 6 H), 1.21 (m, 4 H). FAB-MS calcd for (C₂₇H₃₂FNOS) 437, found 438 (M+H). Anal. Calcd for C₂₇H₃₂FNOS: C, 74.11; H, 7.37; N, 3.20; S, 7.33. Found: C, 74.07; H, 7.23; N, 3.09; S, 7.23. mp 102-103°C. R_f = 0.5 (20% ethyl acetate/hexane).

25

30

0

EXAMPLE 63


5

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(4-isopropylphenyl)thio]methylpyridine

10

The title compound was prepared from 4-isopropylthiophenol according to the procedures described in Example 47. ^1H NMR (300 MHz, CDCl_3): δ 7.25 (m, 2 H), 7.06 (m, 6 H), 4.35 (d, $J = 5.5$ Hz, 2 H), 3.79 (s, 2 H), 3.43 (m, 2 H), 2.86 (sept, $J = 7$ Hz, 1 H), 1.34 (d, $J = 6.6$ Hz, 6 H), 1.32 (d, $J = 6.6$ Hz, 6 H), 1.22 (d, $J = 7$ Hz, 6 H), 1.20 (t, $J = 5.5$ Hz, 1 H). FAB-MS calcd for $(\text{C}_{28}\text{H}_{34}\text{FNOS})$ 451, found 452 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{28}\text{H}_{34}\text{FNOS}$: C, 74.46; H, 7.59; N, 3.10; S, 7.10. Found: C, 74.51; H, 7.48; N, 3.04; S, 6.85. mp 108-109°C. $R_f = 0.5$ (20% ethyl acetate/hexane).

15

EXAMPLE 64


20

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-benzylthio-methylpyridine

The title compound was prepared from benzyl mercaptan according to the procedures described in Example 47. ^1H NMR (300 MHz, CDCl_3): δ 7.23 (m, 5 H), 7.08 (m, 4 H), 4.31 (d, $J = 5.5$ Hz, 2 H), 3.55 (s, 2 H), 3.40 (sept, $J = 6.6$ Hz, 1 H), 3.24 (s, 2 H), 3.19 (sept, $J = 6.6$ Hz, 1 H), 1.31 (d, $J = 6.6$ Hz, 6 H), 1.24 (d, $J = 6.6$ Hz, 6 H), 1.17 (t, $J = 5.5$ Hz, 1 H). FAB-MS calcd for $(\text{C}_{26}\text{H}_{30}\text{FNOS})$ 423, found 424 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{26}\text{H}_{30}\text{FNOS}$: C, 73.72; H, 7.14; N, 3.31; S, 7.57. Found: C, 73.58;

0 H, 7.25; N, 3.05; S, 7.45. mp 150-151°C. R_f = 0.5 (20% ethyl acetate/hexane).

EXAMPLE 65




5

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(phenethyl)-thiomethyl]pyridine

The title compound was prepared from phenethyl mercaptan according to the procedures described in Example 47. ^1H NMR (300 MHz, CDCl_3): δ 7.28 (m, 5 H), 7.11 (m, 4 H), 4.34 (d, J = 5.5 Hz, 2 H), 3.39 (m, 4 H), 2.70 (m, 2 H), 2.61 (m, 2 H), 1.33 (d, J = 6.6 Hz, 6 H), 1.32 (d, J = 6.6 Hz, 6 H), 1.20 (t, J = 5.5 Hz, 1 H). FAB-MS calcd for $(\text{C}_{27}\text{H}_{32}\text{FNOS})$ 437, found 438 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{27}\text{H}_{32}\text{FNOS}$: C, 74.11; H, 7.37; N, 3.20; S, 7.33. Found: C, 73.99; H, 7.46; N, 2.96; S, 7.23. Gummy oil. R_f = 0.5 (20% ethyl acetate/hexane).

15

EXAMPLE 66




20 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(propylthio)-methylpyridine

The title compound was prepared from propyl mercaptan according to the procedures described in Example 47. ^1H NMR (300 MHz, CDCl_3): δ 7.30 (m, 2 H),

- 0 7.14 (m, 2 H), 4.34 (d, $J = 5.5$ Hz, 2 H), 3.41 (m, 2 H), 3.37 (m, 2 H), 2.31 (t, $J = 7.0$ Hz, 2 H), 1.31 (m, 15 H), 0.89 (t, $J = 7.4$ Hz, 3 H). FAB-MS calcd for (C₂₂H₃₀NFOS) 375, found 376 (M+H); Anal. Calcd for C₂₂H₃₀NOFS: C, 70.36; H, 8.05; N, 3.73; F, 5.06; S, 8.54. Found: C, 70.32; H, 7.97; N, 3.58; F, 4.76; S, 8.49. mp 98°C (dec.). $R_f = 0.3$ (10% ethyl acetate/hexane).


5

EXAMPLE 67

- 10 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(methylthio)-methylpyridine

The title compound was prepared from methyl mercaptan according to the procedures described in Example 47. ¹H NMR (300 MHz, CDCl₃): δ 7.30 (m, 2 H), 7.16 (m, 2 H), 4.35 (d, $J = 5.5$ Hz, 2 H), 3.43 (m, 2 H), 3.38 (m, 2 H), 1.95 (s, 3 H), 1.30 (m, 12 H). FAB-MS calcd for (C₂₀H₂₆NFOS) 347, found 348 (M+H). Anal. Calcd for C₂₀H₂₆NOFS: C, 69.13; H, 7.54; N, 4.03; F, 5.47. Found: C, 69.29; H, 7.54; N, 3.91; F, 5.45. mp 49°C (dec.). $R_f = 0.2$ (10% ethyl acetate/hexane).

15

EXAMPLE 68

20

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(4-nitrophenyl)-thio]methylpyridine

0 Step A: 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-
 [(t-butyldimethylsiloxy)methyl]pyridine

 A solution of 3 g (8.3 mmol) of methyl 2,6-diisopropyl-4-(4-fluorophenyl)-5-hydroxymethyl-3-pyridinecarboxylate (Example 47, Step A) in anhydrous DMF (75 mL), was treated at room temperature with imidazole (1.3 g, 19 mmol), 4-dimethylaminopyridine (50 mg, 0.4 mmol) and *t*-butyldimethylsilyl chloride (1.4 g, 9.3 mmol). The reaction mixture was allowed to stir at room temperature for 48 hr. The solution was diluted with diethyl ether (200 mL) and washed with water (2 x 100 mL), 1N HCl (100 mL), sat. NaHCO₃ (50 mL) and brine (100 mL), dried (MgSO₄) and concentrated to 4 g as an oil: R_f = 0.4 (10% ethyl acetate/hexane).

10 This intermediate (4 g) was dissolved in anhydrous THF (100 mL), stirred under argon and treated with lithium aluminum hydride (17 mL, 17 mmol, 1.0M in THF). The reaction mixture was stirred at reflux for 1 hr, then allowed to cool to room temperature. The reaction was quenched by the successive dropwise addition of water (0.6 mL), 20% NaOH (0.6 mL) and water (1.9 mL). The resulting

15 suspension was filtered through a cake of celite and concentrated. Purification by flash silica gel chromatography (5% ethyl acetate/hexane) afforded a colorless resin (1.8 g, 4.2 mmol, 51%). ¹H NMR (300 MHz, CDCl₃) δ 7.25 (m, 2 H), 7.12 (m, 2 H), 4.38 (d, *J* = 5 Hz, 2 H), 4.28 (s, 2 H), 3.44 (sept, *J* = 6.6 Hz, 1 H), 3.39 (sept, *J* = 6.6 Hz, 1 H), 1.33 (t, *J* = 6.6 Hz, 12 H), 1.24 (t, *J* = 5.5 Hz, 1 H), 0.84 (s, 9 H), -0.08 (s, 6 H).

20 FAB-MS calcd for (C₂₅H₃₈FNSiO₂) 431, found 432 (M+H). Anal. Calcd for C₂₅H₃₈FNSiO₂: C, 69.56; H, 8.87; N, 3.24. Found: C, 69.70; H, 8.82; N, 3.12. R_f = 0.2 (10% ethyl acetate/hexane).

25 Step B: 2,6-Diisopropyl-3-bromomethyl-4-(4-fluorophenyl)-5-
 [(t-butyldimethylsiloxy)methyl]pyridine

 The intermediate obtained in Step A (1.7 g, 3.9 mmol) was dissolved in acetonitrile (50 mL) at 0°C and treated with dibromotriphenylphosphorane (2.6 g, 6.2 mmol) in portions. The suspension was then allowed to warm to room temperature and stirred for 2 hr. The solvent was removed *in vacuo* and the

30 residue partitioned between diethyl ether (150 mL) and water (100 mL). The ether layer was washed with brine (50 mL), dried (MgSO₄) and concentrated. Purification by chromatography through silica (5% diethyl ether/hexane) afforded a viscous oil (1.4 g, 2.8 mmol, 72%) which slowly solidified on standing: ¹H NMR (300 MHz, CDCl₃): δ 7.28 (m, 2 H), 7.13 (m, 2 H), 4.23 (m, 4 H), 3.37 (m, 2 H), 1.34

35 (d, *J* = 6.6 Hz, 6 H), 1.30 (d, *J* = 6.6 Hz, 6 H), 0.83 (s, 9 H), -0.09 (s, 6 H). FAB-MS calcd for (C₂₇H₃₇BrFSiNO) 493, found 494 (M+H). mp 72-73°C. R_f = 0.5 (10% ethyl acetate/hexane).


0

Step C: 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(4-nitrophenyl)thio]methylpyridine

The intermediate obtained in Step B (200 mg, 0.40 mmol) was dissolved in anhydrous THF (5 mL), stirred under argon at room temperature and treated with 4-nitrothiophenol (118 mg, 0.6 mmol, 80% tech. grade) and N-methylmorpholine (0.2 mL, 1.8 mmol). The reaction mixture was allowed to stir at reflux for 18 hr, then cooled to room temperature. The mixture was treated with tetrabutylammonium fluoride (0.8 mL, 0.8 mmol, 1.0M in THF) and allowed to stir at room temperature for 24 hr. The solvent was removed *in vacuo*, the residue dissolved in ethyl acetate (100 mL), washed with 1N HCl (50 mL), sat. NaHCO₃ (50 mL) and brine (50 mL), dried (MgSO₄) and concentrated. Purification by chromatography through silica (step gradient 5-10% ethyl acetate/hexane) afforded the title compound as a lightly colored solid (130 mg, 0.28 mmol, 70%). ¹H NMR (300 MHz, CDCl₃): δ 8.08 (d, *J* = 8.5 Hz, 2 H), 7.27 (m, 2 H), 7.13 (m, 4 H), 4.37 (d, *J* = 5.5 Hz, 2 H), 3.91 (s, 2 H), 3.46 (sept, *J* = 6.6 Hz, 1 H), 3.33 (sept, *J* = 6.6 Hz, 1 H), 1.35 (d, *J* = 6.6 Hz, 6 H), 1.34 (d, *J* = 6.6 Hz, 6 H), 1.27 (t, *J* = 5 Hz, 1 H). FAB-MS calcd for (C₂₅H₂₇FSN₂O₃) 454, found 455 (M+H). mp 178-180°C. R_f = 0.3 (20% ethyl acetate/hexane).

20

EXAMPLE 69



2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(morpholinomethyl)pyridine

Step A: Methyl-2,6-diisopropyl-4-(4-fluorophenyl)-5-(morpholino)methyl-3-pyridinecarboxylate

A solution of methyl-2,6-diisopropyl-4-(4-fluorophenyl)-5-bromomethyl-3-pyridinecarboxylate (Example 47, Step B) (500 mg, 1.22 mmol) in CH₂Cl₂ (20 mL)

0 was treated with morpholine (0.14 mL, 1.61 mmol) under argon. The reaction was stirred at room temperature for 48 hours. It was then diluted with CH₂Cl₂ (70 mL), washed with saturated NaHCO₃ (2 x 40 mL), water (1 x 40 mL), and brine (1 x 40 mL). The organic layer was dried with MgSO₄, filtered, and concentrated to afford a white solid (495 mg, 1.2 mmol, 98%). ¹H NMR (300 MHz, CDCl₃): δ 7.16 (m, 2 H), 7.07 (m, 2 H), 3.54 (t, J = 4.4 Hz, 4 H), 3.49 (m, 4 H), 3.27 (s, 2 H), 2.98 (septet, J = 6.6 Hz, 1 H), 2.19 (t, J = 4.8 Hz, 4 H), 1.30 (m, 12 H). FAB-MS calcd for (C₂₄H₃₁N₂FO₃) 414, found 415 (M+H); Anal. Calcd for C₂₄H₃₁N₂O₃F: C, 69.54; H, 7.54; N, 6.76; F, 4.58. Found: C, 69.55; H, 7.43; N, 6.50; F, 4.45. mp 132-134°C. R_f = 0.2 (20% diethyl ether/hexane).


10

Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(morpholinomethyl)pyridine

The intermediate obtained in Step A (375 mg, 0.905 mmol) was dissolved in dry THF (50 mL), treated dropwise with lithium aluminum hydride (1M/THF, 1.81 mL) and the reaction stirred at reflux for 24 hours. The reaction was quenched by the successive dropwise addition of water (0.1ml), NaOH 20% (0.1ml), and water again (0.3ml). Concentration *in vacuo* afforded a white residue which was partitioned between CH₂Cl₂ and water. The organic layer was dried with MgSO₄, filtered, and concentrated to afford an oil. The product was passed through a pad of silica (40% diethyl ether/hexanes) yielding an oil which slowly solidified to give the title compound as a white solid (295 mg, 0.76 mmol, 84%). ¹H NMR (300 MHz, CDCl₃): δ 7.14 (m, 4 H), 4.35 (d, 2 H), 3.53 (t, J = 4.8 Hz, 4 H), 3.45 (m, 2 H), 3.18 (s, 2 H), 2.18 (t, J = 4.5 Hz, 4 H), 1.26 (m, 13 H); FAB-MS calcd for (C₂₃H₃₁N₂FO₂) 386, found 387 (M+H). Anal. Calcd for C₂₃H₃₁N₂O₂F: C, 71.47; H, 8.08; N, 7.25; F, 4.92. Found: C, 71.55; H, 8.16; N, 7.05; F, 4.70. mp 93.5-95.5°C. R_f = 0.4 (40% diethyl ether/hexane).

25

EXAMPLE 70



30

0


2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(piperidinomethyl)pyridine

The title compound was prepared from piperidine according to the procedures described in Example 69. ^1H NMR (300 MHz, CDCl_3): δ 7.05 (m, 4 H), 4.27 (d, $J = 5.5$ Hz, 2 H), 3.38 (m, 2 H), 3.01 (s, 2 H), 2.02 (m, 4 H), 1.22 (m, 24 H). FAB-MS calcd for $(\text{C}_{24}\text{H}_{33}\text{N}_2\text{FO})$ 384, found 385 (M+H). Anal. Calcd for $\text{C}_{24}\text{H}_{33}\text{N}_2\text{OF}$: C, 74.96; H, 8.65; N, 7.28; F, 4.94. Found: C, 75.13; H, 8.48; N, 6.92; F, 4.77. Gummy oil. $R_f = 0.5$ (40% diethyl ether/hexane).

5

EXAMPLE 71


10

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(pyrrolidinomethyl)pyridine

15

The title compound was prepared from pyrrolidine according to the procedures described in Example 69. ^1H NMR (300 MHz, CDCl_3): δ 7.13 (m, 4 H), 4.34 (d, $J = 4.8$ Hz, 2 H), 3.52 (septet, $J = 6.6$ Hz, 1 H), 3.42 (septet, $J = 6.6$ Hz, 1 H), 3.28 (s, 2 H), 2.22 (t, $J = 6.3$ Hz, 4 H), 1.60 (t, $J = 3.3$ Hz, 5 H), 1.27 (m, 12 H). FAB-MS calcd for $(\text{C}_{23}\text{H}_{31}\text{N}_2\text{FO})$ 370, found 371 (M+H). Anal. Calcd for $\text{C}_{23}\text{H}_{31}\text{N}_2\text{OF}$: C, 74.56; H, 8.43; N, 7.56; F, 5.13. Found: C, 74.67; H, 8.72; N, 7.35; F, 5.01. mp 122-124°C. $R_f = 0.3$ (40% diethyl ether/hexane).

20

EXAMPLE 72


0

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[4-phenylpiperidin-1-yl)methyl]pyridine

The title compound was prepared from 4-phenylpiperidine according to the procedures described in Example 69. ¹H NMR (300 MHz, CDCl₃): δ 7.29 (m, 2 H), 7.15 (m, 7 H), 4.36 (d, J = 5.2 Hz, 2 H), 3.48 (m, 2 H), 3.19 (s, 2 H), 2.71 (d, J = 11.0 Hz, 2 H), 2.38 (m, 1 H), 1.86 (m, 2 H), 1.71 (m, 2 H), 1.58 (m, 2 H), 1.58 (m, 13 H). FAB-MS calcd for (C₃₀H₃₁N₂FO) 460, found 461 (M+H). Anal. Calcd for C₂₃H₃₁N₂OF: C, 78.22; H, 8.10; N, 6.08; F, 4.12. Found: C, 78.01; H, 8.21; N, 5.96; F, 4.41. mp 66-68°C. R_f = 0.5 (40% diethyl ether/hexane).

10

EXAMPLE 73




Methyl-2,6-diisopropyl-4-(4-fluorophenyl)-5-(4-piperidinopiperidin-1-yl)methyl-3-pyridinecarboxylate

The title compound was prepared from 4-piperdinopiperidine according to the procedure described in Example 69 (Step A). ¹H NMR (300 MHz, CDCl₃): δ 7.16 (m, 2 H), 7.04 (m, 2 H), 3.51 (septet, J = 5.5 Hz, 1 H), 3.47 (s, 3 H), 3.20 (s, 2 H), 2.98 (septet, J = 6.6 Hz, 1 H), 2.65 (d, J = 11.0 Hz, 2 H), 2.44 (m, 4 H), 2.05 (m, 1 H), 1.62 (m, 10 H), 1.31 (m, 16 H). FAB-MS calcd for (C₃₀H₄₂N₃FO₂) 495, found 496 (M+H). Anal. Calcd for C₃₀H₄₂N₃O₂F: C, 72.69; H, 8.54; N, 8.48; F, 3.83. Found: C, 72.43; H, 8.56; N, 8.37; F, 3.74. mp 59-61°C. R_f = 0.1 (70% diethyl ether/hexane + 1 drop MeOH).

25

30

0

EXAMPLE 74


5

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(4-piperidinopiperidin-1-yl)methyl]pyridine

10

The title compound was prepared from 4-piperidinopiperidine according to the procedures described in Example 69. ^1H NMR (300 MHz, CDCl_3): δ 7.12 (m, 4 H), 4.34 (d, $J = 3.7$ Hz, 2 H), 3.45 (m, 2 H), 3.10 (m, 2 H), 2.63 (d, $J = 11.0$ Hz, 2 H), 2.44 (m, 4 H), 2.03 (m, 1 H), 1.44 (m, 29 H). FAB-MS calcd for $(\text{C}_{29}\text{H}_{42}\text{N}_3\text{FO})$ 467, found 468 (M+H). Anal. Calcd for $\text{C}_{29}\text{H}_{42}\text{N}_3\text{OF}$: C, 74.48; H, 9.05; N, 8.98; F, 4.06. Found: C, 74.93; H, 9.35; N, 8.39; F, 3.83. mp 143-145°C. $R_f = 0.1$ (50% diethyl ether/hexane + 2 drops of MeOH).

15

EXAMPLE 75


20

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(4-phenylpiperazin-1-yl)methyl]pyridine

The title compound was prepared from 4-phenylpiperazine according to the procedures described in Example 69. ^1H NMR (300 MHz, CDCl_3): δ 7.16 (m, 6 H), 6.85 (m, 3 H), 4.36 (d, $J = 5.2$ Hz, 2 H), 3.47 (m, 2 H), 3.24 (s, 2 H), 3.04 (t, $J = 4.8$ Hz, 4 H), 2.35 (t, $J = 4.8$ Hz, 4 H), 1.29 (m, 13 H). FAB-MS calcd for $(\text{C}_{29}\text{H}_{36}\text{N}_3\text{FO})$ 461, found 462 (M+H). Anal. Calcd for $\text{C}_{29}\text{H}_{36}\text{N}_3\text{OF}$: C, 75.46; H, 7.86; N, 9.10; F, 4.12.

- 0 Found: C, 75.35; H, 7.82; N, 8.80; F, 3.99. mp 111-113°C. R_f = 0.5 (40% diethyl ether/hexane).

EXAMPLE 76




5

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(imidazol-1-yl)-methylpyridine

- 10 The title compound was prepared from imidazole according to the procedures described in Example 69. ^1H NMR (300 MHz, CDCl_3): δ 7.01 (m, 6 H), 6.57 (s, 1 H), 4.84 (s, 2 H), 4.39 (s, 2H), 3.49 (septet, J = 6.6 Hz, 1 H), 3.23 (septet, J = 6.6 Hz, 1 H), 1.70 (s, 1 H), 1.36 (d, J = 6.6 Hz, 6 H), 1.27 (d, J = 6.6 Hz, 6 H). FAB-MS calcd for $(\text{C}_{22}\text{H}_{26}\text{N}_3\text{FO})$ 367, found 368 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{22}\text{H}_{26}\text{N}_3\text{OF}$: C, 71.91; H, 7.13; N, 11.43; F, 5.17. Found: C, 71.26; H, 7.24; N, 11.03; F, 5.35. mp
- 15 184-186°C. R_f = 0.1 (50% diethyl ether/hexane w/ 2 drops MeOH).

EXAMPLE 77




20

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(cyclopropylamino)methylpyridine

The title compound was prepared from cyclopropylamine according to the

- 0 procedures described in Example 69. ^1H NMR (300 MHz, CDCl_3): δ 7.04 (m, 4 H), 4.21 (s, 2 H), 3.35 (s, 2 H), 3.26 (septet, $J = 6.6$ Hz, 2 H), 1.78 (m, 1 H), 1.17 (m, 13 H), 0.153 (m, 2 H), -0.006 (m, 2 H). FAB-MS calcd for $(\text{C}_{22}\text{H}_{29}\text{N}_2\text{FO})$ 356, found 357 (M+H). Anal. Calcd for $\text{C}_{22}\text{H}_{29}\text{N}_2\text{OF}$: C, 74.12; H, 8.20; N, 7.86; F, 5.33. Found: C, 74.29; H, 8.62; N, 7.93; F, 4.90. mp 81-83°C. $R_f = 0.3$ (40% diethyl ether/hexane).

5

EXAMPLE 78


- 10 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(cyclohexylamino)methylpyridine

The title compound was prepared from cyclohexylamine according to the procedures described in Example 69. ^1H NMR (300 MHz, CDCl_3): δ 7.25 (m, 2 H), 7.13 (m, 2 H), 4.34 (s, 2 H), 3.38 (m, 4 H), 2.16 (m, 1 H), 1.58 (m, 5 H), 1.23 (m, 16 H), 0.936 (m, 2 H). FAB-MS calcd for $(\text{C}_{25}\text{H}_{35}\text{N}_2\text{FO})$ 398, found 399 (M+H). Anal. Calcd for $\text{C}_{25}\text{H}_{35}\text{N}_2\text{OF}$: C, 74.12; H, 8.20; N, 7.86; F, 5.33. Found: C, 74.29; H, 8.62; N, 7.93; F, 4.90. mp 131-133°C. $R_f = 0.1$ (40% diethyl ether/hexane).

15

EXAMPLE 79


20



2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(dimethylamino)methylpyridine

- 0 The title compound was prepared from dimethylamine hydrochloride according to the procedures described in Example 69. ^1H NMR (300 MHz, CDCl_3): δ 7.12 (m, 4 H), 4.25 (m, 2 H), 4.09 (m, 1 H), 3.68 (septet, $J = 6.6$ Hz, 1 H), 3.41 (septet, $J = 6.6$ Hz, 1 H), 2.18 (m, 1 H), 1.69 (d, $J = 4.1$ Hz, 1 H), 1.26 (m, 12 H), 0.947 (d, $J = 6.3$ Hz, 3 H), 0.555 (d, $J = 7.0$ Hz, 1 H). FAB-MS calcd for $(\text{C}_{22}\text{H}_{30}\text{NFO}_2)$ 359, found 360 (M+H). Anal. Calcd for $\text{C}_{22}\text{H}_{30}\text{NO}_2\text{F}$: C, 73.51; H, 8.41; N, 3.90; F, 5.28. Found: C, 73.69; H, 8.40; N, 3.82; F, 5.04. mp 77-79°C. $R_f = 0.2$ (40% diethyl ether/hexane).


EXAMPLE 80



2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(dibutylamino)-methypyridine

- 15 The title compound was prepared from dibutylamine according to the procedures described in Example 69. ^1H NMR (300 MHz, CDCl_3): δ 7.11 (m, 4 H), 4.33 (d, $J = 5.5$ Hz, 2 H), 3.62 (septet, $J = 6.6$ Hz, 1 H), 3.62 (septet, $J = 6.6$ Hz, 1 H), 3.24 (s, 2 H), 2.12 (t, $J = 7.0$ Hz, 4 H), 1.55 (s, 1 H), 1.33 (t, $J = 6.6$ Hz, 6 H), 1.26 (t, $J = 6.6$ Hz, 6 H), 1.16 (m, 8 H), 0.796 (t, $J = 6.6$ Hz, 6 H). FAB-MS calcd for $(\text{C}_{27}\text{H}_{41}\text{N}_2\text{FO})$ 428, found 429 (M+H). Anal. Calcd for $\text{C}_{27}\text{H}_{41}\text{N}_2\text{OF}$: C, 75.66; H, 9.64; N, 6.54; F, 4.43. Found: C, 75.91; H, 9.83; N, 6.26; F, 4.33. Gummy oil. $R_f = 0.6$ (40% diethyl ether/hexane).


EXAMPLE 81



0

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-methylpyridine

A solution of methyl-2,6-diisopropyl-4-(4-fluorophenyl)-5-bromomethyl-3-pyridinecarboxylate (Example 47, Step B) (300 mg, 0.7 mmol), in anhydrous THF (10 mL) was stirred under argon at room temperature and treated dropwise with lithium aluminum hydride (2.1 mL, 1.0 M in THF, 2.1 mmol). The reaction mixture was heated at reflux for 1 hr, then allowed to cool to room temperature. The reaction was quenched by the dropwise sequential addition at room temperature of water (80 μ L), 20% NaOH (80 μ L) and water (240 μ L). The resulting suspension was filtered through a pad of celite and concentrated. Purification by chromatography through silica (5% ethyl acetate/hexane) afforded the title compound as a white solid (182 mg, 0.6 mmol, 85%). ^1H NMR (300 MHz, CDCl_3): δ 7.15 (d, J = 7 Hz, 4 H), 4.36 (d, J = 5.5 Hz, 2 H), 3.42 (sept, J = 6.6 Hz, 1 H), 3.26 (sept, J = 6.6 Hz, 1 H), 1.94 (s, 3 H), 1.33 (d, J = 6.6 Hz, 6 H), 1.29 (d, J = 6.6 Hz, 6 H), 1.19 (t, J = 5.5 Hz, 1 H); FAB-MS calcd for ($\text{C}_{19}\text{H}_{24}\text{FNO}$) 301, found 302 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{19}\text{H}_{24}\text{FNO}$: C, 75.72; H, 8.03; N, 4.65. Found: C, 75.62; H, 8.02; N, 4.57. mp 127-128°C. R_f = 0.3 (20% ethyl acetate/hexane).

EXAMPLE 82

20

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(3-phenyl-2-propenyl)pyridine

25 Step A: Methyl-2,6-diisopropyl-4-(4-fluorophenyl)-5-(2-oxoethyl)-3-pyridinecarboxylate

Methoxymethyl triphenylphosphonium chloride (1.15 g, 3.35 mmol) was suspended in 25 mL of dry, distilled THF under argon and stirred at -78°C. Butyllithium (1.6 M/hexane, 1.2 eq., 2.1 mL) was added dropwise and then the reaction mixture was allowed to stir at 0°C for 1.0 hour. The solution was cooled

30


0 again to -78°C, treated dropwise with a solution of 5-carboethoxy-2,6-diisopropyl-4-(4-fluorophenyl)-3-pyridinecarboxaldehyde (Example 1, Step E) (1 g, 2.8 mmol) in 20 mL of dry THF, and then warmed to room temperature and stirred overnight. The reaction was quenched 2 mL water and the THF was evaporated *in vacuo*. Diethyl ether was added and washed with water (2 x 40 mL), brine (1 x 40 mL), and
5 dried with MgSO₄. The residue was dissolved in THF (20 ml), treated with a solution of concentrated HCl and stirred at room temperature for 1h. The reaction mixture was diluted with diethyl ether (150 ml) washed with water (50 ml), brine (50 ml), dried with MgSO₄ and evaporated *in vacuo*. Flash chromatography (10% ethyl acetate/hexane) afforded 335 mg (0.9 mmol, 32%) of product. ¹H NMR (300 MHz, CDCl₃): δ 9.62 (s, 1 H), 7.09 (m, 4 H), 3.97 (q, J = 7 Hz, 2 H), 3.60 (s, 2 H), 3.06 (sept, J = 6.6 Hz, 1 H), 3.00 (sept, J = 6.6 Hz, 1 H), 1.32 (d, J = 6.6 Hz, 6 H), 1.27 (d, J = 6.6 Hz, 6 H), 0.97 (t, J = 7 Hz, 3 H). FAB-MS: calcd for (C₂₂H₂₆FNO₃) 371, found 372 (M+H). Anal. Calcd for C₂₂H₂₆FNO₃: C, 71.14; H, 7.06; N, 3.77. Found: C, 70.91; H, 6.91; N, 3.63. mp 69-71°C. R_f = 0.3 (10% ethyl acetate/hexane).

15

Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(3-phenyl-2-propenyl)pyridine

The title compound was prepared from the intermediate obtained in Step A and benzyl triphenylphosphonium bromide/sodium amide according to the
20 procedures described in Example 1, Steps F-G. The product was obtained as a 6:4 mixture of trans:cis isomers. ¹H NMR (300 MHz, CDCl₃): δ 7.19 (m, 8 H), 6.96 (m, 1 H), 6.32 (d, J = 11 Hz, 0.4 H), 6.09 (dt, J = 5.5, 16 Hz, 0.6 H), 5.96 (d, J = 16 Hz, 0.6 H), 5.45 (dt, J = 7, 11 Hz, 0.4 H), 4.37 (d, J = 5 Hz, 1.25 H), 4.33 (d, J = 5.5 Hz, 0.75 H), 3.41 (m, 1.6 H), 3.25 (m, 2 H), 3.08 (m, 0.4 H), 1.35 (m, 5 H), 1.30 (d, J = 6.6 Hz, 5 H),
25 1.21 (m, 3 H). FAB-MS: calcd for (C₂₇H₃₀FNO) 403, found 404 (M+H). Anal. Calcd for C₂₇H₃₀FNO: C, 80.36; H, 7.49; N, 3.47. Found: C, 80.15; H, 7.44; N, 3.26. mp 72-73°C. R_f = 0.3 (20% ethyl acetate/hexane).

EXAMPLE 83




30

0

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(3-phenyl-propyl)pyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(3-phenyl-2-propenyl)pyridine (Example 82) according to the procedure described in Example 1, Step H. ¹H NMR (300 MHz, CDCl₃): δ 7.11 (m, 9 H), 4.31 (s, 2 H), 3.40 (sept, *J* = 6.6 Hz, 1 H), 3.12 (sept, *J* = 6.6 Hz, 1 H), 2.46 (t, *J* = 7.35 Hz, 2 H), 2.29 (m, 2 H), 1.62 (m, 2 H), 1.32 (d, *J* = 6.6 Hz, 6 H), 1.26 (d, *J* = 6.6 Hz, 6 H), 1.16 (bm, 1 H). FAB-MS: calcd for (C₂₇H₃₂FN₂O) 405, found 406 (M+H). mp 137-140°C. R_f = 0.3 (20% ethyl acetate/hexane).

10


EXAMPLE 842,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[3-(2-methyl-phenyl)propyl]pyridine

The title compound was prepared from methyl-2,6-diisopropyl-4-(4-fluorophenyl)-5-(2-oxoethyl)-3-pyridinecarboxylate (Example 82, Step A) and 2-methylbenzyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps F-H. ¹H NMR (300 MHz, CDCl₃): δ 7.07 (m, 7 H), 6.90 (m, 1 H), 4.31 (s, 2 H), 3.39 (sept, *J* = 6.6 Hz, 1 H), 3.15 (sept, *J* = 6.6 Hz, 1 H), 2.43 (t, *J* = 7.5 Hz, 2 H), 2.34 (m, 2 H), 2.17 (s, 3 H), 1.56 (m, 2 H), 1.31 (d, *J* = 6.6 Hz, 6 H), 1.27 (d, *J* = 6.6 Hz, 6 H), 1.15 (m, 1 H). FAB-MS: calcd for (C₂₈H₃₄FN₂O) 419, found 420 (M+H). Anal. Calcd for C₂₈H₃₄FN₂O: C, 80.15; H, 8.17; N, 3.34. Found: C, 80.12; H, 8.01; N, 3.25. mp 65-70°C. R_f = 0.4 (20% ethyl acetate/hexane).


25

30

0

EXAMPLE 852,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[3-(3-methylphenyl)propyl]pyridine


The title compound was prepared from methyl-2,6-diisopropyl-4-(4-fluorophenyl)-5-(2-oxoethyl)-3-pyridinecarboxylate (Example 82, Step A) and 3-methylbenzyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps F-H. ^1H NMR (300 MHz, CDCl_3): δ 7.09 (m, 5 H), 6.98 (m, 1 H), 6.78 (m, 2 H), 4.31 (s, 2 H), 3.39 (sept, $J = 6.6$ Hz, 1 H), 3.12 (sept, $J = 6.6$ Hz, 1 H), 2.42 (t, $J = 7$ Hz, 2 H), 2.30 (s, 3 H), 2.28 (m, 2 H), 1.58 (m, 2 H), 1.31 (d, $J = 6.6$ Hz, 6 H), 1.26 (d, $J = 6.6$ Hz, 6 H), 1.15 (m, 1 H). FAB-MS: calcd for $(\text{C}_{28}\text{H}_{34}\text{FNO})$ 419, found 420 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{28}\text{H}_{34}\text{FNO}$: C, 80.15; H, 8.17; N, 3.34. Found: C, 80.23; H, 8.17; N, 3.23. mp 68-70°C. $R_f = 0.4$ (20% ethyl acetate/hexane).

EXAMPLE 862,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[3-(4-methylphenyl)propyl]pyridine

The title compound was prepared from methyl-2,6-diisopropyl-4-(4-fluorophenyl)-5-(2-oxoethyl)-3-pyridinecarboxylate (Example 82, Step A) and 4-methylbenzyl triphenylphosphonium bromide according to the procedures

- 0 described in Example 1, Steps F-H. ^1H NMR (300 MHz, CDCl_3): δ 7.08 (m, 4 H), 7.01 (d, $J = 8$ Hz, 2 H), 6.85 (d, $J = 8$ Hz, 2 H), 4.30 (s, 2 H), 3.39 (sept, $J = 6.6$ Hz, 1 H), 3.13 (sept, $J = 6.6$ Hz, 1 H), 2.41 (t, $J = 7$ Hz, 2 H), 2.31 (s, 3 H), 2.27 (m, 2 H), 1.58 (m, 2 H), 1.31 (d, $J = 6.6$ Hz, 6 H), 1.26 (d, $J = 6.6$ Hz, 6 H), 1.15 (m, 1 H). FAB-MS: calcd for $(\text{C}_{28}\text{H}_{34}\text{FNO})$ 419, found 420 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{28}\text{H}_{34}\text{FNO}$: C, 80.15; H, 8.17; N, 3.34. Found: C, 80.33; H, 8.28; N, 3.22. mp 79-80°C. $R_f = 0.4$ (20% ethyl acetate/hexane).
- 5

EXAMPLE 87




10

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(2-propenyl)-pyridine

- The title compound was prepared from methyl-2,6-diisopropyl-4-(4-fluorophenyl)-5-(2-oxoethyl)-3-pyridinecarboxylate (Example 82, Step A) and methyl triphenylphosphonium bromide according to the procedures described in
- 15 Example 1, Steps F-H. ^1H NMR (300 MHz, CDCl_3): δ 7.13 (m, 4 H), 5.73 (m, 1 H), 4.81 (dd, $J = 4.8, 1.8$ Hz, 2 H), 4.35 (s, 2 H), 3.43 (septet, $J = 6.6$ Hz, 1 H), 3.21 (septet, $J = 6.6$ Hz, 1 H), 3.07 (d, $J = 1.8$ Hz, 2 H), 1.24 (m, 13 H). FAB-MS: calcd for $(\text{C}_{21}\text{H}_{26}\text{FNO})$ 327, found 328 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{21}\text{H}_{26}\text{FNO}$: C, 74.17; H, 7.71; N, 4.12; F, 5.59 + 0.7 H_2O . Found: C, 74.17; H, 7.57; N, 3.94; F, 5.26. mp 69-
- 20 71°C. $R_f = 0.35$ (15% ethyl acetate/hexane).

EXAMPLE 88




0

2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(4-hydroxy-butyl)pyridine

To a solution of 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[3-(1,3-dioxolan-2-yl)propyl]pyridine (Example 46) (2 g, 5 mmol) in THF (50 mL) was added 2N aq. HCl (10 mL). The solution was allowed to stir for 17 hr at room temperature. The THF was removed *in vacuo* and the residual suspension carefully neutralized to pH 7 with sat. aq. NaHCO₃. The aqueous phase was extracted with diethyl ether (3 x 100 mL), the combined ether extract washed with brine (50 mL), dried (MgSO₄) and concentrated. Purification by chromatography through silica (step gradient, 10%-20% ethyl acetate/hexane) afforded a white solid (1.5 g, 4.2 mmol, 83%): ¹H NMR (300 MHz, CDCl₃): δ 9.57 (s, 1 H), 7.16 (m, 4 H), 4.33 (d, *J* = 5 Hz, 2 H), 3.42 (m, 1 H), 3.24 (m, 1 H), 2.33 (m, 2 H), 2.27 (dt, *J* = 1.8, 7.4 Hz, 2 H), 1.61 (m, 2 H), 1.32 (m, 12 H), 1.20 (m, 1 H). FAB-MS: calcd for (C₂₂H₃₀FNO₂) 359, found 340 (M+H). R_f = 0.3 (20% ethyl acetate/hexane).

This intermediate (200 mg, 0.56 mmol) was dissolved in absolute ethanol (5 mL) and treated at room temperature, with stirring, with sodium borohydride (32 mg, 0.85 mmol). After stirring for 1 hr, the reaction was quenched by the dropwise addition of 2N HCl (3 mL). The solution was stirred 5 min, then neutralized by the careful addition of sat. NaHCO₃. The aqueous phase was extracted with diethyl ether (3 x 50 mL), the combined extracts dried (MgSO₄) and concentrated. Purification by chromatography through silica (20% ethyl acetate/hexane) afforded the title compound as a white solid (88 mg, 0.25 mmol, 44%): ¹H NMR (300 MHz, CDCl₃): δ 7.16 (m, 4 H), 4.33 (d, *J* = 5 Hz, 2 H), 3.46 (m, 2 H), 3.41 (m, 1 H), 2.23 (m, 1 H), 2.32 (m, 2 H), 1.40 (m, 4 H), 1.32 (m, 12 H), 1.19 (m, 1 H), 1.09 (m, 1 H). FAB-MS: calcd for (C₂₂H₃₀FNO₂) 359, found 360 (M+H). Anal. Calcd for C₂₂H₃₀FNO₂: C, 73.51; H, 8.41; N, 3.90. Found: C, 73.37; H, 8.41; N, 3.72. mp 135-137°C. R_f = 0.4 (50% ethyl acetate/hexane);

EXAMPLE 89


30

0 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(3-dimethyl-
amino)propyl]pyridine

5 The title compound was prepared from 5-carboethoxy-2,6-diisopropyl-4-(4-fluorophenyl)-3-pyridinecarboxaldehyde (Example 1, Step E) and (2-dimethylaminoethyl)triphenylphosphonium bromide according to the procedures described in Example 1, Steps F-H. ¹H NMR (300 MHz, CDCl₃): δ 7.17 (m, 4 H), 4.33 (s, 2 H), 3.41 (sept, *J* = 6.6 Hz, 1 H), 3.21 (sept, *J* = 6.6 Hz, 1 H), 2.32 (m, 2 H), 2.16 (m, 2 H), 2.14 (s, 6 H), 1.49 (m, 2 H), 1.32 (m, 13 H). FAB-MS: calcd for (C₂₃H₃₃FN₂O) 372, found 373 (M+H). mp 50-51°C. R_f = 0.35 (20% ethanol/CH₂Cl₂).

10

EXAMPLE 90



15 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(3-dimethyl-
amino)heptyl]pyridine

Step A: 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(4-
oxobutyl)pyridine

20 To a solution of 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[3-(1,3-dioxolan-2-yl)propyl]pyridine (Example 46) (2 g, 5 mmol) in THF (50 mL) was added 2N aq. HCl (10 mL). The solution was allowed to stir for 17 hr at room temperature. The THF was removed *in vacuo* and the residual suspension carefully neutralized to pH 7 with sat. NaHCO₃. The aqueous phase was extracted with diethyl ether (3 x 100 mL), the combined ether extract washed with brine (50 mL),
 25 dried (MgSO₄) and concentrated. Purification by chromatography through silica (step gradient, 10%-20% ethyl acetate/hexane) afforded a white solid (1.5 g, 4.2 mmol, 83%). ¹H NMR (300 MHz, CDCl₃): δ 9.57 (s, 1 H), 7.16 (m, 4 H), 4.33 (d, *J* = 5 Hz, 2 H), 3.42 (m, 1 H), 3.24 (m, 1 H), 2.33 (m, 2 H), 2.27 (dt, *J* = 1.8, 7.4 Hz, 2 H), 1.61 (m, 2 H), 1.32 (m, 12 H), 1.20 (m, 1 H). FAB-MS: calcd for (C₂₂H₂₈FNO₂) 357,
 30 found 358 (M+H). R_f = 0.3 (20% ethyl acetate/hexane).


0

Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(3-dimethylamino)heptyl]pyridine

The intermediate prepared in Step A was treated with (3-dimethylamino)propyl triphenylphosphonium bromide according to the procedures described in Example 1, Steps F-H, to afford the title compound as a solid. ¹H NMR (300 MHz, CDCl₃): δ 7.16 (m, 4 H), 4.32 (s, 2 H), 3.41 (sept, *J* = 6.6 Hz, 1 H), 3.22 (sept, *J* = 6.6 Hz, 1 H), 2.28 (s, 6 H), 2.26 (m, 4 H), 1.43 (m, 2 H), 1.33 (d, *J* = 6.6 Hz, 6 H), 1.30 (d, *J* = 6.6 Hz, 6 H), 1.27 (m, 3 H), 1.31 (m, 6 H). FAB-MS: calcd for (C₂₇H₄₁FN₂O) 428, found 429 (M+H). mp 85-87°C. R_f = 0.1 (20% EtOH/CH₂Cl₂).

10

EXAMPLE 91



15


2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(8-carboxyheptyl)pyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(4-oxobutyl)pyridine (Example 90, Step A) and (4-carboxybutyl)triphenylphosphonium bromide according to the procedure described in Example 90, Step B. ¹H NMR (300 MHz, CD₃OD): δ 7.17 (m, 4 H), 4.23 (s, 2 H), 3.44 (sept, *J* = 6.6 Hz, 1 H), 3.23 (sept, *J* = 6.6 Hz, 1 H), 2.28 (m, 2 H), 2.14 (t, *J* = 7.5 Hz, 2 H), 1.54 (m, 2 H), 1.28 (d, *J* = 6.6 Hz, 6 H), 1.24 (d, *J* = 6.6 Hz, 6 H), 1.22 (m, 4 H), 1.17 (m, 2 H), 1.10 (m, 4 H). EI-MS: calcd for (C₂₇H₃₈FN₂O₃) 443, found 443 (M⁺). mp 240°C (dec). R_f = 0.3 (50% ethyl acetate/hexane).

25

30

0

EXAMPLE 922,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(3-carboxypropyl)pyridine

5 To a solution of 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[3-(1,3-dioxolan-2-yl)propyl]pyridine (Example 46) (2 g, 5 mmol) in THF (50 mL) was added 2N aq. HCl (10 mL). The solution was allowed to stir for 17 hr at room temperature. The THF was removed *in vacuo* and the residual suspension carefully neutralized to pH 7 with sat. NaHCO₃. The aqueous phase was extracted with
10 diethyl ether (3 x 100 mL), and the combined ether extract washed with brine (50 mL), dried (MgSO₄) and concentrated. Purification by chromatography through silica (step gradient, 10%-20% ethyl acetate/hexane) afforded 1.5 g of the intermediate as a white solid: R_f = 0.3 (20% ethyl acetate/hexane).


280 mg of the intermediate was dissolved in dry pyridine (5 mL), stirred at
15 room temperature under argon and treated with acetic anhydride (0.37 mL, 3.9 mmol). The reaction mixture was allowed to stir at room temperature for 17 hr. The pyridine was removed *in vacuo*, and the residue dissolved in diethyl ether (50 mL), washed with sat. CuSO₄ (10 mL), water (20 mL), sat. NaHCO₃ (20 mL) and brine (10 mL), dried (MgSO₄) and concentrated. Purification by chromatography
20 through silica (20% ethyl acetate/hexane) afforded 220 mg as a viscous yellow oil: R_f = 0.6 (50% ethyl acetate/hexane).

200 mg of the oil was dissolved in acetone (5 mL), stirred at room temperature and treated with Jones reagent (2 mL, prepared from 67 g CrO₃, 125 mL H₂O and 58 mL con. H₂SO₄). The reaction mixture was stirred 0.5 hr,
25 quenched by the addition of 2-propanol, filtered through a short pad of silica and concentrated. The residue was dissolved in MeOH (5 mL), treated with 20% NaOH (2 mL) and stirred 14 hr at room temperature. After neutralizing to pH 7 with aq. HCl, the solution was saturated with NaCl and extracted with CHCl₃ (3 x 20 mL). The combined extract was dried (MgSO₄) and concentrated. Purification by
30 chromatography through silica (1:1 ethyl acetate/hexane) afforded the title

0 compound as a white foam (22 mg). ^1H NMR (300 MHz, CD_3OD): δ 7.18 (m, 4 H), 4.24 (s, 2 H), 3.46 (sept, $J = 6.6$ Hz, 1 H), 3.33 (sept, $J = 6.6$ Hz, 1 H), 2.34 (m, 2 H), 1.99 (t, $J = 7$ Hz, 2 H), 1.60 (m, 2 H), 1.29 (d, $J = 6.6$ Hz, 6 H), 1.26 (d, $J = 6.6$ Hz, 6 H). FAB-MS: calcd for ($\text{C}_{22}\text{H}_{28}\text{FNO}_3$) 373, found 374 ($\text{M}+\text{H}$). mp 160°C . $R_f = 0.3$ (50% ethyl acetate/hexane).

5

EXAMPLE 93



10 (±)-2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-hydroxyethyl)pyridine

Step A: (±)-Ethyl-2,6-diisopropyl-4-(4-fluorophenyl)-5-(1-hydroxyethyl)-3-pyridinecarboxylate

15 To 5-carboethoxy-2,6-diisopropyl-4-(4-fluorophenyl)-3-pyridine-carboxaldehyde (Example 1, Step E) (1 g, 2.91 mmol) in THF (30 mL) was added methyllithium (1.4 M, 1.0 eq., 2.08 mL) dropwise at -78°C under argon. The reaction was stirred for 2 hours, then quenched with water and the THF evaporated to afford a white solid. The product was partitioned between diethyl
20 ether and water. The organic layer was then dried with MgSO_4 , filtered, and concentrated to afford a white solid. The product was passed through a plug of silica (10% ethyl acetate/hexane) to afford a white solid (857 mg, 2.4 mmol, 82%). ^1H NMR (300 MHz, CDCl_3): δ 7.14 (m, 4 H), 4.86 (dq, $J = 3.7$, $J = 6.6$ Hz, 1 H), 3.80 (septet, $J = 6.6$ Hz, 1 H), 3.47 (s, 3 H), 2.96 (septet, $J = 6.6$ Hz, 1 H), 1.65 (d, $J = 3.7$ Hz, 1 H), 1.46 (d, $J = 6.6$ Hz, 3 H), 1.27 (m, 12 H). FAB-MS: calcd for ($\text{C}_{21}\text{H}_{26}\text{NFO}_3$) 359, found 360 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{21}\text{H}_{26}\text{NO}_3\text{F}$: C, 69.54; H, 7.54; N, 6.76; F, 4.58. Found: C, 69.55; H, 7.43; N, 6.50; F, 4.45. mp $169\text{--}171^\circ\text{C}$. $R_f = 0.2$ (10% ethyl acetate/hexane).


30

0 Step B: (±)-2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-hydroxyethyl)pyridine

15 The intermediate obtained in Step A (300 mg, 0.835 mmol) was dissolved in 40 mL of dry THF, for a dropwise addition of a solution of LAH (1 M/THF, 1.67 mL, 2 eq.). The reaction mixture was stirred at reflux for 24 hours then cooled to room temperature and quenched with water (70 µL), 20% NaOH (70 µL), and water (140 µL). After filtration, the solvent was evaporated to afford a white residue. The product was subjected to flash chromatography (20% ethyl acetate/hexane) which afforded the title compound as a white solid (84 mg, 0.25 mmol, 30%). ¹H NMR (300 MHz, CDCl₃): δ 7.15 (m, 4 H), 4.71 (dq, *J* = 3.7, *J* = 6.6 Hz, 1 H), 4.30 (m, 2 H), 3.79 (septet, *J* = 6.6 Hz, 1 H), 3.42 (septet, *J* = 6.6 Hz, 1 H), 1.62 (d, *J* = 3.68 Hz, 1 H), 1.58 (s, 1H), 1.43 (d, *J* = 6.6 Hz, 3 H), 1.28 (m, 16 H). FAB-MS: calcd for (C₂₀H₂₆NFO₂) 331, found 332 (M+H). Anal. Calcd for C₂₀H₂₆NO₂F: C, 76.84; H, 8.69; N, 3.90. Found: C, 76.67; H, 8.76; N, 3.77. mp 184-186°C. R_f = 0.2 (20% ethyl acetate/hexane).

15

EXAMPLE 94




20 (±)-2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-hydroxypropyl)pyridine

25 The title compound was prepared from 5-carboethoxy-2,6-diisopropyl-4-(4-fluorophenyl)-3-pyridinecarboxaldehyde (Example 1, Step E) and ethyl magnesium bromide, according to the procedures described in Example 93. ¹H NMR (300 MHz, CDCl₃): δ 7.15 (m, 4 H), 4.40 (dq, *J* = 3.7, *J* = 5.2 Hz, 1 H), 4.30 (d, *J* = 5.5 Hz, 2 H), 3.72 (septet, *J* = 6.6 Hz, 1 H), 3.42 (septet, *J* = 6.6 Hz, 1 H), 1.88 (m, 1 H), 1.63 (t, *J* = 5.5 Hz, 1H), 1.27 (m, 14 H), 0.804 (t, *J* = 7.36 Hz, 3 H). FAB-MS: calcd for (C₂₁H₂₈NFO₂) 345, found 346 (M+H). Anal. Calcd for C₂₁H₂₈NO₂F: C, 76.84; H, 8.69; N, 3.90. Found: C, 76.67; H, 8.76; N, 3.77. mp 173-175°C. R_f = 0.2 (20% ethyl acetate/hexane);

30


0

EXAMPLE 955 (±)-2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-hydroxypentyl)pyridine

The title compound was prepared from 5-carboethoxy-2,6-diisopropyl-4-(4-fluorophenyl)-3-pyridinecarboxaldehyde (Example 1, Step E) and n-butyllithium, according to the procedures described in Example 93. ¹H NMR (300 MHz, CDCl₃):

10 δ 7.16 (m, 4 H), 4.49 (m, 1 H), 4.31 (d, *J* = 5.5 Hz, 2 H), 3.74 (septet, *J* = 6.6 Hz, 1 H), 3.42 (septet, *J* = 6.6 Hz, 1 H), 1.88 (m, 1 H), 1.58 (d, *J* = 3.3 Hz, 1 H), 1.18 (m, 18 H), 0.821 (t, *J* = 4.1 Hz, 3 H). FAB-MS: calcd for (C₂₃H₃₂NFO₂) 373, found 374 (M+H). Anal. Calcd for C₂₃H₃₂NO₂F: C, 73.96; H, 8.64; N, 3.75; F, 5.09. Found: C, 73.81; H, 8.60; N, 3.58; F, 5.02. mp 166-168°C. R_f = 0.3 (20% ethyl acetate/hexane).


15

EXAMPLE 9620 (±)-2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(hydroxyphenylmethyl)pyridine

The title compound was prepared from 5-carboethoxy-2,6-diisopropyl-4-(4-fluorophenyl)-3-pyridinecarboxaldehyde (Example 1, Step E) and phenyllithium, according to the procedures described in Example 93. ¹H NMR (300 MHz, CDCl₃):

- 0 δ 7.23 (m, 7 H), 7.06 (m, 2 H), 5.71 (d, J = 5.14 Hz, 1 H), 4.38 (d, J = 5.5 Hz, 2 H), 3.47
(septet, J = 6.6 Hz, 1 H), 3.12 (septet, J = 6.6 Hz, 1 H), 2.12 (d, J = 5.1 Hz, 1 H), 1.57 (s,
1H), 1.29 (m, 10 H), 0.797 (d, J = 6.6 Hz, 3 H). FAB-MS: calcd for (C₂₅H₂₈NFO₂)
393, found 394 (M+H). Anal. Calcd for C₂₅H₂₈NO₂F: C, 76.84; H, 8.69; N, 3.90.
5 Found: C, 76.67; H, 8.76; N, 3.77. mp 202-204°C. R_f = 0.2 (20% ethyl
acetate/hexane).

EXAMPLE 97




10

(±)-2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-[(1-hydroxy-2-methyl)propyl]pyridine

- The title compound was prepared from 5-carboethoxy-2,6-diisopropyl-4-(4-fluorophenyl)-3-pyridinecarboxaldehyde (Example 1, Step E) and isopropyl
15 magnesium bromide, according to the procedures described in Example 93. ¹H
NMR (300 MHz, CDCl₃): δ 7.14 (m, 4 H), 4.35 (d, 2 H), 3.53 (t, J = 4.8 Hz, 4 H), 3.45
(m, 2 H), 3.18 (s, 2 H), 2.18 (t, J = 4.5 Hz, 4 H), 1.26 (m, 13 H). FAB-MS: calcd for
(C₂₃H₃₁N₂FO₂) 386, found 387 (M+H). Anal. Calcd for C₂₃H₃₁N₂O₂F: C, 76.84;
H, 8.69; N, 3.90. Found: C, 76.67; H, 8.76; N, 3.77. mp 139-140°C. R_f = 0.3 (20%
20 ethyl acetate/hexane).

EXAMPLE 98



0

(±)-2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-methoxyethyl)pyridine

5

Step A: Methyl-2,6-diisopropyl-4-(4-fluorophenyl)-5-(2-methoxyethyl)-3-pyridinecarboxylate

10

15

(±)-Ethyl-2,6-diisopropyl-4-(4-fluorophenyl)-5-(1-hydroxyethyl)-3-pyridinecarboxylate (Example 93, Step A) (487 mg, 1.36 mmol) was dissolved in 50 mL of dry THF, treated with NaH (0.20 g, 8.13 mmol) under argon, stirred for 15 min. and treated with methyl iodide (0.34 mL, 5.24 mmol). The reaction mixture was stirred at reflux for 2 hours, then cooled to room temperature, quenched with water, and concentrated to afford a watery residue. The product was partitioned between diethyl ether and water, the organic layer was dried with MgSO₄, filtered, and concentrated to afford a white solid. The product was passed through a pad of silica (5% ethyl acetate/hexane) to yield a white solid (495 mg, 1.33 mmol, 98%). ¹H NMR (300 MHz, CDCl₃): δ 7.13 (m, 4 H), 4.25 (q, J = 6.6 Hz, 1 H), 3.80 (septet, J = 6.6 Hz, 1 H), 3.48 (s, 3 H), 3.10 (s, 3 H), 2.97 (septet, J = 6.6 Hz, 1 H), 1.41 (d, J = 6.6 Hz, 3 H), 1.29 (m, 12 H). FAB-MS: calcd for (C₂₂H₃₁FNO₃) 373, found 374 (M+H). Anal. Calcd for C₂₄H₃₁N₂O₃F: C, 70.75; H, 7.56; N, 3.75; F, 5.09. Found: C, 70.70; H, 7.63; N, 3.59; F, 4.77. mp 132-134°C. R_f = 0.5 (10% ethyl acetate/hexane).

20

Step B: (±)-2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-methoxyethyl)pyridine


25

30

The intermediate obtained in Step A (359 mg, 0.961 mmol) was dissolved in 40 mL of dry THF, for a dropwise addition of a solution of LAH (1 M/THF, 1.92 mL, 2 eq.). The reaction mixture was stirred at reflux for 24 hours then cooled to room temperature and quenched with water (80 µL), 20% NaOH (80 µL), and water (160 µL). After filtration, the solvent was evaporated to afford a residue which was filtered through to a pad of silica (10% ethyl acetate/hexane) to afford the title compound as a white solid (281 mg, 0.72 mmol, 85%). ¹H NMR (300 MHz, CDCl₃): δ 7.13 (m, 4 H), 4.32 (dq, J = 5.2 J = 11.4 Hz, 1 H), 4.11 (q, J = 6.3 Hz, 1 H), 3.77 (septet, J = 6.6 Hz, 1 H), 3.42 (septet, J = 6.6 Hz, 1 H), 3.10 (s, 3 H), 1.29 (m, 16 H). FAB-MS: calcd for (C₂₁H₂₈FNO₂) 345, found 346 (M+H). Anal. Calcd for C₂₁H₂₈NO₂F: C, 76.84; H, 8.69; N, 3.90. Found: C, 76.67; H, 8.76; N, 3.77. mp 151-153°C. R_f = 0.4 (20% ethyl acetate/hexane).

35


0

EXAMPLE 99

5 (±)-2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-methoxy-
propyl)pyridine

The title compound was prepared from (±)-2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-hydroxypropyl)pyridine (Example 94) according to the procedures described in Example 98. ¹H NMR (300 MHz, CDCl₃): δ 7.11 (m, 4 H), 4.32 (m, 2 H), 3.83 (m, 1 H), 3.74 (septet, *J* = 6.6 Hz, 1 H), 3.41 (septet, *J* = 6.6 Hz, 1 H), 3.12 (s, 2 H), 1.88 (m, 1 H), 1.56 (m, 2 H), 1.27 (m, 12 H), 0.776 (t, *J* = 3.7 Hz, 3 H). FAB-MS: calcd for (C₂₂H₃₀NFO₂) 359, found 360 (M+H). Anal. Calcd for C₂₂H₃₀NO₂F: C, 73.51; H, 8.41; N, 3.90; F, 5.28. Found: C, 73.55; H, 8.54; N, 3.75; F, 5.06. mp 147-149°C. R_f = 0.5 (20% ethyl acetate/hexane).

15


EXAMPLE 100

20 (±)-2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-methoxy-
pentyl)pyridine

The title compound was prepared from (±)-2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-hydroxypentyl)pyridine (Example 95) according to the procedures described in Example 98. ¹H NMR (300 MHz, CDCl₃): δ 7.10 (m, 4 H), 4.32 (m, 2 H), 3.92 (m, 1 H), 3.76 (septet, *J* = 7.0 Hz, 1 H), 3.42

- 0 (septet, $J = 6.6$ Hz, 1 H), 3.12 (s, 3 H), 1.87 (m, 1 H), 1.52 (m, 2 H), 1.19 (m, 16 H), 0.821 (t, $J = 7.4$ Hz, 3 H). FAB-MS: calcd for $(C_{24}H_{34}NFO_2)$ 387, found 388 (M+H). Anal. Calcd for $C_{24}H_{34}NO_2F$: C, 74.38; H, 8.84; N, 3.61; F, 4.90. Found: C, 74.38; H, 8.82; N, 3.45; F, 4.90. mp 121-123°C. $R_f = 0.5$ (20% ethyl acetate/hexane).

5

EXAMPLE 101

10 (±)-2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-propylpyridine

Step A: (±)-2,6-Diisopropyl-4-(4-fluorophenyl)-5-propyl-3-pyridine-carboxaldehyde


- To a solution of 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-propylpyridine (Example 25) (5.7 g, 17 mmol) in dichloromethane (250 mL) was added Brockman I, neutral alumina (3.5 g, 34 mmol). The suspension was stirred at room temperature and treated with pyridinium chlorochromate (PCC) (7.5 g, 34 mmol). Stirring was continued at room temperature for 1 hr. The suspension was poured into 10% ethyl acetate/hexane (500 mL), filtered through a pad of silica and concentrated *in vacuo* to afford (4.2 g/12.8 mmol, 74%) as a waxy solid. 1H NMR ($CDCl_3$, 300 MHz): δ 9.72 (s, 1 H), 7.15 (m, 4 H), 3.83 (sept, $J = 6.6$ Hz, 1 H), 3.28 (sept, $J = 6.6$ Hz, 1 H), 2.31 (m, 2 H), 1.30 (m, 14 H), 0.78 (t, $J = 7.4$ Hz, 3 H). FAB-MS: calcd for $(C_{21}H_{26}FNO)$ 327, found 328 (M+H). mp 81-83°C. $R_f = 0.6$ (10% ethyl acetate/hexane).

25 Step B: (±)-2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-propylpyridine

- The intermediate obtained in Step A (400 mg, 1.22 mmol) in THF (10 mL) at -78°C under argon atmosphere was added dropwise MeLi (1.4 M, 1.2 eq, 1.05 mL). The reaction was stirred for 20 min, then another 0.5 eq. of MeLi was added, as starting material was still present. After 20 min., the reaction was quenched with

- 0 water (2 mL) and the THF is evaporated in vacuo to afford an oil. The product was
partitioned between water and CH₂Cl₂ (50 mL) and the organic layer was dried
with MgSO₄, filtered, and concentrated to yield a gummy solid. Flash
Chromatography using silica gel (60% CH₂Cl₂/hexane) to afford an oil which
slowly solidified to give the title compound as a solid (0.387 g/1.13 mmol, 92%). ¹H
5 NMR (300 MHz, CDCl₃): δ 7.10 (m, 4 H), 4.66 (dq, *J* = 3.3, 6.6 Hz, 1 H), 3.75 (septet, *J*
= 6.6 Hz, 1 H), 3.20 (septet, *J* = 6.6 Hz, 1 H), 2.17 (t, *J* = 1.5 Hz, 2 H), 1.58 (d, *J* = 5.2
Hz, 1 H), 1.41 (d, *J* = 6.6 Hz, 3 H), 1.29 (m, 14 H), 0.74 (t, *J* = 7.4 Hz, 3 H). FAB-MS:
calcd for (C₂₂H₃₀FNO) 343, found 344 (M+H). Anal. Calcd for C₂₂H₃₀FNO: C,
76.93; H, 8.80; N, 4.08; F, 5.53. Found: C, 76.98; H, 8.73; N, 3.93; F, 5.80. mp 124.5-
10 126.5°C. R_f = 0.2 (60% CH₂Cl₂/hexane).

EXAMPLE 102




15

(+)-2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-propylpyridine


- The enantiomeric mixture of (±)-2,6-diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-propylpyridine (Example 101) was separated by chiral HPLC with a Chiralpak AD column, isocratic elution (99% hexane/methyl *t*-butyl ether). The
20 first enantiomer to elute was obtained in 99% ee, mp 103-104°C, [α]_D +40.4°.

EXAMPLE 103




2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-propyl-pyridine

The enantiomeric mixture of (\pm)-2,6-diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-propyl-pyridine (Example 101) was separated by chiral HPLC with a Chiralpak AD column, isocratic elution (99% hexane/methyl *t*-butyl ether). The second enantiomer to elute was obtained in 90% ee. mp 95-97°C.

EXAMPLE 104(\pm)-2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-butyl-pyridine


The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-butylpyridine (Example 24) according to the procedures described in Example 101. ^1H NMR (300 MHz, CDCl_3): δ 7.1 (m, 4 H), 4.7 (dq, $J = 3$ Hz, 1 H), 3.7 (septet, $J = 7$ Hz, 1 H), 3.2 (septet, $J = 7$ Hz, 1 H), 2.2 (t, $J = 1.5$ Hz, 2 H), 1.6 (d, $J = 5$ Hz, 1 H), 1.4 (d, $J = 7$ Hz, 3 H), 1.3 (m, 16 H), 0.8 (t, $J = 7$ Hz, 3 H). FAB-MS: calcd for ($\text{C}_{23}\text{H}_{32}\text{FNO}$) 357, found 358 ($\text{M}+\text{H}$). mp 103-104°C. $R_f = 0.2$ (60% CH_2Cl_2 /hexane).

EXAMPLE 105(\pm)-2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-pentyl-pyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-pentylpyridine (Example 24) according to the procedures described in Example 101.

- 0 (4-fluorophenyl)-5-pentylpyridine (Example 1) according to the procedures described in Example 101. ^1H NMR (300 MHz, CDCl_3): δ 7.10 (m, 4 H), 4.65 (dq, J = 2.8, 6.6 Hz, 1 H), 3.75 (septet, J = 6.6 Hz, 1 H), 3.20 (septet, J = 6.6 Hz, 1 H), 2.19 (t, J = 8.1 Hz, 2 H), 1.63 (d, J = 2.6 Hz, 1 H), 1.40 (d, J = 7.0 Hz, 3 H), 1.31 (m, 14 H), 1.11 (m, 4 H), 0.79 (t, J = 6.6 Hz, 3 H). FAB-MS: calcd for $(\text{C}_{24}\text{H}_{34}\text{FNO})$ 371, found 372
- 5 (M+H). Anal. Calcd for $\text{C}_{24}\text{H}_{34}\text{FNO}$: C, 77.59; H, 9.22; N, 3.77; F, 5.11. Found: C, 77.59; H, 9.34; N, 3.75; F, 5.26. mp 99-101°C. R_f = 0.2 (70% CH_2Cl_2 /hexane).


EXAMPLE 106



2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-pentylpyridine

- The enantiomeric mixture of (\pm)-2,6-diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-pentylpyridine (Example 105) was separated by chiral HPLC with a
- 15 Chiralpak AD column, isocratic elution (99% hexane/methyl *t*-butyl ether). The first enantiomer to elute was obtained in 99% ee. mp 83°C.

EXAMPLE 107




2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-pentylpyridine

- The enantiomeric mixture of (\pm)-2,6-diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-pentylpyridine (Example 105) was separated by chiral HPLC with a

- 0 Chiralpak AD column, isocratic elution (99% hexanemethyl *t*-butyl ether). The second enantiomer to elute was obtained in 93% ee. mp 84-86°C.


EXAMPLE 108



(±)-2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-hexylpyridine

- The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-hexylpyridine (Example 23) according to the procedures described in Example 101. ¹H NMR (300 MHz, CDCl₃): δ 7.13 (m, 3 H), 7.04 (m, 1 H), 4.65 (m, 1 H), 3.73 (sept, *J* = 6.6 Hz, 1 H), 3.19 (sept, *J* = 6.6 Hz, 1 H), 2.18 (m, 2 H), 1.39 (d, *J* = 6.6 Hz, 3 H), 1.30 (m, 13 H), 1.18 (m, 4 H), 1.09 (m, 4 H), 0.81 (t, *J* = 7 Hz, 3 H). FAB-MS: calcd for (C₂₅H₃₆FNO) 385, found 386 (M+H). Anal. Calcd for C₂₅H₃₆FNO: C, 77.88; H, 9.41; N, 3.63. Found: C, 77.84; H, 9.49; N, 3.65. mp 96-99°C. R_f = 0.3 (10% ethyl acetate/hexane).
- 10
- 15


EXAMPLE 109



2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-hexylpyridine


The enantiomeric mixture of (±)-2,6-diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-hexylpyridine (Example 108) was separated by chiral HPLC with a Chiralpak AD column, isocratic elution (99% hexane/methyl *t*-butyl ether). The first enantiomer to elute was obtained in 98% ee. mp 75-77°C.

0

EXAMPLE 1105 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-hexylpyridine

The enantiomeric mixture of (\pm)-2,6-diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-hexylpyridine (Example 108) was separated by chiral HPLC with a Chiralpak AD column, isocratic elution (99% hexane/methyl *t*-butyl ether). The second enantiomer to elute was obtained in 88% ee. mp 66-68°C.

10

EXAMPLE 11115 2,6-Diisopropyl-3-[1-hydroxy-2-((S)-toluylsulfoxy)ethyl]-4-(4-fluoro-phenyl)-5-pentylpyridine


A solution of lithium diisopropylamide was prepared by the addition of *n*-butyllithium (3.5 mL, 2 eq., 1.6 M/hexane) to a solution of diisopropylamine (0.73 mL, 5.57 mmol) in anhydrous tetrahydrofuran (50 mL) at 0°C. To this was added a solution of (*S*)-(-)-methyl *p*-tolylsulfoxide (0.863 g, 5.60 mmol) in anhydrous tetrahydrofuran (10 mL) dropwise, with stirring. The mixture was stirred at 0°C for 2 hr, then treated with a solution of 2,6-diisopropyl-4-(4-fluorophenyl)-5-pentyl-3-pyridinecarboxaldehyde (Example 114, Step A) (1.0 g, 2.80 mmol) in anhydrous tetrahydrofuran (20 mL) dropwise and with stirring. After stirring 15 min at 0 °C, the reaction mixture was quenched by the addition of sat. NH₄Cl (1 mL). The

20

25

0 solvent was removed *in vacuo* and the residue partitioned between CHCl_3 (150 mL) and water (50 mL). The organic phase was washed with sat. NaHCO_3 (100 mL), water (100 mL) and brine (50 mL), dried over MgSO_4 and concentrated. The crude product consisted of a 1.2:1 ratio of diastereomers. Flash chromatography (step gradient 5%-10%-20% ethyl acetate/hexane) afforded 740 mg (52%) of the first
 5 diastereomer to elute. ^1H NMR (CDCl_3 , 500 MHz): δ 7.4 (m, 4 H), 7.0 (m, 2 H), 6.7 (m, 2 H), 5.1 (m, 1 H), 4.6 (s, 1 H), 3.8 (m, 2 H), 2.6 (sept, $J = 6.6$ Hz, 1 H), 2.5 (s, 3 H), 2.3 (m, 1 H), 2.1 (m, 2 H), 1.4 (m, 18 H), 0.8 (m, 3 H). FAB-MS: calcd for $(\text{C}_{31}\text{H}_{40}\text{FNO}_2\text{S})$ 509, found 510 ($\text{M}+\text{H}$). Anal. calcd for $\text{C}_{31}\text{H}_{40}\text{FNO}_2\text{S}$: C, 73.05; H, 7.91; N, 2.75; S, 6.29. Found: C, 72.88; H, 7.95; N, 2.50; S, 6.38. mp 170-171°C. R_f
 10 = 0.3 (20% ethyl acetate/hexane).

EXAMPLE 112




15

2,6-Diisopropyl-3-[1-hydroxy-2-(S)-toluylsulfoxyethyl]-4-(4-fluoro-phenyl)-5-pentylpyridine

From the flash chromatography described in Example 111, the second diastereomer to elute afforded 600 mg (42%) of the title compound. ^1H NMR
 20 (CDCl_3 , 500 MHz): δ 7.4 (m, 2 H), 7.2 (m, 2 H), 7.0 (m, 3 H), 6.8 (m, 1 H), 4.8 (m, 1 H), 3.8 (m, 1 H), 3.7 (m, 1 H), 3.2 (sept, $J = 6.6$ Hz, 1 H), 3.1 (s, 1 H), 2.7 (m, 1 H), 2.4 (s, 3 H), 2.1 (m, 2 H), 1.3 (m, 18 H), 0.6 (m, 3 H). FAB-MS: calcd for $(\text{C}_{31}\text{H}_{40}\text{FNO}_2\text{S})$ 509, found 510 ($\text{M}+\text{H}$). Anal. calcd for $\text{C}_{31}\text{H}_{40}\text{FNO}_2\text{S}$: C, 73.05; H, 7.91; N, 2.75; S, 6.29. Found: C, 72.90; H, 7.95; N, 2.50; S, 6.54. mp 190°C. $R_f = 0.1$ (20% ethyl
 25 acetate/hexane).

30

0


EXAMPLE 113

5

(±)-2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-phenylthio-methylpyridine

The title compound was prepared from 2,6-diisopropyl-3-(1-hydroxymethyl)-4-(4-fluorophenyl)-5-[(phenylthio)methyl]pyridine (Example 47) according to the procedures described in Example 101. ^1H NMR (300 MHz, CDCl_3): δ 7.19 (m, 4 H), 7.09 (m, 5 H), 4.67 (m, 1 H), 3.74 (m, 3 H), 3.38 (sept, $J = 6.6$ Hz, 1 H), 1.58 (d, $J = 4$ Hz, 1 H), 1.41 (d, $J = 6.6$ Hz, 3 H), 1.31 (m, 12 H). FAB-MS: calcd for $(\text{C}_{26}\text{H}_{30}\text{FNOS})$ 423, found 424 ($\text{M}+\text{H}$). Anal. Calcd for $\text{C}_{26}\text{H}_{30}\text{FNOS}$: C, 73.72; H, 7.14; N, 3.31; S, 7.57. Found: C, 73.52; H, 7.12; N, 3.20; S, 7.51. mp 125-128°C. $R_f = 0.5$ (20% ethyl acetate/hexane).

15

EXAMPLE 114

20

(±)-2,6-Diisopropyl-3-(1-hydroxy-2-propenyl)-4-(4-fluorophenyl)-5-pentylpyridine

Step A: 2,6-Diisopropyl-4-(4-fluorophenyl)-5-pentyl-3-pyridine-carboxaldehyde


2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-pentylpyridine (Example 1) (2.30 g, 6.43 mmol) was dissolved in 175 mL of CH_2Cl_2 under argon

- 0 atmosphere and treated with 2 eq. of alumina (neutral, 1.31 g, 12.87 mmol) followed by 2 eq of pyridinium chlorochromate (PCC) (2.77 g, 12.87 mmol). The reaction was stirred at room temperature for 1.5 h. The suspension was added to 500 mL of 1:1 hexane/diethyl ether, then filtered through a pad of silica (300 g). The pad was washed with 100 mL diethyl ether and the filtrate was combined and
- 5 concentrated *in vacuo* to afford a solid. Flash chromatography (60:40, CH₂Cl₂/hexane) using silica afforded 1.84 g of an off-white solid (5.2 mmol, 80%). ¹H NMR (300 MHz, CDCl₃): δ 9.74 (s, 1 H), 7.17 (m, 4 H), 3.85 (septet, *J* = 6.6 Hz, 1 H), 3.30 (septet, *J* = 6.6 Hz, 1 H), 2.34 (t, *J* = 5.2 Hz, 2 H), 1.30 (m, 14 H), 1.15 (m, 4 H), 0.80 (t, *J* = 6.6 Hz, 3 H). FAB-MS: calcd for (C₂₃H₃₀FNO) 355, found 356. Anal.
- 10 Calcd for C₂₃H₃₀FNO: C, 77.71; H, 8.51; N, 3.94; F, 5.34 Found: C, 77.91; H, 8.47; N, 3.83; F, 5.42. mp 75.5-77.5°C. R_f = 0.4 (50% CH₂Cl₂/hexane).

Step B: (±)-2,6-Diisopropyl-3-(1-hydroxy-2-propenyl)-4-(4-fluorophenyl)-5-pentylpyridine

- 15 To a solution of the intermediate obtained in Step A (100 mg, 0.281 mmol) in THF (10 mL) at -78°C under argon was added vinyl magnesium bromide (1 M, 1.5 eq., 0.42 mL) dropwise. After 1 h., a saturated solution of NH₄Cl (2 mL) was added and the aqueous phase was extracted with diethyl ether. A precipitate formed when the NH₄Cl was added and was filtered off. The ether layer was dried with
- 20 MgSO₄, filtered and concentrated to yield a gummy oil. Flash chromatography (60% CH₂Cl₂/hexane) afforded the title compound as a solid (38 mg, 0.1 mmol, 35%). ¹H NMR (300 MHz, CDCl₃): δ 7.11 (m, 4 H), 6.06 (δ, *J* = 17.4 Hz, *J* = 10.3 Hz, *J* = 4.0 Hz, 1 H), 5.08 (q, *J* = 1.5 Hz, 1 H), 5.00 (m, 2 H), 3.51 (septet, *J* = 6.6 Hz, 1 H), 3.21 (septet, *J* = 6.6 Hz, 1 H), 2.21 (t, *J* = 4.4 Hz, 2 H), 1.74 (d, *J* = 4.1 Hz, 1 H), 1.27 (m, 14 H), 1.11 (m, 4 H), 0.783 (t, *J* = 6.6 Hz, 3 H). FAB-MS: calcd for (C₂₅H₃₄FNO) 383, found 384 (M+H). Anal. Calcd for C₂₅H₃₄NOF: C, 78.29; H, 8.93; N, 3.65; F, 4.95. Found: C, 78.28; H, 8.97; N, 3.53; F, 5.04. mp 83-85°C. R_f = 0.2 (50% CH₂Cl₂/hexane).

EXAMPLE 115




0

(±)-2,6-Diisopropyl-3-(1-hydroxypentyl)-4-(4-fluorophenyl)-5-pentyl-pyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-pentylpyridine (Example 1) and butyllithium according to the procedures described in Example 114. ¹H NMR (300 MHz, CDCl₃): δ 6.95 (m, 4 H), 4.33 (m, 1 H), 3.59 (septet, *J* = 6.6 Hz, 1 H), 3.09 (septet, *J* = 6.6 Hz, 1 H), 2.08 (t, *J* = 5.2 Hz, 2 H), 1.75 (m, 2 H), 1.47 (m, 2 H), 1.04 (m, 22 H), 0.719 (t, *J* = 7.0 Hz, 3 H), 0.674 (t, *J* = 7.0 Hz, 3 H). FAB-MS: calcd for (C₂₇H₄₀FNO) 413, found 414 (M+H). Anal. Calcd for C₂₇H₄₀FNO: C, 78.41; H, 9.75; N, 3.39; F, 4.59. Found: C, 77.84; H, 9.51; N, 3.27; F, 5.08. mp 66-68°C. R_f = 0.2 (50% CH₂Cl₂/hexane).

10


EXAMPLE 116(±)-2,6-Diisopropyl-3-(1-hydroxy-2-butenyl)-4-(4-fluorophenyl)-5-pentylpyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-pentylpyridine (Example 1) and allylmagnesium bromide according to the procedures described in Example 114. ¹H NMR (300 MHz, CDCl₃): δ 7.09 (m, 4 H), 6.58 (m, 1 H), 5.06 (s, 1 H), 5.01 (m, 1 H), 4.47 (m, 1 H), 3.71 (septet, *J* = 6.6 Hz, 1 H), 3.20 (septet, *J* = 6.6 Hz, 1 H), 2.59 (m, 1 H), 2.35 (m, 1 H), 2.18 (t, *J* = 4.8 Hz, 2 H), 1.72 (d, *J* = 2.9 Hz, 1 H), 1.28 (m, 14 H), 1.11 (m, 4 H), 0.783 (t, *J* = 6.6 Hz, 3 H). FAB-MS: calcd for (C₂₆H₃₆FNO) 397, found 398 (M+H). Anal. Calcd for C₂₆H₃₆FNO: C, 77.88; H, 9.41; N, 3.63; F, 4.93. Found: C, 78.10; H, 9.21; N, 3.43; F, 4.89. mp 70-72°C. R_f = 0.2 (50% CH₂Cl₂/hexane).

25


30

0

EXAMPLE 117(±)-2,6-Diisopropyl-3-(1-hydroxy-2-propyl)-4-(4-fluorophenyl)-5-pentylpyridine

5 The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-pentylpyridine (Example 1) and ethylmagnesium chloride according to the procedures described in Example 114. ¹H NMR (300 MHz, CDCl₃): δ 7.10 (m, 4 H), 4.35 (dq, *J* = 3.7, 8.8 Hz, 1 H), 3.68 (septet, *J* = 6.3 Hz, 1 H), 3.20 (septet, *J* = 6.6 Hz, 1 H), 2.18 (t, *J* = 5.2 Hz, 2 H), 1.86 (septet, *J* = 5.5 Hz, 1 H), 1.63 (m, 2 H), 1.28 (m, 14 H), 1.09 (m, 4 H), 0.789 (m, 6 H). FAB-MS: calcd for (C₂₅H₃₆FNO) 385, found 386 (M+H). Anal. Calcd for C₂₅H₃₆FNO: C, 77.88; H, 9.41; N, 3.63; F, 4.93. Found: C, 77.44; H, 9.37; N, 3.35; F, 4.87. mp 77-79°C. R_f = 0.2 (50% CH₂Cl₂/hexanes).

15


EXAMPLE 118

20 (±)-2,6-Diisopropyl-3-(2,2,2-trifluoro-1-hydroxy)ethyl-4-(4-fluoro-phenyl)-5-pentylpyridine

A stirred solution of 2,6-diisopropyl-4-(4-fluorophenyl)-5-pentyl-3-pyridinecarboxaldehyde (Example 114, Step A) (190 mg, 0.53 mmol) in anhydrous THF (5 mL), under argon at 22°C, was treated with trimethyl(trifluoromethyl)silane (5.3 mL, 2.65 mmol, 0.5M in THF) followed by tetrabutylammonium fluoride (100

0 uL, 1.0M in THF). After stirring at 22°C for 5 min, tetrabutylammonium fluoride (3 mL, 3 mmol, 1.0 M in THF) was added and the reaction mixture stirred for 17 hr. The solvent was removed *in vacuo*, the residue dissolved in diethyl ether (50 mL), washed with 1N HCl (50 mL), saturated NaHCO₃ (50 mL), water (50 mL), brine (20 mL), dried (MgSO₄) and concentrated. Purification by flash silica gel
 5 chromatography (2% ethyl acetate/hexane) afforded 153 mg (68%) of the title compound as a white solid. ¹H NMR (300 MHz, CDCl₃): δ 7.11 (m, 4 H), 4.90 (bs, 1 H), 3.64 (bs, 1 H), 3.21 (sept, *J* = 6.6 Hz, 1 H), 2.35 (m, 1 H), 2.15 (m, 2 H), 1.30 (d, *J* = 6.6 Hz, 6 H), 1.29 (d, *J* = 6.6 Hz, 6 H), 1.26 (m, 2 H), 1.10 (m, 4 H), 0.77 (t, *J* = 6.6 Hz, 3 H). FAB-MS: calcd for (C₂₄H₃₁F₄NO) 425, found 426 (M+H). Anal. Calcd for
 10 C₂₄H₃₁F₄NO: C, 67.75; H, 7.34; N, 3.29; F, 17.86. Found: C, 67.82; H, 7.13; N, 3.02; F, 18.05. mp 88-89°C. R_f = 0.35 (10% ethyl acetate/hexane).

EXAMPLE 119



2,6-Diisopropyl-3-(2-hydroxyethyl)-4-(4-fluorophenyl)-5-pentylpyridine

Step A: 2,6-Diisopropyl-3-(2-oxoethyl)-4-(4-fluorophenyl)-5-pentylpyridine

20 A solution of (methoxymethyl)triphenylphosphonium chloride (350 mg, 0.985 mmol) in THF (30 mL) was treated with butyllithium (1.6 M, 1.2 eq., 0.74 mL) at -78°C. The reaction was stirred at 0°C for 1 h. and then is cooled to -78°C again. 2,6-Diisopropyl-4-(4-fluorophenyl)-5-pentyl-3-pyridinecarboxaldehyde (Example
 25 114, Step A) (350 mg, 0.985 mol) in THF (5 mL) was added dropwise and the reaction mixture allowed to come to room temperature. After 24 h., the reaction was quenched with water and the THF evaporated *in vacuo*. The residue was partitioned between ether and water. The organic layer was dried with MgSO₄, filtered, and concentrated to yield an oil. Flash chromatography (10% CH₂Cl₂/hexanes) afforded an oil (172 mg).


30 The oil (172 mg) was taken up in THF (15 mL) and treated with 4 mL conc.

0 HCl. The solution was stirred for 1.5 hours and then diluted with ether (150 mL). The reaction was washed with NaHCO₃ (2 x 50 mL) and dried with MgSO₄. Filtration and concentration yielded a solid (20 mg, 0.054 mmol, 6%). The product was taken directly to the next step without further purification.

5 Step B: 2,6-Diisopropyl-3-(2-hydroxyethyl)-4-(4-fluorophenyl)-5-pentylpyridine

To the intermediate obtained in Step A (20 mg, 0.054 mmol) in dry THF (10 mL) was added dropwise LAH (2 eq., 1 M, 0.11 mL) under argon and the mixture was stirred at reflux for 1 h. The reaction was quenched with water (3.9 μ L), 20% NaOH (3.9 μ L), and water (7.8 μ L) again. Concentration afforded a white solid. The product was subjected to a pad of silica gel (CH₂Cl₂) to afford the title compound as a white solid (14 mg, 0.038 mmol, 70%). ¹H NMR (300 MHz, CDCl₃): δ 7.39 (m, 2 H), 7.12 (m, 2 H), 3.52 (t, *J* = 5.5 Hz, 2 H), 3.23 (m, 2 H), 2.60 (t, *J* = 2.9 Hz, 2 H), 2.20 (t, *J* = 3.7 Hz, 2 H), 1.30 (m, 14 H), 1.11 (m, 4 H), 0.771 (t, *J* = 6.3 Hz, 3 H). FAB-MS: calcd for (C₂₄H₃₄FNO) 371, found 372 (M+H). Anal. Calcd for C₂₄H₃₄FNO: C, 77.59; H, 9.22; N, 3.77. Found: C, 77.57; H, 9.44; N, 3.05. mp 81-83°C. R_f = 0.6 (10% ether/hexane).

20 EXAMPLE 120




2,6-Diisopropyl-3-methylaminomethyl-4-(4-fluorophenyl)-5-pentyl-pyridine

25 Methylammonium chloride (37.99 mg, 0.563 mmol) was added to a stirred solution of methylamine in methanol (2 M, 0.28 mL) under argon in an oven-dried round bottom flask equipped with a stir bar. Then sodium cyanoborohydride (4 eq., 10.60 mg, 0.169 mmol) was added and 2,6-diisopropyl-4-(4-fluorophenyl)-5-pentyl-3-pyridinecarboxaldehyde (Example 114, Step A) (100 mg, 0.281 mmol) was added as a solution in methanol (2 mL). The reaction was refluxed for 18 hours and then quenched with water. Concentration and addition of CH₂Cl₂ (25 mL) allowed

- 0 washings with water (2 x 15 mL), brine (1 x 25 mL), following which the solution was dried with MgSO₄, filtered, and concentrated to afford a clear oil. Flash chromatography using silica gel (40% ether/CH₂Cl₂) yielded the title compound as a white solid (21 mg, 0.057 mmol, 20%). ¹H NMR (300 MHz, CDCl₃): δ 7.13 (m, 4 H), 3.26 (m, 4 H), 2.24 (m, 5 H), 1.20 (m, 19 H), 0.783 (t, *J* = 6.6 Hz, 3 H). FAB-MS: 5 calcd for (C₂₄H₃₅FN₂) 370, found 371 (M+H). mp 77-79°C. R_f = 0.2 (20% ether/CH₂Cl₂).


EXAMPLE 121



2,6-Diisopropyl-3-aminomethyl-4-(4-fluorophenyl)-5-pentylpyridine

- The title compound was prepared from 2,6-diisopropyl-4-(4-fluorophenyl)-5-pentyl-3-pyridinecarboxaldehyde (Example 114, Step A) and NH₄OAc, according to the procedures described in Example 120. ¹H NMR (300 MHz, CDCl₃): δ 7.10 (m, 4 H), 2.61 (m, 4 H), 2.20 (t, *J* = 5.5 Hz, 2 H), 1.17 (m, 20 H), 0.776 (t, *J* = 6.6 Hz, 3 H). FAB-MS: calcd for (C₂₃H₃₃FN₂) 356, found 357 (M+H). Anal. Calcd for C₂₃H₃₃N₂F: C, 77.48; H, 9.33; N, 7.86; F, 5.33. Found: C, 77.42; H, 9.12; N, 7.64; F, 5.51. mp 47-49°C. R_f = 0.6 (50% CH₂Cl₂/hexanes).

EXAMPLE 122




0 2,6-Diisopropyl-3-(dimethylamino)methyl-4-(4-fluorophenyl)-5-pentyl-pyridine

The title compound was prepared from 2,6-diisopropyl-4-(4-fluorophenyl)-5-pentyl-3-pyridinecarboxaldehyde (Example 114, Step A) and dimethylamine hydrochloride, according to the procedures described in Example 120. ¹H NMR (300 MHz, CDCl₃): δ 7.09 (m, 4 H), 3.49 (septet, *J* = 6.6 Hz, 1 H), 3.21 (septet, *J* = 6.6 Hz, 1 H), 3.05 (s, 2 H), 2.22 (t, *J* = 5.2 Hz, 2 H), 1.99 (s, 6 H), 1.18 (m, 18 H), 0.790 (t, *J* = 6.3 Hz, 3 H). FAB-MS: calcd for (C₂₅H₃₇FN₂) 384, found 385 (M+H). Anal. Calcd for C₂₃H₃₇FN₂: C, 78.08; H, 9.70; N, 7.28; F, 4.94. Found: C, 77.95; H, 9.66; N, 7.12; F, 5.25. mp 69-71°C. R_f = 0.4 (20% ether/CH₂Cl₂).

10

EXAMPLE 123




2,6-Diisopropyl-3-(ethylamino)methyl-4-(4-fluorophenyl)-5-pentylpyridine

The title compound was prepared from 2,6-diisopropyl-4-(4-fluorophenyl)-5-pentyl-3-pyridinecarboxaldehyde (Example 114, Step A) and ethylamine, according to the procedures described in Example 120. ¹H NMR (300 MHz, CDCl₃): δ 7.06 (m, 4 H), 3.18 (m, 4 H), 2.32 (q, *J* = 7.4 Hz, 2 H), 2.15 (t, *J* = 5.2 Hz, 2 H), 1.13 (m, 18 H), 0.839 (t, *J* = 7.4 Hz, 3 H), 0.698 (t, *J* = 6.6 Hz, 3 H). FAB-MS: calcd for (C₂₅H₃₇FN₂) 384, found 385 (M+H). Anal. Calcd for C₂₃H₃₇FN₂: C, 78.08; H, 9.70; N, 7.28; F, 4.94. Found: C, 77.85; H, 9.50; N, 6.99; F, 4.79. mp 48-50°C. R_f = 0.1 (20% ether/CH₂Cl₂).

20

EXAMPLE 124




0 (±)-2,6-Diisopropyl-3-(1,2-dihydroxyethyl)-4-(4-fluorophenyl)-5-pentyl-pyridineStep A: 2,6-Diisopropyl-3-ethenyl-4-(4-fluorophenyl)-5-pentylpyridine

Methyl triphenylphosphonium bromide was suspended in 15 mL of dry THF under argon and stirred at -78°C. Butyllithium (1.6 M, 0.42 mL) was added dropwise over 2 min. and then the reaction mixture was allowed to stir at 0°C for 1.5 hours. The solution was cooled again to -78°C, treated dropwise with a solution of 2,6-diisopropyl-4-(4-fluorophenyl)-5-pentyl-3-pyridinecarbox-aldehyde (Example 114, Step A) in 5 mL of dry THF, and then stirred at 0°C for 2.5 hours. The reaction was quenched with water (10 mL) and the THF evaporated *in vacuo*. Diethyl ether was added and the mixture was washed with water (2 x 20 mL), brine (1 x 20 mL), and dried with MgSO₄. Filtration, concentration and flash chromatography (30% CH₂Cl₂/hexanes) yielded a solid (0.132 g, 0.37 mmol, 66%). ¹H NMR (300 MHz, CDCl₃) δ 7.08 (m, J = 1.1 Hz, 4 H), 6.34, 6.28 (d, J = 11.4 Hz, J = 11.4 Hz, 1 H), 5.19 (d, J = 1.8 Hz, 1 H), 4.96 (d, J = 1.8 Hz, 1 H), 3.39 (septet, J = 6.6 Hz, 1 H), 3.24 (septet, J = 6.6 Hz, 1 H), 2.30 (t, J = 5.2 Hz, 2 H), 1.20 (m, J = 2.2 Hz, 18 H), 0.979 (t, J = 6.0 Hz, 3 H). FAB-MS: calcd for (C₂₄H₃₂FN) 353, found 354 (M+H). Anal. Calcd for C₂₄H₃₂FN: C, 81.54; H, 9.12; N, 3.96; F, 5.37. Found: C, 81.46; H, 9.06; N, 3.78; F, 5.59. mp 44-46°C. R_f = 0.7 (30% CH₂Cl₂/hexanes).

20 Step B: (±)-2,6-Diisopropyl-3-(1,2-dihydroxyethyl)-4-(4-fluoro-phenyl)-5-pentylpyridine

To an oven-dried round bottom flask equipped with a stir bar was added the intermediate obtained in Step A (150 mg, 0.424 mmol), in pyridine (10 mL) under argon. The solution was stirred and OsO₄ (0.129 g, 0.509 mmol) was added in one portion. The reaction turned black as stirring continued at room temperature. After 3 hours, the pyridine was evaporated *in vacuo* and the residue was dissolved in CH₂Cl₂ (10 mL) and sat. NaHSO₃ (10 mL). The resulting heterogenous solution was stirred very rapidly for 18 hours. The layers were separated and the aqueous layer was extracted several times with CH₂Cl₂. The combined organic layers were dried (MgSO₄), filtered, and concentrated to give a white solid. The product was subjected to a pad of silica (65/35; CH₂Cl₂/ether) to yield a white solid (70 mg, 0.18 mmol, 43%). ¹H NMR (300 MHz, CDCl₃): δ 7.08 (m, 4 H), 4.57 (d, J = 1.5 Hz, 1 H), 3.85 (m, 1H), 3.65 (septet, J = 6.6 Hz, 1 H), 3.50 (m, 1 H), 3.20 (septet, J = 6.6 Hz, 1 H), 2.19 (m, 2 H), 1.96 (m, 1 H), 1.24 (m, 14 H), 1.07 (m, 4 H), 0.780 (t, J = 6.6 Hz, 3 H). FAB-MS: calcd for (C₂₄H₃₄FNO) 387, found 388 (M+H). Anal. Calcd for C₂₄H₃₄FNO: C, 74.38; H, 8.84; N, 3.61; F, 4.90. Found: C, 74.60; H, 9.03; N, 3.83; F, 5.04. mp 175-177°C. R_f = 0.5 (65/35; CH₂Cl₂/ether).

0

EXAMPLE 125

5 2,6-Diisopropyl-3-hydroxymethyl-4-[(4-trifluoromethyl)phenyl]-5-(pent-1-enyl)pyridine

Step A: Diethyl 1,4-dihydro-2,6-diisopropyl-4-[(4-trifluoromethyl)phenyl]pyridine-3,5-dicarboxylate

10 Following the procedure of Chucholowski (U.S. Patent 4,950,675), to a solution of 18.0 g (0.11 mol) of ethyl isobutyrylacetate and 9.9 g (56.8 mmol) of 4-(trifluoromethyl)benzaldehyde in ethanol (25 mL) was added concentrated ammonium hydroxide (3.0 mL). This reaction mixture was heated at reflux for 12 hrs. After cooling to room temperature, the reaction mixture was concentrated under vacuum to yield a yellow oil. The crude product was taken directly to the
15 next step without purification.

Step B: Diethyl 2,6-diisopropyl-4-[(4-trifluoromethyl)phenyl]-pyridine-3,5-dicarboxylate

20 Prepared from the intermediate obtained in Step A by the procedure described in Example 160, Step B. ¹H NMR (300 MHz, CDCl₃): δ 0.92 (t, J=7.0 Hz, 6H), 1.33 (d, J=6.6 Hz, 12H), 3.14 (m, 4H), 4.0 (q, J=7.0 Hz, 4H), 7.42 (d, J=8.0 Hz, 2H). mp 100-101°C.

25 Step C: Ethyl 2,6-diisopropyl-4-[(4-trifluoromethyl)phenyl]-5-hydroxymethylpyridine-3-carboxylate

30 Prepared from the intermediate obtained in Step B by the procedure described in Example 1, Step D. ¹H NMR (300 MHz, CDCl₃): δ 0.91 (t, J=7.0 Hz, 3H), 1.32 (d, J=6.6 Hz, 6H), 1.35 (d, J=6.6 Hz, 6H), 3.08 (m, 1H), 3.50 (m, 1H), 3.96 (q, J=7.0 Hz, 2H), 4.43 (d, J=4.0 Hz, 2H), 7.44 (d, J=8.0 Hz, 2H), 7.68 (d, J=8.0 Hz, 2H). mp 102-103°C.

0

Step D: 5-Ethoxycarbonyl-2,6-diisopropyl-4-[(4-trifluoromethyl)-phenyl]pyridine-3-carboxaldehyde

To a solution of the intermediate obtained in Step C (1.9 g, 4.6 mmol) in dichloromethane (50 mL) was added Celite (2.0 g). The suspension was stirred at room temperature and treated with pyridinium chlorochromate (PCC) (2.0 g, 9.3 mmol) in three portions. The suspension was stirred at room temperature for 1 hr, then poured into 1:1 diethyl ether/hexane (250 mL), filtered through a pad of silica, the pad washed with diethyl ether (250 mL) and the combined eluent concentrated to afford 1.7 g (93%) of the product as a viscous oil which slowly solidified. ¹H NMR (300 MHz, CDCl₃): δ 0.94 (t, J=7.0 Hz, 3H), 1.33 (d, J=6.6 Hz, 6H), 1.34 (d, J=6.6 Hz, 6H), 3.14 (m, 1H), 3.88 (m, 1H), 4.0 (q, J=7.0 Hz, 2H), 7.42 (d, J=8.0 Hz, 2H), 7.71 (d, J=8.0 Hz, 2H), 9.86 (s, 1H). mp 105-106°C.


Step E: Ethyl 2,6-diisopropyl-4-[(4-trifluoromethyl)phenyl]-5-(pent-1-enyl)pyridine-3-carboxylate

Prepared from the intermediate obtained in Step D by the procedure described in Example 1, Step D. ¹H NMR (300 MHz, CDCl₃): δ 0.69 (t, J=7.0 Hz, 3H), 0.90 (t, J=7.0 Hz, 3H), 1.09-1.34 (m, 14H), 1.92 (δ, J=14.0, 7.0, 1.5 Hz, 2H), 3.07 (m, 1H), 3.38 (m, 1H), 3.96 (q, J=7.0 Hz, 2H), 5.29 (m, 1H), 6.05 (m, 1H), 7.31 (d, J=8.0 Hz, 2H), 7.59 (d, J=8.0 Hz, 2H). mp 70-72°C.

Step F: 2,6-Diisopropyl-3-hydroxymethyl-4-[(4-trifluoromethyl)phenyl]-5-(pent-1-enyl)pyridine

The intermediate obtained in Step E (0.91 g, 2.04 mmol) was dissolved in anhydrous THF (100 mL) under argon and treated dropwise at room temperature with lithium aluminum hydride (1.0 M in THF, 10 mL, 10 mmol). The reaction mixture was stirred at reflux for 1 hr, cooled to room temperature and quenched by the sequential addition of H₂O, 20% aqueous NaOH and H₂O. The resulting suspension was filtered through a cake of Celite and the filtrate concentrated and purified by flash chromatography through silica (5% ethyl acetate/n-hexane) to afford 0.77 g (1.90 mmol, 93%) of the title compound as a white foam. ¹H NMR (300 MHz, CDCl₃): δ 0.68 (t, J=7.0 Hz, 3H), 1.05-1.40 (m, 14H), 1.90 (δ, J=14.7, 1.5 Hz, 2H), 3.34 (m, 1H), 3.45 (m, 1H), 4.37 (d, J=5.5 Hz, 2H), 5.26 (m, 1H), 5.95 (m, 1H), 7.30 (d, J=8.0 Hz, 2H), 7.65 (d, J=8.0 Hz, 2H). R_f=0.36 (10% ethyl acetate/n-hexane). mp 77-78°C.


0

EXAMPLE 1262,6-Diisopropyl-3-hydroxymethyl-4-[(4-trifluoromethyl)phenyl]-5-pentylpyridine

5 To 0.59 g (1.46 mmol) of the compound 2,6-diisopropyl-3-hydroxymethyl-4-[(4-trifluoromethyl)phenyl]-5-(pent-1-enyl)pyridine (Example 125) was dissolved in absolute ethanol (50 mL) and treated with 10% palladium on carbon (0.1 eq). The reaction flask was purged under aspirator vacuum and filled with hydrogen gas (3x). The reaction mixture was stirred under a hydrogen atmosphere for 6 hr.

10 After purging the system with argon, the catalyst was removed by filtration through a pad of Celite. The solvent was removed by concentration under vacuum and the crude product was purified by flash chromatography (10% ethyl acetate/n-hexane) to yield 0.58 g (1.41 mmol, 97%) of the title compound as a white solid. ¹H NMR (300 MHz, CDCl₃): δ 0.78 (t, J=7.0 Hz, 3H), 1.12 (m, 4H), 1.31 (m, 14H), 2.26 (m, 2H), 3.25 (m, 1H), 3.42 (m, 1H), 4.29 (s, 2H), 7.34 (d, J=8.0 Hz, 2H), 7.72 (d, J=8.0 Hz, 2H). R_f=0.36 (10% ethyl acetate/n-hexane). mp 99-100°C.

15

EXAMPLE 127

20

2,6-Diisopropyl-3-hydroxymethyl-4-(3-fluorophenyl)-5-(pent-1-enyl)-pyridine

25 Step A: Ethyl 2,6-diisopropyl-4-(3-fluorophenyl)-5-(pent-1-enyl)-pyridine-3-carboxylate


0 Prepared from 3-fluorobenzaldehyde, ethyl isobutyrylacetate and
concentrated ammonium hydroxide by the procedures described in Example 125,
Steps A-E. ¹H NMR (300 MHz, CDCl₃): (reported as a mixture of olefin isomers): δ
0.76 (m, 3H), 0.97 (t, J=7.0 Hz, 3H), 1.13-1.37 (m, 14H), 1.95 (m, 2H), 3.07 (m, 1H),
3.21-3.45 (m, 1H), 4.0 (m, 2H), 5.30-5.60 (m, 1H), 6.06 (m, 1H), 6.90-7.03 (m, 3H), 7.27
5 (m, 1H).

Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-(3-fluorophenyl)-5-(pent-1-
enyl)pyridine

10 The title compound was prepared from the intermediate obtained in Step A
by the procedure described in Example 125, Step F. ¹H NMR (300 MHz, CDCl₃)
(reported as a mixture of olefin isomers): δ 0.78 (m, 3H), 1.13-1.37 (m, 14H), 1.93 (m,
2H), 3.41 (m, 2H), 4.40 (s, 2H), 5.28-5.45 (m, 1H), 6.0 (m, 1H), 6.87-7.07 (m, 3H), 7.34
(m, 1H). R_f=0.36 (10% ethyl acetate/n-hexane). mp 117-118°C.

15

EXAMPLE 128




2,6-Diisopropyl-3-hydroxymethyl-4-(3-fluorophenyl)-5-pentylpyridine

20 The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-
(3-fluorophenyl)-5-(pent-1-enyl)pyridine (Example 127) by the procedure described
in Example 126. ¹H NMR (300 MHz, CDCl₃): δ 0.79 (t, J=7.0 Hz, 3H), 1.10-1.35 (m,
18H), 2.28 (m, 2H), 3.24 (m, 1H), 3.42 (m, 1H), 4.33 (s, 2H), 6.96 (m, 2H), 7.12 (m,
1H), 7.40 (m, 1H). mp 117-118°C. R_f=0.36 (10% ethyl acetate/n-hexane).

25

30

0

EXAMPLE 1292,6-Diisopropyl-3-hydroxymethyl-4-(4-methylphenyl)-5-(pent-1-enyl)-pyridine

5

Step A: Ethyl 2,6-diisopropyl-4-(4-methylphenyl)-5-(pent-1-enyl)-pyridine-3-carboxylate

Prepared from 4-methylbenzaldehyde, ethyl isobutyrylacetate and concentrated ammonium hydroxide by the procedures described in Example 125, Steps A-E. ¹H NMR (300 MHz, CDCl₃): δ 0.75 (t, J=7.4 Hz, 3H), 0.95 (t, J=7.4, 3 H), 1.20-1.40 (m, 14H), 1.95 (tdd, J=7.4, 7.4, 1.5 Hz, 2H), 2.35 (s, 3H), 3.10 (m, 1H), 3.40 (m, 1H), 3.99 (q, J=7.4, 2H), 5.30-5.40 (m, 1H), 6.05 (dt, J=16.2, 1.5 Hz, 1H), 7.0-7.2 (m, 4H). mp 74-77°C.


15 Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-(4-methylphenyl)-5-(pent-1-enyl)-pyridine

The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 125, Step F. ¹H NMR (300 MHz, CDCl₃) (reported as a mixture of olefin isomers): δ 0.77 (t, J=7.0 Hz, 3 H), 1.1-1.3 (m, 15 H), 2.27 (m, 2 H), 2.42 (s, 3H), 3.4 (m, 2 H), 4.34 (d, J=6.0 Hz, 2 H), 5.30-5.40 (m, 1 H), 5.90 (d, J=16.0 Hz, 1 H), 7.0 (d, J=8.0 Hz, 2 H), 7.18 (d, J=8.0 Hz, 2 H). FAB-MS: calculated for C₂₄H₃₃NO 352; found 352 (M+H, 100%). R_f=0.38 (10% ethyl acetate/n-hexane). mp 72-75°C.


25

30

0

EXAMPLE 130

5 2,6-Diisopropyl-3-hydroxymethyl-4-(4-methylphenyl)-5-pentylpyridine The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-methylphenyl)-5-(pent-1-enyl)pyridine (Example 129) by the procedure described in Example 126. ¹H NMR (300 MHz, CDCl₃): δ 0.77 (t, J=7.0 Hz, 3 H), 1.10-1.40 (m, 19 H), 2.27 (m, 2 H), 2.42 (s, 3 H), 3.22 (m, 1 H), 3.41 (m, 1 H), 4.34 (d, J=6.0 Hz, 2 H), 7.10 (d, J=8.0 Hz, 2 H), 7.20 (d, J=8.0 Hz, 2 H). FAB-MS: calculated for C₂₄H₃₅NO 354; found 354 (M+H, 100%). R_f=0.38 (10% ethyl acetate/n-hexane). mp 92-94°C

EXAMPLE 131

15 2,6-Diisopropyl-3-hydroxymethyl-4-(4-ethylphenyl)-5-(pent-1-enyl)-pyridine

Step A: Ethyl 2,6-diisopropyl-4-(4-ethylphenyl)-5-(pent-1-enyl)-pyridine-3-carboxylate


20 Prepared from 4-ethylbenzaldehyde, ethyl isobutyrylacetate and concentrated ammonium hydroxide by the procedures described in Example 125, Steps A-E. ¹H NMR (300 MHz, CDCl₃): δ 0.78 (t, J=7.4 Hz, 3H), 0.90 (t, J=7.4 Hz, 3H), 1.10-1.40 (m, 17H), 1.94 (tdd, J=7.0, 7.0, 1.5 Hz, 2H), 2.64 (q, J=7.7 Hz, 2H), 3.0 (m, 1H), 3.40 (m, 1H), 3.96 (q, J=7.4 Hz, 2H), 5.35 (m, 1H), 6.08 (dt, J=16.2, 1.5 Hz, 1H), 7.10 (m, 4H). mp 67-68°C.

0 Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-(4-ethylphenyl)-5-(pent-1-enyl)pyridine

The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 125, Step F. ¹H NMR (300 MHz, CDCl₃) (reported as a mixture of olefin isomers): δ 0.73 (t, J= 7.0 Hz, 3H), 1.10-1.40 (m, 18H), 1.91 (tdd, J=7.0, 7.0, 1.0, 2H), 2.68 (q, J=7.4 Hz, 2H), 3.3-3.5 (m, 2H), 4.41 (d, J= 5.5 Hz, 2H), 5.20-5.40 (m, 1H), 6.0 (dt, J=16.0, 1.0 Hz, 1H), 7.0 (d, J=8.5 Hz, 2H), 7.23 (d, J= 8.5 Hz, 2H). FAB-MS: calculated for C₂₅H₃₅NO 366; found 366 (M+H, 100%). R_f=0.31 (10% ethyl acetate/n-hexane).

10


EXAMPLE 132



2,6-Diisopropyl-3-hydroxymethyl-4-(4-ethylphenyl)-5-pentylpyridine

15 The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-ethylphenyl)-5-(pent-1-enyl)pyridine (Example 131) by the procedure described in Example 126. ¹H NMR (300 MHz, CDCl₃): δ 0.77 (t, J=7.0 Hz, 3H), 1.0-1.40 (m, 22H), 2.28 (m, 2H), 2.73 (q, J= 7.5 Hz, 2H), 3.35 (m, 1H), 3.45 (m, 1H), 4.35 (s, 2H), 7.10 (d, J=8.0 Hz, 2H), 7.18-7.34 (d, J=8.0 Hz, 2H). FAB-MS: calculated for C₂₅H₃₇NO 368; found 368 (M+H, 100%). R_f=0.31 (10% ethyl acetate/n-hexane).
20 mp 87-88°C.

EXAMPLE 133




0

2,6-Diisopropyl-3-hydroxymethyl-4-(4-isopropylphenyl)-5-(pent-1-enyl)pyridineStep A: Ethyl 2,6-diisopropyl-4-(4-isopropylphenyl)-5-(pent-1-enyl)pyridine-3-carboxylate

5 Prepared from 4-isopropylbenzaldehyde, ethyl isobutyrylacetate and concentrated ammonium hydroxide by the procedures described in Example 125, Steps A-E. ¹H NMR (300 MHz, CDCl₃): δ 0.70 (t, J=7.7 Hz, 3H), 0.84 (t, J=7.4, 3H), 1.10-1.40 (m, 20H), 1.95 (tdd, J=7.0, 7.0, 1.5 Hz, 2H), 2.80-3.10 (m, 2H), 3.40 (m, 1H), 3.94 (q, J=7.4 Hz, 2H), 5.30 (m, 1H), 6.10 (dt, J=15.8, 1.5 Hz, 1H), 7.0-7.20 (m, 4H).
 10 mp 41-45°C.

Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-(4-isopropylphenyl)-5-(pent-1-enyl)pyridine

15 The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 125, Step F. ¹H NMR (300 MHz, CDCl₃) (reported as a mixture of olefins): δ 0.68 (t, J=7.4 Hz, 3 H), 1.0-1.4 (m, 21 H), 1.90 (tdd, J=7.0, 7.0, 1.5 Hz, 2 H), 2.9 (m, 1H), 3.3-3.5 (m, 2 H), 4.43 (d, J=6.0 Hz, 2 H), 5.20-5.35 (m, 1 H), 6.0 (dt, J= 16.0, 1.5 Hz, 1 H), 7.0 (d, J=8.0 Hz, 2 H), 7.25 (d, J=8.0 Hz, 2 H). FAB-MS: calculated for C₂₆H₃₇NO 380; found 380 (M+H, 100%). R_f=0.40
 20 (10% ethyl acetate/n-hexane).

EXAMPLE 134

25


2,6-Diisopropyl-3-hydroxymethyl-4-(4-isopropylphenyl)-5-pentylpyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-isopropylphenyl)-5-(pent-1-enyl)pyridine (Example 133) by the procedure described in Example 126. ¹H NMR (300 MHz, CDCl₃): δ 0.74 (t, J= 7.0 Hz, 3 H),
 30 1.0-1.40 (m, 25 H), 2.25 (m, 2 H), 2.95 (m, 1 H), 3.25 (m, 1 H), 3.40 (m, 1 H), 4.35 (d,

- 0 J=6.0 Hz, 2 H), 7.1, (d, J=8.5 Hz, 2 H), 7.25 (d, J= 8.5 Hz, 2 H). FAB-MS: calculated for C₂₆H₃₉NO 382; found 382 (M+H, 100%). R_f=0.40 (10% ethyl acetate/n-hexane). mp 42-44°C.

EXAMPLE 135

5



2,6-Diisopropyl-3-hydroxymethyl-4-[4-(phenyl)phenyl]-5-(pent-1-enyl)pyridine


- 10 Step A: Ethyl 2,6-diisopropyl-4-[4-(phenyl)phenyl]-5-(pent-1-enyl)pyridine-3-carboxylate

Prepared from 4-phenylbenzaldehyde, ethyl isobutyrylacetate and concentrated ammonium hydroxide by the procedures described in Example 125, Steps A-E. ¹H NMR (300 MHz, CDCl₃): δ 0.73 (t, J=7.4 Hz, 3H), 0.93 (t, J=7.0 Hz, 3H), 1.10-1.40 (m, 14H), 1.97 (tdd, J=7.0, 7.0, 1.1 Hz, 2H), 3.10 (m, 1H), 3.45 (m, 1H), 4.0 (q, J=7.4 Hz, 2 H), 5.40 (m, 1H), 6.10 (dt, J=16.2, 1.1 Hz, 1H), 7.20-7.70 (m, 9H). mp 104-106°C.

- 20 Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-[4-(phenyl)phenyl]-5-(pent-1-enyl)pyridine


The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 125, Step F. ¹H NMR (300 MHz, CDCl₃) (reported as a mixture of olefin isomers): δ 0.70 (t, J= 7.0 Hz, 3H), 1.10-1.40 (m, 15H), 1.90 (tdd, J=7.0, 7.0, 1.5, 2H), 3.30-3.50 (m, 2H), 4.40 (d, J=6.0 Hz, 2H), 5.35 (m, 1H), 6.05 (dt, J=16.0, 1.5 Hz, 1H), 7.20-7.24 (m, 2H), 7.35-7.70 (m, 7H). FAB-MS: calculated for C₂₉H₃₅NO 414; found 414 (M+H, 100 %). R_f=0.15 (6% ethyl acetate/n-hexane). mp 50-52°C.

0

EXAMPLE 136

5 2,6-Diisopropyl-3-hydroxymethyl-4-[4-(phenyl)phenyl]-5-pentylpyridine The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-[4-(phenyl)phenyl]-5-(pent-1-enyl)pyridine (Example 135) by the procedure described in Example 126. ¹H NMR (300 MHz, CDCl₃): δ 0.76 (t, J=7.0 Hz, 3H), 1.0-1.40 (m, 19H), 2.31 (m, 2H), 3.25 (m, 1H), 3.44 (m, 1H), 4.40 (d, J=5.9 Hz, 2H), 7.22-7.70 (m, 9H). FAB-MS: calculated for C₂₉H₃₇NO 416; found 416 (M+H, 100 %). R_f=0.34 (10% ethyl acetate/n-hexane). mp 56-58°C.

10

EXAMPLE 137

15 2,6-Diisopropyl-3-hydroxymethyl-4-(2-fluorophenyl)-5-(pent-1-enyl)-pyridine

Step A: Ethyl 2,6-diisopropyl-4-(2-fluorophenyl)-5-(pent-1-enyl)-pyridine-3-carboxylate

20 Prepared from 2-fluorobenzaldehyde, ethyl isobutyrylacetate and concentrated ammonium hydroxide by the procedures described in Example 125, Steps A-E. ¹H NMR (300 MHz, CDCl₃): (reported as a mixture of olefin isomers): δ 0.70 (m, 3H), 0.92 (t, J= 7.0 Hz, 3H), 1.05-1.40 (m, 14H), 1.90 (m, 2H), 3.10 (m, 1H), 3.35 (m, 1H), 3.97 (m, 2H), 5.29-5.50 (m, 1H), 6.16 (m, 1H), 7.08-7.32 (m, 4H).


0

Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-(2-fluorophenyl)-5-(pent-1-enyl)pyridine

The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 125, Step F. ¹H NMR (300 MHz, CDCl₃) (reported as a mixture of olefin isomers): δ 0.69-0.82 (m, 3H), 1.09-1.40 (m, 14H), 1.90 (m, 2H), 3.20-3.45 (m, 2H), 4.40 (m, 2H), 5.25-5.45 (m, 1H), 6.08 (m, 1H), 7.08-7.41 (m, 5H). R_f=0.24 (10% ethyl acetate/n-hexane).

10

EXAMPLE 138




2,6-Diisopropyl-3-hydroxymethyl-4-(2-fluorophenyl)-5-pentylpyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(2-fluorophenyl)-5-(pent-1-enyl)pyridine (Example 137) by the procedure described in Example 126. ¹H NMR (300 MHz, CDCl₃): δ 0.78 (t, J=7.0 Hz, 3H), 1.07-1.40 (m, 18H), 2.29 (m, 2H), 3.26 (m, 1H), 3.46 (m, 1H), 4.34 (m, 2H), 7.20 (m, 3H), 7.42 (m, 1H). R_f=0.24 (10% ethyl acetate/n-hexane).

20

EXAMPLE 139



2,6-Diisopropyl-3-hydroxymethyl-4-(3-methylphenyl)-5-(pent-1-enyl)-pyridine


Step A: Ethyl 2,6-diisopropyl-4-(3-methylphenyl)-5-(pent-1-enyl)-pyridine-3-carboxylate

0 Prepared from 3-methylbenzaldehyde, ethyl isobutyrylacetate and concentrated ammonium hydroxide by the procedures described in Example 125, Steps A-E. ^1H NMR (300 MHz, CDCl_3): δ 0.74 (t, $J=7.4$ Hz, 3H), 0.92 (t, $J=7.0$ Hz, 3H), 1.10-1.40 (m, 14H), 1.95 (tdd, $J=7.0, 7.0, 1.5$ Hz, 2H), 2.32 (s, 3H), 3.10 (m, 1H), 3.40 (m, 1H), 3.96 (q, $J=7.4$ Hz, 2H), 5.40 (m, 1H), 6.05 (dt, $J=16.2, 1.5$ Hz, 1H), 6.90-7.20 (m, 4H).

Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-(3-methylphenyl)-5-(pent-1-enyl)pyridine

10 The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 125, Step F. ^1H NMR (300 MHz, CDCl_3) (reported as a mixture of olefins): δ 0.73 (t, $J=7.0$ Hz, 3 H), 1.10-1.40 (m, 15H), 1.90 (tdd, $J=7.0, 7.0, 1.0$, 2H), 2.36 (s, 3H), 3.30-3.50 (m, 2H), 4.40 (d, $J=4.0$ Hz, 2H), 5.20-5.40 (m, 1H), 5.95 (dt, $J=16.0, 1.0$ Hz, 1H), 6.90 (m, 2H), 7.10-7.30 (m, 2H). FAB-MS: calculated for $\text{C}_{24}\text{H}_{33}\text{NO}$ 352; found 352 ($\text{M}+\text{H}$, 100%). $R_f=0.34$ (10% ethyl acetate/*n*-hexane). mp 94-97°C.


EXAMPLE 140



2,6-Diisopropyl-3-hydroxymethyl-4-(3-methylphenyl)-5-pentylpyridine

20 The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(3-methylphenyl)-5-(pent-1-enyl)pyridine (Example 139) by the procedure described in Example 126. ^1H NMR (300 MHz, CDCl_3): δ 0.77 (t, $J=7.0$ Hz, 3 H), 1.0-1.40 (m, 19H), 2.25 (m, 2H), 2.39 (s, 3H), 3.23 (m, 1H), 3.44 (m, 1H), 4.34 (s, 2H), 6.97 (m, 2H), 7.18-7.34 (m, 2H). FAB-MS: calculated for $\text{C}_{24}\text{H}_{35}\text{NO}$ 354; found 354 ($\text{M}+\text{H}$, 100 %). $R_f=0.34$ (10% ethyl acetate/*n*-hexane). mp 88-90°C.

0

EXAMPLE 1412,6-Diisopropyl-3-hydroxymethyl-4-(2-methylphenyl)-5-(pent-1-enyl)-pyridine

5

Step A: Ethyl 2,6-diisopropyl-4-(2-methylphenyl)-5-(pent-1-enyl)-pyridine-3-carboxylate


Prepared from 2-methylbenzaldehyde, ethyl isobutyrylacetate and concentrated ammonium hydroxide by the procedures described in Example 125, Steps A-E. ¹H NMR (300 MHz, CDCl₃): δ 0.70 (t, J=7.4 Hz, 3H), 0.88 (t, J=7.0 Hz, 3H), 1.0-1.40 (m, 14H), 1.90 (td, J=7.0, 7.0 Hz, 2H), 2.0 (s, 3H), 3.10 (m, 1H), 3.40 (m, 1H), 3.90 (m, 2H), 5.30-5.40 (m, 1H), 6.0 (m, 1H), 7.0-7.20 (m, 4H).

15

Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-(2-methylphenyl)-5-(pent-1-enyl)pyridine

The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 125, Step F. ¹H NMR (300 MHz, CDCl₃) (reported as a mixture of olefin isomers): δ 0.70 (t, J= 7.5 Hz, 3H), 1.10-1.40 (m, 15H), 1.87 (tdd, J=7.5, 7.5, 1.5, 2H), 1.95 (s, 3H), 3.30-3.50 (m, 2H), 4.20 (m, 1H), 4.45 (m, 1H), 5.30 (m, 1H), 5.93 (m, 2H), 6.90-7.30 (m, 4H). FAB-MS: calculated for C₂₄H₃₃NO 352; found 352 (M+H, 100%). R_f=0.32 (10% ethyl acetate/n-hexane). mp 76-79°C.

25


EXAMPLE 142

0

2,6-Diisopropyl-3-hydroxymethyl-4-(2-methylphenyl)-5-pentylpyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(2-methylphenyl)-5-(pent-1-enyl)pyridine (Example 141) by the procedure described in Example 126. ¹H NMR (300 MHz, CDCl₃): δ 0.76 (t, J=6.6 Hz, 3H), 1.0-1.40 (m, 19H), 1.97 (s, 3H), 2.0 (m, 1H), 2.35 (m, 1H), 3.22 (m, 1H), 3.42 (m, 1H), 4.16 (dd, J=12.0, 5.0 Hz, 1H), 4.40 (dd, J=12.0, 5.0 Hz, 1H), 7.0-7.10 (m, 1H), 7.20-7.40 (m, 3H). FAB-MS: calculated for C₂₄H₃₅NO 354; found 354 (M+H, 100%). R_f=0.32 (10% ethyl acetate/n-hexane). mp 81-83°C.

10

EXAMPLE 143

15


2,6-Diisopropyl-3-hydroxymethyl-4-(4-chlorophenyl)-5-(pent-1-enyl)-pyridineStep A: Ethyl 2,6-diisopropyl-4-(4-chlorophenyl)-5-(pent-1-enyl)-pyridine-3-carboxylate

Prepared from 4-chlorobenzaldehyde, ethyl isobutyrylacetate and concentrated ammonium hydroxide by the procedures described in Example 125, Steps A-E. ¹H NMR (300 MHz, CDCl₃) (reported as a mixture of olefin isomers): δ 0.76 (m, 3H), 0.98 (m, 3H), 1.15-1.35 (m, 14H), 1.95 (m, 2H), 3.05 (m, 1H), 3.39 (m, 1H), 4.0 (m, 2H), 5.29-5.48 (m, 1H), 6.03 (m, 1H), 7.11 (m, 2H), 7.30 (m, 2H).

Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-(4-chlorophenyl)-5-(pent-1-enyl)pyridine

The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 125, Step F. ¹H NMR (300 MHz, CDCl₃) (reported as a 6:1 mixture of olefin isomers): δ 0.73-0.83 (m, 3H), 1.10-1.40 (14H), 1.91 (m, 2H), 3.93 (m, 2H), 4.39 (d, J=5.0 Hz, 2H), 5.25-5.45 (m, 1H), 5.98 (m, 1H), 7.11 (m, 2H), 7.35 (m, 2H). R_f=0.36 (10% ethyl acetate/n-hexane).


0

EXAMPLE 1442,6-Diisopropyl-3-hydroxymethyl-4-(4-chlorophenyl)-5-pentylpyridine

5

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(4-chlorophenyl)-5-(pent-1-enyl)pyridine (Example 143) by the procedure described in Example 126. ^1H NMR (300 MHz, CDCl_3): δ 0.79 (t, $J=7.0$ Hz, 3H), 1.08-1.38 (m, 18H), 2.26 (m, 2H), 3.22 (m, 1H), 3.40 (m, 1H), 4.31 (d, $J=5.0$ Hz, 1H), 7.13 (d, $J=8.0$ Hz, 2H), 7.42 (d, $J=8.0$ Hz, 2H). mp 83-85°C. $R_f=0.36$ (10% ethyl acetate/n-hexane).

10

EXAMPLE 1452,6-Diisopropyl-3-hydroxymethyl-4-(3-chlorophenyl)-5-(pent-1-enyl)-pyridine

Step A: Ethyl 2,6-diisopropyl-4-(3-chlorophenyl)-5-(pent-1-enyl)-pyridine-3-carboxylate


Prepared from 3-chlorobenzaldehyde, ethyl isobutyrylacetate and concentrated ammonium hydroxide by the procedures described in Example 125, Steps A-E. ^1H NMR (300 MHz, CDCl_3): δ 0.75 (t, $J=7.4$ Hz, 3H), 0.98 (t, $J=7.0$ Hz, 3H), 1.20-1.40 (m, 14H), 1.96 (tdd, $J=7.0, 7.0, 1.5$ Hz, 2H), 3.05 (m, 1H), 3.40 (m, 1H), 4.0 (q, $J=7.0$ Hz, 2H), 5.45 (m, 1H), 6.05 (dt, $J=16.2, 1.5$ Hz, 1H), 7.0-7.30 (m, 4H).

25

0 Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-(3-chlorophenyl)-5-(pent-1-
enyl)pyridine

The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 125, Step F. ¹H NMR (300 MHz, CDCl₃) (reported as a mixture of olefin isomers): δ 0.75 (t, J=7.5 Hz, 3H), 1.10-1.40 (m, 15H), 1.93 (tdd, J=7.0, 7.0, 1.0 Hz, 2H), 3.30-3.50 (m, 2H), 4.37 (d, J=12.0 Hz, 1H), 4.43 (d, J=12.0 Hz, 1H), 5.20-5.40 (m, 1H), 5.9 (dt, J=16.0, 1.1 Hz, 1H), 7.0-7.40 (m, 4H). FAB-MS: calculated for C₂₃H₃₀NOCl 372; found 372 (M+H, 100%). R_f=0.26 (10% ethyl acetate/n-hexane). mp 101-104°C.


10 **EXAMPLE 146**



2,6-Diisopropyl-3-hydroxymethyl-4-(3-chlorophenyl)-5-pentylpyridine

15 The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(3-chlorophenyl)-5-(pent-1-enyl)pyridine (Example 145) by the procedure described in Example 126. ¹H NMR (300 MHz, CDCl₃): δ 0.80 (t, J=7.0 Hz, 3H), 1.0-1.40 (m, 19H), 2.26 (m, 2H), 3.23 (m, 1H), 3.41 (m, 1H), 4.34 (m, 2H), 7.05-7.45 (m, 4H). FAB-MS: calculated for C₂₃H₃₂NOCl 374; found 374 (M+H, 100%). R_f 0.26 (10% ethyl
20 acetate/n-hexane). mp 94-95°C.

EXAMPLE 147




0 2,6-Diisopropyl-3-hydroxymethyl-4-(2,4-dichlorophenyl)-5-(pent-1-enyl)pyridineStep A: Ethyl 2,6-diisopropyl-4-(2,4-dichlorophenyl)-5-(pent-1-enyl)pyridine-3-carboxylate

Prepared from 2,4-dichlorobenzaldehyde, ethyl isobutyrylacetate and concentrated ammonium hydroxide by the procedures described in Example 125, Steps A-E. ¹H NMR (300 MHz, CDCl₃) (reported as a 1:1 mixture of olefin isomers): δ 0.79 (m, 3H), 0.99 (m, 3H), 1.12-1.38 (m, 14H), 1.91 (m, 2H), 3.12 (m, 1H), 3.32 (m, 1H), 4.0 (m, 2H), 5.20-5.60 (m, 1H), 6.09 (m, 1H), 7.05-7.41 (m, 3H).

10 Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-(2,4-dichlorophenyl)-5-(pent-1-enyl)pyridine


The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 125, Step F. ¹H NMR (300 MHz, CDCl₃) (reported as a 1:1 mixture of olefins): δ 0.75-0.87 (m, 3H), 1.13-1.37 (m, 14H), 1.65-2.0 (m, 2H), 3.20-3.51 (m, 2H), 4.30 (m, 1H), 4.42 (m, 1H), 5.31-5.50 (m, 1H), 6.0 (m, 1H), 7.05 (m, 1H), 7.28 (m, 1H), 7.47 (m, 1H). R_f 0.38 (10% ethyl acetate/n-hexane).

EXAMPLE 14820 2,6-Diisopropyl-3-hydroxymethyl-4-(2,4-dichlorophenyl)-5-pentylpyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(2,4-dichlorophenyl)-5-(pent-1-enyl)pyridine (Example 147) by the procedure described in Example 126. ¹H NMR (300 MHz, CDCl₃): δ 0.80 (t, J=7.0 Hz, 3H), 1.12-1.48 (m, 18H), 2.12 (m, 1H), 2.35 (m, 1H), 3.26 (m, 1H), 3.45 (m, 1H), 4.31 (AB, J=12.0 Hz, 2H), 7.16 (d, J=8.0 Hz, 1H), 7.36 (dd, J=8.0, 2.0 Hz, 1H), 7.54 (d, J=2.0, 1H). R_f 0.38 (10% ethyl acetate/n-hexane).

30

0

EXAMPLE 1492,6-Diisopropyl-3-hydroxymethyl-4-(3,4-dichlorophenyl)-5-(pent-1-enyl)pyridine

5

Step A: Ethyl 2,6-diisopropyl-4-(3,4-dichlorophenyl)-5-(pent-1-enyl)pyridine-3-carboxylate

Prepared from 3,4-dichlorobenzaldehyde, ethyl isobutyrylacetate and concentrated ammonium hydroxide by the procedures described in Example 160, Steps A-E. ¹H NMR (300 MHz, CDCl₃) (reported as a 6:1 mixture of olefin isomers): δ 0.78 (m, 3H), 1.04 (m, 3H), 1.16-1.35 (m, 14H), 1.98 (m, 2H), 3.04 (m, 1H), 3.57 (m, 1H), 5.31-5.58 (m, 1H), 6.02 (m, 1H), 7.04 (m, 1H), 7.28-7.42 (m, 2H).


10

Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-(3,4-dichlorophenyl)-5-(pent-1-enyl)pyridine

15

The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 125, Step F. ¹H NMR (300 MHz, CDCl₃) (reported as a 6:1 mixture of olefin isomers): δ 0.80 (m, 3H), 1.16-1.57 (m, 14H), 1.95 (m, 2H), 3.40 (m, 2H), 4.41 (m, 2H), 5.28-5.42 (m, 1H), 6.0 (m, 1H), 7.05 (s, 1H), 7.30 (s, 1H), 7.45 (m, 1H). mp 46-48°C. R_f=0.38 (10% ethyl acetate/n-hexane).

20

EXAMPLE 150

0 2,6-Diisopropyl-3-hydroxymethyl-4-(2,4-difluorophenyl)-5-(pent-1-enyl)pyridine

Step A: Ethyl 2,6-diisopropyl-4-(2,4-difluorophenyl)-5-(pent-1-enyl)pyridine-3-carboxylate


5 Prepared from 2,4-difluorobenzaldehyde, ethyl isobutyrylacetate and concentrated ammonium hydroxide by the procedures described in Example 125, Steps A-E. ¹H NMR (300 MHz, CDCl₃): δ 0.75 (t, J=7.4 Hz, 3H), 1.0 (t, J=7.0 Hz, 3H), 1.10-1.40 (m, 14H), 1.93 (tdd, J=7.4, 7.4, 1.5 Hz, 2H), 3.10 (m, 1H), 3.35 (m, 1H), 4.0 (q, J=7.0 Hz, 2H), 5.30 (dt, J=15.0, 7.0 Hz, 1H), 6.10 (m, 1H), 6.80-7.20 (m, 3H).

10 Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-(2,4-difluorophenyl)-5-(pent-1-enyl)pyridine

The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 125, Step F. ¹H NMR (300 MHz, CDCl₃) (reported as a mixture of olefin isomers): δ 0.75 (t, J=7.5 Hz, 3H), 1.10-1.40 (m, 15H), 1.92 (tdd, J=7.0, 7.0, 1.5, 2H), 3.30-3.60 (m, 2 H), 4.34 (dd, J=12.0, 6.0 Hz, 1H), 4.43 (dd, J=12.0, 5.0 Hz, 1H), 5.3 (m, 1H), 6.05 (d, J=16.0, Hz, 1H), 6.80-7.20 (m, 3H). FAB-MS: calculated for C₂₃H₂₉NOF₂ 374; found 374 (M+H, 100%). R_f 0.24 (10% ethyl acetate/n-hexane). mp 59-62°C.

20

EXAMPLE 151




2,6-Diisopropyl-3-hydroxymethyl-4-(2,4-difluorophenyl)-5-pentylpyridine

25 The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(2,4-difluorophenyl)-5-(pent-1-enyl)pyridine (Example 150) by the procedure described in Example 126. ¹H NMR (300 MHz, CDCl₃): δ 0.79 (t, J=7.0 Hz, 3H), 1.10-1.40 (m, 18H), 2.30 (m, 2 H), 3.20 (m, 1H), 3.40 (m, 1H), 4.30 (d, J=12.0 Hz, 1H), 4.36 (d, J=12.0 Hz, 1H), 6.90-7.20 (m, 3H). FAB-MS: calculated for C₂₃H₃₁F₂NO 376; found 376 (M+H, 100%). R_f 0.24 (10% ethyl acetate/n-hexane). mp 93-95°C.

30

0

EXAMPLE 1522,6-Diisopropyl-3-hydroxymethyl-4-(3-benzyloxyphenyl)-5-(pent-1-enyl)pyridineStep A: Ethyl 2,6-diisopropyl-4-(3-benzyloxyphenyl)-5-(pent-1-enyl)pyridine-3-carboxylate

5

Prepared from 3-benzyloxybenzaldehyde, ethyl isobutyrylacetate and concentrated ammonium hydroxide by the procedures described in Example 160, Steps A-E. ^1H NMR (300 MHz, CDCl_3): δ 0.75 (t, $J=7.4$ Hz, 3H), 0.93 (t, $J=7.2$ Hz, 3H), 1.25 (m, 14H), 1.93 (tdd, $J=7.4, 7.4, 1.1$ Hz, 2H), 3.07 (m, 1H), 3.40 (m, 1H), 3.97 (m, 2H), 5.04 (bs, 2H), 5.35 (m, 1H), 6.06 (dt, $J=16.2, 1.5$ Hz, 1H), 6.79 (m, 2H), 6.89 (m, 1H), 7.31 (m, 6H).


10

Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-(3-benzyloxyphenyl)-5-(pent-1-enyl)pyridine

15

The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 125, Step F. ^1H NMR (300 MHz, CDCl_3) (reported as a mixture of olefin isomers): δ 0.74 (t, $J=7.4$ Hz, 3H), 1.25 (m, 14H), 1.90 (m, 2H), 3.39 (m, 2H), 4.39 (d, $J=6.0$ Hz, 2H), 5.07 (s, 2H), 5.32 (m, 1H), 5.97 (m, 1H), 6.74 (m, 2H), 6.95 (m, 1H), 7.35 (m, 7H). FAB-MS: calculated for $\text{C}_{30}\text{H}_{37}\text{NO}_2$, 444; found 444 ($\text{M}+\text{H}$, 100%). Elemental analysis: calculated for $\text{C}_{30}\text{H}_{37}\text{NO}_2$: C 81.22; H 8.41; N 3.16, found: C 80.51; H 8.41; N 3.36. R_f 0.5 (25% ethyl acetate/*n*-hexane).

20


EXAMPLE 153

0

2,6-Diisopropyl-3-hydroxymethyl-4-(3-hydroxyphenyl)-5-pentylpyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(3-benzyloxyphenyl)-5-(pent-1-enyl)pyridine (Example 152) by the procedure described in Example 126. ¹H NMR (300 MHz, CDCl₃): δ 0.78 (t, J=7.0 Hz, 3H), 1.28 (m, 18H), 2.28 (m, 2H), 3.22 (m, 1H), 3.39 (m, 1H), 4.34 (m, 2H), 5.52 (s, 1H), 6.63 (m, 1H), 6.71 (d, J=8.0 Hz, 1H), 6.81 (m, 1H), 7.26 (m, 1H). FAB-MS: calculated for C₂₃H₃₃NO₂ 356; found 357 (M+H, 100%). Elemental analysis: calculated for C₂₃H₃₃NO₂: C 77.70; H 9.36; N 3.94, found: C 76.51; H 9.49; N 3.85. R_f 0.21 (10% ethyl acetate/n-hexane). mp 121-122°C.

10

EXAMPLE 154

15 2,6-Diisopropyl-3-hydroxymethyl-4-(3-trifluoromethyl)phenyl-5-(pent-1-enyl)pyridine

Step A: Ethyl 2,6-diisopropyl-4-(3-trifluoromethyl)phenyl-5-(pent-1-enyl)pyridine-3-carboxylate

20 Prepared from 3-(trifluoromethyl)benzaldehyde, ethyl isobutyrylacetate and concentrated ammonium hydroxide by the procedures described in Example 125, Steps A-E. ¹H NMR (300 MHz, CDCl₃) (reported as a 6:1 mixture of olefin isomers): δ 0.72 (m, 3H), 0.94 (m, 3H), 1.10-1.40 (m, 14H), 1.94 (m, 2H), 3.07 (m, 1H), 3.41 (m, 1H), 3.97 (m, 2H), 5.33 (m, 1H), 6.05 (m, 1H), 7.29-7.60 (m, 4H).

25


Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-(3-trifluoromethyl)phenyl-5-(pent-1-enyl)pyridine

The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 125, Step F. ¹H NMR (300 MHz, CDCl₃) (reported as a 6:1 mixture of olefin isomers): δ 0.67-0.87 (m, 3H), 1.08-1.38 (m, 14H), 1.90 (m, 2H), 3.20-3.50 (m, 2H), 4.39 (qd, J=12.0, 5.0 Hz, 2H), 5.24-5.50 (m, 1H), 5.93-

30

0 6.02 (m, 1H), 7.37-7.62 (m, 3H). mp 100-103°C. R_f 0.36 (10% ethyl acetate/n-hexane).


EXAMPLE 155



2,6-Diisopropyl-3-hydroxymethyl-4-(3-trifluoromethyl)phenyl-5-pentylpyridine

10 The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(3-trifluoromethyl)phenyl-5-(pent-1-enyl)pyridine (Example 154) by the procedure described in Example 126. ¹H NMR (300 MHz, CDCl₃): δ 0.75 (t, J=6.5 Hz, 3H), 1.07-1.39 (m, 18H), 2.24 (m, 2H), 3.24 (m, 1H), 3.42 (m, 1H), 4.31 (qd, J=12.0, 5.0 Hz, 2H), 7.42 (d, J=8.0 Hz, 1H), 7.50 (s, 1H), 7.57 (t, J=8.0 Hz, 1H), 7.67 (d, J=8.0 Hz, 1H). mp 96-97°C. R_f 0.36 (10% ethyl acetate/n-hexane).

EXAMPLE 156



2,6-Diisopropyl-3-hydroxymethyl-4-(2-ethynylphenyl)-5-(pent-1-enyl)-pyridine

Step A: Diethyl 2,6-diisopropyl-4-(2-iodophenyl)pyridine-3,5-dicarboxylate

20 Prepared from 2-iodobenzaldehyde, ethyl isobutyrylacetate and concentrated ammonium hydroxide by the procedures described in Example 125, Steps A-B. ¹H NMR (300 MHz, CDCl₃): δ 0.94 (t, J= 7.0 Hz, 6H), 1.30 (d, J= 6.6 Hz, 6H), 1.34 (d, J= 6.6 Hz, 6H), 3.19 (septet, J= 6.6 Hz, 2H), 4.0 (q, J= 7.0 Hz, 4H), 7.0-7.40 (m, 3H), 7.85 (m, 1H).

0

Step B: Diethyl 2,6-diisopropyl-4-[(2-trimethylsilylethynyl)phenyl]pyridine-3,5-dicarboxylate

5 A solution of 1.50 g (3 mmole) of the intermediate obtained in Step A in toluene was treated with 1.48 g (15 mmole) of trimethylsilyl acetylene, 87.1 g (0.86 mol) of triethylamine, 0.1 g (0.15 mmol) of *bis*(triphenylphosphine) palladium(II) chloride, 0.2 g (0.8 mmole) of triphenyl phosphine and 0.2 g (1.17 mmole) of copper iodide. This reaction mixture was stirred at rt for 1hr and heated at 90°C, in a sealed reaction vessel, for 16 hrs. The reaction mixture was cooled to temperature, filtered through Celite, and stripped to give a dark oil which upon
10 purification by flash silica gel chromatography to yield 1.22 g (2.5 mmole) of the product. ¹H NMR (300 MHz, CDCl₃): δ 0.0 (s, 9H), 0.93 (t, J= 7.0, 6H), 1.32 (d, J= 6.6 Hz, 6H), 1.33 (d, J=6.6 Hz, 6H), 3.18 (septet, J= 6.6, 2H), 3.90 (q, J= 7.0 Hz, 4H), 7.20-7.50 (m, 4H).

15 Step C: Diethyl 2,6-diisopropyl-4-(2-ethynylphenyl)pyridine-3,5-dicarboxylate

 A solution of 5.68 g (11.9 mmole) of the intermediate obtained in Step B in 800 mL ethanol was treated with 2.8 g (20.3 mmole) of potassium carbonate and the reaction mixture was allowed to stir at room temperature for 16 hours. The mixture was diluted with ethyl acetate and washed with saturated aqueous solution
20 of ammonium chloride, brine and separated. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude material was purified by flash silica gel chromatography, eluting with 10 ethyl acetate/n-hexane, to give 3.95 g (9.6 mmole) of the product. ¹H NMR (300 MHz, CDCl₃): δ 0.90 (t, J= 7.0 Hz, 6H), 1.32 (m, 12H), 2.97 (s, 1H), 3.21 (septet, J=6.6, 2H),
25 3.90 (q, J= 7.0, 4H), 7.2-7.6 (m, 4H).

Step D: Ethyl 2,6-diisopropyl-4-(2-ethynylphenyl)-5-(pent-1-enyl)-pyridine-3-carboxylate


 Prepared from the intermediate obtained in Step C by the procedures described in Example 125, Steps A-E. ¹H NMR (300 MHz, CDCl₃): δ 0.68 (t, J=7.4 Hz, 3H), 0.88 (td, J=7.0, 2.4 Hz, 3H), 1.20-1.40 (m, 14H), 1.88 (tdd, J=7.0, 7.0, 1.1 Hz, 2H), 2.92 (d, J= 2.4 Hz, 1H), 3.0-3.40 (m, 2H), 3.90 (m, 2H), 5.28 (dt, J=16.2, 7.0 Hz, 1H), 6.15 (dt, J=16.2, 1.5 Hz, 1H), 7.10-7.60 (m, 4H).

35 Step E: 2,6-Diisopropyl-3-hydroxymethyl-4-(2-ethynylphenyl)-5-(pent-1-enyl)pyridine


 The title compound was prepared from the intermediate obtained in Step D

0 by the procedure described in Example 125, Step F. ^1H NMR (300 MHz, CDCl_3) (reported as a mixture of olefin isomers): δ 0.81 (t, J = 7.4 Hz, 3H), 1.0-1.40 (m, 15H), 1.75 (m, 2H), 2.98 (d, J = 3.3 Hz, 1H), 3.20-3.60 (m, 2H), 4.20-4.50 (m, 2H), 5.40 (m, 1H), 6.0 (m, 1H), 7.0-7.60 (m, 4H). R_f = 0.23 (10% ethyl acetate/*n*-hexane).

5

EXAMPLE 1572,6-Diisopropyl-3-hydroxymethyl-4-(2-ethenylphenyl)-5-pentylpyridine

10 The title compound was prepared from ethyl 2,6-diisopropyl-3-hydroxymethyl-4-(2-ethynylphenyl)-5-(pent-1-enyl)pyridine-3-carboxylate by the procedure described in Example 125, Step F. ^1H NMR (300 MHz, CDCl_3) (reported as a mixture of olefin isomers): δ 0.60-0.90 (m, 3H), 1.0-1.40 (m, 15H), 1.60-1.90 (m, 2H), 3.20-3.50 (m, 2H), 4.20-4.40 (m, 2H), 5.14 (dt, J = 11.0, 1.0 Hz, 1H), 5.40 (m, 1H),
 15 5.90 (m, 1H), 6.30 (m, 1H), 7.0-7.70 (m, 4H). FAB-MS: calculated for $\text{C}_{25}\text{H}_{33}\text{NO}$ 363.5; found 364 ($\text{M}+\text{H}$, 100%). R_f 0.28 (10% ethyl acetate/*n*-hexane).

EXAMPLE 158

20

2,6-Diisopropyl-3-hydroxymethyl-4-(3,4-difluorophenyl)-5-(pent-1-enyl)pyridine

Step A: Ethyl 2,6-diisopropyl-4-(3,4-difluorophenyl)-5-(pent-1-enyl)pyridine-3-carboxylate

0 Prepared from 3,4-difluorobenzaldehyde, ethyl isobutyrylacetate and concentrated ammonium hydroxide by the procedures described in Example 1, Steps A-E. ¹H NMR (300 MHz, CDCl₃) (reported as a 8:1 mixture of olefin isomers): δ 0.78 (m, 3H), 1.03 (m, 3H), 1.18-1.33 (m, 14H), 1.97 (m, 2H), 3.04 (m, 1H), 3.38 (m, 1H), 4.04 (m, 2H), 5.30-5.45 (m, 1H), 6.02 (m, 1H), 6.89-7.17 (m, 3H).


5

Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-(3,4-difluorophenyl)-5-(pent-1-enyl)pyridine

10 The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 125, Step F. ¹H NMR (300 MHz, CDCl₃) (reported as a mixture of olefin isomers): δ 0.75 (m, 3H), 1.05-1.38 (m, 14H), 1.90 (m, 2H), 3.35 (m, 2H), 4.35 (m, 2H), 5.25 (m, 1H), 5.91 (m, 1H), 6.80-7.20 (m, 4H). mp 105-106°C. R_f=0.30 (10% ethyl acetate/n-hexane).

15

EXAMPLE 159




2,6-Diisopropyl-3-hydroxymethyl-4-(3,4-difluorophenyl)-5-pentylpyridine

20 The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(3,4-difluorophenyl)-5-(pent-1-enyl)pyridine (Example 158) by the procedure described in Example 126. ¹H NMR (300 MHz, CDCl₃): δ 0.81 (t, J=7.0 Hz, 3H), 1.12 (m, 4H), 1.30 (m, 14H), 2.27 (m, 2H), 3.24 (m, 1H), 3.41 (m, 1H), 4.32 (d, J=4.0 Hz, 2H), 6.95 (m, 1H), 7.06 (m, 1H), 7.25 (m, 1H). mp 106-107°C. R_f 0.30 (10% ethyl acetate/n-hexane).

25

30

0

EXAMPLE 160

5

2,6-Diisopropyl-3-hydroxymethyl-4-(4-benzyloxyphenyl)-5-(pent-1-enyl)pyridineStep A: Diethyl 1,4-dihydro-2,6-diisopropyl-4-(4-benzyloxyphenyl)-3,5-pyridinedicarboxylate

To 4-benzyloxybenzaldehyde (24.3 g, 114 mmol) and ethyl isobutyryl acetate (37.8 g, 239 mmol) were added ethanol (50 mL), acetic acid (1 mL), and piperidine (1.7 mL). The mixture was stirred under an argon atmosphere at 25°C for 12 hours. Freshly prepared sodium ethoxide in ethanol (15%, 15 mL) was then added and the reaction mixture was stirred at 25°C for 2 hours. To this mixture was added a solution of ammonium acetate (13.1 g, 171 mmol) in acetic acid (100 mL). The reaction was heated at reflux for 14 h and was then cooled to 25°C, during which time a white precipitate developed. To the mixture was added a 40% (v/v) solution of 2-propanol in water. The mixture was stirred for 0.5 hours at 25°C and was then cooled to -20°C for 2 hours. The white solid was collected by filtration with vacuum and washed with a 50% (v/v) solution of isopropanol in water to provide the product (41.8 g, 85 mmol, 75%) as a pure white solid (mp 140-141°C). ¹H NMR (300 MHz, CDCl₃): δ 1.14-1.29 (m, 18H), 4.10 (q, J = 6.9 Hz, 4H), 4.19 (sept, J = 6.9 Hz, 2H), 4.95 (s, 1H), 5.01 (s, 2H), 6.12 (s, 1H), 6.82 (d, J = 8.7 Hz, 2H), 7.17 (d, J = 8.7 Hz, 2H), 7.27-7.45 (m, 5H).

Step B: Diethyl 2,6-diisopropyl-4-(4-benzyloxyphenyl)-3,5-pyridine-dicarboxylate

To a solution of the intermediate obtained in Step A (39.72 g, 81 mmol) in acetone (400 mL) stirred under argon at 25°C was added an aqueous solution of ammonium cerium(IV) nitrate ("CAN") (1M, 162 mL). The mixture was stirred at 25°C for 0.5 hours and the acetone was then removed under reduced pressure. The resultant mixture was diluted with dichloromethane (400 mL) and poured into

- 0 water (100 mL). The organic layer was saved and the aqueous layer is extracted with dichloromethane (100 mL). The combined organic layer was washed with a saturated solution of sodium chloride (100 mL), dried over sodium sulfate, and concentrated under reduced pressure to afford the product as a white powder (39.51 g, 100%) (mp 87°C). ¹H NMR (300 MHz, CDCl₃): δ 0.96 (t, J = 6.9 Hz, 6H),
5 1.31 (d, J = 6.6 Hz, 12H), 3.10 (sept, J = 6.6 Hz, 2H), 4.01 (q, J = 7.5 Hz, 4H), 5.09 (s, 2H), 6.95 (d, J = 8.7 Hz, 2H), 7.21 (d, J = 8.7 Hz, 2H), 7.32-7.46 (m, 5H).


Step C: Ethyl 2,6-diisopropyl-4-(4-benzyloxyphenyl)-5-(pent-1-enyl)-3-pyridinecarboxylate

- 10 Prepared from the intermediate obtained in Step B by the procedure described in Example 1, Steps D-F. ¹H NMR (300 MHz, CDCl₃): δ 0.77 (t, J = 7.2 Hz, 3H), 0.95 (t, J = 7.2 Hz, 3H), 1.21-1.34 (m, 14H), 1.96 (q, J = 7.2 Hz, 2H), 3.05 (septet, J = 6.6 Hz, 1H), 3.42 (septet, J = 6.6 Hz, 1H), 3.94-4.03 (m, 2H), 5.06-5.12 (m, 2H), 5.32-5.42 (m, 1H), 6.03-6.15 (m, 1H), 6.94 (d, J = 9.0 Hz, 2H), 7.10 (d, J = 9.0 Hz,
15 2H), 7.34-7.47 (m, 5H).

Step D: 2,6-Diisopropyl-3-hydroxymethyl-4-(4-benzyloxyphenyl)-5-(pent-1-enyl)pyridine


- 20 The intermediate obtained in Step C (6 g, 12.35 mmol) was dissolved in anhydrous tetrahydrofuran ("THF") (130 mL) under argon and treated dropwise at room temperature with lithium aluminum hydride ("LAH") (1.0 M in THF, 24.7 mL, 24.7 mmol). The reaction mixture was stirred at reflux for 3 hr, cooled to room temperature and quenched by the addition of 0.9 mL H₂O, 0.9 mL 20% aqueous NaOH, and 2.7 mL H₂O. The resulting suspension was filtered through a cake of
25 Celite and the filtrate concentrated and purified by chromatography through silica (20% ethyl acetate/hexane) to afford 4.76 g of the title compound as a colorless wax. ¹H NMR (300 MHz, CDCl₃): δ 0.73-0.83 (m, 3H), 1.37-1.70 (m, 14H), 1.56 (s, 1H), 1.92 (dq, J = 0.90, 6.90 Hz, 2H), 3.41 (δ, J = 6.60, 13.20, 24.60 Hz, 2H), 4.43 (d, J = 5.1 Hz, 2H), 5.10 (s, 2H), 5.27-5.37 (m, 1H), 5.97 (d, J = 15.90 Hz, 1H), 6.97-7.09 (m,
30 4H), 7.35-7.48 (m, 5H).

0

EXAMPLE 1612,6-Diisopropyl-3-hydroxymethyl-4-(4-hydroxyphenyl)-5-pentylpyridine


5 2,6-Diisopropyl-3-hydroxymethyl-4-(4-benzyloxyphenyl)-5-(pent-1-enyl)pyridine (Example 160) (500 mg, 1.13 mmol) was dissolved in absolute ethanol (10 mL) under argon, treated with 10% palladium on carbon (15 mg), then stirred under a hydrogen atmosphere for 14 h. After purging the system with argon, the catalyst was removed by filtration through a pad of Celite. The solvent was removed and the residue is purified by flash chromatography (5% methanol-methylene chloride) to yield 371 mg of the title compound as a waxy solid (mp 158.5°C). ¹H NMR (300 MHz, CDCl₃): δ 0.79 (t, J = 6.6 Hz, 3H), 1.06-1.36 (m, 21H), 2.24-2.31 (m, 2H), 3.22 (sept, J = 6.6 Hz, 1H), 3.40 (sept, J = 6.6 Hz, 1H), 4.36 (d, J = 5.4 Hz, 2H), 4.85 (s, 1H), 6.89 (d, J = 8.4 Hz, 1H), 7.05 (d, J = 8.7 Hz, 1H).

15

EXAMPLE 1622,6-Diisopropyl-3-hydroxymethyl-4-(2-benzyloxyphenyl)-5-(pent-1-enyl)pyridine


20 The title compound was prepared as a waxy solid from 2-benzyloxybenzaldehyde by the procedures described in Example 160. ¹H NMR (300 MHz, CDCl₃): δ 0.69-0.74 (m, 3H), 1.07-1.38 (m, 14H), 1.69-1.79 (m, 1H) 1.84-1.99 (m, 2H), 3.26-3.54 (m, 2H) 4.28-4.46 (m, 2H), 4.90-5.09 (m, 2H), 5.26-5.47 (m, 1H), 25 6.00 (dd, J = 15.9, 1.2 Hz, 1H), 7.05-7.10 (m, 5H), 7.24-7.36 (m, 4H).

0

EXAMPLE 1635 2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxyphenyl)-5-pentylpyridine

The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(2-benzyloxyphenyl)-5-(pent-1-enyl)pyridine (Example 162) by the method detailed in Example 161. ¹H NMR (300 MHz, CDCl₃): δ 0.75-0.73 (m, 3H), 1.09-1.15 (m, 4H), 1.30-1.37 (m, 14H), 1.70-1.73 (m, 1H), 2.16-2.28 (m, 1H), 2.32-2.42 (m, 1H), 3.22-3.32 (m, 1H), 3.39-3.51 (m, 1H), 4.29-4.35 (m, 1H), 4.48-4.54 (m, 1H), 5.14 (br s, 1H), 7.02-7.05 (m, 3H), 7.28-7.36 (m, 1H). FAB-MS: calcd for (C₂₃H₃₃NO₂) 355, found 356 (M + 1). Anal. calc. for C₂₃H₃₃NO₂: C, 77.70; H, 9.36; N, 3.94. Found: C, 77.63; H, 9.12; N, 3.75. mp 125.5°C.

15

EXAMPLE 164

20

2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxyphenyl)-5-pentylpyridine

Step A: 2,6-Diisopropyl-(2-benzyloxyphenyl)-5-pentyl-3-pyridine-carboxaldehyde

2,6-Diisopropyl-3-hydroxymethyl-4-(2-benzyloxyphenyl)-5-(pent-1-enyl)-pyridine (Example 162) (680 mg, 1.53 mmol) was dissolved in 15 mL of methylene chloride under an argon atmosphere and treated with a mixture of Celite (661 mg) and pyridinium chlorochromate ("PCC") (661 mg, 2 eq). The reaction was stirred at

- 0 room temperature for 1.5 h. The suspension was filtered through a pad of silica and the pad was washed with 50 mL CH₂Cl₂ and the filtrate was combined and concentrated *in vacuo* to afford 572.4 mg of product (84%). ¹H NMR (300 MHz, CDCl₃): δ 0.70 (t, J = 7.2 Hz, 3H), 1.08-1.35 (m, 15H), 1.85-1.93 (m, 1H), 3.26-3.45 (m, 1H), 3.87-3.97 (m, 1H), 4.97-5.06 (m, 2H), 5.27-5.50 (m, 1H), 6.01-6.10 (m, 1H), 6.94-
5 7.34 (m, 9H), 9.82 (d, J = 3.6 Hz, 1H).

Step B: 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-benzyloxyphenyl)-5-(pent-1-enyl)pyridine

- 10 Prepared as a separable mixture of two diastereomers from the intermediate from Step A by the method detailed in Example 101, Step B. The two diastereomers were separated by flash chromatography on silica eluting with 10% ethyl acetate-hexane.

Diastereomer 1: colorless oil, ¹H NMR (300 MHz, CDCl₃): δ 0.68-1.91 (m, 23H), 3.19-3.40 (m, 1H), 3.77 (sept, J = 6.6 Hz, 1H), 4.69-4.79 (m, 1H), 4.94 (dd, J =
15 12.3, 3.9 Hz, 1H), 5.05 (d, J = 12.3 Hz, 1H), 5.20-5.43 (m, 1H), 5.90-6.05 (m, 1H), 6.94-7.38 (m, 9H). FAB-MS: calcd for (C₃₁H₃₉NO₂) 457, found 458 (M + 1).

Diastereomer 2: colorless oil, ¹H NMR (300 MHz, CDCl₃): δ 0.69 (t, J = 7.2 Hz, 3H), 1.05-1.40 (m, 17H), 1.67-1.73 (m, 1H), 1.80-1.88 (m, 2H), 3.18-3.41 (m, 1H), 3.68-3.80 (m, 1H), 4.84-5.08 (m, 3H), 5.25-5.42 (m, 1H), 5.86-6.08 (m, 1H), 6.90-7.38
20 (m, 9H). FAB-MS: calcd for (C₃₁H₃₉NO₂) 457, found 458 (M + 1).

Step C: 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxyphenyl)-5-pentylpyridine


- 25 The diastereomeric mixture of intermediates from Step B (39 mg) was dissolved in absolute ethanol (1.5 mL) under argon, treated with 10% palladium on carbon (4 mg), then stirred under a hydrogen atmosphere for 8 hr. After purging the system with argon, the catalyst was removed by filtration through a pad of Celite. The solvent was removed and the product dried *in vacuo* to afford 32 mg of the title compound as a colorless solid. Preparative thin layer chromatography
30 ("prep TLC") using a 20% ethyl acetate-hexane mixture as the eluent provided the two diastereomers.

Diastereomer 1 (D1) (11.2 mg): ¹H NMR (300 MHz, CDCl₃): δ 0.68 (t, J = 7.30 Hz, 3H), 0.99-1.03 (m, 4H), 1.19-1.34 (m, 17H), 1.62 (d, J = 3.60 Hz, 1H), 1.97-2.07 (m, 1H), 2.16-2.26 (m, 1H), 3.14 (septet, J = 7.30 Hz, 1H), 3.67 (septet, J = 7.30
35 Hz, 1H), 4.72 (br s, 1H), 4.83 (dq, J = 4.20, 6.60 Hz, 1H), 6.89-6.97 (m, 3H), 7.19-7.25 (m, 1H). FAB-MS: calcd for (C₂₄H₃₅NO₂) 369, found 370 (M + 1).

Diastereomer 1 (D1) could be resolved into the constituent enantiomers as follows. A Waters Prep LC 2000 HPLC system was equipped with a chiral HPLC column (BRB-9668A; 6 x 50 cm ID). The system was equilibrated with a mobile phase consisting of 2% (1% acetic acid, 99% ethanol) and 98% hexane at a flow rate of 175 mL/min. The sample was dissolved in mobile phase (20 mg/mL) and 5 mL aliquots were injected at 30 minute intervals. The effluent was monitored at 280 nm and two fractions (corresponding to the enantiomers) were collected at (15-17 min, 100% ee) and (19-26 min, >99% ee), respectively.

Diastereomer 2 (D2) (11.8 mg): ^1H NMR (300 MHz, CDCl_3): δ 0.68 (t, J = 6.60 Hz, 3H), 0.99-1.03 (m, 4H), 1.16-1.32 (m, 17H), 1.86 (br s, 1H), 2.00-2.10 (m, 1H), 2.19-2.29 (m, 1H), 3.14 (septet, J = 6.60 Hz, 1H), 3.67 (septet, J = 6.60 Hz, 1H), 4.57 (q, J = 6.60 Hz, 1H), 4.76 (br s, 1H), 6.84-6.93 (m, 3H), 7.19-7.24 (m, 1H). FAB-MS: calcd for $(\text{C}_{24}\text{H}_{35}\text{NO}_2)$ 369, found 370 ($M+1$).

EXAMPLE 165



2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxyphenyl)-5-propylpyridine

Step A: Diethyl-2,6-diisopropyl-4-(2-benzyloxyphenyl)-3,5-pyridine-dicarboxylate

Prepared from 2-benzyloxybenzaldehyde by the methods detailed in Example 160, Steps A-B. ^1H NMR (300 MHz, CDCl_3): δ 0.87 (t, J = 6.9 Hz, 6H), 1.32 (d, J = 6.6 Hz, 6H), 1.33 (d, J = 6.6 Hz, 6H), 3.19 (sept, J = 6.6 Hz, 2H), 3.97 (q, J = 7.2 Hz, 4H), 5.01 (s, 2H), 6.88 (d, J = 8.1 Hz, 1H), 6.94 (dt, J = 7.2, 0.6 Hz, 1H), 7.16 (dd, J = 7.8, 1.8 Hz, 1H), 7.14-7.30 (m, 6H).

Step B: 5-Ethoxycarbonyl-2,6-diisopropyl-4-(2-benzyloxyphenyl)-3-pyridinecarboxaldehyde

Prepared from the intermediate from Step A by the methods detailed in Example 1, Steps D-E. ^1H NMR (300 MHz, CDCl_3): δ 0.91 (t, J = 6.6 Hz, 3H), 1.30-

- 0 1.39 (m, 12H), 3.18 (septet, $J = 6.0$ Hz, 1H), 3.91-4.03 (m, 3H), 5.04 (dd, $J = 6.6$, 12.6 Hz, 2H), 6.96-7.05 (m, 2H), 7.17-7.28 (m, 6H), 7.34-7.40 (m, 1H).

Step C: 2,6-Diisopropyl-4-(2-benzyloxyphenyl)-3-ethoxycarbonyl-5-(prop-1-enyl)pyridine

- 5 Ethyltriphenylphosphonium bromide (4.01 g, 10.8 mmol) was suspended in anhydrous THF (130 mL) under argon and stirred at -78°C . A 1.6 M solution of *n*-butyllithium in hexanes (6.75 mL, 10.8 mmol) was added dropwise. The reaction mixture was allowed to come to 0°C and stirred at that temperature for 1 hr. The resulting brightly colored solution was cooled again to -78°C and treated dropwise
10 with a solution of the intermediate obtained in Step B (4.0 g, 9.0 mmol) in THF (20 mL). The reaction mixture was allowed to stir at 25°C for 3 hrs, then quenched by the addition of water (5 mL). The THF was removed *in vacuo*, the residue partitioned between ethyl ether (200 mL) and water (50 mL). The organic layer was washed with brine (50 mL), dried over MgSO_4 and concentrated. Flash
15 chromatography through silica (5% ethyl acetate/hex) afforded 4.1 g of the product (E, Z mixture) as a viscous oil. ^1H NMR (300 MHz, CDCl_3): δ 0.86-0.92 (m, 3H), 1.40-1.21 (m, 15H), 3.06-3.28 (m, 2H), 3.91-4.01 (m, 2H), 5.00 (br s, 2H), 5.29-5.56 (m, 1H), 6.10-6.19 (m, 1H), 6.89-6.97 (m, 2H), 7.08-7.12 (m, 1H), 7.15-7.19 (m, 2H), 7.22-7.29 (m, 4H).

20

Step D: 2,6-Diisopropyl-3-hydroxymethyl-4-(2-benzyloxyphenyl)-5-(prop-1-enyl)pyridine

- Prepared from the intermediate from Step C by the method detailed in Example 160, Step D. ^1H NMR (300 MHz, CDCl_3): δ 1.21-1.60 (m, 15H), 1.90-1.95
25 (m, 1H), 3.18-3.53 (m, 2H), 4.26-4.58 (m, 2H), 4.87-4.94 (m, 1H), 5.06 (d, $J = 12.3$ Hz, 1H), 5.27-5.57 (m, 1H), 5.95-6.05 (m, 1H), 7.00-7.06 (m, 5H), 7.22-7.37 (m, 4H).

Step E: 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxyphenyl)-5-propylpyridine


- 30 The intermediate from Step D was converted into the title compound by the methods detailed in Example 164, Steps A-C. The diastereomers were separated by radial band chromatography using a gradient eluent of 100% hexane to 5% ethyl acetate-hexane.

- Diastereomer 1 (D1): ^1H NMR (300 MHz, CDCl_3): δ 0.66 (t, $J = 7.50$ Hz, 3H),
35 1.15-1.34 (m, 15H), 1.59 (br s, 1H), 1.96-2.06 (m, 1H), 2.15-2.25 (m, 1H), 3.15 (sept, $J = 6.60$ Hz, 1H), 3.56 (sept, $J = 6.60$ Hz, 1H), 4.70 (br s, 1H), 4.81-4.87 (m, 1H), 6.90-6.97 (m, 3H), 7.19-7.26 (m, 1H). FAB-MS: calcd for $(\text{C}_{22}\text{H}_{31}\text{NO}_2)$ 341, found 342 ($\text{M}+1$).

Diastereomer 1 (D1) was resolved into its constituent enantiomers as follows. A Waters Prep LC 2000 HPLC system was equipped with a chiral HPLC column (BRB-9466AD; 6 x 50 cm ID). The system was equilibrated with a mobile phase consisting of 25% hexane and 75% of a mixture of (15% THF in heptane) at 150 mL/min. The sample was dissolved in mobile phase (10 mg/mL) and 5 mL aliquots were injected at 35 min intervals. The effluent was monitored at 280 nm. Peaks overlapped and were thus shaved. Mixed fractions were then evaporated and reinjected. The collected enantiomers were assayed off line on an analytical column (BRB-9705A) at 1.5 mL/min with a mobile phase of 1% (1% acetic acid in ethanol) and 99% hexane. The low R_t enantiomer from the preparative column was the high R_t enantiomer on the analytical column with R_t = 8.80 min; 98.8% ee. The high R_t enantiomer from the preparative column was the low R_t enantiomer on the analytical column with R_t = 3.71 min; 81% ee.

Diastereomer 2 (D2): ^1H NMR (300 MHz, CDCl_3): δ 0.72 (t, J = 7.50 Hz, 3H), 1.22-1.36 (m, 15H), 2.03-2.15 (m, 1H), 2.23-2.33 (m, 1H), 2.56 (d, J = 3.0 Hz, 1H), 3.21 (septet, J = 6.60 Hz, 1H), 3.73 (septet, J = 6.60 Hz, 1H), 4.56-4.63 (dq, J = 3.0, 6.0 Hz, 1H), 5.66 (br s, 1H), 6.88-6.99 (m, 3H), 7.25-7.28 (m, 1H). FAB-MS: calcd for ($\text{C}_{22}\text{H}_{31}\text{NO}_2$) 341, found 342 ($M+1$).

EXAMPLE 166



2,6-Diisopropyl-3-hydroxymethyl-4-[(4-fluoro-2-hydroxy)phenyl]-5-pentylpyridine

25 Step A: 2-Benzyloxy-4-fluorobromobenzene

To a solution containing 2-bromo-5-fluorophenol (50 g, 0.26 mol) in 500 mL acetone was added potassium carbonate (54.2 g, 0.39 mmol) and benzyl bromide (34.3 mL, 0.288 mol). The reaction was heated at reflux under an argon atmosphere for 2 h and then allowed to cool to 25°C. The acetone was removed under reduced pressure and the residue was taken up in ether (400 mL). The organic layer was

0 washed with water (5 x 100 mL) and brine (1 x 100 mL) and then dried (MgSO₄).
The solution was then concentrated under reduced pressure and subjected to flash
chromatography using hexane as the eluent. In this manner, 2-benzyloxy-4-
fluorobenzene was obtained as a white solid. ¹H NMR (300 MHz, CDCl₃): δ 5.14
(s, 2H), 6.57-6.63 (m, 1H), 6.69 (dd, J = 2.7, 10.2 Hz, 1H), 7.32-7.52 (m, 6H).

5

Step B: 2-Benzyloxy-4-fluorobenzaldehyde

To a slurry of magnesium (9.52 g, 0.39 mol) in THF (25 mL) in a 1 L round
bottom flask fitted with a condenser was added the intermediate obtained in Step A
(1 g). A vigorous reflux commenced at once. To this refluxing mixture was added
10 a solution of the intermediate from Step A (109 g) at a rate which maintained reflux.
After completion of addition the reaction was allowed to proceed until it cooled to
25°C and was then heated at reflux for 1 h. The reaction was allowed to cool to
25°C and DMF (48 mL) was then added portionwise. The reaction was allowed to
cool to 25°C and was then filtered through a plug of Celite. The THF was removed
15 under reduced pressure and the residue was dissolved in ethyl acetate (500 mL) and
washed sequentially with water (100 mL), 10% HCl (100 mL), saturated sodium
bicarbonate solution (100 mL), and brine (100 mL). The organic layer was dried
(Na₂SO₄) and concentrated under reduced pressure. The resultant residue was
purified by flash chromatography (10% ethyl acetate-hexane) to provide 77.3 g of
20 2-benzyloxy-4-fluorobenzaldehyde. ¹H NMR (300 MHz, CDCl₃): δ 5.16 (s, 2H),
6.70-6.76 (m, 2H), 7.34-7.44 (m, 5H), 7.87-7.92 (m, 1H), 10.43 (s, 1H). FAB-MS: calcd
for (C₁₄H₁₁O₂F) 230; found 231 (M+1).

25 Step C: 2,6-Diisopropyl-3-hydroxymethyl-4-[(2-benzyloxy-4-fluoro)phenyl]-
5-(pent-1-enyl)pyridine


Prepared from the intermediate obtained in Step B by the methods
described in Example 160, Steps A-D. ¹H NMR (300 MHz, CDCl₃): δ 0.73 (t, J = 7.4
Hz, 3H), 1.09-1.36 (m, 14H), 1.63-1.73 (m, 2H), 1.89 (q, J = 6.9 Hz, 1H), 3.25 (septet, J
= 6.6 Hz, 1H), 3.46 (d septet, J = 2.7, 6.6 Hz, 1H), 4.29-4.42 (m, 2H), 4.89-5.06 (m, 2H),
30 5.24-5.47 (m, 1H), 5.95-6.00 (m, 1H), 6.70-6.79 (m, 3H), 7.00-7.07 (m, 5H). FAB-MS:
calcd for (C₃₀H₃₆NO₂F) 461, found 462.

Step D: 2,6-Diisopropyl-3-(hydroxymethyl)-4-[(4-fluoro-2-hydroxy)phenyl]-5-
pentylpyridine

35 The title compound was prepared as a racemate from the intermediate
obtained in Step C by the method detailed in Example 161. ¹H NMR (300 MHz,

- 0 CDCl₃): δ 0.78 (t, J = 6.6 Hz, 3H), 1.09-1.35 (m, 18H), 1.65 (t, J = 5.0 Hz, 1H), 2.13-2.23 (m, 1H), 2.28-2.38 (m, 1H), 3.24 (sept, J = 6.6 Hz, 1H), 3.39 (sept, J = 6.6 Hz, 1H), 4.29 (dd, J = 11.1, 5.0 Hz, 1H), 4.52 (dd, J = 11.1, 5.1 Hz, 1H), 5.45 (bs, 1H), 6.71-6.78 (m, 2H), 6.95-7.00 (m, 1H). FAB-MS: calcd for (C₂₃H₃₂NO₂F) 373, found 374 (M + 1). R_f = 0.15 (20% ether-hexanes). mp 152°C.

5

EXAMPLE 167

10 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-[(4-fluoro-2-hydroxy)phenyl]-5-pentylpyridine

- The title compound was prepared as two separable diastereomers from 2,6-diisopropyl-3-hydroxymethyl-4-[(2-benzyloxy-4-fluoro)phenyl]-5-(pent-1-enyl)pyridine (Example 166, Step C) by the methods detailed in Example 164, Steps A-C. The diastereomers were separated by radial band chromatography using a gradient eluent of 100% hexane to 20% ether-hexane.


- 15 Diastereomer 1 (D1): ¹H NMR (300 MHz, CDCl₃): δ 0.80 (t, J = 6.6 Hz, 3H), 1.10-1.42 (m, 21H), 1.64 (d, J = 3.6 Hz, 1H), 2.03-2.13 (m, 1H), 2.21-2.31 (m, 1H), 3.15-3.26 (septet, 1H), 3.54-3.65 (septet, 1H), 4.89-4.98 (m, 1H), 4.99 (br s, 1H), 6.69-6.75 (m, 2H), 6.94-6.99 (d, J = 2.7, 6.5, 6.5 Hz, 1H). FAB-MS: calcd for (C₂₄H₃₄NO₂F) 387, found 388 (M + 1). R_f = 0.41 (40% ether-hexanes). mp 124-126°C.

- Diastereomer 1 (D1) was resolved into its constituent enantiomers as follows. A Waters Prep LC 2000 HPLC system was equipped with a chiral HPLC column (BRB-9668A; 6 x 50 cm ID). The system was equilibrated with a mobile phase consisting of 2% (1% acetic acid, 99% ethanol) and 98% hexane at a flow rate of 175 mL/min. The sample was dissolved in mobile phase (50 mg/mL) and 5 mL aliquots were injected at 30 min intervals. The effluent was monitored at 280 nm and two fractions (corresponding to the two enantiomers) were collected at (13-18 min, 100% ee) and (18.5-27 min, >99% ee), respectively.

30

0 Diastereomer 2 (D2): ^1H NMR (300 MHz, CDCl_3): δ 0.78 (t, $J = 6.5$ Hz, 3H),
 1.06-1.40 (m, 21H), 1.75 (d, $J = 3.6$ Hz, 1H), 2.06-2.16 (m, 1H), 2.26-2.37 (m, 1H), 3.21
 (septet, $J = 6.6$ Hz, 1H), 3.74 (septet, $J = 6.6$, 1H), 4.59-4.67 m, 1H), 4.83 (br s, 1H),
 6.68-6.75 (m, 2H), 6.86-6.91 (δ , $J = 3.0, 6.6, 6.6$ Hz, 1H); FAB-MS: calcd for
 5 $(\text{C}_{24}\text{H}_{34}\text{NO}_2\text{F})$ 387, found 388 ($M + 1$). $R_f = 0.24$ (40% ether-hexanes). mp 157-
 159°C.

EXAMPLE 168




10

2,6-Diisopropyl-3-hydroxymethyl-4-(4-methoxyphenyl)-5-(pent-1-enyl)pyridine

The title compound was prepared from 4-methoxybenzaldehyde by the methods detailed in Example 125. ^1H NMR (300 MHz, CDCl_3): δ 0.76 and 0.81 (t, $J = 7.2$ Hz, 3H), 1.12-1.39 (m, 14H), 1.60-1.80 (bs, 1H), 1.86-1.97 (m, 2H), 3.33-3.50 (m, 2H), 3.85 (s, 3H), 4.43 (m, 2H), 5.27-5.48 (m, 1H), 5.93-6.05 (m, 1H), 6.92 (d, $J = 8.4$ Hz, 2H), 7.07 (d, $J = 8.4$ Hz, 2H). FAB-MS: calcd for $(\text{C}_{24}\text{H}_{33}\text{NO}_2)$ 367, found 368 ($M+1$).

15

EXAMPLE 169




20

2,6-Diisopropyl-3-hydroxymethyl-4-(4-methoxyphenyl)-5-pentylpyridine

- 0 The title compound was prepared as a white solid from 2,6-diisopropyl-3-hydroxymethyl-4-(4-methoxyphenyl)-5-(pent-1-enyl)pyridine (Example 168) by the methods detailed in Example 126. ¹H NMR (300 MHz, CDCl₃): δ 0.80 (t, J = 6.6 Hz, 3H), 1.08-1.19 (m, 4H), 1.24-1.38 (m, 15H), 2.27-2.33 (m, 2H), 3.24 (sept, J = 6.6 Hz, 1H), 3.42 (sept, J = 6.6 Hz, 1H), 3.87 (s, 3H), 4.35 (d, J = 5.7 Hz, 2H), 6.97 (d, J = 8.7 Hz, 2H), 7.11 (d, J = 8.7 Hz, 2H). FAB-MS: calcd for (C₂₄H₃₅NO₂) 369, found 370 (M + 1). mp 47-49°C.
- 5

EXAMPLE 170




10

2,6-Diisopropyl-3-hydroxymethyl-4-(3-methoxyphenyl)-5-(pent-1-enyl)pyridine

- The title compound was prepared from 3-methoxybenzaldehyde by the methods detailed in Example 125. ¹H NMR (300 MHz, CDCl₃): δ 0.78 (t, J = 7.5 Hz, 3H), 1.17-1.41 (m, 14H), 1.65 (s, 1H), 1.97 (δ, J = 14.0, 7.2, 1.5 Hz, 2H), 3.39-3.55 (m, 2H), 3.81 (s, 3H), 4.45 (s, 2H), 5.35-5.50 (m, 1H), 6.01-6.09 (m, 1H), 6.73-6.77 (m, 2H), 6.89 (δ, J = 8.1, 2.1, 0.9 Hz, 1H), 7.30 (t, J = 8.0 Hz, 1H). FAB-MS: calcd for (C₂₄H₃₃NO₂) 367, found 368 (M + 1). mp 71-75°C.
- 15

20

EXAMPLE 171




2,6-Diisopropyl-3-hydroxymethyl-4-(3-methoxyphenyl)-5-pentylpyridine

- 25 The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-

- 0 (3-methoxyphenyl)-5-(pent-1-enyl)pyridine (Example 170) by the methods detailed
in Example 126. ^1H NMR (300 MHz, CDCl_3): δ 0.79 (t, J = 6.6 Hz, 3H), 1.09-1.33 (m,
7H), 1.30 (d, J = 6.6 Hz, 6H), 1.33 (d, J = 6.6 Hz, 6H), 2.25-2.31 (m, 2H), 3.23 (sept, J =
6.6 Hz, 1H), 3.42 (sept, J = 6.6 Hz, 1H), 3.82 (s, 3H), 4.35 (d, J = 6.0 Hz, 2H), 6.73 (dd,
5 J = 2.4, 1.5 Hz, 1H), 6.76 (dt, J = 7.5, 1.4 Hz), 6.93 (δ , J = 8.4, 3.6, 1.2 Hz, 1H), 7.34 (t, J
= 8.1 Hz, 1H). FAB-MS: calcd for $(\text{C}_{24}\text{H}_{35}\text{NO}_2)$ 369, found 370 ($M + 1$). mp 65-66°.

EXAMPLE 172




10

2,6-Diisopropyl-3-hydroxymethyl-4-(2-methoxyphenyl)-5-(pent-1-enyl)pyridine

- The title compound was prepared from 2-methoxybenzaldehyde by the
methods detailed in Example 125. ^1H NMR (300 MHz, CDCl_3): δ 0.82 and 0.72 (t, J
= 7 Hz, 3H), 1.05-1.47 (m, 15H), 1.80-2.00 (m, 1H), 2.05 (bs, 1H), 3.21-3.60 (m, 2H),
15 3.75 and 3.76 (s, 3H), 4.27 (d, J = 11.4 Hz, 1H), 4.43 (d, J = 11.4 Hz, 1H), 5.25-5.44 (m,
1H), 6.01-6.07 (m, 1H), 6.93-7.03 (m, 3H), 7.29-7.37 (m, 1H).

EXAMPLE 173




20

2,6-Diisopropyl-3-hydroxymethyl-4-(2-methoxyphenyl)-5-pentylpyridine

- The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-
(2-methoxyphenyl)-5-(pent-1-enyl)pyridine (Example 172) by the methods detailed
25 in Example 126. ^1H NMR (300 MHz, CDCl_3): δ 0.77 (t, J = 6.6 Hz, 3H), 1.06-1.11 (m,
4H), 1.22-1.38 (m, 14H), 1.87 (dd, J = 9.3, 3.3 Hz, 1H), 2.14 -2.40 (m, 2H), 3.25 (sept, J

0 = 6.6 Hz, 1H), 3.46 (sept, J = 6.6 Hz, 1H), 3.76 (s, 3H), 4.19 (dd, J = 11.7, 3.0 Hz, 1H), 4.39 (dd, J = 11.7, 9.0 Hz), 7.00-7.08 (m, 3H), 7.35-7.42 (m, 1H).

EXAMPLE 174




5

2,6-Diisopropyl-3-hydroxymethyl-4-[4-(methylthio)phenyl]-5-(pent-1-enyl)pyridine

The title compound was prepared as a thick colorless oil from 4-(methylthio)benzaldehyde by the methods detailed in Example 125. ¹H NMR (300 MHz, CDCl₃): δ 0.66 and 0.72 (t, J = 7.5 Hz, 3H), 1.05-1.32 (m, 14H), 1.51-1.70 (bs, 1H), 1.80-1.89 (m, 2H), 2.43 (s, 3H), 3.12-3.41 (m, 2H), 4.32 (bs, 2H), 5.17-5.40 (m, 1H), 5.85-5.97 (m, 1H), 6.99 (d, J = 8.1 Hz), 7.18 (d, J = 8.1 Hz, 2H).

10

EXAMPLE 175



15

2,6-Diisopropyl-3-hydroxymethyl-4-[4-(methylsulfinyl)phenyl]-5-(pent-1-enyl)pyridine


2,6-Diisopropyl-3-hydroxymethyl-4-[4-(methylthio)phenyl]-5-(pent-1-enyl)pyridine (100 mg, 0.261 mmol) (Example 174) was dissolved in methylene chloride (1.5 mL) and stirred at 0°C under an argon atmosphere. To this mixture was added a solution containing 3-chloroperoxybenzoic acid ("mCPBA") (85%, 53 mg, 0.261 mmol) in methylene chloride (1 mL). The mixture was stirred for 1.5 h at 0°C and is quenched with the addition of a saturated aqueous solution of NaHSO₃

20

0 (3 mL). The reaction mixture was further diluted through the addition of water (5 mL) and then extracted with methylene chloride (3 x 10 mL). The combined organic layer was washed sequentially with a saturated aqueous solution of sodium bicarbonate (10 mL) and brine (10 mL), dried (Na₂SO₄), and concentrated under reduced pressure. The resultant residue was purified by flash chromatography to
 5 yield the title compound (52 mg, 50%) as a white solid, mp 133-135°C. ¹H NMR (300 MHz, CDCl₃): δ 0.77 and 0.69 (t, J = 7.5 Hz, 3H), 1.08-1.36 (m, 14H), 1.70-1.92 (m, 3H), 2.75 and 2.76 (s, 3H), 3.19-3.51 (m, 2H), 4.32-4.40 (m, 2H), 5.20-5.45 (m, 1H), 5.93-6.00 (m, 1H), 7.31-7.38 (m, 2H), 7.59-7.70 (m, 2H). Anal. calc. for C₂₄H₃₃NO₂S: C, 71.86; H, 8.29; N, 3.39; S, 7.73. Found: C, 72.14; H, 8.32; N, 3.51; S, 8.02.

10

EXAMPLE 176



15


2,6-Diisopropyl-3-hydroxymethyl-4-[4-(methylsulfonyl)phenyl]-5-(pent-1-enyl)pyridine

2,6-Diisopropyl-3-hydroxymethyl-4-[4-(methylsulfonyl)phenyl]-5-(pent-1-enyl)pyridine (100 mg, 0.261 mmol) (Example 174) was dissolved in methylene
 20 chloride (1.5 mL) and stirred at 0°C under an argon atmosphere. To this mixture was added a solution containing 3-chloroperoxybenzoic acid ("mCPBA") (85%, 53 mg, 0.261 mmol) in methylene chloride (1 mL). The mixture was stirred for 1.5 h at 0°C and quenched with the addition of a saturated aqueous solution of NaHSO₃ (3 mL). The reaction mixture was further diluted through the addition of water (5
 25 mL) and is then extracted with methylene chloride (3 x 10 mL). The combined organic layer was washed sequentially with a saturated aqueous solution of sodium bicarbonate (10 mL) and brine (10 mL), dried (Na₂SO₄), and concentrated under reduced pressure. The resultant residue was purified by flash chromatography to yield the title compound (31.1 mg, 29%). ¹H NMR (300 MHz, CDCl₃): δ 0.69 and
 30 0.79 (t, J = 7.2 Hz, 3H), 1.08-1.37 (m, 14H), 1.45 (t, J = 4.2 Hz, 1H), 1.86-1.93 (m, 2H),

- 0 3.10 and 3.11 (s, 3H), 3.25-3.50 (m, 2H), 4.34-4.36 (m, 2H), 5.20-5.50 (m, 1H), 5.93-6.00 (m, 1H), 7.41 (d, $J = 8.4$ Hz, 2H), 7.96 (d, $J = 8.4$ Hz, 2H). Anal. calc. for $C_{24}H_{33}NO_3S$: C, 69.28; H, 7.91; N, 3.18; S, 7.50. Found: C, 69.36; H, 8.00; N, 3.37; S, 7.71.

EXAMPLE 177

5



2,6-Diisopropyl-3-hydroxymethyl-4-[(4-fluoro-3-hydroxymethyl)phenyl]-5-pentylpyridine

10

Step A: 2,6-Diisopropyl-3-[(*t*-butyldimethylsiloxy)methyl]-4-(4-fluorophenyl)-5-pentylpyridine

- To a solution of 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-pentylpyridine (3.14 g, 8.78 mmol) (Example 1, Step H) in methylene chloride (45 mL) were added imidazole (0.9 g, 13.17 mmol, 1.5 eq) and *t*-butyl-dimethylsilyl chloride (2.0 g, 13.17 mmol, 1.5 eq). A white precipitate began to form immediately. The mixture was stirred for 14 h at 25°C and was then diluted with methylene chloride (100 mL) and washed sequentially with 10% hydrochloric acid (20 mL), saturated aqueous sodium bicarbonate (20 mL), and brine (20 mL). The organic layer was concentrated under reduced pressure and the resultant residue was recrystallized from methanol to provide the product (3.27 g, 79%) as a white fluffy crystalline solid. 1H NMR (300 MHz, $CDCl_3$): δ -0.10 (s, 6H), 0.79 (t, $J = 6.9$ Hz, 3H), 0.83 (s, 9H), 1.07-1.20 (m, 4H), 1.29-1.32 (m, 14H), 2.23-2.30 (m, 2H), 3.21 (sept, $J = 6.6$ Hz, 1H), 3.35 (sept, $J = 6.6$ Hz, 1H), 4.24 (s, 2H), 7.05-7.18 (m, 4H). Anal. calc. for $C_{29}H_{46}NOFSi$: C, 73.83; H, 9.83; N, 2.97. Found: C, 73.82; H, 9.95; N, 2.86.

Step B: 2,6-Diisopropyl-3-[(*t*-butyldimethylsiloxy)methyl]-4-[(4-fluoro-3-hydroxymethyl)phenyl]-5-pentylpyridine

- To a solution of the intermediate from Step A (5.4 g, 11.4 mmol) in THF (80

0 mL) was added *sec*-butyllithium (1.3 M, 26.4 mL, 3 eq) at -78°C under an argon atmosphere. The yellow solution was stirred for 1 h at -78°C and quenched through the addition of water (50 mL). The mixture was allowed to warm to 25°C and extracted with ethyl acetate (3 x 50 mL) and the organic layer was washed with water (50 mL) and brine (50 mL), dried (Na₂SO₄), and concentrated under
5 reduced pressure to afford the crude intermediate. (6.41 g).


This intermediate (3.2 g) was dissolved in THF (50 mL) and stirred at 0°C as lithium aluminum hydride ("LAH") (1M in THF, 25.7 mL, 25.7 mmol) was added to it. The resultant mixture was stirred at 0°C for 1.5 h and quenched through the sequential addition of water (1 mL), 1N aqueous sodium hydroxide (1 mL), and
10 water (3 mL). The resultant mixture was filtered and the precipitate rinsed with ether (100 mL). The combined organic layer was washed with water (25 mL) and brine (25 mL), dried (Na₂SO₄), and concentrated under reduced pressure. The resultant residue was subjected to flash chromatography using a 10% ether-hexane mixture as the eluent. In this manner, 1.1 g of the product was obtained. ¹H NMR (300 MHz, CDCl₃): δ -0.09 (s, 6H), 0.83 (s, 9H), 1.07-1.20 (m, 4H), 1.29-1.33 (m, 17H),
15 1.96-2.02 (m, 1H), 2.22-2.31 (m, 2H), 3.23 (sept, J = 6.6 Hz, 1H), 3.36 (sept, J = 6.6 Hz, 1H), 4.22-4.32 (m, 2H), 4.70-4.90 (m, 2H), 7.09-7.12 (m, 2H), 7.23-7.28 (m, 1H).

20 Step C: 2,6-Diisopropyl-3-hydroxymethyl-4-[(4-fluoro-3-hydroxy-methyl)phenyl]-5-pentylpyridine

To a solution of the intermediate from Step B (123 mg, 0.245 mmol) in THF (3 mL) was added tetrabutylammonium fluoride (1M in THF, 0.7 mL, 0.7 mmol) at 25°C under an argon atmosphere. The mixture was stirred for 14 h at 25°C and is then diluted with water (5 mL) and extracted with methylene chloride (3 x 5 mL).
25 The combined organic layer was washed with brine (5 mL), dried (Na₂SO₄) and concentrated under reduced pressure. The resultant residue was purified by flash chromatography using a 40% ethyl acetate-hexane mixture as the eluent. In this manner, the title compound (79 mg, 83%) was produced as a colorless oil. ¹H NMR (300 MHz, CDCl₃): δ 0.78 (t, J = 6.6 Hz, 3H), 1.10-1.17 (m, 4H), 1.24-1.35 (m, 14H),
30 2.10-2.40 (m, 2H), 2.73 (bs, 1H), 3.22 (sept J = 6.6 Hz, 1H), 3.34 (sept, J = 6.6 Hz, 1H), 3.85 (bs, 1H), 4.06 (d, J = 11.4 Hz, 1H), 4.35 (d, J = 11.4 Hz, 1H), 4.48 (d, J = 14.1 Hz, 1H), 4.73 (d, J = 14.1 Hz, 1H), 7.00-7.06 (m, 2H), 7.25 (d, J = 7.2 Hz, 1H).

35

0

EXAMPLE 178

5 2,6-Diisopropyl-3-hydroxymethyl-4-[(4-fluoro-3-methoxycarbonyl)-phenyl]-5-pentylpyridine

Step A: 2,6-Diisopropyl-3-[(t-butyldimethylsiloxy)methyl]-4-[(4-fluoro-3-formyl)phenyl]-5-pentylpyridine

10 To a solution of 2,6-diisopropyl-3-[(t-butyldimethylsiloxy)methyl]-4-[(4-fluoro-3-hydroxymethyl)phenyl]-5-pentylpyridine (Example 177, Step B) (1.09 g, 2.18 mmol) in methylene chloride (100 mL) was added a mixture of PCC (0.94 g, 4.35 mmol, 2 eq) and Celite (0.94 g). The resultant mixture was stirred for 2 h at 25°C and then filtered through a pad of silica gel. The silica gel pad was rinsed with a 10% ethyl acetate-hexane mixture (200 mL) and the combined organic layer was
15 concentrated to afford the crude product (0.78 g) as a white waxy solid.

Step B: 2,6-Diisopropyl-3-[(t-butyldimethylsiloxy)methyl]-4-[(4-fluoro-3-methoxycarbonyl)phenyl]-5-pentylpyridine

20 To a solution of the intermediate from Step A (82 mg, 0.164 mmol) in methanol (3 mL) were added potassium cyanide (53 mg, 0.82 mmol) and activated manganese dioxide (71 mg, 5 eq). The mixture was stirred at 25°C for 14 h and is then filtered through a pad of Celite. The Celite pad was rinsed with ethyl acetate (25 mL) and the combined organic layer was washed with brine (5 mL), dried (Na₂SO₄), and concentrated under reduced pressure. The resultant residue was
25 purified by flash chromatography to provide the intermediate (70 mg). ¹H NMR (300 MHz, CDCl₃): δ -0.13 (s, 6H), 0.75 (t, J = 6.6 Hz, 3H), 1.06-1.40 (m, 27H), 2.20-2.35 (m, 2H), 3.20 (sept, J = 6.6 Hz, 1H), 3.32 (sept, J = 6.6 Hz, 1H), 4.15 (d, J = 10.8 Hz, 1H), 4.25 (d, J = 10.8 Hz, 1H), 7.15-7.25 (m, 1H), 7.40-7.50 (m, 1H), 7.69 (dd, J = 6.6, 2.4 Hz, 1H), 10.41 (s, 1H). FAB-MS: calcd for (C₃₀H₄₆NO₂FSi) 499, found 500
30 (M+1).

0


Step C: 2,6-Diisopropyl-3-hydroxymethyl-4-[(4-fluoro-3-methoxy-
carbonyl)phenyl]-5-pentylpyridine

The title compound was prepared from the intermediate obtained in Step B by the method detailed in Example 177, Step C. ¹H NMR (300 MHz, CDCl₃): δ 0.78

5 (t, J = 6.6 Hz, 3H), 1.08-1.16 (m, 4H), 1.23-1.34 (m, 15H), 2.20-2.30 (m, 2H), 3.22 (sept, J = 6.6 Hz, 1H), 3.40 (sept, J = 6.6 Hz, 1H), 3.93 (s, 3H), 4.25-4.39 (m, 2H), 7.12 (dd, J = 10.3, 8.5 Hz, 1H), 7.28 (d, J = 8.5, 4.8, 2.2 Hz, 1H), 7.69 (dd, J = 6.6, 2.2 Hz, 1H).

EXAMPLE 179

10



2,6-Diisopropyl-3-hydroxymethyl-4-[(4-fluoro-3-pentyl)phenyl]-5-pentylpyridine

15 Step A: 2,6-Diisopropyl-3-[(t-butyldimethylsiloxy)methyl]-4-[(4-fluoro-3-
(pent-1-enyl))phenyl]-5-pentylpyridine

To a solution of 2,6-diisopropyl-3-[(t-butyldimethylsiloxy)methyl]-4-[(4-fluoro-3-formyl)phenyl]-5-pentylpyridine (Example 178, Step A) (200 mg, 0.40 mmol) in THF (10 mL) was added a butyltriphenylphosphonium bromide/sodium amide mixture (Fluka, 0.55 g, 3 eq) under an argon atmosphere. The reaction was stirred at 25°C for 1.5 h and is quenched by dropwise addition of water (3 mL) and further diluted with brine (5 mL). The mixture was extracted with ethyl acetate (2 x 20 mL) and the combined organic layer was dried (Na₂SO₄) and concentrated under reduced pressure. The resultant residue was subjected to flash chromatography to yield the intermediate (205 mg). ¹H NMR (300 MHz, CDCl₃): δ -0.13 (s, 6H), 0.75-1.47 (m, 35H), 2.13-2.33 (m, 4H), 3.21 (septet, J = 6.6 Hz, 1H), 3.34 (septet, J = 6.6 Hz, 1H), 2.7 (d, J = 2.7 Hz, 2H), 5.75-6.31 (m, 1H), 6.41-6.59 (m, 1H), 6.98-7.09 (m, 3H). FAB-MS: calcd for (C₃₄H₅₄NOFSi) 539, found 540 (M + 1).

30


0 Step B: 2,6-Diisopropyl-3-[(*t*-butyldimethylsiloxy)methyl]-4-[(4-fluoro-3-pentyl)phenyl]-5-pentylpyridine

5 The intermediate from Step A (200 mg) was dissolved in ethanol (10 mL) and the mixture purged with argon. A quantity of 10% Pd-C (20 mg) was then added and the mixture was purged with hydrogen and stirred under a hydrogen atmosphere at 25°C for 16 h. The mixture was then filtered through a pad of silica and the silica pad is rinsed with ethanol (25 mL). The organic layer was concentrated under reduced pressure and the resultant residue was subjected to flash chromatography using hexane as the eluent to afford the intermediate (150 mg, 75%). ¹H NMR (300 MHz, CDCl₃): δ -0.11 (s, 6H), 0.76-1.65 (m, 39H), 2.17-2.33 (m, 2H), 2.51-2.78 (m, 2H), 3.21 (septet, J = 6.6 Hz, 1H), 3.35 (septet, J = 6.6 Hz, 1H), 4.42 (dd, J = 10.2, 16.2, 2H), 6.92-7.05 (m, 3H). FAB-MS: calcd for (C₃₄H₅₆NOFSi) 541, found 542 (M+1).

15 Step C: 2,6-Diisopropyl-3-hydroxymethyl-4-[(4-fluoro-3-pentyl)-phenyl]-5-pentylpyridine

20 The title compound was prepared as a colorless oil from the intermediate from Step B by the method detailed in Example 177, Step C. ¹H NMR (300 MHz, CDCl₃): δ 0.77 (t, J = 6.9 Hz, 3H), 0.88 (t, J = 6.9 Hz, 3H), 1.08-1.34 (m, 24H), 1.57-1.65 (m, 1H), 2.22-2.29 (m, 2H), 2.57-2.75 (m, 2H), 3.21 (sept, J = 6.6 Hz, 1H), 3.40 (sept, J = 6.6 Hz, 1H), 4.33 (dd, J = 5.6, 1.4 Hz, 2H), 6.93-7.09 (m, 3H). FAB-MS: calcd for (C₂₈H₄₂NOF) 427, found 428 (M + 1). R_f = 0.42 (20% ether-hexanes).

EXAMPLE 180




25 2,6-Diisopropyl-3-hydroxymethyl-4-[(4-fluoro-3-ethyl)phenyl]-5-pentylpyridine

30 The title compound was prepared as a white wax from 2,6-diisopropyl-3-[(*t*-butyldimethylsiloxy)methyl]-4-[(4-fluoro-3-formyl)phenyl]-5-pentylpyridine (Example 178, Step A) (200 mg, 0.40 mmol) and an ethyltriphenylphosphonium

- 0 bromide/sodium amide mixture (Fluka) by the methods detailed in Example 179, Steps A-C. ^1H NMR (300 MHz, CDCl_3): δ 0.77 (t, J = 6.9 Hz, 3H), 1.10-1.33 (m, 22H), 2.17-2.33 (m, 2H), 2.60-2.80 (m, 2H), 3.21 (sept, J = 6.6 Hz, 1H), 3.40 (sept, J = 6.6 Hz, 1H), 4.34 (dd, J = 5.7, 1.8 Hz, 2H), 6.94-7.09 (m, 3H). FAB-MS: calcd for ($\text{C}_{25}\text{H}_{36}\text{NOF}$) 385, found 386 ($M+1$). R_f = 0.38 (20% ether-hexanes).

5

EXAMPLE 181

- 10 2,6-Diisopropyl-3-hydroxymethyl-4-[4-fluoro-3-(α -hydroxy-4-fluorobenzyl)]-5-pentylpyridine


Step A: 2,6-Diisopropyl-3-(*t*-butyldimethylsilyloxymethyl)-4-[4-fluoro-3-(α -hydroxy-4-fluorobenzyl)phenyl]-5-pentyl-pyridine

- 15 To a solution of 2,6-diisopropyl-3-[(*t*-butyldimethylsiloxy)methyl]-4-[(4-fluoro-3-formyl)phenyl]-5-pentylpyridine (160 mg, 0.321 mmol) (Example 178, Step A) in THF (10 mL) was added 4-fluorophenyl magnesium bromide (1.0 M in THF, 0.4 mL, 2.5 eq) under an argon atmosphere at 25°C. The mixture was stirred for 30 min and then quenched by the dropwise addition of water (5 mL). The mixture
- 20 was extracted with ether (2 x 10 mL) and the combined organic layer was washed with brine, dried (Na_2SO_4), and concentrated under reduced pressure. The resultant residue was purified by flash chromatography using a 10% ether-hexane mixture as the eluent to provide 150 mg of the intermediate. ^1H NMR (300 MHz, CDCl_3): δ -0.19 (d, 6.3 Hz, 3H), -0.10 (d, J = 7.2 Hz, 3H), 0.71-1.30 (m, 30 H), 2.17-2.28 (m, 3H), 3.18 (septet, J = 6.6 Hz, 1H), 3.25-3.40 (m, 1H), 4.04-4.38 (m, 2H), 6.14 (dd, J = 4.4, 17.9 Hz, 1H), 6.97-7.38 (m, 7H). FAB-MS: calcd for ($\text{C}_{36}\text{H}_{51}\text{NOF}_2\text{Si}$) 595, found 596 ($M + 1$).
- 25

- Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-[4-fluoro-3-(α -hydroxy-4-fluorobenzyl)phenyl]-5-pentylpyridine
- 30

- 0 The title compound was prepared from the intermediate from Step A by the method detailed in Example 177, Step C. ^1H NMR (300 MHz, CDCl_3): δ 0.72-1.45 (m, 22H), 2.13-2.36 (m, 2H), 2.65 (d, $J = 4.2$ Hz, 1H), 3.21 (sept, $J = 6.6$ Hz, 1H), 3.39 (sept, $J = 6.6$ Hz, 1H), 4.21-4.39 (m, 2H), 6.14-6.17 (m, 1H), 6.98-7.12 (m, 4H), 7.35-7.42 (m, 3H). FAB-MS: calcd for $(\text{C}_{30}\text{H}_{37}\text{NO}_2\text{F}_2)$ 481, found 482 ($M + 1$). $R_f = 0.21$,
 5 0.51 (50% ether-hexanes). mp 118-120°C.

EXAMPLE 182




10

2,6-Diisopropyl-3-hydroxymethyl-4-[4-fluoro-3-(1-hydroxyethyl)phenyl]-5-pentylpyridine

- The title compound was prepared as an oil from 2,6-diisopropyl-3-[(*t*-butyldimethylsiloxy)methyl]-4-[(4-fluoro-3-formyl)phenyl]-5-pentylpyridine
 15 (Example 178, Step A) and methylmagnesium bromide by the methods detailed in Example 181, Steps A-B. ^1H NMR (300 MHz, CDCl_3): δ 0.76 (t, $J = 6.0$ Hz, 3H), 1.09-1.53 (m, 21H), 1.84 (br s, 1H), 2.18-2.27 (m, 2H), 2.87 (br s, 1H), 3.20 (septet, $J = 6.6$ Hz, 1H), 3.37 (septet, $J = 6.6$ Hz, 1H), 4.16 (d, $J = 11.4$ Hz, 1H), 4.28-4.35 (m, 1H), 5.16-5.19 (m, 1H), 7.01-7.07 (m, 2H), 7.25-7.34 (m, 1H). FAB-MS: calcd for
 20 $(\text{C}_{25}\text{H}_{36}\text{NO}_2\text{F})$ 401, found 402 ($M + 1$). $R_f = 0.32$ and 0.20 (50% ether-hexanes).

EXAMPLE 183



0

2,6-Diisopropyl-3-hydroxymethyl-4-[4-fluoro-3-((N-((pyridin-2-yl)-methyl)amino)methyl)]phenyl-5-pentylpyridine

5

Step A: 2,6-Diisopropyl-3-[(t-butyldimethylsiloxy)methyl]-4-[4-fluoro-3-((N-((pyridin-2-yl)methyl)amino)methyl)]phenyl-5-pentylpyridine

To a solution of 2,6-diisopropyl-3-[(t-butyldimethylsiloxy)methyl]-4-[(4-fluoro-3-formyl)phenyl]-5-pentylpyridine (500 mg, 1 mmol) (Example 178, Step A) in methanol (10 mL) and ether (2 mL) was added 2-methylaminopyridine (0.42 mL, 4 mmol, 4 eq) under an argon atmosphere at 25°C. To this solution were added ZnCl₂ (68.1 mg, 0.5 eq) and sodium cyanoborohydride (62.8 mg, 1 eq) in methanol (6 mL). The reaction was allowed to stir for 20 h and was then quenched with the addition of aqueous sodium hydroxide (0.1N, 7 mL). The methanol was removed under reduced pressure and the aqueous residue was extracted with ethyl acetate (3 x 30 mL). The organic layer was washed with water (10 mL) and brine (10 mL), dried (Na₂SO₄), and concentrated under reduced pressure. The resultant residue was subjected to flash chromatography using a 60% ether-hexane mixture as the eluent to provide the intermediate (260 mg, 44%). ¹H NMR (300 MHz, CDCl₃): δ - 0.12 (s, 6H), 0.72-0.81 (m, 12H), 1.80 (br s, 1H), 1.07-1.15 (m, 4H), 1.27-1.31 (m, 14H), 2.23-2.29 (m, 2H), 3.20 (septet, J = 6.6 Hz, 1H), 3.34 (septet, J = 6.6 Hz, 1H), 3.83-4.03 (m, 4H), 4.25 (dd, J = 10.5, 27.6 Hz, 2H), 7.06-7.33 (m, 5H), 7.64 (δ, J = 1.8, 7.5, 7.5 Hz, 1H), 8.54-8.56 (m, 1H). FAB-MS: calcd for (C₃₆H₅₄N₃OFSi) 591, found 592 (M + 1).

25


Step B: 2,6-Diisopropyl-3-hydroxymethyl-4-[4-fluoro-3-((N-((pyridin-2-yl)methyl)amino)methyl)]phenyl-5-pentylpyridine

30

The title compound was prepared as a colorless oil from the intermediate obtained in Step A by the method detailed in Example 177, Step C. ¹H NMR (300 MHz, CDCl₃): δ 0.75 (t, J = 6.9 Hz, 3H), 1.07-1.36 (m, 18H), 1.75 (bs, 2H), 2.19-2.36 (m, 2H), 3.20 (sept, J = 6.6 Hz, 1H), 3.47 (sept, J = 6.6 Hz, 1H), 3.74 (d, J = 14.1 Hz, 1H), 3.79 (d, J = 13.5 Hz, 1H), 3.89 (d, J = 13.5 Hz, 1H), 4.07 (d, J = 14.1 Hz, 1H), 4.20 (d, J = 11.4 Hz, 1H), 4.41 (d, J = 11.4 Hz, 1H), 7.02-7.25 (m, 4H), 7.38 (d, J = 7.8 Hz, 1H), 7.66 (δ, J = 7.5, 7.5, 1.8 Hz, 1H), 8.47 (m, 1H). FAB-MS: calcd for (C₃₀H₄₀N₃OF) 477, found 478 (M + 1). R_f = 0.4 (ethyl acetate).

35


0

EXAMPLE 184

5 2,6-Diisopropyl-3-hydroxymethyl-4-[4-fluoro-3-(pyrrolidin-1-yl)methyl]phenyl-5-pentylpyridine

The title compound was prepared from 2,6-diisopropyl-3-[(*t*-butyldimethylsiloxy)methyl]-4-[(4-fluoro-3-formyl)phenyl]-5-pentylpyridine (Example 178, Step A) by the methods detailed in Example 183, Steps A-B. ¹H NMR (300 MHz, CDCl₃): δ 0.77 (t, J = 6.6 Hz, 3H), 1.05-1.31 (m, 18 H), 1.75-1.85 (m, 5 H), 2.23-2.29 (m, 2H), 2.50-3.50 (m, 4H), 3.20 (sept, J = 6.6 Hz, 1H), 3.41 (sept, J = 6.6 Hz, 1 H), 3.71 (d, J = 12.9 Hz, 1H), 3.82 (d, J = 12.9 Hz, 1H), 4.29 (dd, J = 11.7, 20.4 Hz, 2H), 7.03-7.13 (m, 2H), 7.26-7.30 (m, 1H). FAB-MS: calcd for (C₂₈H₄₁N₂OF) 440, found 441 (M + 1). R_f = 0.2 (ethyl acetate).

15

EXAMPLE 185


20 2,6-Diisopropyl-3-hydroxymethyl-4-[4-fluoro-3-(butylamino)methyl]phenyl-5-pentylpyridine

The title compound was prepared from 2,6-diisopropyl-3-[(*t*-butyldimethylsiloxy)methyl]-4-[(4-fluoro-3-formyl)phenyl]-5-pentylpyridine (Example 178, Step A) by the methods detailed in Example 183, Steps A-B. ¹H NMR (300 MHz, CDCl₃): δ 0.79 (t, J = 6.8 Hz, 3 H), 0.91 (t, J = 7.4 Hz, 3 H), 1.10-1.61 (m, 24 H),

- 0 2.25-2.31 (m, 2 H), 2.62 (t, $J = 7.2$ Hz, 2 H), 3.23 (sept, $J = 6.6$ Hz, 1 H), 3.42 (sept, $J = 6.6$ Hz, 1H), 3.89 (s, 2H), 4.32 (dd, 11.7 Hz, 2H), 7.04-7.20 (m, 3 H). FAB-MS: calcd for $(C_{28}H_{43}N_2OF)$ 442, found 443 ($M+1$). $R_f = 0.33$ (ethyl acetate).

EXAMPLE 186


5



2,6-Diisopropyl-3-hydroxymethyl-4-(pyridin-3-yl)-5-pentylpyridine

- 10 The title compound was prepared as an oil from ethyl isobutyryl acetate, ammonium acetate and pyridine-3-carboxaldehyde in 0.56% yield by the methods described in Example 125. FAB-MS: calculated for $C_{22}H_{32}N_2O$ 340; found 341 ($M+1$). 1H NMR (300 MHz, CD_3OD): δ 0.77 (t, $J = 6.5$ Hz, 3H), 1.08-1.32 (m, 18H), 2.27-2.33 (m, 2H), 3.28 (septet, $J = 6.6$ Hz, 1H), 3.48 (septet, $J = 6.6$ Hz, 1H), 4.25 (s, 2H), 7.52-7.57 (m, 1H), 7.73-7.76 (m, 1H), 8.42-8.43 (m, 2H), 8.59 (dd, $J = 5.1, 1.5$ Hz, 1H). Anal. calc for $C_{22}H_{32}N_2O$: C, 77.60; H, 9.47; N, 8.23. Found: C, 75.96; H, 9.32; N, 7.88. $R_f = 0.40$ (diethyl ether).
- 15

EXAMPLE 187




20

2,6-Diisopropyl-3-hydroxymethyl-4-(3-furyl)-5-(pent-1-enyl)pyridine

- 25 Substituting 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) for ceric ammonium nitrate (CAN) to oxidize the dihydropyridine intermediate to the phenyl pyridine, the title compound was prepared as a mixture of *E* and *Z* isomers (4.5:1, *E*:*Z*) from ethyl isobutyryl acetate, ammonium acetate and furan-3-carboxaldehyde in 10% yield by the methods described in Example 125. FAB-MS:


- 0 calculated for $C_{21}H_{29}NO_2$ 327; found 328 (M+1). 1H NMR (300 MHz, CD_3OD): δ 0.84 (t, $J = 7.4$ Hz, 3H), 1.17-1.38 (m, 14H), 2.01-2.04 (m, 2H), 3.39 (septet, $J = 6.6$ Hz, 1H), 3.47 (septet, $J = 6.6$ Hz, 1H), 4.44 (s, 2H), 5.40-5.58 (m, 2H), 6.11-6.25 (m, 1H), 6.38-6.40 (m, 1H), 7.41-7.54 (m, 2H).

5

EXAMPLE 1882,6-Diisopropyl-3-hydroxymethyl-4-(3-furyl)-5-pentylpyridine

- 10 The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-(3-furyl)-5-(pent-1-enyl)pyridine (Example 187) in 6% yield by the methods described in Example 125. FAB-MS: calculated for $C_{21}H_{31}NO_2$ 329; found 330 (M+1). 1H NMR (300 MHz, CD_3OD): δ 0.83 (t, $J = 6.8$ Hz, 3H), 1.19-1.36 (m, 19H), 2.42-2.48 (m, 2H), 3.25 (septet, $J = 6.6$ Hz, 1H), 3.45 (septet, $J = 6.6$ Hz, 1H), 4.38 (s, 2H), 6.42 (m, 1H), 7.45-7.46 (m, 1H), 7.61-7.62 (t, $J = 1.7$ Hz, 1H). Anal. calc for $C_{21}H_{31}NO_2$: C, 76.55; H, 9.48; N, 4.25. Found: C, 76.41; H, 9.76; N, 4.24. $R_f = 0.59$ (20% EtOAc/hex). mp 98-100°C.
- 15


20

EXAMPLE 1892,6-Diisopropyl-3-hydroxymethyl-4-(thiophen-3-yl)-5-(pent-1-enyl)-pyridine

- 25 The title compound was prepared as a mixture of *E* and *Z* isomers (5.5:1, *E*:*Z*) from ethyl isobutyrylacetate, ammonium acetate and thiophene-3-carboxaldehyde in 7% yield by the methods described in Example 125. FAB-MS:

- 0 calculated for $C_{21}H_{29}NOS$ 343; found 344 ($M+1$). 1H NMR (300 MHz, $CDCl_3$): δ 0.78-0.84 (m, 3H), 1.22-1.37 (m, 15H), 1.96-2.00 (m, 2H), 3.37-3.50 (m, 2H), 4.47 (d, J = 5.7 Hz, 2H), 5.32-5.43 (m, 1H), 6.02-6.12 (m, 1H), 6.95-6.97 (m, 1H), 7.12-7.13 (m, 1H), 7.35-7.38 (m, 1H). Anal. calc for $C_{21}H_{29}NOS$: C, 73.43; H, 8.52; N, 4.08; S, 9.32. Found: C, 73.38; H, 8.75; N, 3.97; S, 9.03. R_f = 0.65 (20% EtOAc/hex). mp 85-87°C.

5

EXAMPLE 19010 3,5-Diisopropyl-2-hydroxymethyl-6-pentyl-4'-fluoro-1,1'-biphenyl

Step A: 1-(2-Methoxyethoxy)methoxymethyl-2,4-diisopropyl-5-
hydroxymethylbenzene

- 15 A mixture of 1,5-bis(hydroxymethyl)-2,4-diisopropylbenzene (0.947 g, 4.26 mmol) (prepared by the method of Fey, *et al.* U.S. Patent 5,138,090), methoxyethoxymethyl chloride (0.49 mL, 4.29 mmol), and diisopropylethylamine (1.1 mL, 6.31 mmol) in CH_2Cl_2 (9.6 mL) was stirred overnight. The mixture was diluted with water (50 mL) and extracted with CH_2Cl_2 (3 x 50 mL). Silica gel chromatography (67:33 hexanes/ethyl acetate) provided a colorless oil (0.679 g, 51%). 1H NMR ($CDCl_3$, 300 MHz): δ 7.31 (s, 1H), 7.29 (s, 1H), 4.83 (s, 2H), 4.72 (s, 2H), 4.66 (s, 2H), 3.76 (m, 2H), 3.60 (m, 2H), 3.43 (s, 3H), 3.26 (m, 2H), 1.27 (d, 7.0 Hz, 12H). EI-MS: calculated for $C_{18}H_{30}O_4$ 310; found 292 ($M-H_2O$, 24%), 221 (100%).

25 Step B: 3-(2-Methoxyethoxy)methoxymethyl-4,6-diisopropylbenzaldehyde

- Prepared from the intermediate obtained in Step A by the procedure described in Example 1, Step E. 1H NMR ($CDCl_3$, 300 MHz): δ 10.29 (s, 1H), 7.80 (s, 1H), 7.39 (s, 1H), 4.83 (s, 2H), 4.70 (s, 2H), 3.98 (sept, 6.8 Hz, 1H), 3.76 (m, 2H), 3.59 (m, 2H), 3.42 (s, 3H), 3.26 (sept, 6.8 Hz, 1H), 1.30 (d, 7.0 Hz, 6H), 1.28 (d, 7.0 Hz, 6H). FAB-MS: calculated for $C_{18}H_{28}O_4$ 308; found 309 ($M+H$).

30

0

Step C: N-Phenyl 3-(2-methoxyethoxy)methoxymethyl-4,6-diisopropylbenzidine

A mixture of the intermediate from Step B (2.35 g, 7.62 mmol), aniline (700 mL, 7.68 mmol), *p*-toluenesulfonic acid (58.8 mg, 309 mmol), and molecular sieves (20.7 g) in toluene was refluxed overnight. The mixture was cooled to room temperature and filtered. The filtrate was diluted with ethyl acetate (65 mL) and washed with saturated aqueous NaHCO₃ solution (50 mL) and water (50 mL), dried (MgSO₄), and concentrated to give an orange oil (2.78 g, 96%). The product was used in the next step without purification. ¹H NMR (C₆D₆, 300 MHz): δ 8.70 (s, 1H), 8.48 (s, 1H), 7.31 (s, 1H), 7.17 (m, 4H), 7.00 (m, 1H), 4.61 (s, 2H), 4.60 (s, 2H), 3.56 (m, 2H), 3.46 (sept, 6.8 Hz, 1H), 3.29 (m, 2H), 3.20 (sept, 6.8 Hz, 1H), 3.07 (s, 3H), 1.17 (d, 7.0 Hz, 6H), 1.12 (d, 7.0 Hz, 6H).

Step D: Bis[(2-N-phenylmethylimino)-3,5-diisopropyl-6-(2-methoxyethoxy)methoxymethylphenyl]dipalladium

A mixture of the intermediate from Step C (2.78 g, 7.27 mmol) and Pd(OAc)₂ (1.63 g, 7.26 mmol) in acetic acid (34 mL) was refluxed for 1 h. The mixture was cooled to rt, poured into water (135 mL), and filtered through a medium porosity fritted funnel. The filtrate was lyophilized. The residue was dissolved in ethyl acetate (100 mL) and washed with saturated aqueous NaHCO₃ (50 mL) and saturated aqueous NaCl (50 mL), dried (MgSO₄), and concentrated to give a brown solid. The solid was mixed with 50:50 petroleum ether/ethyl acetate (17 mL) and cooled in the freezer. The resulting precipitate was collected and dried to give a brown solid (0.951 g, 27%). ¹H NMR (C₆D₆, 300 MHz): δ 7.70 (s, 1H), 7.65 (s, 1H), 7.63 (s, 1H), 7.11 (s, 1H), 7.08 (s, 1H), 6.99 (m, 1H), 6.73 (s, 1H), 5.33 (s, 2H), 5.08 (s, 2H), 4.19 (m, 2H), 3.35 (m, 2H), 3.04 (s, 3H), 2.68 (sept, 6.8 Hz, 1H), 2.15 (sept, 6.8 Hz, 1H), 1.01 (d, 7.0 Hz, 6H), 0.96 (d, 7.0 Hz, 6H). FAB-MS: calculated for C₄₈H₆₄N₂O₆Pd₂ 976; found 488 (M/2).

Step E: 3,5-Diisopropyl-2-formyl-6-(2-methoxyethoxy)methoxymethyl-4'-fluoro-1,1'-biphenyl

A mixture of 1,2-dibromoethane (80 mL) and magnesium turnings (0.349 g, 14.4 mmol) in diethyl ether (1 mL) was heated to reflux for several minutes. The mixture was diluted with diethyl ether and a solution of 1-bromo-4-fluorobenzene (950 mL, 8.65 mmol) and 1,2-dibromoethane (160 mL) in diethyl ether (3 mL) was added over several minutes. The reflux was continued for 1 h then the mixture was cooled to room temperature. The supernatant liquid was added via cannula to a

0 solution of the intermediate obtained in Step D (0.951 g, 973 μ mol) and triphenylphosphine (2.02 g, 7.71 μ mol) in benzene (19 mL) and the mixture stirred overnight. Aqueous 6N HCl (6 mL) was added and the mixture stirred for 2 h. The mixture was filtered and the solids washed with diethyl ether (75 mL). The combined filtrates were washed with saturated aqueous sodium chloride solution
5 (50 mL). Silica gel chromatography provided a colorless solid (0.413 g, 53%). ^1H NMR (CDCl_3 , 300 MHz): δ 9.70 (s, 1H), 7.50 (s, 1H), 7.26 (m, 2H), 7.11 (m, 2H), 4.59 (s, 2H), 4.30 (s, 2H), 3.89 (sept, 6.8 Hz, 2H), 3.55 (m, 2H), 3.44 (m, 2H), 3.37 (s, 3H), 1.33 (d, 6.6 Hz, 6H), 0.96 (d, 7.0 Hz, 6H). FAB-MS: calculated for $\text{C}_{24}\text{H}_{31}\text{FO}_4$ 402; found 403 (M+H).

10

Step F: 3,5-Diisopropyl-2-(2-methoxyethoxy)methoxymethyl-6-(pent-1-enyl)-4'-fluoro-1,1'-biphenyl

Prepared from the intermediate obtained in Step E by the procedure described in Example 1, Step F. The olefin was a mixture of cis and trans isomers in
15 a ratio of 9:91. ^1H NMR (CDCl_3 , 300 MHz): δ 7.32 (s, 1H), 7.12 (m, 2H), 7.01 (m, 2H), 5.95 (d, 16.2 Hz, 1H), 5.23 (dt, 16.2 Hz, 7.0 Hz, 1H), 4.57 (s, 2H), 4.29 (s, 2H), 3.53 (m, 2H), 3.43 (m, 2H), 3.37 (s, 3H), 3.31 (m, 2H), 1.89 (m, 2H), 1.32 (d, 6.6 Hz, 6H), 1.23 (d, 7.0 Hz, 6H), 1.2 (m, 2 H), 0.74 (t, 7.4 Hz, 3H). FAB-MS: calculated for $\text{C}_{28}\text{H}_{39}\text{FO}_3$ 442; found 442 (M^+).

20

Step G: 3,5-Diisopropyl-2-(2-methoxyethoxy)methoxymethyl-6-pentyl-4'-fluoro-1,1'-biphenyl

Prepared from the intermediate obtained in Step F by the procedure described in Example 1, Step H. ^1H NMR (CDCl_3 , 300 MHz): δ 7.29 (s, 1H), 7.19
25 (m, 2H), 7.07 (m, 2H), 4.52 (s, 2H), 4.21 (s, 2H), 3.51 (m, 2H), 3.41 (m, 2H), 3.37 (s, 3H), 3.27 (sept, 6.8 Hz, 1H), 3.16 (sept, 6.8 Hz, 1H), 2.27 (m, 2H), 1.30 (d, 7.0 Hz, 6H), 1.27 (m, 2H), 1.23 (d, 7.0 Hz, 6H), 1.10 (m, 4H), 0.77 (t, 6.8 Hz, 3H). FAB-MS: calculated for $\text{C}_{28}\text{H}_{41}\text{FO}_3$ 444; found 445 (M+H).

30 Step H: 3,5-Diisopropyl-2-acetoxymethyl-6-pentyl-4'-fluoro-1,1'-biphenyl

Chlorotrimethylsilane (110 mL, 867 μ mol) was added to a cooled (0°C) mixture of the intermediate from Step G (62.4 mg, 140 μ mol) and NaI (132 mg, 880 μ mol) in CH_3CN (1.4 mL). After 25 min. the mixture was filtered through silica gel (5:1 hexanes/ethyl acetate) and the filtrate concentrated. A mixture of the
35 residue and sodium acetate (122 mg, 1.49 μ mol) in dimethyl formamide (2.3 mL) was heated to 80°C overnight. The solvent was removed and the residue dissolved in water (15 mL) and extracted with CH_2Cl_2 (3 x 15 mL). Silica gel

0 chromatography (95:5 hexane/ethyl acetate) provided a colorless oil (38.2 mg, 69%). ^1H NMR (CDCl_3 , 300 MHz): δ 7.31 (s, 1H), 7.15 (m, 2H), 7.07 (m, 2H), 4.76 (s, 2H), 3.18 (sept, 6.8 Hz, 1H), 3.12 (sept, 6.8 Hz), 2.28 (m, 2H), 1.97 (s, 3H), 1.29 (d, 6.6 Hz, 6H), 1.29 (m, 2H), 1.29 (d, 6.6 Hz, 6H), 1.14 - 1.07 (m, 4H), 0.78 (t, 6.8 Hz, 3H). FAB-MS: calculated for $\text{C}_{26}\text{H}_{35}\text{FO}_2$ 398; found 338 (M-AcOH).


5

Step I: 3,5-Diisopropyl-2-hydroxymethyl-6-pentyl-4'-fluoro-1,1'-biphenyl

A solution of the intermediate obtained in Step H (11.2 mg, 28.1 mmol) and potassium hydroxide (109 mg, 1.65 mmol) in methanol (2 mL) was heated at 50°C for 3 h. The solvent was removed, and the residue dissolved in saturated aqueous ammonium chloride (15 mL) and extracted with diethyl ether (3 x 15 mL). Silica gel chromatography (5:1 hexane/ethyl acetate) provided the title compound as a colorless crystalline solid (12.0 mg, 120%). ^1H NMR (CDCl_3 , 300 MHz): δ 7.30 (s, 1H), 7.19 (m, 2H), 7.11 (m, 2H), 4.32 (s, 2H), 3.37 (sept, 6.9 Hz, 1H), 3.16 (sept, 6.9 Hz, 1H), 2.26 (m, 2H), 1.31 (d, 6.6 Hz, 6H), 1.29 (m, 2H), 1.28 (d, 7.0 Hz, 6H), 1.17 - 1.03 (m, 4H), 0.77 (t, 6.8 Hz, 3H). FAB-MS: calculated for $\text{C}_{24}\text{H}_{33}\text{FO}$ 356; found 356 (M^+). R_f = 0.33 (83:17 hexanes/ethyl acetate). Anal. calculated for $\text{C}_{24}\text{H}_{33}\text{FO}$: C, 80.85; H, 9.33 Found: C, 80.63; H, 9.40. mp 98-99°C.

15

EXAMPLE 191



20

3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-4'-fluoro-1,1'-biphenyl

Step A: 3,5-Diisopropyl-2-formyl-6-pentyl-4'-fluoro-1,1'-biphenyl

25 Prepared from 3,5-diisopropyl-2-hydroxymethyl-6-pentyl-4'-fluoro-1,1'-biphenyl (Example 190) by the procedure described in Example 1, Step E. ^1H NMR (CDCl_3 , 300 MHz): δ 9.70 (s, 1H), 7.42 (s, 1H), 7.23-7.10 (m, 4H), 3.88 (sept, 6.8 Hz, 1H), 3.23 (sept, 6.8 Hz, 1H), 2.34 (m, 2H), 1.31 (d, 6.6 Hz, 6H), 1.29 (d, 7.0 Hz, 6H), 1.28 (m, 2H), 1.14 (m, 4H), 0.79 (t, 6.6 Hz, 3H). FAB-MS: calculated for $\text{C}_{24}\text{H}_{31}\text{FO}$ 354; found 355 (M+H).


30

0

Step B: 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-4'-fluoro-1,1'-biphenyl

The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 101, Step B. ¹H NMR (CDCl₃, 300 MHz): δ 7.32 (s, 1H), 7.19-7.06 (m, 4H), 4.70 (dq, 7.0 Hz, 2.9 Hz, 1H), 3.88 (sept, 6.8 Hz, 1H), 3.13 (sept, 6.8 Hz, 1H), 2.20 (m, 2H), 1.63 (d, 2.9 Hz, 1H), 1.40 (d, 6.6 Hz, 3H), 1.30 (d, 7.0 Hz, 6H), 1.3 (m, 2H), 1.27 (d, 7.0 Hz, 6H), 1.08 (m, 4H), 0.78 (t, 6.8 Hz, 3H). FAB-MS: calculated for C₂₅H₃₅FO 370; found 370 (M⁺). R_f = 0.36 (83:17 hexanes/ethyl acetate). mp 126°C.

10


EXAMPLE 1923,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-4'-fluoro-1,1'-biphenyl

In a separate experiment, the title compound was prepared by the methods described in Example 191. ¹H NMR (300 MHz, CDCl₃): δ 0.76 - 0.80 (m, 3H), 1.04 - 1.31 (m, 19H), 1.40 (d, J = 6.6 Hz, 3H), 2.17 - 2.22 (m, 2H), 3.11 - 3.16 (m, 1H), 3.86 - 3.90 (m, 1H), 4.66 - 4.73 (m, 1H), 7.06 - 7.22 (m, 4H), 7.32 (s, 1H). ¹³C NMR (75 MHz, CDCl₃) δ 13.87, 22.01, 23.37, 24.22, 24.55, 24.61, 25.08, 28.66, 28.94, 29.91, 31.02, 32.22, 68.89, 114.65 - 115.15 (2d, 2C), 124.25, 130.33 - 131.28 (2d, 2C), 135.51, 136.96, 137.72, 139.00, 145.80 (2C), 161.67 (d, J = 245.7 Hz, 1C). FAB-MS: calculated for C₂₅H₃₅OF 370; found 370 (M⁺). Anal. calc for C₂₅H₃₅OF: C, 81.03; H, 9.52. Found: C, 81.05; H, 9.70. R_f = 0.37 (9:1 hexanes:ethyl acetate). HPLC: (C-18, A = 0.05 % aqueous trifluoroacetic acid, B = CH₃CN; linear gradient: 75% - 100 %B over 30 min; 254 nm, 1 mL/min): R.T. 20.0 min. (91.1 area %); (Daicel Chiralcel OD-H; isocratic 99:1 hexanes:methyl *t*-butyl ether; 254 nm, 1.5 mL/min); R.T. = 5.83 min (49.0 area %), 7.67 min. (51 area %). mp 124.0-125.0°C.

30

0

EXAMPLE 193



(+)-3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-4'-fluoro-1,1'-biphenyl

Step A: 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-4'-fluoro-1,1'-biphenyl,
hemi-phthalate ester


A solution of 1.90 g (5.36 mmol) of 3,5-diisopropyl-2-formyl-6-pentyl-4'-fluoro-1,1'-biphenyl (Example 191, Step A) in 36 mL of tetrahydrofuran at -78°C under an argon atmosphere was treated with a dropwise addition of 4.6 mL (6.43 mmol) of a 1.4 M solution of methyllithium in ether. The reaction mixture was allowed to warm to room temperature over one hour. 1.03 g (6.97 mmol) of phthalic anhydride was then added as a solid and stirring was continued for another hour. The reaction was quenched with 30 mL saturated aqueous ammonium chloride and extracted with 60 mL ethyl acetate. Separated organic phase was washed again with 30 mL saturated aqueous ammonium chloride. Combined aqueous portions were extracted with several portions of 20 mL of ethyl acetate. Combined organic portions were dried (Na₂SO₄) and concentrated in vacuo. The crude mixture was purified by flash column chromatography on silica using hexanes:ethyl acetate:acetic acid (75:24:1) as eluent to provide 2.55 g (4.94 mmol, 97 %) of the product. FAB-MS: calculated for C₃₃H₃₉O₄F 518; found 519 (M+H). ¹H NMR (300 MHz, CDCl₃): δ 0.77 (t, J = 7.0 Hz, 3H), 1.03 - 1.30 (m, 18H), 1.53 (d, J = 7.0 Hz, 3H), 2.16 - 2.22 (m, 2H), 3.05 - 3.20 (m, 1H), 3.53 - 3.65 (m, 1H), 5.87 - 5.93 (m, 1H), 7.05 - 7.37 (m, 4H), 7.54 - 8.06 (m, 5H). R_f = 0.47 (75:24:1 hexanes:ethyl acetate:acetic acid).

Step B: (+)-3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-4'-fluoro-1,1'-biphenyl

30 A solution of 2.54 g (4.90 mmol) of the hemi-phthalate ester from Step A in 50 mL of hexane and 0.5 mL of methanol at reflux was treated with 0.63 mL (4.90 mmol) of (R)-(+)- α -methylbenzylamine. Reflux was continued until solids began to


0 precipitate. At this point, the flask was removed from the hot plate and allowed to cool. Further cooling was achieved by placing the flask in a freezer (-25°C) overnight. Crystals were harvested via filtration and washed with hexane. The amine salt crystals were then suspended in hexane and methanol was added at reflux until the crystals dissolved. Reflux was continued until solids began to
5 precipitate. At this point, the flask was removed from the hot plate and allowed to cool. Further cooling was not necessary and the salt crystals were harvested as above. The salts were crystallized a third time via the second method described, and the harvested crystals were placed in a vacuum oven overnight at 50°C to afford 0.57 g (0.89 mmol, 18 %) of crystalline amine salt. A solution of 0.57 g (0.89
10 mmol) of the amine salt in 5 mL dioxane was treated with a 20% solution (w/v) of NaOH/H₂O and was held at reflux for 3.5 hours. After cooling to room temperature, the reaction mixture was diluted with 20 mL of ethyl acetate. The separated aqueous phase was extracted with ethyl acetate (2 x 10 mL). Combined organic extracts were dried (Na₂SO₄) and concentrated in vacuo. The crude oil was
15 purified by flash column chromatography on silica using hexanes:ethyl acetate (19:1) and the resulting material placed in a vacuum oven overnight (at 50°C) to afford 0.26 g (0.70 mmol, 79%) of the title compound as a white solid. ¹H NMR (300 MHz, CDCl₃): δ 0.75 - 0.80 (m, 3H), 1.02 - 1.31 (m, 19H), 1.40 (d, J = 6.6 Hz, 3H), 2.17 - 2.22 (m, 2H), 3.08 - 3.18 (m, 1H), 3.83 - 3.92 (m, 1H), 4.66 - 4.73 (m, 1H), 7.05 -
20 7.23 (m, 4H), 7.32 (s, 1H). ¹³C NMR (75 MHz, CDCl₃): δ 13.88, 22.02, 23.38, 24.23, 24.56, 24.63, 25.09, 28.68, 28.96, 29.92, 31.04, 32.23, 68.91, 114.66 - 115.16 (2d, 2C), 124.27, 130.34 - 131.30 (2d, 2C), 135.53, 136.98, 137.74, 139.02, 145.82 (2C), 161.68 (d, J = 245.4 Hz, 1C). FAB-MS: calculated for C₂₅H₃₅OF 370; found 370 (M⁺). Anal. calc for C₂₅H₃₅OF: C, 81.03; H, 9.52. Found: C, 81.15; H, 9.68. R_f = 0.36 (9:1
25 hexanes:ethyl acetate). HPLC: (C-18, A = 0.05 % aqueous trifluoroacetic acid, B = CH₃CN; linear gradient: 75%-100% B over 30 min; 254 nm, 1 mL/min): R.T. 20.0 min (93.9 area %), (Daicel Chiralcel OD-H; isocratic 99:1 hexanes:methyl *t*-butyl ether; 254 nm, 1.5 mL/min); R.T. 5.23 min.(98.0 area %), 8.37 min. (0.89 area %); 98.2 % e.e. [α]_D = +26.9° (c = 0.00196 g/mL, CH₂Cl₂).
30 mp 95.0-96.0°C.

0

EXAMPLE 1943,5-Diisopropyl-2-hydroxymethyl-6-(pent-1-enyl)-4'-fluoro-1,1'-biphenyl

5 The title compound was prepared from the intermediate obtained in Example 190, Step F by the procedures described in Example 190, Steps H and I. The olefin was a mixture of cis and trans isomers in a ratio of 17:83. ¹H NMR (CDCl₃, 300 MHz): δ 7.33 (s, 1H), 7.15-7.02 (m, 4H), 5.95 (d, 16.2 Hz, 1H), 5.24 (dt, 16.2 Hz, 7.0 Hz, 1H), 4.40 (s, 2H), 3.41 (sept, 6.8 Hz, 1H), 3.30 (sept, 6.8 Hz, 1H), 1.89 (dt, 7.2 Hz, 7.2 Hz, 2H), 1.33 (d, 6.6 Hz, 6H), 1.24 (d, 7.0 Hz, 6H), 1.2 (m, 2H), 0.74 (t, 7.4 Hz, 3H). FAB-MS: calculated for C₂₄H₃₁FO 354; found 354 (M⁺). R_f = 0.36 (83:17 hexanes/ethyl acetate). Anal. calculated for C₂₄H₃₁FO: C, 81.31; H, 8.81 Found: C, 81.04; H, 8.65. mp 85-95°C.

15

EXAMPLE 1953,5-Dimethyl-2-(1-hydroxyethyl)-6-propyl-4'-fluoro-1,1'-biphenyl

20

Step A: 2-Allyloxy-4,6-dimethylacetophenone

A solution of 2-hydroxy-4,6-dimethylacetophenone (4.99 g, 30.4 mmol) in dimethylformamide (31 mL) was added to a cooled (0°C) suspension of sodium hydride (0.772 g, 32.1 mmol) in dimethylformamide (8 mL). The mixture was warmed to room temperature for 2.5 h. The mixture was recooled to 0°C and allyl

25

- 0 bromide (5.4 mL, 62.4 mmol) added. The mixture was warmed to room temperature and stirred 25 h. The mixture was diluted with saturated aqueous sodium chloride solution (150 mL) and extracted with diethyl ether (250 mL + 2 x 125 mL). The combined organic phase was washed with 1 N KOH (2 x 125 mL) and saturated aqueous sodium chloride solution. Silica gel chromatography provided a colorless oil (5.74 g, 92%). ¹H NMR (CDCl₃, 300 MHz): δ 6.64 (s, 1H), 6.56 (s, 1H), 6.03 (ddt, 17.3 Hz, 10.7 Hz, 5.2 Hz, 1H), 5.38 (d, 17.3 Hz, 1H), 5.27 (d, 10.7 Hz, 1H), 4.55 (d, 5.0 Hz, 2H), 2.51 (s, 3H), 2.31 (s, 3H), 2.22 (s, 3H).

Step B: 2-Hydroxy-3-(prop-2-enyl)-4,6-dimethylacetophenone

- 10 A solution of the intermediate obtained in Step A (6.30 g, 30.8 mmol) and 2,6-di-*t*-butyl-4-methylphenol (71.9 mg, 326 mmol) in xylenes was degassed by three freeze-pump-thaw cycles. The mixture was heated in an oil bath at 225°C for 8 h. The mixture was cooled to room temperature and concentrated in vacuo. Silica gel chromatography provided a yellow oil (5.47 g, 87%). ¹H NMR (CDCl₃, 300 MHz): δ 13.09 (s, 1H), 6.56 (s, 1H), 5.93 (m, 1H), 4.95 (m, 2H), 3.42 (d, 6.0 Hz, 2H), 2.65 (s, 3H), 2.55 (s, 3H), 2.27 (s, 3H). EI MS: 204 (M⁺, 70), 189 (100).

Step C: 2-Acetyl-3,5-dimethyl-6-(prop-2-enyl)phenyltriflate

- 20 A solution of triflic anhydride (1.10 mL, 6.54 mmol) in CH₂Cl₂ (3.8 mL) was added to a cooled (-10°C) solution of pyridine (0.58 mL, 6.54 mmol) in CH₂Cl₂ (9.6 mL). After 35 min. a solution of the intermediate obtained in Step B (0.271 g, 1.33 mmol) in CH₂Cl₂ (6.4 mL) was added and the mixture allowed to warm to room temperature. After 5 h the mixture was poured into ice water and extracted with CH₂Cl₂ (2 x 15 mL). Silica gel chromatography provided a yellow oil (0.426 g, 95%). ¹H NMR (CDCl₃, 300 MHz): δ 7.09 (s, 1H), 5.86 (m, 1H), 5.09 (d, 10.3 Hz, 1H), 4.93 (d, 17.1 Hz, 1H), 3.51 (d, 5.6 Hz, 2H), 2.52 (s, 3H), 2.34 (s, 3H), 2.30 (s, 3H).

Step D: 3,5-Dimethyl-2-acetyl-6-(prop-2-enyl)-4'-fluoro-1,1'-biphenyl

- 30 A mixture of the intermediate obtained in Step C (3.25 g, 9.68 mmol), 4-fluorophenylboronic acid (2.06 g, 14.7 mmol), Pd(PPh₃)₄ (1.13 g, 976 mmol), K₃PO₄ (4.10 g, 19.3 mmol), and KBr (1.97 g, 16.6 mmol) in 1,4-dioxane (50 mL) was heated at 85°C for 16.5 h. The mixture was poured into saturated aqueous ammonium chloride (100 mL) and extracted with diethyl ether (100 mL + 2 x 75 mL). Silica gel chromatography (95:5 hexanes/ethyl acetate) provided a yellow oil (1.03 g, 38%). ¹H NMR (CDCl₃, 300 MHz): δ 7.18 (m, 2H), 7.06 (m, 3H), 5.76 (m, 1H), 4.97 (d, 10.2 Hz, 1H), 4.72 (d, 17.0 Hz, 1H), 3.15 (d, 5.5 Hz, 2H), 2.32 (s, 3H), 2.24 (s, 3H), 1.91 (s, 3H).

0

Step E: 3,5-Dimethyl-2-acetyl-6-propyl-4'-fluoro-1,1'-biphenyl


Prepared from the intermediate obtained in Step D by the procedure described in Example 1, Step H. ^1H NMR (CDCl_3 , 300 MHz): δ 7.19 (m, 2H), 7.07 (m, 3H), 2.36 (m, 5H), 2.22 (s, 3H), 1.91 (s, 3H), 1.32 (m, 2H), 0.75 (t, 7.2 Hz, 3H).

5 FAB-MS: calculated for $\text{C}_{19}\text{H}_{21}\text{FO}$ 284; found 285 (M+H).

Step F: 3,5-Dimethyl-2-(1-hydroxyethyl)-6-propyl-4'-fluoro-1,1'-biphenyl


A mixture of the intermediate obtained in Step E (21.0 mg, 73.8 μmol) and lithium aluminum hydride (31.0 mg, 0.818 mmol) in tetrahydrofuran (2 mL) was
10 refluxed overnight. Aqueous hydrochloric acid (5%, 1 mL) was added and the mixture stirred 1h. The mixture was diluted with 5% aqueous hydrochloric acid (25 mL) and extracted with diethyl ether (3 x 15 mL). Silica gel chromatography provided the title compound as a colorless crystalline solid (15.7 mg, 74%). ^1H NMR (CDCl_3 , 300 MHz): δ 7.19-7.01 (m, 5H), 4.71 (dq, 6.7 Hz, 3.2 Hz, 1H), 2.56 (s, 3H), 2.32 (s, 3H), 2.20 (m, 2H), 1.52 (d, 3.3 Hz, 1H), 1.38 (d, 7.0 Hz, 3H), 1.28 (m, 2H),
15 0.73 (t, 7.2 Hz). EI-MS: calculated for $\text{C}_{19}\text{H}_{23}\text{FO}$ 286; found 286 (M^+ , 29), 225 (100). R_f = 0.31 (83:17 hexanes/ethyl acetate). Anal. calculated for $\text{C}_{19}\text{H}_{23}\text{FO}$: C, 79.68; H, 8.10 found: C, 79.46; H, 7.95. mp 98-99°C.

20

EXAMPLE 1963,5-Dimethyl-2-(1-hydroxyethyl)-6-(prop-2-enyl)-4'-fluoro-1,1'-biphenyl

25 The title compound was prepared from the intermediate obtained in Example 195, Step D by the procedure described in Example 195, Step F. ^1H NMR (CDCl_3 , 300 MHz): δ 7.16-7.02 (m, 5H), 5.66 (m, 1H), 4.90 (d, 10.2 Hz, 1H), 4.75-4.62 (m, 2H), 2.99 (d, 5.5 Hz, 2H), 2.57 (s, 3H), 2.28 (s, 3H), 1.50 (d, 3.7 Hz, 1H), 1.38 (d, 7.0 Hz, 3H). R_f = 0.27 (83:17 hexanes/ethyl acetate). Anal. calculated for
30 $\text{C}_{19}\text{H}_{21}\text{FO}$: C, 80.25; H, 7.44 Found: C, 80.14; H, 7.36. mp 92°C.

0

EXAMPLE 197

5

2-Isopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-pentyl-6-methyl-pyridineStep A: 2-Isopropyl-3-carboethoxy-4-(4-fluorophenyl)-5-carbomethoxy-6-methyl-1,4-dihydropyridine

10 A mixture of methyl 3-aminocrotonate (13 g, 114 mmol) and 4-carboethoxy-5-(4-fluorophenyl)-2-methylpent-4-en-2-one (30 g, 114 mmol) (prepared by the method of Angerbauer, et al. U.S. Patent 5,169,857) in absolute ethanol (300 mL) was refluxed overnight. The mixture was concentrated in vacuo and the crude product taken to the next step without purification.

15

Step B: 2-Isopropyl-3-carboethoxy-4-(4-fluorophenyl)-5-(pent-1-enyl)-6-methylpyridine

20 Prepared from the intermediate obtained in Step A by the procedures described in Example 1, Steps C-F. The olefin was obtained as a mixture of cis and trans isomers in a ratio of 34:66. ¹H NMR (300 MHz, CDCl₃): δ 7.16 (m, 2H), 7.04 (m, 2H), 6.02 (m, 1 H), 5.46 (m, 1H), 4.01 (m, 2H), 3.06 (m, 1H), 2.61 (s, 3H, major isomer), 2.50 (s, 3H, minor isomer), 1.99 (m, 1H), 1.67 (m, 1H), 1.4 - 1.15 (m, 8H), 0.98 (m, 3H), 0.79 (m, 3H).

25

Step C: 2-Isopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(pent-1-enyl)-6-methylpyridine

30 A mixture of 1.25 g (3.38 mmol) the intermediate obtained in Step B and lithium aluminum hydride (0.28 g, 6.8 mmol) in tetrahydrofuran (50 mL) was refluxed for 2.5 h. The mixture was quenched with water (10 mL) and extracted with ethyl acetate to provide a colorless crystalline solid (1.0 g, 90%). The olefin was obtained as a mixture of cis and trans isomers in a ratio of 19:81. ¹H NMR (300 MHz, CDCl₃): δ 7.10 (m, 4H), 5.88 (d, 16.2 Hz, 1 H), 5.39 (dt, 16.2 Hz, 7.0 Hz, 1H),

0 4.39 (d, 5.5 Hz, 2H), 3.44 (sept, 7.0 Hz, 1H), 2.57 (s, 3H, major isomer), 2.46 (s, 3H, minor isomer), 1.92 (m, 2H), 1.4 - 1.15 (m, 4H), 1.33 (d, 6.6 Hz, 6H), 0.75 (t, 7.4 Hz, 3H). FAB-MS: calculated for C₂₁H₂₆FNO 310; found 326 ((M-H)⁺). R_f = 0.44 (80:20 hexanes/ethyl acetate). Anal. calculated for C₂₁H₂₆FNO: C, 77.03; H, 8.00; F, 5.80; N, 4.28. Found: C, 77.02; H, 8.14; F, 5.99; N, 4.22. mp 106-108°C.


5

Step D: 2-Isopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-pentyl-6-methylpyridine

A mixture of the intermediate obtained in Step C (1.3 g) and 10% Pd/C (0.1 g) in absolute ethanol (50 mL) was stirred under an atmosphere of hydrogen overnight. The mixture was filtered through a pad of silica gel and the pad washed with ethyl acetate. Silica gel chromatography (80:20 hexanes/ethyl acetate) followed by recrystallization from ethyl acetate afforded the title compound as colorless crystals (650 mg, 50%). ¹H NMR (300 MHz, CDCl₃): δ 7.25 (s, 2H), 7.23 (s, 2H), 4.43 (d, 5.5 Hz, 2H), 3.53 (sept, 7.0 Hz, 1H), 2.69 (s, 3H), 2.35 (m, 2H), 1.44 (d, 6.6 Hz, 6H), 1.4 (m, 2H), 1.2 (m, 4H), 0.88 (t, 6.6 Hz, 3H). FAB-MS: calculated for C₂₁H₂₈FNO 310; found 328 ((M-H)⁺). R_f = 0.43 (80:20 hexanes/ethyl acetate). Anal. calculated for C₂₁H₂₈FNO: C, 76.56; H, 8.57; F, 5.77; N, 4.25. Found: C, 76.71; H, 8.60; F, 6.04; N, 4.21. mp 83-85°C.

20

EXAMPLE 198



2-Isopropyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-methylpyridine

25

Step A: 2-Isopropyl-3-carboethoxy-4-(4-fluorophenyl)-5-hydroxymethyl-6-methylpyridine

Prepared from the intermediate obtained in Example 197, Step A by the procedures described in Example 1, Steps C and D. ¹H NMR (300 MHz, CDCl₃): δ 7.25 (m, 2H), 7.09 (m, 2H), 4.44 (d, 5.1 Hz, 2H), 3.97 (q, 7.1 Hz, 2H), 3.04 (sept, 6.8

30

0 Hz, 1H), 2.71 (s, 3H), 1.53 (t, 5.2 Hz, 1H), 1.30 (d, 6.6 Hz, 6H), 0.96 (t, 7.2 Hz, 3H).
EI-MS: calculated for C₁₉H₂₂FNO₃ 331; found 331.

Step B: 2-Isopropyl-3-carboethoxy-4-(4-fluorophenyl)-5-(*t*-butyl-dimethylsiloxy)methyl-6-methylpyridine

5 A solution of the intermediate obtained in Step A (3.41 g, 10.3 mmol)
t-butyldimethylsilylchloride (1.86 g, 1.2 equiv), and imidazole (1.75 g, 2.5 equiv) in
 dimethylformamide (6 mL) was stirred overnight. The mixture was diluted with
 water and extracted with ethyl acetate. Silica gel chromatography (95:5
 hexanes/ethyl acetate) provided a colorless solid (3.5 g, 76%). ¹H NMR (300 MHz,
 10 CD₃OD): δ 7.30 (m, 2H), 7.20 (m, 2H), 4.49 (s, 2H), 4.03 (q, 7 Hz, 2H), 3.1 (sept, 1H),
 2.72 (s, 3H), 1.34 (d, 7.0 Hz, 6H), 1.01 (t, 7.0 Hz, 3H), 0.90 (s, 9H), 0.00 (s, 6H). FAB-
 MS: calculated for C₂₅H₃₆FNO₃Si 331; found 446 (M+H).

15 Step C: 2-Isopropyl-3-(pent-1-enyl)-4-(4-fluorophenyl)-5-(*t*-butyl-
dimethylsiloxy)methyl-6-methylpyridine

Prepared from the intermediate obtained in Step B by the procedures described in Example 1, Steps D, E, and F. ¹H NMR (300 MHz, CD₃OD): δ 7.2-7.0 (m, 4H), 5.99 (d, 16.2 Hz, 1H), 5.28 (dt, 15.6 Hz, 7.2 Hz, 1H), 4.30 (s, 2H), 3.38 (m, 1H), 2.67 (m, 3H), 1.92 (m, 2H), 1.4-1.2 (m, 8H), 0.85 (s, 9H), 0.75 (t, 7.4 Hz, 3H), -0.06 (s, 6H).

Step D: 2-Isopropyl-3-(pent-1-enyl)-4-(4-fluorophenyl)-5-hydroxymethyl-6-methylpyridine


25 Tetrabutylammonium fluoride (1 mL of 1.0 M solution in tetrahydrofuran,
2.5 equiv) was added to a solution of the intermediate obtained in Step C (200 mg,
0.45 mmol) in tetrahydrofuran (10 mL). After 2 h the mixture was concentrated in
vacuo. The residue was dissolved in water and extracted with ethyl acetate. Silica
gel chromatography (80:20 hexanes/ethyl acetate) provided a colorless solid (120
mg, 81%). The olefin was obtained as a mixture of cis and trans isomers in a ratio
30 of 8:92. ^1H NMR (300 MHz, CDCl_3): δ 7.09 (m, 4H), 5.96 (d, 16.2 Hz, 1 H), 5.27 (dt,
16.2 Hz, 1H), 4.38 (d, 5.5 Hz, 2H), 3.36 (sept, 1H), 2.69 (s, 3H), 1.90 (m, 2H), 1.4 - 1.1
(m, 4H), 1.25 (d, 6.6 Hz, 6H), 0.73 (t, 7.4 Hz, 3H). FAB-MS: calculated for
C₂₁H₂₆FNO 327; found 327 (M^+). R_f = 0.23 (80:20 hexanes/ethyl acetate). Anal.
calculated for C₂₁H₂₆FNO: C, 77.03; H, 8.00; F, 5.80; N, 4.28. Found: C, 76.92; H,
35 8.07; F, 5.92; N, 4.15. mp 119-120°C.

0 Step E: 2-Isopropyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-methylpyridine

The title compound was obtained as a colorless solid in 86% yield from the intermediate obtained in Step D by the procedure described in Example 1, Step H. ¹H NMR (300 MHz, CDCl₃): δ 7.2 (m, 4H), 4.29 (d, 5.5 Hz, 2H), 3.24 (sept, 6.6 Hz, 1H), 2.65 (s, 3H), 2.26 (m, 2H), 1.29 (d, 6.6 Hz, 6H), 1.25 (m, 4H), 1.1 (m, 4H), 0.76 (t, 7.0 Hz, 3H). FAB-MS: calculated for C₂₁H₂₈FNO 329; found 328 ((M-H)⁺). R_f = 0.20 (80:20 hexanes/ethyl acetate). Anal. calculated for C₂₁H₂₈FNO: C, 76.56; H, 8.57; F, 5.77; N, 4.25. Found: C, 76.49; H, 8.55; F, 5.78; N, 4.21. mp 110-112°C.

10

EXAMPLE 199



15 2-Morpholinomethyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

Step A: 2-Isopropyl-3-(*t*-butyldiphenylsiloxy)methyl-4-(4-fluorophenyl)-5-pentyl-6-methylpyridine

20 A solution of the intermediate from Example 197, Step D (50 mg, 0.15 mmol), *t*-butyldiphenylsilylchloride (50 mg, 1.2 equiv), and imidazole (25 mg, 2.5 equiv) in dimethylformamide (0.5 mL) was stirred for 2 h. The mixture was diluted with water and extracted with ethyl acetate. Silica gel chromatography (95:5 hexanes/ethyl acetate) provided a colorless solid (64 mg, 75%). ¹H NMR (300 MHz, CD₃OD): δ 7.41 (m, 6H), 7.33 (m, 4H), 7.05 (m, 4H), 4.25 (s, 2H), 3.13 (sept, 6.8 Hz, 1H), 2.57 (s, 3H), 2.23 (m, 2H), 1.3 (m, 2H), 1.17 (d, 6.6 Hz, 6H), 1.15 (m, 4H), 0.99 (s, 9H), 0.78 (t, 6.4 Hz, 3H).

Step B: 2-Isopropyl-3-(*t*-butyldiphenylsiloxy)methyl-4-(4-fluorophenyl)-5-pentyl-6-methylpyridine N-oxide

30 A mixture of the intermediate from Step A (60 mg, 0.11 mmol) and 3-

- 0 chloroperoxybenzoic acid (52 mg, 1.4 equiv) in chloroform (5 mL) was refluxed for 15 min. The mixture was diluted with ethyl acetate (30 mL) and washed with saturated aqueous sodium bicarbonate solution (3 x 25 mL). The organic phase was filtered through a shoroom temperature pad of silica gel and concentrated to give a yellow solid (54 mg, 84%). ¹H NMR (300 MHz, CDCl₃): δ 7.31 (m, 6H), 7.24 (m, 4H), 6.96 (m, 4H), 4.13 (s, 2H), 3.16 (br s, 1H), 2.47 (s, 3H), 2.18 (m, 2H), 1.33 (d, 6.6 Hz, 6H), 1.25 (m, 2H), 1.05 (m, 4H), 0.93 (s, 9H), 0.70 (t, 6.4 Hz, 3H).

Step C: 2-Chloromethyl-3-pentyl-4-(4-fluorophenyl)-5-(*t*-butyl-diphenylsiloxy)methyl-6-isopropylpyridine

- 10 Phosphorus oxychloride (9.5 g) and triethyl amine (8.6 mL) were added simultaneously to a refluxing solution of the intermediate obtained in Step B (15 g, 25.8 mmol) in CH₂Cl₂ (30 mL). After 3 h, the mixture was diluted with CH₂Cl₂ (100 mL) and washed with saturated aqueous sodium bicarbonate solution (3 x 100 mL). Silica gel chromatography (90:10 hexanes/ethyl acetate) provided a solid (9.4 g, 61%). ¹H NMR (300 MHz, CDCl₃): δ 7.41 (m, 6H), 7.32 (m, 4H), 7.06 (m, 4H), 4.75 (s, 2H), 4.27 (s, 2H), 3.15 (sept, 6.8 Hz, 1H), 2.39 (m, 2H), 1.35 (m, 2H), 1.18 (d, 6.6 Hz, 6H), 1.12 (m, 4H), 1.00 (s, 9H), 0.79 (t, 6.6 Hz, 3H).

Step D: 2-Morpholinomethyl-3-pentyl-4-(4-fluorophenyl)-5-(*t*-butyldiphenylsiloxy)methyl-6-isopropylpyridine


- 20 A mixture of the intermediate prepared in Step C (0.5 g, 0.83 mmol), morpholine (0.108 g, 1.5 equiv), and 4-dimethylaminopyridine (0.172 g, 1.7 equiv) in CH₂Cl₂ (15 mL) was refluxed for 2 h. The mixture was washed with saturated aqueous sodium chloride solution. Silica gel chromatography (90:10 hexanes/ethyl acetate) provided a yellow oil (170 mg, 30%). ¹H NMR (300 MHz, CDCl₃): δ 7.41 (m, 6H), 7.34 (m, 4H), 7.05 (m, 4H), 4.26 (s, 2H), 3.71 (m, 4H), 3.67 (s, 2H), 3.13 (sept, 6.8 Hz, 1H), 2.61 (m, 4H), 2.35 (m, 2H), 1.15 (d, 6.6 Hz, 6H), 1.1 (m, 4H), 0.99 (s, 9H), 0.9 (m, 2H), 0.78 (t, 7.0 Hz, 3H).

Step E: 2-Morpholinomethyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

- 30 The title compound was prepared from the intermediate obtained in Step D by the procedure described in Example 198, Step D. ¹H NMR (300 MHz, CDCl₃): δ 7.17 (m, 4H), 4.36 (d, 5.1 Hz, 2H), 3.68 (m, 6H), 3.42 (sept, 6.6 Hz, 1H), 2.59 (m, 4H), 2.39 (m, 2H), 1.32 (d, 6.6 Hz, 6H), 1.25 (m, 2H), 1.1 (m, 4H), 0.78 (t, 6.6 Hz, 3H). FAB-MS: calculated for C₂₅H₃₅FN₂O₂ 414; found 415 (M+H). Anal. calculated for

- 0 C₂₅H₃₅FN₂O₂: C, 72.43; H, 8.51; F, 4.58; N, 6.76. Found: C, 72.49; H, 8.42; F, 4.71; N, 7.05.

EXAMPLE 200



2,5-Bis(hydroxymethyl)-3-pentyl-4-(4-fluorophenyl)-6-isopropylpyridine

Step A: 2-Acetoxymethyl-3-pentyl-4-(4-fluorophenyl)-5-(*t*-butyl-diphenylsiloxy)methyl-6-isopropylpyridine

A mixture of the intermediate obtained in Example 199, Step B (4.8 g, 7.97 mmol) and acetic anhydride (20 mL) was heated to 100°C for 20 min. The mixture was poured onto ice and the aqueous phase extracted with ethyl acetate (3 x 30 mL). The combined organic phase was washed with saturated aqueous sodium bicarbonate solution (3 x 50 mL), and saturated aqueous sodium chloride solution (3 x 50 mL). Silica gel chromatography provided a yellow oil (4.4 g, 90%). ¹H NMR (300 MHz, CDCl₃): δ 7.40 (m, 6H), 7.31 (m, 4H), 7.06 (m, 4H), 5.29 (s, 2H), 4.26 (s, 2H), 3.14 (sept, 6.8 Hz, 1H), 2.2 (m, 2H), 2.18 (s, 3H), 1.2 (m, 2H), 1.16 (d, 6.6 Hz, 6H), 1.05 (m, 4H), 0.99 (s, 9H), 0.77 (t, 6.8 Hz, 3H).

Step B: 2-Hydroxymethyl-3-pentyl-4-(4-fluorophenyl)-5-(*t*-butyl-diphenylsiloxy)methyl-6-isopropylpyridine

A mixture of the intermediate obtained in Step A (60 mg, 0.096 mmol) and potassium carbonate (5 equiv) in methanol (8 mL) and water (2 mL) was refluxed for 1.5 h. The mixture was diluted with ethyl acetate and washed with saturated aqueous sodium chloride solution. Concentration of the organic phase provided a colorless solid (60 mg, 100%) that was used in the next step without purification. ¹H NMR (300 MHz, CDCl₃): δ 7.4-7.2 (m, 10H), 7.11 (m, 4H), 4.90 (s, 2H), 4.39 (s, 2H), 3.34 (sept, 7.0 Hz, 1H), 2.34 (m, 2H), 1.25 (d, 7.0 Hz, 6H), 1.2 (m, 2H), 1.04 (m, 4H), 0.90 (s, 9H), 0.68 (t, 7.0 Hz, 3H).


0

Step C: 2,5-Bis(hydroxymethyl)-3-pentyl-4-(4-fluorophenyl)-6-isopropylpyridine

The title compound was prepared from the intermediate obtained in Step B by the procedure described in Example 198, Step D. ¹H NMR (300 MHz, CD₃OD):
 5 δ 7.21 (m, 4H), 4.70 (s, 2H), 4.30 (s, 2H), 3.54 (sept, 6.6 Hz, 1H), 2.28 (m, 2H), 1.32 (d, 6.6 Hz, 6H), 1.25 (m, 2H), 1.1 (m, 4H), 0.75 (t, 6.8 Hz, 3H). FAB-MS: calculated for C₂₁H₂₈FNO₂ 345; found 346 (M+H). Anal. calculated for C₂₁H₂₈FNO₂: C, 73.01; H, 8.17; F, 5.50; N, 4.05. Found: C, 72.89; H, 8.25; F, 5.21; N, 4.41. mp 135-136°C.

10

EXAMPLE 201



2-Methoxymethyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

15

Step A: 2-Methoxymethyl-3-pentyl-4-(4-fluorophenyl)-5-(*t*-butyl-diphenylsiloxy)methyl-6-isopropylpyridine


A mixture of the intermediate obtained in Example 200, Step B (0.1 g, 0.17 mmol), methyl iodide (0.013 mL, 1.2 equiv), and sodium hydride (8 mg of a 60% dispersion in mineral oil, 1.2 equiv) in tetrahydrofuran (1 mL) was heated at 40°C
 20 for 3 h. The mixture was diluted with water and extracted with ethyl acetate (3 x 10 mL). The combined organic phase was washed with saturated aqueous sodium chloride solution (3 x 10 mL). Silica gel chromatography provided a colorless solid
 25 (40 mg, 40%). ¹H NMR (300 MHz, CDCl₃): δ 7.41 (m, 6H), 7.32 (m, 4H), 7.06 (m, 4H), 4.62 (s, 2H), 4.27 (s, 2H), 3.48 (s, 3H), 3.15 (sept, 6.6 Hz, 1H), 2.36 (m, 2H), 1.27 (m, 2H), 1.18 (d, 6.6 Hz, 6H), 1.12 (m, 2H), 1.00 (s, 9H), 0.87 (m, 2H), 0.78 (t, 6.6 Hz, 3H).

30

0 Step B: 2-Methoxymethyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-
 isopropylpyridine

The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 198, Step D. ¹H NMR (300 MHz, CDCl₃): δ 7.14 (m, 4H), 4.62 (s, 2H), 4.36 (d, 5.2 Hz, 2H), 3.46 (s, 3H), 3.44 (sept, 6.6 Hz, 1H),
 5 2.38 (m, 2H), 1.34 (d, 7.0 Hz, 6H), 1.23 (m, 2H), 1.12 (m, 4H), 0.77 (t, 6.8 Hz, 3H). FAB-MS: calculated for C₂₂H₃₀FNO₂ 359; found 360 (M+H). Anal. calculated for C₂₂H₃₀FNO₂: C, 73.51; H, 8.41; F, 5.28; N, 3.90. Found: C, 73.40; H, 8.47; F, 5.19; N, 3.91.

EXAMPLE 202




10

2-Ethoxymethyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

The title compound was prepared from the intermediate obtained in
 15 Example 200, Step B by the procedures described in Example 201, Step A, and Example 198, Step D. ¹H NMR (300 MHz, CDCl₃): δ 7.18 (m, 4H), 4.68 (s, 2H), 4.35 (d, 4.4 Hz, 2H), 3.65 (q, 7.0 Hz, 2H), 3.44 (sept, 6.6 Hz, 1H), 2.40 (m, 2H), 1.4 (m, 2H), 1.34 (d, 6.6 Hz, 6H), 1.26 (t, 7.0 Hz, 3H), 1.13 (m, 4H), 0.78 (t, 6.6 Hz, 3H). FAB-MS: calculated for C₂₃H₃₂FNO₂ 373; found 374 (M+H). Anal. calculated for
 20 C₂₃H₃₂FNO₂: C, 73.96; H, 8.64; F, 5.09; N, 3.75. Found: C, 73.97; H, 8.83; F, 5.33; N, 3.52.

EXAMPLE 203




0

2-(Prop-2-enyloxy)methyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

The title compound was prepared from the intermediate obtained in Example 200, Step B by the procedures described in Example 201, Step A, and Example 198, Step D. ¹H NMR (300 MHz, CDCl₃): δ 7.15 (m, 4H), 5.97 (ddt, 17.1 Hz, 10.5 Hz, 6 Hz, 2H), 5.33 (d, 17.3 Hz, 1H), 5.21 (d, 10.3 Hz, 1H), 4.68 (s, 2H), 4.34 (s, 2H), 4.12 (d, 5.5 Hz, 2H), 3.44 (sept, 6.8 Hz, 1H), 2.39 (m, 2H), 1.33 (d, 6.6 Hz, 6H), 1.29 (m, 2H), 1.10 (m, 4H), 0.77 (t, 6.8 Hz, 3H). FAB-MS: calculated for C₂₄H₃₂FNO₂ 385; found 386 (M+H). Anal. calculated for C₂₄H₃₂FNO₂: C, 74.8; H, 8.37; F, 4.93; N, 3.63. Found: C, 75.2; H, 8.54; F, 4.90; N, 3.52.

EXAMPLE 204




15

2-Benxyloxymethyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

The title compound was prepared from the intermediate obtained in Example 200, Step B by the procedures described in Example 201, Step A, and Example 198, Step D. ¹H NMR (300 MHz, CDCl₃): δ 7.43-7.30 (m, 5H), 7.17 (m, 4H), 4.73 (s, 2H), 4.66 (s, 2H), 4.36 (s, 2H), 3.46 (sept, 6.6 Hz, 1H), 2.38 (m, 2H), 1.36 (d, 6.6 Hz, 6H), 1.25 (m, 2H), 1.05 (m, 4H), 0.75 (t, 6.6 Hz, 3H). FAB-MS: calculated for C₂₄H₃₂FNO₂ 435; found 436 (M+H). Anal. calculated for C₂₈H₃₄FNO₂: C, 77.21; H, 7.87; F, 4.36; N, 3.22. Found: C, 77.26; H, 7.84; F, 4.42; N, 3.11. mp 110-112°C.

30

0

EXAMPLE 205

5

2-(1-Hydroxybut-3-enyl)-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

Step A: 2-Formyl-3-pentyl-4-(4-fluorophenyl)-5-(*t*-butyldiphenylsiloxy)methyl-6-isopropylpyridine

10

Prepared from 2-hydroxymethyl-3-pentyl-4-(4-fluorophenyl)-5-[(*t*-butyldiphenylsiloxy)methyl]-6-isopropylpyridine (Example 200, Step B) by the procedure described in Example 1, Step E. ^1H NMR (300 MHz, CDCl_3): δ 10.20 (s, 1H), 7.41 (m, 6H), 7.33 (m, 4H), 7.04 (m, 4H), 4.33 (s, 2H), 3.23 (sept, 6.6 Hz, 1H), 2.66 (m, 2H), 1.3-1.1 (m, 6H), 1.22 (d, 6.6 Hz, 6H), 1.01 (s, 9H), 0.79 (t, 7.0 Hz, 3H). FAB-MS: calculated for $\text{C}_{37}\text{H}_{44}\text{FNO}_2\text{Si}$ 581; found 582 ($\text{M}+\text{H}$).

15

Step B: 2-(1-Hydroxybut-3-enyl)-3-pentyl-4-(4-fluorophenyl)-5-(*t*-butyldiphenylsiloxy)methyl-6-isopropylpyridine

20

A mixture of the intermediate obtained in Step A (0.2 g, 0.34 mmol) and allylmagnesium bromide (1 mL of 1.0 M solution in tetrahydrofuran, 3 equiv) in tetrahydrofuran (10 mL) was refluxed for 1.5 h. The mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate and washed with saturated aqueous sodium chloride solution. Silica gel chromatography (97:3 hexanes/ethyl acetate) provided a yellow oil (110 mg, 52%). ^1H NMR (300 MHz, CDCl_3): δ 7.42 (m, 6H), 7.2 (m, 4H), 7.06 (m, 4H), 5.94 (m, 1H), 5.14-5.08 (m, 2H), 4.99-4.90 (m, 2H), 4.28 (d, 2.2 Hz, 2H), 3.16 (sept, 6.8 Hz, 1H), 2.55 (m, 1H), 2.45-2.15 (m, 3H), 1.3 (m, 2H), 1.20 (d, 6.6 Hz, 3H), 1.15 (d, 6.6 Hz, 3H), 1.1 (m, 4H), 0.76 (t, 6.6 Hz, 3H).


25

Step C: 2-(1-Hydroxybut-3-enyl)-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

30

The title compound was prepared from the intermediate obtained in Step B by the procedure described in Example 198, Step D. ^1H NMR (300 MHz, CDCl_3): δ

- 0 7.16 (m, 4H), 5.94 (m, 1H), 5.13 (d, 7.7 Hz, 1H), 5.08 (s, 1H), 4.92 (s, 2H), 4.38 (m, 2H), 3.47 (sept, 6.7 Hz, 1H), 2.51 (m, 1H), 2.4-2.1 (m, 3H), 1.35 (d, 6.6 Hz, 3H), 1.34 (d, 6.6 Hz, 3H), 1.29 (m, 2H), 1.10 (m, 4H), 0.77 (t, 6.6 Hz, 3H). FAB-MS: calculated for $C_{24}H_{32}FNO_2$ 385; found 386 (M+H). R_f = 0.15 (85:15 hexanes/ethyl acetate). Anal. calculated for $C_{24}H_{32}FNO_2$: C, 74.77; H, 8.37; F, 4.93; N, 3.63. Found: C, 74.85; H, 8.53; F, 4.99; N, 3.50.
- 5


EXAMPLE 206

10 2-(1-Hydroxyprop-2-enyl)-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

Prepared from the intermediate in Example 205, Step A by the procedures described in Example 205, Step B, and Example 198, Step D. 1H NMR (300 MHz, $CDCl_3$): δ 7.16 (m, 4H), 5.89 (δ , 17.0 Hz, 10.0 Hz, 7.1 Hz, 1H), 5.66 (d, 5.5 Hz, 1H),

- 15 5.37 (d, 16.9 Hz, 1H), 5.26 (t, 5.7 Hz, 1H), 5.20 (d, 9.9 Hz, 1H), 4.38 (d, 4.8 Hz, 2H), 3.49 (sept, 6.7 Hz, 1H), 2.33 (m, 1H), 2.13 (m, 2H), 1.35 (d, 6.6 Hz, 3H), 1.34 (d, 6.6 Hz, 3H), 1.2 (m, 2H), 1.10 (m, 4H), 0.76 (t, 6.8 Hz, 3H). FAB-MS: calculated for $C_{23}H_{30}FNO_2$ 371; found 372 (M+H). R_f = 0.15 (85:15 hexanes/ethyl acetate). MP = 113-115°C. Anal. calculated for $C_{23}H_{30}FNO_2$: C, 74.36; H, 8.14; F, 5.11; N, 3.77.

- 20 Found: C, 74.16; H, 8.28; F, 5.11; N, 3.60.

EXAMPLE 207


0

2-(Hydroxy-*p*-tolyl)methyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine, hydrochloride

Prepared from the intermediate in Example 205, Step A by the procedures described in Example 205, Step B, and Example 198, Step D. ¹H NMR (CD₃OD, 300 MHz): δ 7.28 (m, 6H), 7.21 (m, 2H), 6.90 (d, 7.7 Hz, 1H), 6.43 (s, 1H), 4.48 (d, 11.8 Hz, 1H), 4.41 (d, 11.8 Hz, 1H), 3.96 (sept, 6.8 Hz, 1H), 2.46 (s, 3H), 2.19 (m, 2H), 1.61 (d, 7.0 Hz, 3H), 1.58 (d, 7.0 Hz, 3H), 1.0-0.6 (m, 5H), 0.57 (t, 7.0 Hz, 3H), 0.3 (m, 1H). FAB-MS: calculated for C₂₈H₃₄FNO₂ 435; found 436 (M+H). Anal. calculated for C₂₈H₃₄FNO₂·HCl: C, 71.25; H, 7.47; Cl, 7.51; F, 4.02; N, 2.97. Found: C, 71.43; H, 7.49; Cl, 7.48; F, 4.10; N, 2.87. mp 178-180°C.

10

EXAMPLE 208



15

2-(a-Hydroxy)benzyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine


Prepared from the intermediate in Example 205, Step A by the procedures described in Example 205, Step B, and Example 198, Step D. ¹H NMR (CDCl₃, 300 MHz): δ 7.30 (m, 5H), 7.17 (m, 4H), 6.43 (d, 6.6 Hz, 1H), 5.79 (d, 6.6 Hz, 1H), 4.40 (m, 2H), 3.55 (sept, 6.6 Hz, 1H), 2.21-2.09 (m, 2H), 1.45 (d, 6.6 Hz, 3H), 1.43 (d, 6.6 Hz, 3H), 1.32 (m, 1H), 1.14-0.88 (m, 6H), 0.69 (t, 3H). FAB-MS: calculated for C₂₇H₃₂FNO₂ 421; found 422 (M+H). R_f = 0.10 (85:15 hexanes/ethyl acetate). Anal. calculated for C₂₇H₃₂FNO₂: C, 76.93; H, 7.65; F, 4.51; N, 3.32. Found: C, 76.70; H, 7.86; F, 4.45; N, 3.14.

20

25

30

0

EXAMPLE 209


5

2-(4-Fluorophenyl)hydroxymethyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

10

Prepared from the intermediate in Example 205, Step A by the procedures described in Example 205, Step B, and Example 198, Step D. ^1H NMR (CDCl_3 , 300 MHz): δ 7.24 (m, 2H), 7.15 (m, 4H), 6.98 (m, 2H), 6.40 (d, 5.9 Hz, 1H), 5.77 (d, 5.5 Hz, 1H), 4.40 (m, 2H), 3.55 (sept, 6.6 Hz, 1H), 2.13 (m, 2H), 1.43 (d, 6.3 Hz, 3H), 1.41 (d, 6.6 Hz, 3H), 1.08 (m, 1H), 0.99 (m, 6H), 0.69 (t, 6.6 Hz, 3H). FAB-MS: calculated for $\text{C}_{27}\text{H}_{31}\text{F}_2\text{NO}_2$ 439; found 440 ($\text{M}+\text{H}$). R_f = 0.15 (85:15 hexanes/ethyl acetate). Anal. calculated for $\text{C}_{27}\text{H}_{31}\text{F}_2\text{NO}_2$: C, 73.78; H, 7.11; F, 8.64; N, 3.19. Found: C, 73.49; H, 7.23; F, 8.45; N, 3.01.

15

EXAMPLE 210

20

2-(1-Hydroxyethyl)-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

Step A: 2-(1-Hydroxyethyl)-3-pentyl-4-(4-fluorophenyl)-5-(*t*-butyldiphenysiloxy)methyl-6-isopropylpyridine

0 Prepared from the intermediate in Example 205, Step A by the procedure described in Example 205, Step B. ^1H NMR (300 MHz, CDCl_3): δ 7.42 (m, 6H), 7.32 (m, 4H), 7.05 (m, 4H), 5.16 (d, 7.7 Hz, 1H), 4.99 (m, 1H), 4.28 (s, 2H), 3.16 (sept, 6.8 Hz, 1H), 2.25 (m, 2H), 1.45 (d, 6.3 Hz, 2H), 1.19 (d, 6.6 Hz, 3H), 1.16 (d, 6.6 Hz, 3H), 1.10 (m, 6H), 0.76 (t, 6.8 Hz, 3H).


5

Step B: 2-(1-Hydroxyethyl)-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

The title compound was prepared from the intermediate in Step A by the procedure described in Example 198, Step D. ^1H NMR (CDCl_3 , 300 MHz): δ 7.19-7.15 (m, 4H), 5.12 (d, 7.0 Hz, 1H), 4.99 (t, 1H), 4.38 (d, 5.5 Hz, 2H), 3.48 (sept, 6.8 Hz, 1H), 2.27 (m, 2H), 1.43 (d, 6.3 Hz, 1H), 1.35 (d, 6.6 Hz, 6H), 1.30 (m, 2H), 1.09 (m, 7H), 0.76 (t, 6.6 Hz, 3H). FAB-MS: calculated for $\text{C}_{22}\text{H}_{30}\text{FNO}_2$ 359; found 360 (M+H). R_f = 0.15 (85:15 hexanes/ethyl acetate). Anal. calculated for $\text{C}_{22}\text{H}_{30}\text{FNO}_2$: C, 73.51; H, 8.41; F, 5.28; N, 3.90. Found: C, 73.24; H, 8.40; F, 5.41; N, 3.85. mp 125-127°C.

15

EXAMPLE 211




20

2-(1-Hydroxybutyl)-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

Prepared from the compound obtained in Example 205 by the procedure described in Example 1, Step H. ^1H NMR (300 MHz, CDCl_3): δ 7.17 (m, 4H), 4.92 (br s, 2H), 4.85 (br s, 2H), 4.37 (d, 5.2 Hz, 2H), 3.47 (sept, 6.6 Hz, 1H), 2.29-2.23 (m, 2H), 1.62-1.53 (m, 5H), 1.35 (d, 6.6 Hz, 3H), 1.34 (d, 6.6 Hz, 3H), 1.3 (m, 1H), 1.11 (m, 5H), 0.94 (t, 7.0 Hz, 3H), 0.77 (t, 6.4 Hz, 3H). FAB-MS: calculated for $\text{C}_{24}\text{H}_{34}\text{FNO}_2$ 387; found 388 (M+H). Anal. calculated for $\text{C}_{24}\text{H}_{34}\text{FNO}_2$: C, 74.38; H, 8.84; F, 4.90; N, 3.61. Found: C, 74.11; H, 8.93; F, 4.96; N, 3.51.

30


0

EXAMPLE 212

5 2-(1-Hydroxypropyl)-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-
isopropylpyridine

The title compound was prepared from the intermediate obtained in Example 206 by the procedure described in Example 1, Step H. ¹H NMR (300 MHz, CDCl₃): δ 7.18 (m, 4H), 4.94 (br s, 1H), 4.82 (br s, 1H), 4.39 (d, 4.8 Hz, 2H), 3.48 (sept, 6.6 Hz, 1H), 2.3-2.1 (m, 2H), 1.82 (m, 1H), 1.36 (d, 5.5 Hz, 3H), 1.34 (d, 6.3 Hz, 3H), 1.11 (m, 8H), 1.02 (t, 7.4 Hz, 3H), 0.78 (t, 6.6 Hz, 3H). FAB-MS: calculated for C₂₃H₃₂FNO₂ 373; found 374 (M+H). R_f = 0.15 (85:15 hexanes/ethyl acetate). Anal. calculated for C₂₃H₃₂FNO₂: C, 73.96; H, 8.64; F, 5.09; N, 3.75. Found: C, 73.88; H, 8.57; F, 5.17; N, 3.53. mp 89-90°C.

15

EXAMPLE 213

20 2-N-(2-Methoxyphenyl)aminomethyl-3-pentyl-4-(4-fluorophenyl)-5-
hydroxymethyl-6-isopropylpyridine


Step A: 2-N-(2-Methoxyphenyl)aminomethyl-3-pentyl-4-(4-fluorophenyl)-5-
(*t*-butyldiphenysiloxy)methyl-6-isopropylpyridine

0 A mixture of the intermediate from Example 205, Step A (60 mg, 0.10 mmol) and *m*-anisidine (50 mg, 4 equiv) in methanol (10 mL) was treated with a mixture of zinc chloride (7 mg, 0.5 equiv) and sodium cyanoborohydride (6 mg, 1 equiv) in methanol (15 mL). After stirring at room temperature overnight the mixture was
 5 organic phase was washed with saturated aqueous sodium chloride solution (3 x 15 mL). Silica gel chromatography provided a colorless solid (70 mg, 99%). ¹H NMR (300 MHz, CDCl₃): δ 7.43 (m, 6H), 7.32 (m, 4H), 7.16 (m, 1H), 7.06 (m, 4H), 6.43 (m, 1H), 6.32 (m, 2H), 5.98 (br s, 1H), 4.38 (s, 2H), 4.29 (s, 2H), 3.83 (s, 3H), 3.19 (sept, 6.6 Hz, 1H), 2.28 (m, 2H), 1.25 (m, 2H), 1.22 (d, 6.6 Hz, 6H), 1.14 (m, 2H), 0.99 (s, 9H),
 10 0.80 (t, 6.8 Hz, 3H).

Step B: 2-N-(2-Methoxyphenyl)aminomethyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

15 The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 198, Step D. ¹H NMR (300 MHz, CDCl₃): δ 7.16 (m, 5H), 6.43 (m, 1H), 6.32 (m, 2H), 4.40 (s, 2H), 4.39 (s, 2H), 3.83 (s, 3H), 3.50 (sept, 6.6 Hz, 1H), 2.32 (m, 2H), 1.39 (d, 6.6 Hz, 6H), 1.31 (m, 2H), 1.16 (m, 4H), 0.80 (t, 6.4 Hz, 3H). FAB-MS: calculated for C₂₈H₃₅FN₂O₂ 450; found 451 (M+H). Anal. calculated for C₂₈H₃₅FN₂O₂: C, 74.64; H, 7.83; N, 6.22. Found: C, 74.44; H, 7.75;
 20 N, 6.03. mp 109-110°C.

EXAMPLE 214



2-Ethenyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

Step A: 2-Ethenyl-3-pentyl-4-(4-fluorophenyl)-5-(*t*-butyldiphenylsiloxy)methyl-6-isopropylpyridine


30 *n*-Butyl lithium (0.03 mL of 1.6 M solution in hexanes) was added to a cooled

0 (0°C) solution of methyltriphenylphosphonium bromide (18 mg) in tetrahydrofuran (3 mL). After 2 h, a solution of 2-formyl-3-pentyl-4-(4-fluorophenyl)-5-(*t*-butyldiphenylsiloxy)methyl-6-isopropylpyridine (Example 205, Step A) in tetrahydrofuran (1 mL) was added and the mixture warmed to room temperature. After 30 min. the mixture was quenched with water and extracted with ethyl acetate. Silica gel chromatography (95:5 hexanes/ethyl acetate) afforded a colorless solid (20 mg). ¹H NMR (CDCl₃, 300 MHz): δ 7.44-7.36 (m, 6H), 7.34-7.27 (m, 4H), 7.08-6.98 (m, 5H), 6.59 (dd, 16.7 Hz, 2.7 Hz, 1H), 5.48 (dd, 10.5 Hz, 2.8 Hz, 1H), 4.26 (s, 2H), 3.16 (sept, 6.6 Hz, 1H), 2.29 (m, 2H), 1.4-1.2 (m, 2H), 1.19 (d, 6.6 Hz, 6H), 1.15 (m, 4H), 0.98 (s, 9H), 0.78 (t, 6.8 Hz, 3H).

10 Step B: 2-Ethenyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 198, Step D. ¹H NMR (CDCl₃, 300 MHz): δ 7.17 (s, 2H), 7.14 (s, 2H), 7.04 (dd, 16.7 Hz, 10.5 Hz, 1H), 6.61 (dd, 16.7 Hz, 2.8 Hz, 1H), 5.51 (dd, 10.5 Hz, 2.8 Hz, 1H), 4.36 (s, 2H), 3.45 (sept, 6.7 Hz, 1H), 2.32 (m, 2H), 1.37 (d, 6.6 Hz, 6H), 1.34 (m, 2H), 1.15 (m, 4H), 0.80 (t, 6.6 Hz, 3H). FAB-MS: calculated for C₂₂H₂₈FNO 341; found 342 (M+H). Anal. calculated for C₂₂H₂₈FNO: C, 77.38; H, 8.27; N, 4.10. Found: C, 77.15; H, 7.98; N, 4.06.

20 EXAMPLE 215



25 2-(2-Carbomethoxyethenyl)-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

Step A: 2-(2-Carbomethoxyethenyl)-3-pentyl-4-(4-fluorophenyl)-5-(*t*-butyldiphenylsiloxy)methyl-6-isopropylpyridine


30 A mixture of the intermediate obtained in Example 205, Step A (50 mg, 85

0 mmol) and methyl (triphenylphosphoranylidene)acetate (31 mg, 1.1 equiv) in toluene (5 mL) was heated to reflux for 5 h. The mixture was cooled to rt and concentrated in vacuo. Silica gel chromatography provided a yellow oil (60 mg). ¹H NMR (CDCl₃, 300 MHz): δ 7.96 (d, 15.1 Hz, 1H), 7.42 (m, 6H), 7.34-7.21 (m, 5H), 7.05 (s, 2H), 7.03 (s, 2H), 4.28 (s, 2H), 3.84 (s, 3H), 3.17 (sept, 6.8 Hz, 1H), 2.38 (m, 5
2H), 1.31 (m, 2H), 1.19 (d, 6.6 Hz, 6H), 1.14 (m, 4H), 1.00 (s, 9H), 0.79 (t, 6.6 Hz, 3H).

Step B: 2-(2-Carbomethoxyethenyl)-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

The title compound was prepared from the intermediate obtained in Step A
10 by the procedure described in Example 198, Step D. ¹H NMR (CDCl₃, 300 MHz): δ 7.95 (d, 15.1 Hz, 1H), 7.25 (d, 15.1 Hz, 1H), 7.17 (s, 2H), 7.15 (s, 2H), 4.37 (d, 3.7 Hz, 2H), 3.84 (s, 3H), 3.45 (sept, 6.6 Hz, 1H), 2.40 (m, 2H), 1.35 (d, 6.6 Hz, 6H), 1.3 (m, 4H), 1.14 (m, 4H), 1.00 (s, 9H), 0.79 (t, 6.6 Hz, 3H). EI-MS: calculated for C₂₄H₃₀FNO₃ 399; found 399 (M⁺). Anal. calculated for C₂₄H₃₀FNO₃: C, 72.16; H,
15 7.57; N, 3.51. Found: C, 71.79; H, 7.50; N, 3.32. mp 82-83°C.


EXAMPLE 216



2-(1-Methoxyethyl)-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine


The title compound was prepared from the intermediate obtained in Example 210, Step A by the procedures described in Example 201, Step A, and
25 Example 198, Step D. ¹H NMR (CDCl₃, 300 MHz): δ 7.15 (m, 4H), 4.75 (q, 6.3 Hz, 1H), 4.35 (d, 3.7 Hz, 2H), 3.44 (sept, 6.4 Hz, 1H), 3.31 (s, 3H), 2.4-2.2 (m, 2H), 1.58 (d, 6.3 Hz, 3H), 1.35 (d, 6.3 Hz, 3H), 1.34 (d, 6.6 Hz, 3H), 1.27 (m, 2H), 1.11 (m, 4H), 0.78 (t, 6.6 Hz, 3H). FAB-MS: calculated for C₂₃H₃₂FNO₂ 373; found 374 (M+H). Anal. calculated for C₂₃H₃₂FNO₂: C, 73.96; H, 8.64; F, 5.09; N, 3.75. Found: C, 73.92; H,
30 8.75; F, 4.93; N, 3.60.

0

EXAMPLE 217

5 2-(1-Ethoxyethyl)-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-
isopropylpyridine

The title compound was prepared from the intermediate obtained in
 Example 210, Step A by the procedures described in Example 201, Step A, and
 10 Example 198, Step D. ¹H NMR (CDCl₃, 300 MHz): δ 7.16 (m, 4H), 4.83 (q, 6.5 Hz,
 1H), 4.34 (d, 4.4 Hz, 2H), 3.5-3.2 (m, 3H), 2.4-2.2 (m, 2H), 1.57 (d, 6.6 Hz, 3H), 1.34
 (d, 6.6 Hz, 3H), 1.33 (d, 6.6 Hz, 3H), 1.27 (m 2H), 1.10 (m, 4H), 1.20 (t, 7.2 Hz, 3H),
 0.77 (t, 6.8 Hz, 3H). FAB-MS: calculated for C₂₄H₃₄FNO₂ 387; found 388 (M+H).
 Anal. calculated for C₂₄H₃₄FNO₂: C, 74.38; H, 8.84; F, 4.90; N, 3.61. Found: C,
 15 74.67; H, 9.00; F, 5.14; N, 3.27.

EXAMPLE 218

20 2-Acetyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine


Step A: 2-Acetyl-3-pentyl-4-(4-fluorophenyl)-5-(*t*-butyldiphenylsiloxy)methyl-
6-isopropylpyridine

0 A mixture of the intermediate obtained in Example 210, Step A (210 mg, 0.35 mmol), pyridinium chlorochromate (113 mg, 1.5 equiv), and Celite (110 mg) in CH₂Cl₂ (13 mL) was stirred overnight. The mixture was filtered through a short pad of silica gel. Silica gel chromatography (95:5 hexanes/ethyl acetate) afforded a colorless solid (120 mg, 57%). ¹H NMR (CDCl₃, 300 MHz): δ 7.41 (m, 6H), 7.34 (m, 4H), 7.06 (s, 2H), 7.03 (s, 2H), 4.29 (s, 2H), 3.18 (sept, 6.6 Hz, 1H), 2.75 (s, 3H), 2.54 (m, 2H), 1.3 (m, 2H), 1.19 (d, 6.6 Hz, 6H), 1.15 (m, 4H), 1.00 (s, 9H), 0.77 (m, 3H).

Step B: 2-Acetyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

10 The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 198, Step D. ¹H NMR (CDCl₃, 300 MHz): δ 7.17 (s, 2H), 7.15 (s, 2H), 4.39 (d, 5.2 Hz, 2H), 3.48 (sept, 6.8 Hz, 3H), 2.74 (s, 3H), 2.55 (m, 2H), 1.35 (d, 6.6 Hz, 6H), 1.3 (m, 2H), 1.1 (m, 4H), 0.77 (t, 6.6 Hz, 3H). FAB-MS: calculated for C₂₂H₂₈FNO₂ 357; found 358 (M+H). Anal. calculated for C₂₂H₂₈FNO₂: C, 73.92; H, 7.90; N, 3.92. Found: C, 73.89; H, 8.14; N, 3.88. mp 69-70°C.

EXAMPLE 219



20

2-(1-Hydroxy-1-methylethyl)-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

Step A: 2-(1-Hydroxy-1-methylethyl)-3-pentyl-4-(4-fluorophenyl)-5-(*t*-butyldiphenylsiloxy)methyl-6-isopropylpyridine

25


Prepared from the intermediate obtained in Example 218, Step A by the procedure described in Example 205, Step B. ¹H NMR (CDCl₃, 300 MHz): δ 7.41 (m, 6H), 7.32 (m, 4H), 7.08 (m, 4H), 4.25 (s, 2H), 3.13 (sept, 6.8 Hz, 1H), 2.44 (m, 2H), 1.62 (s, 6H), 1.2 (m, 2H), 1.17 (d, 6.6 Hz, 6H), 1.03 (m, 4H), 1.01 (s, 9H), 0.72 (t, 6.8 Hz, 3H).

30

0
Step B: 2-(1-Hydroxy-1-methylethyl)-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

The title compound was prepared from the intermediate obtained in Step A by the procedure described in Example 198, Step D. ¹H NMR (CDCl₃, 300 MHz): δ 7.19 (m, 4H), 4.36 (d, 5.5 Hz, 2H), 3.48 (sept, 6.6 Hz, 1H), 2.47 (m, 2H), 1.60 (s, 6H), 1.35 (d, 6.6 Hz, 6H), 1.25 (m, 2H), 1.05 (m, 4H), 0.72 (t, 6.6 Hz, 3H). FAB-MS: calculated for C₂₃H₃₂FNO₂ 373; found 374 (M+H). Anal. calculated for C₂₃H₃₂FNO₂: C, 73.96; H, 8.63; F, 5.09; N, 3.75. Found: C, 73.88; H, 8.64; F, 4.81; N, 3.59. mp 180-182°C.


10
EXAMPLE 220



15
2-(1-Methoxy-1-methyl)ethyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

The title compound was prepared from the intermediate obtained in Example 219, Step A by the procedures described in Example 201, Step A, and Example 198, Step D. ¹H NMR (CDCl₃, 300 MHz): δ 7.26-7.12 (m, 4H), 4.34 (d, 5.5 Hz, 2H), 3.40 (sept, 6.5 Hz, 1H), 3.12 (s, 3H), 2.76 (m, 2H), 1.67 (s, 6H), 1.31 (d, 6.6 Hz, 6H), 1.3-0.9 (m, 6H), 0.72 (t, 6.8 Hz, 3H). FAB-MS: calculated for C₂₄H₃₄FNO₂ 387; found 388 (M+H). Anal. calculated for C₂₄H₃₄FNO₂: C, 74.38; H, 8.84; N, 3.61. Found: C, 74.64; H, 8.97; N, 3.61. mp 57-59°C.

0

EXAMPLE 221


5

2-(1-Ethoxy-1-methyl)ethyl-3-pentyl-4-(4-fluorophenyl)-5-hydroxymethyl-6-isopropylpyridine

10

The title compound was prepared from the intermediate obtained in Example 219, Step A by the procedures described in Example 201, Step A, and Example 198, Step D. ^1H NMR (CDCl_3 , 300 MHz): δ 7.23-7.11 (m, 4H), 4.33 (d, 5.1 Hz, 2H), 3.39 (sept, 6.6 Hz, 1H), 3.28 (q, 7.0 Hz, 2H), 2.80 (m, 2H), 1.67 (s, 6H), 1.30 (d, 6.6 Hz, 6H), 1.15 (t, 7.0 Hz, 3 H), 1.15-0.9 (m, 6H), 0.71 (t, 6.6 Hz, 3H). FAB-MS: calculated for $\text{C}_{25}\text{H}_{36}\text{FNO}_2$ 401; found 402 (M+H). Anal. calculated for $\text{C}_{25}\text{H}_{36}\text{FNO}_2$: C, 74.78; H, 9.04; N, 3.49. Found: C, 74.89; H, 9.22; N, 3.24.

15

EXAMPLE 222(+)-2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-propylpyridine

20

Step A: (\pm)-2,6-Diisopropyl-3-[1-hydroxy-2-(S)-toluylsulfoxyethyl]-4-(4-fluorophenyl)-5-propylpyridine

A solution of lithium diisopropylamide was prepared by the addition of *n*-butyllithium (15 mL, 23 mmol, 1.6 M/hexane) to a solution of diisopropylamine (3 mL, 23 mmol) in anhydrous tetrahydrofuran (100 mL) at 0 °C. To this was added a

0 solution of (S)-(-)-methyl *p*-tolylsulfoxide (3.6 g, 23 mmol) in anhydrous tetrahydrofuran (20 mL) dropwise, with stirring. The mixture was stirred at 0°C for 2 hr, then treated with a solution of 2,6-diisopropyl-4-(4-fluorophenyl)-5-propyl-3-pyridinecarboxaldehyde (Example 101, Step A) (3.8 g, 11 mmol) in anhydrous tetrahydrofuran (50 mL) dropwise and with stirring. After stirring 15 min at 0 °C, the reaction mixture was quenched by the addition of saturated NH₄Cl (5 mL). The solvent was removed *in vacuo* and the residue partitioned between CHCl₃ (300 mL) and water (100 mL). The organic phase was washed with saturated NaHCO₃ (100 mL), water (100 mL) and brine (50 mL), dried over MgSO₄ and concentrated. The crude product consisted of a 1.3:1 ratio of diastereomers which were separated by flash chromatography (step gradient 5%-15%-20% ethyl acetate/hexane), which afforded 1.5 g of the faster diastereomer (I), followed by 2.7 g of the slower diastereomer (II) and 0.83 g of a mixed fraction. Diastereomer II is recrystallized once from ethanol/hexane to afford fine white needles (1.7 g, 3.5 mmol, 30% yield). I: mp 225-227°C; R_f = 0.4 (30% ethyl acetate/hexane); ¹H NMR (CDCl₃, 500 MHz): δ 7.23 (m, 4 H), 6.95 (m, 2 H), 6.63 (m, 1 H), 6.55 (m, 1 H), 5.03 (d, *J* = 11.0 Hz, 1 H), 4.53 (s, 1 H), 3.79 (m, 2 H), 3.11 (sept, *J* = 6.6 Hz, 1 H), 2.46 (s, 3 H), 2.30 (dd, *J* = 1.9, 14.1 Hz, 1 H), 2.01 (m, 2 H), 1.25 (m, 12 H), 1.16 (m, 2 H), 0.64 (t, *J* = 7.3 Hz, 3 H). FAB-MS: calcd for C₂₉H₃₆FNO₂S, 481, found 482 (M+H). II: mp 205-206°C; R_f = 0.2 (30% ethyl acetate/hexane); ¹H NMR (CDCl₃, 500 MHz): δ 7.38 (d, *J* = 8.2 Hz, 2 H), 7.24 (m, 2 H), 7.05 (m, 1 H), 7.03 (m, 1 H), 6.97 (m, 1 H), 6.87 (m, 1 H), 4.84 (dt, *J* = 2.7, 10.8 Hz, 1 H), 3.69 (sept, *J* = 6.6 Hz, 1 H), 3.49 (dd, *J* = 10.8, 13.1 Hz, 1 H), 3.14 (sept, *J* = 6.6 Hz, 1 H), 3.00 (d, *J* = 2.5 Hz, 1 H), 2.68 (dd, *J* = 2.5, 13.1 Hz, 1 H), 2.41 (s, 3 H), 2.10 (m, 2 H), 1.23 (m, 14 H), 0.69 (t, *J* = 7.3 Hz, 3 H). FAB-MS calcd for C₂₉H₃₆FNO₂S, 481, found 482 (M+H).

25


Step B: (+)-2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-propylpyridine

A suspension of Raney nickel (20 g) in methanol (50 mL) was stirred under a hydrogen atmosphere for 1 hr. The suspension was cooled to 0 °C and treated with a solution of the intermediate II obtained in Step A (1.6 g, 3.3 mmol) in methanol (50 mL). The suspension was stirred vigorously under hydrogen at 0 °C for 16 hr. After purging with argon, the methanolic solution was decanted from the catalyst, the catalyst washed and decanted 3 more times with methanol. The combined decanted solution was filtered through celite and concentrated. Flash chromatography through a plug of silica (10% ethyl acetate/hexane) afforded the title compound (99% e.e.) as a white solid (1.1 g, 3.2 mmol, 96%). ¹H NMR (CDCl₃, 300 MHz): δ 7.11 (m, 3 H), 7.04 (m, 1 H), 4.64 (dq, *J* = 3.7, 6.6 Hz, 1 H), 3.73 (sept, *J*

0 = 6.6 Hz, 1 H), 3.18 (sept, $J = 6.6$ Hz, 1 H), 2.15 (m, 2 H), 1.56 (d, $J = 3.7$ Hz, 1 H), 1.39 (d, $J = 6.6$ Hz, 3 H), 1.28 (m, 14 H), 0.73 (t, $J = 7.35$ Hz, 3 H). FAB-MS calcd for $C_{22}H_{30}FNO$, 343, found 344 ($M+H$). Anal. Calcd for $C_{22}H_{30}FNO$: C, 76.93; H, 8.80; N, 4.08; F, 5.53. Found: C, 76.98; H, 8.71; N, 3.76; F, 5.73. $[\alpha]_D = +41.5^\circ$ ($CHCl_3$). mp 101-103°C. $R_f = 0.3$ (10% ethyl acetate/hexane).

5

EXAMPLE 223



10 (+)-2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-propyl-pyridine

Step A: 2,6-Diisopropyl-4-(4-fluorophenyl)-5-propyl-3-[(1-oxo-2-toluylsulfoxy)ethyl]pyridine

To a solution of diisopropylamine (4.8 mL, 36.7 mmol) in anhydrous tetrahydrofuran (160 mL) was added n-butyllithium (23 mL, 33.4 mmol, 1.45 M/THF) at 0°C. To the reaction mixture was added a solution of (S)-(-)-methyl p-tolylsulfoxide (5.65 g, 36.7 mmol) in anhydrous tetrahydrofuran (30 mL). The mixture was stirred for 1.5 hours, then treated with a solution of 2,6-diisopropyl-4-(4-fluorophenyl)-5-propyl-3-pyridinecarboxaldehyde (Example 101, Step A) (8.0 g, 24.4 mmol) in anhydrous tetrahydrofuran (100 mL) at 0°C. After stirring 15 minutes at 0°C, the reaction was quenched by addition of saturated ammonium chloride solution (8 mL). The solvent was removed in vacuo and the residue dissolved in chloroform (480 mL). The organic phase was washed with water (2 x 160 mL) and brine (160 mL), dried over magnesium sulfate and concentrated. The residue was dissolved in dichloromethane (800 mL) and manganese (IV) dioxide (40 g, 464 mmol) is added. The suspension was stirred vigorously with a mechanical stirrer and refluxed for 16 hours. The manganese (IV) dioxide was removed by filtration through celite, washed with dichloromethane (100 mL) and the solvent removed in vacuo. Filtration through a pad of silica gel (7.5% diethyl ether-dichloromethane) afforded a white solid (10.2 g, 21.3 mmol, 87%). 1H NMR (300 MHz, $CDCl_3$): δ 7.39 (m, 2 H), 7.26 (m, 2 H), 7.05 (m, 4 H), 3.72 (d, $J = 16$ Hz, 1 H),

0 3.38 (d, $J = 16$ Hz, 1 H), 3.24 (sept, $J = 6.6$ Hz, 1 H), 2.59 (sept, $J = 6.6$ Hz, 1 H), 2.42 (s, 3 H), 2.32 (m, 2 H), 1.27 (m, 8 H), 1.20 (m, 8 H), 0.75 (t, $J = 7.35$ Hz, 3 H). FAB-MS: calculated for $C_{29}H_{34}FNO_2S$, 479, found 480 (M+H). mp 140-142°C. $R_f = 0.2$ (20% ethyl acetate/hexane).


5 Step B: 2,6-Diisopropyl-3-(1-hydroxy-2-(S)-toluylsulfoxyethyl)-4-(4-fluorophenyl)-5-propylpyridine

To a solution of the intermediate obtained in Step A (5.8 g, 12.1 mmol) in anhydrous tetrahydrofuran (145 mL) at -78°C was added rapidly a solution of lithium aluminum hydride (169 mL, 169 mmol, 1.0 M/THF). After 15 minutes the
10 reaction mixture became turbid and was slowly quenched at -78°C with water (6 mL), 20% aqueous sodium hydroxide solution (6 mL) and water (18 mL). The reaction mixture was allowed to warm to room temperature and the resulting suspension was filtered through a pad of celite. The solvent was evaporated and the residue purified by silica gel chromatography (10% diethyl
15 ether/dichloromethane) to afford a white solid (4.8 g, 10 mmol, 83%). 1H NMR (300 MHz, $CDCl_3$): δ 7.41 (d, $J = 8.5$ Hz, 2 H), 7.27 (m, 2 H), 7.06 (d, $J = 7$ Hz, 2 H), 7.00 (m, 1 H), 6.89 (m, 1 H), 4.85 (dt, $J = 2.2, 11$ Hz, 1 H), 3.71 (sept, $J = 6.6$ Hz, 1 H), 3.51 (dd, $J = 11, 13$ Hz, 1 H), 3.16 (sept, $J = 6.6$ Hz, 1 H), 3.02 (d, $J = 2.2$ Hz, 1 H), 2.70 (dd, $J = 2.2, 13$ Hz, 1 H), 2.43 (s, 3 H), 2.12 (m, 2 H), 1.25 (m, 14 H), 0.71 (t, $J = 7.35$
20 Hz, 3 H). FAB-MS calculated for $C_{29}H_{36}FNO_2S$, 481, found 482 (M+H). mp 204-206°C. $R_f = 0.2$ (30% ethyl acetate/hexane).

Step C: (+)-2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-propylpyridine

25 A suspension of Raney nickel (40 g, washed with 3 x 100mL ethanol) in ethanol (80 mL) was stirred under hydrogen atmosphere for 1.5 hours. The suspension was treated with a solution of the intermediate obtained in Step B (4.1 g, 8.5 mmol) in ethanol (180 mL) at room temperature and stirred vigorously for 5 hours. The suspension was carefully filtered through celite and concentrated.
30 Filtration through silica gel (CH_2Cl_2) afforded the title compound (99% e.e.) as a white solid (2.74 g, 8 mmol, 94 %). 1H NMR (300 MHz, $CDCl_3$): δ 7.11 (m, 3 H), 7.04 (m, 1 H), 4.64 (dq, $J = 3.7, 6.6$ Hz, 1 H), 3.73 (sept, $J = 6.6$ Hz, 1 H), 3.18 (sept, $J = 6.6$ Hz, 1 H), 2.15 (m, 2 H), 1.56 (d, $J = 3.7$ Hz, 1 H), 1.39 (d, $J = 6.6$ Hz, 3 H), 1.28 (m, 14 H), 0.73 (t, $J = 7.35$ Hz, 3 H). FAB-MS calculated for $(C_{22}H_{31}FNO, M+H)$ 344, found 344. Anal. Calcd for $C_{22}H_{30}FNO$: C, 76.93; H, 8.80; N, 4.08; F, 5.53; Found: C, 77.20; H, 8.97; N, 4.01; F, 5.60. $[a]_D = +39.4^\circ$ (CH_2Cl_2). mp 104-106°C. $R_f = 0.4$ (CH_2Cl_2).

0

EXAMPLE 2245 (+)-2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-propyl-pyridineStep A: 2,6-Diisopropyl-3-(1-oxoethyl)-4-(4-fluorophenyl)-5-propylpyridine


To (±)-2,6-diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-propylpyridine (Example 101) (8.03 g, 23.4 mmol) in CH₂Cl₂ (600 mL) was added
 10 pyridinium chlorochromate (10.08 g, 46.76 mmol) and celite (10.1 g) under argon. The reaction was stirred at room temperature for 16 hours. The reaction was added to a 1:1 mixture of diethyl ether/hexane (1 L), then filtered through a plug of silica. The pad was washed with 150 mL of diethyl ether and the combined filtrates were concentrated in vacuo to afford a white solid (7.95 g, 23.3 mmol, 98%).
 15 NMR (300 MHz, CDCl₃): δ 7.12 (m, 4 H), 3.26 (septet, *J* = 6.6 Hz, 1 H), 2.85 (septet, *J* = 6.6 Hz, 1 H), 2.36 (m, 2 H), 1.97 (s, 3 H), 1.33 (m, 14 H), 0.774 (t, *J* = 7.4 Hz, 3 H). FAB-MS calcd for (C₂₂H₂₈NOF) 341, found 342 (M+H). mp 131-133°C. R_f = 0.5 (50% CH₂Cl₂/hexane).

20 Step B: (+)-2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-propylpyridine

To a solution of (1S,2R)-(+)-N-methylephedrine (31.1 g, 0.174 mol) in ether (208 mL) was added lithium aluminum hydride (1M/diethyl ether, 1.5 eq., 174 mL) dropwise at 0°C under argon. The reaction was refluxed for 1.5 h. turning from a
 25 clear solution to a white milky solution. The reaction was cooled to room temperature and then -78°C. The intermediate obtained in Step A (39.53g, 0.116 mmol) was dissolved in 400 mL of dry diethyl ether and cooled to 0°C for a dropwise addition to the reaction mixture (~2 mL/min., the temperature should not rise above -60°C). The reaction was kept at -78°C for 4.0 hours and then
 30 allowed to warm overnight. The reaction was quenched at 0°C with isopropanol

- 0 (70 mL) and diluted with ether (700 mL), washed with water (4 x 500 mL), 10% HCl (2 x 500 mL), brine (2 x 500 mL) and dried with MgSO₄. Filtration and concentration afforded a residue which was filtered through a pad of silica (600 g, 10% diethyl ether/hexane) to give the title compound (97% e.e.) as a white solid (36.67 g, 107 mmol, 92%). ¹H NMR (300 MHz, CDCl₃): δ 7.11 (m, 4 H), 4.67 (dq, *J* = 3.3, 6.6 Hz, 1 H), 3.74 (septet, *J* = 6.6 Hz, 1 H), 3.20 (septet, *J* = 6.6 Hz, 1 H), 2.17 (m, 2 H), 1.61 (d, *J* = 2.9 Hz, 1 H), 1.40 (d, *J* = 7.0 Hz, 3 H), 1.30 (m, 14 H), 0.741 (t, *J* = 7.4 Hz, 3 H). FAB-MS: calcd for (C₂₂H₃₀NOF) 343, found 344 (M+H). mp 102-104°C. R_f = 0.2 (60% CH₂Cl₂/hexane).

10

EXAMPLE 225

15 2-Isopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-pentyl-6-(2-trans-phenylethyl)pyridine

Step A: 2-Bromomethyl-3-pentyl-4-(4-fluorophenyl)-5-(*t*-butyldiphenylsiloxy)methyl-6-isopropylpyridine

- 20 Prepared from the intermediate obtained in Example 200, Step B by the procedure described in Example 47, Step B. ¹H NMR (300 MHz, CDCl₃): δ 7.40 (m, 6H), 7.32 (m, 4H), 7.04 (m, 4H), 4.64 (s, 2H), 4.26 (s, 2H), 3.14 (sept, 6.8 Hz, 1H), 2.38 (m, 2H), 1.34 (m, 2H), 1.17 (d, 7.0 Hz, 6H), 1.12 (m, 4H), 1.00 (s, 9H), 0.78 (t, 6.6 Hz, 3H).

25 Step B: 2-(Diethylphosphono)methyl-3-pentyl-4-(4-fluorophenyl)-5-(*t*-butyldiphenylsiloxy)methyl-6-isopropylpyridine

- 30 A mixture of diethylphosphite (280 mg) and sodium metal (50 mg) in benzene (5 mL) was stirred overnight. A mixture of the sodium diethylphosphite solution (1 mL) and the intermediate obtained in Step A (110 mg, 0.17 mmol) in benzene (5 mL) was refluxed for 2 h. The mixture was concentrated in vacuo. The

0 residue was dissolved in ethyl acetate (30 mL) and washed with saturated aqueous
sodium chloride solution (3 x 10 mL). Silica gel chromatography (70:30
hexanes/ethyl acetate) provided a yellow oil (80 mg, 67%). ¹H NMR (300 MHz,
CDCl₃): δ 7.41 (m, 6H), 7.32 (m, 4H), 7.04 (m, 4H), 4.25 (s, 2H), 4.15 (dq, 7.2 Hz,
4H), 3.49 (d, 22.4 Hz, 2H), 3.14 (sept, 6.8 Hz, 1H), 2.38 (m, 2H), 1.30 (t, 7.2 Hz, 6H),
5 1.25 (m, 2H), 1.16 (d, 6.6 Hz, 6H), 1.10 (m, 4H), 0.99 (s, 9H), 0.77 (t, 6.8 Hz, 3H).


Step C: 2-(trans-2-Phenylethenyl)-3-pentyl-4-(4-fluorophenyl)-5-
(t-butyl)diphenylsiloxy)methyl-6-isopropylpyridine

10 Sodium hydride (8 mg) was added to a mixture of the intermediate obtained
in Step B (90 mg, 128 μmol) and benzaldehyde (20 mg) in THF (2.7 mL). After 15
min. the mixture was diluted with ethyl acetate and washed with saturated aqueous
sodium chloride solution. Silica gel chromatography (97:3 hexanes/ethyl acetate)
provided a yellow oil (100 mg). ¹H NMR (300 MHz, CDCl₃): δ 8.00 (d, 15.4 Hz,
1H), 7.61 (m, 2H), 7.45-7.27 (m, 14H), 7.04 (m, 4H), 4.29 (s, 2H), 3.20 (sept, 6.4 Hz,
15 1H), 2.38 (m, 2H), 1.40 (m, 2H), 1.25 (d, 6.6 Hz, 6H), 1.18 (m, 4H), 1.00 (s, 9H), 0.81
(m, 3H).

Step D: 2-(trans-2-Phenylethenyl)-3-pentyl-4-(4-fluorophenyl)-5-
hydroxymethyl-6-isopropylpyridine

20 The title compound was prepared from the intermediate obtained in
Step C by the procedure described in Example 198, Step D. Silica gel
chromatography (94:6 hexanes/ethyl acetate) provided a yellow oil (24 mg, 38%).
¹H NMR (300 MHz, CDCl₃): δ 8.02 (d, 15.5 Hz, 1H), 7.63 (m, 2H), 7.43-7.31 (m, 4H),
7.16 (m, 4H), 4.38 (s, 2H), 3.48 (sept, 6.6 Hz, 1H), 2.41 (m, 2H), 1.42 (d, 6.6 Hz, 6H),
25 1.4 (m, 2H), 1.19 (m, 4H), 0.82 (t, 6.8 Hz, 3H). FAB-MS: calculated for C₂₈H₃₂FNO
417; found 418 (M+H). R_f = 0.13 (90:10 hexanes/ethyl acetate). Anal. calculated for
C₂₈H₃₂FNO: C, 80.54; H, 7.72; N, 3.35. Found: C, 80.34; H, 7.79; N, 3.10. mp 98-
100°C.

EXAMPLE 226




0

2-Isopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-pentyl-6-(2-methyl-propenyl)pyridine


The title compound was prepared as a yellow oil from the intermediate obtained in Example 225, Step B by the procedure described in Example 225, Step C and Example 198, Step D. The product was obtained as an inseparable mixture of the title compound and the corresponding deconjugated olefin in a ratio of 84:16. ^1H NMR (300 MHz, CDCl_3): δ 7.16 (m, 4H), 6.43 (s, 1H), 4.82 (s, 1H, minor isomer), 4.60 (s, 1H, minor isomer), 4.36 (s, 2H), 3.58 (s, 2H, minor isomer), 3.46 (sept, 6.6 Hz, 1H), 2.26 (m, 2H), 2.07 (s, 3H), 1.99 (s, 3H), 1.82 (s, 3H, minor isomer), 1.35 (d, 7.0 Hz, 6H), 1.28 (m, 2H), 1.13 (m, 4H), 0.79 (t, 6.8 Hz, 3H). FAB-MS: calculated for $\text{C}_{24}\text{H}_{32}\text{FNO}$ 369; found 370 (M+H). R_f = 0.16 (90:10 hexanes/ethyl acetate). Anal. calculated for $\text{C}_{24}\text{H}_{32}\text{FNO}$: C, 78.01; H, 8.73; N, 3.79. Found: C, 77.73; H, 8.86; N, 3.97.

15

EXAMPLE 227



0

EXAMPLE 228


5

2-Isopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-pentyl-6-(2-methylpropyl)pyridine

10

The title compound was prepared as a colorless crystalline solid from the intermediate obtained in Example 226 by the procedure described in Example 1, Step H. ^1H NMR (300 MHz, CDCl_3): δ 7.15 (m, 4H), 4.33 (d, 5.2 Hz, 2H), 3.41 (sept, 6.6 Hz, 1H), 2.67 (d, 7.0 Hz, 2H), 2.34 (m, 2H), 2.25 (m, 2H), 1.32 (d, 6.6 Hz, 6H), 1.20 (m, 2H), 1.12 (m, 4H), 0.99 (d, 6.6 Hz, 6H), 0.78 (t, 6.6 Hz, 3H). FAB-MS: calculated for $\text{C}_{24}\text{H}_{34}\text{FNO}$ 371; found 372 ($\text{M}+\text{H}$). R_f = 0.77 (90:10 hexanes/ethyl acetate). Anal. calculated for $\text{C}_{24}\text{H}_{34}\text{FNO}$: C, 77.59; H, 9.22; N, 3.77. Found: C, 77.49; H, 9.20; N, 3.73.

15

EXAMPLE 229


20

2-Isopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-pentyl-6-(3-methylbutyl)pyridine

The title compound was prepared as a yellow oil from the intermediate obtained in Example 225, Step B by the procedures described in Example 225, Steps C and D, and Example 1, Step H. ^1H NMR (300 MHz, CDCl_3): δ 7.14 (m, 4H), 4.34

0 (d, 3.7 Hz, 2H), 3.41 (sept, 6.8 Hz, 1H), 2.80 (m, 2H), 2.26 (m, 2H), 1.68 (m, 3H), 1.33 (d, 6.6 Hz, 6H), 1.29 (m, 2H), 1.12 (m, 4H), 0.98 (d, 6.3 Hz, 6H), 0.79 (t, 6.6 Hz, 3H). FAB-MS: calculated for C₂₅H₃₆FNO 385; found 386 (M+H). R_f = 0.15 (90:10 hexanes/ethyl acetate). Anal. calculated for C₂₅H₃₆FNO: C, 77.88; H, 9.41; N, 3.63. Found: C, 77.62; H, 9.13; N, 3.42.

5

EXAMPLE 230

10 2-Isopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5,6,7,8-tetrahydro-8,8-dimethylquinoline

Step A: 2-[(4-Fluorophenyl)methylene]-4-methyl-3-oxopentanoic acid

15 To a solution of ethyl isobutyryl acetate (30 g, 0.190 mol) in ethanol (75 mL) was added cyclohexane (120 mL), acetic acid (0.6 mL), piperidine (0.6 mL), and 4-fluorobenzaldehyde (20.35 mL, 0.190 mol). The reaction was heated at reflux with a Dean-Starck trap for 5 hours. The mixture was poured into 200 mL of diethyl ether and washed with brine (1 x 75 mL). The organic layer was dried with MgSO₄, filtered, and concentrated to afford an orange oil. The product was taken directly
20 to the next step without any further purification. R_f = 0.1 (50% CH₂Cl₂/hexane).

Step B: 2-Isopropyl-3-carboethoxy-4-(4-fluorophenyl)-5,6,7,8-tetrahydro-8,8-dimethylquinoline

25 To a solution of lithium bis(trimethylsilyl)amide (1.0 M/THF, 2 eq. 13.6 mL) in THF (15 mL) was added 2,2-dimethylcyclohexanone (1.88 mL, 13.6 mmol) at -78°C. The reaction was stirred for 15 minutes, and then the intermediate obtained in Step A (3 g, 11.4 mmol) was added dropwise. The reaction was stirred overnight and allowed to warm to room temperature. To the crude product was added acetic acid (19.4 mL), ammonium acetate (2.62 g, 34.0 mmol) and copper acetate (5.14 g, 28.3 mmol). The reaction mixture was heated at 100°C and the THF was removed
30


0 by distillation. The reaction was heated to 130°C and allowed to reflux for 24 hours. Ethyl acetate (100 mL) was added and washed with sodium bicarbonate (2 x 30 mL), water (2 x 20 mL), brine (2 x 20 mL), dried with MgSO₄, filtered, and concentrated to afford an oil. Flash chromatography (5 % ethyl acetate/hexane) afforded a white solid (1.36 g, 3.7 mmol, 32%). ¹H NMR (300 MHz, CDCl₃): δ 7.17 (m, 2 H), 7.08 (m, 2 H), 3.98 (q, *J* = 7.4 Hz, 2 H), 3.03 (septet, *J* = 7.0 Hz, 1 H), 2.35 (t, *J* = 5.9 Hz, 2 H), 1.70 (m, 4 H), 1.36 (s, 6 H), 1.31 (d, *J* = 4.1 Hz, 6 H), 0.965 (t, *J* = 7.4 Hz, 3 H). FAB-MS: calculated for (C₂₃H₂₈FNO) 369, found 370 (M+H). mp 124-126°C. R_f = 0.6 (50% CH₂Cl₂/hexane).

10 Step C: 2-Isopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5,6,7,8-tetrahydro-8,8-dimethylquinoline

To the intermediate obtained in Step B (1.32 g, 3.6 mmol) in THF (35 mL) was added lithium aluminum hydride (1 M/THF, 2 eq., 7.2 mL) dropwise. The reaction was refluxed for 1.5 hours and cooled to room temperature. Then the reaction was quenched with water and the THF was evaporated. The residue was partitioned between diethyl ether (150 mL) and water (100 mL). The organic layer was washed with brine (1 x 100 mL), dried with MgSO₄, filtered, and concentrated to afford a solid. Flash chromatography (40% CH₂Cl₂/hexane) afforded the title compound as a white solid (808 mg, 2.5 mmol, 70%). ¹H NMR (300 MHz, CDCl₃): δ 7.13 (d, *J* = 7.0 Hz, 4 H), 4.36 (d, *J* = 5.5 Hz, 2 H), 3.42 (septet, *J* = 6.6 Hz, 1 H), 2.24 (t, *J* = 5.5 Hz, 2 H), 1.67 (m, 4 H), 1.32 (m, 13 H). FAB-MS: calculated for (C₂₁H₂₆FNO) 327, found 328 (M+H). mp 146-149°C. R_f = 0.2 (50% CH₂Cl₂/hexane).

25

EXAMPLE 231



30 2-Isopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5,6,7,8-tetrahydro-8,8-dimethylquinoline

0


Step A: 2-Isopropyl-3-carboxaldehyde-4-(4-fluorophenyl)-5,6,7,8-tetrahydro-8,8-dimethylquinoline

To a solution of 2-isopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5,6,7,8-tetrahydro-8,8-dimethylquinoline (Example 230) (765 mg, 2.34 mmol) in dichloromethane (30 mL) was added Celite (1.01 g) and pyridinium chlorochromate (1.01 g, 4.69 mmol). The reaction was stirred at room temperature for 2 hours and then added to a 1:1 diethyl ether/hexane solution (500 mL). The solution was passed through a pad of silica and washed several times with diethyl ether. Concentration yielded a white solid (568 mg, 1.75 mmol, 75%). ¹H NMR (300 MHz, CDCl₃): δ 9.78 (s, 1 H), 7.15 (m, 4 H), 3.86 (septet, *J* = 6.6 Hz, 1 H), 2.31 (t, *J* = 5.9 Hz, 2 H), 1.70 (m, 4 H), 1.37 (s, 6 H), 1.30 (m, 6 H). FAB-MS: calculated for (C₂₁H₂₄FNO) 325, found 326 (M+H). mp 94-96°C. R_f = 0.7 (50% CH₂Cl₂/hexane).

Step B: 2-Isopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5,6,7,8-tetrahydro-8,8-dimethylquinoline

To the intermediate obtained in Step A (508 mg, 1.56 mmol) in THF (20 mL) was added methylmagnesium bromide (0.57 mL, 3.0 M/ether, 1.1 eq.) dropwise at -78°C. After 2 hours, the reaction was quenched with saturated ammonium chloride (30 mL) and diluted with dichloromethane (100 mL). The solid was filtered and the mother liquor was washed with water (1 x 50 mL), brine (1 x 50 mL), dried with MgSO₄, filtered, and concentrated to afford a white solid. Flash chromatography (50% dichloromethane/hexane) gave a white solid (205 mg, 0.6 mmol, 39%). ¹H NMR (300 MHz, CDCl₃): δ 7.13 (m, 3 H), 7.01 (m, 1 H), 4.73, 4.71 (dq, *J* = 3.7, 6.6 Hz, 1 H), 3.74 (septet, *J* = 6.6 Hz, 1 H), 2.13 (q, *J* = 4.4 Hz, 2 H), 1.64 (m, 3 H), 1.31 (m, 17 H). FAB-MS: calculated for (C₂₂H₂₇FNO) 341, found 342 (M+H). mp 56.5-58.5°C. R_f = 0.2 (50% CH₂Cl₂/hexane).

EXAMPLE 232




30

0 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-(1-butenyl)pyridine


The title compound was prepared from ethyl isobutyrylacetate, 4-fluorobenzaldehyde and 3-methyl-1-phenyl-2-butanone according to the procedures described in Example 230. ¹H NMR (300 MHz, CDCl₃): δ 7.16 (m, 3 H), 6.91 (m, 6 H), 4.45 (d, *J* = 5.1 Hz, 2 H), 3.52 (sept., *J* = 6.6 Hz, 1 H), 2.86 (sept., *J* = 6.6 Hz, 1 H), 1.55 (s, 1 H), 1.36 (m, 6 H), 1.17 (d, *J* = 6.6 Hz, 6 H). FAB-MS: calculated for (C₂₄H₂₆FNO) 363, found 364 (M+H). mp 115-117°C. R_f = 0.3 (60% CH₂Cl₂/hexane).

10

EXAMPLE 23315 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-phenylpyridine

The title compound was prepared according to the procedures described in Example 231. ¹H NMR (300 MHz, CDCl₃): δ 7.14 (m, 3 H), 6.88 (m, 6 H), 4.80 (dq, *J* = 7.0, 3.7 Hz, 1 H), 3.84 (sept., *J* = 6.6 Hz, 1 H), 2.79 (sept., *J* = 6.6 Hz, 1 H), 1.66 (d, *J* = 3.7 Hz, 1 H), 1.48 (d, *J* = 7.0 Hz, 3 H), 1.39 (m, 6 H). FAB-MS: calculated for (C₂₅H₂₈FNO) 377, found 378 (M+H). mp 155-157°C. R_f = 0.4 (60% CH₂Cl₂/hexane).


20

EXAMPLE 234

0 2-Isopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-7,7-dimethyl-5H-cyclo-
penta[b]pyridine

The title compound was prepared from ethyl isobutyrylacetate, 4 fluorobenzaldehyde and 2,2-dimethylcyclopentanone according to the procedures described in Example 230. ¹H NMR (300 MHz, CDCl₃): δ 7.29 (m, 2 H),
5 7.14 (m, 2 H), 4.49 (d, *J* = 5.2 Hz, 2 H), 3.46 (sept., *J* = 6.6 Hz, 1 H), 2.56 (t, *J* = 7.0 Hz, 2 H), 1.90 (t, *J* = 7.0 Hz, 2 H), 1.34 (m, 13 H). FAB-MS: calculated for (C₂₀H₂₄FNO) 313, found 314 (M+H). mp 141-143°C. R_f = 0.1 (60% CH₂Cl₂/hexane).

10 EXAMPLE 235




15 2-Isopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-7,7-dimethyl-5H-cyclo-
penta[b]pyridine

The title compound was prepared according to the procedures described in Example 231. ¹H NMR (300 MHz, CDCl₃): δ 7.15 (m, 4 H), 4.95 (dq, *J* = 6.6, 3.7 Hz, 1 H), 3.77 (sept., *J* = 6.6 Hz, 1 H), 2.44 (m, 2 H), 1.88 (t, *J* = 7.4 Hz, 2 H), 1.62 (d, *J* = 3.7 Hz, 1 H), 1.48 (d, *J* = 7.0 Hz, 3 H), 1.32 (m, 12 H). FAB-MS: calculated for (C₂₁H₂₆FNO) 327, found 328 (M+H). mp 90-92°C. R_f = 0.1 (60% CH₂Cl₂/hexane).

20


EXAMPLE 236



0 2-Isopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5,6-dihydro-6,6,8-
trimethylquinoline

The title compound was prepared from ethyl isobutyrylacetate, 4 fluorobenzaldehyde and 2,4,4-trimethyl-2-cyclohexen-1-one according to the procedures described in Example 230. ¹H NMR (300 MHz, CDCl₃): δ 7.16 (m, 4 H), 5.81 (s, 1 H), 4.41 (d, *J* = 5.2 Hz, 2 H), 3.45 (sept., *J* = 6.6 Hz, 1 H), 2.29 (s, 2 H), 2.16 (s, 3 H), 1.58 (s, 1 H), 1.35 (d, *J* = 6.6 Hz, 6 H), 0.95 (s, 6 H). FAB-MS: calculated for (C₂₂H₂₆FNO) 339, found 340 (M+H). mp 112-114°C. R_f = 0.2 (60% CH₂Cl₂/hexane).


10 EXAMPLE 237



15 2-Isopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5,6-dihydro-6,6,8-
trimethylquinoline

The title compound was prepared according to the procedures described in Example 231. ¹H NMR (300 MHz, CDCl₃): δ 7.14 (m, 3 H), 7.00 (m, 1 H), 5.78 (s, 1 H), 4.77 (dq, *J* = 6.6, 3.7 Hz, 1 H), 3.76 (sept., *J* = 6.6 Hz, 1 H), 2.18 (s, 2 H), 2.14 (s, 3 H), 1.61 (d, *J* = 3.7 Hz, 1 H), 1.43 (d, *J* = 6.6 Hz, 3 H), 1.33 (m, 6 H), 0.91 (s, 6 H). FAB-MS: calculated for (C₂₃H₂₈FNO) 353, found 354 (M+H). mp 117-119°C. R_f = 0.3 (60% CH₂Cl₂/hexane).

20 EXAMPLE 238



0

2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluoro-2-hydroxyphenyl)-5-propylpyridine

Step A: 2,6-Diisopropyl-3-hydroxymethyl-4-[(2-benzyloxy-4-fluoro)phenyl]-5-prop-1-enyl)pyridine

5 Prepared from the intermediate obtained in Example 166, Step B by the methods described in Example 160, Steps A-D. ¹H NMR (300 MHz, CDCl₃): δ 1.20-1.34 (m, 12H), 1.56-1.59 (m, 3H), 1.68-1.74 (m, 1H), 3.13-3.50 (m, 2H), 4.23-4.42 (m, 2H), 4.87-5.05 (m, 2H), 5.25-5.56 (m, 1H), 5.23-6.03 (m, 1H), 6.69-6.77 (m, 2H), 6.95-7.08 (m, 3H), 7.22-7.27 (m, 3H). FAB-MS: calcd for (C₂₈H₃₂NO₂F) 433; found 434
10 (M + 1). R_f = 0.30 (10% ethyl acetate-hexane).

Step B: 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluoro-2-hydroxyphenyl)-5-propylpyridine


15 The title compound was prepared as two separable diastereomers from the intermediate obtained in Step A by the methods described in Example 164, Steps A-C. The diastereomers were separated by radial band chromatography using a gradient eluent of 100% hexane to 20% ether-hexane.

Diastereomer 1: ¹H NMR (300 MHz, CDCl₃): δ 0.75 (t, J = 7.2 Hz, 3H), 1.27-1.40 (m, 17H), 1.66 (br s, 1H), 2.02-2.12 (m, 1H), 2.20-2.31 (m, 1H), 3.21 (sept, J = 6.6
20 Hz, 1H), 3.60 (sept, J = 6.6 Hz, 1H), 4.94 (m, 1H), 5.03 (br s, 1H), 6.70-6.76 (m, 2H), 6.94-7.00 (m, 1H); FAB-MS: calcd for (C₂₂H₃₀NO₂F) 359, found 360 (M + 1). R_f = 0.29 (20% ethyl acetate-hexane). mp 152-153°C.

Diastereomer 1 was resolved into its constituent enantiomers as follows. A Waters Prep LC 2000 HPLC system was equipped with a chiral HPLC column
25 (BRB-9668A; 6 x 50 cm ID). The system was equilibrated with a mobile phase consisting of 1% (1% acetic acid, 99% ethanol) and 99% hexane at a flow rate of 150 mL/min. The sample was dissolved in chloroform (50 mg/mL) and 5 mL aliquots were injected at 40 min intervals. The effluent was monitored at 280 nm and two fractions (corresponding to the two enantiomers) were collected at (17-23 min, 100%
30 ee) and (23-32 min, 98% ee), respectively.


Diastereomer 2: ¹H NMR (300 MHz, CDCl₃): δ 0.75 (t, J = 7.2 Hz, 3H), 1.26-1.31 (m, 14H), 1.38 (d, J = 6.9 Hz, 3H), 1.84-1.87 (m, 1H), 2.05-2.14 (m, 1H), 2.24-2.34 (m, 1H), 3.20 (septet, J = 6.6 Hz, 1H), 3.72 (septet, J = 6.6, 1H), 4.58-4.65 (m, 1H), 5.06 (br s, 1H), 6.67-6.74 (m, 2H), 6.85-6.90 (m, 1H); FAB-MS: calcd for (C₂₂H₃₀NO₂F)
35 359, found 360 (M + 1). R_f = 0.19 (20% ether-hexanes). mp 157-159°C.

0

EXAMPLE 2392,6-Diisopropyl-3-(1-hydroxymethyl)-4-(4-fluoro-2-hydroxyphenyl)-5-propylpyridine

5 The title compound was prepared from 2,6-diisopropyl-3-hydroxymethyl-4-
[(2-benzyloxy-4-fluoro)phenyl]-5-(prop-1-enyl)pyridine (Example 238, Step A) by
the method described in Example 161, Step A (mp 138-141°C). ¹H NMR (300 MHz,
CDCl₃): δ 0.76 (t, J = 7.2 Hz, 3H), 1.24-1.35 (m, 14H), 1.82 (br s, 1H), 2.12-2.22 (m,
1H), 2.27-2.37 (m, 1H), 3.24 (sept, J = 6.6 Hz, 1H), 3.39 (sept, J = 6.6 Hz, 1H), 4.29 (d, J
10 = 11.4 Hz, 1H), 4.52 (d, J = 10.8 Hz, 1H), 5.72 (br s, 1H), 7.70-6.77 (m, 2H), 6.94-7.00
(m, 1H). FAB-MS: calcd for (C₂₁H₂₈NO₂F) 345; found 346 (M + 1). R_f = 0.30 (10%
ethyl acetate-hexane).

 The racemate was resolved into its constituent enantiomers as follows. A
Waters Prep LC 2000 HPLC system was equipped with a chiral HPLC column
15 (BRB-9668A; 6 x 50 cm ID). The system was equilibrated with a mobile phase
consisting of 1% (1% acetic acid, 99% ethanol) and 99% hexane at a flow rate of 100
mL/min. The sample was dissolved in mobile phase (5 mg/mL) and 3 mL aliquots
were injected at 30 min intervals. The effluent was monitored at 280 nm and two
fractions (corresponding to the two enantiomers) were collected at (24-36 min, 100%
20 ee) and (26-30 min, 95.5% ee), respectively.

EXAMPLE 240

0

2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluoro-2-hydroxyphenyl)-5-ethylpyridine

Step A: 2,6-Diisopropyl-3-hydroxymethyl-4-[(2-benzyloxy-4-fluoro)phenyl]-5-ethenyl)pyridine

5

Prepared from the intermediate obtained in Example 166, Step B by the methods described in Example 160, Steps A-D. ¹H NMR (300 MHz, CDCl₃): δ 1.25-1.33 (m, 12H), 1.66-1.70 (m, 1H), 3.34-3.50 (m, 2H), 4.28-4.41 (m, 2H), 4.89-5.18 (m, 4H), 6.29-6.39 (m, 1H), 6.67-6.78 (m, 2H), 7.23-7.25 (m, 3H). FAB-MS: calcd for (C₂₇H₃₀NO₂F) 419; found 420 (M + 1). R_f = 0.29 (10% ethyl acetate-hexane).

10

Step B: 2,6-Diisopropyl-3-carboxaldehyde-4-[(2-benzyloxy-4-fluoro)phenyl]-5-ethenyl)pyridine

15

Prepared from the intermediate obtained in Step A by the method described in Example 164, Step A. ¹H NMR (300 MHz, CDCl₃): δ 1.25-1.33 (m, 12H), 3.24 (sept, 1H, J = 6.6 Hz), 3.89 (sept, 1H, J = 6.6 Hz), 4.93-5.04 (m, 3H), 5.23 (dd, 1H, J = 1.5, 11.4 Hz), 6.40 (dd, 1H, J = 11.4, 17.7 Hz), 6.70-7.04 (m, 2H), 6.99-7.04 (m, 1H), 7.10-7.14 (m, 2H), 7.24-7.29 (m, 3H), 9.82 (s, 1H). FAB-MS: calcd for (C₂₇H₂₈NO₂F) 417; found 418 (M + 1). R_f = 0.68 (10% ethyl acetate-hexane).

20

Step C: 2,6-Diisopropyl-3-(2-hydroxyethyl)-4-[(2-hydroxy-4-fluoro)phenyl]-5-ethyl)pyridine

25

To an oven-dried 250 mL three-neck round bottom flask equipped with a thermometer were added copper(I) iodide (3.21 g, 16.9 mmol) and toluene (40 mL) under an argon atmosphere. The slurry was cooled to an internal temperature of 0°C. Methyllithium (1.4M in ether, 25 mL, 0.03314 mol) was added at a rate to maintain reaction temperature <5°C. The reaction was then allowed to stir at 0°C for 50 min. At the end of this time the intermediate from Step B (1.33 g, 3.19 mmol) in 10 mL toluene was added via syringe at a rate to maintain reaction temperature <5°C. The syringe was rinsed with an additional 4 mL toluene and this rinse was added to the reaction mixture at a rate to maintain reaction temperature <5°C. The reaction was stirred at 0°C for 35 min. The reaction was then quenched by the addition of a saturated solution of ammonium chloride (20 mL) and was allowed to stir for 36 h at 25°C. The reaction mixture was poured into a separatory funnel and was extracted with ethyl acetate (3 x 50 mL). The combined organic layer was then concentrated to yield the crude intermediate (1.4 g, yellow oil, 9:1 ratio of diastereomers). The crude intermediate was dissolved in a mixture of ethanol (30 mL) and tetrahydrofuran (10 mL) under argon, treated with 10% palladium on

30

35

0 carbon (140 mg), and was then stirred under a hydrogen atmosphere for 14 h. After purging the system with argon, the catalyst was removed by filtration through a pad of Celite. The solvent was removed and the residue was purified by flash chromatography (12-15% ethyl acetate-hexane) to yield 1.0 g of the title compound as two separate diastereomers.


5 Diastereomer 1: ^1H NMR (300 MHz, CDCl_3): δ 0.91 (t, $J = 7.4$ Hz, 3H), 1.28-1.40 (m, 15H), 1.70 (d, $J = 3.9$ Hz, 1H), 2.12-2.24 (m, 1H), 2.29-2.41 (m, 1H), 3.24 (sept, $J = 6.6$ Hz, 1H), 3.61 (sept, $J = 6.6$ Hz, 1H), 4.89-5.00 (m, 1H), 5.10 (br s, 1H), 6.70-6.76 (m, 2H), 6.96-7.01 (m, 1H); FAB-MS: calcd for $(\text{C}_{21}\text{H}_{28}\text{NO}_2\text{F})$ 345, found 346 ($M + 1$). $R_f = 0.43$ (30% ether-hexane). mp 190-191°C.

10 Diastereomer 1 was resolved into its constituent enantiomers as follows. A Waters Prep LC 2000 HPLC system was equipped with a chiral HPLC column (BRB-9668A; 6 x 50 cm ID). The system was equilibrated with a mobile phase consisting of 1% (1% acetic acid, 99% ethanol) and 99% hexane at a flow rate of 100 mL/min. The sample (1 g) was dissolved in a mixture of CH_2Cl_2 (40 mL), ethanol
15 (1 mL), and 10 mL of the mobile phase. The mixture was injected and the effluent was monitored at 280 nm and two fractions (corresponding to the two enantiomers) were collected at (27-29 min, 99.8% ee) and (37-57 min, 99.4% ee), respectively. Fraction 1 (27-29 min): $[\alpha]^{25}_{\text{D}} +4.7^\circ$ ($c = 0.54$, CH_2Cl_2).

20 Diastereomer 2: ^1H NMR (300 MHz, CDCl_3): δ 0.89 (t, $J = 7.5$ Hz, 3H), 1.26-1.38 (m, 15H), 1.92 (d, $J = 3$ Hz, 1H), 2.12-2.25 (m, 1H), 2.31-2.43 (m, 1H), 3.23 (septet, $J = 6.6$ Hz, 1H), 3.72 (septet, $J = 6.6$, 1H), 4.56-4.63 (m, 1H), 5.14 (br s, 1H), 6.68-6.74 (m, 2H), 6.85-6.91 (m, 1H); FAB-MS: calcd for $(\text{C}_{21}\text{H}_{28}\text{NO}_2\text{F})$ 345, found 346 ($M + 1$). $R_f = 0.27$ (30% ether-hexane). mp 201-202°C.

25

EXAMPLE 241



3,5-Diisopropyl-2-hydroxymethyl-6-propyl-4'-fluoro-2'-hydroxy-1,1'-biphenyl

30

0 Step A: Dimethyl 4,6-diethyl-2-hydroxy-1,3-benzenedicarboxylate

 A mixture of dimethyl 1,3-acetonedicarboxylate (200 g, 1.15 mol), 3,5-heptanedione (140 g, 1.09 mol) and sodium methoxide (70 g, 1.25 mol) in methanol (1.5 L) was held at reflux overnight. Methanol was removed via rotary evaporation and the resulting orange sludge was partitioned between diethyl ether (1 L) and 10 % aqueous hydrochloric acid (1 L). The separated aqueous layer was extracted with diethyl ether (0.5 L x 2). The combined organic portions were washed with saturated aqueous sodium chloride (0.1 L), dried over sodium sulfate, filtered through a pad of silica (40 mm x 100 mm) and concentrated in vacuo. The crude oil was purified via vacuum distillation at 0.25 Torr to afford the clean product as translucent yellow oil (bp: 125-145°C, 202 g, 70 %): ¹H NMR (300 MHz, CDCl₃): δ 1.20 (t, J = 7.4 Hz, 6H), 2.71 - 2.80 (m, 4H), 3.95 (s, 6H), 6.64 (s, 1H), 11.67 (s, 1H). ¹³C NMR (75 MHz, CDCl₃): δ 15.42, 28.31, 52.27, 115.22, 121.91, 148.63, 159.71, 169.86. EI-MS: calculated for C₁₄H₁₈O₅ 266; found 266 (M⁺). Anal. calc for C₁₄H₁₈O₅: C, 63.15; H, 6.81. Found: C, 63.23; H, 6.92. R_f = 0.38 (9:1 hexanes:ethyl acetate). HPLC: (C-18, A=0.05 % aqueous trifluoroacetic acid, B=CH₃CN; linear gradient: 50%-100% B over 30 min; 254 nm, 1 mL/min): R.T. 14.4 min (100.0 area %).

20 Step B: Dimethyl 4,6-diethyl-2-methoxy-1,3-benzenedicarboxylate

 A mixture of the crude intermediate obtained in Step A (241.6 g, 0.91 mol), potassium carbonate (204 g, 1.48 mol) and dimethyl sulfate (129 mL, 1.37 mol) in acetone (1 L) was stirred vigorously overnight. After six hours at reflux, the reaction was cooled to room temperature, additional dimethyl sulfate (43 mL, 0.46 mol) was added, and reflux was continued overnight. The mixture was filtered through a pad of Celite, diethyl ether (1 L) was used to wash the Celite pad, and the combined filtrates were concentrated in vacuo. The resulting crude oil was purified via vacuum distillation to afford the pure product as a translucent yellow oil (bp: 180-190°C, 178.1 g, 58 % (2 steps)): ¹H NMR (300 MHz, CDCl₃): δ 1.16-1.25 (m, 6H), 2.55-2.66 (m, 4H), 3.81 (s, 3H), 3.91 (s, 6H), 6.89 (s, 1H). R_f = 0.34 (9:1 hexanes:ethyl acetate).

30 Step C: Dimethyl 4,6-diisopropyl-2-methoxy-1,3-benzenedicarboxylate

 A solution of diisopropylamine (26.7 mL, 0.20 mol) in dry tetrahydrofuran (0.2 L) at -78°C under an argon atmosphere was treated with slow addition of n-butyllithium (2.47M in hexanes, 85.0 mL, 0.20 mol). After the reaction stirred for fifteen minutes, a solution of the intermediate from Step B (58.0 g, 0.16 mol) in dry tetrahydrofuran (0.2 L) was added to the solution of LDA over 45

0 minutes. Stirring was continued for 80 minutes while the internal temperature was held at -76°C. Neat iodomethane (13.2 mL, 0.21 mol) was added to the reaction mixture via syringe; two-thirds of the charge was transferred at the outset, the reaction was allowed to stir for 30 minutes, then the final third of the charge was added, followed by another 30 minutes of stirring. A second pot of LDA (0.2 mol) in dry tetrahydrofuran (0.2 L) was produced by the above procedure and was transferred to the reaction mixture via cannula over 45 minutes. Stirring was continued for 80 minutes at -76 °C then a second portion of neat iodomethane (13.2 mL, 0.21 mol) was added to the reaction mixture using the addition sequence described above. The cooling bath was removed and the reaction mixture was quenched with saturated aqueous ammonium chloride solution (0.4 L). The mixture was extracted with diethyl ether (3 x 0.4 L) and the combined organic portions were dried over magnesium sulfate, filtered through a plug of silica gel and concentrated in vacuo to afford the clean product as an off-white solid (60.2 g, 98 %). ¹H NMR (300 MHz, CDCl₃): δ 1.24 (d, J = 6.6 Hz, 12H), 2.84-2.96 (m, 2H), 3.82 (s, 3H), 3.92 (s, 6H), 7.04 (s, 1H). ¹³C NMR (75 MHz, CDCl₃): δ 23.72, 31.36, 52.30, 63.56, 117.95, 125.66, 148.68, 153.76, 168.36. FAB-MS: calculated for C₁₇H₂₄O₅ 308; found 309 ((M+H)+). Anal. calc for C₁₇H₂₄O₅: C, 66.21; H, 7.84. Found: C, 66.22; H, 7.94. R_f = 0.3 (9:1 hexanes:ethyl acetate). HPLC: (C-18, A=0.05 % aqueous trifluoroacetic acid, B=CH₃CN; linear gradient: 50%-100% B over 30 min; 254 nm, 1 mL/min): R.T. 16.2 min (97.6 area%). mp 70.5-71.5 °C.

Step D: Diisopropyl 4,6-diisopropyl-2-methoxy-1,3-benzenedicarboxylate

Isopropanol (50 mL) was cautiously added to a flask charged with sodium hydride (95%, 0.33 g, 13.8 mmol). A solution of the intermediate obtained in Step C (8.5 g, 27.6 mmol) in isopropanol (100 mL) was added and the resulting mixture was held at reflux overnight. Additional sodium hydride (95%, 0.33 g, 13.8 mmol) and isopropanol (50 mL) were added to push the reaction to completion. Reflux was continued for five hours then the reaction mixture was cooled to ambient temperature and quenched with 10 % aqueous hydrochloric acid (60 mL). Isopropanol was removed in vacuo and the residual aqueous layer was extracted with diethyl ether (2 x 150 mL). The combined ethereal extracts were dried over magnesium sulfate, concentrated in vacuo, and chromatographed on silica (300 g) using dichloromethane:hexanes (1:1) as eluent to provide the clean product as a colorless crystalline solid (8.5 g, 85 %). ¹H NMR (300 MHz, CDCl₃): δ 1.25 (d, J = 7.0 Hz, 12H), 1.37 (d, J = 6.3 Hz, 12H), 2.90-2.98 (m, 2H), 3.85 (s, 3H), 5.30 (septet, J = 6.3 Hz, 2H), 7.02 (s, 1H). ¹³C NMR (75 MHz, CDCl₃): δ 21.77, 23.74, 31.12, 63.59, 68.92, 117.78, 126.44, 148.08, 153.20, 167.40. FAB-MS: calculated for C₂₁H₃₂O₅ 364; found

0 365 ((M+H)+). Anal. calc for C₂₁H₃₂O₅: C, 69.20; H, 8.85. Found: C, 69.23; H, 8.86. R_f = 0.42 (9:1 hexanes:ethyl acetate). HPLC: (C-18, A=0.05 % aqueous trifluoroacetic acid, B = CH₃CN; linear gradient: 50%-100% B over 30 min; 254 nm, 1 mL/min): R.T. 24.4 min (96.6 area %). mp 68.0-69.0°C.

5 Step E: Diisopropyl 3,5-diisopropyl-2'-benzyloxy-4'-fluoro-1,1'-biphenyl-2,6-dicarboxylate

A dry flask containing freshly ground magnesium turnings (2.88 g, 120 mmol) and a crystal of iodine was heated until a dark purple iodine atmosphere had formed. The flask was cooled to ambient temperature and a solution of 2-bromo-5-fluorophenyl benzyl ether (33.8 g, 120 mmol, Example 166, Step A) in dry tetrahydrofuran (60 mL) was added in several portions over 40 minutes at a rate sufficient to maintain reflux. Reflux was continued for 45 minutes, then the reaction was cooled to room temperature. This solution of Grignard reagent was transferred via syringe to a second flask containing a solution of the intermediate from Step D (11.0 g, 30.2 mmol) in dry benzene (66 mL). The reaction mixture was held at reflux for one hour, quenched with 10% aqueous hydrochloric acid (300 mL) and extracted with diethyl ether (3 x 300 mL). The combined extracts were dried over magnesium sulfate and concentrated in vacuo to give a brown oil which was subjected to flash column chromatography on silica (80 mm x 19.5") using a stepwise gradient elution of dichloromethane:hexanes (1:3, 1:2, 1:1, 4L each). The fractions containing the product were combined and concentrated to afford an inseparable mixture of the product and an unidentified side product in about a 1:1 ratio as a pale yellow gum (5.3 g, 33% mass balance). This material was not fully characterized and was used without further purification.

25 Step F: Isopropyl 3,5-diisopropyl-6-hydroxymethyl-2'benzyloxy-4'-fluoro-1,1'-biphenyl-2-carboxylate

A mixture of the intermediate from Step E (5.83 g, 10.9 mmol) and Red-Al (3.3 mL, 10.9 mmol) in dry tetrahydrofuran (100 mL) was held at reflux for 2.5 hours. Additional Red-Al was added (in 3.3 mL aliquots) and reflux maintained until the lower R_f spot disappeared (21 hours, total 8 eq. Red-Al; i.e. the by-product from the previous step reacted faster than the desired diester). The reaction mixture was cooled to 0 °C, carefully quenched with water (14 mL), and vigorously stirred for 2 hours. The precipitated solids were removed via vacuum filtration through paper and the collected solids were washed with ethyl acetate (3 x 100 mL) and refiltered. The combined filtrates were washed with a 1:1 mixture of water and saturated aqueous sodium chloride (100 mL), followed by water (75 mL) and

0 saturated aqueous sodium chloride (50 mL). The organic portion was separated, dried over sodium sulfate and concentrated in vacuo. Purification by flash column chromatography on silica (80 mm x 6") using hexanes:ethyl acetate (19:1) as eluent gave pure diisopropyl 3,5-diisopropyl-2'-benzyloxy-4'-fluoro-1,1'-biphenyl-2,6-dicarboxylate (2.63 g, 4.92 mmol). This was resubjected to the reaction conditions
5 with Red-Al (2.95 mL, 9.84 mmol) in dry tetrahydrofuran (45 mL). Additional Red-Al was added (in 2.95 mL aliquots) and reflux maintained until the reaction was complete (30 hours, total 12 eq. Red-Al). Worked up as above and subjected crude product to flash column chromatography on silica (40 mm x 7") using hexanes:ethyl acetate (19:1) as eluent to provide the desired product as a translucent colorless oil
10 (1.25 g, 55 %). ¹H NMR (300 MHz, CDCl₃): δ 0.91 (d, J = 6.6 Hz, 3H), 1.09 (d, J = 6.3 Hz, 3H), 1.20-1.33 (m, 9H), 1.35 (d, J = 7.0 Hz, 3H), 1.91-2.00 (br s, 1H), 2.94-3.07 (m, 1H), 3.37-3.50 (m, 1H), 4.24-4.46 (m, 2H), 4.84-5.06 (m, 3H), 6.73-6.87 (m, 2H), 7.01-7.08 (m, 2H), 7.14-7.29 (m, 4H), 7.39 (s, 1H). FAB-MS: calculated for C₃₀H₃₅O₄F 478; found 479 ((M+H)⁺). R_f = 0.23 (9:1 hexanes:ethyl acetate).

15

Step G: Isopropyl 3,5-diisopropyl-6-formyl-2'-benzyloxy-4'-fluoro-1,1'-biphenyl-2-carboxylate

A chilled (0°C) mixture of the intermediate from Step F (0.73 g, 1.52 mmol), Celite (1.46 g), and pyridinium chlorochromate (0.61 g, 2.84 mmol) in dry
20 dichloromethane (30 mL) was stirred for 5 hours, while warming to room temperature. The mixture was diluted with ethyl acetate (30 mL) and hexane (60 mL) and filtered through a plug of silica (30 mm x 3"). Elution was continued with ethyl acetate:hexanes (1:1 mixture, 2 x 120 mL). The combined filtrates were concentrated in vacuo to afford the desired product as a clear colorless oil (0.72 g,
25 99 %). ¹H NMR (300 MHz, CDCl₃): δ 0.90 (d, J = 6.3 Hz, 3H), 1.07 (d, J = 6.3 Hz, 3H), 1.23-1.36 (m, 12H), 2.99-3.10 (m, 1H), 3.92-4.02 (m, 1H), 4.85-5.06 (m, 3H), 6.65-6.76 (m, 2H), 7.15-7.30 (m, 6H), 7.46 (s, 1H), 9.84 (s, 1H). FAB-MS: calculated for C₃₀H₃₃O₄F 476; found 477 ((M+H)⁺). R_f = 0.47 (9:1 hexanes:ethyl acetate).

30 Step H: Isopropyl 3,5-diisopropyl-6-(prop-1-enyl)-2'-benzyloxy-4'-fluoro-1,1'-biphenyl-2-carboxylate

A chilled (-70°C) suspension of (ethyl)triphenylphosphonium bromide (0.88 g, 2.37 mmol) in dry tetrahydrofuran (6 mL) was treated with dropwise addition of n-butyllithium (2.47M in hexanes, 1.04 mL, 2.56 mmol). The mixture was
35 immediately warmed to 0 °C, stirred for 90 minutes at 0 °C, and recooled to -70 °C. A solution of the intermediate from Step G (0.94 g, 1.97 mmol) in dry tetrahydrofuran (6 mL) was added to the solution of ylide over several minutes

0 and the reaction mixture was warmed again to 0 °C and stirred for one hour. The
reaction was quenched with water (3 mL) and diluted with ethyl acetate (25 mL).
The organic portion was washed with saturated aqueous sodium chloride solution
(2 x 15 mL). The combined aqueous portions were back-extracted with ethyl
5 acetate (10 mL). The combined organic portions were dried over sodium sulfate
and concentrated in vacuo to provide the crude solid which was subjected to flash
column chromatography on silica (30 mm x 6") using hexanes:ethyl acetate (19:1) as
eluent. The clean fractions were combined and concentrated in vacuo to afford the
desired product as a pale yellow oil (0.81 g, 84 %). ¹H NMR (300 MHz, CDCl₃): δ
10 0.84-0.92 (m, 3H), 1.02-1.59 (m, 18H), 2.96-3.31 (m, 2H), 4.82-4.97 (m, 1H), 4.98 (s,
2H), 5.19-5.52 (m, 1H), 6.07- 6.19 (m, 1H), 6.57-6.69 (m, 2H), 7.05-7.31 (m, 7H). FAB-
MS: calculated for C₃₂H₃₇O₃F 488; found 489 (M+H)⁺. R_f = 0.58 (9:1 hexanes:ethyl
acetate).

15 Step I: 3,5-Diisopropyl-2-hydroxymethyl-6-(prop-1-enyl)-2'-benzyloxy-4'-
fluoro-1,1'-biphenyl


A reaction flask was charged with a suspension of lithium aluminum hydride
(95%, 0.14 g, 3.3 mmol) in dry tetrahydrofuran (5 mL) and heated to reflux. A
solution of the intermediate from Step H (0.80 g, 1.64 mmol) in dry
tetrahydrofuran (10 mL) was added to the refluxing suspension dropwise from a
20 syringe. The reaction mixture was held at reflux for 23 hours, cooled to ambient
temperature and quenched using saturated aqueous sodium sulfate solution which
was added dropwise until gas evolution stopped. The mixture was then diluted
with ethyl acetate (15 mL), stirred for several minutes and filtered through a pad of
Celite. The pad was washed copiously with additional ethyl acetate. The combined
25 filtrates were concentrated in vacuo and subjected to flash column chromatography
on silica (30 mm x 3") to afford the clean product as a clear oil (0.53 g, 75 %). ¹H
NMR (300 MHz, CDCl₃): δ 1.05-1.46 (m, 15H), 1.68-1.78 (br s, 1H), 3.07-3.49 (m, 2H),
4.27-4.47 (m, 2H), 4.85-5.05 (m, 2H), 5.25-5.52 (m, 1H), 5.92-6.08 (m, 1H), 6.68-6.76
(m, 2H), 6.98-7.13 (m, 3H), 7.18-7.29 (m, 3H), 7.35 (s, 1H). FAB-MS: calculated for
30 C₂₉H₃₃O₂F 432; found 432 (M)⁺. R_f = 0.29 (9:1 hexanes:ethyl acetate).

Step J: 3,5-Diisopropyl-2-hydroxymethyl-6-propyl-4'-fluoro-2'-hydroxy-1,1'-
biphenyl

A mixture of the intermediate from Step I (0.53 g, 1.23 mmol), and 10%
35 Pd/C (53 mg) in methanol (12 mL) was stirred under one atmosphere of hydrogen
gas for 18 hours. The reaction mixture was then filtered through a pad of Celite
and the pad was rinsed thoroughly with methanol (100 mL). The combined

0 filtrates were concentrated in vacuo and subjected to flash column chromatography on silica (20 mm x 4") using hexanes:ethyl acetate (9:1) as eluent. In this manner, the pure product was obtained as a clear oil which slowly solidified to provide the title compounds as a white solid (0.37 g, 87 %). ¹H NMR (300 MHz, CDCl₃): δ 0.76 (t, J = 7.4 Hz, 3H), 1.16-1.36 (m, 15H), 2.11-2.42 (m, 2H), 3.12-3.25 (m, 1H), 3.30-3.43 (m, 1H), 4.29-4.47 (m, 2H), 6.69-6.80 (m, 2H), 7.00-7.07 (m, 1H), 7.36 (s, 1H). ¹³C NMR (75 MHz, CDCl₃): δ 14.65, 24.29, 24.34, 24.50, 24.58, 29.21, 32.18, 59.61, 103.6 (d, J=24.4 Hz), 107.6 (d, J=22.0 Hz), 123.50, 123.67 (d, J=2.4 Hz), 131.21 (d, J=9.8 Hz), 134.07, 134.66, 137.42, 146.30, 148.12, 154.26 (d, J=12.2 Hz), 163.01 (d, J=244.2 Hz). FAB-MS: calculated for C₂₂H₂₉O₂F 344; found 344 (M)⁺. Anal. calc for C₂₂H₂₉O₂F: C, 76.71; H, 8.49. Found: C, 76.66; H, 8.34. R_f = 0.41 (4:1 hexanes:ethyl acetate). HPLC: (C-18, A=0.05 % aqueous trifluoroacetic acid, B=CH₃CN; linear gradient: 50%-100% B over 30 min; 254 nm, 1 mL/min): R.T. 17.1 min (97.5 area %). mp 127.5 - 129.0°C.

15

EXAMPLE 2423,5-Diisopropyl-2-(1-hydroxyethyl)-6-propyl-4'-fluoro-2'-hydroxy-1,1'-biphenyl

20

Step A: 3,5-Diisopropyl-2-hydroxymethyl-6-propyl-4'-fluoro-2'-benzyloxy-1,1'-biphenyl

25 A mixture of the racemic compound prepared in Example 241 (293 mg, 851 μmol), benzyl bromide (110 μL, 925 μmol), and potassium carbonate (303 mg, 2.19 mmol) in acetone (29 mL) was heated to reflux for 3 h. The mixture was diluted with saturated aqueous ammonium chloride solution (50 mL) and extracted with Et₂O (3 x 50 mL). Silica gel chromatography (90:10 hexane/ethyl acetate) provided a colorless oil (0.369 g, 100%). ¹H NMR (CDCl₃, 300 MHz): δ 7.34 (s, 1H), 7.23 (m, 3H), 7.12 (m, 1H), 7.03 (m, 2H), 6.84-6.75 (m, 2H), 5.04 (d, 12.1 Hz, 1H), 4.94 (d, 12.1

30

0 Hz, 1H), 4.38 (dd, 11.4 Hz, 8.5 Hz, 1H), 4.25 (dd, 11.4 Hz, 3.3 Hz, 1H), 3.39 (sept, 6.9 Hz, 1H), 3.18 (sept, 6.9 Hz, 1H), 2.30-2.40 (m, 1H), 2.09-2.20 (m, 1H), 1.65 (dd, 8.5 Hz, 3.3 Hz, 1H), 1.26-1.34 (m, 14H), 0.72 (t, 7.4 Hz, 3H).

5 Step B: 3,5-Diisopropyl-2-formyl-6-propyl-4'-fluoro-2'-benzyloxy-1,1'-biphenyl

Prepared from the intermediate obtained in Step A by the procedure described in Example 218, Step A. Silica gel chromatography (95:5 hexane/EtOAc) provided a colorless crystalline solid (0.323 g, 88%). ¹H NMR (CDCl₃, 300 MHz): δ 9.74 (s, 1H), 7.41 (s, 1H), 7.22-7.28 (m, 3H), 7.06-7.13 (m, 3H), 6.72-6.80 (m, 2H), 5.00 (s, 2H), 3.91 (sept, 6.8 Hz, 1H), 3.23 (sept, 6.7 Hz, 1H), 2.37-2.46 (m, 1H), 2.17-2.27 (m, 1H), 1.20-1.36 (m, 14H), 0.73 (t, 7.4 Hz, 3H). FAB-MS: calculated for C₂₉H₃₃FO₂ 432; found 433 (M+H).

15 Step C: 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-propyl-4'-fluoro-2'-benzyloxy-1,1'-biphenyl

Methyl lithium (2.7 mL of 1.4 M solution in Et₂O, 3.78 mmol) was added dropwise over five minutes to a cooled (ice-water bath) suspension of CuI (715 mg, 3.75 mmol, purified by extraction with THF) in toluene (10.8 mL) such that the internal temperature of the mixture was ≤3°C. The addition produced first a yellow-orange suspension and then a colorless solution. After 25 minutes the mixture was again a yellow-orange suspension. A solution of the intermediate obtained in Step B (306 mg, 707 μmol) in toluene (1 mL) was added dropwise over four minutes such that the internal temperature of the mixture was ≤2°C. After 30 minutes 1/3 saturated aqueous NH₄OH solution (40 mL) was added. After an additional 60 minutes the mixture was diluted with saturated aqueous NH₄Cl solution (40 mL) and extracted with Et₂O (3 x 40 mL). Silica gel chromatography (83:17 hexane/EtOAc) provided a colorless solid (0.290 g, 91%). The product was a mixture of diastereomers in a ratio of 93:7 as judged by HPLC. ¹H NMR (CDCl₃, 300 MHz, only peaks corresponding to the major diastereomer were visible): δ 7.35 (s, 1H), 7.22-7.24 (m, 3H), 7.11 (dd, 8.1 Hz, 7.0 Hz, 1H), 7.04 (m, 2H), 6.70-6.78 (m, 2H), 4.99 (d, 2.6 Hz, 2H), 4.83 (qd, J_q=6.8 Hz, J_d=2.8 Hz, 1H), 3.84 (sept, 6.8 Hz, 1H), 3.14 (sept, 6.9 Hz, 1H), 2.29 (m, 1H), 2.07 (m, 1H), 1.74 (d, 2.9 Hz, 1H), 1.25-1.35 (m, 17H), 0.70 (t, 7.4 Hz, 3H). EI-MS: calculated for C₃₀H₃₇FO₂ 448; found 448 (M⁺).

35 Step D: 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-propyl-4'-fluoro-2'-hydroxy-1,1'-biphenyl

0 The title compound was prepared from the intermediate obtained in Step C by the procedure described in Example 1, Step H. Silica gel chromatography (83:17 hexane/EtOAc) provided two colorless solids (0.229 g, 99%).

Diastereomer 1 was obtained as a colorless crystalline solid (0.214 g, 92%).
1H NMR (CDCl3, 300 MHz): δ 7.37 (s, 1H), 7.03 (m, 1H), 6.72 (m, 2H), 4.80-4.89 (m,
5 2H), 3.79 (sept, 6.8 Hz, 1H), 3.14 (sept, 6.8 Hz, 1H), 2.31 (m, 1H), 2.08 (m, 1H), 1.64 (d, 3.3 Hz, 1H), 1.41 (d, 7.0 Hz, 3H), 1.26-1.31 (m, 14H), 0.74 (t, 7.4 Hz, 3H). FAB-MS: calculated for C23H31FO2 358; found 341 (M-OH). mp 149-150°C. Rf = 0.25 (83:17 hexane/ethyl acetate).


Diastereomer 1 (212 mg) was resolved into its constituent enantiomers as
10 follows: a Waters Prep LC 4000 HPLC system was equipped with a chiral HPLC column (BRB-9668A; 6 x 50 cm ID). The system was equilibrated with a mobile phase consisting of 1% butanol and 99% heptane at a flow rate of 100 mL/min. The sample was dissolved in dichloromethane (70 mg/mL) and 1 mL aliquots were injected at 40 min intervals. The effluent was monitored at 285 nm and two
15 fractions (corresponding to the two enantiomers) were collected at (19-23 min, 100% ee) and (30-37 min, \geq 98% ee), respectively.

Enantiomer 1 was obtained as a colorless solid (78 mg). 1H NMR (CDCl3, 300 MHz): δ 7.37 (s, 1H), 7.02 (m, 1H), 6.71 (m, 2H), 4.77-4.89 (m, 2H), 3.77 (m, 1H), 3.14 (sept, 6.8 Hz, 1H), 2.31 (m, 1H), 2.08 (m, 1H), 1.63 (d, 2.9 Hz, 1H), 1.41 (d, 6.6
20 Hz, 3H), 1.26-1.31 (m, 14H), 0.74 (t, 7.2 Hz, 3H). FAB-MS: calculated for C23H31FO2 358; found 341 (M-OH).

Enantiomer 2 was obtained as a colorless solid (74 mg). 1H NMR (CDCl3, 300 MHz): δ 7.38 (s, 1H), 7.03 (m, 1H), 6.72 (m, 2H), 4.80-4.90 (m, 2H), 3.79 (sept, 6.6
25 Hz, 1H), 3.14 (sept, 6.7 Hz, 1H), 2.30 (m, 1H), 2.07 (m, 1H), 1.63 (d, 3.3 Hz, 1H), 1.41 (d, 6.6 Hz, 3H), 1.26-1.31 (m, 14H), 0.74 (t, 7.2 Hz, 3H). FAB-MS: calculated for C23H31FO2 358; found 341 (M-OH).

Diastereomer 2 was obtained as a colorless crystalline solid (15.3 mg, 7%).
1H NMR (CDCl3, 300 MHz): δ 7.37 (s, 1H), 6.92 (m, 1H), 6.70 (m, 2H), 5.1 (br s, 1H), 4.64 (q, 6.7 Hz, 1H), 3.85 (sept, 6.7 Hz, 1H), 3.14 (sept, 6.8 Hz, 1H), 2.32 (m, 1H), 2.09
30 (m, 1H), 1.8 (br s, 1H), 1.37 (d, 6.6 Hz, 3H), 1.24-1.30 (m, 14H), 0.74 (t, 7.2 Hz, 3H). FAB-MS: calculated for C23H31FO2 358; found 341 (M-OH). mp 179-180°C.

0

EXAMPLE 243(+)-3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-4'-fluoro-1,1'-biphenyl

5

Step A: 3,5-Diisopropyl-2-(1-oxoethyl)-6-pentyl-4'-fluoro-1,1'-biphenyl

A mixture of 3,5-diisopropyl-2-(1-hydroxyethyl)-6-pentyl-4'-fluoro-1,1'-biphenyl (Example 192, 13.7 g, 37.1 mmol), Celite (26 g), and pyridinium chlorochromate (14.9 g, 69.3 mmol) in dichloromethane (750 mL) was stirred for 45 minutes. The mixture was diluted with ethyl acetate (750 mL) and hexane (1.5 L) and filtered through a plug of silica (100 mm x 2") topped with Celite (100 mm x 0.5"). Elution was continued with ethyl acetate:hexanes (1:1 mixture, 3L x 2). The combined filtrates were concentrated *in vacuo* to afford the desired product as a white solid (13.5 g, 99 %). ¹H NMR (300 MHz, CDCl₃): δ 0.75 - 0.80 (m, 3H), 1.06 - 1.31 (m, 18H), 1.95 (s, 3H), 2.33 - 2.39 (m, 2H), 2.78 (septet, J = 7.0 Hz, 1H), 3.18 (septet, J = 7.0 Hz, 1H), 7.03 - 7.09 (m, 2H), 7.17 - 7.22 (m, 2H) 7.26 (s, 1H). ¹³C NMR (75 MHz, CDCl₃): δ 13.75, 22.02, 24.32, 24.37, 28.99, 29.10, 29.28, 30.60, 31.04, 32.06, 33.03, 114.85 (d, J = 20.8 Hz, 2C), 122.06, 132.03 (d, J = 7.3 Hz, 2C), 135.52 (d, J = 2.4 Hz, 1C) 135.58, 135.76, 140.13, 140.85, 147.66 161.99 (d, J = 246.6 Hz, 1C), 208.23. EI-MS: calculated for C₂₅H₃₃OF 368; found 368 (M⁺). Anal. calc for C₂₅H₃₃OF: C, 80.86; H, 8.96. Found: C, 81.04; H, 9.06. R_f = 0.65 (9:1 hexanes:ethyl acetate). HPLC: (C-18, A = 0.05 % aqueous trifluoroacetic acid, B = CH₃CN; linear gradient: 75%-100% B over 30 min; 254 nm, 1 mL/min): R.T. 22.7 min (94.0 area %). mp 123.0-124.5°C.

25


Step B: (+)-3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-4'-fluoro-1,1'-biphenyl

A mixture of (1S,2R)-(+)-N-methylephedrine (13.9 g, 77.3 mmol) in diethyl ether (225 mL) at 0 °C under an argon atmosphere was treated with slow addition of lithium aluminum hydride (1M in diethyl ether, 77.3 mL, 77.3 mmol). The

30

0 mixture was held at reflux for one hour and then cooled to -75 °C. A solution of
the intermediate from Step A (13.5 g, 36.7 mmol) in diethyl ether (500 mL, 50 mL
rinse) was then added to the reaction mixture in such a manner that the internal
temperature did not rise above -68 °C. The reaction stirred for 3 hours at -75 °C
and was warmed to ambient temperature overnight. The reaction was cooled to 0
5 °C, quenched by adding water (500 mL), and diluted with diethyl ether (750 mL).
The aqueous portion was separated and back-extracted with diethyl ether (200 mL).
The combined organic portions were washed with water (2 x 500 mL), 10 %
aqueous hydrochloric acid (500 mL), and saturated aqueous sodium chloride (2 x
500 mL), dried over sodium sulfate, filtered through a pad of silica (80 mm x 1.25")
10 and concentrated *in vacuo*. The resulting solid was recrystallized from
ethanol:water (2:1) and dried *in vacuo* with several minutes of heating to provide
the title compound as a fine white powder (11.08 g, 82 %). ¹H NMR (300 MHz,
CDCl₃): δ 0.75 - 0.80 (m, 3H), 1.02 - 1.31 (m, 19H), 1.40 (d, J = 6.6 Hz, 3H), 2.17 - 2.22
(m, 2H), 3.08 - 3.18 (m, 1H), 3.83 - 3.92 (m, 1H), 4.66 - 4.73 (m, 1H), 7.05 - 7.23 (m,
15 4H), 7.32 (s, 1H). ¹³C NMR (75 MHz, CDCl₃): δ 13.88, 22.02, 23.38, 24.23, 24.56,
24.63, 25.09, 28.68, 28.96, 29.92, 31.04, 32.23, 68.91, 114.80 (d, J = 20.8 Hz, 1C), 115.02
(d, J = 20.8 Hz, 1C), 124.27, 130.40 (d, J = 8.5 Hz, 1C), 131.25 (d, J = 7.3 Hz, 1C),
135.53, 136.98, 137.73 (d, J = 2.4 Hz, 1C), 139.02, 145.82 (2C), 161.68 (d, J = 245.4 Hz,
1C). FAB-MS: calculated for C₂₅H₃₅OF 370; found 370 (M⁺). Anal. calc for
20 C₂₅H₃₅OF: C, 81.03; H, 9.52. Found: C, 81.15; H, 9.68. R_f = 0.36 (9:1 hexanes:ethyl
acetate). HPLC: (C-18, A = 0.05 % aqueous trifluoroacetic acid, B = CH₃CN; linear
gradient: 75%-100% B over 30 min; 254 nm, 1 mL/min): R.T. 22.6 min (98.3 area %),
(Daicel Chiralcel OD-H; isocratic 99:1 hexanes:methyl *t*-butyl ether; 254 nm, 1.5
mL/min); R.T. 6.20 min.(97.2 area %), 8.37 min. (0.36 area %); 99.5 % e.e. [α]_D =
25 +26.9° (c = 0.00196 g/mL, CH₂Cl₂). mp 108.5-109.5°C.

EXAMPLE 244



30 (+)-3,5-Diisopropyl-2-(1-hydroxyethyl)-6-ethyl-4'-fluoro-1,1'-biphenyl

0

Step A: Dimethyl 4,6-diethyl-2-trifluoromethanesulfonyloxy-1,3-benzenedicarboxylate

5 A solution of 90 g (338 mmol) of dimethyl 4,6-diethyl-2-hydroxy-1,3-benzenedicarboxylate (Example 241, Step A) in dichloromethane (1 L) was treated with pyridine (109 mL, 1.35 mol). The mixture was stirred under argon at 0°C and treated dropwise with triflic anhydride (83 mL, 507 mmol). The reaction mixture was warmed to room temperature and stirred for 3 hours. Then was washed with 5% HCl (1.5 L), water (1 L), saturated sodium bicarbonate (2 x 500 mL), and dried with MgSO₄. Filtration and concentration afforded a dark oil (129.7 g, 326 mmol, 10 96%). R_f = 0.4 (10% ethyl acetate/hexane). ¹H NMR (300 MHz, CDCl₃): δ 7.20 (s, 1 H), 3.93 (s, 6 H), 2.74 (q, J = 7.4 Hz, 4 H), 1.22 (t, J = 4.8 Hz, 6 H). FAB-MS: calculated for (C₁₅H₂₇F₃O₇) 398, found 399 (M+H).

Step B: 3,5-Diethyl-2,6-dicarboxymethyl-4'-fluoro-1,1'-biphenyl

15 To a solution of the intermediate obtained in Step A (129.7 g, 326 mmol) in dioxane (2.5 L) was added 4-fluorobenzene boronic acid (68.4 g, 492 mmol), potassium phosphate (145 g, 683 mmol), potassium bromide (58.1 g, 488 mmol), tetrakis(triphenylphosphine)palladium (18.8 g, 16.3 mmol), and water (20 mL). The reaction mixture was stirred under argon at reflux for 24 hrs. The reaction mixture 20 was filtered through a pad of celite and concentrated *in vacuo*. The oily residue was filtered twice through a pad of silica (700 g, 40% dichloromethane/hexane) to afford a yellow solid. Recrystallization from hexane afforded a white solid (52.6 g, 153 mmol, 47%). mp = 98-99°C. R_f = 0.4 (10% ethyl acetate/hexane). ¹H NMR (300 MHz, CDCl₃): δ 7.26 (m, 2 H), 7.17 (s, 1 H), 7.04 (m, 2 H), 3.49 (s, 6 H), 2.67 (q, J = 7.7 Hz, 4 H), 1.25 (t, J = 7.7 Hz, 6 H). FAB-MS: calculated for (C₂₀H₂₁FO₄) 344, found 345 (M+H).

Step C: 3,5-Diisopropyl-2,6-dicarboxymethyl-4'-fluoro-1,1'-biphenyl

30 A solution of diisopropylamine (22.7 mL, 0.174 mol) in dry tetrahydrofuran (0.2 L) at -78°C under an argon atmosphere was treated with slow addition of n-butyllithium (2.5M in hexanes, 70 mL, 0.174 mol). After the reaction stirred for fifteen minutes, a solution of the intermediate from Step B (46.0 g, 0.133 mol) in dry tetrahydrofuran (0.2 L) was added to the solution of LDA over 15 minutes. Stirring was continued for 30 minutes while the temperature was held at -78°C. Neat 35 iodomethane (11.2 mL, 0.180 mol) was added to the reaction mixture via syringe; two-thirds of the charge was transferred at the outset, the reaction was allowed to stir for 20 minutes, then the final third of the charge was added, followed by

- 0 another 10 minutes of stirring. A second pot of LDA (0.174 mol) in dry tetrahydrofuran (0.2 L) was produced by the above procedure and was transferred to the reaction mixture via cannula over 15 minutes. Stirring was continued for 30 minutes at -78 °C then a second portion of neat iodomethane (11.2 mL, 0.180 mol) was added to the reaction mixture using the addition sequence described above.
- 5 The cooling bath was removed and the reaction mixture was quenched with saturated aqueous ammonium chloride solution (0.4 L). The mixture was extracted with diethyl ether (3 x 0.4 L) and the combined organic portions were dried over magnesium sulfate and concentrated in vacuo to afford an oil, which crystallized upon standing. The white solid was washed with a small portion of hexane (41.7 g, 84 %). mp 128-130°C. $R_f = 0.5$ (10% ethyl acetate/hexane). ^1H NMR (300 MHz, CDCl_3): δ 7.33 (s, 1 H), 7.26 (m, 2 H), 7.03 (m, 2 H), 3.49 (s, 6 H), 2.97 (sept, $J = 6.6$ Hz, 2 H), 1.29 (d, $J = 7.0$ Hz, 6 H). FAB-MS: calculated for ($\text{C}_{22}\text{H}_{25}\text{FO}_4$) 372, found 373 (M+H).

15 Step D: 3,5-Diisopropyl-2-hydroxymethyl-6-carboxymethyl-4'-fluoro-1,1'-biphenyl

- To a solution of the intermediate obtained in Step C (37.3 g, 100 mmol) in anhydrous tetrahydrofuran (350 mL) stirred under argon at 0°C was added a solution of 3.4M of sodium bis(2-methoxyethoxy)aluminum hydride in toluene (Red-Al) (105 mL, 204 mmol, 65 wt% in toluene) via syringe over 20 min. The reaction mixture was allowed to stir at room temperature for 24 hr, then cooled again to 0°C and carefully quenched by the dropwise addition of water. The solution was decanted from the solid which forms and the solvent removed *in vacuo*. The residue was purified by flash chromatography (500 g silica) via step
- 20 gradient. Elution with 5% diethyl ether/hexane affords 9.8 g (26.3 mmol, 28%) of recovered starting material and elution with 40% diethyl ether(Et_2O)/hexane affords the desired product as a white solid (26.8 g, 77.8 mmol, 78%). mp 124-126°C. $R_f = 0.2$ (10% ethyl acetate/hexane). ^1H NMR (300 MHz, CDCl_3): δ 7.35 (s, 1 H), 7.27 (m, 2 H), 7.08 (m, 2 H), 4.44 (d, $J = 5.5$ Hz, 2 H), 3.43 (m, 4 H), 2.92 (sept, $J = 6.6$ Hz, 1 H), 1.59 (s, 1 H), 1.28 (m, 12 H). FAB-MS: calculated for ($\text{C}_{21}\text{H}_{25}\text{FO}_3$) 344, found 345 (M+H).

35 Step E: 3,5-Diisopropyl-2-carboxaldehyde-6-carboxymethyl-4'-fluoro-1,1'-biphenyl

- To a solution of the intermediate obtained in Step D (26.8 g, 77.8 mmol) in dichloromethane (400 mL) was added celite (33.6 g). The suspension was stirred at room temperature and treated with pyridinium chlorochromate (PCC) (33.6 g, 15.6

0 mmol) in three portions. The suspension was stirred at room temperature for 2 hr, then poured into 1:1 diethyl ether/hexane (1 L), filtered through a pad of silica, the pad was washed with diethyl ether (600 mL) and the combined eluent concentrated to afford a gummy oil (23.3 g, 68.1 mmol, 87%): $R_f = 0.4$ (10% ethyl acetate/hexane). $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 9.87 (s, 1 H), 7.36 (s, 1 H), 7.28 (m, 2 H), 7.15 (m, 2 H), 3.48 (s, 3 H), 3.89 (sept, $J = 6.6$ Hz, 1 H), 3.10 (sept, $J = 6.6$ Hz, 1 H), 1.35 (m, 12 H); FAB-MS calcd for $(\text{C}_{21}\text{H}_{23}\text{FO}_3)$ 342, found 343 ($\text{M}+\text{H}$).

Step F: 3,5-Diisopropyl-2-carboxymethyl-6-ethenyl-4'-fluoro-1,1'-biphenyl

10 Methyltriphenylphosphonium bromide (15.5 g, 43.4 mmol) was suspended in anhydrous THF (250 mL) under argon and stirred at -78°C . A 1.6 M solution of *n*-butyllithium in hexanes (25 mL, 40.2 mmol) was added dropwise. The reaction mixture was allowed to come to 0°C and was stirred at that temperature for 1.5 hr. The resulting brightly colored solution was cooled again to -78°C and treated dropwise with a solution of the intermediate obtained in Step E (11.4 g, 33.3 mmol) in THF (100 mL). The reaction mixture was allowed to stir at 0°C for 1 hr, then quenched by the addition of water (30 mL). The THF was removed *in vacuo*, the residue partitioned between diethyl ether (400 mL) and water (400 mL). The organic layer was washed with brine (100 mL), dried over MgSO_4 and concentrated. Flash chromatography through silica (5% diethyl ether/hexane) affords a solid (10.3 g, 30.3 mmol, 91%) (E, Z mixture). $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 7.31 (s, 1 H), 7.16 (m, 2 H), 7.02 (m, 2 H), 6.10 (dd, $J = 6.3, 11.4$ Hz, 1 H), 6.04 (dd, $J = 1.8, 13.6$ Hz, 1 H), 5.48 (dd, $J = 1.8, 19.9$ Hz, 1 H), 3.46 (s, 3 H), 3.35 (sept, $J = 6.6$ Hz, 1 H), 2.93 (sept, $J = 6.6$ Hz, 1 H), 1.29 (m, 12 H). EI-MS calculated for $(\text{C}_{22}\text{H}_{25}\text{FO}_2)$ 340, found 340 (M^+). mp $58-61^\circ\text{C}$. $R_f = 0.6$ (10% ethyl acetate/hexane).

25 Step G: 3,5-Diisopropyl-2-hydroxymethyl-6-ethenyl-4'-fluoro-1,1'-biphenyl

30 The intermediate obtained in Step F (10.0 g, 29.4 mmol) was dissolved in anhydrous THF (150 mL) under argon and treated dropwise at room temperature with lithium aluminum hydride (1.0 M in THF, 41 mL, 41 mmol). The reaction mixture was stirred at reflux for 2 hours, cooled to room temperature and quenched by the addition of 30 mL H_2O . The THF was removed *in vacuo*, the residue partitioned between diethyl ether (400 mL) and water (3×400 mL). The organic layer was washed with brine (300 mL), dried over MgSO_4 and concentrated. Flash chromatography through silica (5% diethyl ether/hexane) affords a solid (7.7 g, 24.7 mmol, 84%). $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 7.38 (s, 1 H), 7.14 (m, 4 H), 6.35 (dd, $J = 6.3, 11.4$ Hz, 1 H), 5.20 (dd, $J = 1.8, 13.6$ Hz, 1 H), 4.98 (dd, $J = 1.8, 19.9$ Hz, 1 H), 4.40 (d, $J = 5.5$ Hz, 2 H), 3.39 (m, 2 H), 1.29 (m, 12 H). FAB-MS

- 0 calculated for (C₂₁H₂₅FO) 312, found 312 (M⁺). mp 97-99°C. R_f = 0.1 (50% dichloromethane/hexane).

Step H: 3,5-Diisopropyl-2-hydroxymethyl-6-ethyl-4'-fluoro-1,1'-biphenyl

- 5 The intermediate obtained in Step G (7.7 g, 24.7 mmol) was dissolved in absolute ethanol (200 mL) under argon, treated with 10% palladium on carbon (610 mg, 0.1 eq), then stirred under a hydrogen atmosphere for 2 hr. After purging the system with argon, the catalyst was removed by filtration through a pad of Celite. The solvent was removed and the product dried *in vacuo* to afford the title compound as a white solid (7.7 g, 25 mmol, 99%). ¹H NMR (300 MHz, CDCl₃): δ
- 10 7.32 (s, 1 H), 7.15 (m, 4 H), 4.33 (m, 2 H), 3.39 (septet, *J* = 7 Hz, 1 H), 3.32 (septet, *J* = 7 Hz, 1 H), 2.37 (q, *J* = 7.7 Hz, 2 H), 1.29 (m, 13 H), 0.92 (t, *J* = 7.7 Hz, 3 H). FAB-MS calculated for (C₂₁H₂₇FO) 314, found 314 (M⁺). mp 106-108°C. R_f = 0.1 (50% dichloromethane /hexane).

15 Step I: 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-ethyl-4'-fluoro-1,1'-biphenyl

- The intermediate obtained in Step H (7.65 g, 24.3 mmol) was dissolved in dichloromethane (250 mL), treated with celite (10.5 g). The suspension was stirred at room temperature and treated with pyridinium chlorochromate (PCC) (10.5 g, 48.7 mmol). Stirring was continued at room temperature for 2 hrs. The suspension
- 20 was poured into 1:1 diethyl ether/hex (1 L), filtered through a pad of silica, the pad washed with diethyl ether (600 mL) and the combined eluent concentrated to afford a solid (7.25 g, 23.2 mmol, 95%).

- The intermediate (7.25 g, 23.2 mmol) was dissolved in THF (75 mL) at 0°C under argon atmosphere and treated dropwise with Methyl magnesium bromide
- 25 (3 M, 1.3 eq, 10.1 mL). The reaction was stirred for 1 hr. The reaction was quenched with saturated ammonium chloride (7 mL) and the THF was evaporated *in vacuo* to afford an oil. The product was partitioned between water (100 mL) and diethyl ether (250 mL) and the organic layer was dried with MgSO₄, filtered, and concentrated to yield a white solid. Flash chromatography using silica gel (60%
- 30 CH₂Cl₂/hexane) afforded a white solid (7.2 g, 22 mmol, 99%). mp 138-140°C; R_f = 0.1 (50% CH₂Cl₂/hexane); ¹H NMR (300 MHz, CDCl₃): δ 7.34 (s, 1 H), 7.15 (m, 4 H), 4.69 (dq, *J* = 2.9, 7 Hz, 1 H), 3.88 (septet, *J* = 7 Hz, 1 H), 3.17 (septet, *J* = 6.6 Hz, 1 H), 2.28 (q, *J* = 7.4 Hz, 2 H), 1.64 (d, *J* = 2.9 Hz, 1 H), 1.39 (d, *J* = 6.6 Hz, 3 H), 1.27 (m, 12 H), 0.89 (t, *J* = 7.4 Hz, 3 H); FAB-MS calcd for (C₂₂H₂₉FO) 328, found 328
- 35 (M⁺).


0 Step J: 3,5-Diisopropyl-2-(1-oxoethyl)-6-ethyl-4'-fluoro-1,1'-biphenyl

 The intermediate obtained in Step I (7.23 g, 22 mmol) in dichloromethane (100 mL) was added pyridinium chlorochromate (9.49 g, 44 mmol) and celite (9.49 g) under argon. The reaction was stirred at room temperature for 24 hours. The reaction was added to a 1:1 mixture of diethyl ether/hexane (1 L), then filtered
5 through a plug of silica. The pad was washed with 650 mL of diethyl ether and the combined filtrates were concentrated in vacuo to afford a white solid (7.18 g, 22 mmol, 99%). mp 121-23°C; R_f = 0.3 (50% CH₂Cl₂/hexane); ¹H NMR (300 MHz, CDCl₃): δ 7.27 (s, 1 H), 7.21 (m, 2 H), 7.07 (m, 2 H), 3.22 (septet, J = 7 Hz, 1 H), 2.78 (septet, J = 7 Hz, 1 H), 2.43 (q, J = 7.4 Hz, 2 H), 1.96 (s, 3 H), 1.28 (m, 12 H), 0.930 (t, J = 7.7 Hz, 3 H); FAB-MS calcd for (C₂₂H₂₇FO) 326, found 327 (M+H).
10

Step K: (+)-3,5-Diisopropyl-2-(1-hydroxyethyl)-6-ethyl-4'-fluoro-1,1'-biphenyl

 To a solution of (1S,2R)-(+)-N-methylephedrine (6.29 g, 35.1 mol) in diethyl ether (45 mL) was added lithium aluminum hydride (1M/diethyl ether, 1.5 eq., 35 mL) dropwise at 0°C under argon. The reaction was refluxed for 1.5 h. turning
15 from a clear solution to a white milky solution. The reaction was cooled to room temperature and then -78°C. The intermediate obtained in Step J (6.64 g, 20.3 mmol) was dissolved in 60 mL of dry diethyl ether for a dropwise addition to the reaction mixture (~2 mL/min., the temperature should not rise above -60°C). The
20 reaction was kept at -78°C for 2.0 hours and then allowed to warm overnight. The reaction was quenched at 0°C with water (30 mL) and diluted with diethyl ether (250 mL), washed with water (3 x 200 mL), brine (100 mL) and dried with MgSO₄. Filtration and concentration afford a residue which was filtered through a pad of silica (400 g, 80% dichloromethane/hexane) to give the titled compound (99% e.e.)
25 as a white solid (5.85 g, 17.8 mmol, 88%). mp 143-145°C; R_f = 0.1 (50% CH₂Cl₂/hexane); ¹H NMR (300 MHz, CDCl₃): δ 7.34 (s, 1 H), 7.15 (m, 4 H), 4.68 (dq, J = 3.3, 7 Hz, 1 H), 3.88 (septet, J = 7 Hz, 1 H), 3.18 (septet, J = 7 Hz, 1 H), 2.29 (q, J = 7.7 Hz, 2 H), 1.68 (s, 1 H), 1.37 (d, J = 4.8 Hz, 3 H), 1.26 (m, 12 H), 0.890 (t, J = 7.4 Hz, 3 H); FAB-MS calcd for (C₂₂H₂₉FO) 328, found 328 (M+); Anal. Calcd for C₂₂H₂₉FO: C, 80.45; H, 8.90; F, 5.78. Found: C, 80.19; H, 8.77; F, 5.84; $[\alpha]^{22}_D$ = +26.6.
30


0

EXAMPLE 245(+)-3,5-Diisopropyl-2-(1-hydroxyethyl)-6-propyl-4'-fluoro-1,1'-biphenyl

5

The title compound (99% ee) was prepared from the intermediate obtained in Step E, Example 244 and ethyl triphenylphosphonium bromide according to the procedures described in Example 244, Steps F-K. ^1H NMR (300 MHz, CDCl_3): δ 7.33 (s, 1 H), 7.14 (m, 4 H), 4.70 (dq, $J = 2.9, 7$ Hz, 1 H), 3.88 (septet, $J = 6.62$ Hz, 1 H), 3.14 (septet, $J = 6.62$ Hz, 1 H), 2.18 (m, 2 H), 1.67 (d, $J = 2.9$ Hz, 1 H), 1.37 (d, $J = 7$ Hz, 3 H), 1.29 (m, 14 H), 0.719 (t, $J = 7$ Hz, 3 H); FAB-MS calcd for $(\text{C}_{23}\text{H}_{31}\text{FO})$ 342, found 342 (M^+); Anal. Calcd for $\text{C}_{23}\text{H}_{31}\text{FO}$: C, 80.66; H, 9.12; F, 5.55. Found: C, 80.71; H, 8.99; F, 5.34; $[\alpha]^{22} = +23.8$. mp 114-116°C; $R_f = 0.1$ (50% CH_2Cl_2 /hexane).

15

EXAMPLE 24620 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-ethyl-4'-fluoro-2'-hydroxy-1,1'-biphenylStep A: Di-tert-butyl 4,6-diethyl-2-hydroxy-1,3-benzenedicarboxylate

A mixture of di-tert-butyl 1,3-acetonedicarboxylate (10 g, 38.7 mmol), 3,5-heptanedione (6.5 g, 50.3 mmol) and sodium methoxide (2.7 g, 50.3 mmol) in

0 methanol (100 mL) was stirred at room temperature overnight. Methanol was removed via rotary evaporation and the resulting orange sludge was partitioned between diethyl ether (100 mL) and 10 % aqueous hydrochloric acid (100 mL). The separated aqueous layer was extracted with diethyl ether (50 mL x 2). The combined organic portions were washed with saturated aqueous sodium chloride
5 (20 mL), dried over sodium sulfate, filtered through a pad of silica (20 mm x 40 mm) and concentrated in vacuo to yield a yellow oil (13.23 g, 97 %): ¹H NMR (300 MHz, CDCl₃): δ 1.20 (t, 6H), 1.60 (s, 18H) 2.74 (q, 4H), 6.55 (s, 1H), 11.73 (s, 1H).

10 Step B: Di-tert-butyl 3,5-diisopropyl-2'-benzyloxy-4'-fluoro-1,1'-biphenyl-2,6-dicarboxylate

The title compound was prepared from the intermediate obtained in Step A by the methods described in Example 241, Steps B, C, and E. ¹H NMR (300 MHz, CDCl₃): δ 1.15 (s, 18H), 1.27 (dd, J=5.15, 1.65 Hz, 12 H), 3.06 (m, 2H), 4.95 (s, 2H), 6.65 (m, 2H), 7.27 (m, 7H).

15 Step C: 3,5-Diisopropyl-2'-benzyloxy-4'-fluoro-1,1'-biphenyl-2,6-dicarboxylate

To a solution of 14.37 g (25.53 mmol) of the intermediate obtained in Step B in dichloromethane (150 mL) at 0°C was added trifluoroacetic acid (20 mL, 259.60 mmol). This reaction mixture was allowed to warm to room temperature
20 overnight. The reaction mixture was concentrated to dryness and the residue was partitioned between diethyl ether and aqueous sodium hydroxide. The organic layer was removed, washed with aqueous sodium hydroxide and the two aqueous layers were combined. The combined aqueous layers were washed with diethyl ether (1x) then made acidic by addition of HCl (10%) and extracted with diethyl
25 ether (3x). The combined organic layers were dried over magnesium sulfate, filtered and concentrated to yield an off-white solid. The crude product was taken directly to the next step without any further purification.

30 Step D: Dimethyl 3,5-diisopropyl-2'-benzyloxy-4'-fluoro-1,1'-biphenyl-2,6-dicarboxylate

To a suspension of 7.17 g (15.93 mmol) of the intermediate obtained in Step C in dichloromethane (200 mL) at 0°C was added solid potassium carbonate (10.05 g, 72.71 mmol) followed by iodomethane (5.0 mL, 80.31 mmol). The mixture was allowed to warm to room temperature. After stirring for 1 day the mixture was
35 diluted with water and extracted with diethyl ether (3x). The combined extracts were washed with brine (1x), dried over magnesium sulfate, filtered and concentrated to yield an off-white solid. ¹H NMR (300 MHz, CDCl₃): δ 1.22 (dd,

0 J=4.41, 2.4 Hz, 12H), 2.94 (m, 2H), 3.39 (s, 6H), 4.93 (s, 2H), 6.55 (m, 2H), 7.05 (m, 1H), 7.18 (m, 6H).

Step E: 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-ethyl-4'-fluoro-2'-hydroxy-1,1'-biphenyl

5 The title compound was prepared from the intermediate obtained in Step D by the methods described in Example 241 steps F-I (using ethyl triphenylphosphonium bromide in Step H) followed by Example 242 steps B-D. Silica gel chromatography (90% hexane/10% EtOAc) provided two colorless solids (1.129g, 84%).

10 Diastereomer 1 was obtained as a colorless crystalline solid (1.029g, 77%). ¹H NMR (300 MHz, CDCl₃): δ 0.89 (t, J=7.36 Hz, 3H), 1.28 (m, 12H), 1.40 (d, J=6.62 Hz, 3H), 1.63 (bs, 1H), 2.29 (m, 2H), 3.17 (m, 1H), 3.78 (m, 1H), 4.84 (m, 1H), 6.70 (m, 2H), 7.03 (m, 1H), 7.38 (s, 1H). FAB-MS: calculated for C₂₂H₂₉O₂F, 344; found 367 [M+Na]. mp 174-175°C.


15 Diastereomer 1 (1.029 g) was resolved into its constituent enantiomers as follows: a Waters Prep LC 4000 HPLC system was equipped with a chiral HPLC column (BRB-9668A; 6 x 50 cm ID). The system was equilibrated with a mobile phase consisting of 0.75% butanol and 99.25% hexane at a flow rate of 100 mL/min. The sample was dissolved in dichloromethane (20 mg/mL) and the sample was
20 injected in one injection. The effluent was monitored at 285 nm and two fractions (corresponding to the two enantiomers) were collected at (26-32 min, ≥98% ee) and (34-48 min, ≥99% ee), respectively.

Enantiomer 1 was obtained as a colorless solid (480 mg). ¹H NMR (300 MHz, CDCl₃): δ 0.89 (t, J=7.54 Hz, 3H), 1.28 (m, 12H), 1.40 (d, J=5.14 Hz, 3H), 1.65
25 (bs, 1H), 2.19 (m, 1H), 2.35 (m, 1H), 3.17 (m, 1H), 3.78 (m, 1H), 4.85 (m, 1H), 6.71 (m, 2H), 7.03 (m, 1H), 7.38 (s, 1H). mp condenses at 57-59°C.

Enantiomer 2 was obtained as a colorless solid (483 mg). ¹H NMR (300 MHz, CDCl₃): δ 0.89 (t, J=7.36 Hz, 3H), 1.28 (m, 12H), 1.39 (d, J=6.99 Hz, 3H), 1.63
30 (bs, 1H), 2.29 (m, 2H), 3.17 (m, 1H), 3.78 (m, 1H), 4.84 (m, 1H), 6.70 (m, 2H), 7.03 (m, 1H), 7.38 (s, 1H). FAB-MS: calculated for C₂₂H₂₉O₂F, 344; found 367 [M+Na]. mp condenses at 57-59°C.

Diastereomer 2 was obtained as a colorless crystalline solid (100 mg, 7%). ¹H NMR (CDCl₃, 300 MHz): δ 0.88 (t, J=7.54 Hz, 3H), 1.27 (m, 12H), 1.36 (d, J=6.62 Hz, 3H), 1.8 (bs, 1H), 2.19 (m, 1H), 2.39 (m, 1H), 3.16 (m, 1H), 3.84 (m, 1H), 4.63 (q,
35 J=6.62 Hz, 1H), 5.09 (bs, 1H), 6.69 (m, 2H), 6.92 (t, J=7.35 Hz, 1H), 7.37 (s, 1H). mp 183-184°C.

0

EXAMPLE 2473,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-4'-fluoro-2'-hydroxy-1,1'-biphenyl5 Step A: 3,5-Diisopropyl-2-hydroxymethyl-6-(pent-1-enyl)-2'-benzyloxy-4'-fluoro-1,1'-biphenyl

The desired compound was prepared from dimethyl 3,5-diisopropyl-2'-benzyloxy-4'-fluoro-1,1'-biphenyl-2,6-dicarboxylate (Example 246, Step D) by the procedure described in Example 241, Steps F - I (using pentyl triphenylphosphonium bromide in Step H). The pure product obtained was a clear oil (4.73 g, 52 % over 4 steps). ¹H NMR (300 MHz, CDCl₃): δ 0.67 - 0.78 (m, 3H), 1.09 - 1.34 (m, 14H), 1.66 - 1.88 (m, 3H), 3.16 - 3.46 (m, 2H), 4.29 - 4.44 (m, 2H), 4.88 - 5.04 (m, 2H), 5.27 - 5.41 (m, 1H), 5.94 - 6.01 (m, 1H), 6.69 - 6.78 (m, 2H), 7.00 - 7.06 (m, 3H), 7.22 - 7.26 (m, 3H), 7.35 (s, 1H). ¹³C NMR (75 MHz, CDCl₃): δ 14.18, 14.52, 22.89, 23.05, 24.39, 24.64, 24.94, 25.11, 25.38, 29.73, 30.50, 30.66, 31.68, 35.85, 60.78, 71.07, 71.45, 102.25, 102.59, 108.08, 108.37, 122.33, 122.54, 127.11, 127.22, 127.92, 128.11, 128.51, 129.16, 132.70, 132.83, 133.39, 134.06, 135.96, 136.96, 137.29, 137.35, 147.48, 147.63, 147.79, 156.90, 156.93, 163.26 (d, J = 246.6 Hz, 1C). FAB-MS: calculated for C₃₁H₃₇O₂F 460; found 460 (M⁺). Anal. calc for C₃₁H₃₇O₂F: C, 80.83; H, 8.10. Found: C, 80.91; H, 8.01. R_f = 0.34 (9:1 hexanes:ethyl acetate). HPLC: (C-18, A = 0.05 % aqueous trifluoroacetic acid, B = CH₃CN; linear gradient: 80%-100% B over 20 min; 254 nm, 1 mL/min): R.T. 14.8 min (37.7 area %), 15.2 min (56.0 area %); 93.7 % purity (cis- and trans-).

25 Step B: 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-4'-fluoro-2'-hydroxy-1,1'-biphenyl

The title compound was prepared from the intermediate obtained in Step A utilizing the procedures outlined in Example 242, Steps B-D. The crude product was subjected to flash column chromatography on silica (50 mm x 6") using hexanes:ethyl acetate (19:1 and 9:1) as eluent to separate the diastereomers (2.19 g,

0 90 %, 75 % over 3 steps).

Diastereomer 1 was obtained as a white solid (2.03 g, 83 %). ^1H NMR (300 MHz, CDCl_3): δ 0.78 (t, J = 6.6 Hz, 3H), 0.96 - 1.23 (m, 19H), 1.41 (d, J = 7.0 Hz, 3H), 2.04 - 2.37 (m, 2H), 3.09 - 3.19 (m, 1H), 3.74 - 3.84 (m, 1H), 4.81 - 4.90 (m, 2H), 6.68 - 6.75 (m, 2H), 6.99 - 7.06 (m, 1H), 7.37 (s, 1H). ^{13}C NMR (75 MHz, CDCl_3): δ 13.83, 21.94, 23.83, 24.27, 24.38, 24.50, 24.88, 28.70, 29.05, 29.80, 30.76, 32.20, 68.21, 102.98 (d, J = 24.4 Hz, 1C), 107.33 (d, J = 20.8 Hz, 1C), 123.58 (d, J = 2.4 Hz, 1C), 125.45, 130.70 (d, J = 9.8 Hz, 1C), 131.78, 137.45, 138.55, 146.48, 146.94, 154.29 (d, J = 6.1 Hz, 1C), 163.04 (d, J = 244.2 Hz, 1C). FAB-MS: calculated for $\text{C}_{25}\text{H}_{35}\text{O}_2\text{F}$ 386; found 409 ($\text{M}+\text{Na}$) $^+$. Anal. calc for $\text{C}_{25}\text{H}_{35}\text{O}_2\text{F}$: C, 77.68; H, 9.13. Found: C, 77.38; H, 9.20. R_f = 0.30 (9:1 hexanes:ethyl acetate). HPLC: (C-18, A = 0.05 % aqueous trifluoroacetic acid, B = CH_3CN ; linear gradient: 70%-100% B over 30 min; 254 nm, 1 mL/min): R.T. 12.9 min (91.3 area %); (silica, A = hexanes, B = isopropanol, isocratic run: 3 % B over 15 min; 254 nm, 1 mL/min): R.T. 5.1 min (100 area %). mp 122.5-124.0°C.

Diastereomer 1 (1.92 g) was resolved into its constituent enantiomers as follows: a Waters Prep LC 4000 HPLC system was equipped with a chiral HPLC column (BRB-9668A; 6 x 50 cm ID). The system was equilibrated with a mobile phase consisting of 0.75% butanol and 99.25% hexane at a flow rate of 100 mL/min. The sample was dissolved in dichloromethane (40 mg/mL) and the sample was loaded in two injections. The effluent was monitored at 285 nm and two fractions (corresponding to the two enantiomers) were collected.


Enantiomer 1 was obtained as a white crystalline solid (0.78 g). ^1H NMR (300 MHz, CDCl_3): δ 0.78 (t, J = 6.6 Hz, 3H), 0.96 - 1.23 (m, 19H), 1.41 (d, J = 7.0 Hz, 3H), 2.04 - 2.37 (m, 2H), 3.09 - 3.19 (m, 1H), 3.74 - 3.84 (m, 1H), 4.81 - 4.90 (m, 2H), 6.68 - 6.75 (m, 2H), 6.99 - 7.06 (m, 1H), 7.37 (s, 1H). ^{13}C NMR (75 MHz, CDCl_3): δ 13.83, 21.94, 23.83, 24.27, 24.38, 24.50, 24.88, 28.70, 29.05, 29.80, 30.76, 32.20, 68.21, 102.98 (d, J = 24.4 Hz, 1C), 107.33 (d, J = 20.8 Hz, 1C), 123.58 (d, J = 2.4 Hz, 1C), 125.45, 130.70 (d, J = 9.8 Hz, 1C), 131.78, 137.45, 138.55, 146.48, 146.94, 154.29 (d, J = 6.1 Hz, 1C), 163.04 (d, J = 244.2 Hz, 1C). FAB-MS: calculated for $\text{C}_{25}\text{H}_{35}\text{O}_2\text{F}$ 386; found 409 ($\text{M}+\text{Na}$) $^+$. Anal. calc for $\text{C}_{25}\text{H}_{35}\text{O}_2\text{F}$: C, 77.68; H, 9.13. Found: C, 77.74; H, 9.00. R_f = 0.30 (9:1 hexanes:ethyl acetate). HPLC: (C-18, A = 0.05 % aqueous trifluoroacetic acid, B = CH_3CN ; linear gradient: 70%-100% B over 30 min; 254 nm, 1 mL/min): R.T. 12.8 min (94.9 area %); (BRB-9668, 99 % (1 % butanol in hexanes), 5 min, 285 nm, 2mL/min): R.T. 2.6 min (100 area %, 100 % e.e.). $[\alpha]_D = -14.3^\circ$ (c = 0.00200 g/mL, CH_2Cl_2). mp 105.0-106.5°C.

Enantiomer 2 was obtained as a white flaky solid (0.73 g). ^1H NMR (300 MHz, CDCl_3): δ 0.78 (t, J = 6.6 Hz, 3H), 0.96 - 1.23 (m, 19H), 1.41 (d, J = 7.0 Hz, 3H), 2.04 - 2.37 (m, 2H), 3.09 - 3.19 (m, 1H), 3.74 - 3.84 (m, 1H), 4.81 - 4.90 (m, 2H), 6.68 -

0 6.75 (m, 2H), 6.99 - 7.06 (m, 1H), 7.37 (s, 1H). ^{13}C NMR (75 MHz, CDCl_3): δ 13.83, 21.94, 23.83, 24.27, 24.38, 24.50, 24.88, 28.70, 29.05, 29.80, 30.76, 32.20, 68.21, 102.98 (d, $J = 24.4$ Hz, 1C), 107.33 (d, $J = 20.8$ Hz, 1C), 123.58 (d, $J = 2.4$ Hz, 1C), 125.45, 130.70 (d, $J = 9.8$ Hz, 1C), 131.78, 137.45, 138.55, 146.48, 146.94, 154.29 (d, $J = 6.1$ Hz, 1C), 163.04 (d, $J = 244.2$ Hz, 1C). FAB-MS: calculated for $\text{C}_{25}\text{H}_{35}\text{O}_2\text{F}$ 386; found 409
 5 (M+Na) $^+$. Anal. calc for $\text{C}_{25}\text{H}_{35}\text{O}_2\text{F}$: C, 77.68; H, 9.13. Found: C, 77.64; H, 9.06. $R_f = 0.30$ (9:1 hexanes:ethyl acetate). HPLC: (C-18, A = 0.05 % aqueous trifluoroacetic acid, B = CH_3CN ; linear gradient: 70%-100% B over 30 min; 254 nm, 1 mL/min): R.T. 12.8 min (94.7 area %); (BRB-9668, 99 % (1 % butanol in hexanes), 5 min, 285 nm, 2mL/min): R.T. 1.7 min (0.51 area %), 2.9 min (0.97 area %), 4.0 min (98.5 area %,
 10 %, 98 % e.e.). $[\alpha]_D = +16.0^\circ$ ($c = 0.00200$ g/mL, CH_2Cl_2). mp 103.5-105.5°C.

Diastereomer 2 was obtained as a white solid (0.16 g, 7 %). ^1H NMR (CDCl_3 , 300 MHz): δ 0.78 (t, $J = 6.6$ Hz, 3H), 0.96 - 1.33 (m, 19H), 1.37 (d, $J = 6.6$ Hz, 3H), 2.05 - 2.38 (m, 2H), 3.09 - 3.19 (m, 1H), 3.80 - 3.89 (m, 1H), 4.61 - 4.68 (m, 1H), 4.75 - 5.25 (br s, 1H), 6.66 - 6.74 (m, 2H), 6.90 - 6.96 (m, 1H), 7.37 (s, 1H). ^{13}C
 15 NMR (75 MHz, CDCl_3): δ 13.83, 21.94, 23.43, 24.08, 24.48, 24.56, 24.98, 28.70, 29.04, 29.80, 30.76, 32.19, 68.89, 102.80 (d, $J = 24.4$ Hz, 1C), 107.36 (d, $J = 22.0$ Hz, 1C), 123.24 (d, $J = 2.4$ Hz, 1C), 125.64, 131.25 (d, $J = 9.8$ Hz, 1C), 131.56, 137.08, 138.44, 146.81, 146.84, 154.37 (d, $J = 12.2$ Hz, 1C), 163.03 (d, $J = 244.2$ Hz, 1C). FAB-MS: calculated for $\text{C}_{25}\text{H}_{35}\text{O}_2\text{F}$ 386; found 409 (M+Na) $^+$. Anal. calc for $\text{C}_{25}\text{H}_{35}\text{O}_2\text{F}$: C, 77.68; H, 9.13. Found: C, 77.70; H, 9.12. $R_f = 0.17$ (9:1 hexanes:ethyl acetate). HPLC: (C-18, A = 0.05 % aqueous trifluoroacetic acid, B = CH_3CN ; linear gradient: 70%-100% B over 30 min; 254 nm, 1 mL/min): R.T. 17.6 min (86.9 area %); (silica, A = hexanes, B = isopropanol, isocratic run: 3 % B over 15 min; 254 nm, 1 mL/min): R.T. 4.9 min (100 area %). mp 148.0-150.0°C.

25

EXAMPLE 248

30 (+)-3,5-Diisopropyl-2-[(p-methylbenzyloxy)methyl]-6-(1-hydroxyethyl)-4'-fluoro-1,1'-biphenyl

0

Step A: 3,5-Diisopropyl-2-[(p-methylbenzyloxy)methyl]-6-hydroxymethyl-4'-fluoro-1,1'-biphenyl


To a solution of 3,5-diisopropyl-2-hydroxymethyl-6-carboxymethyl-4'-fluoro-1,1'-biphenyl (Example 244, Step D) (4.09 g, 11.9 mmol) in THF (70 mL) was added at room temperature sodium hydride (0.85 g, 35.4 mmol) in portions. The reaction mixture was stirred for 10 min. and then treated with α -bromo-*p*-xylene (2.64 g, 14.3 mmol). The reaction mixture was heated at reflux for 24 hrs then cooled to room temperature and quenched with water (30 mL). The solvent was removed *in vacuo* and the residue partitioned between diethyl ether (300 mL) and water (200 mL). The ether layer was dried (MgSO₄) and concentrated, the residue was purified through silica (70% CH₂Cl₂/hexane) which afforded a white solid (4.5 g, 10.3 mmol, 84%). The product was dissolved in THF (40 mL) was treated with lithium aluminum hydride (19.8 mL, 19.8 mmol, 1.0M in THF). The reaction mixture was heated at reflux for 2 hrs then allowed to cool to room temperature. The mixture was quenched with water (6 mL), and the solvent was removed *in vacuo*. The residue was partitioned between diethyl ether (200 mL) and water (300 mL). The organic layer was washed with water (3 X 300mL), brine (100 mL), dried (MgSO₄), filtered and concentrated. The residue was filtered through a cake of silica (CH₂Cl₂, 1L) and evaporated to afford a white solid (3.26 g, 7.7 mmol, 78%). mp 99-101°C; R_f = 0.07 (80% CH₂Cl₂/hexane); ¹H NMR (300 MHz, CDCl₃): δ 7.38 (s, 1 H), 7.24 (m, 2 H), 7.09 (m, 6 H), 4.36 (d, *J* = 5.5 Hz, 2 H), 4.27 (s, 2 H), 4.11 (s, 2 H), 3.42 (septet, *J* = 6.6 Hz, 1 H), 3.32 (septet, *J* = 6.6 Hz, 1 H), 2.35 (s, 3 H), 1.60 (s, 1 H), 1.22 (m, 12 H); FAB-MS calcd for (C₂₈H₃₃FO₂) 420, found 403 (M-OH).

Step B: (+)-3,5-Diisopropyl-2-[(p-methylbenzyloxy)methyl]-6-(1-hydroxyethyl)-4'-fluoro-1,1'-biphenyl

The title compound was prepared by subjecting the intermediate obtained in Step A to the procedures described in Example 244, Steps I-K. mp 84-86°C; R_f = 0.1 (80% CH₂Cl₂/hexane); ¹H NMR (300 MHz, CDCl₃): δ 7.39 (s, 1 H), 7.27 (m, 2 H), 7.09 (m, 6 H), 4.76 (dq, *J* = 1.5, 7 Hz, 1 H), 4.22 (s, 2 H), 4.03 (s, 2 H), 3.89 (septet, *J* = 6.6 Hz, 1 H), 3.26 (septet, *J* = 6.6 Hz, 1 H), 2.35 (s, 3 H), 1.66 (s, 1 H), 1.40 (d, *J* = 6.6 Hz, 3 H), 1.26 (m, 12 H); FAB-MS calcd for (C₂₉H₃₅FO₂) 434, found 417 (M-OH); Anal. Calcd for C₂₉H₃₅FO₂: C, 80.15; H, 8.12; F, 4.37. Found: C, 80.10; H, 8.30; F, 4.24; [α]_D²² = +30.7.

35

0

EXAMPLE 249


5

(+)-3,5-Diisopropyl-2-[(p-tolylthio)methyl]-6-(1-hydroxyethyl)-4'-fluoro-1,1'-biphenyl

10

The title compound was prepared from *p*-thiocresol and 3,5-diisopropyl-2-hydroxymethyl-6-carboxymethyl-4'-fluoro-1,1'-biphenyl (Example 244, Step D), according to the procedures described in Example 47, Steps B and C, followed by the procedures described in Example 244, Steps I-K. $R_f = 0.36$ (70% CH_2Cl_2 /hexane); ^1H NMR (300 MHz, CDCl_3): δ 7.40 (s, 1 H), 7.28 (m, 2 H), 7.11 (m, 6 H), 4.76 (dq, $J = 1.8, 7$ Hz, 1 H), 3.92 (septet, $J = 6.6$ Hz, 1 H), 3.78 (s, 2 H), 3.26 (septet, $J = 6.6$ Hz, 1 H), 2.36 (s, 3 H), 1.66 (s, 1 H), 1.40 (d, $J = 6.6$ Hz, 3 H), 1.28 (m, 12 H); FAB-MS calcd for $(\text{C}_{28}\text{H}_{33}\text{FO}_2)$ 436, found 436 (M^+); Anal. Calcd for $\text{C}_{29}\text{H}_{35}\text{FO}_2$: C, 77.02; H, 7.62; S, 7.34; F, 4.35. Found: C, 76.90; H, 7.77; S, 7.30; F, 4.37; $[\alpha]^{22} = +32.2$.

15


EXAMPLE 250

20

(+)-3,5-Diisopropyl-2-[(4-methoxythiophenyl)methyl]-6-(1-hydroxyethyl)-4'-fluoro-1,1'-biphenyl

0 The title compound was prepared from 4-methoxy thiophenol and 3,5-diisopropyl-2-hydroxymethyl-6-carboxymethyl-4'-fluoro-1,1'-biphenyl (Example 244, Step D), according to the procedures described in Example 47, Steps B and C, followed by the procedures described in Example 244, Steps I-K. $R_f = 0.23$ (70% CH_2Cl_2 /hexane); mp $140-2^\circ\text{C}$; ^1H NMR (300 MHz, CDCl_3): δ 7.36 (s, 1 H), 7.30 (m, 2 H), 7.08 (m, 4 H), 6.75 (m, 2 H), 4.72 (q, $J = 7$ Hz, 1 H), 3.89 (septet, $J = 7$ Hz, 1 H), 3.78 (s, 3 H), 3.68 (m, 2 H), 3.38 (septet, $J = 7$ Hz, 1 H), 1.57 (m, 1 H), 1.40 (d, $J = 6.6$ Hz, 3 H), 1.31 (m, 12 H); FAB-MS calcd for $(\text{C}_{28}\text{H}_{33}\text{FO}_2\text{S})$ 452, found 452 (M^+); Anal. Calcd for $\text{C}_{28}\text{H}_{33}\text{FO}_2\text{S}$: C, 74.30; H, 7.35; S, 7.08; F, 4.20. Found: C, 74.06; H, 7.46; S, 6.87; F, 4.09; $[\alpha]^{22} = +24.5$.

10


EXAMPLE 251

15 (+)-3,5-Diisopropyl-2-[(4-thiomethylthiophenyl)-methyl]-6-(1-hydroxyethyl)-4'-fluoro-1,1'-biphenyl

20 The title compound was prepared from 4-(methylthio)phenol and 3,5-diisopropyl-2-hydroxymethyl-6-carboxymethyl-4'-fluoro-1,1'-biphenyl (Example 244, Step D), according to the procedures described in Example 47, Steps B and C, followed by the procedures described in Example 244, Steps I-K. $R_f = 0.52$ (90% CH_2Cl_2 /hexane); mp $157-9^\circ\text{C}$; ^1H NMR (300 MHz, CDCl_3): δ 7.37 (s, 1 H), 7.30 (m, 2 H), 7.12 (m, 6 H), 4.71 (q, $J = 7$ Hz, 1 H), 3.90 (septet, $J = 7$ Hz, 1 H), 3.75 (d, $J = 11$ Hz, 1 H), 3.70 (d, $J = 11$ Hz, 1 H), 3.33 (septet, $J = 7$ Hz, 1 H), 2.46 (s, 3 H), 1.58 (s, 1 H), 1.40 (d, $J = 6.6$ Hz, 3 H), 1.29 (m, 12 H); EI-MS calcd for $(\text{C}_{28}\text{H}_{33}\text{FOS}_2)$ 468, found 468 (M^+); Anal. Calcd for $\text{C}_{28}\text{H}_{33}\text{FOS}_2$: C, 71.76; H, 7.10; S, 13.68; F, 4.05. Found: C, 71.54; H, 7.22; S, 13.26; F, 4.17; $[\alpha]^{22} = +40.6$.

30

0

EXAMPLE 252


5

(+)-3,5-Diisopropyl-2-[(4-trifluoromethylthiophenyl)-methyl]-6-(1-hydroxyethyl)-4'-fluoro-1,1'-biphenyl

10

15

The title compound was prepared from 4-(trifluoromethyl)benzene thiol and 3,5-diisopropyl-2-hydroxymethyl-6-carboxymethyl-4'-fluoro-1,1'-biphenyl (Example 244, Step D), according to the procedures described in Example 47, Steps B and C, followed by the procedures described in Example 244, Steps I-K. $R_f = 0.39$ (80% CH_2Cl_2 /hexane); mp $171-3^\circ\text{C}$; ^1H NMR (300 MHz, CDCl_3): δ 7.45 (s, 1 H), 7.42 (s, 1 H), 7.39 (s, 1 H), 7.30 (m, 1 H), 7.09 (m, 5 H), 4.72 (q, $J = 7$ Hz, 1 H), 3.91 (septet, $J = 7$ Hz, 1 H), 3.83 (d, $J = 11$ Hz, 1 H), 3.78 (d, $J = 11$ Hz, 1 H), 3.28 (septet, $J = 7$ Hz, 1 H), 1.60 (s, 1 H), 1.41 (d, $J = 6.6$ Hz, 3 H), 1.29 (m, 12 H); FAB-MS calcd for $(\text{C}_{28}\text{H}_{30}\text{F}_4\text{OS})$ 490, found 490 (M^+); Anal. Calcd for $\text{C}_{28}\text{H}_{30}\text{F}_4\text{OS}$: C, 68.55; H, 6.16; S, 6.53; F, 15.49. Found: C, 68.67; H, 6.15; S, 6.56; F, 15.33; $[\alpha]^{22} = +25.6$.


EXAMPLE 253

20

(+)-3,5-Diisopropyl-2-[(4-trifluoromethoxythiophenyl)-methyl]-6-(1-hydroxyethyl)-4'-fluoro-1,1'-biphenyl

0 The title compound was prepared from 4-(trifluoromethoxy)benzene thiol and 3,5-diisopropyl-2-hydroxymethyl-6-carboxymethyl-4'-fluoro-1,1'-biphenyl (Example 244, Step D), according to the procedures described in Example 47, Steps B and C, followed by the procedures described in Example 244, Steps I-K. $R_f = 0.39$ (80% CH_2Cl_2 /hexane); mp $124-6^\circ\text{C}$; ^1H NMR (300 MHz, CDCl_3): δ 7.38 (s, 1 H), 7.30 (m, 2 H), 7.09 (m, 6 H), 4.73 (q, $J = 7$ Hz, 1 H), 3.91 (septet, $J = 7$ Hz, 1 H), 3.78 (d, $J = 11$ Hz, 1 H), 3.73 (d, $J = 11$ Hz, 1 H), 3.31 (septet, $J = 7$ Hz, 1 H), 1.60 (s, 1 H), 1.41 (d, $J = 7$ Hz, 3 H), 1.28 (m, 12 H); FAB-MS calcd for $(\text{C}_{28}\text{H}_{30}\text{F}_4\text{O}_2\text{S})$ 506, found 506 (M^+); Anal. Calcd for $\text{C}_{28}\text{H}_{30}\text{F}_4\text{O}_2\text{S}$: C, 66.39; H, 5.97; S, 6.33; F, 15.00. Found: C, 66.71; H, 6.06; S, 6.22; F, 15.24; $[\alpha]^{22} = +25.8$.

10


EXAMPLE 254

15 (+)-3,5-Diisopropyl-2-[(4-fluorothiophenyl)-methyl]-6-(1-hydroxyethyl)-4'-fluoro-1,1'-biphenyl

The title compound was prepared from 4-fluorothiophenol and 3,5-diisopropyl-2-hydroxymethyl-6-carboxymethyl-4'-fluoro-1,1'-biphenyl (Example 244, Step D), according to the procedures described in Example 47, Steps B and C, followed by the procedures described in Example 244, Steps I-K. $R_f = 0.35$ (70% CH_2Cl_2 /hexane); mp $138-140^\circ\text{C}$; ^1H NMR (300 MHz, CDCl_3): δ 7.37 (s, 1 H), 7.30 (m, 2 H), 7.05 (m, 4 H), 6.90 (m, 2 H), 4.71 (q, $J = 7$ Hz, 1 H), 3.90 (septet, $J = 6.6$ Hz, 1 H), 3.72 (m, 2 H), 3.33 (septet, $J = 6.6$ Hz, 1 H), 1.52 (s, 1 H), 1.39 (d, $J = 6.6$ Hz, 3 H), 1.27 (m, 12 H); FAB-MS calcd for $(\text{C}_{28}\text{H}_{30}\text{FO}_2\text{S})$ 506, found 506 (M^+); Anal. Calcd for $\text{C}_{28}\text{H}_{33}\text{FO}_2\text{S}$: C, 74.30; H, 7.35; S, 7.08; F, 4.20. Found: C, 74.06; H, 7.46; S, 6.87; F, 4.09; $[\alpha]^{22} = +17.6$.

30

0

EXAMPLE 255

5


3,5-Diisopropyl-2-(thiophenylmethyl)-6-(hydroxymethyl)-4'-fluoro-1,1'-biphenyl

- 10 A suspension of Wang-resin (100 g, 1.09 mmol/g hydroxylated) was suspended in 1 L of a solution of 4N HCl in dioxane and gently stirred at room temperature for two days. After filtration, the chlorinated resin was washed 6 times with each of the following solvents; dioxane, isopropanol and finally THF. The resin
- 15 was then dried at 60°C overnight. From this resin, 2.5 g (2.2 mmol based on the chlorine content detected by elemental analysis) was suspended in DMF (25 mL) and stirred at room temperature for 5 minutes, then the DMF was decanted off for the addition of a solution of 3,5-diisopropyl-2-hydroxymethyl-6-carboxymethyl-4'-fluoro-1,1'-biphenyl (Example 244, Step D) (1.13 g, 3.3 mmol) in DMF (25 mL),
- 20 followed by a solution of sodium hydride (60 % in mineral oil, 170 mg, 3.3 mmol) in DMF (12.5 mL). The suspension was stirred at room temperature for two days under an argon atmosphere. The suspension was then filtered and the resulting resin was successively washed 10 times with each of the following solvents; DMF, a mixture THF/water (1:1), THF and finally with CH₂Cl₂.
- 25 The resin residue was then treated with a solution of lithium aluminum hydride (1 M in THF, 15 mL, 15 mmol) and heated at reflux for 2 days. The suspension was filtered and the resulting residue was washed successively 10 times with each of the following solvents; THF, a mixture of THF/water (1:1), a mixture of THF/water (2:1), THF and finally with CH₂Cl₂.
- 30 The residue was suspended in THF (25 mL) and slowly treated with PBr₃ (835 µL, 8.7 mmol) at room temperature. The resin was filtered out and washed 10 times with each of the following solvents; THF, mixture of THF/1N sodium bicarbonate (1:1), THF/water (1:1), THF and finally CH₂Cl₂, then dried at 60°C overnight which afforded 2.25 g of resin (0.62 mmol/g based on the bromine content detected by elemental analysis).

- 0 To 25 mg of this intermediate coupled with a resin was added thiophenol (26.4 mg, 0.24 mmol) in dry THF (500 μ L) and N-methylmorpholine (26 μ L, 0.24 mmol), then the suspension was refluxed for 8 hours. After filtration, the resin was washed successively 10 times with each of the following solvents; THF, a mixture of THF/water (1:1) and THF. The resin was then suspended in a mixture of TFA and
- 5 CH_2Cl_2 (1:1) and stirred at room temperature for one hour. The resin was filtered off and the solvent recovered then evaporated. The residue was dissolved in a mixture of methanol and acetonitrile (1:1) and one drop of diisopropylethylamine, then stirred for one hour; HPLC: 12.5 min (Hypersil BDS-C18, 5 μ m, 125 x 2 mm/Hewlett Packard, Flow 0.5 mL, 0-13 min 30-90% C , 13-15 min 90% C , Solvent A:
- 10 Water/0.1% TFA; Solvent B: Acetonitrile). After evaporation of the solvent, the remaining residue was transferred in a microtiterplate for testing.

The compounds identified in the following Table as Examples 256-288 were prepared analogously to the compound of Example 255.

Table of Exemplary Compounds 255-288



Example	R	HPLC R.T. (method)	Est.'d Purity (%)
255	H	12.5 (I)	60-70
256	4-tBu	14.9 (I)	90
257	4-OMe	12.2 (I)	60-70
258	4-Me	13.2 (I)	50-60
259	4-ipr	14.4 (I)	50-60
260	4-F	12.5 (I)	90
261	4-Et	15.1 (I)	90
262	4-CF ₃	13.4 (I)	70-80

Example	R	HPLC R.T. (method)	Est.'d Purity (%)
263	4-Br	13.9 (I)	90
264	3-Me	13.2 (I)	90
265	3-F	13.0 (I)	70-80
266	3-Cl	13.5 (I)	90
267	3-CF ₃	13.4 (I)	90
268	2-Me	13.2 (I)	90
269	2-F	12.4 (I)	60-70
270	2-Cl	12.9 (I)	50-60
271	2,3-Me	ND	ND
272	2,3-Cl	6.8 (III)	50-60
273	2,4-Me	13.9 (I)	50-60
274	2,4-Cl	14.2 (I)	60-70
275	2,4-F	12.6 (I)	60-70
276	2-Me-4-Cl	14.2 (I)	90
277	2-Cl-4-F	13.3 (I)	80-90
278	2,5-Cl	14.0 (I)	60-70
279	2,6-Cl	13.7 (II)	50
280	3,4-Me	15.0 (I)	90
281	3,4-Cl	14.3 (I)	90
282	3-Cl-4-F	13.5 (I)	90
283	3,5-Me	13.9 (I)	90
284	3,5-CF ₃	14.4 (I)	90
285	3,5-Cl	14.8 (I)	90
286	2,3,5,6-F-4-Me	14.0 (I)	80-90
287	2,3,5,6-F-4-Cl	14.0 (I)	60-70
288	2,3,5,6-F	12.9 (I)	60-70

0

HPLC: The Retention times (R.T.) for the compounds shown in the above table of exemplary compounds 255-290 were measured in minutes according to one of the three methods described below:

(I) Hypersil BDS-C18, 5 μ m, 125 x 2 mm/Hewlett Packard, Flow 0.5 mL, 0-13 min 30-90%C, 13-15 min 90% C, Solvent A: Water/0.1% TFA; Solvent B: Acetonitrile.

0 (II) Hypersil BDS-C18, 5 μ m, 125 x 2 mm/Hewlett Packard, Flow 0.5 mL, 0-13 min 30-90%C, 13-25 min 90% C, Solvent A: Water/0.1% TFA; Solvent B: Acetonitrile.

(III) NPS ODS-1, 1.5mm, 33 x 4.6 mm/Micra, Flow 1.0 mL, 0-8 min 15-70% C, Solvent A: Water/0.1% TFA; Solvent B: Acetonitrile.

5 The estimated purity numbers were determined by comparison of peak areas, not by reference to standards.

10 The pharmaceutical utility of compounds of this invention is indicated by the following assay for glucagon receptor activity.

The affinity for the glucagon receptor of compounds of the present invention is determined by the glucagon receptor binding assay. Membranes were prepared from Chinese Hamster Ovary cells expressing the glucagon receptor (CHO-HGR) by scraping the cells into hypotonic lysis buffer (10 mM Tris, pH 7.4, 2 mM EDTA, 5 mM MgCl₂ and 1 mM PMSF) and subjecting the material to Polytron homogenization. Nuclei were removed by a 15-min 800 x g centrifugation step conducted at 4°C. Membranes containing the receptor were collected by centrifugation at 15,000 x g for 15 min at 4°C. The membranes were washed once in lysis buffer and suspended in 0.25 M sucrose, 10 mM Tris, 5 mM EDTA, pH 7.4. The membranes were used in ligand binding studies as reported (Yoo-Warren, H., Willse, A.G., Hancock, N., Hull, J., McCaleb, M., and Livingston, J. Regulation of Rat Glucagon Receptor Expression. *Biochem. Biophysical Res. Commun.* 1994, 205, 347-353). In brief, 10 ug of membrane protein was incubated in 130 μ l of binding buffer that consisted of 20 mM Tris, pH 7.4, 1 mM EDTA, 1 mg/ml BSA, and 1 mg/ml bacitracin. The membrane suspension was placed in each well of a 96-well filtration plate (glass fiber type C, Millipore). Twenty μ l of test compound was added to each well to give final concentrations ranging from 2 nM to 20 μ M. Following the addition of test compound, 50 μ l of ¹²⁵I-glucagon (9 fmol) (NEN) was added to each well. Control wells contained membranes, 0.5% DMSO (solvent for test compounds), radiolabeled glucagon without and with excess native glucagon (1 μ M) to establish nonspecific binding. The plates were incubated for 60 min at room temperature, and then filtered on a Millipore vacuum apparatus. Following a wash step with ice-cold PBS/0.1% BSA, the filters were punched into test tubes, and the membrane bound radioactivity was determined. An IC₅₀ value (the concentration of test compound needed to reduce membrane binding of radiolabelled glucagon by 50%) was calculated for each compound. If 20 μ M

- 0 compound did not reduce glucagon binding by 50%, the % reduction at 20 μ M was reported in place of an IC₅₀ value. The binding characteristics for compounds of this invention are shown in Table I(C).

Table I(C)

5

Example	IC ₅₀ (μ M)	% Inhibition (20 μ M)
1	0.6	
2		2.73
3		1.52
4		1.98
5		12.42
6		34.23
7		42.14
8		17.02
9		16.56
11	8	
12	1.7	
13	3	
14	1.4	
15	1.7	
16	0.85	
17	0.6	
18	0.75	
19	0.7	
20	1.3	
21	0.8	
22	1.1	
23	0.39	
24	0.75	
25	0.4	
26	1	
27	20	
28	1	

Example	IC ₅₀ (μ M)	% Inhibition (20 μ M)
29	1	
30	0.9	
31	2.6	
32	1.1	
33	1.8	
34	0.6	
35	0.7	
36	1.8	
37	0.75	
38	0.6	
39	1.3	
40	0.75	
41	0.6	
42	0.7	
43	1.8	
44	1.0	
45	1.1	
46	9	
47	1.5	
48	1.8	
49	1.1	
50	0.9	
51	16	
52	20	
53	4.9	
54	1.8	
55		15.66
56	1.9	
57	1.1	
58	1.5	
59	1	
60	1.6	

Example	IC ₅₀ (μ M)	% Inhibition (20 μ M)
61	3.4	
62	1.1	
63	1.7	
64	1.1	
65	0.75	
66	1	
67	1.1	
68	13	
69		40.21
70	12	
71		46.33
72		42.15
73		17.46
74		27.08
75		34.16
76		5.18
77	6	
78	7.5	
79	10	
80		38.76
81	7.5	
82	1.9	
83	0.65	
84	1.9	
85	1.5	
86	1.1	
87	1.9	
88		24.75
89		36.03
90		29.14
91		14.15
92		11.59

Example	IC ₅₀ (μ M)	% Inhibition (20 μ M)
93		28.33
94		38.54
95		26.53
96		27.84
97		29.25
98	14	
99		43.18
100		39.61
101	0.22	
102	0.11	
103	1.9	
104	0.25	
105	0.3	
106	0.15	
107	3	
108	0.24	
109	0.12	
110	2	
112		4.17
113	0.6	
114		38.49
115		21.12
116		17.03
117		45.14
118	13	
119		30.2
120		37.01
121		26.19
122		7.54
123		49.22
124	12	

Example	IC ₅₀ (μ M)	% Inhibition (20 μ M)
125		31.62
126		35.29
127		45.53
128	3	
129	1.5	
130	1	
131		37.27
132		42.48
133		35.46
134		34.41
135		4.64
136		2.37
137	11	
138	9	
139	17	
140		46.28
141		34.05
142		33.11
143	0.9	
144	0.8	
145		41.44
146		48.78
148		7.78
149		39.03
150	4.5	
151	10.5	
152		25.35
153	6	
154		20.71
155		25.25
156		26.05
157		32.6

Example	IC ₅₀ (μ M)	% Inhibition (20 μ M)
158	1.8	
159	1.1	
160		21.03
161		23.99
162		13.88
163	0.5	
164 - D1	0.045	
164 - D2	0.1	
165 - D1	0.04	
165 - D2	1.1	
166	0.19	
167 - D1	0.03	
167 - D2	2.2	
169		37.06
170		45.45
171		48.37
173		27.4
174		33.38
175		40.88
176		13.83
177	19	
178		25.98
179		26.79
180		38.21
181		45.96
182		49.07
183		13.23
184		28.93
185		41.22
186	20	
187	12	
188	10.5	

Example	IC ₅₀ (μ M)	% Inhibition (20 μ M)
189	12	
190	0.3	
191	0.13	
192	0.13	
193	0.086	
194	1	
195	12	
196		40.32
197	7	
198	17	
199		8.67
200		32.77
201		46.67
202	9	
203	6.3	
204	1.8	
205	18	
206		44.57
207		43.97
208	19	
210	18	
211	19	
212	14	
213	7	
214	5	
215	19	
217	8	
218	6.5	
219		5.11
220	1.3	
221	1.3	
222	0.11	

Example	IC ₅₀ (μ M)	% Inhibition (20 μ M)
223	0.11	
224	0.11	
225	7	
226	3	
227	1.3	
228	2	
229	0.8	
230	0.9	
231	0.5	
232	1.2	
233	0.6	
234	8	
235	3.1	
236	4	
237	1.2	
238	0.01	
239 - rac	0.08	
239 - E1	2.5	
239 - E2	0.05	
240	0.016	
241	0.11	
242	0.005	
243	0.086	
244	0.18	
245	0.3	
246	0.011	
247	0.006	
248	0.31	
249	0.13	
250	0.2	
251	0.4	
252	0.18	

Example	IC ₅₀ (μ M)	% Inhibition (20 μ M)
253	0.18	
254	0.11	
255	3	
256	7	
257	7.3	
258	7	
259	6	
260	2.5	
261	5.4	
262	1.7	
263	4.4	
264	3.4	
265	3	
266	2	
267	1.7	
268	4.1	
269	3.4	
270	5	
271	12	
272	2.6	
273	5	
274	12	
275	3	
276	20	
277	2	
278	10	
279	20	
280	10	
281	5.4	
282	1.7	
283	12	
284	7	

Example	IC ₅₀ (μ M)	% Inhibition (20 μ M)
285	9	
286	18	
287	20	
288	2	

0

Preferred phenyl pyridine compounds of general formula (IC) and more particularly of general formula 1B are shown in the following list:

- 5 2,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-ethylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-ethylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(4-chlorophenyl)-5-ethylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(4-methylphenyl)-5-ethylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxyphenyl)-5-ethylpyridine;
 10 2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxy-4-fluorophenyl)-5-ethylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-propylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-propylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(4-chlorophenyl)-5-propylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(4-methylphenyl)-5-propylpyridine;
 15 2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxyphenyl)-5-propylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxy-4-fluorophenyl)-5-propylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-butylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-butylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(4-chlorophenyl)-5-butylpyridine;
 20 2,6-Diisopropyl-3-hydroxymethyl-4-(4-methylphenyl)-5-butylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxyphenyl)-5-butylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxy-4-fluorophenyl)-5-butylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-pentylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-pentylpyridine;
 25 2,6-Diisopropyl-3-hydroxymethyl-4-(4-chlorophenyl)-5-pentylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(4-methylphenyl)-5-pentylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxyphenyl)-5-pentylpyridine;

- 0 2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxy-4-fluorophenyl)-5-pentylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-hexylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-hexylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-(4-chlorophenyl)-5-hexylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-(4-methylphenyl)-5-hexylpyridine;
5 2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxyphenyl)-5-hexylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxy-4-fluorophenyl)-5-hexylpyridine;
2,6-Diisopropyl-3-[(p-tolylthio)methyl]-4-phenyl-5-hydroxymethyl-pyridine;
2,6-Diisopropyl-3-[(p-tolylthio)methyl]-4-(4-fluorophenyl)-5-hydroxymethyl-
pyridine;
10 2,6-Diisopropyl-3-[(p-tolylthio)methyl]-4-(4-chlorophenyl)-5-hydroxymethyl-
pyridine;
2,6-Diisopropyl-3-[(p-tolylthio)methyl]-4-(4-methylphenyl)-5-hydroxymethyl-
pyridine;
2,6-Diisopropyl-3-[(p-tolylthio)methyl]-4-(2-hydroxyphenyl)-5-hydroxymethyl-
15 pyridine;
2,6-Diisopropyl-3-[(p-tolylthio)methyl]-4-(2-hydroxy-4-fluorophenyl)-5-
hydroxymethyl-pyridine;
2,6-Diisopropyl-3-[(4-fluorophenyl)thio)methyl]-4-phenyl-5-hydroxymethyl-
pyridine;
20 2,6-Diisopropyl-3-[(4-fluorophenyl)thio)methyl]-4-(4-fluorophenyl)-5-
hydroxymethyl-pyridine;
2,6-Diisopropyl-3-[(4-fluorophenyl)thio)methyl]-4-(4-chlorophenyl)-5-
hydroxymethyl-pyridine;
2,6-Diisopropyl-3-[(4-fluorophenyl)thio)methyl]-4-(4-methylphenyl)-5-
25 hydroxymethyl-pyridine;
2,6-Diisopropyl-3-[(4-fluorophenyl)thio)methyl]-4-(2-hydroxyphenyl)-5-
hydroxymethyl-pyridine;
2,6-Diisopropyl-3-[(4-fluorophenyl)thio)methyl]-4-(2-hydroxy-4-fluorophenyl)-5-
hydroxymethyl-pyridine;
30 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-phenyl-5-ethylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-ethylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-chlorophenyl)-5-ethylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-methylphenyl)-5-ethylpyridine;

- 0 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxyphenyl)-5-ethylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxy-4-fluorophenyl)-5-ethylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-phenyl-5-propylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-propylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-chlorophenyl)-5-propylpyridine;
5 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-methylphenyl)-5-propylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxyphenyl)-5-propylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxy-4-fluorophenyl)-5-propylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-phenyl-5-butylpyridine;
10 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-butylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-chlorophenyl)-5-butylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-methylphenyl)-5-butylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxyphenyl)-5-butylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxy-4-fluorophenyl)-5-butylpyridine;
15 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-phenyl-5-pentylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-pentylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-chlorophenyl)-5-pentylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-methylphenyl)-5-pentylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxyphenyl)-5-pentylpyridine;
20 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxy-4-fluorophenyl)-5-pentylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-phenyl-5-hexylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-hexylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-chlorophenyl)-5-hexylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-methylphenyl)-5-hexylpyridine;
25 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxyphenyl)-5-hexylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxy-4-fluorophenyl)-5-hexylpyridine;
2,6-Diisopropyl-3-[(*p*-tolylthio)methyl]-4-phenyl-5-(1-hydroxyethyl)-pyridine;
2,6-Diisopropyl-3-[(*p*-tolylthio)methyl]-4-(4-fluorophenyl)-5-(1-hydroxyethyl)-pyridine;
30 2,6-Diisopropyl-3-[(*p*-tolylthio)methyl]-4-(4-chlorophenyl)-5-(1-hydroxyethyl)-pyridine;
2,6-Diisopropyl-3-[(*p*-tolylthio)methyl]-4-(4-methylphenyl)-5-(1-hydroxyethyl)-pyridine;

- 0 2,6-Diisopropyl-3-[(*p*-tolylthio)methyl]-4-(2-hydroxyphenyl)-5-(1-hydroxyethyl)-pyridine;
 2,6-Diisopropyl-3-[(*p*-tolylthio)methyl]-4-(2-hydroxy-4-fluorophenyl)-5-(1-hydroxyethyl)-pyridine;
 2,6-Diisopropyl-3-[(4-fluorophenylthio)methyl]-4-phenyl-5-(1-hydroxyethyl)-pyridine;
 5 2,6-Diisopropyl-3-[(4-fluorophenylthio)methyl]-4-(4-fluorophenyl)-5-(1-hydroxyethyl)-pyridine;
 2,6-Diisopropyl-3-[(4-fluorophenylthio)methyl]-4-(4-chlorophenyl)-5-(1-hydroxyethyl)-pyridine;
 10 2,6-Diisopropyl-3-[(4-fluorophenylthio)methyl]-4-(4-methylphenyl)-5-(1-hydroxyethyl)-pyridine;
 2,6-Diisopropyl-3-[(4-fluorophenylthio)methyl]-4-(2-hydroxyphenyl)-5-(1-hydroxyethyl)-pyridine;
 2,6-Diisopropyl-3-[(4-fluorophenylthio)methyl]-4-(2-hydroxy-4-fluorophenyl)-5-(1-hydroxyethyl)-pyridine.
 15

Preferred biphenyl compounds of general formula (IC) and more particularly of general formula 1D are shown in the following list:

- 20 3,5-Diisopropyl-2-hydroxymethyl-6-ethyl-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-ethyl-4'-fluoro-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-ethyl-4'-chloro-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-ethyl-4'-methyl-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-ethyl-2'-hydroxy-1,1'-biphenyl;
 25 3,5-Diisopropyl-2-hydroxymethyl-6-ethyl-2'-hydroxy-4'-fluoro-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-propyl-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-propyl-4'-fluoro-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-propyl-4'-chloro-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-propyl-4'-methyl-1,1'-biphenyl;
 30 3,5-Diisopropyl-2-hydroxymethyl-6-propyl-2'-hydroxy-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-propyl-2'-hydroxy-4'-fluoro-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-butyl-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-butyl-4'-fluoro-1,1'-biphenyl;

- 0 3,5-Diisopropyl-2-hydroxymethyl-6-butyl-4'-chloro-1,1'-biphenyl;
3,5-Diisopropyl-2-hydroxymethyl-6-butyl-4'-methyl-1,1'-biphenyl;
3,5-Diisopropyl-2-hydroxymethyl-6-butyl-2'-hydroxy-1,1'-biphenyl;
3,5-Diisopropyl-2-hydroxymethyl-6-butyl-2'-hydroxy-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-hydroxymethyl-6-pentyl-1,1'-biphenyl;
5 3,5-Diisopropyl-2-hydroxymethyl-6-pentyl-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-hydroxymethyl-6-pentyl-4'-chloro-1,1'-biphenyl;
3,5-Diisopropyl-2-hydroxymethyl-6-pentyl-4'-methyl-1,1'-biphenyl;
3,5-Diisopropyl-2-hydroxymethyl-6-pentyl-2'-hydroxy-1,1'-biphenyl;
3,5-Diisopropyl-2-hydroxymethyl-6-pentyl-2'-hydroxy-4'-fluoro-1,1'-biphenyl;
10 3,5-Diisopropyl-2-hydroxymethyl-6-hexyl-1,1'-biphenyl;
3,5-Diisopropyl-2-hydroxymethyl-6-hexyl-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-hydroxymethyl-6-hexyl-4'-chloro-1,1'-biphenyl;
3,5-Diisopropyl-2-hydroxymethyl-6-hexyl-4'-methyl-1,1'-biphenyl;
3,5-Diisopropyl-2-hydroxymethyl-6-hexyl-2'-hydroxy-1,1'-biphenyl;
15 3,5-Diisopropyl-2-hydroxymethyl-6-hexyl-2'-hydroxy-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-hydroxymethyl-1,1'-biphenyl;
3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-hydroxymethyl-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-hydroxymethyl-4'-chloro-1,1'-biphenyl;
3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-hydroxymethyl-4'-methyl-1,1'-biphenyl;
20 3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-hydroxymethyl-2'-hydroxy-1,1'-biphenyl;
3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-hydroxymethyl-2'-hydroxy-4'-fluoro-1,1'-
biphenyl;
3,5-Diisopropyl-2-[(4-fluorophenyl)thio)methyl]-6-hydroxymethyl-1,1'-biphenyl;
3,5-Diisopropyl-2-[(4-fluorophenyl)thio)methyl]-6-hydroxymethyl-4'-fluoro-1,1'-
25 biphenyl;
3,5-Diisopropyl-2-[(4-fluorophenyl)thio)methyl]-6-hydroxymethyl-4'-chloro-1,1'-
biphenyl;
3,5-Diisopropyl-2-[(4-fluorophenyl)thio)methyl]-6-hydroxymethyl-4'-methyl-1,1'-
biphenyl;
30 3,5-Diisopropyl-2-[(4-fluorophenyl)thio)methyl]-6-hydroxymethyl-2'-hydroxy-1,1'-
biphenyl;
3,5-Diisopropyl-2-[(4-fluorophenyl)thio)methyl]-6-hydroxymethyl-2'-hydroxy-4'-
fluoro-1,1'-biphenyl;

- 0 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-ethyl-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-ethyl-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-ethyl-4'-chloro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-ethyl-4'-methyl-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-ethyl-2'-hydroxy-1,1'-biphenyl;
5 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-ethyl-2'-hydroxy-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-propyl-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-propyl-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-propyl-4'-chloro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-propyl-4'-methyl-1,1'-biphenyl;
10 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-propyl-2'-hydroxy-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-propyl-2'-hydroxy-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-butyl-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-butyl-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-butyl-4'-chloro-1,1'-biphenyl;
15 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-butyl-4'-methyl-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-butyl-2'-hydroxy-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-butyl-2'-hydroxy-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-4'-fluoro-1,1'-biphenyl;
20 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-4'-chloro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-4'-methyl-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-2'-hydroxy-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-2'-hydroxy-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-hexyl-1,1'-biphenyl;
25 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-hexyl-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-hexyl-4'-chloro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-hexyl-4'-methyl-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-hexyl-2'-hydroxy-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-hexyl-2'-hydroxy-4'-fluoro-1,1'-biphenyl;
30 3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-(1-hydroxyethyl)-1,1'-biphenyl;
3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-(1-hydroxyethyl)-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-(1-hydroxyethyl)-4'-chloro-1,1'-biphenyl;
3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-(1-hydroxyethyl)-4'-methyl-1,1'-biphenyl;


- 0 3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-(1-hydroxyethyl)-2'-hydroxy-1,1'-
biphenyl;
3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-(1-hydroxyethyl)-2'-hydroxy-4'-fluoro-
1,1'-biphenyl;
3,5-Diisopropyl-2-[((4-fluorophenyl)thio)methyl]-6-(1-hydroxyethyl)-1,1'-biphenyl;
5 3,5-Diisopropyl-2-[((4-fluorophenyl)thio)methyl]-6-(1-hydroxyethyl)-4'-fluoro-1,1'-
biphenyl;
3,5-Diisopropyl-2-[((4-fluorophenyl)thio)methyl]-6-(1-hydroxyethyl)-4'-chloro-1,1'-
biphenyl;
3,5-Diisopropyl-2-[((4-fluorophenyl)thio)methyl]-6-(1-hydroxyethyl)-4'-methyl-1,1'-
10 biphenyl;
3,5-Diisopropyl-2-[((4-fluorophenyl)thio)methyl]-6-(1-hydroxyethyl)-2'-hydroxy-
1,1'-biphenyl;
3,5-Diisopropyl-2-[((4-fluorophenyl)thio)methyl]-6-(1-hydroxyethyl)-2'-hydroxy-4'-
15 fluoro-1,1'-biphenyl.

15

Other embodiments of the invention will be apparent to the skilled in the art from a consideration of this specification or practice of the invention disclosed herein. It is intended that the specification and examples be considered as
20 exemplary only, with the true scope and spirit of the invention being indicated by the following claims.

0 We claim:

1. Substituted pyridines of the general formula (IA),



5

in which

10 A stands for aryl with 6 to 10 carbon atoms, which is optionally substituted up to 3 times in an identical manner or differently by halogen, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl, acyl, or alkoxy with up to 7 carbon atoms each, or by a group of the formula $-NR^1R^2$,

wherein

15

R^1 and R^2 are identical or different and denote hydrogen, phenyl, or straight-chain or branched alkyl with up to 6 carbon atoms,

20

D stands for straight-chain or branched alkyl with up to 8 carbon atoms, which is substituted by hydroxy,

25

E and L are either identical or different and stand for straight-chain or branched alkyl with up to 8 carbon atoms, which is optionally substituted by cycloalkyl with 3 to 8 carbon atoms, or stands for cycloalkyl with 3 to 8 carbon atoms,

or

30

E has the above-mentioned meaning

and

L in this case stands for aryl with 6 to 10 carbon atoms, which is optionally substituted up to 3 times in an identical manner or

0 differently by halogen, hydroxy, trifluoromethyl, trifluoromethoxy,
or by straight-chain or branched alkyl, acyl, or alkoxy with up to 7
carbon atoms each, or by a group of the formula $-NR^3R^4$,

wherein

5

R^3 and R^4 are identical or different and have the meaning given
above for R^1 and R^2 ,

or

10

E stands for straight-chain or branched alkyl with up to 8 carbon atoms,
or

15

stands for aryl with 6 to 10 carbon atoms, which is optionally
substituted up to 3 times in an identical manner or differently by
halogen, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-
chain or branched alkyl, acyl, or alkoxy with up to 7 carbon atoms
each, or by a group of the formula $-NR^5R^6$,

wherein

20

R^5 and R^6 are identical or different and have the meaning given
above for R^1 and R^2 ,


and

25

L in this case stands for straight-chain or branched alkoxy with up to 8
carbon atoms or for cycloalkyloxy with 3 to 8 carbon atoms,

T stands for a radical of the formula

30



wherein

- 0 R^7 and R^8 are identical or different and denote cycloalkyl with 3 to 8
carbon atoms, or aryl with 6 to 10 carbon atoms,
or denote a 5- to 7-member aromatic, optionally benzo-
condensed, heterocyclic compound with up to 3 heteroatoms
5 from the series S, N and/or O, which are optionally substituted
up to 3 times in an identical manner or differently by
trifluoromethyl, trifluoromethoxy, halogen, hydroxy, carboxyl,
by straight-chain or branched alkyl, acyl, alkoxy, or
alkoxycarbonyl with up to 6 carbon atoms each, or by phenyl,
10 phenoxy, or thiophenyl, which can in turn be substituted by
halogen, trifluoromethyl, or trifluoromethoxy,

and/or the rings are substituted by a group of the formula -
 $NR^{11}R^{12}$,

15 wherein

 R^{11} and R^{12} are identical or different and have the meaning
 given above for R^1 and R^2 ,

20 X denotes a straight or branched alkyl chain or alkenyl chain with
2 to 10 carbon atoms each, which are optionally substituted up
to 2 times by hydroxy,

 R^9 denotes hydrogen,
25 and

 R^{10} denotes hydrogen, halogen, azido, trifluoromethyl, hydroxy,
mercapto, trifluoromethoxy, straight-chain or branched alkoxy
30 with up to 5 carbon atoms, or a radical of the formula -
 $NR^{13}R^{14}$,

 wherein

35 R^{13} and R^{14} are identical or different and have the meaning
 given above for R^1 and R^2 ,

0 or

R⁹ and R¹⁰ form a carbonyl group together with the carbon atom,
and the salts thereof.

5

2. Substituted pyridines of the formula according to claim 1, in which

10 A stands for naphthyl or phenyl, which are optionally substituted up to 3 times in an identical manner or differently by fluorine, chlorine, bromine, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl, acyl, or alkoxy with up to 6 carbon atoms each, or by a group of the formula -NR¹R²,

wherein

15

R¹ and R² are identical or different and denote hydrogen, phenyl, or straight-chain or branched alkyl with up to 4 carbon atoms,

20 D stands for straight-chain or branched alkyl with up to 6 carbon atoms, which is substituted by hydroxy,

25 E and L are either identical or different and stand for straight-chain or branched alkyl with up to 6 carbon atoms, which is optionally substituted by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, or stand for cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl,

or

30 E has the above-mentioned meaning

and

35 L in this case stands for naphthyl or phenyl, which are optionally substituted up to 3 times in an identical manner or differently by fluorine, chlorine, bromine, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl or alkoxy

0 with up to 6 carbon atoms each, or by a group of the formula
-NR³R⁴,

wherein

5 R³ and R⁴ are identical or different and have the meaning given
above for R¹ and R²,

or

10 E stands for straight-chain or branched alkyl with up to 5 carbon atoms,
or
stands for naphthyl or phenyl, which are optionally substituted up to
3 times in an identical manner or differently by fluorine, chlorine,
bromine, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-
15 chain or branched alkyl, acyl, or alkoxy with up to 6 carbon atoms
each, or by a group of the formula -NR⁵R⁶,


wherein

20 R⁵ and R⁶ are identical or different and have the meaning given
above for R¹ and R²,

and

25 L in this case stands for straight-chain or branched alkoxy with up to 6
carbon atoms, or for cyclopropyloxy, cyclobutyloxy, cyclopentyloxy,
cyclohexyloxy, or cycloheptyloxy,

30 T stands for a radical of the formula



wherein

- 0 R^7 and R^8 are identical or different and denote cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or adamantyl, or
- 5 denote naphthyl, phenyl, pyridyl, quinolyl, indolyl, benzothiazolyl, or benzoxazolyl, which are optionally substituted up to 3 times in an identical manner or differently by trifluoromethyl, trifluoromethoxy, fluorine, chlorine, bromine, hydroxy, carboxyl, by straight-chain or branched alkyl, alkoxy, or alkoxycarbonyl with up to 5 carbon atoms each, or by phenyl, phenoxy, or thiophenyl, which can in turn
- 10 by substituted by fluorine, chlorine, bromine, trifluoromethyl, or trifluoromethoxy,
- and/or the rings are optionally substituted by a group of the formula $-NR^{11}R^{12}$,
- 15 wherein
- R^{11} and R^{12} are identical or different and have the meaning given above for R^1 and R^2 ,
- 20 X denotes a straight or branched alkyl chain or alkenyl chain with 2 to 8 carbon atoms each, which are optionally substituted up to 2 times by hydroxy,
- 25 R^9 denotes hydrogen,
- and
- 30 R^{10} denotes hydrogen, fluorine, chlorine, bromine, azido, trifluoromethyl, hydroxy, mercapto, trifluoromethoxy, straight-chain or branched alkoxy with up to 4 carbon atoms, or a radical of the formula $-NR^{13}R^{14}$,
- wherein
- 35 R^{13} and R^{14} are identical or different and have the meaning given above for R^1 and R^2 ,

0

or

R⁹ and R¹⁰ form a carbonyl group together with the carbon atom,

5

and the salts thereof.

3. Substituted pyridines of the formula according to claim 1, in which

10

A stands for phenyl, which is optionally substituted up to 2 times in an identical manner or differently by fluorine, chlorine, bromine, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl or alkoxy with up to 5 carbon atoms each,

15

D stands for straight-chain or branched alkyl with up to 5 carbon atoms, which is substituted by hydroxy,

20

E and L are either identical or different and stand for straight-chain or branched alkyl with up to 5 carbon atoms, which is optionally substituted by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, or stand for cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl,

or

25

E has the above-mentioned meaning

and

30

L in this case stands for phenyl, which is optionally substituted up to 2 times in an identical manner or differently by fluorine, chlorine, bromine, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl or alkoxy with up to 5 carbon atoms each,

or

35

E stands for straight-chain or branched alkyl with up to 4 carbon atoms, or


0 stands for phenyl, which is optionally substituted up to 2 times in an identical manner or differently by fluorine, chlorine, bromine, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl or alkoxy with up to 5 carbon atoms each,

5 and

L in this case stands for straight-chain or branched alkoxy with up to 5 carbon atoms, or for cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, or cycloheptyloxy,

10

T stands for a radical of the formula



15

wherein

R^7 and R^8 are identical or different and denote cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or adamantyl, or

20

denote phenyl, pyridyl, quinolyl, indolyl, naphthyl, benzothiazolyl, or benzoxazolyl, which are optionally substituted up to 2 times in an identical manner or differently by trifluoromethyl, trifluoromethoxy, fluorine, chlorine, bromine, hydroxy, carboxyl, by straight-chain or branched alkyl, alkoxy, or alkoxycarbonyl with up to 4 carbon atoms each, or by phenyl, phenoxy, or thiophenyl, which can in turn be substituted by fluorine, chlorine, bromine, trifluoromethyl, or trifluoromethoxy,

25

30

X denotes a straight or branched alkyl chain with 2 to 6 carbon atoms each, which are optionally substituted up to 2 times by hydroxy,

R^9 denotes hydrogen,

35

0 and

R¹⁰ denotes hydrogen, fluorine, chlorine, bromine, azido, amino, trifluoromethyl, hydroxy, mercapto, trifluoromethoxy, straight-chain or branched alkoxy with up to 3 carbon atoms,

5 or

R⁹ and R¹⁰ form a carbonyl group together with the carbon atom,
10 and the salts thereof.



15 4. Substituted pyridines of the formula according to claim 1, in which

A stands for phenyl, which is optionally substituted by fluorine, chlorine, or methyl.

20 5. Substituted pyridines according to claims 1 through 4 for therapeutic use.

6. Process for the production of substituted pyridines according to claims 1 through 4, characterized by the fact that

25 compounds of the general formula (II) or (III)



in which

30

A, E, L, and T have the above-mentioned meanings,

and

0 R15 stands for straight-chain or branched alkoxy carbonyl with up to 4 carbon atoms,

are either first reacted, using the Grignard or Wittig reaction, in an inert solvent, with further derivatization optionally being carried out according to the customary methods, and then are reduced in inert solvents,

or, in the case of compounds with the general formula (III), direct reductions are carried out, optionally via several steps.


10 7. Pharmaceutical product containing the substituted pyridines according to claims 1 through 4 and, if appropriate, a pharmacologically tolerable formulation adjuvant.

15 8. Pharmaceutical product according to claim 7 for the inhibition of cholesterol ester transfer proteins.

9. Use of the substituted pyridines according to claims 1 through 4 for the production of pharmaceutical products.

20 10. Use of substituted pyridines according to claims 1 through 4 for the production of cholesterol ester transfer protein inhibitors.

11. 3-heteroalkyl-aryl-substituted pyridines of general formula (IB)



25

in which

30 A stands for aryl with 6 to 10 carbon atoms, which is optionally substituted up to 3 times in an identical manner or differently by halogen, hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl, acyl, or alkoxy with up to 7 carbon atoms each, or by a group of the formula $\text{-NR}^2\text{R}^3$ and/or -WR^4 ,

wherein

35

0 R² and R³ are the same or different and
 denote hydrogen, phenyl, or straight-chain or branched alkyl
 with up to 6 carbon atoms,

5 W denotes an oxygen or sulfur atom,

 R⁴ denotes aryl with 6 to 10 carbon atoms, which is optionally
 substituted up to 3 times in an identical manner or differently
 by halogen, trifluoromethyl, trifluoromethoxy, hydroxy, or by
10 straight-chain or branched alkyl or alkoxy with up to 6 carbon
 atoms each,

 D and E are identical or different and
 stand for a straight-chain or branched alkyl chain with up to 8 carbon
15 atoms,

 or

 E stands for a bond,

20 V stands for an oxygen or sulfur atom or for a group of the formula
 -NR⁵-,

 wherein

25 R⁵ denotes hydrogen or straight-chain or branched alkyl with up
 to 6 carbon atoms or phenyl,

 R¹ stands for cycloalkyl with 3 to 6 carbon atoms, or
 stands for aryl with 6 to 10 carbon atoms or for a 5- to 7-member,
30 optionally benzo-condensed, saturated or unsaturated, mono-, bi-, or
 tricyclic heterocyclic compound with up to 4 heteroatoms from the
 series S, N, and/or O,

 in which the rings, also via the N function in the case of
 nitrogen-containing rings, are optionally substituted up to 3 times in
35 an identical manner or differently by halogen, trifluoromethyl,
 hydroxy, cyano, carboxyl, trifluoromethoxy, straight-chain or
 branched acyl, alkyl, alkylthio, alkylalkoxy, alkoxy, or alkoxycarbonyl
 with up to 6 carbon atoms each, by aryl with 6 to 10 carbon atoms, or
 by an optionally benzo-condensed, aromatic 5- to 7-member

0 heterocyclic compound with up to 3 heteroatoms from the series S, N,
and/or O,
and/or are substituted by a group of the formula -OR⁶, -SR⁷, -SO₂R⁸,
or -NR⁹R¹⁰,

5 wherein

R⁶, R⁷, and R⁸ are identical or different and
denote aryl with 6 to 10 carbon atoms, which in turn is substituted up
to 2 times in an identical manner or differently by phenyl or halogen
10 or by straight-chain or branched alkyl with up to 4 carbon atoms,

R⁹ and R¹⁰ are identical or different and have the above-indicated
meaning of R² and R³,

15 L and T are identical or different and
stand for trifluoromethyl or straight-chain or branched alkyl with up
to 8 carbon atoms, which are optionally substituted by cycloalkyl with
3 to 7 carbon atoms, or by aryl with 6 to 10 carbon atoms, which in
turn can be substituted up to 2 times in an identical manner or
20 differently by halogen, trifluoromethyl, trifluoromethoxy, or by
straight-chain or branched alkyl, acyl, or alkoxy with up to 7 carbon
atoms each,

25 or

L and/or T stand for cycloalkyl with 3 to 7 carbon atoms or
stand for aryl with 6 to 10 carbon atoms or for a 5- to 7-member,
saturated, partially unsaturated, or unsaturated heterocyclic
compound with up to 3 heteroatoms from the series S, N and/or O,
30 with binding in the case of a nitrogen atom also being possible via this
atom, with the rings optionally being substituted up to 3 times in an
identical manner or differently by halogen, nitro, trifluoromethyl,
trifluoromethoxy, or by straight-chain or branched alkyl, acyl, or
alkoxy with up to 7 carbon atoms each,

35 and the salts thereof.

12. 3-heteroalkyl-aryl-substituted pyridines of the formula according to Claim
40 11, in which

- 0 A stands for naphthyl or phenyl, which are optionally substituted up to
3 times in an identical manner or differently by fluorine, chlorine,
hydroxy, trifluoromethyl, trifluoromethoxy, or by straight-chain or
5 branched alkyl, acyl, or alkoxy with up to 6 carbon atoms each, or by
a group of the formula $-NR^2R^3$ and/or by a group of the formula
 $-W-R^4$,
- wherein
- 10 R^2 and R^3 are identical or different and
denote hydrogen, phenyl, or straight-chain or branched alkyl
with up to 4 carbon atoms,
- W denotes an oxygen or sulfur atom,
- 15 R^4 denotes phenyl or benzyl, which are optionally substituted up
to 3 times in an identical manner or differently by fluorine,
chlorine, trifluoromethyl, trifluoromethoxy, hydroxy, or by
straight-chain or branched alkyl or alkoxy with up to 5 carbon
20 atoms each,
- D and E are identical or different and
stand for a straight-chain or branched alkyl chain with up to 6 carbon
atoms,
- 25 or
- E stands for a bond,
- V stands for an oxygen or sulfur atom or for a group of the formula
30 $-NR^5$,
- wherein
- R^5 denotes hydrogen or straight-chain or branched alkyl with up
35 to 4 carbon atoms or phenyl,
- R^1 stands for cyclopropyl, cyclopentyl, or cyclohexyl, or
tetrahydropyrimidyl or stands for phenyl, naphthyl, pyridyl,
40 tetrazolyl, pyrimidyl, pyrazinyl, pyrrolidinyl, tetrahydropyrimidyl,
indolyl, morpholinyl, imidazolyl, benzothiazolyl, phenoxathiin-2-yl,
benzoxazolyl, furyl, quinolyl, pyrazolopyrimidyl, or pyrine-yl,

0 with the rings, also via the N function in the case of
nitrogen-containing rings, being optionally substituted up to 3 times
in an identical manner or differently by fluorine, chlorine,
bromine, trifluoromethyl, hydroxy, cyano, carboxyl,
trifluoromethoxy, straight-chain or branched acyl, alkyl, alkylthio,
5 alkylalkoxy, alkoxy, or alkoxycarbonyl with up to 4 carbon atoms
each, triazolyl, tetrazolyl, benzoxathiazolyl, or phenyl,
and/or by a group of the formula -OR⁶, -SR⁷, or -SO₂R⁸,

10 wherein

R⁶, R⁷, and R⁸ are identical or different and
denote phenyl, which in turn is substituted up to 2 times in an
identical manner or differently by phenyl, fluorine, chlorine, or
by straight-chain or branched alkyl with up to 4 carbon atoms,

15 L and T are identical or different and
stand for trifluoromethyl, pyrrolidiny, or for straight-chain or
branched alkyl with up to 7 carbon atoms, which is optionally
substituted by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
20 cycloheptyl, naphthyl, or phenyl, which in turn can be substituted up
to 2 times in an identical manner or differently by fluorine, chlorine,
bromine, trifluoromethyl, trifluoromethoxy, or by straight-chain or
branched alkyl, acyl, or alkoxy with up to 6 carbon atoms each,

25 or

L and/or T stand for cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or
cycloheptyl, or for naphthyl, phenyl, pyridyl, or furyl, which
optionally can be substituted up to 3 times in an identical manner or
30 differently by fluorine, chlorine, bromine, nitro, trifluoromethyl,
trifluoromethoxy, or by straight-chain or branched alkyl, acyl, or
alkoxy with up to 6 carbon atoms each,

and the salts thereof.

35 13. 3-heteroalkyl-aryl-substituted pyridines of the formula according to Claim
11, in which

40 A stands for phenyl, which is optionally substituted up to 2 times in an
identical manner or differently by fluorine, chlorine, hydroxy,
trifluoromethyl, trifluoromethoxy, or by straight-chain or branched

0 alkyl, acyl, or alkoxy with up to 4 carbon atoms each or by benzyloxy,
which in turn can be substituted by fluorine or chlorine.

5 D and E are identical or different and
stand for a straight-chain or branched alkyl chain with up to 3 carbon
atoms,

or

10 E stands for a bond,

V stands for an oxygen or sulfur atom or for a group of the formula
-NR⁵,

15 wherein

R⁵ denotes hydrogen or straight-chain or branched alkyl with up
to 3 carbon atoms,

20 R¹ stands for cyclopropyl, cyclopentyl, cyclohexyl, tetrahydropyridyl,
phenyl, naphthyl, pyridyl, tetrazolyl, pyrimidyl, pyrazinyl,
tetrahydropyrimidyl, phenoxathiin-2-yl, indolyl, imidazolyl,
pyrrolidinyl, morpholinyl, benzothiazolyl, benzoxazolyl, furyl,
quinolyl, pyrazolopyrimidyl, or purine-yl,
25 with the rings, also via the N-function in the case of
nitrogen-containing rings, optionally being substituted up to 3 times
in an identical manner or differently by fluorine, chlorine,
trifluoromethyl, hydroxy, cyano, carboxyl, trifluoromethoxy,
straight-chain or branched alkyl, alkylthio, alkylalkoxy, alkoxy, or
alkoxycarbonyl with up to 3 carbon atoms each, triazolyl, tetrazolyl,
30 benzoxathiazolyl, or phenyl,
and/or substituted by a group of the formula -OR⁶, -SR⁷, or -SO₂R⁸,

wherein

35 R⁶, R⁷, and R⁸ are identical or different and denote phenyl, which in
turn is substituted up to 2 times in an identical manner or
differently by phenyl, fluorine, chlorine, or is substituted by
straight-chain or branched alkyl with up to 3 carbon atoms,

40 L and T are identical or different and

stand for trifluoromethyl, pyrrolidinyl, or for straight-chain or branched alkyl with up to 6 carbon atoms, which are optionally substituted by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or phenyl, which in turn may be substituted up to 2 times in an identical manner or differently by fluorine, chlorine, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl or alkoxy with up to 4 carbon atoms each,

or

L and/or T stand for cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, or stand for naphthyl, phenyl, or furyl, which are optionally substituted up to 2 times in an identical manner or differently by fluorine, chlorine, trifluoromethyl, trifluoromethoxy, or by straight-chain or branched alkyl or alkoxy with up to 3 carbon atoms each,

and the salts thereof.


14. 3-heteroalkyl-aryl-substituted pyridines of the formula according to Claim 11, in which

A stands for phenyl, which is optionally substituted up to 2 times in an identical manner or differently by fluorine, chlorine, trifluoromethyl, methoxy, methyl, or by fluorine- or chlorine-substituted benzyloxy.

15. 3-heteroalkyl-aryl-substituted pyridines according to Claims 11 through 14 for therapeutic treatment.

16. Process for the production of 3-heteroalkyl-aryl-substituted pyridines according to Claims 11 through 14, characterized in that

[A] in the case of $V = O$
compounds of general formula (II)




in which

A, D, L, and T have the indicated meaning,

0

and

R¹¹ stands for straight-chain or branched alkoxy carbonyl with up to 4 carbon atoms or for the group of the formula



5

are reacted with compounds of general formula (III)



10

in which

R¹ and E have the indicated meaning

15

and


Z stands for halogen, preferably chlorine or bromine,

20

in inert solvents, optionally in the presence of bases and/or auxiliary agents, and reductive separation is then carried out, depending on the meaning of the group R¹¹,

[B] compounds of general formula (II) are next converted by reactions with compounds of general formula (IV)

25




in which

R¹² stands for straight-chain alkyl with up to 4 carbon atoms,

30


into compounds of general formula (V)



in which

A, D, L, T, R¹¹, and R¹² have the indicated meaning,

and these are then reacted with compounds of general formula (VI)




in which

R¹, E, and V have the indicated meaning,

and reductive separation is carried out,

and optionally, the groups listed under substituents A, L, T, and R¹ are introduced or varied according to customary methods.

17. Pharmaceutical product containing 3-heteroalkyl-aryl-substituted pyridines according to Claims 11 through 14, as well as a pharmacologically safe formulation auxiliary.
18. Pharmaceutical product according to Claim 17 for the treatment of hyperlipoproteinemia.
19. Use of 3-heteroalkyl-aryl-substituted pyridines according to Claims 11 through 14 for the production of pharmaceutical products.
20. Use according to Claim 19 for the production of pharmaceutical products for the treatment of hyperlipoproteinemia.
21. A compound having glucagon receptor antagonistic activity and the structural formula 1A



wherein

R^{1a} and R^{1b} independently represent trifluoromethyl, (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, substituted (C₂-C₁₀)-alkynyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-cycloalkenyl, or (C₁-C₆)-alkanoyl;

R^2 represents (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, substituted (C₂-C₁₀)-alkynyl, (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl, or substituted (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl; the substituents on said substituted alkyl, substituted alkenyl, substituted alkynyl, and substituted cycloalkyl R^2 groups being independently from 1 to 3 of halogen, phenyl, substituted phenyl, 1,3-dioxolan-2-yl, -C(O)NR⁴R⁵, or -S(O)_mR⁷ wherein m is 0, 1, or 2;

R^4 and R^5 independently represent hydrogen, (C₁-C₆)-alkyl, (C₃-C₆)-alkenyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-cycloalkyl-(C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl, naphthyl-(C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl;

R^4 and R^5 optionally may be joined together to form - (CH₂)_rA(CH₂)_s- wherein

r and s are independently 1, 2, or 3; and wherein

A represents O, S(O)_n, CHR⁶, or NR⁶; wherein

n is 0, 1, or 2; and

R^6 represents hydrogen, (C₁-C₆)-alkyl, piperidin-1-yl, phenyl, or phenyl-(C₁-C₆)-alkyl;

R^7 represents (C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, pyridyl, substituted pyridyl, pyridyl-(C₁-C₆)-alkyl, substituted pyridyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl, naphthyl-(C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl;

R^2 optionally may be joined to R^{1b} to form an alkylene bridge containing from 3 to 5 carbon atoms, between the ring carbon atoms to which R^2 and R^{1b} are attached;

0 R³ represents hydroxy, trifluoroacetyl, (C₁-C₆)-alkanoyl, substituted (C₁-C₆)-alkyl, or substituted (C₃-C₆)-alkenyl; the substituents on said substituted alkyl and substituted alkenyl R³ groups being from 1 to 3 hydroxyl or trifluoromethyl groups; and

5 Ar' represents an optionally mono-, di-, or tri-substituted heteroaromatic ring selected from the group consisting of pyridyls, furanyls, thiophenyls, pyrrolyls, imidazolyls, pyrazolyls, triazolyls, tetrazolyls, oxazolyls, isoxazolyls, thiazolyls and isothiazolyls, wherein the substituents are independently from 1 to 3 of halogen, (C₁-C₆)-alkyl, substituted (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, substituted (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, substituted (C₂-C₆)-alkynyl, (C₃-C₇)-cycloalkyl, cyano, nitro, trifluoromethyl, -OR⁴, -C(O)R⁴, -OC(O)R⁴, -CO₂R⁴, -NR⁴R⁵, -C(O)NR⁴R⁵, or -S(O)_mR⁷ wherein m is 0, 1, or 2; and

pharmaceutically acceptable salts thereof.

15 22. A compound of claim 21, wherein in structural formula 1A, R^{1a} and R^{1b} independently represent trifluoromethyl, (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl, (C₃-C₇)-cycloalkyl, or (C₃-C₇)-cycloalkenyl;

20 R² represents (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl or substituted (C₂-C₁₀)-alkenyl, wherein the substituents on said substituted alkyl and substituted alkenyl groups are independently from 1 to 3 of halogen, phenyl, substituted phenyl, -C(O)NR⁴R⁵, or -S(O)_mR⁷ wherein m is 0, 1, or 2;

25 R⁴ and R⁵ independently represent hydrogen, (C₁-C₆)-alkyl, (C₃-C₆)-alkenyl, (C₃-C₇)-cycloalkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl, naphthyl-(C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl;

 R⁶ represents hydrogen, (C₁-C₆)-alkyl, phenyl, or phenyl-(C₁-C₆)-alkyl;

30 R⁷ represents (C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, pyridyl, substituted pyridyl, pyridyl-(C₁-C₆)-alkyl, or substituted pyridyl-(C₁-C₆)-alkyl;

35 R² optionally may be joined to R^{1b} to form an alkylene bridge containing from 3 to 4 carbon atoms, between the ring carbon atoms to which R² and R^{1b} are attached;

0 R³ represents (C₁-C₆) alkanoyl, substituted (C₁-C₆)-alkyl, or substituted (C₃-C₆)-alkenyl, wherein the substituents are from 1 to 3 hydroxyl groups; and

5 Ar' is selected from the group consisting of pyridyls, furanyls, thiophenyls, pyrazolyls, triazolyls, oxazolyls and thiazolyls, and the optional substituents on Ar' are independently from 1 to 3 of halogen, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, (C₃-C₇)-cycloalkyl, cyano, -OR⁴, or -OC(O)R⁴, where R⁴ is hydrogen, (C₁-C₆) alkyl, phenyl (C₁-C₆) alkyl or substituted phenyl (C₁-C₆) alkyl.

10 23. A compound of claim 21, wherein in structural formula 1A, R^{1a} and R^{1b} independently represent (C₁-C₆)-alkyl or (C₂-C₆)-alkenyl;

15 R² represents (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀) alkyl, (C₂-C₁₀)-alkenyl, or substituted (C₂-C₁₀)-alkenyl, wherein the substituents on said substituted alkyl and substituted alkenyl groups are independently from 1 to 3 of halogen or -S(O)_mR⁷ wherein m=0,

 R⁷ represents (C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl (C₁-C₆)-alkyl or substituted phenyl (C₁-C₆)-alkyl;

20 R³ represents substituted (C₁-C₆)-alkyl or substituted (C₃-C₆)-alkenyl, wherein the substituents are 1 or 2 hydroxyl groups; and

 Ar' is selected from the group consisting of pyridyls, furanyls and thiophenyls, and the optional substituents are independently from 1 to 3 of halogen, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, -OR⁴, or -OC(O)R⁴, where R⁴ is hydrogen or (C₁-C₆) alkyl.


25 24. A pharmaceutical composition for use in treating a glucagon-mediated condition, which comprises: a compound of claim 21, and a pharmaceutically acceptable carrier.

30 25. A method for treating a glucagon-mediated condition which comprises administering to a subject an effective amount of a compound of claim 21.

35 26. The method of claim 25, wherein the subject is human, the glucagon-mediated condition is diabetes, and the treatment results in lowering of blood glucose.

0

27. A compound having glucagon receptor antagonistic activity and the structural formula 1B



wherein

5

R^{1a} and R^{1b} independently represent trifluoromethyl, (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, substituted (C₂-C₁₀)-alkynyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-cycloalkenyl, or (C₁-C₆)-alkanoyl;

10

R^2 represents (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, substituted (C₂-C₁₀)-alkynyl, (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl, or substituted (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl; the substituents on said substituted alkyl, substituted alkenyl, substituted alkynyl, and substituted cycloalkyl R^2 groups being independently from 1 to 3 of halogen, phenyl, substituted phenyl, 1,3-dioxolan-2-yl, -C(O)NR⁴R⁵, or -S(O)_mR⁷ wherein m is 0, 1, or 2;

15

R^4 and R^5 independently represent hydrogen, (C₁-C₆)-alkyl, (C₃-C₆)-alkenyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-cycloalkyl-(C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl, naphthyl-(C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl;

20

R^4 and R^5 optionally may be joined together to form - (CH₂)_rA(CH₂)_s- wherein

r and s are independently 1, 2, or 3; and wherein

A represents O, S(O)_n, CHR⁶, or NR⁶; wherein

25

n is 0, 1, or 2; and

R⁶ represents hydrogen, (C₁-C₆)-alkyl, piperidin-1-yl, phenyl, or phenyl-(C₁-C₆)-alkyl;

30

R⁷ represents (C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, pyridyl, substituted pyridyl, pyridyl-(C₁-C₆)-alkyl, substituted pyridyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl, naphthyl-(C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl;

0 R² optionally may be joined to R^{1b} to form an alkylene bridge containing from 3 to 5 carbon atoms, between the ring carbon atoms to which R² and R^{1b} are attached;

 R³ represents hydroxy, trifluoroacetyl, (C₁-C₆)-alkanoyl, substituted (C₁-C₆)-alkyl, or substituted (C₃-C₆)-alkenyl; the substituents on said
5 substituted alkyl and substituted alkenyl R³ groups being from 1 to 3 hydroxyl or trifluoromethyl groups; and

 Arⁿ represents an optionally mono-, di-, or tri-substituted aromatic ring selected from the group consisting of phenyls and naphthyls, wherein the substituents are independently from 1 to 3 of halogen, (C₁-C₆)-alkyl,
10 substituted (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, substituted (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, substituted (C₂-C₆)-alkynyl, (C₃-C₇)-cycloalkyl, cyano, nitro, trifluoromethyl, -OR⁴, -C(O)R⁴, -OC(O)R⁴, -CO₂R⁴, -NR⁴R⁵, -C(O)NR⁴R⁵, or -S(O)_mR⁷ wherein m is 0, 1, or 2; and

 pharmaceutically acceptable salts thereof.

15

28. A compound of claim 27, wherein in structural formula 1B,

 R^{1a} and R^{1b} independently represent trifluoromethyl, (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl, (C₃-C₇)-cycloalkyl, or (C₃-C₇)-cycloalkenyl;

20

 R² represents (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl or substituted (C₂-C₁₀)-alkenyl, wherein the substituents on said substituted alkyl and substituted alkenyl groups are independently from 1 to 3 of halogen, phenyl, substituted phenyl, -C(O)NR⁴R⁵, or -S(O)_mR⁷ wherein m is 0, 1, or 2;

25

 R⁴ and R⁵ independently represent hydrogen, (C₁-C₆)-alkyl, (C₃-C₆)-alkenyl, (C₃-C₇)-cycloalkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl, naphthyl-(C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl;

30

 R⁶ represents hydrogen, (C₁-C₆)-alkyl, phenyl, or phenyl-(C₁-C₆)-alkyl;

 R⁷ represents (C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, pyridyl, substituted pyridyl, pyridyl-(C₁-C₆)-alkyl, or substituted pyridyl-(C₁-C₆)-alkyl;

35

 R² optionally may be joined to R^{1b} to form an alkylene bridge containing from 3 to 4 carbon atoms, between the ring carbon atoms to which R² and R^{1b} are attached;

- 0 R³ represents (C₁-C₆) alkanoyl, substituted (C₁-C₆)-alkyl, or substituted (C₃-C₆)-alkenyl, wherein the substituents are from 1 to 3 hydroxyl groups; and
- 5 Ar'' represents a phenyl ring, and the optional substituents on Ar'' are independently from 1 to 3 of halogen, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, (C₃-C₇)-cycloalkyl, cyano, -OR⁴, or -OC(O)R⁴, where R⁴ is hydrogen, (C₁-C₆) alkyl, phenyl (C₁-C₆) alkyl or substituted phenyl (C₁-C₆) alkyl.
- 10 29. A compound of claim 27, wherein in structural formula 1B,
 R^{1a} and R^{1b} independently represent (C₁-C₆)-alkyl or (C₂-C₆)-alkenyl;
 R² represents (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀) alkyl, (C₂-C₁₀)-alkenyl, or substituted (C₂-C₁₀) alkenyl, wherein the substituents on said substituted alkyl and substituted alkenyl groups are independently from 1 to
 15 3 of halogen or -S(O)_mR⁷ wherein m=0;
 R⁷ represents (C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl (C₁-C₆)-alkyl or substituted phenyl (C₁-C₆)-alkyl;
 R³ represents substituted (C₁-C₆)-alkyl or substituted (C₃-C₆)-alkenyl, wherein the substituents are 1 or 2 hydroxyl groups; and
 20 Ar'' represents a phenyl ring, and the optional substituents are independently from 1 to 3 of halogen, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, -OR⁴, or -OC(O)R⁴, where R⁴ is hydrogen or (C₁-C₆) alkyl.
- 25 30. A compound of claim 27, selected from the following group of compounds:
 2,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-ethylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-ethylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(4-chlorophenyl)-5-ethylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(4-methylphenyl)-5-ethylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxyphenyl)-5-ethylpyridine;
 30 2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxy-4-fluorophenyl)-5-ethylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-propylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-propylpyridine;
 2,6-Diisopropyl-3-hydroxymethyl-4-(4-chlorophenyl)-5-propylpyridine;


- 0 2,6-Diisopropyl-3-hydroxymethyl-4-(4-methylphenyl)-5-propylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxyphenyl)-5-propylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxy-4-fluorophenyl)-5-
propylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-butylpyridine;
- 5 2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-butylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-(4-chlorophenyl)-5-butylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-(4-methylphenyl)-5-butylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxyphenyl)-5-butylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxy-4-fluorophenyl)-5-butyl-
pyridine;
- 10 2,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-pentylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-pentylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-(4-chlorophenyl)-5-pentylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-(4-methylphenyl)-5-pentylpyridine;
- 15 2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxyphenyl)-5-pentylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxy-4-fluorophenyl)-5-pentyl-
pyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-phenyl-5-hexylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-hexylpyridine;
- 20 2,6-Diisopropyl-3-hydroxymethyl-4-(4-chlorophenyl)-5-hexylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-(4-methylphenyl)-5-hexylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxyphenyl)-5-hexylpyridine;
2,6-Diisopropyl-3-hydroxymethyl-4-(2-hydroxy-4-fluorophenyl)-5-hexyl-
pyridine;
- 25 2,6-Diisopropyl-3-[(*p*-tolylthio)methyl]-4-phenyl-5-hydroxymethylpyridine;
2,6-Diisopropyl-3-[(*p*-tolylthio)methyl]-4-(4-fluorophenyl)-5-hydroxymethyl-
pyridine;
2,6-Diisopropyl-3-[(*p*-tolylthio)methyl]-4-(4-chlorophenyl)-5-hydroxymethyl-
pyridine;
- 30 2,6-Diisopropyl-3-[(*p*-tolylthio)methyl]-4-(4-methylphenyl)-5-
hydroxymethylpyridine;
2,6-Diisopropyl-3-[(*p*-tolylthio)methyl]-4-(2-hydroxyphenyl)-5-
hydroxymethylpyridine;

- 0 2,6-Diisopropyl-3-[(*p*-tolylthio)methyl]-4-(2-hydroxy-4-fluorophenyl)-5-hydroxymethyl-pyridine;
2,6-Diisopropyl-3-[(4-fluorophenylthio)methyl]-4-phenyl-5-hydroxymethyl-pyridine;
2,6-Diisopropyl-3-[(4-fluorophenylthio)methyl]-4-(4-fluorophenyl)-5-hydroxymethyl-pyridine;
5 2,6-Diisopropyl-3-[(4-fluorophenylthio)methyl]-4-(4-chlorophenyl)-5-hydroxymethyl-pyridine;
2,6-Diisopropyl-3-[(4-fluorophenylthio)methyl]-4-(4-methylphenyl)-5-hydroxymethyl-pyridine;
10 2,6-Diisopropyl-3-[(4-fluorophenylthio)methyl]-4-(2-hydroxyphenyl)-5-hydroxymethyl-pyridine;
2,6-Diisopropyl-3-[(4-fluorophenylthio)methyl]-4-(2-hydroxy-4-fluorophenyl)-5-hydroxymethyl-pyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-phenyl-5-ethylpyridine;
15 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-ethylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-chlorophenyl)-5-ethylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-methylphenyl)-5-ethylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxyphenyl)-5-ethylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxy-4-fluorophenyl)-5-ethylpyridine;
20 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-phenyl-5-propylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-propylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-chlorophenyl)-5-propylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-methylphenyl)-5-propylpyridine;
25 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxyphenyl)-5-propylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxy-4-fluorophenyl)-5-propylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-phenyl-5-butylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-butylpyridine;
30 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-chlorophenyl)-5-butylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-methylphenyl)-5-butylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxyphenyl)-5-butylpyridine;

- 0 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxy-4-fluorophenyl)-5-butylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-phenyl-5-pentylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-pentylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-chlorophenyl)-5-pentylpyridine;
5 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-methylphenyl)-5-pentylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxyphenyl)-5-pentylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxy-4-fluorophenyl)-5-pentylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-phenyl-5-hexylpyridine;
10 2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-fluorophenyl)-5-hexylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-chlorophenyl)-5-hexylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(4-methylphenyl)-5-hexylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxyphenyl)-5-hexylpyridine;
2,6-Diisopropyl-3-(1-hydroxyethyl)-4-(2-hydroxy-4-fluorophenyl)-5-hexylpyridine;
15 2,6-Diisopropyl-3-[(*p*-tolylthio)methyl]-4-phenyl-5-(1-hydroxyethyl)-pyridine;
2,6-Diisopropyl-3-[(*p*-tolylthio)methyl]-4-(4-fluorophenyl)-5-(1-hydroxyethyl)-pyridine;
20 2,6-Diisopropyl-3-[(*p*-tolylthio)methyl]-4-(4-chlorophenyl)-5-(1-hydroxyethyl)-pyridine;
2,6-Diisopropyl-3-[(*p*-tolylthio)methyl]-4-(4-methylphenyl)-5-(1-hydroxyethyl)-pyridine;
2,6-Diisopropyl-3-[(*p*-tolylthio)methyl]-4-(2-hydroxyphenyl)-5-(1-hydroxyethyl)-pyridine;
25 2,6-Diisopropyl-3-[(*p*-tolylthio)methyl]-4-(2-hydroxy-4-fluorophenyl)-5-(1-hydroxyethyl)-pyridine;
2,6-Diisopropyl-3-[(4-fluorophenylthio)methyl]-4-phenyl-5-(1-hydroxyethyl)-pyridine;
30 2,6-Diisopropyl-3-[(4-fluorophenylthio)methyl]-4-(4-fluorophenyl)-5-(1-hydroxyethyl)-pyridine;
2,6-Diisopropyl-3-[(4-fluorophenylthio)methyl]-4-(4-chlorophenyl)-5-(1-hydroxyethyl)-pyridine;

- 0 2,6-Diisopropyl-3-(((4-fluorophenyl)thio)methyl)-4-(4-methylphenyl)-5-(1-hydroxyethyl)-pyridine;
 2,6-Diisopropyl-3-(((4-fluorophenyl)thio)methyl)-4-(2-hydroxyphenyl)-5-(1-hydroxyethyl)-pyridine;
 2,6-Diisopropyl-3-(((4-fluorophenyl)thio)methyl)-4-(2-hydroxy-4-
 5 fluorophenyl)-5-(1-hydroxyethyl)-pyridine.

31. A pharmaceutical composition for use in treating a glucagon-mediated condition, which comprises: a compound of claim 27, and a pharmaceutically acceptable carrier.
- 10 32. A method for treating a glucagon-mediated condition which comprises administering to a subject an effective amount of a compound of claim 27.
- 15 33. The method of claim 32, wherein the subject is human, the glucagon-mediated condition is diabetes, and the treatment results in lowering of blood glucose.
34. A compound having glucagon receptor antagonistic activity and the structural formula 1C



1C

20 wherein

 R⁸ represents hydrogen, halogen, trifluoromethyl, phenyl, substituted phenyl, (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₁-C₆)-alkoxy, (C₃-C₇)-cycloalkyl, phenyl-(C₁-C₃)-alkoxy, (C₁-C₆)-alkanoyloxy, (C₁-C₆)-alkoxycarbonyl, carboxy, formyl, or -NR⁴R⁵;

 R⁴ and R⁵ independently represent hydrogen, (C₁-C₆)-alkyl, (C₃-C₆)-alkenyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-cycloalkyl-(C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl, naphthyl-(C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl;

0 R^4 and R^5 optionally may be joined together to form -
 (CH₂)_rA(CH₂)_s- wherein

 r and s are independently 1, 2, or 3, and wherein

 A represents O, S(O)_n, CHR⁶, or NR⁶; wherein

 n is 0, 1, or 2; and

5 R^6 represents hydrogen, (C₁-C₆)-alkyl, piperidin-1-yl,
 phenyl, or phenyl-(C₁-C₆)-alkyl;

R^{1a} and R^{1b} independently represent trifluoromethyl, (C₁-C₁₀)-alkyl,
 substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl,
 (C₂-C₁₀)-alkynyl, substituted (C₂-C₁₀)-alkynyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-
 10 cycloalkenyl, or (C₁-C₆)-alkanoyl;

R^2 represents (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-
 alkenyl, substituted (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, substituted (C₂-
 C₁₀)-alkynyl, (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl, or substituted (C₃-C₆)-
 cycloalkyl-(C₁-C₆)-alkyl; the substituents on said substituted alkyl,
 15 substituted alkenyl, substituted alkynyl, and substituted cycloalkyl R^2
 groups being independently from 1 to 3 of halogen, phenyl, substituted
 phenyl, 1,3-dioxolan-2-yl, -C(O)NR⁴R⁵, or -S(O)_mR⁷ wherein m is 0, 1, or 2;

R^7 represents (C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl-(C₁-
 C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, pyridyl, substituted pyridyl,
 20 pyridyl-(C₁-C₆)-alkyl, substituted pyridyl-(C₁-C₆)-alkyl, naphthyl,
 substituted naphthyl, naphthyl-(C₁-C₆)-alkyl, or substituted naphthyl-(C₁-
 C₆)-alkyl;

R^2 optionally may be joined to R^{1b} to form an alkylene bridge
 containing from 3 to 5 carbon atoms, between the ring carbon atoms to
 25 which R^2 and R^{1b} are attached;

R^3 represents hydroxy, trifluoroacetyl, (C₁-C₆)-alkanoyl, substituted
 (C₁-C₆)-alkyl, or substituted (C₃-C₆)-alkenyl; the substituents on said
 substituted alkyl and substituted alkenyl R^3 groups being from 1 to 3
 hydroxyl or trifluoromethyl groups;

30 Ar' represents an optionally mono-, di-, or tri-substituted
 heteroaromatic ring selected from the group consisting of pyridyls, furanyls,
 thiophenyls, pyrrolyls, imidazolyls, pyrazolyls, triazolyls, tetrazolyls,
 oxazolyls, isoxazolyls, thiazolyls and isothiazolyls, wherein the substituents
 are independently from 1 to 3 of halogen, (C₁-C₆)-alkyl, substituted (C₁-
 35 C₆)-alkyl, (C₂-C₆)-alkenyl, substituted (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl,
 substituted (C₂-C₆)-alkynyl, (C₃-C₇)-cycloalkyl, cyano, nitro,

0 trifluoromethyl, -OR⁴, -C(O)R⁴, -OC(O)R⁴, -CO₂R⁴, -NR⁴R⁵, -C(O)NR⁴R⁵,
or -S(O)_mR⁷ wherein m is 0, 1, or 2 and

 pharmaceutically acceptable salts thereof.

35. A compound of claim 34, wherein in structural formula 1C,

5 R⁸ represents hydrogen, halogen, trifluoromethyl or (C₁-C₁₀) alkyl;

 R^{1a} and R^{1b} independently represent trifluoromethyl, (C₁-C₁₀)-alkyl,
substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl,
(C₃-C₇)-cycloalkyl, or (C₃-C₇)-cycloalkenyl;

10 R² represents (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-
alkenyl or substituted (C₂-C₁₀)-alkenyl, wherein the substituents on said
substituted alkyl and substituted alkenyl groups are independently from 1 to
3 of halogen, phenyl, substituted phenyl, -C(O)NR⁴R⁵, or -S(O)_mR⁷ wherein
m is 0,1,or 2;

15 R⁴ and R⁵ independently represent hydrogen, (C₁-C₆)-alkyl, (C₃-C₆)-
alkenyl, (C₃-C₇)-cycloalkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-
alkyl, substituted phenyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl,
naphthyl-(C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl;

 R⁶ represents hydrogen, (C₁-C₆)-alkyl, phenyl, or phenyl-(C₁-C₆)-
alkyl;

20 R⁷ represents (C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl-(C₁-
C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, pyridyl, substituted pyridyl,
pyridyl-(C₁-C₆)-alkyl, or substituted pyridyl-(C₁-C₆)-alkyl;

25 R² optionally may be joined to R^{1b} to form an alkylene bridge
containing from 3 to 4 carbon atoms, between the ring carbon atoms to
which R² and R^{1b} are attached;

 R³ represents (C₁-C₆) alkanoyl, substituted (C₁-C₆)-alkyl, or
substituted (C₃-C₆)-alkenyl, wherein the substituents are from 1 to 3
hydroxyl groups; and

30 Ar' is selected from the group consisting of pyridyls, furanyls,
thiophenyls, pyrazolyls, triazolyls, oxazolyls and thiazolyls, and the optional
substituents on Ar' are independently from 1 to 3 of halogen, (C₁-C₆)-alkyl,
(C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, (C₃-C₇)-cycloalkyl, cyano, -OR⁴, or -
OC(O)R⁴, where R⁴ is hydrogen, (C₁-C₆) alkyl, phenyl (C₁-C₆) alkyl or
substituted phenyl (C₁-C₆) alkyl.

35


- 0 36. A compound of claim 34, wherein in structural formula 1C,
 R^8 represents hydrogen;
 R^{1a} and R^{1b} independently represent (C₁-C₆)-alkyl or (C₂-C₆)-
 alkenyl;
 R^2 represents (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀) alkyl, (C₂-C₁₀)-
 5 alkenyl, or substituted (C₂-C₁₀)-alkenyl, wherein the substituents on said
 substituted alkyl and substituted alkenyl groups are independently from 1 to
 3 of halogen or -S(O)_mR⁷ wherein m=0,
 R^7 represents (C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl (C₁-
 C₆)-alkyl or substituted phenyl (C₁-C₆)-alkyl;
 10 R^3 represents substituted (C₁-C₆)-alkyl or substituted (C₃-C₆)-
 alkenyl; where the substituents are 1 or 2 hydroxyl groups; and
 Ar' is selected from the group consisting of pyridyls, furanyls and
 thiophenyls, and the optional substituents are independently from 1 to 3 of
 halogen, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, -OR⁴, or -OC(O)R⁴, where R⁴ is
 15 hydrogen or (C₁-C₆) alkyl.

37. A pharmaceutical composition for use in treating a glucagon-mediated
 condition, which comprises: a compound of claim 34, and a pharmaceutically
 acceptable carrier.

38. A method for treating a glucagon-mediated condition which comprises
 administering to a subject an effective amount of a compound of claim 34.

39. The method of claim 38, wherein the subject is human, the glucagon-
 mediated condition is diabetes, and the treatment results in lowering of
 blood glucose.

40. A compound having glucagon receptor antagonistic activity and the
 structural formula 1D



wherein

0 R⁸ represents hydrogen, halogen, trifluoromethyl, phenyl, substituted phenyl, (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₁-C₆)-alkoxy, (C₃-C₇)-cycloalkyl, phenyl-(C₁-C₃)-alkoxy, (C₁-C₆)-alkanoyloxy, (C₁-C₆)-alkoxycarbonyl, carboxy, formyl, or -NR⁴R⁵;

5 R⁴ and R⁵ independently represent hydrogen, (C₁-C₆)-alkyl, (C₃-C₆)-alkenyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-cycloalkyl-(C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl, naphthyl-(C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl;

10 R⁴ and R⁵ optionally may be joined together to form - (CH₂)_rA(CH₂)_s- wherein

r and s are independently 1, 2, or 3, and wherein

A represents O, S(O)_n, CHR⁶, or NR⁶, wherein

n is 0, 1, or 2; and

15 R⁶ represents hydrogen, (C₁-C₆)-alkyl, piperidin-1-yl, phenyl, or phenyl-(C₁-C₆)-alkyl;

R^{1a} and R^{1b} independently represent trifluoromethyl, (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, substituted (C₂-C₁₀)-alkynyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-cycloalkenyl, or (C₁-C₆)-alkanoyl;

20 R² represents (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl, (C₂-C₁₀)-alkynyl, substituted (C₂-C₁₀)-alkynyl, (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl, or substituted (C₃-C₆)-cycloalkyl-(C₁-C₆)-alkyl; the substituents on said substituted alkyl, substituted alkenyl, substituted alkynyl, and substituted cycloalkyl R² groups being independently from 1 to 3 of halogen, phenyl, substituted phenyl, 1,3-dioxolan-2-yl, -C(O)NR⁴R⁵, or -S(O)_mR⁷ wherein m is 0, 1, or 2;

25 R⁷ represents (C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, pyridyl, substituted pyridyl, pyridyl-(C₁-C₆)-alkyl, substituted pyridyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl, naphthyl-(C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl;

30 R² optionally may be joined to R^{1b} to form an alkylene bridge containing from 3 to 5 carbon atoms, between the ring carbon atoms to which R² and R^{1b} are attached;

35 R³ represents hydroxy, trifluoroacetyl, (C₁-C₆)-alkanoyl, substituted (C₁-C₆)-alkyl, or substituted (C₃-C₆)-alkenyl; the substituents on said

0 substituted alkyl and substituted alkenyl R^3 groups being from 1 to 3 hydroxyl or trifluoromethyl groups;

Ar" represents an optionally mono-, di-, or tri-substituted aromatic ring selected from the group consisting of phenyls and naphthyls, wherein the substituents are independently from 1 to 3 of halogen, (C₁-C₆)-alkyl, substituted (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, substituted (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, substituted (C₂-C₆)-alkynyl, (C₃-C₇)-cycloalkyl, cyano, nitro, trifluoromethyl, -OR⁴, -C(O)R⁴, -OC(O)R⁴, -CO₂R⁴, -NR⁴R⁵, -C(O)NR⁴R⁵, or -S(O)_mR⁷ wherein m is 0, 1, or 2; and pharmaceutically acceptable salts thereof.

10

41. A compound of claim 40, wherein in structural formula 1D,

R^8 represents hydrogen, halogen, trifluoromethyl or (C₁-C₁₀) alkyl;

R^{1a} and R^{1b} independently represent trifluoromethyl, (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl, substituted (C₂-C₁₀)-alkenyl, (C₃-C₇)-cycloalkyl, or (C₃-C₇)-cycloalkenyl;

R^2 represents (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀)-alkyl, (C₂-C₁₀)-alkenyl or substituted (C₂-C₁₀)-alkenyl, wherein the substituents on said substituted alkyl and substituted alkenyl groups are independently from 1 to 3 of halogen, phenyl, substituted phenyl, -C(O)NR⁴R⁵, or -S(O)_mR⁷ wherein m is 0,1,or 2;

R^4 and R^5 independently represent hydrogen, (C₁-C₆)-alkyl, (C₃-C₆)-alkenyl, (C₃-C₇)-cycloalkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, naphthyl, substituted naphthyl, naphthyl-(C₁-C₆)-alkyl, or substituted naphthyl-(C₁-C₆)-alkyl;

R^6 represents hydrogen, (C₁-C₆)-alkyl, phenyl, or phenyl-(C₁-C₆)-alkyl;

R^7 represents (C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl-(C₁-C₆)-alkyl, substituted phenyl-(C₁-C₆)-alkyl, pyridyl, substituted pyridyl, pyridyl-(C₁-C₆)-alkyl, or substituted pyridyl-(C₁-C₆)-alkyl;

R^2 optionally may be joined to R^{1b} to form an alkylene bridge containing from 3 to 4 carbon atoms, between the ring carbon atoms to which R^2 and R^{1b} are attached;

R^3 represents (C₁-C₆) alkanoyl, substituted (C₁-C₆)-alkyl, or substituted (C₃-C₆)-alkenyl, wherein the substituents are from 1 to 3 hydroxyl groups; and

35

- 0 Ar'' represents a phenyl ring, and the optional substituents on Ar'' are independently from 1 to 3 of halogen, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, (C₃-C₇)-cycloalkyl, cyano, -OR⁴, or -OC(O)R⁴, where R⁴ is hydrogen, (C₁-C₆) alkyl, phenyl (C₁-C₆) alkyl or substituted phenyl (C₁-C₆) alkyl.
- 5
42. A compound of claim 40, wherein in structural formula 1D,
 R⁸ represents hydrogen;
 R^{1a} and R^{1b} independently represent (C₁-C₆)-alkyl or (C₂-C₆)-alkenyl;
 10 R² represents (C₁-C₁₀)-alkyl, substituted (C₁-C₁₀) alkyl, (C₂-C₁₀)-alkenyl, or substituted (C₂-C₁₀) alkenyl, wherein the substituents on said substituted alkyl and substituted alkenyl groups are independently from 1 to 3 of halogen or -S(O)_mR⁷ wherein m=0;
 R⁷ represents (C₁-C₆)-alkyl, phenyl, substituted phenyl, phenyl (C₁-C₆)-alkyl or substituted phenyl (C₁-C₆)-alkyl;
 15 R³ represents substituted (C₁-C₆)-alkyl or substituted (C₃-C₆)-alkenyl; where the substituents are 1 or 2 hydroxyl groups; and
 Ar'' represents a phenyl ring, and the optional substituents are independently from 1 to 3 of halogen, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, -OR⁴, or -OC(O)R⁴, where R⁴ is hydrogen or (C₁-C₆) alkyl.
- 20
43. A compound of claim 40, selected from the following group of compounds:
 3,5-Diisopropyl-2-hydroxymethyl-6-ethyl-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-ethyl-4'-fluoro-1,1'-biphenyl;
 25 3,5-Diisopropyl-2-hydroxymethyl-6-ethyl-4'-chloro-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-ethyl-4'-methyl-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-ethyl-2'-hydroxy-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-ethyl-2'-hydroxy-4'-fluoro-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-propyl-1,1'-biphenyl;
 30 3,5-Diisopropyl-2-hydroxymethyl-6-propyl-4'-fluoro-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-propyl-4'-chloro-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-propyl-4'-methyl-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-propyl-2'-hydroxy-1,1'-biphenyl;

- 0 3,5-Diisopropyl-2-hydroxymethyl-6-propyl-2'-hydroxy-4'-fluoro-1,1'-
 biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-butyl-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-butyl-4'-fluoro-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-butyl-4'-chloro-1,1'-biphenyl;
5 3,5-Diisopropyl-2-hydroxymethyl-6-butyl-4'-methyl-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-butyl-2'-hydroxy-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-butyl-2'-hydroxy-4'-fluoro-1,1'-
 biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-pentyl-1,1'-biphenyl;
10 3,5-Diisopropyl-2-hydroxymethyl-6-pentyl-4'-fluoro-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-pentyl-4'-chloro-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-pentyl-4'-methyl-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-pentyl-2'-hydroxy-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-pentyl-2'-hydroxy-4'-fluoro-1,1'-
15 biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-hexyl-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-hexyl-4'-fluoro-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-hexyl-4'-chloro-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-hexyl-4'-methyl-1,1'-biphenyl;
20 3,5-Diisopropyl-2-hydroxymethyl-6-hexyl-2'-hydroxy-1,1'-biphenyl;
 3,5-Diisopropyl-2-hydroxymethyl-6-hexyl-2'-hydroxy-4'-fluoro-1,1'-
 biphenyl;
 3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-hydroxymethyl-1,1'-biphenyl;
 3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-hydroxymethyl-4'-fluoro-1,1'-
25 biphenyl;
 3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-hydroxymethyl-4'-chloro-1,1'-
 biphenyl;
 3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-hydroxymethyl-4'-methyl-1,1'-
 biphenyl;
30 3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-hydroxymethyl-2'-hydroxy-1,1'-
 biphenyl;
 3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-hydroxymethyl-2'-hydroxy-4'-
 fluoro-1,1'-biphenyl;

- 0 3,5-Diisopropyl-2-(((4-fluorophenyl)thio)methyl)-6-hydroxymethyl-1,1'-
biphenyl;
3,5-Diisopropyl-2-(((4-fluorophenyl)thio)methyl)-6-hydroxymethyl-4'-
fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-(((4-fluorophenyl)thio)methyl)-6-hydroxymethyl-4'-
5 chloro-1,1'-biphenyl;
3,5-Diisopropyl-2-(((4-fluorophenyl)thio)methyl)-6-hydroxymethyl-4'-
methyl-1,1'-biphenyl;
3,5-Diisopropyl-2-(((4-fluorophenyl)thio)methyl)-6-hydroxymethyl-2'-
hydroxy-1,1'-biphenyl;
10 3,5-Diisopropyl-2-(((4-fluorophenyl)thio)methyl)-6-hydroxymethyl-2'-
hydroxy-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-ethyl-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-ethyl-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-ethyl-4'-chloro-1,1'-biphenyl;
15 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-ethyl-4'-methyl-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-ethyl-2'-hydroxy-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-ethyl-2'-hydroxy-4'-fluoro-1,1'-
biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-propyl-1,1'-biphenyl;
20 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-propyl-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-propyl-4'-chloro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-propyl-4'-methyl-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-propyl-2'-hydroxy-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-propyl-2'-hydroxy-4'-fluoro-1,1'-
25 biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-butyl-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-butyl-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-butyl-4'-chloro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-butyl-4'-methyl-1,1'-biphenyl;
30 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-butyl-2'-hydroxy-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-butyl-2'-hydroxy-4'-fluoro-1,1'-
biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-1,1'-biphenyl;

- 0 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-4'-chloro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-4'-methyl-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-2'-hydroxy-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-pentyl-2'-hydroxy-4'-fluoro-1,1'-
5 biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-hexyl-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-hexyl-4'-fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-hexyl-4'-chloro-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-hexyl-4'-methyl-1,1'-biphenyl;
10 3,5-Diisopropyl-2-(1-hydroxyethyl)-6-hexyl-2'-hydroxy-1,1'-biphenyl;
3,5-Diisopropyl-2-(1-hydroxyethyl)-6-hexyl-2'-hydroxy-4'-fluoro-1,1'-
biphenyl;
3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-(1-hydroxyethyl)-1,1'-biphenyl;
3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-(1-hydroxyethyl)-4'-fluoro-1,1'-
15 biphenyl;
3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-(1-hydroxyethyl)-4'-chloro-1,1'-
biphenyl;
3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-(1-hydroxyethyl)-4'-methyl-1,1'-
biphenyl;
20 3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-(1-hydroxyethyl)-2'-hydroxy-1,1'-
biphenyl;
3,5-Diisopropyl-2-[(*p*-tolylthio)methyl]-6-(1-hydroxyethyl)-2'-hydroxy-4'-
fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-[(4-fluorophenyl)thio)methyl]-6-(1-hydroxyethyl)-1,1'-
25 biphenyl;
3,5-Diisopropyl-2-[(4-fluorophenyl)thio)methyl]-6-(1-hydroxyethyl)-4'-
fluoro-1,1'-biphenyl;
3,5-Diisopropyl-2-[(4-fluorophenyl)thio)methyl]-6-(1-hydroxyethyl)-4'-
chloro-1,1'-biphenyl;
30 3,5-Diisopropyl-2-[(4-fluorophenyl)thio)methyl]-6-(1-hydroxyethyl)-4'-
methyl-1,1'-biphenyl;
3,5-Diisopropyl-2-[(4-fluorophenyl)thio)methyl]-6-(1-hydroxyethyl)-2'-
hydroxy-1,1'-biphenyl;

0 3,5-Diisopropyl-2-(((4-fluorophenyl)thio)methyl)-6-(1-hydroxyethyl)-2'-
 hydroxy-4'-fluoro-1,1'-biphenyl.

44. A pharmaceutical composition for use in treating a glucagon-mediated
 condition, which comprises: a compound of claim 40, and a pharmaceutically
5 acceptable carrier.
45. A method for treating a glucagon-mediated condition which comprises
 administering to a subject an effective amount of a compound of claim 40.
- 10 46. The method of claim 45, wherein the subject is human, the glucagon-
 mediated condition is diabetes, and the treatment results in lowering of
 blood glucose.
- 15 47. A compound of claim 21, 27, 34, or 40 wherein the substituent shown as R³ is
 a hydroxyethyl group having the following stereochemistry

